<SEC-DOCUMENT>0001493152-24-010427.txt : 20240319
<SEC-HEADER>0001493152-24-010427.hdr.sgml : 20240319
<ACCEPTANCE-DATETIME>20240319083054
ACCESSION NUMBER:		0001493152-24-010427
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240319
DATE AS OF CHANGE:		20240319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		24761173

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:LIXT="http://lixte.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2023%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_038_LIXT_lixte.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AmendmentFlag" id="ixv-19813">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-19814">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCentralIndexKey" id="ixv-19815">0001335105</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0166" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_FR" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" id="xdx2ixbrl0662" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" id="xdx2ixbrl0664" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" id="xdx2ixbrl0678" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" id="xdx2ixbrl0680" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" id="xdx2ixbrl0682" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" id="xdx2ixbrl0684" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1095" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1097" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" id="xdx2ixbrl1237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-02</xbrli:startDate>
        <xbrli:endDate>2023-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:LegalFirmsAndOtherVendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:LegalFirmsAndOtherVendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_FR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_FR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-03-172015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-03-17</xbrli:startDate>
        <xbrli:endDate>2015-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-11</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-242023-08-07_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-15_custom_DrReneBernardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-06_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-26_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_DirectorMember_custom_MrSchwartbergMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-10</xbrli:startDate>
        <xbrli:endDate>2021-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-04</xbrli:startDate>
        <xbrli:endDate>2021-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-18</xbrli:startDate>
        <xbrli:endDate>2018-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-01_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BastiaanVanDerBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-23</xbrli:startDate>
        <xbrli:endDate>2013-12-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-12</xbrli:startDate>
        <xbrli:endDate>2015-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-09</xbrli:startDate>
        <xbrli:endDate>2022-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-15</xbrli:startDate>
        <xbrli:endDate>2023-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseZeroPharmacologyStudyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-23</xbrli:startDate>
        <xbrli:endDate>2024-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueWithinSixtyDaysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueWithinSixtyDaysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>LIXT:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>LIXT:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001328" toRefs="Footnote001345"/>
  <ix:relationship fromRefs="Fact001330" toRefs="Footnote001345"/>
  <ix:relationship fromRefs="Fact001332" toRefs="Footnote001345"/>
  <ix:relationship fromRefs="Fact001334" toRefs="Footnote001345"/>
  <ix:relationship fromRefs="Fact001320" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001322" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001324" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001326" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001336" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001338" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001340" toRefs="Footnote001346"/>
  <ix:relationship fromRefs="Fact001342" toRefs="Footnote001346"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20230101__20231231_zdPVLoxFh7E5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentType" id="ixv-22167">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentAnnualReport_c20230101__20231231_zivtb9cGbjd7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="ixv-22168">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20230101__20231231_zOGYgQZSwef2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-48"><span id="xdx_906_edei--CurrentFiscalYearEndDate_c20230101__20231231_zjlTFoRKbJZb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="ixv-22169">December 31</ix:nonNumeric></span>, <span id="xdx_90A_edei--DocumentFiscalYearFocus_c20230101__20231231_zbwZOPXAs7Jd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-22170">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--DocumentTransitionReport_c20230101__20231231_zO2OXCUUcPgj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="ixv-22171">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from ______ to ______</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityFileNumber_c20230101__20231231_zfeYJqHItLok"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-22172">001-39717</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20230101__20231231_ztqiMcOe6dx4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-22173">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20230101__20231231_z6PDqXaNOz8j"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-22174">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20230101__20231231_zS7l55ITFhr4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-22175">20-2903526</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20230101__20231231_zZ573RkX8NI6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-22176">680
    East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20230101__20231231_zGXtg7YPkGJ8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine2" id="ixv-22177">Suite 180</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20230101__20231231_zCNNer3ocPfi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-22178">Pasadena</ix:nonNumeric></span>,
    <span id="xdx_908_edei--EntityAddressStateOrProvince_c20230101__20231231_zhiJsiPheHv3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-22179">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20230101__20231231_zXgaXRhvyjje"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-22180">91101</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number: <b><span style="text-decoration: underline"><span id="xdx_90E_edei--CityAreaCode_c20230101__20231231_zL7aagaS0DKe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:CityAreaCode" id="ixv-22181">(631)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20230101__20231231_zoYIsqDSJGgb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-22182">830-7092</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zCAx57LAPmE"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle" id="ixv-22183">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zp8PGZ3Y1Kgj"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol" id="ixv-22184">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90D_edei--SecurityExchangeName_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zfdyHHNbyMmj"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-22185">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zYSXi3rky8ka"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle" id="ixv-22186">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zCNIVTePDNib"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol" id="ixv-22187">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_908_edei--SecurityExchangeName_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_ziLJQ2eATRC2"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-22188">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;<span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zfKMd1F21ln7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-22189">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes&#160;&#9744;&#160;<span id="xdx_906_edei--EntityVoluntaryFilers_c20230101__20231231_zJlXqbP5hCGe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityVoluntaryFilers" id="ixv-22190">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20230101__20231231_zgoROsGSSFs4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-22191">Yes</ix:nonNumeric></span>  &#9746; No &#9744; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20230101__20231231_zU2MbpGATaY9"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-22192">Yes</ix:nonNumeric></span>  &#9746; No &#9744; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting,
or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20230101__20231231_z35SOImr2Gn2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-22193">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntitySmallBusiness_c20230101__20231231_zdWyV6Y9L0Cf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="ixv-22194">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20230101__20231231_zd8WolCo86s6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-22195">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_906_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zvvLAD5fiCpb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" id="ixv-22196">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_907_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_zu2mtWv5kgSa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-22197">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No <span id="xdx_907_edei--EntityShellCompany_dbF_c20230101__20231231_zH5ZIl3MD0il"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="ixv-22198">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2023 was approximately $<span id="xdx_90B_edei--EntityPublicFloat_iI_c20230630_zMq3imrKhUW"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22199">1,125,215</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20240301_zJ5rjQ3PrcTi"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22200">2,249,290</ix:nonFraction></span> shares of common stock, $0.0001 par value, issued and outstanding as of March 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents
incorporated by reference: <span id="xdx_90A_edei--DocumentsIncorporatedByReferenceTextBlock_c20230101__20231231_z8g8FGs0RlJb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-22201">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">TABLE
OF CONTENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    Number</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#p_003">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#p_002">BUSINESS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#p_001">RISK FACTORS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_001">UNRESOLVED STAFF COMMENTS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_002">CYBERSECURITY</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_003">PROPERTIES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_004">LEGAL PROCEEDINGS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_005">MINE SAFETY DISCLOSURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_006">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_007">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_008">RESERVED</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_009">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_010">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_011">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_012">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_013">CONTROLS AND PROCEDURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_014">OTHER INFORMATION</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">75</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9C. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_015">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>75</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_016">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_017">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_018">EXECUTIVE COMPENSATION</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">82<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_019">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_020">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_021">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_022">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_023">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_024">FORM 10-K SUMMARY</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_025">INDEX TO EXHIBITS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">95</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_026">SIGNATURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ns_001">CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introductory
Comment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Annual Report on Form 10-K, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;Lixte,&#8221;
the &#8220;Company&#8221; and the &#8220;Registrant&#8221; refer to Lixte Biotechnology Holdings, Inc., a Delaware corporation, and Lixte
Biotechnology, Inc., a Delaware corporation, our wholly-owned subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (the &#8220;Report&#8221;) contains certain forward-looking statements. For example, statements regarding
our financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about
future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements
are generally accompanied by words such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;potential(ly),&#8221; &#8220;continue,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect&#8221; or the negative of such terms
or other comparable terminology. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable,
based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove
to have been correct or that we will take any action that we may presently be planning. However, these forward-looking statements are
inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, competition from other similar businesses, and market and general policies, competition from other similar businesses,
and market and general economic factors. This discussion should be read in conjunction with the consolidated financial statements and
notes thereto included in this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results
may vary materially from what we project. Any forward-looking statement you read in this Report reflects our current views with respect
to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations,
growth strategy, and liquidity. All subsequent forward-looking statements attributable to us or individuals acting on our behalf are
expressly qualified in their entirety by this paragraph. You should specifically consider the factors identified in this Report, which
would cause actual results to differ before making an investment decision. We are under no duty to update any of these forward-looking
statements after the date of this Report or to conform these statements to actual results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="p_003"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="p_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by developing a drug class called
Protein Phosphatase 2A inhibitors. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents
and/or x-ray, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have
significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein
phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little
or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
cancer patients are treated with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is
a high unmet medical need to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both
chemotherapy and Immunotherapy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100,
a small molecule potent inhibitor of PP2A was designed and developed by the Company. Numerous preclinical studies have documented that
LB-100 potentiates most if not all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when
given with cytotoxic drugs. This synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase
in cell division rate. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval
in the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its initial Phase 1 clinical trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine
believed to be caused by inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximally Tolerated Dose (&#8220;MTD&#8221;)
was 2.33mg/m2 daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease,
3 patients had stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles.
One patient with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the DNA damage enhancing effect of PP2A inhibition with LB-100, the Company initiated a study in Advanced Soft Tissue Sarcoma (&#8220;ASTS&#8221;)
with the Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;) for a collaborative clinical
trial in Madrid, Spain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
doses of LB-100 have now been shown to enhance immune checkpoint inhibition (&#8220;ICI&#8221;) by several different mechanisms affecting
the tumor compartment and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation,
and cytokine production induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically
&#8220;cold&#8221; to &#8220;hot&#8221; cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian
clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with
immune checkpoint inhibitors, were recently found to have markedly longer survival than patients without the mutation in their cancers.
Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated
patients with a PPP2R1A mutation in their tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the observations in ovarian clear cell carcinoma, the Company has initiated a clinical trial in this disease combining LB-100 with
a monoclonal antibody blocking PD-1, a protein found on T-cells (NCT06065462). Further, in an ongoing Phase 1b clinical trial in previously
untreated patients with small cell lung cancer, LB-100 is being escalated with a combination of full dose carboplatin, etoposide, and
atezolizumab (NCT04560972). This clinical trial is being sponsored and conducted at the City of Hope National Medical Center in Duarte,
California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research on the LB-100 series was initiated in 2006 under a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with
the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that
was subsequently extended through a series of amendments until it terminated on April 1, 2013.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has also designed and developed the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced
to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical
development of our LB-200 series of compounds at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spanish
Sarcoma Group Collaboration Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma
Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a study entitled
&#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&#8221;.
The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin
in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared
by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n
Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The Phase 1b portion
of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on both response and toxicity
from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able to proceed to a related Phase
2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Research Support Agreement with the City of Hope National Medical Center</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical Center, an NCI-designated
comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;), to carry out a Phase 1b
clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an FDA-approved standard regimen
for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100 will be given in combination
with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated ED-SCLC patients. The
dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (&#8220;RP2D&#8221;).
Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the safety of the LB-100 combination
and to look for potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free
survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability,
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MD
Anderson Cancer Center Clinical Trial</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding
LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly,
may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). The clinical trial
is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The University
of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial support for
the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The Company currently
expects that this clinical trial will be completed by July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Cancer Institute Pharmacologic Clinical Trial</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted
and funded by the NCI under a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical
compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moffitt
Cancer Center Clinical Trial Research Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research Institute Hospital
Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years, unless terminated earlier by the Company pursuant to
30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical
trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound LB-100 to be administered
intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally
well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent
in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. In this clinical trial, single agent LB-100 was used on a new schedule of
days 1, 3, and 5 every 3 weeks. Although the MTD was not achieved, there was no dose-limiting toxicity on this schedule at doses that
were greater than the MTD in the Phase 1 clinical trial of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Institute of Health</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with the National Institute
of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;), each an institute or
center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has licensed exclusively
NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) subject invention
co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination
with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for
the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis,
until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed
territory, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moffitt
Cancer Center</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement, Moffitt granted
the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating to the treatment
of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results, clinical data,
and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents or the use,
development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed
Patents. The clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Significant Agreements and Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (&#8220;NKI&#8221;),
one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center,
for a term of three years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto. The Development
Collaboration Agreement is intended to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues,
to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
The Company agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. On October 3, 2023, the Company
entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research activities and
extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by NKI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Future Clinical Trials</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to initiate a Phase 1b/2 clinical trial of LB-100 in combination with immunotherapy. Our ability to conduct such a clinical
trial, and possibly other clinical trials, is dependent on the conclusion and results of our ongoing clinical trials and is subject to
the availability of additional financial resources. The clinical trial would study the ability of LB-100 to enhance the effectiveness
of an immunoblocker by adding LB-100 in treatment of one of several cancers in which immunotherapy alone has modest activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 1b/2 clinical trial in LB-100 plus a PD-1 blocker in yet to be specified solid tumors would require additional financing in excess
of that currently budgeted and/or partnering relationships with other pharmaceutical companies. From time to time, we engage in discussions
with various parties with respect to financing clinical trials evaluating the benefit of adding LB-100 to immunotherapy. There can be
no assurance that we will be able to obtain such financing and/or partnering relationships on acceptable terms or at all. Our longer-term
objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer research and drug
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products will ultimately be based on our intellectual property and are expected to be covered by our patents. These patents now cover
sole rights to the composition and synthesis of our LB-100 series of drugs, which is the Company&#8217;s lead clinical compound in development.
The Company has filed patent applications covering the treatment of cancer with LB-100. The Company has also filed joint patent applications
with the NIH and the Netherlands Cancer Institute for the treatment of cancer using LB-100 in combination with other drugs, including,
but not limited to, immune checkpoint inhibitors and WEE1 inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications for the LB-100 series (oxabicycloheptanes and heptenes) have been filed in the United States and internationally under the
Patent Cooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in the United
States, Mexico, Australia, Japan, China, Hong Kong, Canada, Germany, France, the United Kingdom, and by the European Patent Office and
the Eurasian Patent Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we do not plan to allocate resources to further develop our LB-200 series of drug candidates, we decided to abandon patents that cover
sole rights to the composition and synthesis of the LB-200 series of drugs, with coverage of the LB-200 series now limited to maintenance
of those patents issued in the United States. We also decided to abandon patents that cover rights in treating other diseases than cancer,
including, but not limited to, diabetes, neurodegenerative disease and reperfusion injury.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company strives to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the
development of its business, including seeking, maintaining, and defending its patent rights, which are owned solely by our wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc., except in several&#160; instances where they are jointly owned with one of our collaborators.
The Company also relies on trade secrets relating to its proprietary pipeline of product candidates and on know-how and continuing technological
innovation to develop and strengthen its pipeline. The Company intends to rely on regulatory protection afforded by regulatory agencies
through data exclusivity, market exclusivity, and patent term extensions, where available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in large part on its ability to obtain and maintain patent and other proprietary protection for commercially
important technology, inventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of
its trade secrets; and operate without infringing valid and enforceable patents or proprietary rights of third parties. The Company&#8217;s
ability to stop third parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to
which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases,
enforcement of these rights may depend on cooperation of the owners of our jointly owned patents and patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to both the Company&#8217;s solely and jointly owned intellectual property, the Company cannot be sure that patents will be granted
on any of its pending patent applications or on any patent applications filed solely or jointly by the Company in the future; we cannot
be sure that any of the Company&#8217;s existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting the Company&#8217;s intended commercial products or therapeutic methods; and the Company cannot be sure that an
agency or court would determine that the Company&#8217;s solely or jointly owned patents are valid and enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolios for the Company&#8217;s most important programs involving the development of the LB-100 series are summarized and presented
below, along with related information, as of December 31, 2023, followed by a detailed listing of U.S. and non-U.S. patents that have
been issued. The projected patent expiration dates assume that that all required maintenance or annuity fees for the patents are timely
paid and that a court or agency does not determine that the patents are invalid or unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company appointed a new President and Chief Executive Officer, who, with the assistance of the Company&#8217;s management,
Board of Directors and patent legal counsel, conducted a comprehensive analysis of the Company&#8217;s extensive patent portfolio in order
to implement a program to balance patent prosecution costs with intellectual property protection benefits. As a result, the Company identified
certain patent filings that it does not intend to continue to support in 2024 and thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100</i></b>.
The Company&#8217;s lead compound LB-100 is covered by U.S. Patent Nos. 8,822,461 and 7,998,957, which are solely owned by Lixte Biotechnology,
Inc., the Company&#8217;s wholly-owned subsidiary. These patents are projected to expire in 2030 or 2028, exclusive of any available
patent term extension. Counterpart non-U.S. patents are projected to expire in 2028. Pharmaceutical compositions of LB-100 are covered
by U.S. Patent Nos. 10,532,050, 10,023,587 and 8,822,461, which are solely owned by Lixte Biotechnology, Inc. These patents and their
non-U.S. counterparts are projected to expire in 2034 or 2028, exclusive of any available patent term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with a Checkpoint Inhibitor</i></b>. LB-100 combination therapy with a checkpoint inhibitor for treating cancer is
covered by a pending U.S. patent application and by non-U.S. patents and patent applications. These patents and patent applications are
jointly owned by Lixte Biotechnology, Inc., and The United States of America, as represented by the Secretary, Department of Health and
Human Services. These patents and patents issuing from these patent applications are projected to expire in 2037, exclusive of any patent
term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with Carboplatin, Etoposide and Atezolizumab</i></b>. LB-100 combination therapy with carboplatin, etoposide and
atezolizumab for treating small-cell lung cancer is covered by pending U.S., and non-U.S.&#160; patent applications that are solely owned
by Lixte Biotechnology, Inc. Patents issuing from these patent applications are projected to expire in 2041, exclusive of any patent
term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with Another Investigational Compound</i></b>. LB-100 combination therapy with one of several other investigational
compounds for treating cancer, or preventing, inhibiting or reducing risk of metastasis of the cancer, is covered by pending U.S. and
non-U.S. patent applications that are jointly owned by Lixte Biotechnology, Inc., and Stichting Het Nederlands Kanker Instituut &#8211;
Antoni Van Leeuwenhoek Ziekenhuis. Patents issuing from these patent applications are projected to expire in 2043, exclusive of any patent
term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
for Treating Cancer</i></b>. LB-100 for treating breast cancer, colon cancer, large cell lung cancer, adenocarcinoma of the lung, small
cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyelocytic leukemia,
chronic myelocytic leukemia or acute lymphocytic leukemia, is covered by U.S. Patent No. 9,079,917, which is solely owned by Lixte Biotechnology,
Inc. This patent and its non-U.S. counterparts are projected to expire in 2028, exclusive of any patent term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Prodrugs and Analogs</i></b>. LB-100 prodrugs and analogs are covered by U.S. Patent Nos. 10,618,908, 9,988,394, 8,822,461, 8,227,473
and 7,998,957, which are solely owned by Lixte Biotechnology, Inc. These patents and their non-U.S. counterparts are projected to expire
in 2036, 2030 or 2028, exclusive of any patent term extension. Pharmaceutical compositions of LB-100 prodrugs or analogs are covered
by U.S. Patent Nos. 11,931,354 ,11,236,102, 10,532,050, 10,023,587, 8,822,461, 8,227,473 and 7,998,957, which are solely owned by Lixte
Biotechnology, Inc. These patents and their non-U.S. counterparts are projected to expire in 2034, 2030 or 2028, exclusive of any patent
term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio of solely or jointly owned U.S. and non-U.S. issued patents is summarized below&#160;. We have additional U.S. and non-U.S.
patent applications pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100
Series of Compounds - Phosphatase Inhibitors &#8211; Composition and Use in Cancer Treatment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxabicycloheptanes
and Oxabicycloheptenes, Their Preparation and Use</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 64%">Patent</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 16%">Issue/Grant Date</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: center">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AU 2008214299</td><td>&#160;</td>
    <td style="text-align: right">1/19/2014</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>CA 2,676,422</td><td>&#160;</td>
    <td style="text-align: right">10/16/2018</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>CN 101662939</td><td>&#160;</td>
    <td style="text-align: right">11/25/2015</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>CN 103788108</td><td>&#160;</td>
    <td style="text-align: right">4/12/2017</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>EP 2124550</td><td>&#160;</td>
    <td style="text-align: right">4/19/2017</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>EA 023804</td><td>&#160;</td>
    <td style="text-align: right">7/29/2016</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>JP 5693850</td><td>&#160;</td>
    <td style="text-align: right">4/1/2015</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 7,998,957</td><td>&#160;</td>
    <td style="text-align: right">8/16/2011</td><td>&#160;</td>
    <td style="text-align: right">2/20/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 8,426,444</td><td>&#160;</td>
    <td style="text-align: right">4/23/2013</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 8,227,473</td><td>&#160;</td>
    <td style="text-align: right">7/24/2012</td><td>&#160;</td>
    <td style="text-align: right">3/11/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 8,541,458</td><td>&#160;</td>
    <td style="text-align: right">9/24/2013</td><td>&#160;</td>
    <td style="text-align: right">7/17/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 8,822,461</td><td>&#160;</td>
    <td style="text-align: right">9/2/2014</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 9,079,917</td><td>&#160;</td>
    <td style="text-align: right">7/14/2015</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 10,023,587</td><td>&#160;</td>
    <td style="text-align: right">7/17/2018</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 10,399,993</td><td>&#160;</td>
    <td style="text-align: right">9/3/2019</td><td>&#160;</td>
    <td style="text-align: right">2/6/2028</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulations
of Oxabicycloheptanes and Oxabicycloheptenes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 66%">Patent</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Issue/Grant Date</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AU 2014251087</td><td>&#160;</td>
    <td style="text-align: right">5/2/2019</td><td>&#160;</td>
    <td style="text-align: right">4/8/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>CN 105209036</td><td>&#160;</td>
    <td style="text-align: right">10/26/2018</td><td>&#160;</td>
    <td style="text-align: right">4/8/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>IL 241945</td><td>&#160;</td>
    <td style="text-align: right">4/30/2019</td><td>&#160;</td>
    <td style="text-align: right">4/8/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 10,532,050</td><td>&#160;</td>
    <td style="text-align: right">1/14/2020</td><td>&#160;</td>
    <td style="text-align: right">7/5/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 11,931,354</td><td>&#160;</td>
    <td style="text-align: right">3/19/2024</td><td>&#160;</td>
    <td style="text-align: right">4/8/2034</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
of Synthesizing 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabicyclo [2.2.1] Heptane-2-Carboxylic Acid</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 66%">Patent</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Issue/Grant Date</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 9,994,584</td><td>&#160;</td>
    <td style="text-align: right">6/12/2018</td><td>&#160;</td>
    <td style="text-align: right">10/14/2035</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protein
Phosphatase 2A Inhibitors for Treating Myelodysplastic Syndromes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 66%">Patent</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Issue/Grant Date</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>JP 6453441</td><td>&#160;</td>
    <td style="text-align: right">1/16/2019</td><td>&#160;</td>
    <td style="text-align: right">7/23/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 10,071,094</td><td>&#160;</td>
    <td style="text-align: right">9/11/2018</td><td>&#160;</td>
    <td style="text-align: right">7/23/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 10,434,100</td><td>&#160;</td>
    <td style="text-align: right">10/8/2019</td><td>&#160;</td>
    <td style="text-align: right">7/23/2035</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxabicycloheptane
Prodrugs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 66%">Patent</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Issue/Grant Date</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 13%">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AU 2016263079</td><td>&#160;</td>
    <td style="text-align: right">8/15/2019</td><td>&#160;</td>
    <td style="text-align: right">5/12/2036</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>EP 3294287</td><td>&#160;</td>
    <td style="text-align: right">4/8/2020</td><td>&#160;</td>
    <td style="text-align: right">5/12/2036</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>IL 255516</td><td>&#160;</td>
    <td style="text-align: right">2/27/2020</td><td>&#160;</td>
    <td style="text-align: right">5/12/2036</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 9,988,394</td><td>&#160;</td>
    <td style="text-align: right">6/5/2018</td><td>&#160;</td>
    <td style="text-align: right">5/13/2036</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>US 10,364,252</td><td>&#160;</td>
    <td style="text-align: right">7/30/2019</td><td>&#160;</td>
    <td style="text-align: right">5/13/2036</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>US 10,618,908</td><td>&#160;</td>
    <td style="text-align: right">4/14/2020</td><td>&#160;</td>
    <td style="text-align: right">5/13/2036</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Cancer
Drugs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the mechanism by which compounds of the LB-100 series affects cancer cell growth is different from cancer agents currently
approved for clinical use. Lead compounds of the LB-100 series have activity against a broad spectrum of common and rarer human cancers
in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma
multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Lead compounds of the LB-100 series also have activity
against melanoma, breast cancer and sarcoma in animal models and enhance the effectiveness of commonly used anti-cancer drugs in animal
models. The enhancement of anti-cancer activity of these commonly-used anti-cancer drugs occurs at doses of LB-100 that do not significantly
increase toxicity in animals. It is therefore hoped that when combined with standard anti-cancer regimens against many tumor types, LB-100
will improve therapeutic benefit without unacceptable toxicity in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary goal to date has been to take our primary compound, LB-100, through Phase 2 clinical trials evaluating whether LB-100 will enhance
anti-cancer therapies. Because of the novelty and spectrum of activity of LB-100, we believe it is reasonably likely we may find a partner
in the pharmaceutical industry with interest in this compound at some stage of its clinical development. However, we would prefer to
delay the partnering/licensing decision until the potential value of our products are augmented by demonstrating there is no impediment
to clinical evaluation and a therapeutic dose level is determined in clinical trials. Demonstration of clinical usefulness would be expected
to substantially increase the value of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
development of lead compounds in addition to LB-100 will require pharmacokinetic/ pharmacodynamic characterization (i.e., how long a
drug persists in the blood and how long the drug is active at the intended target) and large animal toxicologic evaluation under conditions
meeting FDA requirements. Most anti-cancer drugs fail in development because of unacceptable toxicity. However, by analogy with mechanistically
related compounds, there is good reason to believe that lead compounds in addition to LB-100 will be able to be given to humans safely
by routes and at doses resulting in concentration of drug producing anti-cancer activity in animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to FDA regulations as it conducts clinical trials. Additionally, any product for which we obtain marketing approval, along
with the manufacturing processes, post-approval clinical data and promotional activities for such product, will be subject to continual
review and periodic inspections by the FDA and other regulatory bodies. Even if regulatory approval of a product is granted, the approval
may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for costly post-marketing
testing and surveillance to monitor the safety or efficacy of the product. Later discovery of previously unknown problems with our products,
including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturer or manufacturing processes,
or failure to comply with regulatory requirements, may result in restrictions on such products or manufacturing processes, withdrawal
of the products from the market, voluntary or mandatory recall, fines, suspension of regulatory approvals, product seizures, injunctions
or the imposition of civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
life sciences industry is highly competitive and subject to rapid and profound technological change. Our present and potential competitors
include major pharmaceutical companies, as well as specialized biotechnology and life sciences firms in the United States and in other
countries. Most of these companies have considerably greater financial, technical and marketing resources than we do. Additionally, mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated in our competitors.
Our existing or prospective competitors may develop processes or products that are more effective than ours or be more effective at implementing
their technologies to develop commercial products faster. Our competitors may succeed in obtaining patent protection and/or receiving
regulatory approval for commercializing products before we do. Developments by our competitors may render our product candidates obsolete
or non-competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also experience competition from universities and other research institutions, and we are likely to compete with others in acquiring
technology from those sources. There can be no assurance that other organizations will not develop technologies with significant advantages
over those that we are seeking to develop. Any such development could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete with universities and other research institutions engaged in research in these areas. Many of our competitors have greater technical
and financial resources than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete successfully is based on numerous factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost-effectiveness of any product that we ultimately commercialize relative to competing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ease of use and ready availability of any product that we bring to market; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative speed with which we are able to bring any product resulting from its research to market in our target markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to distinguish our products from competing products, or if competing products reach the market first, we may be unable
to compete successfully with current or future competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees
and Human Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2024, we had three full-time officer/employees and one part-time officer/employee. The Company relies to a significant extent
on outside consultants and advisors with various technical skills and expertise that the Company can draw on as necessary to conduct
its research and development and clinical trial programs. We consider our relationship with our employees to be good. Our future performance
depends significantly upon the continued service of our key personnel and our ability to attract highly skilled employees. We provide
our employees with opportunities for equity ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2024, we do not operate any facilities. We contract out research and development activities, drug production, and drug storage
to various commercial laboratories, drug manufacturers and storage facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to the regulations of the FDA as it conducts clinical trials. Clinical trials are research studies to answer specific
questions about new therapies or new ways of using known treatments. Clinical trials determine whether new drugs or treatments are both
safe and effective and the FDA has determined that carefully conducted clinical trials are the fastest and safest way to find treatments
that work in people.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also requires that an independent review body consider the benefits and risks of a clinical trial and grant approval for the proposed
study including selecting of initial doses, plans for escalation of dose, plans for modification of dose if toxicity is encountered,
plans for monitoring the wellbeing of individuals participating in the study, and for defining and measuring, to the extent possible,
any untoward effects related to drug administration. Serious adverse effects, such as life-threatening toxicities and death, are immediately
reportable to the review body and to the FDA. To minimize risk when studying a new drug, the initial dose is well below that expected
to cause any toxicity. No more than three patients are entered at a given dose. In general, a dose is not escalated within an individual
patient. Once safety is established by the absence of toxicity or low toxicity in a group of three patients, a planned higher dose is
then evaluated in a subsequent group of three individuals and so on until dose-limiting toxicity is encountered. The dose level producing
acceptable toxicity is then selected as the dose level to be evaluated in Phase 2 trials. Thus, the goal of Phase 1 studies is to determine
the appropriate dose level for evaluation of drug efficacy in patients with cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations imposed by the FDA, depending on our future activities, we may become subject to regulation under various federal
and state statutes and regulations, such as the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances
Control Act, the Research Conservation and Recovery Act, national restrictions on technology transfer, and import, export and customs
regulations. From time to time, other federal agencies and congressional committees have indicated an interest in implementing further
regulation of biotechnology applications. We are not able to predict whether any such regulations will be adopted or whether, if adopted,
such regulations will apply to our business, or whether we or our collaborators would be able to comply with any applicable regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as we intend to market our products in international markets, we will be required to obtain separate regulatory approvals from
the European Union and many other foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory authorities in other
countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries
or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products
in any market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. We are not currently subject
to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="p_001"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following risk factors, together with the other information presented in this document, including the financial statements and the notes
thereto, should be considered by investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Resources and Capital Needs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to develop LB-100 in combination with other anti-cancer therapies to treat cancer. We are seeking to do
so through our internal research programs or strategic partnerships. A significant portion of the research and development that we are
conducting involves new and unproven technologies. Research programs to identify new disease targets and product candidates or to develop
them require substantial technical, financial and human resources whether or not any candidates or technologies are ultimately identified
or proven successful. Our research programs might initially show promise in identifying potential product candidates, yet fail to yield
product candidates for clinical development for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research methodology used might not be successful in identifying potential product candidates; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates for drugs might on further study be shown to have harmful side effects or other characteristics that indicate they are
    unlikely to be effective drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to discover suitable potential product candidates, develop additional delivery technologies through internal research programs
or strategic partnerships, or in-license suitable products or delivery technologies on acceptable business terms, our business prospects
will suffer. Even if we discover additional product candidates, new clinical trials of one or more additional drug candidates may show
that these product candidates are unsafe or ineffective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common
diseases and then design novel compounds to attack those threats. We do not have any products approved by a regulatory authority and
have not generated any revenue from collaboration or licensing agreements or product sales to date, and have incurred significant research,
development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have
not been profitable and have incurred significant operating losses since our inception. For the years ended December 31, 2023 and 2022,
we reported a net loss of $5,087,029 and $6,312,535, respectively. As of December 31, 2023 and 2022, we had an accumulated deficit of
$48,481,728 and $43,394,699, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to generate revenues for many years, if at all. We expect to continue to incur significant expenses and operating losses
for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals
for one or more of our product candidates and any additional product candidates we might acquire, and potentially begin to commercialize
product candidates that might achieve regulatory approval. We might also encounter unforeseen expenses, difficulties, complications,
delays and other unknown factors that could adversely affect our business. The size of our future net losses will depend, in part, on
the rate of future growth of our expenses and our ability to generate revenues. Our expenses will further increase as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    clinical trials of our lead product candidate, LB-100;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in-license
    or acquire rights to, and pursue development of, other products, product candidates or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, manufacturing, quality control, quality assurance and scientific personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    marketing approval for any product candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    our outsourced manufacturing and commercial activities and establish sales, marketing and distribution capabilities, if we receive,
    or expect to receive, marketing approval for any product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    operational, financial and management information systems and personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception, and management has determined that substantial doubt exists about
the Company&#8217;s ability to continue as a going concern. As a result, our independent registered public accounting firm has included
an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated financial statements
as of and for the year ended December 31, 2023. This going concern opinion could materially limit our ability to raise additional funds
through the sale of equity securities in the future, and subsequent reports by our independent registered public accounting firm on our
consolidated financial statements may also include an explanatory paragraph with respect to our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of
our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our
product development programs or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our existing cash resources as of December 31, 2023 will provide sufficient working capital resources to fund our operations,
including our clinical trial programs with respect to the development of our lead anti-cancer clinical compound LB-100, through approximately
September 30, 2024. Our existing cash resources will not be sufficient to complete development of and obtain regulatory approval for
our lead product candidate, and we will need to raise significant additional capital to be able to continue our efforts in this regard.
The Company estimates that it will need to raise additional capital to fund its operations by mid-2024, including its various clinical
trial commitments, to be able to proactively manage its current business plan during the remainder of 2024 and during 2025. In addition,
our operating plan might change as a result of many factors currently unknown to us, including possible additional clinical trials, and
we might need additional funds sooner than planned. The Company is considering various strategies and alternatives to obtain the required
additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to expend substantial resources for the foreseeable future to continue the clinical development and manufacturing of our lead
product candidate and the advancement and expansion of our preclinical research pipeline. These expenditures will include costs associated
with research and development, potentially acquiring new product candidates or technologies, conducting preclinical studies and clinical
trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved
for sale, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Budgets
and future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of our ongoing and planned development programs for our lead product candidate, as well as any
    additional clinical trials we undertake to obtain data sufficient to seek marketing approval for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of, and the costs involved in, obtaining regulatory approvals for our lead drug candidate if our clinical trials are successful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities for our lead product candidate, if it is approved for sale, including marketing, sales and distribution
    costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing our lead product candidate for clinical trials in preparation for regulatory approval, including the cost and
    timing of process development, manufacturing scale-up and validation activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to in-license future product candidates or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation
    costs and the outcome of such litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs in defending and resolving future derivative and securities class action litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing technologies or other adverse market developments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds might not be available when we need them on terms that are acceptable to us, or at all. We have no committed source of additional
capital. If adequate funds are not available to us on a timely basis, we might not be able to continue as a going concern or we might
be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product
candidates or target indications, or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other
activities that may be necessary to commercialize our lead product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no source of revenues. We might never generate revenues or achieve profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not generate any revenues from product sales or otherwise. Even if we are able to successfully achieve regulatory approval for
our lead product candidate, we do not know when we will generate revenues or become profitable, if at all. Our ability to generate revenues
from product sales and achieve profitability will depend on our ability to successfully commercialize products, including our lead product
candidate, LB-100, and any other product candidates that we might develop, in-license or acquire in the future. Our ability to generate
revenues and achieve profitability also depends on a number of additional factors, including our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    complete development activities, including the necessary clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    and submit a New Drug Application (&#8220;NDA&#8221;) to the FDA and obtain U.S. regulatory approval for an indication for which
    there is a commercial market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    and submit applications to foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval in territories with viable market sizes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate reimbursement from third parties, including government and private payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
    commercially viable prices for our intended product, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with reliable third parties and/or build our own manufacturing facility and ensure
    adequate, legally and globally compliant manufacturing of bulk drug substances and drug products to maintain that supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    distribution processes for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    commercial quantities of our lead product candidate, once approved, at acceptable cost levels; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    additional funding, if required to develop and commercialize our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves, in the markets
    in which we choose to commercialize on our own;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance of one or more of our intended products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect
    our rights in our intellectual property portfolio.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets
in the territories for which it gains regulatory approval, the accepted price for the product, the ability to get reimbursement at any
price, and whether we own the commercial rights for that territory. If the number of our addressable-disease patients is not as significant
as our estimates, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population
for treatment is narrowed by competition, physician choice or treatment guidelines, we might not generate significant revenues from sales
of such products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved
product candidate. As a result, even if we generate revenues, we might not become profitable and might need to obtain additional funding
to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we might be
unable to continue our operations at planned levels and might be forced to reduce our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use net operating losses to offset future taxable income might be subject to limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$28,111,000 and $32,617,000, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period, but the
deductibility of such federal NOL&#8217;s may be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $19,141,000 that were incurred in the State of New York and approximately $13,476,000
that were incurred in the State of California, which are subject to various restrictions and limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Development and Regulatory Approval of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical-stage
biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might entail
substantial risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a lead product candidate in clinical development. The success of our lead product
candidate will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing,
    conducting and successfully completing preclinical development activities, including preclinical efficacy and IND-enabling studies,
    for our lead product candidate or product candidates that we might, in the future, in-license or acquire;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing,
    conducting and completing clinical trials with positive results for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of regulatory approvals from applicable authorities;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements with third party manufacturers, receiving regulatory approval of our manufacturing processes and our third party manufacturers&#8217;
    facilities from applicable regulatory authorities and ensuring adequate supply of drug product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    our lead product candidate at an acceptable cost;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    launching commercial sales of our lead product candidate, if approved, whether alone or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    acceptance of our lead product candidate, if approved, by patients, the medical community and third party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    competing with other therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our lead product candidate is approved, obtaining and maintaining coverage and adequate reimbursement by third party payors, including
    government payors, for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with all applicable regulatory requirements, including FDA current Good Clinical Practices (&#8220;GCP&#8221;), Current Good Manufacturing
    Practices (&#8220;CGMP&#8221;), and standards, rules and regulations governing promotional and other marketing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the lead product candidate during development and following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully develop and commercialize our lead product candidate, which could materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our product
candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our lead product candidate is essential to our success. The timing of our
clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our lead product candidate,
and we might experience delays in our clinical trials if we encounter difficulties in enrollment. If we experience delays in our clinical
trials, the timeline for obtaining regulatory approval of our lead product candidate will most likely be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
factors might affect our ability to identify, enroll and maintain qualified patients, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
    criteria of our ongoing and planned clinical trials with specific characteristics appropriate for inclusion in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
    of the clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&#8217;
    perceptions as to risks and benefits of the lead product candidate under study and the participation in a clinical trial generally
    in relation to other available therapies, including any new drugs that might be approved for the indications we are investigating;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability and efficacy of competing therapies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pendency
    of other trials underway in the same patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">willingness
    of physicians to participate in our planned clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    of patients to clinical sites;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    who are noncompliant or do not otherwise complete the trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    with a contract research organization (a &#8220;CRO&#8221;) and/or with other vendors that are involved with our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not be able to initiate or continue to support clinical trials of LB-100, our lead product candidate, for one or more indications,
or any future product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these trials as
required by the FDA or one or more other regulatory authorities. Even if we are able to enroll a sufficient number of patients in our
clinical trials, if the pace of enrollment is slower than we expect, the development costs for our lead product candidate might increase
and the completion of our trials might be delayed or our trials could become too expensive to complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trials of our lead product candidate, the commercial prospects
of our lead product candidate could be harmed, and our ability to generate product revenue from any of our product candidates could be
delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product
candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences
might harm our business, financial condition, and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our lead product candidate
in clinical trials, and any other product candidates that might advance into clinical trials, might not have favorable results in later
clinical trials or receive regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate
the efficacy and safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including
those with greater resources and experience than we have, have suffered significant setbacks in clinical trials, even after seeing promising
results in earlier preclinical studies or clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the results reported in earlier preclinical studies or clinical trials for our lead product candidate, we do not know whether the clinical
trials that we might conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our lead product
candidate for a particular indication, in any particular jurisdiction. Efficacy data from prospectively designed trials might differ
significantly from those obtained from retrospective subgroup analyses. If later-stage clinical trials do not produce favorable results,
our ability to achieve regulatory approval for our lead product candidate might be adversely impacted. Even if we believe that we have
adequate data to support an application for regulatory approval to market our lead product candidate or any future product candidates,
the FDA or other regulatory authorities might not agree and might require that we conduct additional clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, with the outcome inherently uncertain. Failure can occur at any time during
the clinical trial process. Before obtaining approval from regulatory authorities for the sale of our lead product candidate, we must
conduct extensive clinical trials to demonstrate the safety and efficacy of our lead product candidate in humans. Prior to initiating
clinical trials, a sponsor must complete extensive preclinical testing of a product candidate, including, in most cases, preclinical
efficacy experiments as well as IND-enabling toxicology studies. These experiments and studies might be time-consuming and expensive
to complete. The necessary preclinical testing might not be completed successfully for a preclinical product candidate and a potentially
promising product candidate might therefore never be tested in humans. Once it commences, clinical testing is expensive, difficult to
design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur
at any stage of testing. The outcome of preclinical testing and early clinical trials might not be predictive of the success of later
clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We
might experience numerous unforeseen events during drug development that could delay or prevent our ability to receive marketing approval
or commercialize our lead product candidate. In particular, clinical trials of our lead product candidate might produce inconclusive
or negative results. We have limited data regarding the safety, tolerability and efficacy of our lead product candidate. Clinical trials
also require the review and oversight of an institutional review board (&#8220;IRB&#8221;). An inability or delay in obtaining IRB approval
could prevent or delay the initiation and completion of clinical trials, and the FDA might decide not to consider any data or information
derived from a clinical investigation not subject to initial and continuing IRB review and approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might experience delays in our ongoing or future clinical trials, and we do not know whether planned clinical trials will begin or enroll
subjects on time, will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA or another
regulatory agency will not put clinical trials of our lead product candidate on hold in the future. Clinical trials might be delayed,
suspended or prematurely terminated for a variety of reasons, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in reaching agreement with the FDA or a foreign regulatory authority on a clinical trial design that we are able to execute;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority
    regarding the scope or design of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject
    to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in obtaining IRB approval or the approval of other reviewing entities, including comparable foreign regulatory authorities,
    to conduct a clinical trial at each site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial sites from our clinical trials or the ineligibility of a site to participate in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in subjects completing a trial or returning for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or
    dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs,
    including some that may be for the same indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third party clinical trial managers, CROs, clinical trial sites, contracted laboratories or other third party vendors to satisfy
    their contractual duties, meet expected deadlines or return trustworthy data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in adding new trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interim
    results or data that are ambiguous or negative or are inconsistent with earlier results or data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alteration
    of trial design necessitated by re-evaluation of design assumptions based upon observed data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">feedback
    from the FDA, the IRB or a foreign regulatory authority, or results from earlier stage or concurrent preclinical studies and clinical
    trials, that might require modification to the protocol for a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decision by the FDA, the IRB, a foreign regulatory authority, or us to suspend or terminate clinical trials at any time for safety
    issues or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unacceptable
    risk-benefit profile, unforeseen safety issues or adverse side effects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate a benefit from using a product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in manufacturing, obtaining, from one or more third parties, or qualifying sufficient quantities of a product candidate to start
    or to use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue a trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct
    additional studies or increased expenses associated with the services of our CROs and other third parties; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in governmental regulations or administrative actions or lack of adequate funding to continue a clinical trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion or termination of any clinical trial of our lead product candidate, the approval and commercial
prospects of our lead product candidate will be harmed, delaying our ability to generate product revenues from such product candidate
and our costs will most likely increase. The required regulatory approvals may also be delayed, thereby jeopardizing our ability to commence
product sales and generate revenues and the period of commercial exclusivity for our intended product may be shortened. Regulatory approval
of our lead product candidate may be denied for the same reasons that caused the delay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
associated with operating in foreign countries could materially adversely affect our product development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an agreement to conduct a clinical trial in Spain. Consequently, we will also be subject to risks related to operating
in foreign countries. Risks associated with conducting operations in foreign countries include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    stringent privacy requirements for data to be supplied to our operations in the United States, but generated outside of the United
    States, e.g., General Data Protection Regulation in the European Union;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers and regulatory requirements; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign countries, economies or markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding or payroll taxes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to
    doing business or operating in another country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geopolitical actions or events, including civil or political unrest (such as the ongoing conflict between
    Ukraine and Russia), sanctions, war and terrorism.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or
have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result
in significant negative consequences following any regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our current or future product candidates, their delivery methods or dosage levels could cause us, our collaborators
or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial
of regulatory approval or termination of clinical trials by the FDA or other foreign regulatory authorities; or an IRB, that approves
and, monitors biomedical research to protect the rights and welfare of human subjects. As a result of safety or toxicity issues that
we might experience in our clinical trials, or negative or inconclusive results from the clinical trials of others for drug candidates
that might be similar to our own, we might not receive approval to market our current lead product candidate or any product candidates
we may pursue, which could prevent us from ever generating revenues or achieving profitability. Results of our trials could reveal an
unacceptably high severity or incidence of side effects. In such an event, our trials or those or our collaborators could be suspended
or terminated, and the FDA or foreign regulatory authorities could order us or our collaborators to cease further development of or deny
approval of our current or any future product candidates for any or all targeted indications. Any drug-related side effects could also
affect patient recruitment or the ability of enrolled subjects to complete clinical trials or result in potential product liability claims.
Any of these occurrences could have a material adverse effect on our business, results of operations, financial condition, cash flows
and future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if our lead product candidate receives regulatory approval, and we or others later identify undesirable side effects caused by such product,
a number of potentially significant negative consequences could result, including that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be forced to suspend marketing of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities might withdraw their approvals of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities might require additional warnings on the label that could diminish the usage or otherwise limit the commercial success
    of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to conduct post-marketing studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to subjects or patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our lead product candidate, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more patients
and for greater periods of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration
of exposure, we cannot be fully assured that rare and severe side effects of our lead product candidate will be uncovered. Such rare
and severe side effects might only be uncovered with a significantly larger number of patients exposed to our lead product candidate.
If such safety problems occur or are identified after our lead product candidate reaches the market, the FDA might require that we amend
the labeling of the product or recall the product, or might even withdraw approval for the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success is dependent on the regulatory approval of our lead product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is dependent on our ability to obtain regulatory approval for our lead product candidate in a timely manner. We cannot commercialize
our lead product candidate in the United States without first obtaining regulatory approval for the product from the FDA. Similarly,
we cannot commercialize our lead product candidate outside of the United States without obtaining regulatory approval from one or more
foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our lead product candidate for a target
indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, that the product candidate
is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with
respect to such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and foreign regulatory authorities is unpredictable but typically takes many years following
the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of
the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval
may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product candidate were to successfully obtain approval from the FDA and one or more foreign regulatory authorities, any approval
might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications,
or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our lead product
candidate or any future product candidates we may pursue, once obtained, may be withdrawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
lead product candidate and future product candidates could fail to receive regulatory approval from the FDA.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not obtained regulatory approval for our lead product candidate, and it is possible that our lead product candidate or any future
product candidates will not obtain regulatory approval, for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the regulatory authorities regarding the scope, design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate that a product candidate is safe and effective for our proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of clinical trials to meet the level of statistical significance required for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    insufficiency of data collected from clinical trials of our lead product candidate to support the submission and filing of an NDA
    or other submission or to obtain regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to obtain approval of our manufacturing processes or facilities of third party manufacturers with whom we contract for clinical and
    commercial supplies or our own manufacturing facility; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or a foreign regulatory authority might require more information, including additional preclinical or clinical data, to support approval
or additional studies, which might delay or prevent approval or our commercialization plans, or we might decide to abandon the development
program. The FDA or a foreign regulatory authority might also require the manufacture of a new lead product candidate in accordance with
new or revised standards. If we were to obtain approval, regulatory authorities might approve our lead product candidate and any future
product candidates we might pursue for fewer or more limited indications than we request (including failing to approve the most commercially
promising indications), might grant approval contingent on the performance of costly post-marketing clinical trials, or might approve
a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization
of that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain regulatory approval for our lead product candidate in one or more jurisdictions, or if any approval contains
significant limitations, we might not be able to obtain sufficient funding to continue the development of that product or generate revenues
attributable to that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, to market and sell our lead product candidate in the European Union, in the United Kingdom,
in many Asian countries and in other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying
regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions,
and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries
or jurisdictions or by the FDA. The regulatory approval process outside the United States generally includes all of the risks associated
with obtaining FDA approval as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. The approval
procedure varies among countries and can require additional data or involve additional testing. The time required to obtain foreign approval
may differ substantially from that required to obtain FDA approval. We might not be able to obtain approvals from regulatory authorities
outside the United States on a timely basis, if at all. Clinical trials accepted in one country might not be accepted by regulatory authorities
in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before
it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country might not receive
reimbursement approval in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not be able to file for regulatory approvals and might not receive necessary approvals to commercialize our intended product in
any market. If we are unable to obtain approval of any of our current product candidate or any future product candidates we might pursue
by regulatory authorities in the European Union, United Kingdom, Asia or elsewhere, the commercial prospects of that product candidate
might be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results
of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our current primary product candidate received regulatory approval, it might still face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our lead product candidate, LB-100, that approval would be subject to ongoing requirements by the
FDA and foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage,
distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety
and other post-marketing information. These requirements can include submissions of safety and other post-marketing information and reports,
registration, as well as continued compliance by us and/or our CMOs and CROs for any post-approval clinical trials that we or our collaborators
might conduct. The safety profile of any product will continue to be closely monitored by the FDA and foreign regulatory authorities
after approval. If the FDA or foreign regulatory authorities become aware of new safety information after approval of our lead product
candidate, they might require labeling changes or establishment of a risk evaluation and mitigation strategy, impose significant restrictions
on such product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and
other regulatory authorities for compliance with CGMP, GCP, and other regulations. If we, a collaborator or a regulatory agency discover
previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured, a regulatory agency might impose restrictions on that product, the manufacturing facility or us, including
requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our lead product candidate or the
manufacturing facilities for our lead product candidate fail to comply with applicable regulatory requirements, a regulatory agency might:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters or untitled letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandate
    modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due
    dates for specific actions and penalties for noncompliance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to applications filed by us or a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above might inhibit our ability to successfully commercialize our intended product and generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of any product candidate that obtains approval in the United States is heavily scrutinized by the FDA, the Department of
Justice, the Office of Inspector General of Health and Human Services, state attorneys general, members of Congress and the public. A
company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance
with the provisions of the approved label. Additionally, advertising and promotion of any product candidate that obtains approval outside
of the United States is heavily scrutinized by foreign regulatory authorities. Violations, including actual or alleged promotion of our
intended product for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal
sanctions by the FDA, as well as prosecution under the federal False Claims Act. Any actual or alleged failure to comply with labeling
and promotion requirements can have a negative impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Dependence on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could adversely
affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#8217;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors. Dr. Kovach was also the Company&#8217;s Chief Scientific Officer.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our success depended, in part, on the continued availability and contributions of Dr. Kovach, we were able to replace Dr. Kovach on a
timely basis with a qualified replacement in Mr. van der Baan. Furthermore, recruiting and retaining qualified scientific personnel to
perform future research and development work is critical to our success. Our inability to attract or retain qualified personnel or advisors
in the future could significantly weaken our management, harm our ability to compete effectively, and harm our business. The competition
for qualified personnel in the pharmaceutical field is intense and, as a result, we might be unable to attract and retain qualified personnel
necessary for the development of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we employ Dr. James S. Miser on a half-time basis as Chief Medical Officer, and we promoted Eric J. Forman to Vice President and Chief
Operating Officer on November 6, 2022. We believe that Dr. Miser and Mr. Forman, led by Mr. van der Baan as President and Chief Executive
Officer, are capable of managing the Company&#8217;s research and clinical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are not
successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain regulatory approval for the commercial sale of our product candidates, we or our collaborators will be required to complete
extensive preclinical studies as well as clinical trials in humans to demonstrate to the FDA and foreign regulatory authorities that
our product candidates are safe and effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miser is experienced in the design and conduct of early stage clinical trials. However, we expect to rely on collaborative partners and
CROs for their performance and management of clinical trials of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intended products under development might not be effective in treating any of our targeted disorders or might prove to have undesirable
or unintended side effects, toxicities or other characteristics that might prevent or limit their commercial use. Institutional review
boards or regulators, including the FDA, might hold, suspend or terminate our clinical research or the clinical trials of our product
candidates for various reasons, including non-compliance with regulatory requirements or if, in their opinion, the participating subjects
are being exposed to unacceptable health risks. Additionally, failure of third parties conducting or overseeing the operation of the
clinical trials to perform their contractual or regulatory obligations in a timely fashion could delay the clinical trials. Failure of
clinical trials can occur at any stage. Any of these events would adversely affect our ability to market a product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development process necessary to obtain regulatory approval is lengthy, complex and costly. If we or our collaborative partners do not
obtain necessary regulatory approvals, then our business would not be successful, and the market price of our common stock could decline
substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we, or our collaborative partners, are able to successfully advance a product candidate through the clinic, we, or such
partner, will be required to obtain regulatory approval prior to marketing and selling such product. The process of obtaining FDA and
other required regulatory approvals is costly and lengthy. The time required for FDA and other approvals is uncertain and can typically
take several or many years, depending on the complexity and novelty of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approval to market a product might be subject to limitations on the indicated uses for which we, or our collaborative partners,
may market the product. These limitations might restrict the size of the market for the product and affect reimbursement by third party
payors. In addition, regulatory agencies might not grant approvals on a timely basis or might revoke or significantly modify previously
granted approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
or our collaborative partners, also are subject to numerous foreign regulatory requirements governing the manufacturing and marketing
of our potential future products outside of the United States. The approval procedure varies among countries, additional testing might
be required in some jurisdictions, and the time required to obtain foreign approvals often differs from that required to obtain FDA approvals.
Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries, and vice versa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, we, or our collaborative partners, might not successfully complete clinical trials in the time periods estimated,
if at all. Moreover, if we, or our collaborative partners, incur unanticipated costs and/or delays in development programs or if we fail
to successfully develop and commercialize products based upon our technologies, we might not be able to generate significant operating
revenues or sustainable profitability, as a result of which our stock price could decline substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could adversely affect future operations, revenues, and financial conditions, and might increase our costs and expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes,
floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical
epidemics and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and
those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss,
negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made disasters.
Operating as a virtual company, our employees conduct business outside of our headquarters and leased or owned facilities. These locations
might be subject to additional security and other risk factors due to the limited control of our employees. If such an event as described
above were to occur in the future, it might cause interruptions in our operations, delay research and development programs, clinical
trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees
and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
we will rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events as those described
previously relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or misappropriation
or disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization
of our lead product candidate could be delayed or altogether terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary product candidates might include the formation of collaborative
arrangements with third parties. We have entered into a number of agreements with third parties as described elsewhere in this document.
Existing and future collaborators have significant discretion in determining the efforts and resources they apply and might not perform
their obligations as expected. Potential third party collaborators include biopharmaceutical, pharmaceutical and biotechnology companies,
academic institutions, government agencies and other entities. Third party collaborators may assist us in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    research, preclinical development, clinical trials and manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    and obtaining regulatory approvals; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercializing any future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we might be required to undertake product development and commercialization
at our own expense. Such an undertaking might limit the number of product candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties might subject us to a number of risks. If
we fail to comply with our obligations under these agreements, of if one or more third parties allege that we fail to comply, then one
or more third parties might terminate the agreements. In this event, we might not be able to develop, manufacture or market our product
candidates. This would materially adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
agreements might not be on terms that prove favorable to us and might require us to relinquish certain rights in our product candidates.
To the extent we agree to work exclusively with one collaborator in a particular territory, research area, or therapeutic field of use,
our opportunities to collaborate with other entities could be curtailed. Lengthy negotiations with potential new collaborators might
lead to delays in the research, development or commercialization of product candidates. The decision by our collaborators to pursue alternative
technologies or the failure of our collaborators to develop or commercialize successfully any product candidate to which they have obtained
rights from us could materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our agreements might not be assignable by us without the consent of the respective other party or parties, which might limit
or delay our ability to consummate transactions, adversely impact the value of those transactions, or limit our ability to pursue research,
development or other activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
their intellectual property, or claiming ownership of what we regard as our own intellectual property. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees, consultants, collaborators or contractors have been previously employed at universities or third party pharmaceutical companies,
including our actual or possible competitors, and received confidential and proprietary information from them. Although we try to ensure
that our employees, consultants, collaborators or contractors do not use the proprietary information or know-how of others in their work
for us, we may be subject to claims that these employees, consultants, collaborators or contractors, or we, have used or disclosed intellectual
property, including trade secrets or other proprietary information, of any former employer. We might also be subject to claims that former
employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims.
We might not be successful in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages,
we could lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property.
Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees, consultants, collaborators and contractors who may be involved in the development
of intellectual property to execute agreements assigning such intellectual property to us, we might be unsuccessful in executing such
an agreement with each party who in fact develops intellectual property that we regard as our own. Such assignment agreements might not
be self-executing or may be breached, and we might be forced to bring claims against third parties, or defend claims that third parties
might bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot be certain we will be able to obtain patent protection to protect our product candidates and technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and patent applications are owned solely by our wholly-owned subsidiary, Lixte Biotechnology, Inc., except in several&#160; instances
where they are jointly owned with one of our collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we might not be able to file or prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects
of our research or development before it is too late to obtain patent protection. Therefore, these patents and applications might not
be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent
years been the subject of much litigation. In addition, the laws of foreign countries might not protect our rights to the same extent
as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and
patent applications in the United States and other jurisdictions are typically not published until after filing, or in some cases not
at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our solely owned or jointly
owned patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As
a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and
future patent applications might not result in patents being issued that protect our technology or products, in whole or in part, or
that effectively prevent others from commercializing competitive technologies and products. Changes in the patent laws or their interpretation
by courts or patent offices might diminish the value of our patents or patent applications, or narrow their scope.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, term, validity or enforceability, and our solely or jointly owned
patents might be challenged in a U.S. or non-U.S. court or patent office. Such challenges might result in loss of exclusivity or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using
or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. Given the amount of time required for research, development, testing or regulatory review of product candidates, patents protecting
such candidates might expire before or shortly after such candidates are approved or commercialized. As a result, our solely or jointly
owned patents might not provide us with sufficient rights to exclude others from commercializing intended products similar or identical
to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that all patents applied for will be issued. If a third party has also filed a patent application relating to an invention
claimed by us, solely or jointly with one of our collaborators, we might be required to participate in an interference or derivation
proceeding declared or instituted by the United States Patent and Trademark Office, which could result in substantial uncertainties and
cost for us, even if the eventual outcome is favorable to us. The degree of future protection for our proprietary rights is uncertain.
For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    solely or jointly with our collaborators, might not have been the first to make the inventions covered by our pending or future patent
    applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    solely or jointly with our collaborators, might not have been the first to file patent applications for these inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    might independently develop identical, similar or alternative technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our patent applications will not result in an issued patent or patents, or that the scope of protection granted
    by any patents arising from our patent applications will be significantly narrower than expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might be unaware of prior art that renders one or more of our patent applications unpatentable or one or more of our patents invalid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court might determine that we failed to disclose to a patent office prior art that we were aware of and that is material to patentability
    and, therefore, conclude that one or more of our patents are unenforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    patents under which we hold rights might not cover commercially viable products, might not provide us with any competitive advantages
    or might be challenged by one or more third parties as being not infringed, being invalid, or being unenforceable under United States
    or foreign laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court or patent office might determine that two or more of our patents claim patentably indistinct subject matter, which could adversely
    affect one or more of the patents&#8217; term, validity or enforceability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court or patent office might determine that one or more patents issued to us in the future or under which we hold rights are invalid
    or unenforceable; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might develop additional proprietary technologies that are not patentable and which might not be adequately protected through trade
    secrets or know-how.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we solely or jointly own patents or patent applications in jurisdictions having, or that might in the future have, geopolitical
disputes, including over sovereignty. We cannot guarantee that patents granted in these jurisdictions will be enforceable. An inability
to enforce patents in these jurisdictions could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
our business might be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the term of a patent that covers an FDA-approved drug, its method for use or method for manufacture, can be eligible
for patent term extension. U.S. law provides a patent term extension of up to five years beyond the expiration of the patent for time
during which the drug is under regulatory review. Patent term extension cannot extend the term of a patent beyond a total of 14 years
from the date of regulatory approval; only one patent can be extended for the same regulatory review period; and the scope of a patent&#8217;s
enforceability during a patent term extension is limited to the scope of FDA approval. There is no guarantee that the relevant agencies,
including the United States Patent and Trademark Office (&#8220;USPTO&#8221;), will agree with our assessment of whether such extensions
should be granted, and even if granted, the term of these extensions. We might not be granted patent term extension in the United States
or in any foreign country because of, for example, expiration of our patents before obtaining regulatory approval, failing to exercise
due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior
to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the length of a patent term extension,
as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request.
If we are unable to obtain any patent term extension or if the term of any such extension is less than we request, our competitors might
obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of
operations and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates
that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a
shorter period than we had sought.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights from
third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights that
are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into, and might in the future enter into, one or more intellectual property license agreements that are important to our
business. These license agreements might impose various diligence, milestone payment, royalty and other obligations on us. For example,
we might be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect
to licensed products, and might need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations
under our agreements with any of these licensors, we might be subject to termination of the license agreement in whole or in part, increased
financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop
or commercialize products covered by the license agreement will be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, disputes might arise regarding intellectual property subject to a license agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    our technology, product candidates or processes infringe intellectual property rights that are owned by the licensor, but that are
    not subject to the licensing agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and the activities that satisfy those obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required to sublicense to a third party rights that the license grants to us, but that we do not commercially pursue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership of inventions, data and know-how resulting from joint creation or use of intellectual property by our licensors and us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed, or might in the future license, prevent or impair our ability to maintain
our licensing arrangements on acceptable terms, we may be unable to successfully develop or commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may
fail to obtain any of these licenses at a commercially reasonable cost or on commercially reasonable terms, if at all. Other companies
might have a competitive advantage over us due to their larger size or cash resources or greater clinical development and commercialization
capabilities. We might be unable to further develop or commercialize one or more of our product candidates, which could harm our business
significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing or increase the costs of commercializing our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We cannot guarantee
that our intended products or our product candidates, or manufacture or use of our intended products or our product candidates, will
not infringe third party patents. Furthermore, a third party might claim that we are using without permission one or more inventions
covered by the third party&#8217;s patent rights and might go to court to stop us from engaging in our normal operations and activities,
including making, offering to sell or selling our product candidates. Still further a third party might go to court seeking judgment
that our patents are invalid or unenforceable. These lawsuits are costly and could affect our results of operations and divert the attention
of managerial and scientific personnel. Some of these third parties might be better capitalized and have more resources than us. There
is a risk that a court would decide that we are infringing the third party&#8217;s patents and would order us to stop the activities
covered by the patents. In that event, we might not have a viable way around the patent and might need to halt commercialization of the
relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated
the other party&#8217;s patents. There is also a risk that a court would decide that one or more of our patents are invalid or unenforceable.
In addition, we might be obligated to indemnify our licensors and collaborators against intellectual property infringement claims brought
by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced
a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products
or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we have identified all third party patents or pending patent applications that are or might be necessary for the
commercialization of our intended products and technologies in any jurisdiction. Patent applications in the United States and elsewhere
are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date
being commonly referred to as the priority date. Therefore, patent applications covering our technologies and intended products could
have been filed by others without our knowledge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover
our technologies or intended products. The scope of a patent claim is determined by the interpretation of the law, the words of a patent
claim, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope
of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our intended products.
We might incorrectly determine that our technologies or intended products are not covered by a third party patent or might incorrectly
predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant might be incorrect, and we might incorrectly conclude that
a third party patent does not cover our technology or intended products, is invalid or is unenforceable. Our inability to identify or
correctly interpret relevant patents might negatively impact our ability to develop or market our technologies or intended products.
If we fail to identify or correctly interpret relevant patents, we might be subject to infringement claims. We cannot guarantee that
we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to
being liable for damages, we might be temporarily or permanently enjoined or otherwise prohibited from commercializing any of technologies
or intended products that are held to be infringing. We might, if possible, also be forced to redesign intended products or product formulations
so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail,
could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the pharmaceutical or biotechnology industry expands and more patents are issued, the risk increases that our product candidates or intended
products give rise to claims of infringement of the patent rights of others. There may be third party patents of which we are currently
unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of
our product candidates. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, negotiate and obtain a license
under reasonable terms to us or discontinue performing the allegedly infringing activities. We might not be able to do any of these.
Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence
to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we might incur substantial
costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us.
If we are unable to avoid infringing the patent rights of others, we might be required to seek a license, which might not be available,
and then we will have to defend an infringement action, challenge the validity of the patents in the USPTO or in court, or discontinue
performing the allegedly infringing activities. Patent litigation is costly and time consuming. We might not have sufficient resources
to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology,
fail to defend an infringement action successfully or fail to have infringed patents declared invalid or unenforceable, we might incur
substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing
or selling our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that others have not filed patent applications for technology covered by our pending applications, that we were the
first to invent the technology or that we were the first to file patent applications covering our technology, because:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
    patent applications in the United States are maintained in secrecy until the patents are issued;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
    applications in the United States are typically not published until 18 months after their earliest claimed priority date; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publications
    in the scientific literature often lag behind actual discoveries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors might have filed, and might in the future file, patent applications covering technology similar or identical to ours. Any
such patent applications might dominate our patent applications, which could further require us to obtain rights to issued patents covering
such technologies. If another party has filed US patent applications that cover inventions similar or identical to ours and claim priority
to any applications filed prior to the priority dates of our applications, we might have to participate in an interference proceeding
declared or a derivation proceed instituted by the USPTO to determine priority of invention in the United States. The costs of these
proceedings could be substantial, and it is possible that such efforts would be unsuccessful if the other party had independently arrived
at the same or similar inventions before us, possibly resulting in a loss of our U.S. patent position with respect to such inventions.
Other countries might have similar laws that permit secrecy of patent applications. Either way, the third party&#8217;s patents or patent
applications might be entitled to priority over our applications in such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors might be able to sustain the costs of a patent challenge more effectively than we can because they have substantially
greater resources. In addition, uncertainties regarding the outcome of the challenge could have a material adverse effect on our ability
to raise the funds necessary to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
secrets of one or more third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and pharmaceutical industries, we employ, and might employ in the future, individuals who were previously
employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure
that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work
for us, we might be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. Litigation might be necessary to defend against
these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property
rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation
could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our business
as well as limit our partnership or acquisition appeal.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be subject to competition despite the existence of intellectual property we license or own. We can give no assurance that our intellectual
property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing
competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our
operating results and financial condition. Furthermore, any actual or perceived limitations, in our intellectual property might lessen
the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable
risk to commercialization of our intended products or future products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach includes filing patent applications covering combination therapy with known, studied and/or marketed drugs. Although the protection
afforded by our patent applications might be significant, when looking at our patents&#8217; ability to block competition, the protection
offered by our patents might be, to some extent, more limited than protection provided by patents claiming a composition of matter that
is entirely new and previously unknown. If a competitor were able to successfully design around any combination therapy patents we have
or might have in the future, our business and competitive advantage could be significantly affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress,
copyrights, trade secrets, domain names or other intellectual property rights that we either own or license. We might alternatively elect
to sue a third party, or otherwise make a claim, alleging that we don&#8217;t infringe a third party&#8217;s patents or that the third
party&#8217;s patents are invalid or unenforceable. Any claims that we assert against a third party could provoke the third party to
assert one or more counterclaims against us, for example, alleging that we infringe their patents. In addition, in a patent infringement
proceeding, a court might decide that a patent of ours is invalid or unenforceable, in whole or in part; construe the patent&#8217;s
claims narrowly; or refuse to stop the other party from using the technology at issue. Any litigation proceeding could put one or more
of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we prevail in a lawsuit, a court might
not award remedies that sufficiently compensate us for our losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not prevail in either type of litigation, we might be subject to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">paying
    monetary damages related to the legal expenses of the third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facing
    additional competition that might have a significant adverse effect on our intended-product pricing, market share, business operations,
    financial condition, and the commercial viability of our intended products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restructuring
    our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical
    trials, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third party might also challenge the validity, enforceability or scope of the intellectual property rights that we license or own, and
the result of these challenges might narrow the scope or claims of or invalidate patents that are integral to our product candidates
in the future. There can be no assurance that we will be able to successfully defend patents we own in an action against third parties
due to the unpredictability of litigation and the high costs associated with intellectual property litigation, among other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations of the
United States, and many companies have encountered significant difficulties in protecting and defending such rights in non-U.S. jurisdictions.
The legal systems of some countries are less supportive of enforcement of patents, trade secrets and other intellectual property protection,
than the United States. This could make it difficult for us to enforce our patents or market competing products outside the United States,
in violation of our proprietary rights generally. Proceedings to enforce our patent rights in non-U.S. jurisdictions, whether or not
successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our
patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third
parties to assert claims against us. We might not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, might not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights in all jurisdictions
where we have the rights might be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license. Furthermore, while we seek to protect our intellectual property rights in significant markets, we cannot ensure that we will
be able to initiate or maintain similar efforts in all jurisdictions in which we might wish to market our intended products or our product
candidates. Accordingly, our efforts to protect our intellectual property rights in such countries might be inadequate, which might have
an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets.
If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights important for our business in such jurisdictions, the value of these rights might be diminished, and we might face additional
competition from others in those jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to patent law, for example the Leahy-Smith America Invests Act, AIA or Leahy-Smith Act, of 2011 and the Patent Reform Act of 2009 and
other future article of legislation in the U.S., might substantially change the regulations and procedures surrounding patent applications,
issuance of patents, prosecution of patents, challenges to patent validity, and patent enforcement. We can give no assurance that our
patents or those of our licensor(s) can be defended or will protect us against future intellectual property challenges, particularly
as they pertain to changes in patent law and future patent law interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, enforcing and maintaining our intellectual property protection depends on compliance with various procedural, document-submission,
fee-payment and other requirements imposed by the U.S. Patent and Trademark Office and courts, and foreign government patent agencies
and courts, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some jurisdictions outside the United States can be less extensive than those in the United States.
And filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates
might be prohibitively expensive or impractical. Competitors might use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products or technologies and, further, may export otherwise infringing products or technologies to territories
where we and have patent protection, but where enforcement is not as strong as that in the United States. These third party products
or technologies might compete with our product candidates, and our intellectual property rights may not be effective or sufficient to
prevent third parties from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we might decide to abandon national or regional patent applications while they are still pending or to abandon granted patents.
This might invite or encourage third parties to develop their products or technologies in jurisdictions where we abandon patent applications
or patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer competitive
harm.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on proprietary trade secrets and unpatented know-how to protect our research and development activities, particularly when
we do not believe that patent protection is appropriate or available. However, trade secrets are difficult to protect. We will attempt
to protect our trade secrets and unpatented know-how by requiring our employees, consultants, collaborators, and advisors to execute
a confidentiality and non-use agreement. We cannot guarantee that these agreements will provide meaningful protection; that these agreements
will not be breached, by, e.g., a misappropriating or disclosing our confidential information; that we will have an adequate remedy for
any such breach; or that our trade secrets will not otherwise become known or independently developed by a third party. Our trade secrets,
and those of our present or future collaborators that we utilize by agreement, might become known or might be independently discovered
by others, which could adversely affect the competitive position of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our patents,
defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third party intellectual
property, as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be unaware of or unfamiliar with prior art and/or interpretations of prior art that could potentially impact the validity or scope
of our patents or pending patent applications, or patent applications that we will file. We might have elected, or elect now or in the
future, not to maintain or pursue intellectual property rights that, at some point in time, might be considered relevant to or enforceable
against a competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
take efforts and enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership of and chain of
title in intellectual property rights. However, an inventorship or ownership dispute could arise that might permit one or more third
parties to practice our intellectual property rights, including possible efforts to enforce rights against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not have rights under some patents or patent applications that cover technologies that we use in our research, drug targets that
we select, product candidates and particular uses thereof that we seek to develop and commercialize, as well as synthesis of our product
candidates. Third parties might own or control these patents and patent applications in the United States and elsewhere. These third
parties could bring claims against us or our collaborators that would cause us to incur substantial expenses and, if successful against
us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us or our collaborators, we
or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the
subject of the suit. We or our collaborators therefore might choose to seek, or be required to seek, a license from the third party and
would most likely be required to pay license fees or royalties or both. These licenses might not be available on acceptable terms, or
at all. Even if we or our collaborators were able to obtain a license, the rights might be nonexclusive, which would give our competitors
access to the same intellectual property. Ultimately, we could be prevented from commercializing a product or product candidate, or forced
to cease some aspect of our business operations, as a result of patent infringement claims, which could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on issued U.S. patents are due to be paid to the USPTO, and periodic maintenance fees on issued non-U.S. patents and
pending non-U.S. patent applications are due to be paid to non-U.S. patent offices. Patent offices require compliance with many procedural,
documentary, fee payment and other requirements during the patent application process and after a patent issues or grants. While an inadvertent
lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations
in which non-compliance, for example, caused by geopolitical events such as civil or political unrest (including the ongoing conflict
between Ukraine and Russia), can result in abandonment or lapse of the patent or patent application, resulting in partial or complete
loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a
patent or patent application include, but are not limited to, failure to respond to patent office actions within prescribed time limits,
non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to
enter the market, which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various non-U.S. government agencies require compliance with certain foreign filing requirements during the patent application
process. For example, in some countries, including the United States, a foreign filing license is required before certain patent applications
are filed outside that country. The foreign filing license requirements can vary by country. In some cases, a foreign filing license
may be obtained retroactively in accordance with the applicable rules. There are situations, however, in which non-compliance can result
in abandonment of a pending patent application or can be grounds for revoking or invalidating an issued patent, resulting in the loss
of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the relevant markets with
similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results
of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been substantial litigation and other legal proceedings regarding patent and other intellectual property rights in the pharmaceutical
and biotechnology industries. Although we are not currently a party to any patent litigation or any other adversarial proceeding, including
any interference or derivation proceeding declared or instituted before the United States Patent and Trademark Office, regarding intellectual
property rights with respect to our intended products, our product candidates and our technology, it is possible that we might become
one in the future. We are not currently aware of any actual or reasonably foreseeable third party infringement claim involving our product
candidates. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. The outcome
of patent litigation is subject to uncertainties that cannot be adequately quantified in advance, including the dispute forum, demeanor
and credibility of witnesses and the identity of the adverse party, especially in pharmaceutical and biotechnology related patent cases
that might turn on the testimony of experts as to technical facts upon which experts might reasonably disagree. Some of our competitors
might be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater
financial resources. If a patent or other proceeding is resolved against us, we might be enjoined from researching, developing, manufacturing
or commercializing our intended products or our product candidates without a license from the other party and we might be held liable
for significant damages. We might not be able to obtain any required license on commercially acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could harm our ability to compete in the marketplace.
Patent litigation or other proceedings might also absorb significant management time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect our intellectual property rights, our competitors might develop and market products with similar or identical
features that might reduce demand for our potential products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following factors are important to our success:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
    patent protection for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preventing
    others from infringing our intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    our patent rights and trade secrets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be able to protect our intellectual property rights in patents and trade secrets from unauthorized use by third parties only to
the extent that such intellectual property rights are covered by valid and enforceable patents or are effectively maintained as trade
secrets and we enforce these rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
issues of patentability involve complex legal and factual questions, the issuance, scope or enforceability of patents cannot be predicted
with certainty. Patents can be challenged, invalidated, found unenforceable, or circumvented. United States patents and patent applications
can be subject to interference or derivation proceedings. United States patents can also be subject to post grant proceedings, including
re-examination, derivation, <i>Inter Partes</i> Review and Post Grant Review, in the United States Patent and Trademark Office. Foreign
patents can be subject to opposition or comparable proceedings in corresponding foreign patent offices. Any of these challenges might
result in loss of the patent, rejection of the patent application or loss or reduction in the scope of one or more of the claims of the
patent or patent application. In addition, these proceedings can be costly. Thus, any patents that we own or license from others might
not provide any protection against competitors. Furthermore, an adverse decision in an interference or derivation proceeding can result
in a third party receiving the patent rights sought by us, which in turn could affect our ability to market a potential product to which
that patent filing was directed. Our pending patent applications, those that we might file in the future, or those that we might license
from third parties might not result in patents being issued. If issued, they might not provide us with proprietary protection or competitive
advantages against competitors with similar or identical technology. Furthermore, others might independently develop similar technologies
or duplicate any technology that we have developed. Some countries have compulsory licensing laws under which a patent owner might be
compelled to grant licenses to third parties. For example, compulsory licenses might be required in cases such as where the patent owner
has failed to &#8220;work&#8221; the invention in that country or where a third party has patented improvements. In addition, some countries
might limit the enforceability of patents against government agencies or government contractors. In these countries, we might have limited
infringement remedies, which could materially diminish the value of our patents. Moreover, the legal systems of some countries are less
supportive of enforcement of patents, trade secrets and other intellectual property protection, than the United States, which might make
it difficult to stop infringement in these countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers
who do not advertise or otherwise promote the compounds that are used in their products. Any litigation to enforce or defend our patent
rights, even if we prevail, could be costly and time-consuming and would divert the attention of management and key personnel from business
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also rely on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. We
will seek to protect this information by entering into confidentiality agreements with parties that have access to it, such as strategic
partners, collaborators, employees, contractors and consultants. Any of these parties might breach these agreements and misappropriate
or disclose our confidential information or our competitors might learn of the information in some other way. If any trade secret, know-how
or other technology not protected by a patent were disclosed to, or independently developed by, a competitor, our business, financial
condition and results of operations could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Current Product Candidate and Future Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
if approved, among physicians, patients, healthcare payors and cancer treatment centers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our lead product candidate or any future product candidates, the products might not gain market
acceptance among physicians, healthcare payors, patients or the medical community, including cancer treatment centers. Market acceptance
of any product candidates for which we receive approval depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety of such product candidates as demonstrated in clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications and patient populations for which the product candidate is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adoption of novel immunotherapies by physicians, hospitals and third party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety of product candidates seen in a broader patient group, including our use outside the approved indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    restrictions on use together with other medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling or product insert requirements of the FDA or other regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our intended product as well as competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of manufacturing and distribution processes for commercial scale manufacturing for our lead product candidate and any
    future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from third party payors and government authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our sales and marketing efforts and those of our collaborators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our lead product candidate and any future product candidates are approved but fail to achieve market acceptance among physicians, patients,
healthcare payors or cancer treatment centers, we will not be able to generate significant revenues, which would compromise our ability
to become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our intended
products, which could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for
such product and related treatments will be available from third party payors, including government health administration authorities,
private health insurers and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party payors determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry
is cost containment. Third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. Increasingly, third party payors are requiring that drug companies provide them with predetermined discounts from list prices
and are challenging the prices charged for medical products. Third party payors might also seek additional clinical evidence, beyond
the data required to obtain regulatory approval, demonstrating clinical benefit and value in specific patient populations before covering
our intended product for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product
that we commercialize and, if coverage is available, what the level of reimbursement will be. Coverage and reimbursement might impact
the demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or
is available only at limited levels, we might not be able to successfully commercialize any product candidate for which we obtain regulatory
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
might be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage might be more limited than
the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage
and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, might also not be sufficient
to cover our costs and might only be temporary. Reimbursement rates might vary according to the use of the drug and the clinical setting
in which it is used, might be based on reimbursement levels already set for lower cost drugs and might be incorporated into existing
payments for other services. Net prices for drugs might be reduced by mandatory discounts or rebates required by third party payors and
by any future relaxation of laws that presently restrict imports of drugs from countries where they might be sold at lower prices than
in the United States. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can
differ significantly from payor to payor. Third party payors can rely upon Medicare coverage policy and payment limitations in setting
their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability
to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved product
that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize our intended
product and overall financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative measures aimed at reducing healthcare costs might have a material adverse effect on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain international jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our intended product profitably. In particular, in 2010, the
Affordable Care Act (&#8220;ACA&#8221;) was enacted, which, among other things, subjected biologic products to potential competition
by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by
most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions
of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded
prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
containing or lowering the cost of healthcare. We cannot predict the initiatives that might be adopted in the future. The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce
costs of healthcare and/or impose price controls might adversely affect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    demand for our lead product candidate, if we obtain regulatory approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to receive or set a price that we believe is fair for our intended product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate revenue and achieve or maintain profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of taxes that we are required to pay; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of capital.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other healthcare reform measures that might be adopted in the future, might result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could
lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other
government-funded programs might result in a similar denial or reduction in payments from private payors, which might prevent us from
being able to generate sufficient revenue, attain profitability or commercialize our product candidate, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
controls might be imposed in foreign markets, which might adversely affect our future profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure
by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political,
economic and regulatory developments might further complicate pricing negotiations, and pricing negotiations might continue after reimbursement
has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced
and high-priced member states, can further reduce prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, we or our collaborators might be required to conduct a clinical trial or other studies that compare the cost-effectiveness
of our product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of
discounts by third party payors or authorities might lead to further pressure on the prices or reimbursement levels within the country
of publication and other countries. If reimbursement of our intended product is unavailable or limited in scope or amount, or if pricing
is set at unsatisfactory levels, our business could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Healthcare Compliance Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
profits and future earnings. If we or they are unable to comply with these provisions, we might become subject to civil and criminal
investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third party payors will play a primary role in the recommendation and prescription of any product candidates
for which we obtain regulatory approval. Our current and future arrangements with healthcare providers, healthcare entities, third party
payors and customers might expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that might constrain
the business or financial arrangements and relationships through which we research, develop and will market, sell and distribute our
intended product. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly
to Medicare, Medicaid or other third party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and
patients&#8217; rights are applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations
that might affect our ability to operate include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal healthcare Anti-Kickback Statute which prohibits, among other things, individuals and entities from knowingly and willfully
    soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce
    or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
    for which payment might be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws, including the federal False Claims Act that can be enforced through civil whistleblower or
    qui tam actions, and civil monetary penalty laws, prohibit individuals or entities from knowingly presenting, or causing to be presented,
    to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent
    or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which imposes criminal and civil liability
    for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and
    willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the
    delivery of or payment for healthcare benefits, items or services, as amended by the Health Information Technology for Economic and
    Clinical Health Act of 2009 (&#8220;HITECH&#8221;) which imposes obligations, including mandatory contractual terms, with respect
    to safeguarding the privacy, security and transmission of individually identifiable health information on entities subject to the
    law, such as certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, and their respective
    business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable
    health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician sunshine requirements under the ACA which requires certain manufacturers of drugs, devices, biologics and medical
    supplies, with certain exceptions, to report annually to HHS information related to payments and other transfers of value to physicians,
    other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare
    providers and their immediate family members and applicable group purchasing organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which might apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private
    insurers; some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
    guidelines and the relevant compliance guidance promulgated by the federal government and might require drug manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures
    or pricing information; and certain state and local laws which require the registration of pharmaceutical sales representatives;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each
    other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices might not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that might apply to us, we might be subject to
significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded
healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring
of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be
in compliance with applicable laws, they might be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees might engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause significant liability for us and harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar
regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities,
comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations
and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information
or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity might not be effective
in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results
of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion
from government funded healthcare programs, such as Medicare and Medicaid, and integrity oversight and reporting obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we
might develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability exposure related to the testing of our lead product candidate or future product candidates
in human clinical trials and will face an even greater risk if we commercially sell any products that we might develop. Product liability
claims might be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering
or selling our intended product. If we cannot successfully defend ourselves against claims that our lead product candidate or product
caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims might result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any product candidates or products that we might develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire clinical trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial subjects or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and scientific resources from our business operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any products that we might develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to engaging in future clinical trials, we intend to obtain product liability insurance coverage at a level that we believe is customary
for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks; however, we might be unable
to obtain such coverage at a reasonable cost, if at all. If we are able to obtain product liability insurance, we might not be able to
maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that might arise and such insurance
might not be adequate to cover all liabilities that we might incur. Furthermore, we intend to expand our insurance coverage for products
to include the sale of commercial products if we obtain regulatory approval for our lead product candidate in development, but we might
be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments
have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or
series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies
and private and public research institutions for our lead product candidate. Our commercial opportunities will be reduced or eliminated
if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than
any products that we might develop. Competition could result in reduced sales and pricing pressure on our lead product candidate, if
approved, which in turn would reduce our ability to generate meaningful revenues and have a negative impact on our results of operations.
In addition, significant delays in the development of our lead product candidate could allow our competitors to bring products to market
before we do and impair our ability to commercialize our lead product candidate. The biotechnology industry, including the cancer immunotherapy
market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience
and financial, research and technical resources than us. Potential competitors in the United States and worldwide are numerous and include
pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater
capital resources, marketing experience, research and development staffs and facilities than ours. Some of our competitors might develop
and commercialize products that compete directly with those incorporating our technology or might introduce products to market earlier
than our intended product or on a more cost-effective basis. Our competitors compete with us in recruiting and retaining qualified scientific
and management personnel as well as in acquiring technologies complementary to our technology. We might face competition with respect
to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing
and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including the potentially
dominant patent positions of others. An inability to successfully complete our product development or commercializing our lead product
candidate could result in our having limited prospects for establishing market share or generating revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved products than we do, and as a result might have a competitive advantage over us. Mergers and acquisitions in the pharmaceutical
and biotechnology industries might result in even more resources being concentrated among a smaller number of our competitors. Smaller
or early-stage companies might also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses
complementary to our programs or potentially advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, these competitors might obtain regulatory approval of their products before we are able to obtain patent protection
or other intellectual property rights, which will limit our ability to develop or commercialize our lead product candidate. Our competitors
might also develop drugs that are safer, more effective, more widely used and cheaper than ours, and might also be more successful than
us in manufacturing and marketing their products. These appreciable advantages could render our lead product candidate obsolete or non-competitive
before we can recover the expenses of development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business might be adversely affected by the ongoing coronavirus pandemic.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout the world
as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak has subsided,
the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising
efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business,
we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual
property). The size and complexity of our information technology and information security systems, and those of our third party vendors
with whom we might contract, make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent
or intentional actions by our employees or vendors, or from malicious attacks by third parties. Such attacks are of ever-increasing levels
of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage
and market manipulation) and expertise. While we intend to invest in the protection of data and information technology, there can be
no assurance that our efforts will prevent service interruptions or security breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems, and those of our CROs, our CMOs, and other business vendors on which we might rely, are vulnerable to damage
from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We
exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. If such an
event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs.
Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive
confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow
third parties to gain material, inside information that they use to trade in our securities. For example, the loss of clinical trial
data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data
or applications, or misappropriation or disclosure of confidential or proprietary information, we could incur liability, the further
development of our lead and future product candidates could be delayed and our business could be otherwise adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2024, we had three full-time officer/employees and one part-time officer/employee. The Company relies to a significant extent
on outside consultants and advisors with various technical skills and expertise that the Company can draw on as necessary to conduct
its research and development and clinical trial programs. We might need to grow the size of our organization in order to support our
continued development and potential commercialization of our lead product candidate. As our development and commercialization plans and
strategies continue to develop, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other
resources might increase. Our management, personnel and systems currently in place might not be adequate to support this future growth.
Future growth would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our clinical trials effectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, maintaining, motivating and integrating additional employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors
    and other third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our managerial, development, operational, information technology, and finance systems; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding
    our facilities.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations expand, we will likely also need to manage additional relationships with various strategic partners, suppliers and other
third parties. Our future financial performance and our ability to commercialize our lead product candidate and to compete effectively
will depend, in part, on our ability to manage any future growth effectively, as well as our ability to develop a sales and marketing
force when appropriate for our company. To that end, we must be able to manage our development efforts and preclinical studies and clinical
trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales
and marketing personnel. The failure to accomplish any of these tasks could prevent us from successfully growing our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inadequate
funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business might rely, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other
government agencies on which our operations might rely, including those that fund research and development activities is subject to the
political process, which is inherently fluid and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies might also slow the time necessary for new drugs to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018,
the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical
FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly
impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on
our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public
markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have
serious adverse consequences on our business, financial condition and stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressures and interest rate changes,
increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely
affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, between Israel
and Gaza, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts,
including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures
by the affected countries or others could exacerbate market and economic instability. Future adverse developments with respect to financial
institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies
to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future
credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business
strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable
and unstable market conditions. If the equity markets deteriorate, or if adverse developments are experienced by financial institutions,
it may cause short-term liquidity risk and also make any necessary equity financing more difficult, more costly and more dilutive. Failure
to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our business plans
and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of
our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing risks,
which could directly affect our ability to conduct our business plans on schedule and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Owning our Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and we have elected to comply with certain reduced reporting and disclosure requirements
which could make its common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company,&#8221; as defined in the Regulation S-K of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), which allows us to take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not smaller reporting companies, including (1) not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002, and (2) reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements. In addition, as an emerging growth company, we are only required to provide two years of audited financial
statements in this document. As a result of these reduced reporting and disclosure requirements our financial statements might not be
comparable to SEC registrants not classified as emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive because we might rely on these exemptions. If some investors find
our common stock less attractive as a result, there might be a less active trading market for our common stock and our stock price might
be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm is not be required to formally attest to the effectiveness of our internal control over
financial reporting until we are no longer a &#8220;smaller reporting company&#8221;. We cannot assure you that there will not be material
weaknesses or significant deficiencies in our internal controls in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
might find our common stock less attractive as a result of our election to utilize these exemptions, which could result in a less active
trading market for our common stock and/or the market price of our common stock might be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Warrants are speculative in nature.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants offered in our November 2020 public offering do not confer any rights of common stock ownership on their holders, such as voting
rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically,
holders of the Warrants may exercise their right to acquire the common stock and pay an effective exercise price of $57.00 per share,
which is substantially in excess of the current market price of the Company&#8217;s common stock. Furthermore, each Warrant will expire
five (5) years from the original issuance date. In the event our common stock price does not exceed the exercise price of the Warrants
during the period when the Warrants are exercisable, the Warrants may not have any value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of the Warrants will have no rights as a common stockholder until they acquire our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
the acquisition of shares of our common stock upon exercise of the Warrants, a holder will have no rights with respect to shares of our
common stock issuable upon exercise of the Warrant. Upon exercise of a Warrant, a holder will be entitled to exercise the rights of a
common stockholder as to the security exercised only as to matters for which the record date occurs after the exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a limited market for the Warrants to purchase shares of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Warrants are currently trading on The Nasdaq Capital Market, there can be no assurance that there will be an active trading market
for the Warrants. Without an active trading market, the liquidity of the Warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of the Warrants could discourage an acquisition of us by a third party.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the Warrants could make it more difficult or expensive for a third party to acquire us. The Warrants prohibit us from engaging
in certain transactions constituting &#8220;fundamental transactions&#8221; unless, among other things, the surviving entity assumes
our obligations under the Warrants. These and other provisions of the Warrants could prevent or deter a third party from acquiring us
even where the acquisition could be beneficial to you.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>July
20, 2023 sale of common stock and warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we sold common stock and warrants to an institutional investor and raised gross proceeds of approximately $3,500,000. As part
of this financing, the Company sold warrants to the institutional investor to purchase 583,334 shares of common stock. Each common warrant
had an initial exercise price of $6.00 per share, was immediately exercisable upon issuance, and expires five years thereafter on July
20, 2028. The Company also issued warrants to the placement agent to purchase 35,000 shares of common stock at an exercise price of $6.60
per share and expiring on July 20, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor and to the placement agent are subject to customary adjustments
for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#8217;s
common stock. In addition, the warrants issued to the institutional investor contain a &#8220;fundamental transaction&#8221; provision
whereby in the event of a fundamental transaction (a sale or transfer of assets or ownership of the Company as defined in the warrant
agreement) within the Company&#8217;s control, the holder of the unexercised common stock warrants would be entitled to receive, in exchange
for extinguishment of the warrants, cash consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such
fundamental transaction is not within the Company&#8217;s control, the warrant holder would only be entitled to receive the same form
of consideration (and in the same proportion) as the holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#8217;s assets, to
the extent that the warrants issued to the institutional investor are outstanding at the effective date that such a transaction is closed,
this &#8220;fundamental transaction&#8221; provision would entitle the institutional investor to substantial cash consideration, thus
reducing the amounts to be retained by the Company or potentially distributable to the Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our common stock or Warrants might fluctuate substantially.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock and Warrants to be risky. Some factors that might cause the market price of our common
stock or Warrants to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors,&#8221; are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by our stockholders, executives, and directors and our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our shares of common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical
    trials, and other business activities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of introductions of new products by us or our competitors or any other change in the competitive dynamics of our
    industry, including consolidation among competitors, customers or strategic partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">network
    outages or security breaches;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement,
    enrollment or results of our clinical trials for our lead product candidate or any future clinical trials we might conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the development status of our lead product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays or adverse developments or perceived adverse developments with respect to the FDA&#8217;s review of our planned preclinical
    and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory
    approval for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    safety concerns related to the use of our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to enter into new markets or develop new products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing technologies and products or new technologies and products that might emerge;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general economic, political and market conditions in or any of the regions in which we conduct our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in industry conditions or perceptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in valuations of similar companies or groups of companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which might be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences
a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and might expose us to lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Company&#8217;s Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market, the Company held a special
meeting of stockholders on May 26, 2023 to seek approval for an amendment to the Company&#8217;s Certificate of Incorporation to effect
a reverse stock split of its issued and outstanding shares of common stock. As a result of the approval of this amendment, the Company
effected a 1-for-10 reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. Commencing with
the opening of trading on the Nasdaq Capital Market on Monday, June 5, 2023, the Company&#8217;s common stock began trading on a post-split
basis under the same symbol LIXT. The Company subsequently received confirmation from Nasdaq that it had regained compliance with the
minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria
for continued listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum bid price requirement over time,
or that it will be successful in maintaining compliance with any of the other Nasdaq continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company were to be delisted from Nasdaq, its common stock and warrants may be eligible for trading on an over-the-counter market.
If the Company is not able to obtain a listing on another stock exchange or quotation service for its common stock and warrants, it may
be extremely difficult or impossible for stockholders to sell their shares of common stock and warrants. Moreover, if the Company is
delisted from Nasdaq, but obtains a substitute listing for its common stock and warrants, it will likely be on a market with less liquidity,
and therefore experience potentially more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares
of common stock and warrants on any such substitute market in the quantities, at the times, or at the prices that could potentially be
available on a more liquid trading market. As a result of these factors, if the Company&#8217;s common stock is delisted from Nasdaq,
the value and liquidity of the Company&#8217;s common stock and warrants would likely be significantly adversely affected. A delisting
of the Company&#8217;s common stock from Nasdaq could also adversely affect the Company&#8217;s ability to obtain financing for its operations
and/or could result in a loss of confidence by investors, employees and/or business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
sale or perceived sale of a substantial number of shares of our common stock might cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could fall.
Moreover, the perceived risk of this potential dilution could cause stockholders to attempt to sell their shares and investors to short
our common stock. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a
time and price that we deem reasonable or appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
and economic conditions might negatively impact our business, financial condition and share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
over medical epidemics, energy costs, geopolitical issues, the U.S. mortgage market and a deteriorating real estate market, unstable
global credit markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished
liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global
economy and expectations of slower global economic growth, increased unemployment rates, and increased credit defaults in recent years.
Our general business strategy might be adversely affected by any such economic downturns (including the impact related to the recent
COVID-19 pandemic), volatile business environments and continued unstable or unpredictable economic and market conditions. If these conditions
continue to deteriorate or do not improve, it might make any necessary debt or equity financing more difficult to complete, more costly,
and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse
effect on our growth strategy, financial performance, and share price and could require us to delay or abandon development or commercialization
plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our
stock price and trading volume might decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us,
our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock,
the lack of research coverage might adversely affect the market price of our common stock. Furthermore, if one or more of the analysts
who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price
would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose
visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline
and might also impair our ability to expand our business with existing customers and attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
cause our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital will be needed in the future to continue our planned operations, including increased marketing,
hiring new personnel, commercializing our intended product, and continuing activities as an operating public company. To the extent we
raise additional capital by issuing equity securities, our stockholders might experience substantial dilution. We might sell common stock
(with or without warrants), convertible securities or other equity securities in one or more transactions at prices and in a manner we
determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction,
investors might be materially diluted by subsequent sales. Such sales might also result in material dilution to our existing stockholders,
and new investors could gain rights superior to our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be at risk of securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be at risk of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant
stock price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such
litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our
business and results in a decline in the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage,
delay or prevent a change in control, which might cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law could make it more difficult for a third party to
acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10,000,000 shares
of preferred stock. This preferred stock might be issued in one or more series, the terms of which might be determined at the time of
issuance by our Board of Directors without further action by stockholders. The terms of any series of preferred stock might include voting
rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption
rights and sinking fund provisions. We have designated 350,000 shares of preferred stock as Series A Convertible Preferred Stock, all
of which are issued and outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders
of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of
preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control
by the present management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law also could have the effect of discouraging potential
acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider
favorable. Such provisions might also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular,
the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    the Board of Directors with the ability to alter the bylaws without stockholder approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">place
    limitations on the removal of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted upon
    at stockholder meetings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that vacancies on the Board of Directors might be filled by a majority of directors in office, although less than a quorum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required
to devote substantial time to compliance matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we incur significant additional legal, accounting and other expenses. The obligations of being a public company
in the United States require significant expenditures and will place significant demands on our management and other personnel, including
costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance
practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing
requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective
disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices,
among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent
reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming
and costly, particularly after we are no longer an &#8220;emerging growth company&#8221;. In addition, we expect these rules and regulations
to make it more difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel
will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations,
otherwise we might fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of Sarbanes-Oxley requires annual management assessments of the effectiveness of our internal control over financial reporting. If
we fail to comply with the rules under Sarbanes-Oxley related to disclosure controls and procedures in the future, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult. If material weaknesses or significant deficiencies are discovered or if we otherwise fail
to achieve and maintain the adequacy of our internal control, we might not be able to ensure that we can conclude on an ongoing basis
that we have effective internal controls over financial reporting in accordance with Section 404 of Sarbanes-Oxley. Moreover, effective
internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If
we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose
confidence in our reported financial information, and the trading price of our common stock could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_001"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_002"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our
business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include
identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
these risk assessments, we will redesign, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address
any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. Primary responsibility for assessing,
monitoring and managing our cybersecurity risks rests with an IT consultant, who reports to our Chief Operating Officer, to manage the
risk assessment and mitigation process. As part of our overall risk management system, we monitor and periodically evaluate our safeguards
and advise our executives on these safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engage consultants, or other third parties in connection with our risk assessment processes. These service providers assist us to design
and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards. In the future, we intend to require
each significant third-party service provider to certify that they have the ability to implement and maintain appropriate security measures,
consistent with all applicable laws, to implement and maintain reasonable security measures in connection with their work with us, and
to promptly report any suspected breach of its security measures that may affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not encountered cybersecurity challenges that have materially impaired our operations or financial condition. Additional information
regarding risks from cybersecurity threats is provided at &#8220;Item 1A. Risk Factors&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Operating Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Operating Officer and Chief Financial Officer oversee our cybersecurity policies and processes, including those described above
at &#8220;Risk Management and Strategy&#8221;. The cybersecurity risk management program includes tools and activities to prevent, detect,
and analyze current and emerging cybersecurity threats, and plans and strategies to address threats and incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Operating Officer and IT consultant provide periodic briefings to the audit committee regarding the Company&#8217;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues. Our audit committee provides regular updates to the Board of Directors on such reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_003"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_004"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2023 and
2022, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_005"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_006"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_007"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and warrants have traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively, since November 25, 2020. The stock market in general has experienced significant price fluctuations in the past few years.
In some cases, these fluctuations have been unrelated to the operating performance of the affected companies. Many companies have experienced
dramatic volatility in the market prices of their common stock. The Company believes that a number of factors, both within and outside
its control, could cause the price of the Company&#8217;s common stock to fluctuate, perhaps substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the range of reported closing prices of the Company&#8217;s common stock during the periods presented, and
have been retroactively adjusted for all periods presented to reflect the 1-for-10 reverse split of the Company&#8217;s outstanding shares
of common stock effected on June 2, 2023. Such quotations reflect prices between dealers in securities and do not include any retail
mark-up, markdown, or commissions, and may not necessarily represent actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year Ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">First Quarter</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Second Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Third Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fourth Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.70</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">First Quarter</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Second Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Third Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fourth Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2024, the Company had 46 stockholders of record holding 2,249,290 shares of the Company&#8217;s common stock outstanding,
including 1,950,893 shares of common stock held by an indeterminate number of beneficial owners of securities whose shares are held in
the names of various depository accounts, brokerage firms and clearing agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s dividend policy is determined by its Board of Directors and will depend upon a number of factors, including the Company&#8217;s
financial condition and performance, its cash needs and expansion plans, income tax consequences, and the restrictions that applicable
laws and any credit or other contractual arrangements may then impose. The Company has not paid any cash dividends on its common stock
to date and at the current time the Company does not anticipate paying a cash dividend on its common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized For Issuance Under Equity Incentive Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth in the table below is information regarding awards made through compensation plans or arrangements through December 31, 2023, the
most recently completed fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 securities to<br/>
 be issued upon<br/>
 exercise of<br/>
 outstanding<br/>
 options, warrants<br/>
 and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 price of<br/>
 outstanding<br/>
 options, warrants<br/>
 and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities<br/>
    remaining<br/> available for<br/> future issuance<br/> under&#160;compensation<br/>
 plans (excluding<br/>
 securities reflected<br/>
 in column 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(1)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(2)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(3)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity Compensation Plans Approved by Security Holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">495,000</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11.692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">255,000</td><td style="width: 1%; text-align: left">(2)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Compensation Plans Not Approved by Security Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not include 57,083 shares issuable that were not issued pursuant to a plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    255,000 shares that remain available are pursuant to the Company&#8217;s 2020 Stock Incentive Plan, which was adopted on July 14,
    2020 and amended on October 7, 2022 and November 27, 2023 (see &#8220;ITEM 11. EXECUTIVE COMPENSATION&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_008"></span>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_009"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the following discussion and analysis of our financial condition and results of operations together with and our consolidated
financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information,
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results
may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited
to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>President
and Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#8217;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors. Dr. Kovach was also the Company&#8217;s Chief Scientific Officer.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with the National Institute
of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;), each an institute or
center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has licensed exclusively
NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) subject invention
co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination
with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for
the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis,
until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed
territory, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $50,000 and a first minimum annual royalty
of $30,000, within sixty days from the effective date of the Agreement. The first minimum annual royalty may be prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $30,000 is due each January
1 and may be credited against any earned royalties due for sales made in that year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively,
each with a different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 31, 2024
benchmark is defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The total of all such benchmark payments is $1,225,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of 5% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the Company recorded a net loss of $5,087,029 and used cash in operations of $4,293,265. At December
31, 2023, the Company had cash of $4,203,488 available to fund its operations. Because the Company is currently engaged in various early-stage
clinical trials, it is expected that it will take a significant amount of time and resources to develop any product or intellectual property
capable of generating sustainable revenues. Accordingly, the Company&#8217;s business is unlikely to generate any sustainable operating
revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its technology,
product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive
earnings and operating cash flows. At December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to
clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated approximately $6,344,000, which are currently
scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2023. The Company&#8217;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through approximately &#160;September 30, 2024. However, existing cash resources will not be sufficient to complete the development
of and obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able to proactively
manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating plans may change
as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed
sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Listing and Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbols &#8220;LIXT&#8221;
and &#8220;LIXTW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. No fractional shares were issued in connection with the reverse split,
with any fractional shares resulting from the reverse split being rounded up to the next whole share. All share and per share amounts
and information presented herein have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement
of Nasdaq over time, or that it will be successful in maintaining compliance with any of the other continued listing requirements of
Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued accounting pronouncements that may potentially impact the Company&#8217;s consolidated financial statements,
including their presentation and related disclosures, is provided in Note 2 to consolidated financial statements included elsewhere in
this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing 23.3% and 25.6% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing 18.4% and 30.3%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing 29.9%, 25.2%
and 13.7%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing 21.0%, 19.3%, 15.1% and 12.1%, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company&#8217;s
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#8217;s President
and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and Licensing Legal and Filing Fees and Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs are charged to operations
as incurred. Patent and licensing legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2023 and 2022, patent and licensing legal and filing fees and costs related to the development and protection
of the Company&#8217;s intellectual property, primarily related to LB-100, were $978,244 and $1,268,308, respectively, a decrease of
$290,064, or 22.9%, in 2023 as compared to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
September 2023, the Company appointed a new President and Chief Executive Officer, who, with the assistance of the Company&#8217;s management,
Board of Directors and patent legal counsel, conducted a comprehensive analysis of the Company&#8217;s extensive patent portfolio in
order to implement a program to balance patent prosecution costs with intellectual property protection benefits. As a result, the Company
identified certain patent filings that it does not intend to continue to support in 2024 and thereafter. The Company expects that patent
and licensing legal and filing fees and costs will continue to be a significant continuing cost in 2024 as the Company continues to develop
and expand its patent portfolio related to the clinical development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
descriptive summary of the patent portfolio for the Company&#8217;s most important clinical programs involving the development of LB-100,
as well as a detailed listing of each domestic and international patent that has been issued, is presented at &#8220;ITEM 1. BUSINESS
&#8211; Intellectual Property&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing meet the requirements for equity classification. This assessment, which requires the use
of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Business Activities and Plans </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by developing a drug class called
Protein Phosphatase 2A inhibitors. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents
and/or x-ray, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have
significant therapeutic potential to enhance a broad range of anti-cancer therapies. The Company is focusing on the clinical development
of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses
that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing its development activities on its LB-100 series of drugs. The Company believes that the mechanism by which compounds
of the LB-100 series affect cancer cell growth is different from cancer agents currently approved for clinical use. Lead compounds of
the LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead
compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma,
all cancers of neural tissue. Lead compounds of the LB-100 series also have activity against melanoma, breast cancer and sarcoma in animal
models and enhance the effectiveness of commonly used anti-cancer drugs in these animal models. The enhancement of anti-cancer activity
of these anti-cancer drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that,
when combined with standard anti-cancer regimens against many tumor types, the Company&#8217;s compounds will improve therapeutic benefit
without unacceptable toxicity in humans. The Company is not currently planning to allocate resources to further develop its LB-200 series
of drugs,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to expand the breadth and depth of its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead,
moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain
milestones are reached. The Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements
with pharmaceutical companies with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although Covid-19 outbreak has
subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates has had a material effect on its
operations to date, other than its impact on the general economy. However, there is a risk that the Company&#8217;s operating costs could
become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital may all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations,
and is dependent on its ability to raise equity capital to fund its operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of operations as discussed herein are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
    Ended December 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
    and expenses:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative costs:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    to related parties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,718,180</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,547,615</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    and licensing legal and filing fees and costs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">978,244</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,268,308</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    costs and expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,495,712</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,146,789</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development costs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">898,100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,349,269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    costs and expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,090,236</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,311,481</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,090,236</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,311,481</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,486</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,195</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,875</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency gain (loss)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,954</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,374</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,087,029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,312,535</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per common share &#8211; basic and diluted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.99</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common shares outstanding &#8211; basic and diluted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,915,838</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,582,029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the year ended December 31, 2023, general and administrative costs were $4,192,136, which consisted
of the fair value of vested stock options issued to directors and officers of $773,203, patent and licensing legal and filing fees and
costs of $978,244, other consulting and professional fees of $655,854, insurance expense of $442,976, officer salaries and related costs
of $841,709, cash-based director and board committee fees of $163,479, shareholder reporting costs of $93,860, listing fees of $62,000,
filing fees of $17,125, taxes and licenses of $73,877, investor relations of $59,238, rent of $15,571 and other operating costs of $24,109,
offset by a credit to licensing fees of $9,109 relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, general and administrative costs were $4,962,712, which consisted of the fair value of vested stock
options issued to directors and officers of $1,502,776, patent and licensing legal and filing fees and costs of $1,268,308, other consulting
and professional fees of $450,243, insurance expense of $453,417, officer salaries and related costs of $831,890, cash-based director
and board committee fees of $266,020, shareholder reporting costs of $40,790, listing fees of $59,500, filing fees of $12,183, taxes
and licenses of $15,071, investor relations of $17,293, rent of $937, licensing fees of $25,000, and other operating costs of $19,284.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs decreased by $770,576, or 15.5%, in 2023 as compared to 2022, primarily as a result of a decrease in the fair
value of vested stock options issued to directors and officers of $729,573, a decrease in patent and licensing legal and filing fees
and costs of $290,064, a decrease in cash-based director and board committee fees of $102,541, a decrease in licensing fees of $27,808,
offset by an increase in consulting and professional fees of $205,611, an increase in shareholder reporting of $53,070, an increase in
taxes and licenses of $58,806, an increase in investor relations of $41,945, and an increase in rent of $14,634.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the year ended December 31, 2023, research and development costs were $898,100, which consisted of clinical
and related oversight costs of $416,269, regulatory service costs of $18,738, and preclinical research focused on development of additional
novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $463,093.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, research and development costs were $1,349,269, which consisted of the fair value of vested stock options
issued to a consultant of $43,264, regulatory service costs of $6,770, contractor costs incurred in connection with the synthesis work
done to develop a new supply of LB-100 for the Spanish clinical trial of $352,862, clinical and related oversight costs of $356,384,
and preclinical research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline
of $589,989.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in preclinical research costs for the years ended December 31, 2023 and 2022 were $226,150 and $204,158, respectively, of costs paid
to the Netherlands Cancer Institute, which employs Dr. Ren&#233; Bernards, a director of the Company since June 15, 2022. On October
8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one of the
world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify
the most promising drugs to be combined with LB-100, and potential LB-100 analogues, to be used to treat a range of cancers, as well
as to identify the specific molecular mechanisms underlying the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provides for additional research activities, extends the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and adds 500,000 Euros (approximately $542,000 at December 31, 2023) to the operating budget being funded by the
Company (see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer Institute&#8221;
below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $451,169, or 33.4%, in 2023 as compared to 2022, primarily as a result of a decrease in the fair value
of vested stock options issued to directors and officers of $43,264, a decrease in contractor costs incurred in connection with the synthesis
work done to develop a new supply of LB-100 for the Spanish clinical trial of $352,862, and a decrease in preclinical research focused
on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $126,896, offset by an increase
in clinical and related oversight costs of $59,885.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the year ended December 31, 2023, the Company had interest income of $17,486, as compared to interest income of $11,195
for the year ended December 31, 2022, related to the investment of funds generated by the Company&#8217;s financing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the year ended December 31, 2023, the Company had interest expense of $16,233, as compared to interest expense of $8,875
for the year ended December 31, 2022, related to the financing of the premium for the Company&#8217;s directors and officers liability
insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Gain (Loss)</span>. For the year ended December 31, 2023, the Company had a foreign currency gain of $1,954, as compared to a foreign
currency loss of $3,374 for the year ended December 31, 2022, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the year ended December 31, 2023, the Company incurred a net loss of $5,087,029, as compared to a net loss of $6,312,535
for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources &#8211; December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of cash flows as discussed herein are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,293,265</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,611,737</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,143,361</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,141,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,146,904</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">529,647</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had working capital of $3,994,762, as compared to working capital of $5,165,227 at December 31, 2022,
reflecting a decrease in working capital of $1,170,465 for the year ended December 31, 2023. The decrease in working capital during the
year ended December 31, 2023 was primarily the result of the funding of the Company&#8217;s ongoing research and development activities
and other ongoing operating expenses, including maintaining and developing the Company&#8217;s patent portfolio, offset by proceeds from
the sale of securities on July 20, 2023. At December 31, 2023, the Company had cash of $4,203,488 available to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design, and results of the Company&#8217;s clinical trial program, which, in turn, depends on
the availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through approximately September 30, 2024. However, existing cash resources will not be sufficient to complete the development
of and obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able to proactively
manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating plans may change
as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed
sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred aggregated $6,344,000, which are currently scheduled to be incurred through approximately
December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet
arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Activities</span>. For the year ended December 31, 2023, operating activities utilized cash of $4,293,265, as compared to utilizing cash
of $4,611,737 for the year ended December 31, 2022, to fund the Company&#8217;s ongoing research and development activities and to fund
its other ongoing operating expenses, including maintaining and developing its patent portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investing
Activities</span>. For the years ended December 31, 2023 and 2022, the Company had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Activities</span>. For the year ended December 31, 2023, financing activities consisted primarily of the gross proceeds from the sale of
securities in the Company&#8217;s registered direct offering of $3,499,964, reduced by offering costs of $362,925, and $6,281 from the
exercise of common stock options. For the year ended December 31, 2022, financing activities consisted of the gross proceeds from the
sale of securities in the Company&#8217;s registered direct offering of $5,800,000, reduced by offering costs of $658,616.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $6,412,000, including clinical trial agreements of $6,013,000
and clinical trial monitoring agreements of $399,000, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified, suspended
or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein should be
considered as estimates only based on current clinical assumptions and conditions and are typically subject to significant modifications
and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information with respect to the conduct of the Company&#8217;s clinical trial programs is provide at &#8220;ITEM 1A. RISK FACTORS - Risks
Related to the Development and Regulatory Approval of Our Product Candidates&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Description
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
                                            Trial</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Type
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
                                            Trial</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Institution</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-size: 9pt"><b>Estimated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Start
                                            Date</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Estimated End Date</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-size: 9pt"><b>N<span style="font-family: Times New Roman, Times, Serif">umber
                                            of Patients</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>in
                                            Trial</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Study Objective</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Clinical Update</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">NCT No.</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Financial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Commitment</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 10%; text-align: left"><span style="font-size: 9pt">LB-100 combined with carboplatin, etoposide
    and atezolizumab in small cell lung cancer</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 9pt">Phase 1b</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 9pt">City of Hope and Sarah Cannon</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 9pt">March 2021</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 9pt">March 2026</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 9pt">14 to 36</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 9pt">Determine RP2D</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 9pt">Three patients entered</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 9pt">NCT04560972</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt">2,433,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">LB-100 combined with doxorubicin in sarcoma</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">Phase 1b</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">GEIS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">June 2023</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">June 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">9 to 18</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Determine MTD and RP2D</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">One patient entered</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">NCT05809830</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">3,580,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">LB-100 in high grade gliomas</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Phase 0 pharmacology study</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">National Cancer Institute</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">January 2019</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">August 2022</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">7</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Determine the penetration of LB-100 into high grade gliomas after IV injection</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Closed. No or minimal penetration of LB-100 into high grade gliomas after
    IV injection</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">NCT03027388</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">Doxorubicin with or without LB-100 in sarcoma</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Randomized Phase 2</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">GEIS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">July 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">June 2026</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">150</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Determine efficacy: PFS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">NCT05809830</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-size: 9pt">(1)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">Phase 1b/2</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">MD Anderson</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">March 2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">December 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt">21</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">Determine the survival of patients with ovarian
    clear cell carcinoma</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 9pt">No patients entered at December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-size: 9pt">NCT06065462</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-size: 9pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">6,013,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial contractual commitment of the GEIS Randomized Phase 2 clinical trial is included in the financial contractual commitment
    of the GEIS Phase 1b trial. .</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is no remaining financial contractual commitment associated with this clinical trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated
ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase
2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the
safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration of overall
response, progression-free survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability,
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $69,001 and $0, respectively, pursuant to this agreement, which
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December 31, 2023,
total costs of $447,512 have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $2,433,000
as of December 31, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$800,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $1,144,000. Although the production of new inventory
has been completed, nominal trailing costs subsequent to December 31, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b portion of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2023 and 2022, the Company incurred costs of $268,829 and $260,770, respectively, pursuant to this
agreement. Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of
operations. Through December 31, 2023, the Company has paid GEIS an aggregate of $684,652 for work done under this agreement through
the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $3,580,000
as of December 31, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The clinical trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)
and is being conducted at The University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly
and financial support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical
trial. The Company currently expects that this clinical trial will be completed by July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years, unless terminated earlier by the
Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a
Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound
LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally
well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent
in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. In this clinical trial, single agent LB-100 was used on a new schedule of
days 1, 3, and 5 every 3 weeks. Although MTD was not achieved, there was no dose-limiting toxicity on this schedule at doses that were
greater than the MTD in the Phase 1 clinical trial of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $16,165 and $26,397, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December
31, 2023, total costs of $147,239 have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the years ended December 31, 2023 and 2022, the Company incurred costs of $20,884 and $35,403,
respectively, pursuant to this work order. As of December 31, 2023, total costs of $148,172 have been incurred pursuant to this work
order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the year ended December 31, 2023
(see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to December 31, 2023
are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $335,000. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $20,240 and $33,815, respectively, pursuant to this work order. As of December 31, 2023, total costs of $78,681 have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $258,000 as of December 31, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas. The study
is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately
72% to Theradex for services and approximately 28% for payments for pass-through software costs. During the year ended December 31, 2023,
the Company incurred costs of $14,862, pursuant to this work order. As of December 31, 2023, total costs of $14,862 have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $141,000 as of December 31, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $9,109, representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement. During the year ended December 31, 2022, the Company recorded charges to operations
of $25,000, in connection with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $640,000, payable monthly. These employment agreements were automatically renewable for additional one-year periods unless terminated
by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause.
These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $775,000, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $200,000. In addition,
Mr. Forman is being provided an office allowance of approximately $1,500 per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $150,000. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined at the sole discretion of the Board of Directors. Mr. van der Baan was appointed as Chairman of
the Board of Directors upon the death of Dr. Kovach, who died on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers was $700,000 as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $4,000. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $16,000 and $16,000 for the years
ended December 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation. The Company recorded charges to
operations pursuant to this Collaboration Agreement of $120,000 and $120,000 for the years ended December 31, 2023 and 2022, respectively,
which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht,
a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently modified
by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined with
LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms
underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of 391,000 Euros and provide a sufficient
supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
500,000 Euros (approximately $542,000 at December 31, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred charges in the amount of $226,150 and $204,158, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2023, total costs of $485,556 have been incurred pursuant to this agreement, as amended. The Company&#8217;s aggregate
commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $595,000 as of December
31, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros,
final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $273,980 for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$326,274 for services to be rendered through April 30, 2024. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $32,307 and $27,702, respectively, pursuant to this work order. As of December 31, 2023, total costs of $248,298 have been incurred
pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $78,000 as
of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends,
Events and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development of new pharmaceutical compounds is, by its nature, unpredictable. Although we will undertake research and development
efforts with commercially reasonable diligence, there can be no assurance that our cash position will be sufficient to enable us to develop
our pharmaceutical compounds to the extent needed to create future sales to sustain operations as contemplated herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that our pharmaceutical compound will obtain the regulatory approvals and market acceptance to achieve sustainable
revenues sufficient to support our operations. Even if we are able to generate revenues, there can be no assurance that we will be able
to achieve operating profitability or positive operating cash flows. There can be no assurance that we will be able to secure additional
financing, to the extent required, on acceptable terms or at all. If cash resources are insufficient to satisfy our ongoing cash requirements,
we would be required to reduce or discontinue our research and development programs, or attempt to obtain funds, if available, through
strategic alliances that may require us to relinquish rights to our pharmaceutical compounds, or to curtail or discontinue our operations
entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, we are not currently aware of any trends, events or uncertainties that are likely to have a material effect
on our financial condition in the near term, although it is possible that new trends or events may develop in the future that could have
a material effect on our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_010"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_011"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements and notes thereto and the related report of its independent registered public accounting
firm are attached to this Annual Report on Form 10-K beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_012"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_013"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) that is designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its
principal executive officer(s) and principal financial officer(s), or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed under the supervision and with the participation of
the Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, of the effectiveness of the design
and operation of the Company&#8217;s disclosure controls and procedures as of the fiscal year ended December 31, 2023, the end of the
most recent fiscal year covered by this report. Based on that evaluation, the Company&#8217;s management concluded that the Company&#8217;s
disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the
Company&#8217;s reports filed or submitted under the Exchange Act was recorded, processed, summarized, and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, is responsible for establishing and
maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act). Internal
control over financial reporting is a process, including policies and procedures, designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with
U.S. generally accepted accounting principles. The Company&#8217;s internal control over financial reporting is designed to ensure that
material information regarding the Company&#8217;s operations is made available to management and the Board of Directors to provide them
reasonable assurance that the published financial statements are fairly presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management assessed the Company&#8217;s internal control over financial reporting based on the Internal Control&#8212;Integrated
Framework (2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). The Company&#8217;s
system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those
systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Furthermore, smaller
reporting companies face additional limitations. Smaller reporting companies employ fewer individuals and can find it more difficult
to properly segregate duties. Smaller reporting companies also tend to utilize general accounting software packages that lack a rigorous
set of software controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is
a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented
or deterred on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s evaluation under the framework in COSO, the Company&#8217;s management, with the participation of its Chief Executive
Officer and its Chief Financial Officer, concluded that the Company&#8217;s internal control over financial reporting was effective as
of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the consolidated financial statements included in this report fairly present, in all material respects, the Company&#8217;s
financial condition, results of operations and cash flows as of and for the period ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Auditor&#8217;s
Report on Internal Control Over Financing Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal
control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered
public accounting firm pursuant to rules of the SEC that permit the Company to provide only management&#8217;s report in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, has determined that no change in the
Company&#8217;s internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities
Exchange Act of 1934) occurred during or subsequent to the period ended December 31, 2023 that has materially affected, or is reasonably
likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_014"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
10b5-1 Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended December 31, 2023, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company <span id="xdx_909_eecd--Rule10b51ArrAdoptedFlag_dbF_c20231001__20231231_zTf4aOsA4ui4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90A_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20231001__20231231_zioBqPr8e5Lh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2023-10-012023-12-31" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-22202"><ix:nonNumeric contextRef="From2023-10-012023-12-31" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-22203">adopted</ix:nonNumeric></ix:nonNumeric></span></span>
or <span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbF_c20231001__20231231_ziUGzOyXURH4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90B_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20231001__20231231_ztOtcaNMcHOf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2023-10-012023-12-31" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-22204"><ix:nonNumeric contextRef="From2023-10-012023-12-31" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-22205">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(a) of Regulation S-K. As of December
31, 2023, the Company did not have a &#8220;Rule 10b5-1 trading arrangement&#8221; in effect with respect to its securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted insider trading policies and procedures governing the purchase, sale, and other disposition of its securities, which
has been filed as an exhibit to this report and has been posted to the investor information/governance section of the Company&#8217;s
corporate website (www.lixte.com).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_015"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_017"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and text set forth the names of all of our directors and executive officers as of March 1, 2024. The Board of Directors
is comprised of only one class. All of the directors will serve until the next annual meeting of stockholders and until their successors
are elected and qualified, or until their earlier death, retirement, resignation or removal. The brief descriptions of the business experience
of each director and executive officers and an indication of directorships held by each director in other companies subject to the reporting
requirements under the Federal securities laws are provided herein below. Also provided are the biographies of the members of the Scientific
Advisory Committee and our consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 63%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)
    Held with the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer, and Chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    James S. Miser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    J. Forman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Stephen J. Forman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Yun Yen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ren&#233; Bernards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biographies
of Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bastiaan
van der Baan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
(&#8220;Bas&#8221;) van der Baan was appointed to the Company&#8217;s Board of Directors effective June 17, 2022. Effective September
26, 2023, Mr. van der Baan replaced the Company&#8217;s founder, Dr. John S. Kovach, as President and Chief Executive Officer. Dr. Kovach
passed away on October 5, 2023. Effective October 6, 2023, as a result of the passing of Dr. Kovach, Mr. van der Baan was appointed as
Chairman of the Board of Directors.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
van der Baan has over 20 years of experience in the biotechnology industry, with a key focus on oncology and diagnostics. He has extensive
knowhow in the process of managing a compound from clinical development to reimbursement and commercialization, as well as the establishment
of partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies and governments to successfully
launch new oncology products. Mr. van der Baan was most recently the Chief Clinical Officer of Agendia, an oncology molecular diagnostic
company based in Irvine, California and Amsterdam, Netherlands through July 15, 2023. Mr. van der Baan is an independent director of
Tethis S.p.A., a Milan, Italy-based developer of a novel platform for liquid biopsy testing. Mr. van der Baan was co-founder of ThromboDx,
a liquid biopsy company that was acquired in 2016, Qameleon Therapeutics, a company developing synthetic lethal drug combinations for
cancer treatment, and Oncosence, an oncology drug development company using senescence as target for drug development. Mr. van der Baan
started his career in 1997 at a specialty chemicals division of Unilever that was acquired by ICI. In 2002, Mr. van der Baan joined Kreatech,
a biotechnology company acquired by Leica that specialized in life science reagents for gene expression, DNA and protein analysis. Mr.
van der Baan holds a Master&#8217;s Degree in Molecular Sciences from the Wageningen University in the Netherlands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
James S. Miser</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
S. Miser, M.D., was appointed as Chief Medical Officer effective August 1, 2020. Dr. Miser is a pediatric hematologist/oncologist, internationally
recognized as an expert in the study and treatment of childhood cancers. His outstanding career includes leadership positions as Clinical
Director, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children&#8217;s Hospital and Medical Center and Associate
Member, Fred Hutchinson Cancer Research Center, Seattle, Washington; Chairman, Division of Pediatrics, Director, Department of Pediatric
Hematology/Oncology, President and Chief Executive Officer, and Chief Medical Officer, at the City of Hope National Medical Center, Duarte,
California. Dr. Miser was a member of the Active Staff, Department of Pediatrics at the City of Hope, until 2022, and Chair Professor,
College of Medical Sciences and Technology, Taipei Medical University, Taipei, Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miser has extensive experience in the clinical development of new anti-cancer drugs for pediatric malignancies, leading many clinical
trials at institutional and national cancer study groups. He is expert in the design and monitoring of clinical cancer trials and was
a member of the Soft Tissue Sarcoma Strategy Group, and Member of the New Agents Executive and Steering Committee, Vice Chairman for
Solid Tumors and Phase II Coordinator for the Children&#8217;s Cancer Group and Chairman, Data Monitoring Committee, National Wilms Tumor
Society. He has authored more than a 100 peer-reviewed articles dealing primarily with pediatric clinical cancer studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Robert
N. Weingarten</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Weingarten was appointed to serve as our Vice President and Chief Financial Officer effective August 12, 2020. Mr. Weingarten is an experienced
business consultant and advisor with a consulting practice focusing on accounting and SEC compliance issues. Mr. Weingarten was familiar
with the financial and business operations of the Company, as he had provided accounting and financial consulting services to the Company
for a number of years prior to his appointment as Vice President and Chief Financial Officer with respect to the preparation of the Company&#8217;s
consolidated financial statements and certain other financial and compliance matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
1979, Mr. Weingarten has provided such financial consulting and advisory services, has acted as chief financial officer, and has served
on the boards of directors of numerous public companies in various stages of development, operation or reorganization. Mr. Weingarten
has experience in a variety of industries, including the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Weingarten has been a Director of Guardion Health Sciences, Inc. since June 2015 and Chairman of its Board of Directors since July 2020.
Mr. Weingarten also serves on the audit, compensation, and nominating and corporate governance committees of Guardion Health Sciences,
Inc. Previously, Mr. Weingarten served as Lead Director on Guardion&#8217;s Board of Directors from January 2017 to March 2020. Mr. Weingarten
received a B.A. in Accounting from the University of Washington in 1974, an M.B.A. in Finance from the University of Southern California
in 1975, and is a Certified Public Accountant (inactive) in the State of California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eric
J. Forman, J.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Forman has led our business development efforts since 2013. Effective as of October 1, 2020, Mr. Forman was appointed as our Chief Administrative
Officer, and effective as of November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer. In his roles as
Chief Administrative Officer and Chief Operating Officer, his responsibilities include overseeing all internal operations, the development
of science/business collaborations, and the management of our growing intellectual property portfolio. Prior to his involvement with
our company, he served as Counsel and Senior Project Manager at Shore Group Associates managing in-house legal, tax, and regulatory affairs
and supervising client relations for financial software and mobile application development teams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an attorney, Mr. Forman has represented and advised both technology and biotechnology companies, entrepreneurs, non-profits, and start-ups
with a focus on intellectual property, licensing, corporate structure and transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Forman earned a B.A. degree Cum Laude from Loyola Marymount University and a J.D. from the Benjamin N. Cardozo School of Law. He has
an active law license and is a member of the New York State Bar Association.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Stephen J. Forman</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
J. Forman, M.D., was appointed to our Board of Directors effective May 13, 2016. Dr. Forman is an internationally recognized expert in
hematologic malignancies and bone marrow transplantation, and is a leader in preclinical and clinical cancer research. Dr. Forman was
appointed to our Board of Directors on May 13, 2016. He is co-editor of Thomas&#8217; Hematopoietic Cell Transplantation, a definitive
textbook for clinicians, scientists and health care professionals. Dr. Forman is the Francis and Kathleen McNamara Distinguished Chair
in Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, a position he has held since 1987.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
nearly 40 years at the City of Hope, Dr. Forman has been instrumental in advancing the survival rates for patients suffering from cancers
of the blood and immune system such as leukemia, lymphoma and myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Director of the T Cell Immunotherapy Research Laboratory, his current research is focused on cancer immunotherapy, using the body&#8217;s
own immune system to attack cancer. Pharmacological enhancement of patients&#8217; immune responses to their cancers is of special interest
to the Company, as the enzyme target of its lead clinical compound, LB-100, has been reported to be critical to immune function. Much
of Dr. Forman&#8217;s current work centers on T-cells and their cancer-fighting potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Yun Yen</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yun
Yen, M.D., Ph.D., F.A.C.P., was appointed to our Board of Directors effective August 4, 2018. Dr. Yen is a physician, scientist, innovator,
and philanthropist. Dr. Yen was appointed to our Board of Directors on August 4, 2018. He is widely regarded as an expert in ribonucleotide
reductase, a critical target in cancer therapy and diagnostics. He is President Emeritus of Taipei Medical University (TMU) and Chair
Professor of the Ph.D. Program for Cancer Biology and Drug Discovery. Prior to TMU, Dr. Yen was the Allen and Lee Chao Endowed Chair
in Developmental Cancer Therapeutics, Chair of Molecular Pharmacology Department, Associate Director for Translational Research, and
Co-Director of the Developmental Cancer Therapeutics Program at the City of Hope NCI-designated Comprehensive Cancer Center, Duarte California.
He has published more than 300 peer-reviewed articles, holds over 60 patents, and has commercialized multiple methodologies involving
nanoparticles, small and large molecule drugs, biomarkers, stem cells, and medical devices. Dr. Yen has also founded philanthropic organizations
aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent
Genetics and Tanvex BioPharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regina
Brown, CPA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
Brown was appointed to our Board of Directors effective May 11, 2021. Ms. Brown has been a practicing accountant for over thirty years.
Her practice has a wide range of clients, varying in size, industry and geographic locations, including large national corporations listed
on the New York Stock Exchange, as well as Southern California businesses. Other clients consist of professionals, wholesalers and high
net worth individuals. Many of her clients have international and cross-border operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a consequence of her depth of experience, she regularly assists other professionals with their client&#8217;s issues and performs tax
research and analysis in connection with litigation and other matters, including marital dissolution, tax and accounting with respect
to mergers and acquisitions, implementation of internal controls, and extensive work in the area of trusts and estates. International
tax matters and compliance are also a significant part of her practice. Ms. Brown is a member in good standing of the California Society
of CPAs and the American Institute of Certified Public Accountants and has appeared as a speaker before both organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ren&#233; Bernards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Ren&#233; Bernards was appointed to our Board of Directors effective June 15, 2022. Dr. Bernards is a leader in the field of molecular
carcinogenesis, working at the Netherlands Cancer Institute in Amsterdam. His research focuses on identifying effective new drug combinations,
new drug targets, and mechanisms of resistance to anti-cancer drugs. He has also co-founded four biotechnology companies to bring his
scientific discoveries to clinical oncology practice. He is a member of the Royal Netherlands Academy of Sciences, an International Honorary
Member of the American Academy of Arts and Sciences and an International Member of the National Academy of Sciences (USA). Additionally,
he is a fellow of the American Association for Cancer Research (AACR). Dr. Bernards has presented new data on the unexpected effectiveness
of the Company&#8217;s lead clinical compound, LB-100, when given with a variety of standard and investigational anti-cancer compounds
that have only modest activity on their own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Scientific Advisory Committee was established to advise our management in three areas: human molecular pathology; the clinical management
of human brain tumors; and medicinal chemistry. Our objective is to meet with the committee as a group annually. The committee has been
apprised of our general objectives and several of the specific challenges and leads for developing improved therapies for human brain
tumors. Members of the committee do not serve in any management capacity with us. The committee currently consists of one member, as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Daniel D. Von Hoff</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Daniel D. Von Hoff, M.D., is currently Physician in Chief, Distinguished Professor and Director of the Clinical Translational Research
Division at the Translational Genomics Research Institute in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and
for Scottsdale Healthcare&#8217;s Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale,
Arizona. Dr. Von Hoff is a Fellow of the American College of Physicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Von Hoff&#8217;s major interest is in the development of new anti-cancer agents, both in the clinic and in the laboratory. He and his
colleagues were involved in the beginning of the development of many of the agents that are now used routinely, including mitoxantrone,
fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine and lapatinib. At present, he and his colleagues
are concentrating on the development of molecularly targeted therapies, particularly for patients with advanced pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Von Hoff has published more than 620 papers, 137 book chapters and over 1,050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky
Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant
improvement in patient care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Von Hoff was appointed to President Bush&#8217;s National Cancer Advisory Board from 2004 to 2010. Dr. Von Hoff is the past President
of the American Association for Cancer Research (the world&#8217;s largest cancer research organization), a Fellow of the American College
of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX&#8482; Oncology,
Inc. (acquired by Genzyme in 2004 after Ilex had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia).
Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs &#8211; The Journal of New Anticancer Agents; and, Editor-in-Chief
of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
Forman, our Vice President and Chief Operating Officer, is the son of board member Dr. Stephen Forman and son-in-law of former board
member Gil Schwartzberg, who passed away on October 30, 2022. Julie Forman, the wife of Eric Forman and the daughter of the late Gil
Schwartzberg, is Vice President of Morgan Stanley Wealth Management, where the Company&#8217;s cash is deposited and the Company maintains
a continuing banking relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through
meetings of the Board of Directors and its standing committees. We have a standing audit committee and compensation committee. The Board
of Directors serves in place of a nominating and corporate governance committee. In addition, from time to time, special committees may
be established under the direction of the Board of Directors when necessary to address specific issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the proposed scope and results of the audit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving audit and non-audit fees and services;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving transactions between us and our directors, officers and affiliates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for complaints received by us regarding accounting matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    internal audit functions, if any; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee currently consists of Regina Brown, Dr. Yun Yen and Dr. Ren&#233; Bernards, with Ms. Brown serving as chair. Our Board
of Directors has determined that each of the committee members meet the definition of an &#8220;independent director,&#8221; as defined
under Nasdaq rules, and that they each meet the independence standards under Rule 10A-3 of the Exchange Act. Each member of our audit
committee meets the financial literacy requirements of the Nasdaq rules. In addition, our Board of Directors has determined that Ms.
Brown qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K. Our
Board of Directors has adopted a written charter for the audit committee, which is available on our corporate website at www.lixte.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending the compensation arrangements for executive management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our stock incentive plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee currently consists of Dr. Yun Yen, Regina Brown and Dr. Ren&#233; Bernards, with Dr. Yen serving as chair. Our
Board of Directors has determined that each of the three committee members meet the definition of an &#8220;independent director&#8221;,
as defined under Nasdaq rules. Our Board of Directors has adopted a written charter for the compensation committee, which is available
on our corporate website at www.lixte.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Board of Directors serves in place of a nominating and corporate governance committee, our independent directors on the Board of
Directors are responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominating
    members of the Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    a set of corporate governance principles applicable to the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our Board of Directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors may adopt resolutions addressing, among other things, the nomination process, as may be necessary in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has adopted a code of ethics covering all of our executive officers and key employees. A copy of our code of ethics
will be furnished without charge to any person upon written request. Requests should be sent to: Secretary, Lixte Biotechnology Holdings,
Inc., 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Liability and Indemnification Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation contains provisions that limit the liability of our current and former directors for monetary damages to
the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for
monetary damages for any breach of fiduciary duties as directors, except liability for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation
    Law; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides that we are authorized to indemnify our directors and officers to the fullest extent permitted
by Delaware law. Our Amended and Restated Bylaws provide that we are required to indemnify our directors and executive officers to the
fullest extent permitted by Delaware law. Our Amended and Restated Bylaws also provide that, upon satisfaction of certain conditions,
we are required to advance expenses incurred by a director or executive officer in advance of the final disposition of any action or
proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out
of their actions in that capacity, regardless of whether we would otherwise be permitted to indemnify them under the provisions of Delaware
law. Our Amended and Restated Bylaws also provide our Board of Directors with discretion to indemnify our other officers and employees
when determined appropriate by our Board of Directors. We have entered into agreements to indemnify our directors, executive officers
and other employees as determined by the Board of Directors. With certain exceptions, these agreements provide for indemnification for
related expenses, including, among other things, attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these
individuals in any action or proceeding. We believe that these provisions and agreements are necessary to attract and retain qualified
persons as directors and officers. We have obtained customary directors and officers liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification provisions in our Certificate of Incorporation and Amended and Restated Bylaws may discourage
stockholders from bringing a lawsuit against our directors for an alleged breach of their fiduciary duty. These provisions may also reduce
the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and
other stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement
and damage awards against directors and officers as required by these indemnification provisions. At present, there is no pending litigation
or proceeding involving any of our directors, officers or employees for which indemnification is sought, and we are not aware of any
threatened litigation that may result in claims for indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance
with Section 16(a) of the Securities Exchange Act of 1934, as Amended</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Securities Exchange Act of 1934, as amended, requires the Company&#8217;s directors and executive officers and persons who
own more than 10% of a registered class of the Company&#8217;s equity securities to file various reports with the Securities and Exchange
Commission concerning their holdings of, and transactions in, securities of the Company. Copies of these filings are required to be furnished
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, based solely on its review of the copies of the Section 16(a) reports furnished to the Company and any
written representations to the Company that no other reports were required, the Company believes that all individual filing requirements
applicable to a director, officer, or beneficial owner of more than 10% of the Company&#8217;s common stock were complied with under
Section 16(a) of the Exchange Act during the year ended December 31, 2023, except as follows: Bas van der Baan was late in filing his
Form 4 in connection with his appointment as President and Chief Executive Officer on September 26, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_018"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFICER
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents the compensation awarded to, earned by, or paid to our named executive officers for the years ended December
31, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFICER
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Executive</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Qualified Deferred Compensation Earnings ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Bas van der Baan (6)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: center">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">40,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">403,066</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">443,705</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">John S. Kovach (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,860</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">James S. Miser (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert N. Weingarten (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,640</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eric J. Forman (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,459</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,667</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Consists of grant date fair value of option award calculated pursuant to the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
John S. Kovach was the President and Chief Executive Officer from inception through September 26, 2023. Effective July 15, 2020, the
Company entered into an employment agreement with Dr. Kovach. On November 6, 2022, Dr. Kovach was awarded an option grant for 20,000
shares of common stock, exercisable for a period of five years at $20.00 per share and valued at $3.282 per share. The employment agreement
with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
James S. Miser has been the Chief Medical Officer since August 1, 2020. In connection with his employment agreement, Dr. Miser was awarded
an option grant for 8,334 shares of common stock, exercisable for a period of five years at $71.40 per share and valued at $68.718 per
share. On November 6, 2022, Dr. Miser was awarded an option grant for 20,000 shares of common stock, exercisable for a period of five
years at $20.00 per share and valued at $3.282 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Robert N. Weingarten has been the Vice President and Chief Financial Officer since August 12, 2020. In connection with his employment
agreement, Mr. Weingarten was awarded an option grant for 5,833 shares of common stock, exercisable for a period of five years at $71.40
per share and valued at $68.718 per share. On November 6, 2022, Mr. Weingarten was awarded an option grant for 20,000 shares of common
stock, exercisable for a period of five years at $20.00 per share and valued at $3.282 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Eric J. Forman was the Chief Administrative Officer from July 15, 2020 to November 6, 2020. In connection with his employment agreement,
Mr. Forman was awarded an option grant for 5,833 shares of common stock, exercisable for a period of five years at $71.40 per share and
valued at $68.718 per share. Effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer. On November
6, 2022, Mr. Forman was awarded an option grant for 20,000 shares of common stock, exercisable for a period of five years at $20.00 per
share and valued at $3.282 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Bas van der Baan has been President and Chief Executive Officer since September 26, 2023. In connection with his employment agreement,
Mr. van der Baan was awarded an option grant for 250,000 shares of common stock exercisable for a period of five years at $1.95 per share
and valued at $1.612 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no option exercises by officers during the years ended December 31, 2023, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents information regarding outstanding stock options held by our named executive officers as of December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAME</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GRANT </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VESTING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMENCEMENT</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER OF</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDERLYING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISABLE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER OF</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDERLYING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISABLE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRICE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%; text-align: left">Bas van der Baan</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">September 26, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">20,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">229,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">September 26, 2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. John S. Kovach</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">October 5, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. James S. Miser</td><td>&#160;</td>
    <td style="text-align: center">August 1, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 1, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 1, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert N. Weingarten</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eric J. Forman</td><td>&#160;</td>
    <td style="text-align: center">May 22, 2019</td><td>&#160;</td>
    <td style="text-align: center">May 22, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">May 22, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2027</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $2.35 per share on December 31, 2023, the intrinsic value attributed to exercisable but unexercised common
stock options held by our named executive officers was approximately $8,000 at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements; Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements
are automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the
end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed
for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
John Kovach</b>. On July 15, 2020, the Company entered into an employment agreement with Dr. John Kovach to continue to act as the Company&#8217;s
President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $250,000, payable monthly. His responsibilities
included the oversight of the Company&#8217;s entire operations and strategic planning, and to act as the primary contact between the
Company&#8217;s executive team and the Board of Directors, to whom he reported. Dr. Kovach supervised all scientific endeavors, providing
guidance to the Chief Medical Officer. He was the principal spokesperson for the Company. The effective date of the agreement was October
1, 2020 and remained in effect until the earlier of (i) one year from the effective date, automatically renewable for additional one-year
periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, (ii) his death,
or (iii) termination for cause. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eric
Forman.</b> On July 15, 2020, as amended on August 12, 2020, the Company entered into an employment agreement with Eric Forman, to act
as the Company&#8217;s Chief Administrative Officer reporting directly to the Company&#8217;s Chief Executive Officer, with an annual
salary of $120,000, payable monthly. Effective May 1, 2021, Mr. Forman&#8217;s annual salary was increased to $175,000. Effective November
6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $200,000. Mr. Forman&#8217;s
primary function is to oversee the Company&#8217;s internal operations, including IT, licensing, legal, personnel, marketing, and corporate
governance. Mr. Forman was also granted stock options to acquire 350,000 shares of the Company&#8217;s common stock. The effective date
of the employment agreement was October 1, 2020 and remains in effect until the earlier of (i) one year from the effective date, automatically
renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable
one-year period, (ii) his death, or (iii) termination for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
James Miser</b>. On August 1, 2020, the Company entered into an employment agreement with Dr. James Miser, M.D., pursuant to which Dr.
Miser was appointed as the Company&#8217;s Chief Medical Officer, with an annual salary of $150,000. Effective May 1, 2021, Dr. Miser&#8217;s
annual salary was increased to $175,000. Under the employment agreement, Dr. Miser plays a leadership role in planning, implementation
and oversight of clinical trials. Dr. Miser is responsible for assisting and developing strategic clinical goals and the implementation
and safety monitoring of investigational studies. Dr. Miser is the primary medical monitor for all clinical investigational studies and
for the oversight of third party CRO monitors. Dr. Miser works closely with the Company&#8217;s Chief Executive Officer on the development
of specific goals needed to ensure the timely implementation of appropriate clinical studies needed for successful FDA approval of therapeutic
products and the clinical development of new drugs. Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s
activities. Dr. Miser was also granted stock options to acquire 500,000 shares of the Company&#8217;s common stock. The effective date
of the agreement was August 1, 2020 and remains in effect until the earlier of (i) one year from the effective date, automatically renewable
for additional one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year
period, (ii) his death, or (iii) termination for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
N. Weingarten</b>. On August 12, 2020, the Company entered into an employment agreement with Robert N. Weingarten pursuant to which Mr.
Weingarten was appointed as the Company&#8217;s Vice-President and Chief Financial Officer, with an annual salary of $120,000. Effective
May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased to $175,000. Mr. Weingarten was also granted stock options to acquire
350,000 shares of the Company&#8217;s common stock. The effective date of the agreement was August 12, 2020 and remains in effect until
the earlier of (i) one year from the effective date, automatically renewable for additional one-year periods unless terminated by either
party upon 60 days written notice prior to the end of the applicable one-year period, (ii) his death, or (iii) termination for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bas
van der Baan</b>. Effective September 26, 2023, the Company entered into an employment agreement with Bas van der Baan to act as the
Company&#8217;s President and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $150,000.
Effective October 6, 2023, Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October
5, 2023. Mr. van der Baan&#8217;s annual salary may be increased from time to time at the sole discretion of the Board of Directors.
In addition, Mr. van der Baan will be eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors.
Mr. van der Baan was also granted stock options to acquire 250,000 shares of the Company&#8217;s common stock. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination provisions as described in the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Practices &#8211; Option Grants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors.
</b>The Company has a comprehensive compensation program for its non-officer directors for their service on the Board of Directors. This
program, as amended, has been in place since April 9, 2021. The Company, with the input and advice of its Compensation Committee, has
issued only stock options to its officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors under this compensation program is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase 25,000 shares of common stock, exercisable for a period of five years,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $100,000 to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
10,000 shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $40,000 to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Officers.
</b>The Company has no specific policy or program with respect to the discretionary grant of options to its officers. The Company granted
options to its officers concurrent with their respective appointments during the year ended December 31, 2020. The Company also granted
discretionary stock options to its officers during the year ended December 31, 2022. It is the Company&#8217;s policy that any such option
grants take into account the existence of material non-public information when determining the timing of such a grant and the specific
terms of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Clawback Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that
emphasizes integrity and accountability and that reinforces the Company&#8217;s pay-for-performance compensation philosophy. The Board
of Directors has therefore adopted a compensation recoupment policy, which provides for the recovery of erroneously awarded incentive
compensation from the Company&#8217;s executive officers in the event of a triggering event, and which has been filed as an exhibit to
this report and has been posted to the investor information/governance section of the Company&#8217;s corporate website (www.lixte.com).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2007, the Company entered into a consulting agreement with Gil N Schwartzberg for Mr. Schwartzberg to provide financial
advisory and consulting services to the Company with respect to financing matters, capital structure and strategic development, and to
assist management in communications with investors and stockholders. Consideration under this consulting agreement, including amendments
thereto, was paid exclusively in the form of stock options. On August 2, 2018, the Company entered into a third amendment to the consulting
agreement to extend it to January 28, 2024, as well as to extend the exercise date of previously issued, fully-vested stock options for
66,667 shares of common stock, exercisable at $30.00 per share, from January 28, 2019 to January 28, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Schwartzberg, who was appointed as a director of the Company effective April 9, 2021, died on October 30, 2022. Accordingly, Mr. Schwartzberg&#8217;s
unvested stock options ceased vesting effective as of the date of his death, and the expiration date of all vested stock options owned
by Mr. Schwartzberg contractually expired on October 30, 2023, one year from the date that his service on the Company&#8217;s Board of
Directors terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 6, 2021, in recognition of their service as directors of the Company over the past year, the Company granted stock options to
purchase 5,000 shares of common stock to each of Dr. Winson Sze Chun Ho, Dr. Yun Yen, Dr. Stephen Forman, and Dr. Philip Palmedo (an
aggregate of 20,000 shares), which were fully vested upon issuance and exercisable for a period of five years at $32.10 per share, which
was the approximate fair market value of the Company&#8217;s common stock on such date. The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $571,312 ($28.566 per share) and was charged to general and
administrative costs in the consolidated statement of operations on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, Winson Sze Chun Ho resigned from the Company&#8217;s Board of Directors to focus on clinical and preclinical cancer research
in academic medicine. Concurrent with his resignation, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created
by Dr. Ho&#8217;s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s
cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 25,000
shares of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $32.00 per share (the closing
market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar
quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $753,611 ($30.144 per share), of which $376,800 was attributable to the portion of the stock
options fully vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, although vesting terminated
on October 30, 2022, the date that Mr. Schwartzberg died and his service on the Board of Directors terminated. During the years ended
December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $126,684 and $500,235, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. During the years ended December 31, 2023, 2022 and 2021, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $76,388, $154,042 and $427,944, respectively, with respect to
these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $30.30 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $1,421,095 ($28.4225 per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023.
During the years ended December 31, 2023, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $211,413, $638,915 and $358,200, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors. As a new director, in lieu of
a grant of stock options, Dr. Bernards received a one-time cash board fee of $100,000, payable immediately, and an annual cash board
fee of $40,000, payable quarterly. During the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $62,500 and $133,873, respectively, with respect to his cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share),
of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. During the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $38,885 and $100,249, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $7.40 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($6.334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
For the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $94,881 and $63,777, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase 20,000 shares
(a total of 80,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $20.00
per share, vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the 80,000 stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$262,560 ($3.282 per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. For the years
ended December 31, 2023 and 2022, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $61,448 and $75,520, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 40,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $5.88 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $192,593 ($4.8131 per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
For the year ended December 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $48,464 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents the compensation awarded to, earned by or paid to our named directors for the years ended December 31,
2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position (2)</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Qualified Deferred Compensation Earnings ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Philip F. Palmedo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Director (8)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">63,340</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">21,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">84,488</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">447,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stephen J. Forman (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,866</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Winson Sze Chun Ho</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yun Yen (10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">448,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gil Schwartzberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,037,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,052,386</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regina Brown</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,582</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">961,749</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ren&#233; Bernards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bas van der Baan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,609</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,394</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Consists of grant date fair value of option award calculated pursuant to the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Dr. John S. Kovach, the founder of the Company, served as Chairman of the Board of Directors until his death on October 5, 2023. Prior
to September 26, 2023, Dr. Kovach was also the President, Chief Executive Officer and Chief Scientific Officer of the Company. Dr. Kovach
did not receive any separate compensation for his services as a member of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Resigned as a director of the Company effective April 9, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Appointed as a director of the Company effective April 9, 2021 and died on October 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Appointed as a director of the Company effective May 11, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Appointed as a director of the Company effective June 15, 2022. Dr. Bernards received all of his compensation in 2022 and 2023 in the
form of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Appointed as a director of the Company effective June 17, 2022, and as Chairman of the Board of Directors on October 6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Did not stand for re-election at the annual meeting of stockholders. Accordingly, his term as a director of the Company ended effective
October 7, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Appointed as a director of the Company effective May 13, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
Appointed as a director of the Company effective August 4, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scientific
Advisory Committee Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice in the field of oncology
research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become
a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly
cash fee of $4,000. The agreement has been automatically renewed for additional one-year terms on its anniversary date since 2014. Consulting
and advisory fees charged to operations pursuant to this agreement were $16,000, $16,000 and $16,000 for the years ended December 31,
2023, 2022 and 2021, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020
Stock Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Summary</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of 233,333 shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by 180,000 shares, to a total of 413,333 shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by 336,667 shares, to a total of 750,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, unexpired stock options for 495,000 shares were issued and outstanding under the 2020 Plan and 255,000 shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
an adequate number of shares available for future equity compensation grants is necessary to promote our long-term success and the creation
of stockholder value by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enabling
    us to continue to attract and retain the services of key service providers who would be eligible to receive grants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aligning
    participants&#8217; interests with stockholders&#8217; interests through incentives that are based upon the performance of our common
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motivating
    participants, through equity incentive awards, to achieve long-term growth in our business, in addition to short-term financial performance;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    a long-term equity incentive program that is competitive as compared to other companies with whom we compete for talent.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Plan permits the discretionary award of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NQSOs&#8221;),
restricted stock, restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights (&#8220;SARs&#8221;), other equity awards and/or
cash awards to selected participants. The 2020 Plan will remain in effect until July 14, 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Plan provides for the reservation of 750,000 shares of common stock for issuance thereunder (the &#8220;Share Limit&#8221;), and
provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 750,000 shares (the &#8220;ISO Limit&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Key
Features of the 2020 Plan</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
key features of the 2020 Plan are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    not terminated earlier by our Board of Directors, the 2020 Plan will terminate on July 14, 2030.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to a maximum aggregate of 4,133,333 shares of common stock may be issued under the 2020 Plan. The maximum number of shares that may
    be issued pursuant to the exercise of ISOs is also 4,133,333.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2020 Plan is administered by the Compensation Committee, which is comprised solely of independent members of our Board of Directors.
    The Board of Directors may designate a separate committee to make awards to employees who are not officers subject to the reporting
    requirements of Section 16 of the Exchange Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees,
    consultants and board members are eligible to receive awards, provided that the Compensation Committee has the discretion to determine
    (i) who shall receive any awards, and (ii) the terms and conditions of such awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
    may consist of ISOs, NQSOs, restricted stock, RSUs, SARs, other equity awards and/or cash awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options and SARs may not be granted at a per share exercise price below the fair market value of a share of our common stock on the
    date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options and SARs may not be repriced or exchanged without stockholder approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    maximum exercisable term of stock options and SARs may not exceed ten years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
    are subject to recoupment of compensation policies adopted by us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Eligibility
to Receive Awards</span>.</i> Employees, consultants and members of our Board of Directors are eligible to receive awards under the 2020
Plan. The Compensation Committee determines, in its discretion, the selected participants who will be granted awards under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Shares
Subject to the 2020 Plan</span>. </i>The maximum number of shares of common stock that can be issued under the 2020 Plan is 4,133,333 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares underlying forfeited or terminated awards (without payment of consideration), or unexercised awards become available again for
issuance under the 2020 Plan. No fractional shares may be issued under the 2020 Plan. No shares will be issued with respect to a participant&#8217;s
award unless applicable tax withholding obligations have been satisfied by the participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Administration
of the 2020 Plan</span>.</i> The 2020 Plan is administered by the Compensation Committee of the Board of Directors, which consists of independent
board members. With respect to certain awards issued under the 2020 Plan, the members of the Compensation Committee also must be &#8220;Non-Employee
Directors&#8221; under Rule 16b-3 of the Exchange Act. Subject to the terms of the 2020 Plan, the Compensation Committee has the sole
discretion, among other things, to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Select
    the individuals who will receive awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the terms and conditions of awards (for example, performance conditions, if any, and vesting schedule);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correct
    any defect, supply any omission, or reconcile any inconsistency in the 2020 Plan or any award agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerate
    the vesting, extend the post-termination exercise term or waive restrictions of any awards at any time and under such terms and conditions
    as it deems appropriate, subject to the limitations set forth in the 2020 Plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permit
    a participant to defer compensation to be provided by an award; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpret
    the provisions of the 2020 Plan and outstanding awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may suspend vesting, settlement, or exercise of awards pending a determination of whether a selected participant&#8217;s
service should be terminated for cause (in which case outstanding awards would be forfeited). Awards may be subject to any policy that
the Board of Directors may implement on the recoupment of compensation (referred to as a &#8220;compensation clawback&#8221; policy).
The members of the Board of Directors, the Compensation Committee and their delegates shall be indemnified by us to the maximum extent
permitted by applicable law for actions taken or not taken regarding the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Types
of Awards</span>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Options</span></i>. A stock option is the right to acquire shares at a fixed exercise price over a fixed period of time. The Compensation
Committee determines, among other terms and conditions, the number of shares covered by each stock option and the exercise price of the
shares subject to each stock option, but such per share exercise price cannot be less than the fair market value of a share of our common
stock on the date of grant of the stock option. The exercise price of each stock option granted under the 2020 Plan must be paid in full
at the time of exercise, either with cash, or through a broker-assisted &#8220;cashless&#8221; exercise and sale program, or net exercise,
or through another method approved by the Compensation Committee. Stock options granted under the 2020 Plan may be either ISOs or NQSOs.
In order to comply with Treasury Regulation Section 1.422-2(b), the 2020 Plan provides that no more than 4,133,333 shares may be issued
pursuant to the exercise of ISOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">SARs</span></i>.
A SAR is the right to receive, upon exercise, an amount equal to the difference between the fair market value of the shares on the date
of the SAR&#8217;s exercise and the aggregate exercise price of the shares covered by the exercised portion of the SAR. The Compensation
Committee determines the terms of SARs, including the exercise price (provided that such per share exercise price cannot be less than
the fair market value of a share of our common stock on the date of grant), the vesting and the term of the SAR. Settlement of a SAR
may be in shares of common stock or in cash, or any combination thereof, as the Compensation Committee may determine. SARs may not be
repriced or exchanged without stockholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Restricted
Stock</span></i>. A restricted stock award is the grant of shares of our common stock to a selected participant and such shares may be subject
to a substantial risk of forfeiture until specific conditions or goals are met. The restricted shares may be issued with or without cash
consideration being paid by the selected participant as determined by the Compensation Committee. The Compensation Committee also will
determine any other terms and conditions of an award of restricted stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">RSUs</span></i>.
RSUs are the right to receive an amount equal to the fair market value of the shares covered by the RSU at some future date after the
grant. The Compensation Committee will determine all of the terms and conditions of an award of RSUs. Payment for vested RSUs may be
in shares of common stock or in cash, or any combination thereof, as the Compensation Committee may determine. RSUs represent an unfunded
and unsecured obligation for us, and a holder of a stock unit has no rights other than those of a general creditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Other
Awards</span></i>. The 2020 Plan also provides that other equity awards, which derive their value from the value of our shares or from increases
in the value of our shares, may be granted. In addition, cash awards may also be issued. Substitute awards may be issued under the 2020
Plan in assumption of or substitution for or exchange for awards previously granted by an entity which we may acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Limited
Transferability of Awards</span></i>. Awards granted under the 2020 Plan generally are not transferrable other than by will or by the laws
of descent and distribution. However, the Compensation Committee may in its discretion permit the transfer of awards other than ISOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Change
in Control</span></i>. In the event that we are a party to a merger or other reorganization or similar transaction, outstanding 2020 Plan
awards will be subject to the agreement pertaining to such merger or reorganization. Such agreement may provide for (i) the continuation
of the outstanding awards by us if we are a surviving corporation, (ii) the assumption or substitution of the outstanding awards by the
surviving entity or its parent, (iii) full exercisability and/or full vesting of outstanding awards, or (iv) cancellation of outstanding
awards either with or without consideration, in all cases with or without consent of the selected participant. The Compensation Committee
will decide the effect of a change in control of us on outstanding awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Amendment
and Termination of the 2020 Plan</span></i>. The Board of Directors generally may amend or terminate the 2020 Plan at any time and for any
reason, except that it must obtain stockholder approval of material amendments to the extent required by applicable laws, regulations
or rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_019"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents certain information regarding beneficial ownership of our common stock (the only class of our voting equity
securities issued and outstanding) as of March 1, 2024 by (i) each person or entity who is known by us to own beneficially more than
5% of our outstanding shares of common stock, (ii) each of our directors, and (iii) all of our directors and executive officers as a
group. As of March 1, 2024, there were 2,249,290 shares of our common stock issued and outstanding. In computing the number and percentage
of shares beneficially owned by a person, shares of common stock that a person has a right to acquire within sixty (60) days of March
1, 2024 pursuant to stock options, warrants, convertible preferred stock or other rights are counted as outstanding, while these shares
are not counted as outstanding for computing the percentage ownership of any other person. This table is based upon information supplied
by our directors, officers and principal stockholders and reports filed with the Securities and Exchange Commission. Except as noted,
the Company&#8217;s executive office is reflected as the address of all officers, directors and other stockholders owning more than 5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name and Address of Beneficial Owner</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount
                                                                                 and Nature <br/>
of Beneficial<br/>
 Ownership</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent
of Class</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bas van der Baan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Pasadena, California 91101</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">79,853</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Stephen J. Forman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,919</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Yun Yen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,860</td><td style="text-align: left"><sup>(12)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Ren&#233; Bernards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Regina Brown</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,130</td><td style="text-align: left"><sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Robert N. Weingarten</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,833</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Eric J. Forman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,997</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. James S. Miser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,333</td><td style="text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">All officers and directors as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Stockholders Owning More Than 5%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">John S. Kovach Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Barbara C. H. Kovach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Alexandra E. Kovach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">John and Barbara Kovach 2015 Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Glenn L. Krinsky, Trustee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,333</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Arthur and Jane Riggs 1990 Irrevocable Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Jane Riggs, Trustee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4852 Saint Andres Avenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">La Verne, California 91750</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,750</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Glenn L. Krinsky</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147,499</td><td style="text-align: left"><sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Includes 154,018 shares of common stock and stock warrants to purchase 2,110 shares of common stock owned by the John S. Kovach Trust
dated September 22, 2015. The primary beneficiary of the trust is Barbara C. H. Kovach. Barbara C. H. Kovach and Alexandra E. Kovach
are co-trustees of the trust and have the exclusive right to control the investment of the assets of the trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Includes 11,000 shares of common stock and stock options to purchase 68,853 shares of common stock owned by Bas van der Baan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Includes 375 shares of common stock and stock options to purchase 28,334 shares of common stock owned by Dr. Stephen Forman. Also includes
7,105 shares of common stock and stock warrants to purchase 2,105 shares of common stock owned by the Stephen Forman Living Trust dated
12/16/98. Stephen Forman is trustee of the trust and holds voting and dispositive power over the common stock and common stock warrants
owned by the trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Includes 133,333 shares of common stock transferred by John S. Kovach and his wife, Barbara C.H. Kovach, as grantors, to the John and
Barbara Kovach 2015 Trust, an irrevocable trust dated July 6, 2015. The primary beneficiaries of the trust are the two adult daughters
of John and Barbara Kovach. Glenn L. Krinsky is the trustee of the trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Includes stock options to purchase 17,500 shares of common stock owned by Eric J. Forman. Eric Forman is the husband of Julie (Schwartzberg)
Forman, and the son-in-law of Gil and Debbie Schwartzberg.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,971
    shares of common stock and stock warrants to purchase 526 shares of common stock owned by the Eric Forman Revocable Trust.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
the following, as to which Eric Forman disclaims beneficial ownership or control:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,842
    shares of common stock and stock options to purchase 47,240 shares of common stock owned by the Julie Schwartzberg Trust, as to which
    Julie (Schwartzberg) Forman is the trustee and beneficiary.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,286
    shares of common stock owned by the Schwartzberg Trust fbo Julie Forman, dtd 3/3/23, as to which Julie Forman is the trustee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,972
    shares of common stock and common stock warrants to purchase 5,263 shares of common stock owned by the Julie Forman Inherited IRA.
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,708
    shares of common stock owned by the Julie Forman 2015 Trust, an irrevocable trust, the beneficiaries of which are the minor children
    of Eric and Julie Forman, as to which Scott Forman, brother of Eric Forman, as trustee, has voting, dispositive and investment control.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000
    shares of common stock owned by each of the Savannah Sterling Trust, Amanda Sterling Trust, Daniel Sterling Trust and Charles Sterling
    Trust, as to which Julie Forman is the trustee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Consists of 25,000 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Consists of stock options to purchase 15,833 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Includes 101,833 shares of common stock and 72,917 shares of common stock issuable upon conversion of 350,000 shares of Series A Convertible
Preferred Stock owned by the Arthur and Jane Riggs 1990 Irrevocable Trust dated November 18, 1990. Jane Riggs is the trustee of the Arthur
and Jane Riggs 1990 Irrevocable Trust. The shares of Series A Convertible Preferred Stock were acquired on March 17, 2015 and January
15, 2016, are non-voting, and are immediately convertible into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Consists of stock options to purchase 18,333 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
Includes 14,166 shares of common stock owned by Glenn L. Krinsky. Also includes 133,333 shares of common stock owned by the John and
Barbara Kovach 2015 Trust, as to which Glenn L. Krinsky, as trustee, has voting, dispositive and investment control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)
Includes 630 shares of common stock and stock options to purchase 47,500 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)
Includes 5,263 shares of common stock, stock warrants to purchase 5,263 shares of common stock and stock options to purchase 28,334 shares
of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_020"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023, 2022 and 2021, there were no transactions, either directly or indirectly, between the Company and
any of its officers, directors or affiliates, including their family members, except as described elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers that Dr. Yun Yen, Regina Brown and Dr. Ren&#233; Bernards are each an &#8220;independent director,&#8221; as defined
under Nasdaq rules and by Rule 10A-3 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_021"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company, P.A. acted as our independent registered public accounting firm for the fiscal years ended December 31, 2023 and 2022
and for the interim periods in such fiscal years. The following table shows the fees that were incurred by us for audit and other services
provided by Weinberg &amp; Company, P.A. for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">120,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">111,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Fees<sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">153,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">140,359</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees represent fees for professional services provided in connection with the audit of our annual financial statements included in
    our Annual Reports on Form 10-K and the review of our interim financial statements included in our Quarterly Reports on Form 10-Q
    and services that are normally provided in connection with statutory or regulatory filings, excluding those fees included in Other
    Fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
    fees represent fees for assurance and related services that are reasonably related to the performance of the audit or review of our
    financial statements and not reported above under Audit Fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees represent fees for professional services related to tax compliance, tax advice and tax planning.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    fees represent fees incurred with respect to our Registration Statements on Form S-3 and Form S-8. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
audit and audit-related services, tax services and other services rendered by Weinberg &amp; Company, P.A. during the fiscal years ended
December 31, 2023 and 2022 were pre-approved by either our Audit Committee or by our Board of Directors. The Board of Directors has adopted
a pre-approval policy that provides for the pre-approval of all services performed for us by our independent registered public accounting
firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_022"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_023"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of documents filed as part of this report:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
    is made to the Index to Consolidated Financial Statements on page F-1, where these documents are listed.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial statement schedules have been omitted because the required information is not applicable, or not present in amounts sufficient
    to require submission of the schedules, or because the information is included in the financial statements or notes thereto.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    (b) below.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(b)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    list of exhibits required to be filed as part of this Annual Report on Form 10-K is set forth in the Index to Exhibits, which is
    presented elsewhere in this document, and is incorporated herein by reference.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_024"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_025"></span>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Document</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of November 25, 2020, between the Company and WestPark Capital, Inc. and WallachBeth, LLC, filed as Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420406027818/v047035_ex2-1.htm" style="-sec-extract: exhibit">Share Exchange Agreement dated as of June 8, 2006 among the Company, John S. Kovach and Lixte Biotechnology, Inc., filed as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 7, 2006 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420405023652/v022460_ex3-1.txt" style="-sec-extract: exhibit">Certificate of Incorporation, as filed with the Delaware Secretary of State on May 24, 2005, filed as Exhibit 3.1 to the Company&#8217;s Registration Statement on Form 10-SB, as filed with the Securities and Exchange Commission on August 3, 2005 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420406039012/v053105_pre14c.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation, filed as Appendix A to the Company&#8217;s Information Statement, as filed with the Securities and Exchange Commission on September 19, 2006 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315215000869/ex4-01.htm" style="-sec-extract: exhibit">Certificate of Designations for the Company&#8217;s Series A Convertible Preferred Stock, filed as Exhibit 4.01 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on March 18, 2015 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315216008321/ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Designations of the Series A Convertible Preferred Stock, filed as Exhibit 3.4 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 28, 2016 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2022 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Incorporation, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223020163/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 6, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220004697/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, filed as Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on March 25, 2020 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Public Warrant included in Unit, filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant, filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420413015451/v336103_ex10-15.htm" style="-sec-extract: exhibit">Master Agreement between Lixte Biotechnology Holdings, Inc. and Theradex Systems, Inc. dated January 12, 2010, filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the Securities and Exchange Commission on March 15, 2013 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420414017092/v369493_ex10-16.htm" style="-sec-extract: exhibit">Materials Cooperative Research and Development Agreement between Lixte Biotechnology Holdings, Inc. and the National Institute of Neurological Disorders and Stroke dated October 18, 2013, filed as Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 21, 2014 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420414017092/v369493_ex10-17.htm" style="-sec-extract: exhibit">Scientific Advisory Board Agreement between Lixte Biotechnology Holdings, Inc. and NDA Consulting Corp. dated December 24, 2013, filed as Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 21, 2014 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315215004422/ex10-01.htm" style="-sec-extract: exhibit">Collaboration Agreement between Lixte Biotechnology Holdings, Inc. and BioPharmaWorks LLC effective September 14, 2015, filed as Exhibit 10.01 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 18, 2015 and incorporated herein by reference.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315219011717/ex10-1.htm" style="-sec-extract: exhibit">Collaboration Agreement for an Investigator-Initiated Clinical Trial between Lixte Biotechnology Holdings, Inc. and the Spanish Sarcoma Group as of July 31, 2019 (certain portions of this exhibit have been omitted based on a request for confidential treatment filed by the Company with the Securities and Exchange Commission that was granted on September 19, 2019), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on August 6, 2019 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013560/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement Between the Company and Dr. James Miser, filed as Exhibit 10.03 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220016207/ex10-02.htm" style="-sec-extract: exhibit">Employment Agreement Between the Company and Robert N. Weingarten, filed as Exhibit 10.02 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on August 18, 2020 and incorporated herein by reference.+</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013560/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement Between the Company and Eric Forman, filed as Exhibit 10.02 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315221006882/ex10-21.htm" style="-sec-extract: exhibit">Amendment to Employment Agreement between the Company and Eric Forman, filed as Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 26, 2021.+</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Employment Agreement between the Company and Eric Forman, filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.+ </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013545/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte Technology Holdings, Inc. 2020 Stock Incentive Plan, filed as Exhibit 10.1 to the Company Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223042954/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan (as amended), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 28, 2023 and incorporated herein by reference.+ </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315221001630/ex10-1.htm" style="-sec-extract: exhibit">Investigator-Initiated Clinical Research Support Agreement between City of Hope National Medical Center and City of Hope Medical Foundation and Lixte Biotechnology Holdings, Inc., filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on January 22, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315221027755/ex10-1.htm" style="-sec-extract: exhibit">Development
    Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and
    Oncode Institute, Utrecht, entered into on October 8, 2021 (certain portions of this Exhibit have been omitted), filed as Exhibit
    10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 10,
    2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex10-21.htm" style="-sec-extract: exhibit">Insider Trading Policy, filed as Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-16.htm">Compensation Clawback Policy+*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223016069/ex10-1.htm" style="-sec-extract: exhibit">Amendment
    to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2022, filed as Exhibit 10.1 to the
    Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023 and
    incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between the Company and Bastiaan van der Baan effective September 26, 2023, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 27, 2023 and incorporated herein by reference.</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No. 1 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute,
    Amsterdam, and the Oncode Institute, Utrecht, entered into on October 8, 2021, filed as Exhibit 10.3 to the Company&#8217;s
    Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 9, 2023 and incorporated herein by
    reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 2 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on October 13, 2023 (certain portions of this Exhibit have been omitted), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on October 17, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of
    September 30, 2023, filed as Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and
    Exchange Commission on November 9, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/ex10-1.htm" style="-sec-extract: exhibit">Exclusive Patent License Agreement between Lixte Biotechnology, Inc. and the National Institute of Neurological Disorders and Stroke and the National Cancer Institute, each a component of the National Institute of Health, effective as of February 23, 2024, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 26, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex21-1.htm" style="-sec-extract: exhibit">Subsidiaries of the Registrant, filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Weinberg &amp; Company, P.A., Independent Registered Public Accounting Firm*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Scheme Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_026"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 and 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 19, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BASTIAAN VAN DER BAAN</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant
in the capacity and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BASTIAAN VAN DER BAAN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    ROBERT N. WEINGARTEN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    STEPHEN J. FORMAN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    J. Forman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    RENE BERNARDS</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ren&#233;
    Bernards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    YUN YEN </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yun
    Yen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>/s/
    REGINA BROWN </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    19, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ns_001"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(INCLUDING
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
    Number</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID NO. <span id="xdx_908_edei--AuditorFirmId_c20230101__20231231_zle9GMhw28yl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorFirmId" id="ixv-22206">572</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_002">Consolidated Balance Sheets &#8211; December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_003">Consolidated Statements of Operations &#8211; Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_004">Consolidated Statements of Stockholders&#8217; Equity &#8211; Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_005">Consolidated Statements of Cash Flows &#8211; Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#F_006">Notes to Consolidated Financial Statements &#8211; Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Lixte Biotechnology Holdings, Inc. and subsidiary (the &#8220;Company&#8221;)
as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for
the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going
Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has no recurring source of revenue and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities. These matters
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these
matters are also described in Note 1 to the financial statements. These financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Audit Matter</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Valuation
of Stock-Based Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 6 to the financial statements, the Company recognized $773,203 of compensation expense to certain officers, employees
and consultants related to stock-based awards. The Company accounts for stock-based compensation for all stock-based awards made to officers,
employees and consultants based on estimated fair values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the valuation of stock-based compensation as a critical audit matter because of the subjectivity of the inputs and assumptions
that management utilized in determining the fair value of the stock-based awards. This required a high degree of effort and judgement
in selecting auditor procedures to evaluate management&#8217;s estimates and assumptions as it relates to the determination of the fair
values of stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures related to the of the stock-based awards, including the valuation methodology and related assumptions such as the risk-free
interest rate, volatility, and dividend yield, consisted of the following, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    obtained and read the stock-based award agreements</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    evaluated the reasonableness of management&#8217;s significant valuation assumptions, and tested the mathematical accuracy of management&#8217;s
    valuation analyses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    developed independent estimates for the fair values of the stock-based awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2008.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_904_edei--AuditorName_c20230101__20231231_zlXdvJ64Ctp5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorName" id="ixv-22207">Weinberg &amp; Company, P.A</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20230101__20231231_zaSC8ukNua36"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorLocation" id="ixv-22208">Los
Angeles, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_002"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_zB6AKPWUPDbg" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zDXEgUWnCZ5h" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zoUVHrghd6U3" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzHdt_ztiG7Y3PRLfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22209">4,203,488</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22210">5,353,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AdvancesOnResearchAndDevelopmentContractServices_i02I_maACzHdt_z59MflGW6Zmg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22211">78,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22212">147,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidInsurance_i02I_maACzHdt_z0kLL0JIGLSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22213">17,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22214">49,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maACzHdt_zmLZB7NKvGw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22215">10,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22216">11,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i02TI_mtACzHdt_maAznMO_zh4Pfsimji6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22217">4,308,620</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22218">5,560,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_mtAznMO_zUR1TXftMvDi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22219">4,308,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22220">5,560,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzPkk_z85qHlxwT73" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses, including $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlSAxUPLmNG8" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22221">36,250</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJLFhYzc4AFi" title="Accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22222">46,982</ix:nonFraction></span> to related parties at December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22223">156,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22224">230,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentContractLiabilitiesCurrent_i02I_maLCzPkk_zXNlBmGhO14c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22225">157,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22226">165,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzPkk_maLASEznmy_zgbNiDKhr9Xl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22227">313,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22228">395,756</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_maLASEznmy_zfzuA5hm8uJe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0101">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_maSEzG3y_zuiBUoGy2bJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zASC5Fc9U9Ba" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zsgAthYI2Poi" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22229"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22230">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_z0tYIQlmEXZ1" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zXQStys4GK93" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22231"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22232">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z6cbQZ3zpMm6" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2mVvC7aQgKk" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zRZmQBSb2Qtl" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zb7o9mOn5wYc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22233"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22234"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22235"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22236">350,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series A Convertible Preferred Stock, $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreference_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmX6KhqlLhxg" title="Preferred stock liquidation preference per share"><span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAhR7otpjAUj" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22237"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22238">10.00</ix:nonFraction></ix:nonFraction></span></span> per share stated value, liquidation preference based on assumed conversion into common shares &#8211; <span id="xdx_90B_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zqwvwycusye9" title="Preferred stock, issuable upon conversion"><span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zyJh4EZn0s04" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22239"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22240">72,917</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22241">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22242">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockValue_i02I_maSEzG3y_z3veysR1VEsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zrEWjndlVd6g" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zEBKxbuu8LWa" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22243"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22244">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zzdl4epcARhl" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zE5GnlbA1aD3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22245"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22246">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20231231_zhvmw16lEURa" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zke4yThLPSMl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22247"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22248">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20221231_zzVBPeR1z149" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zq8XH1kN3hnk" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22249"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22250">1,664,706</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22251">225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22252">166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_i02I_maSEzG3y_zmAT6sjSkn7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22253">48,976,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22254">45,059,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzG3y_zYttCHws1zw" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22255">48,481,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22256">43,394,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquity_i02TI_mtSEzG3y_maLASEznmy_zXEZnwCKp0Al" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22257">3,994,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22258">5,165,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEznmy_zJm7tpbJy676" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22259">4,308,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22260">5,560,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_003"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zIzZWKtzUlg" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230101__20231231_z1od7oTXau3b" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220101__20221231_zu1Kndif9ws7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzfCw_zrqsPV2brzWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0165">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0166">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zwtTqK50wpPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvvdX1iMv7ve" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_maOEzto3_zKpLRV1Egc7b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Compensation to related parties, including stock-based compensation of $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zrO0etWFF9x9" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22261">773,203</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zp4SCKwUb9ni" title="Stock-based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22262">1,502,776</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22263">1,718,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22264">2,547,615</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LegalFees_i02_maOEzto3_z4cg2YHvFNua" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22265">978,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22266">1,268,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_zNZVKCdgU7Ml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22267">1,495,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22268">1,146,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzto3_z1Kv9YIGsEjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development costs, including $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zdz5MEnyHUC6" title="Allocated share based, compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22269">0</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zPnu3M33QtOk" title="Stock-based compensation costs"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22270">43,264</ix:nonFraction></span> of stock-based compensation costs to a consultant for the years ended December 31, 2023 and 2022, respectively</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22271">898,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22272">1,349,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtOEzto3_msOILzfCw_z54dfkttfBBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total costs and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22273">5,090,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22274">6,311,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtOILzfCw_maNILzL1K_z6t9gUlIrm64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22275">5,090,236</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22276">6,311,481</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeNonoperating_maNILzL1K_zr5V0L1rZhXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22277">17,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22278">11,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestExpense_iN_di_msNILzL1K_ztIYhMLQQLrg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22279">16,233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22280">8,875</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNILzL1K_zTq0divMCSHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22281">1,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22282">3,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtNILzL1K_zAlE1YOECwke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22283">5,087,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22284">6,312,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zLUqCb1fZXpj" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zyBgublOdEH8" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-22285"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-22286">2.66</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zVqoqCZyoLp5" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zKzKfwK919P2" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-22287"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-22288">3.99</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zb5JdWDPOH5h" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zyIuvUHsYo3e" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22289"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22290">1,915,838</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z609ZMaNg2Q2" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_z3o7dQQc5mZe" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22291"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22292">1,582,029</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_004"></span>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zFQvuVAV60l6" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_z4w9n4h0FsBg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z2MJqGnySnKf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par&#160;Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zmrCPaGIMy41" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxFs9bpCqdDd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_zxLClGD8Wbpe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            A Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Stock</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid-in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par&#160;Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zFrteyme5BAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance, December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zp0dCPibTpC3" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22293">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22294">3,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zskKVIDJboZ5" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22295">1,374,706</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22296">137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22297">38,372,365</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22298">37,082,164</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22299">4,790,338</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zAqW7RXETK07" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of securities in registered direct equity offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkJWfXGwSj7" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22300">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22301">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22302">5,141,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22303">5,141,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ztz5TNzNjjj4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22304">1,546,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22305">1,546,040</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zxCS1GYTOtIa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22306">6,312,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22307">6,312,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zZSM2vgHgDFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBFCBzIAdTI9" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22308">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22309">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWMIsolRMrT2" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22310">1,664,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22311">166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22312">45,059,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22313">43,394,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22314">5,165,227</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zjztk84JAfO7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z75xOEzHFwPj" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22315">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22316">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NHBZRg7kSl" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22317">1,664,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22318">166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22319">45,059,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22320">43,394,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22321">5,165,227</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zKnRtkYSa3i1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of securities in registered direct equity offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsyWCY8zom8l" title="Proceeds from sale of common stock in direct equity offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22322">180,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22323">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22324">3,137,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22325">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zHzSM5iK9tLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs4ODAQ34HQi" title="Exercise of pre-funded common stock warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22326">403,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22327">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22328">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zRBVoZYYElQ8" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHqIV3QfTX8f" title="Exercise of common stock options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22329">1,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22330">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22331">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zN0O188Zieeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22332">773,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22333">773,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z3VFDTtU7tnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22334">5,087,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22335">5,087,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zPzSBy0XfmS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkhf6stkEyCl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22336">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22337">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHgtOJulpFA" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22338">2,249,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22339">225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22340">48,976,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22341">48,481,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22342">3,994,762</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zhVgVAyhGvOb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdIRujzKvOmf" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22343">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22344">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgx0PbHavzQ6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22345">2,249,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22346">225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22347">48,976,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22348">48,481,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22349">3,994,762</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_005"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zMgYRoexo0r1" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230101__20231231_z2oO8bVjC0w9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20221231_zFVrKDVciLk8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zvNFnyATN5P8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maNCPBUz0eM_zhvCsm3BMzhc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22350">5,087,029</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22351">6,312,535</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zNxJ8y7z51Fd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationAbstract_i02B_zT5hiQLes782" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense included in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_i03_maNCPBUz0eM_zNhjMhcwpPIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22352">773,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22353">1,502,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ShareBasedCompensationIncludedInResearchAndDevelopmentCost_i03_maNCPBUz0eM_zJLWtTgEVHQi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22354">43,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i03B_zOshcDQfdoB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_z10wCmSCp65" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Increase) decrease in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_i05N_di_msNCPBUz0eM_z0rgvtiIWJK1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22355">69,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22356">3,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidInsurance_i05N_di_msNCPBUz0eM_zZlWVaMkTzIl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22357">32,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22358">59,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i05N_di_msNCPBUz0eM_z6X77rnufLya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22359">1,350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22360">1,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zhIkx3tYh51g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase (decrease) in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i05_maNCPBUz0eM_zsiuVw5OJLtf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22361">73,976</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22362">2,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_i05_maNCPBUz0eM_zZZlBbWkkFu7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22363">7,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22364">88,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz0eM_maCCERCzMHB_zem9Wx6xr879" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22365">4,293,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22366">4,611,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zITAx6KF9fS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz4w7_zomwp6T2ZUA" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22367">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22368">5,141,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUz4w7_ztk72Kyoot56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22369">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUz4w7_zlzBArefwXC9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22370">6,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz4w7_maCCERCzMHB_zVW0Oat9ja7b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22371">3,143,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22372">5,141,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_ztwq7HfRICl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_mtCCERCzMHB_zbAvnztR2LU7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22373">1,149,904</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22374">529,647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_z5uYW4tzYMQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22375">5,353,392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22376">4,823,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zdh9mqBpaaxh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22377">4,203,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22378">5,353,392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zxBuZRTGlFBf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationRelatedText_i01_zOJtQGtMw5b3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaidNet_i01_z9o5c2LUUG33" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22379">16,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22380">8,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesPaidNet_i01_zeonc7AG8OM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_006"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-16024"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqbb4r9tV0m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82A_z9T7lfLXYdwg">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by developing
a drug class called Protein Phosphatase 2A inhibitors. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents
and/or x-ray, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have
significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein
phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little
or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>President
and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#8217;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors.&#160; Dr. Kovach was also the Company&#8217;s Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing and Reverse Stock Split </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbols &#8220;LIXT&#8221;
and &#8220;LIXTW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zubUZhj3yay7" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-22381">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. No fractional shares were issued in connection with the reverse split,
with any fractional shares resulting from the reverse split being rounded up to the next whole share. All share and per share amounts
and information presented herein have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement
of Nasdaq over time, or that it will be successful in maintaining compliance with any of the other continued listing requirements of
Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the Company recorded a net loss of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zKsABCY8g5kc" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22382">5,087,029</ix:nonFraction> </span>and used cash in operations of $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zN6OfrgYrrll" title="Cash used in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-22383">4,293,265</ix:nonFraction></span>. At December
31, 2023, the Company had cash of $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_z4garxt3CCKg" title="Cash"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22384">4,203,488</ix:nonFraction></span> available to fund its operations. Because the Company is currently engaged in various early-stage
clinical trials, it is expected that it will take a significant amount of time and resources to develop any product or intellectual property
capable of generating sustainable revenues. Accordingly, the Company&#8217;s business is unlikely to generate any sustainable operating
revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its technology,
product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive
earnings and operating cash flows. At December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to
clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated approximately $<span id="xdx_909_eus-gaap--ContractualObligation_iI_pp0p0_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z3W8udyd28W4" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22385">6,344,000</ix:nonFraction></span> (see Note 8),
which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2023. The Company&#8217;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through approximately &#160;September 30, 2024. However, existing cash resources will not be sufficient to complete the development
of and obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able to proactively
manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating plans may change
as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed
sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
comparative amounts in 2022 have been reclassified to conform to the current year&#8217;s presentation. Such reclassifications, individually
and in the aggregate, were not material to the results of operations or financial condition of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-16131"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zAzGVenIrdJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zhR1kFO9agwi">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-16138"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zduPhxVq9TPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoc7VDIezOXf">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles
(&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte
Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-16161"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zXbngsCHDJR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zIj57lMpFsei">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_z9Jlo11H6Yrh" title="Number of operating segments"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20230101__20231231_zZ0IEoAjhbfj" title="Number of reportable segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2023-01-01to2023-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment" id="ixv-22386"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2023-01-01to2023-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment" id="ixv-22387">one</ix:nonFraction></ix:nonFraction></span></span> segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:UseOfEstimates" id="ixv-16175"><p id="xdx_846_eus-gaap--UseOfEstimates_zEPrXuicGeV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z0nO8pvLp7pf">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-16187"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaA2Y0Cmm8k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zSQq5L65qaTl">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231_ziGNzxUsSxP" title="Cash FDIC insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22388">250,000</ix:nonFraction></span> and $<span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20231231_z3Dq2PrmJxXa" title="Cash SIPC insurance"><ix:nonFraction name="LIXT:CashSIPCInsuredAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22389">500,000</ix:nonFraction></span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-16201"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0aYpeETTS95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBhP75WcwqQ1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="LIXT:PrepaidInsurancePolicyTextBlock" id="ixv-16236"><p id="xdx_849_ecustom--PrepaidInsurancePolicyTextBlock_z8TAnVgnsPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z4CV9JesYIM7">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-16248"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkjQNNqrz7Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zobfBdlcAuBi">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zJZYksx9bD8" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22390">978,244</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20221231_zmHFSR6xk1Ge" title="Patent and licensing legal and filing fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22391">1,268,308</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-16262"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI0DaF9ATAd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmwYy0kjFPU4">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zDhOXPncSCxd" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22392">23.3</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zJMnYwHwJItj" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22393">25.6</ix:nonFraction></span>% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxUPoerTkMr6" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22394">18.4</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zphZp5lrDwob" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22395">30.3</ix:nonFraction></span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNTceUgFQ3yj" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22396">29.9</ix:nonFraction></span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcHlgkCXEct" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22397">25.2</ix:nonFraction></span>%
and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpi6KeYmITMe" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22398">13.7</ix:nonFraction></span>%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyYKGW0GeSmd" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22399">21.0</ix:nonFraction>%</span>, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6jJLH7sRfMg" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22400">19.3</ix:nonFraction>%</span>, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUipF1eskioc" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22401">15.1</ix:nonFraction>%</span> and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0jsSDHU2ETh" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22402">12.1</ix:nonFraction>%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-16293"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z1r7XuiboyKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaVrDHWpRtp6">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2023 and
2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2023 or 2022.
Subsequent to December 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-16328"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaRwnM7sC344" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyUGyP3lGbZj">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="LIXT:WarrantsPolicyTextBlock" id="ixv-16352"><p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_z9ZNXjnSFTXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6kX7VOtHIY5">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-16375"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zTmObsInfUOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zLJnKOfudIFl">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-16391"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zLagUHXv6Kr8" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22403">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22404">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22405">808,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22406">190,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22407">552,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22408">389,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22409">1,433,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22410">652,427</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22411">1,433,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22412">652,427</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zsquuEIHR6Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-16487"><p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z6PnzSAKnH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zJsbAmWqz2rj">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations. During the years ended December 31,
2023 and 2022, the Company incurred various costs and expenses denominated in Euros, which were converted into United States dollars
at the average rate of <span id="xdx_909_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20231231_zBMa2lYyC0Yj" title="Foreign currency average rate"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure" id="ixv-22413">1.0824</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20221231_zlmwdoeIgGq3" title="Foreign currency average rate"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure" id="ixv-22414">1.0538</ix:nonFraction></span>, respectively. As of December 31, 2023 and 2022, the Company did not hold any currencies other
than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-16516"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zAc4lmM3qhO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zhHBMFQBT6Gc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-16548"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZy8jlZGlQq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zIEp5H0oXVi4">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation
(Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 &#8212; General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company&#8217;s consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

</ix:nonNumeric><p id="xdx_856_zJclNHr2s8ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-16579"><p id="xdx_804_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z0iLvldCdnG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82D_z5LCav1nyiV5">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock" id="ixv-16586"><p id="xdx_896_ecustom--ScheduleOfResearchAndDevelopmentCostsTableTextBlock_zgQC8oWLcvC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials
involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical regions where
such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zCzvrQhSvuq1" style="display: none">Schedule
of Research and Development Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoukKhcaDt6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zV8Mp80Audbh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zKFQhmg7EOs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22415">359,589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22416">350,618</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zUiHa81jyMi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22417">295,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22418">626,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--FR_zaBG9zPoIS1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">France</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_country_FR" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22419">91,532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zXjM0heYEhgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22420">17,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22421">76,595</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z3TBAtIvBzZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22422">226,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22423">204,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zQlulZwPy08e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22424">898,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22425">1,349,269</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPqfj8riFPW6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22426">898,100</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22427">1,349,269</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zXK7qWiQpx68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-16715"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zeK65tJL6vEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82F_zFWVaeJrtW2f">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zWvSCSMWlLV1" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22428">10,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zQqwXfVUmHth" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22429">0.0001</ix:nonFraction></span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKoo3m3SGDQ2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22430">350,000</ix:nonFraction></span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. <span id="xdx_903_eus-gaap--PreferredStockDividendPaymentTerms_pid_c20150317__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ze5MuyRlP4e2" title="Preferred stock, dividend payment terms"><ix:nonNumeric contextRef="From2015-03-172015-03-17_custom_SeriesAConvertiblePreferredStockMember" name="us-gaap:PreferredStockDividendPaymentTerms" id="ixv-22431">The
holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed</ix:nonNumeric></span>. As of December 31, 2023 and 2022, the
Company had <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zrKwew4rXu4c" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zX3eVFDlTKC9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22432"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22433">9,650,000</ix:nonFraction></ix:nonFraction></span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board of Directors
may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbWNonnBVxs2" title="Preferred stock, conversion description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171" name="us-gaap:PreferredStockConversionBasis" id="ixv-16741">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfHjRvYZhXj" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22434">0.20833</ix:nonFraction></span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQZueNHIfi33" title="Gross proceeds from sale of transaction"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22435">21,875,000</ix:nonFraction></span></ix:nonNumeric></span>. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzGKy3DFcVg2" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQITNxj4L7D8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22436"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22437">350,000</ix:nonFraction></ix:nonFraction></span></span> outstanding shares
of Series A Convertible Preferred Stock would convert into <span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4HWiLUaKk95" title="Preferred stock convertible into common stock"><span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYod8fbPnc1k" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22438"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22439">72,917</ix:nonFraction></ix:nonFraction></span></span> shares of common stock at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zpeyUJE9fKR7" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zlcbkqFUBQ4f" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22440"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22441">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zCLyRzz0J2A8" title="Common stock, par or stated value per share"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zRoLF9BT21ek" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22442"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22443">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of December 31, 2023 and
2022, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zgEyn6NWtOF7" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zStiUdtJgYbh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22444"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22445">2,249,290</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zlGX2Zx74yl4" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zp9n1uTEJ3Q6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22446"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22447">1,664,706</ix:nonFraction></ix:nonFraction></span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLV6dHaygyN4" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-22448">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized number of shares of common stock and the par value per share were not affected by the reverse stock split. No fractional shares
were issued in connection with the reverse stock split, as all fractional shares were rounded up to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTUnTSrdnqy9" title="Shares issued upon exercise of stock option"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22449">1,250</ix:nonFraction></span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zniv5KTadGd7" title="Warrants exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22450">1,250</ix:nonFraction></span> shares exercisable at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuI2xvJfcE" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22451">5.025</ix:nonFraction></span> per share for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCz6Zgvio5gf" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22452">6,281</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">April
12, 2022 Sale of Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMRdaxqMm15b" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22453">290,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKfDzIhoApO2" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22454">20.00</ix:nonFraction></span> per share in a registered direct
offering, generating gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7eB3NJMBrl" title="Proceeds from sale of shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22455">5,800,000</ix:nonFraction></span>. The total cash costs of this offering were $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2xhfCegf6Y2" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22456">658,616</ix:nonFraction></span>, resulting in net proceeds of
$<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9JXifmaGgLi" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22457">5,141,384</ix:nonFraction></span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_z92GGFusENT1" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22458">29,000</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_zVvbf4RvzUv8" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22459">20.00</ix:nonFraction></span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July
20, 2023 Sale of Common Stock and Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDpwCZUmr10d" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22460">180,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6KCsx7vkqad" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22461">6.00</ix:nonFraction></span> per share and pre-funded warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zLkAW4UPZ3Ti" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22462">403,334</ix:nonFraction></span>
shares of common stock at a price of $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z77bVc2EGhDg" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22463">5.9999</ix:nonFraction></span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcwMnjz3QSHa" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22464">0.0001</ix:nonFraction></span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zT2e8Cv9m2Xl" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-07_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22465">403,334</ix:nonFraction></span> pre-funded warrants, exercisable at $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zsQ4Av4Ene1h" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-07_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22466">0.0001</ix:nonFraction></span> per common share, were
exercised for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zY5RROjYe7z1" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-07-242023-08-07_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22467">41</ix:nonFraction></span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxU61230hVwe" title="Shares issued upon exercise of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22468">403,334</ix:nonFraction></span> shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEF23643iTCe" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22469">583,334</ix:nonFraction></span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Oqe9a86D4l" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22470">6.00</ix:nonFraction></span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaMM9zF6h6ei" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-22471">five years</ix:nonNumeric></span>
thereafter on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9QeBHeYG6ng" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="ixv-22472">July 20, 2028</ix:nonNumeric></span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZz6sizVHom7" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22473">3,499,964</ix:nonFraction></span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIM88Pjg0Hd1" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22474">362,925</ix:nonFraction></span>, resulting in net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwnamlXqQqNe" title="Net proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22475">3,137,039</ix:nonFraction></span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z44RKYKRS9zf" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-22476">35,000</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWdnphWJu7n9" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-22477">6.60</ix:nonFraction></span> per share and
expiring on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zHUHgDrAVFSi" title="Warrant expiration date"><ix:nonNumeric contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="ixv-22478">July 20, 2028</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zm3FXY03nsqj" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22479">6.00</ix:nonFraction></span> per share) and to the placement agent (exercisable
at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWHVepD6Uf0i" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares" id="ixv-22480">6.60</ix:nonFraction></span> per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional investor contain
a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction (a sale or transfer of assets or
ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control, the holder of the unexercised common
stock warrants would be entitled to receive, in exchange for extinguishment of such warrants, cash consideration equal to a Black-Scholes
valuation, as defined in the warrant agreement. If such fundamental transaction is not within the Company&#8217;s control, the warrant
holder would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#8217;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash payment
for a warrant redemption as a distribution from stockholders&#8217; equity, as and when such cash payment is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-16883"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsUZvjzFjOoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2023 and 2022 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zDqLPxAqnOT3" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Warrants outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ziuZ25V42jz9" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22481">311,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpfop4SYsGh3" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22482">57.720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMPcOrdOu7A6" title="Number of Shares, Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22483">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxmoqpNrfPr9" title="Weighted Average Exercise Price, Issued" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22484">20.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0PJTORZgZc" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEEzhRKHWGxg" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvOcIHvLYBdd" title="Number of Shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares" id="ixv-22485">150,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHBShZqPwLWi" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22486">60.000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztwbjoJ0GYf1" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22487">190,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTlLmO3UyNg7" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22488">50.161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlsxvt9qJ35l" title="Number of Shares, Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22489">618,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaQOndTeeM9d" title="Weighted Average Exercise Price, Issued" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22490">6.034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjs4Vjx78Zae" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS2JDRMic5j" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZpegNnuXEk9" title="Number of Shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVn24AL1OWo7" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJcyq2t1laBb" title="Number of Shares, Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22491">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zk3z2IZQKWDc" title="Weighted Average Exercise Price, Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22492">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWngRgbiF2Z8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-22493">3.99</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcBMNbidNv04" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22494">190,031</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBHWJsEgkl0l" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22495">50.161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztRuwimAmhk2" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22496">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZcVMAUOaFl2" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22497">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2kd7kcYSxPe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" id="ixv-22498">3.99</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zXB2QmlpJXo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" id="ixv-17109"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zHCdrGKKPNI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z6TB8k2oC2xi" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3qWYGq2AwX8" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22499">6.000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaYnQqKahfc8" title="Warrants Outstanding Shares" style="width: 48%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22500">583,334</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z88RxNZdljD4" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22501">6.600</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8BD11CMmA2k" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22502">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQVqTnzEtcnk" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22503">20.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpKAaCkzXvm8" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22504">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqOgjc8Y5Pve" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22505">37.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zT9bmTbBiKgf" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22506">11,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAMfzu0vpsob" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22507">57.000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuvCd21XPysc" title="Warrants Outstanding Shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22508">149,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231_zIuK0iOOHQwl" title="Warrants Outstanding Shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22509">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zMAkGxvcCTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5MtsnC1APic" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22510">57.00</ix:nonFraction></span> per share at December 31, 2023 consist of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwzCgsTAfoY9" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22511">1,497,000</ix:nonFraction></span> publicly-traded warrants pre-split <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPMvHqXizbGa" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-22512">1-for-10</ix:nonNumeric></span> that were
issued as part of the Company&#8217;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTV4tY7bNks5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22513">5.70</ix:nonFraction></span> per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHA59smDsB" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22514">5.70</ix:nonFraction></span>, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXMUnxLvhYWi" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USD" id="ixv-22515">57.00</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdrlvQepPRM1" title="Fair market value of stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22516">2.35</ix:nonFraction> </span>per share on December 31, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-17221"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZWbPdgQqE97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82F_zRyI2U6dpUz1">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors, and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zrJFA5Ku7CM7" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22517">250,000</ix:nonFraction></span>.
During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztaJjLFKgH2e" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22518">190,860</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBZ4FCtyjWOd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22519">250,000</ix:nonFraction></span>, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zJeAF7MSCCRe" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22520">150,000</ix:nonFraction></span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgUbnZQZjDT8" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22521">175,000</ix:nonFraction></span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the years ended December
31, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zONiQmgNIYNb" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22522">175,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3QXwxJOAPM" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22523">175,000</ix:nonFraction></span>, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zUICFMADDaD3" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22524">120,000</ix:nonFraction></span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z01Wnixvczc1" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22525">175,000</ix:nonFraction></span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ze68UpK9odyk" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22526">200,000</ix:nonFraction></span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which the Company paid $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zc6WKkehCJw4" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22527">15,571</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--PaymentsForRent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zXopDSprRZye" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22528">937</ix:nonFraction></span>, respectively, on Mr. Forman&#8217;s behalf for the years ended December 31, 2023
and 2022. During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVXAuptS4kVj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22529">200,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zlsk2CDDfTM4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22530">178,819</ix:nonFraction></span>, respectively, to Mr. Forman under
this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zkujrcc5uiU2" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22531">120,000</ix:nonFraction></span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zDexGD0ZRBne" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22532">175,000</ix:nonFraction></span>. During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVe50L9PnxQ1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22533">175,000</ix:nonFraction> </span>and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXvycoFS2S4j" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22534">175,000</ix:nonFraction></span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zp0wAVjKlOaa" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22535">150,000</ix:nonFraction></span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#8217;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will
be eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement
is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early
termination provisions as described in the employment agreement. During the year ended December 31, 2023, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbT44YZcqV4d" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22536">40,639</ix:nonFraction></span> to
Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations for such period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_zCa7Ij7F3Evb" title="Cash board fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2022-06-15_custom_DrReneBernardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22537">100,000</ix:nonFraction></span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_90B_ecustom--ManagementFeePayableQuarterly_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_ztWsXJT0Hke4" title="Cash board fee payable quarterly"><ix:nonFraction name="LIXT:ManagementFeePayableQuarterly" contextRef="AsOf2022-06-15_custom_DrReneBernardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22538">40,000</ix:nonFraction></span>, payable quarterly. During the years ended December 31,
2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuH3xUfOjSb1" title="cash board compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22539">62,500</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqX5khH4yg5c" title="Cash board compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22540">133,873</ix:nonFraction></span>, respectively, with respect to his cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zoWo8fqJ6Png" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22541">20,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_906_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zuGEbTrANgm1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22542">10,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zsx8qu4yEiK5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22543">5,000</ix:nonFraction> </span>per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zBPcxliY4I9d" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22544">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zuYabsm4TECd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22545">2,500</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zJ9BWB7gqBf9" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22546">25,000</ix:nonFraction></span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zTiDf3UnL6L2" title="Options exercisable period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22547">five years</ix:nonNumeric></span>,
at the closing market price on the date of grant, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zaqx4NUUnkHb" title="Options vesting term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22548">vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service</ix:nonNumeric></span>. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90B_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zuHSSysIOvEb" title="Cash fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22549">100,000</ix:nonFraction></span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zlt1lIdZQZ9e" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22550">10,000</ix:nonFraction></span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zuCeIKXSJ2c9" title="Options exercisable period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22551">five years</ix:nonNumeric></span>, at the closing market price on the date of grant, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zwsGMMAR9i6" title="Options vesting term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22552">vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director</ix:nonNumeric></span>. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zWoHXc6cKNCg" title="Cash fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22553">40,000</ix:nonFraction></span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_zjBm4kyeOpPk" title="Stock based compensation"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-01-012023-12-31_custom_NonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22554">163,479</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--SalariesAndWages_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_z38adBrazz7h" title="Stock based compensation"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2022-01-012022-12-31_custom_NonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22555">266,020</ix:nonFraction></span>, respectively, for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-17383"><p id="xdx_895_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zpSmtHiyZMPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zPxp7rYaMom1" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJYpwB9sh2b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zilBvtTqTHJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OfficersCompensation_zxY587gtQA2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22556">944,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22557">1,044,839</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zXWkfEGt3Lhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22558">773,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22559">1,502,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zNrpgk7VYNFb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22560">1,718,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22561">2,547,615</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_zWyT1z4sMuM9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22562">1,718,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22563">2,547,615</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<!-- Field: Split-Segment; Name: 002 -->
</ix:nonNumeric><p id="xdx_8A4_zelEUnGjLmO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-17485"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zN0jlIZJ5qi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_823_zKfP6XOA1ANk">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAIV13jsyRq8" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22564">233,333</ix:nonFraction></span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221006__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuc36anq7Ohg" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-06_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22565">180,000</ix:nonFraction></span> shares, to a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUOoYv851l06" title="Number of common shares issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22566">413,333</ix:nonFraction></span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231126__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAJpIr2wZoB" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-11-26_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22567">336,667</ix:nonFraction></span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zClHQvCXLHp2" title="Number of common shares issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22568">750,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, unexpired stock options for <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWlPBRdj86ud" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22569">495,000</ix:nonFraction></span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zM0DAsFRPnBg" title="Shares were available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22570">255,000</ix:nonFraction></span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-17526"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zts1CO8ZeUT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhweWedzOTod" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231_z7a5eJuqSdy8" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22571">4.843</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zZEWVvi5R8oj" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22572">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zTUsUmQ6wPZe" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22573">138.05</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zJ2Ao391EqS" title="Expected life"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-22574">4.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20220101__20221231_zFP0jPpHHLt8" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22575">3.03</ix:nonFraction></span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20220101__20221231_zDTD84iiN9bk" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22576">3.63</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zF5WOiwXBe4c" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22577">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20220101__20221231_zK7PmrqPVWEk" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22578">128.03</ix:nonFraction></span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20220101__20221231_zDs6gylt4lxg" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22579">153.17</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zlDrN4yCin21" title="Expected life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-22580">3.5</ix:nonNumeric></span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zibY8JCgQwy3" title="Expected life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-22581">5</ix:nonNumeric></span> years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zXKnZ3xpsUo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zu64vgFxzDu8" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22582">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zYyTglmsShV5" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22583">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC9UxaqUcAhj" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22584">71.40</ix:nonFraction></span> per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfgfysHE5Il6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22585">The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5PCh2G7LNy3" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22586">400,855</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPikHhfXho69" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22587">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0sQZ24Ncy9b" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22588">100,214</ix:nonFraction></span> was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy87pHHjD803" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22589">61,501</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zh8AJUuTM2T" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22590">100,213</ix:nonFraction></span> for the years ended December 31, 2023 and
2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIzMww3N3Ti5" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22591">8,333</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKMIMgCS3JXk" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22592">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zFAOsILpKIb7" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22593">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zOfcFf0rqD9l" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22594">The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zq0XQBePW8Eb" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22595">572,650</ix:nonFraction></span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7tWuAgrdrR8" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22596">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zeGXCN1y2ifi" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22597">143,163</ix:nonFraction></span> was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjtpezggaflb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22598">83,544</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKVWM0OeW5ub" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22599">143,163</ix:nonFraction></span> for the years ended December 31, 2023 and 2022,
respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_zphFy8RWYTKe" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-08-112020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22600">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7ULeA3KwV01" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22601">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_ziGYCDhRyfP5" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22602">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zxwO14GPDql8" title="Stock options description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22603">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zWhlbjafmEY4" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22604">400,855</ix:nonFraction></span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjh1JCXr2Q" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22605">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJzNCLKbH6Ri" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22606">100,214</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on August 12,
2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was
charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLxKnBcMNje7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22607">61,501</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZWCMPhfPeaj" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22608">100,213</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zogYvlcKIc84" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22609">25,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHv3jT1boV6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22610">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_ztFMRkydEnUc" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22611">32.00</ix:nonFraction></span> per share (the closing market price on the grant
date), <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmutyFMMqFQ5" title="Stock options description"><ix:nonNumeric contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22612">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zJqOs1Dy1N8j" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22613">753,611</ix:nonFraction></span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1YOlqjTXAL6" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22614">30.144</ix:nonFraction></span> per share), of which $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7JYhy3nwM97" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22615">376,800</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on April 9, 2021 and
was therefore charged to operations on that date. Although the remaining unvested portion of the fair value of the stock options was
being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options terminated on October
30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and administrative costs
in the consolidated statement of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zDRCugkODlci" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_srt_DirectorMember_custom_MrSchwartbergMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22616">126,684</ix:nonFraction></span> for the year ended December 31, 2022 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zb7YnFTDFnX8" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22617">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmEtTyWM5gvl" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22618">five year</ix:nonNumeric></span>s
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zksCQFX8knui" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22619">28.00</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zbFTgWyXbBIc" title="Stock options description"><ix:nonNumeric contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22620">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</ix:nonNumeric></span>. The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z7zeFgkdVxJb" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22621">658,363</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zYYsKuYm3Vyf" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22622">26.335</ix:nonFraction></span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z6iijqUQrRcf" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22623">329,188</ix:nonFraction></span> was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zYCWuOIFdfp7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22624">76,388</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2L7T45oQBOi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22625">154,042</ix:nonFraction></span> for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zZqJjf6Xh6sd" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-06-282021-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22626">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zWGDoyJId69b" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22627">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPkaFO7548h8" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22628">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zBrxnT4nsTyc" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22629">30.30</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zUeIn9ikXQli" title="Stock options description"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22630">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</ix:nonNumeric></span>.
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z7niMfKEGSE5" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22631">1,421,095</ix:nonFraction></span>
($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8pSPXynF0C6" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares" id="ixv-22632">28.423</ix:nonFraction></span> per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPJBVOvkKdzf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22633">211,413</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrujbsuwQgld" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22634">638,915</ix:nonFraction></span> for the years ended December 31,
2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIKCHF1nrBxb" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22635">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zu6zHiAtcjje" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-162022-06-17_srt_DirectorMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22636">five years</ix:nonNumeric></span>
at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGpFMtV78sEb" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22637">7.40</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZY487Hv5589" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22638">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service</ix:nonNumeric></span>. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsEN8xk5J8r" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22639">158,525</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zdH129z46FWh" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22640">6.341</ix:nonFraction></span> per share),
of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjIjKIy85IU9" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22641">79,263</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zveU02Pr37P1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22642">38,885</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zFOxkAh9lFZb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22643">100,249</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zT87nCDWBNga" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-22644">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zyV2Kn7lO3Ab" title="Stock price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="5" unitRef="Shares" id="ixv-22645">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zMyTKttTPNLk" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22646">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z1ZT4rosmLV6" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22647">7.40</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_ze3hN3FJIAIa" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22648">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zqoCyyA5BVdf" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22649">316,700</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zJSBCsF0X77g" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares" id="ixv-22650">6.334</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zlj3Xxmr9JBg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22651">94,881</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zzRKnFgxwki1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22652">63,777</ix:nonFraction></span> for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHGlgs0tdYpg" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22653">20,000</ix:nonFraction></span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zEYrIejNSNkd" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22654">80,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zrxWaiOtdlql"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22655">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zAjjbzcJZXua" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22656">20.00</ix:nonFraction></span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziwz06Zd9OBk" title="Stock options description"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22657">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service</ix:nonNumeric></span>. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zY90e42iPLQ1" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22658">80,000</ix:nonFraction></span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zfixxaSlXtxh" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22659">262,560</ix:nonFraction></span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ztCRCbbOj449" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22660">3.282</ix:nonFraction></span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkX8KFyLh88d" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22661">61,448</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNNpYsC1cUn1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22662">75,520</ix:nonFraction></span> for the
years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPCixXgqzqgd" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22663">10,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zapUYn9LEfy"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22664">five years</ix:nonNumeric></span> at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPIZBCH59N6i" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-11-06_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22665">5.025</ix:nonFraction></span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_z62IKo2uhp8g" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22666">43,264</ix:nonFraction></span> ($<span id="xdx_90D_eus-gaap--SharePrice_iI_pp5d_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zB1ZObFeO17h" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares" id="ixv-22667">4.326</ix:nonFraction></span> per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdFjx1cOYqJ5" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22668">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zSyp6k8q6rGj" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22669">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zXdgyO3P6Mn6" title="Number of fully vested option exercisable"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22670">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zhtZcQdeW8kf" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22671">5.88</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zS5gcyomY9Na" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22672">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</ix:nonNumeric></span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zNAksO0Qgov9" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22673">192,593</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLIQVGjp8eEe" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22674">4.8131</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ze8cao2JlpQh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22675">48,464</ix:nonFraction></span> for the
year ended December 31, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zQbD61Hl1kIl" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22676">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJBiGG46a7X6" title="Option exercisable period"><ix:nonNumeric contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-22677">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjFBi9mhE2g5" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22678">1.95</ix:nonFraction></span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2o891JpZz8b" title="Options vesting term"><ix:nonNumeric contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="ixv-22679">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service</ix:nonNumeric></span>. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEyzR4sZfwsd" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22680">403,066</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRiNuWNDQKkf" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares" id="ixv-22681">1.612</ix:nonFraction></span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz3wVVOMbdZ4" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22682">35,178</ix:nonFraction></span> for the year ended December 31, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each such person ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each such person contractually expired one year from the respective dates that each of their services to the Company terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="ixv-17798"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zSC9zzCCuwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvAPnVh1JgPg" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zS7sHAf62vkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zoKqAlRJe31c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwk17zItPW2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22683">773,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22684">1,502,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zcxZR7OKlTtj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22685">43,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zte0Q5Ns2CBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22686">773,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22687">1,546,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zTVL8TCwBUe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-17873"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrM4TFyYWthe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2023 and 2022
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zUwm2Z22xu26" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Stock options outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zSN23ldJK207" title="Number of shares, stock options outstanding, at the beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22688">266,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zAkNGGuWygNb" title="Weighted average exercise price, stock options outstanding, at the beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22689">37.380</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zXucU1LYjXK8" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22690">165,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zAo5fnLSGNw3" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22691">13.370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zUjONXbGyT25" title="Number of shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z8tkTxPvqqXg" title="Weighted average exercise price, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231_z2eCYcoZ8kR5" title="Number of shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22692">42,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEazcrjFExjg" title="Weighted average exercise price, expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22693">19.160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zPKfSZCNAHK7" title="Number of shares, stock options outstanding, at the beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22694">389,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zelJDPkQeHm6" title="Weighted average exercise price, stock options outstanding, at the beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22695">29.183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zTtB0hSpy6Wb" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22696">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zAkrIHec4xT" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22697">2.492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_z7r96UwRPvRg" title="Number of shares, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22698">1,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zjpvkTFgrMT8" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22699">5.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvQCSdvaCO6h" title="Number of shares, expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22700">126,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zdBuzk8Ddun5" title="Weighted average exercise price, expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22701">28.687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zVjyZSjSfXSa" title="Number of shares, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22702">552,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_za5UIoLoxQH" title="Weighted average exercise price, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22703">15.330</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu3K38b1ry9" title="Weighted average remaining contractual life (in years), stock options outstanding"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-22704">3.84</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zAsMNZABJiFd" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22705">281,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z98r6c3kYTql" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22706">32.834</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z3TsDk2fFqhd" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22707">252,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zSNg0pg1CEF3" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22708">28.387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_ziqL2vvQSYke" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-22709">2.89</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zSsE4Xm8WJs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20231231_zlwVt4pmSYb6" title="Deferred compensation expense for unvested stock options"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22710">670,000</ix:nonFraction></span> at December 31, 2023, which
will be recognized subsequent to December 31, 2023 over a weighted-average period of approximately <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20231231_zGiRoN4QN2Yf" title="Weighted-average recognition period"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="ixv-22711">26</ix:nonNumeric></span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-18092"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zaVbuJjQ1Awa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding common stock options,, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zaTHki3lO4if" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                                                                                                                                                                                                                                                          (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zsOVqVl1W8yg" title="Exercise Prices" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22712">1.950</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrTFMhenCA0k" title="Options Outstanding (Shares)" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22713">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOFr8bFgKj7j" title="Options Exercisable (Shares)" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22714">20,833</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmG74Svv61Zi" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22715">5.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8eyyW1MGutk" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22716">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlW3WgZ1zwx" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22717">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zG3Y24X54r92" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22718">5.880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zChzWjLkFQfd" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22719">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWbt32QTpC" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22720">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpAu8ssEk42f" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22721">7.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbTSCiehNDS1" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22722">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqEaJnX2jzck" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22723">44,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIxxkRT7nSGf" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22724">20.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVpaEjQjKLEh" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22725">65,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWtnnhg1v1Z6" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22726">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z3VQUTFWRira" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22727">20.600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVuOOT3HEYl" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22728">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z10zP4OpP6Rg" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22729">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zX5xiBpdvXf1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22730">28.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zV6r3sazVpt3" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22731">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_ziVJDDvxr6q5" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22732">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z110Sw13H9ac" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22733">30.300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbt91km4mvHh" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22734">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0GaP5FPb2t" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22735">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlQTaFGFabI6" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22736">32.100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zvcpJKZwvx1d" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22737">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zpKXtRoGOIeb" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22738">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z62SuWmemyr5" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22739">60.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVLH8Zt4qcC8" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22740">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbEDizTmLd12" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22741">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zyX7mW3f6Bcj" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22742">66.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0JIKDTbWzr9" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22743">3,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxfNEcRsC3Ab" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22744">3,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zdPPdgQja3Bi" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22745">71.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zR9IrHmBaSMb" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22746">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zDm5x3jpqur6" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22747">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zdRaM6sQryx4" title="Exercise Prices" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-12-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-22748">120.000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zyyKTSlOmXy8" title="Options Outstanding (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22749">8,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zeXRwZvBnlz5" title="Options Exercisable (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22750">8,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zdeeRb8UEaa6" title="Options Outstanding (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22751">552,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_z2qehMfT1TI8" title="Options Exercisable (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22752">252,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z9qBfhAIsidb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20231231_zRoppz8aQ2Ga" title="Fair market value, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares" id="ixv-22753">2.35</ix:nonFraction></span> per share on December 31, 2023, the intrinsic value attributed to exercisable but unexercised common
stock options was approximately $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_zVlS68weT1q6" title="Intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22754">8,000</ix:nonFraction></span> at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20231231_zYDJzxxZsf6f" title="Outstanding stock options to acquire shares of common stock not vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-22755">299,791</ix:nonFraction></span> shares of the Company&#8217;s common stock had not vested at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-18327"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zMhXDgaRhSo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_821_zAP1WRUS39i3">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as
of December 31, 2023 and 2022 are as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-18336"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9mvvZNffDAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zH8ndxbWNeX9" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zDYYnNYHG7bh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zma1HyE6kpJ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_za1o89028jIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22756">612,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22757">574,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zaMh0fAWNnB5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22758">844,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_zPgW0YCOKjOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22759">1,631,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22760">2,137,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zEh9c2FvEaJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22761">8,601,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22762">8,135,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_zT7SZsuVpP5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22763">11,688,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22764">10,846,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_ztB060NVs70g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22765">11,688,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22766">10,846,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zirtavUmVtIc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zduRiwKJXMw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2023 and 2022, management
was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwtdaRqYtmib"><span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z8UkT5IppYZ7"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD" id="ixv-22767"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD" id="ixv-22768">No</ix:nonFraction></ix:nonFraction></span></span>
federal tax provision has been provided for the years ended December 31, 2023 and 2022 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2023 and 2022.</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-18446"><p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbGdSjPx7H8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8BB_zj9diyxYUj1" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zwTuNL0UIy8b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zDvQCnh1zpLc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zgBpjzegXLel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.
    S. federal statutory tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22769">21.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22770">21.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_ze3hZVnUtkf7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income taxes, net of federal tax benefit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22771">6.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22772">6.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_zNzF3F1CR3I" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expirations
    related to stock-based compensation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-22773">10.4</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-22774">1.7</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_zxEdgZmUP7U3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
    to deferred tax asset</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22775">0.8</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22776">1.5</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zUn3s9LEl5f5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-22777">17.4</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-22778">26.8</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_zdA9231C6Fv9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22779">0.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22780">0.0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zAKTiw3Imql7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20231231_z7msXVWLyOx9" title="Operating loss carryforwards, federal"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22781">28,111,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231_zvRJKckRK7x" title="Operating loss carryforwards, state"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22782">32,617,000</ix:nonFraction></span>, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zntpcYonTU02" title="Net operating loss carryovers"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22783">19,141,000</ix:nonFraction></span> that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. <span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zovH0B1EvJKf" title="Prior net operating loss conversion utilization"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="ixv-22784">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</ix:nonNumeric></span> The state net
operating loss carryovers also include approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zR6Xjd05F2Zb" title="Operating loss carryforwards, state"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22785">13,476,000</ix:nonFraction></span> that was incurred in the State of California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change&#8221;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company&#8217;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-18660"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcvXxpRiKx1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_829_zjnGezmfzZU6">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2023 and
2022, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20231231_zSCH6kszsCT" title="Clinical trial contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22786">6,412,000</ix:nonFraction></span>, including clinical trial agreements of $<span id="xdx_909_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_z6Lnq9l7o5yb" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-12-31_custom_ClinicalTrialAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22787">6,013,000</ix:nonFraction></span>
and clinical trial monitoring agreements of $<span id="xdx_901_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zAyeISpIsMg3" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-12-31_custom_ClinicalTrialMonitoringAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22788">399,000</ix:nonFraction></span>, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified, suspended
or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein should be
considered as estimates only based on current clinical assumptions and conditions and are typically subject to significant modifications
and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="ixv-18706"><p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zlVIDKd4qdB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z18PItiuPbNj" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Description
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Type
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Institution</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Start
    Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated
    End Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of Patients</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>in
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Study
                                            Objective</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Update</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>NCT
    No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Financial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Contractual</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Commitment</b></span></p></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zKqLsxKkxJm6" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember" name="LIXT:ClinicalTrialDescription" id="ixv-22789">LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">City
    of Hope and Sarah Cannon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zFj003DVZP38" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember" name="LIXT:ContractualClinicalTrialPeriodStartDate" id="ixv-22790">March
    2021</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zzC4w2NuVqAe" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember" name="LIXT:ContractualClinicalTrialPeriodEndDate" id="ixv-22791">March
    2026</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zWpRthhGing2" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer" id="ixv-22792">14</ix:nonFraction></span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zzr4OX51iE1b" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer" id="ixv-22793">36</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Three
    patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT04560972</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 9pt">$</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
    <p id="xdx_98B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztAtIZWzhOsj" title="Remaining financial contractual commitment" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_ClinicalTrialPhase1bMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22794">2,433,000</ix:nonFraction></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zxNJdmnGYtzf" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ClinicalTrialDescription" id="ixv-22795">LB-100
    combined with doxorubicin in sarcoma</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zrF7qrWYgnSg" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ContractualClinicalTrialPeriodStartDate" id="ixv-22796">June
    2023</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zevffWxihBh" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember" name="LIXT:ContractualClinicalTrialPeriodEndDate" id="ixv-22797">June
    2024</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zBmFB9LvJPgh" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer" id="ixv-22798">9</ix:nonFraction></span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zKHo6fCyXfc3" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer" id="ixv-22799">18</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    MTD and RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">One
    patient entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p id="xdx_98E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z0OO1AfG3CK" title="Remaining financial contractual commitment" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_ClinicalTrialPhase1bTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22800">3,580,000</ix:nonFraction></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zw5vzSmBCCfh" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember" id="Fact001320" name="LIXT:ClinicalTrialDescription">LB-100
    in high grade gliomas</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    0 pharmacology study</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">National
    Cancer Institute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zTiIV1t65IAb" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember" id="Fact001322" name="LIXT:ContractualClinicalTrialPeriodStartDate">January
    2019</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zsr0VwnkuAh8" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember" id="Fact001324" name="LIXT:ContractualClinicalTrialPeriodEndDate">August
    2022</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zj8ceD9m0Vk9" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Closed.
    No or minimal penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT03027388</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaWwQbf2nJf5" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001328" name="LIXT:ClinicalTrialDescription">Doxorubicin
    with or without LB-100 in sarcoma</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Randomized
    Phase 2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zoqYwLNBG0p6" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001330" name="LIXT:ContractualClinicalTrialPeriodStartDate">July
    2024</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zuZb7uGuUWu" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001332" name="LIXT:ContractualClinicalTrialPeriodEndDate">June
    2026</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaYRwN5QFTV4" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">150</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    efficacy: PFS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(1)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zcKzEyBN7Iu6" title="Clinical trial, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member" id="Fact001336" name="LIXT:ClinicalTrialDescription">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b/2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">MD
    Anderson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zvabHACetB59" title="Estimated Start Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member" id="Fact001338" name="LIXT:ContractualClinicalTrialPeriodStartDate">March
    2024</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_z5l6cWHN5KYg" title="Estimated End Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member" id="Fact001340" name="LIXT:ContractualClinicalTrialPeriodEndDate">December
    2025</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zzgPI8fkWvA6" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">21</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the survival of patients with ovarian clear cell carcinoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">No
    patients entered at December 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT06065462</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td>
    <td id="xdx_989_eus-gaap--OtherCommitment_iI_c20231231_zedGZLrQIZ6k" title="Remaining financial contractual commitment" style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22813">6,013,000</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt; width: 0.25in"><span id="xdx_F01_zRzkG6rSBs18" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F14_zaauqrobGOth" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001345" xml:lang="en-US">The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .</ix:footnote></span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F09_ziSh4RFXLjA1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F1B_zpeuWm5pbeYc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001346" xml:lang="en-US">There is no remaining financial contractual commitment associated
with this clinical trial.</ix:footnote></span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AA_zGAIIpKMHZY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated
ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase
2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the
safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration of overall
response, progression-free survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability,
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8ZCbmkiikU1" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22816">69,001</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zB3P6C7M7bFa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22817">0</ix:nonFraction></span>, respectively, pursuant to this agreement, which
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December 31, 2023,
total costs of $<span id="xdx_909_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2JT43J4bAl6" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22818">447,512</ix:nonFraction></span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zXq46MUq8lE3" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22819">2,433,000</ix:nonFraction></span>
as of December 31, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$<span id="xdx_908_ecustom--EstimatedAdditionalCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zwFE9eDkOOWc" title="Estimated additional commitment amount"><ix:nonFraction name="LIXT:EstimatedAdditionalCommitment" contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22820">800,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_906_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zzNddjiGs9K5" title="Inventory costs"><ix:nonFraction name="us-gaap:InventoryPartsAndComponentsNetOfReserves" contextRef="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22821">1,144,000</ix:nonFraction></span>. Although the production of new inventory
has been completed, nominal trailing costs subsequent to December 31, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b portion of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zn7ggzuvtuIc" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22822">268,829</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zTtllrZQdws2" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22823">260,770</ix:nonFraction></span>, respectively, pursuant to this
agreement. Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of
operations. Through December 31, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_903_ecustom--AmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTRDt66xc1pc" title="Amount related to milestone payment"><ix:nonFraction name="LIXT:AmountRelatedToMilestonePayment" contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22824">684,652</ix:nonFraction></span> for work done under this agreement through
the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zWsYmLT6OVDc" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22825">3,580,000</ix:nonFraction></span>
as of December 31, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The clinical trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)
and is being conducted at The University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly
and financial support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical
trial. The Company currently expects that this clinical trial will be completed by July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years, unless terminated earlier by the
Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a
Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound
LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally
well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent
in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. In this clinical trial, single agent LB-100 was used on a new schedule of
days 1, 3, and 5 every 3 weeks. Although MTD was not achieved, there was no dose-limiting toxicity on this schedule at doses that were
greater than the MTD in the Phase 1 clinical trial of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z3qMxlqgaRu7" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22826">16,165</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zQyu1JmrpCcj" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22827">26,397</ix:nonFraction></span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December
31, 2023, total costs of $<span id="xdx_900_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zAv0ZLz4T8y" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22828">147,239</ix:nonFraction></span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_z0StsgANnSu7" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22829">20,884</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zwpKupI9CFQi" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22830">35,403</ix:nonFraction></span>,
respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zGLGsIOxn9yk" title="Research and development costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22831">148,172</ix:nonFraction></span> have been incurred pursuant to this work
order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the year ended December 31, 2023
(see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to December 31, 2023
are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zL62WkZJJRSh" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22832">335,000</ix:nonFraction></span>. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zRvc9O8r5DGc" title="Advance amount related to milestone payment"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22833">20,240</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgM4wdKq05Sb" title="Advance amount related to milestone payment"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22834">33,815</ix:nonFraction></span>, respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGJeMthhviWi" title="Cost incurred total"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22835">78,681</ix:nonFraction></span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zsGZtE0lPTPg" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22836">258,000</ix:nonFraction></span> as of December 31, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas. The study
is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zMlopiGEA6u4" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22837">153,000</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zoAGXguiJZY6" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22838">72</ix:nonFraction></span>% to Theradex for services and approximately <span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9j1B0Dd2ZQ9" title="Percentage of payment through software"><ix:nonFraction name="LIXT:ExpectedPaymentThroughSoftware" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22839">28</ix:nonFraction></span>% for payments for pass-through software costs. During the year ended December 31, 2023,
the Company incurred costs of $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z0f0ehl2MJek" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22840">14,862</ix:nonFraction></span>, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_907_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z4ksR7aax2S6" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22841">14,862</ix:nonFraction></span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAGJvhyQENVa" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22842">141,000</ix:nonFraction></span> as of December 31, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zJ9tGSljC0o4" title="Non refundable license issue fee"><ix:nonFraction name="LIXT:NonRefundableLicenseIssueFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22843">25,000</ix:nonFraction></span> after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $<span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zFLmbiY9Dl5d" title="Maintenance fee"><ix:nonFraction name="LIXT:AnnualLicenseMaintenanceFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22844">25,000</ix:nonFraction></span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $<span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zVxLqJqnxnq8" title="Payment on non refundable milestone"><ix:nonFraction name="LIXT:PaymentsOnNonrefundableMilestone" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22845">1,897,000</ix:nonFraction></span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $<span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z6QMIb0GnsVe" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-012023-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22846">9,109</ix:nonFraction></span>, representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement. During the year ended December 31, 2022, the Company recorded charges to operations
of $<span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zfNZKLc4L416" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22847">25,000</ix:nonFraction></span>, in connection with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zIA4dJmidx6d" title="Salary and compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22848">640,000</ix:nonFraction></span>, payable monthly (see Note 5). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210501__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zNavkSvYyYPl" title="Annual compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-05-012021-05-01_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22849">775,000</ix:nonFraction></span>, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zmRyT0OgmGBk" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22850">200,000</ix:nonFraction></span>. In addition,
Mr. Forman is being provided an office allowance of approximately $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zIrrB8gzMuUc" title="Payment of office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22851">1,500</ix:nonFraction></span> per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_907_eus-gaap--OfficersCompensation_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_ziydiDSQpjg1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22852">150,000</ix:nonFraction></span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined at the sole discretion of the Board of Directors. Mr. van der Baan was appointed as Chairman of
the Board of Directors upon the death of Dr. Kovach, who died on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers was $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember_z1vz99lGrBjb" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_srt_OfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22853">700,000</ix:nonFraction></span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zkGkC8GEqLfe" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-22854">4,000</ix:nonFraction></span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOmZNk05bq1b" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2023-01-012023-12-31_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22855">16,000</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zwXOHPNYb3Mg" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2022-01-012022-12-31_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22856">16,000</ix:nonFraction></span> for the years
ended December 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zjnvRLQ3UHx8" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22857">10,000</ix:nonFraction></span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 6). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_903_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDXqRHZ6t8ml" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22858">120,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zn0ukr3Zmww1" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2022-01-012022-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22859">120,000</ix:nonFraction></span> for the years ended December 31, 2023 and 2022,
respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zBkw1k2RH0G3" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR" id="ixv-22860">391,000</ix:nonFraction></span> Euros and
provide a sufficient supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
<span id="xdx_907_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQOlTbUv7rP7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR" id="ixv-22861">500,000</ix:nonFraction></span> Euros (approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQIceSAZqBY7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22862">526,000</ix:nonFraction></span> at October 3, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZpc1uW8wiLi" title="Advance amount related to milestone payment"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22863">226,150</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zfnxcAj7qss5" title="Advance amount related to milestone payment"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22864">204,158</ix:nonFraction></span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2023, total costs of $<span id="xdx_901_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zDARE2RFxlKe" title="Research and development costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22865">485,556</ix:nonFraction></span> have been incurred pursuant to this agreement, as amended. The Company&#8217;s aggregate
commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zkru21Oz2dy3" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22866">595,000</ix:nonFraction></span> as of December
31, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros,
final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zxcsDkx3E23b" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22867">273,980</ix:nonFraction></span> for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$<span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zyMtECBpFl25" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22868">326,274</ix:nonFraction></span> for services to be rendered through April 30, 2024. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z18kwnAj6wtf" title="Advance amount related to milestone payment"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22869">32,307</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgJ9YYCrzQ2f" title="Research and developments costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22870">27,702</ix:nonFraction></span>, respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_904_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zqVTNug3zUFi" title="Total costs incurred"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22871">248,298</ix:nonFraction></span> have been incurred
pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zNNfDOQkcit8" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-12-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22872">78,000</ix:nonFraction></span> as
of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates has had a material effect on its
operations to date, other than its impact on the general economy. However, there is a risk that the Company&#8217;s operating costs could
become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital may all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-19760"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zNwA8ZEEixYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82F_zxvDojBQeNAh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than those matters described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures
in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with the National Institute
of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;), each an institute or
center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has licensed exclusively
NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) subject invention
co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination
with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for
the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis,
until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed
territory, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6N1FIZy3DU8" title="Non refundable license issue royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22873">50,000</ix:nonFraction></span> and a first minimum annual royalty
of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueWithinSixtyDaysMember_z1uCnYQRHCuf" title="Non refundable license issue royalty"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueWithinSixtyDaysMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22874">30,000</ix:nonFraction></span>, within sixty days from the effective date of the Agreement. The first minimum annual royalty may be prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90B_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zmOGlURMzAKc" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22875">30,000</ix:nonFraction></span> is due each January
1 and may be credited against any earned royalties due for sales made in that year.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively,
each with a different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 31, 2024
benchmark is defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The total of all such benchmark payments is $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzpnbkgb6tm7" title="Payment for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-22876">1,225,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_906_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zS8a1cDyQdwl" title="Royalty percentage"><ix:nonFraction name="LIXT:RoyatiesPercentage" contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-22877">5</ix:nonFraction></span>% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

</ix:nonNumeric><p id="xdx_81B_zYC1qBQiCwNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>ex10-16.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.16</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPENSATION
CLAWBACK POLICY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
<U>Purpose and Scope</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) believes that it is in the best interests of Lixte Biotechnology Holdings, Inc. (the
&ldquo;<B>Company</B>&rdquo;) and its stockholders to create and maintain a culture that emphasizes integrity and accountability and
that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore adopted this compensation clawback
policy (the &ldquo;<B>Policy</B>&rdquo;), which provides for the recovery of erroneously awarded incentive compensation from the Company&rsquo;s
executive officers in the event of a Triggering Event (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.
<U>Administration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is designed to comply with Section 10D of the Exchange Act, Rule 10D-1, Nasdaq Listing Rule 5608 and other regulations, rules
and guidance of the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) thereunder, and related securities regulations
and regulations of the stock exchange or association on which Company&rsquo;s common shares are listed. This Policy shall be administered
by the Compensation Committee of the Board (the &ldquo;<B>Committee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
determinations made by the Committee shall be final and binding. In addition, the Company shall file all disclosures with respect to
this Policy in accordance with Rule 10D of the Exchange Act and Rule 10D-1 promulgated by the SEC thereunder, including the disclosures
required by the applicable SEC regulations, and with the disclosure required by any rules or standards adopted by the national securities
exchange on which the Company&rsquo;s securities are listed. The Committee hereby has the power and authority to enforce the terms and
conditions of this Policy and to use any and all of the Company&rsquo;s resources it deems appropriate to recoup any excess Incentive
Compensation subject to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.
<U>Covered Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former Covered Executives, as determined by the Committee in accordance with Section
10D of the Exchange Act, Rule 10D-1 promulgated by the SEC thereunder and the listing standards of the national securities exchange on
which the Company&rsquo;s securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.
<U>Event That Triggers Clawback Under This Policy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board or Committee will be required to recoup any excess Incentive Compensation &ldquo;received&rdquo; by any Covered Executive during
the three (3) completed fiscal years (together with any intermittent stub fiscal year period(s) of less than nine (9) months resulting
from Company&rsquo;s transition to different fiscal year measurement dates) immediately preceding the date the Company is deemed (as
determined pursuant to the immediately following sentence) to be required to prepare an accounting restatement of its financial statements
(the &ldquo;<B>Three-Year Recovery Period</B>&rdquo;) irrespective of any fault, misconduct or responsibility of such Covered Executive
for the accounting restatement of the Company&rsquo;s financial statements. For purposes of the immediately preceding sentence, the Company
is deemed to be required to prepare an accounting restatement of its financial statements on the earlier of: (A) the date upon which
the Board or Committee, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes,
or reasonably should have concluded, that the Company is required to prepare a Covered Accounting Restatement; or (B) the date a court,
regulator, or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (a &ldquo;<B>Triggering Event</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.
<U>Excess Incentive Compensation: Amount Subject to Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of Incentive Compensation to be recovered shall be the excess of the Incentive Compensation &ldquo;received&rdquo; by the Covered
Executive over the amount of Incentive Compensation which would have been received by the Covered Executive had the amount of such Incentive
Compensation been calculated based on the restated amounts, as determined by the Committee. For purposes of this Policy, Incentive Compensation
shall be deemed &ldquo;received&rdquo;, either wholly or in part, in the fiscal year during which any applicable Financial Reporting
Measure is attained (or with respect to, or based on, the achievement of any Financial Reporting Measure which such Incentive Compensation
was granted, earned or vested, as applicable), even if the payment, vesting or grant of such Incentive Compensation occurs after the
end of such fiscal year. Amounts required to be recouped under this Policy will be calculated on a pre-tax basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is specifically understood that, to the extent that the impact of the accounting restatement on the amount of Incentive Compensation
received cannot be calculated directly from the information in the accounting restatement (for example, if such restatement&rsquo;s impact
on the Company&rsquo;s share price is not clear), then such excess amount of Incentive Compensation shall be determined based on the
Committee&rsquo;s reasonable estimate of the effect of the accounting restatement on the share price or total shareholder return upon
which the Incentive Compensation was received. The Company shall maintain documentation for the determination of such excess amount and
provide such documentation to the Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;) as may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.
<U>Method of Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee will determine, in its sole discretion, the methods for recovering excess Incentive Compensation hereunder, which methods may
include, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
                                            reimbursement of cash Incentive Compensation previously paid;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other
                                            disposition of any equity-based awards;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offsetting
                                            the recouped amount from any compensation otherwise owed or to be owed by the Company to
                                            the Covered Executive to the extent applicable;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancelling
                                            outstanding vested or unvested equity awards; and/or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">taking
                                            any other remedial and recovery action permitted by law, as determined by the Committee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.
<U>Impracticability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable,
as determined by the Committee in accordance with Rule 10D-1 of the Exchange Act and the listing standards of the stock exchange or association
on which the Company&rsquo;s securities are listed. It is specifically understood that recovery will only be deemed impractical if: (A)
the direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered (before concluding
that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on the expense of enforcement,
the Committee shall make a reasonable attempt to recover such erroneously awarded Incentive Compensation, document such reasonable attempt(s)
to recover, and provide that documentation to the stock exchange or association on which the Company&rsquo;s common shares are trading);
(B) recovery would violate home country law where that law was adopted prior to November 28, 2022 (before concluding that it would be
impracticable to recover any amount of erroneously awarded Incentive Compensation based on violation of home country law, the Committee
shall obtain an opinion of home country legal counsel, acceptable to the applicable stock exchange or association on which Company&rsquo;s
common shares are listed, that recovery would result in such a violation, and must provide such opinion to Nasdaq as may be required);
or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees
of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.
<U>Other Clawback Rights; Acknowledgement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective
Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this
Policy. Any right of clawback under this Policy is in addition to, and not in lieu of, any other remedies or rights of clawback that
may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar
agreement, and any other legal remedies available to the Company. The Company shall provide notice and seek written acknowledgement of
this Policy from each Covered Executive; <I>provided</I>, that the failure to provide such notice or obtain such acknowledgement shall
have no impact on the applicability or enforceability of this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IX.
<U>No Indemnification or Company-Paid Insurance</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Executives against the loss of any excess Incentive Compensation. In addition, the Company will
be prohibited from paying or reimbursing a Covered Executive for premiums of any third-party insurance purchased to fund any potential
recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X.
<U>Amendment and Termination; Interpretation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect and comply
with further regulations, rules and guidance of the SEC, and rules of the stock exchange or association on which Company&rsquo;s common
shares are listed. The Board may terminate this Policy at any time. The Committee is authorized to interpret and construe this Policy
and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy is designed and
intended be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, Rule 10D-1 and other
regulations, rules and guidance of the SEC thereunder, and related securities regulations and regulations of the stock exchange or association
on which Company&rsquo;s common shares are listed. To the extent of any inconsistency between this Policy and such regulations, rules
and guidance, such regulations, rules and guidance shall control and this Policy shall be deemed amended to incorporate such regulations,
rules and guidance unless the Board or the Committee shall expressly determine otherwise. This Policy shall be applicable, binding and
enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives,
to the fullest extent of the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XI.
<U>Definitions</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;
                                            means the Board of Directors of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
                                            means Lixte Biotechnology Holdings, Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            &ldquo;<B>Covered Accounting Restatement</B>&rdquo; is any accounting restatement of the
                                            Company&rsquo;s financial statements due to the Company&rsquo;s material noncompliance with
                                            any financial reporting requirement under U.S. securities laws. A Covered Accounting Restatement
                                            includes any required accounting restatement to correct an error in previously issued financial
                                            statements that is material to the previously issued financial statements (commonly referred
                                            to as &ldquo;Big R&rdquo; restatements), or that would result in a material misstatement
                                            if the error were corrected in the current period or left uncorrected in the current period
                                            (commonly referred to as &ldquo;little r&rdquo; restatements). A Covered Accounting Restatement
                                            does not include an out-of-period adjustment when the error is immaterial to the previously
                                            issued financial statements, and the correction of the error is also immaterial to the current
                                            period; a permitted retrospective application of a change in accounting principle or a required
                                            adoption of a new accounting policy; retrospective revision to reportable segment information
                                            due to a change in the structure of an issuer&rsquo;s internal organization; retrospective
                                            reclassification due to a discontinued operation; retrospective application of a change in
                                            reporting entity, such as from a reverse recapitalization or reorganization of entities under
                                            common control; and retrospective revision for stock splits, reverse stock splits, stock
                                            dividends or distributions, or other changes in capital structure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Covered
                                            Executive</B>&rdquo; means any person who:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                            received applicable Incentive Compensation:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the Three-Year Recovery Period; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
                                            beginning service as an Executive Officer; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                            served as an Executive Officer at any time during the performance period for such Incentive
                                            Compensation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
                                            Date</B>&rdquo; means the date the Policy is adopted by the Board.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
                                            Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Executive
                                            Officer(s)</B>&rdquo; means an &ldquo;executive officer&rdquo; as defined in Exchange Act
                                            Rule 10D-1(d), and includes any person who is the Company&rsquo;s Chief Executive Officer,
                                            President, Principal Financial Officer, Principal Accounting Officer (or if there is no such
                                            financial or accounting officer, the controller), any Vice President of the issuer in charge
                                            of a principal business unit, division, or function (such as sales, administration, or finance),
                                            any other officer who performs a policy-making function, or any other person who performs
                                            similar policy-making functions for the Company (with any executive officers of the Company&rsquo;s
                                            parent or subsidiaries being deemed Covered Executives of the Company if they perform such
                                            policy making functions for the Company). All executive officers of the Company identified
                                            by the Board pursuant to 17 CFR 229.401(b) shall be deemed &ldquo;Executive Officers&rdquo;.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Financial
                                            Reporting Measure(s)</B>&rdquo; means any measures that are determined and presented in accordance
                                            with the accounting principles used in preparing the Company&rsquo;s financial statements,
                                            and any measure that is derived wholly or in part from such measures, including share price
                                            and total shareholder return, and also including, but not limited to, financial reporting
                                            measures such as &ldquo;non-GAAP financial measures&rdquo; for purposes of Exchange Act Regulation
                                            G and 17 CFR 229.10, as well other measures, metrics and ratios that are not non-GAAP measures,
                                            such as same store sales. Financial Reporting Measures may or may not be included in a filing
                                            with the SEC, and may be presented outside the Company&rsquo;s financial statements, such
                                            as in Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations
                                            or the performance graph. Financial Reporting Measures include, without limitation:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
                                            share price</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                            market capitalization</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                            shareholder return</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
                                            profitability</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            income</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
                                            before interest, taxes, depreciation, and amortization (EBITDA)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
                                            measures such as working capital or operating cash flow</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
                                            measures such as return on invested capital or return on assets</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
                                            measures such as earnings per share</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            operating measures applicable to the Company&rsquo;s research and development and clinical
                                            trial activities</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Incentive
                                            Compensation</B>&rdquo; means any compensation which (A) was approved, awarded or granted
                                            to, or earned by a Covered Executive while the Company has a class of securities listed on
                                            a national securities exchange or a national securities association, and (B) approved, awarded
                                            or granted to, or earned by the Covered Executive following on or after the Effective Date
                                            (including any award under any long-term or short-term incentive compensation plan of the
                                            Company, including any other short-term or long-term cash or equity incentive award or any
                                            other payment) that, in each case, is granted, earned, or vested based wholly or in part
                                            upon the attainment of any Financial Reporting Measure (i.e., any measures that are determined
                                            and presented in accordance with the accounting principles used in preparing the Company&rsquo;s
                                            financial statements, and any measure that is derived wholly or in part from such measures,
                                            including share price and total shareholder return). Incentive Compensation may include (but
                                            is not limited to) any of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                            bonuses and other short-term and long-term cash incentives</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            options</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            appreciation rights</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            shares</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            share units</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
                                            shares</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
                                            units</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-248588), Form S-3 (No. 333-273392 and No.
333-252430), and Form S-8 (No. 333-255407) of our report dated March 19, 2024, relating to the consolidated financial statements of Lixte
Biotechnology Holdings, Inc. as of and for the years ended December 31, 2023 and 2022 (which report includes an explanatory paragraph
relating to substantial doubt about Lixte Biotechnology Holdings, Inc.&rsquo;s ability to continue as a going concern), which appears
in Lixte Biotechnology Holdings, Inc.&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Weinberg
&amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>






<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bastiaan van der Baan, Chief Executive Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Lixte Biotechnology Holdings, Inc. (the
&ldquo;Annual Report&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and I have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision,
to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to me by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report my conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 19, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BASTIAAN VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Bastiaan
    van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert N. Weingarten, Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Lixte Biotechnology Holdings, Inc. (the
&ldquo;Annual Report&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and I have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision,
to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to me by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report my conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 19, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGATEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Robert
    N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Vice
    President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the filing by Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;) of its Annual Report on Form 10-K for
the fiscal year ended December 31, 2023 (the &ldquo;Annual Report&rdquo;) with the Securities and Exchange Commission, I, Bastiaan van
der Baan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act
of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations
of the Registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:
    March 19, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/BASTIAAN
    VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the filing by Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;) of its Annual Report on Form 10-K for
the fiscal year ended December 31, 2023 (the &ldquo;Annual Report&rdquo;) with the Securities and Exchange Commission, I, Robert N. Weingarten,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act
of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations
of the Registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:
    March 19, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "] IX# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:2:AIL92"VOI&^*/A;;:;K?PQU3P^_Q U>;3/B3I=[J*:Q\1_B)XNT^STE=
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ME"I*JW.3G*<I04;3D^6\8RA"I&/+RJ=.#C&+5VHX 'I1117 = 4444 %%%%
M!1110!5L?^/.U_Z]X?\ T6M6JJV/_'G:_P#7O#_Z+6K5 !7RU\4?VMOA7\)_
M&%_X'\5P^*&UFQM+"\F.E:+#?6A@U*!;BVV3OJ-NQD$9Q*#"H1L!6?G'U+7X
M>?MJV.H:I^TKK^GZ3INH:OJ5SH/AH6FF:597&HZE>M%H8F>.SL+..>[N9%B2
M21EAA<K&K.?D4D?RY]+GQ;XV\&?##+>*> *>6UN(,?QMD'#D*&9Y/4SZE7PV
M:87.ZM2CA\MHXC#UZV-J5L!A88=4/;5Y2DZ5+#UIU8Q/V7P,X%X=\0N,\5D?
M%%7&4<JP_#F:YO.K@LPIY94A6P-7+8PG5Q=6C5I0P\:>*K.M[3V5-+EG4KTH
M4Y2/MP?M_? D=+7QUVZ^&8#T.<_\ACU_#VH_X;^^!7&;;QV<'(SX9@.#G/?5
MZ_(;Q;X/\1>!O$.H>&?$^FWNFZCI]W<6PDN=/U*PM]0@M[^?3CJND?VI9V,]
M[I%S-:7!L;U(!#<>6X5@ZNJ=79^ +6X^+&N_#<3:M?6^C:[\0](@DTRVCDUW
M5U\$6?B:ZLX+&V$4\9U'6WT&"UC6.&YV37A\J"=E2-_\[J?TW_I73S)914P'
M 6$S1<38;@^M@<=P.\'BL-Q!BJ6)K4\!B:%?/?;TFH8/$.53V%2"<:480K_6
ML)+%_P!72^C;X(+!O,(8_BNO@5DU;/X8G"\20KT*N54)483Q-&K#*XT9WEB*
M2C#VM.7O2]I*C[*NL/\ J:/V_?@2"<6WCL9.3_Q3,'7N?^0OWIP_;_\ @4.1
M;>.LYSG_ (1B#/<?]!CW-?E1XS\!/X;T3P[K1TGQEX<N=>U'6].B\->-=,CM
M]::+1;71YVUS3I;>VL)KK3IY=7?3Y4O-'T\P7=DYM+G4T:Z.G3Z-X&T77M$\
M-ZM%J.L:6)M1^(5KXNDNK:SU%;'3_AUX,TKQQJM]H-C'_9TTUY<:5?W5C9:9
M?WL7G:K'9I<ZC:6\T[VW<_IH_2Q6;8G(Y4/#6GF>$P."S.6'K\(?4E4PF/67
M2HSI2Q^:Y<X5:5#-,-C,9A<;0RO&8+ 1Q&,Q&#5*CRXCD7T>/ UY?1S..)XS
ME@JV*Q&#]K3SV%;V5;#+$^TC4CA<!BU*G*IA*N'P];#U<;A\1BG1H4:_/5YJ
M/ZH'_@H!\"B<FV\=9P!_R+$'8DC_ )B_;)]OQK9\,_MO?!CQ7XE\/>%M*M_&
M2ZIXFUW2/#VG->>'H8+47^M:A;Z;9&YG75)## +FYB\V58I#$FYQ&^-I_)JV
M\#^'-2TR+QE8:EKMMX+M++Q5/K]M>VNG7/B:PU'PK=^";%M,TV6VEMM*U&#Q
M!=?$OP3%8:Q+%IO]EM=:^+S2K^/P];2Z[T/PXT/3]-^,?[/FK:-<WUSH7BKQ
M[X$U33H]5BMX]4TV>P^(T6@ZIH^H26DCVE[-:WNEM>6FHVB6T-_I.HV%Q-8Z
M=??;-/M?7R+Z9GTF\1GO"U#-I^&%3)<YXAX0P]>67\/X2>*QG#W$/%G#/#M3
M.LLC#/%7EETZV=SP%+,_84Y8?,DX5<N2PE>K'S\R^CYX-T\LSJK@9<;QS#+\
MJSZM2CC,UJ0H8?-LJR/.,VCEN,<LK]G'&PIY<L54P:G-5,&G*&+?MZ4'_04B
M^8-QQ][IPW3')ZC/KC(!SUYJ5D#8SP0>N.?IGJ/7@T)]T?C_ #IU?['+;\_.
MS:_3K=]S^!ELO3S_ ,_ETTTU&>6O<9/J0,YX_EC@9X''2F>0O!&!@D]..?;M
M^'MZ5-11;?SU?G]UOZ]!VOOKMOJM'=:/2R>J6WD1>4N"..2,X&.GT/T_*GJ@
M7(  !] !Z_GU[TZBG_7]>?G>_F'6_7OU^_>WE>VSMH1F-3DX&2<DX'J#_0>^
M0/2GJNT8_P ] .Y/IFEHHV_K^OGW>K#^MW_F-"*#D#GZ#^@IU%%))+;^OZ_/
M4 HHHI@%%%% !1110 444ULX_'D>H/&/Q]N:/4!U>>?$'XI^!OA;HAU_QUXB
MT_0;([UMH9W>74=2F0#-KI.EP+)?ZE<AF172TMY1"&\VX:&%7D7XZ_:=_;(O
MOAAXAU7X:^ =$CF\7:?!9?VIXEUM1)I>D/J%C!?PQ:9I:D-JM\EI<P3-<7LD
M-A;2L(S;:B!(B_EQXJO/B#XXCF^)'BRYU[Q+!>W\FES>*;^22\M(+Z$)+_9+
MO%N@T4"*=)+'3O)L+::(DZ?!*L,PC_;^!_!;,N(*. SCB/&0R#(\>Z$\%3]I
MAWFF:PQ"E.@L-&K4^K8.&)A";HU,3*KB:D;RP^!D^5G\F^+?TI<FX,QF:<,<
M$Y56XNXLRUXJAF-9T,5#A_(:V%DJ6*>,J4:?US,Z^"JSIPQ&'P4*&!HU;4<7
MFJ;G ^M_C7^W5XV\:M>:)\,(;OP!X:DWQ-K3R1GQGJ<()&])X7EMO#D<BX 3
M39+K4E/S#58@3 /A&226::6XGEDGGN)'FGGFDDFGGFE8O+---*[R2RR.6=Y)
M&9V8EF8DDEI1A\QV[<XXYY.&]/;(/]:*_K?AOA7(.%,%]1R++*& IM15>JDZ
MF,Q<X*WM,9C*M\1B9W;DO:3C2@Y-4</1C9/_ #HXSX_XO\0\T><<7YWBLUQ,
M746%P\Y>QR[+:4Y>]0RS+:,HX+ TK<L9.E1EB*JC%XG&8F2NBBBD) Z_YQS7
MT1\C>_R7W+UZ+[D+2<Y  )).  ,DDXZ<_7_.,[4/AS79=!E\5_V/J8\+P:G!
MH[Z^;*5-*;5KF.XGATV&]<)!<WIAMKB22""1Y(4CW3B+>@DRQN#?*B(@Z8+%
MW'(P[$#&!@X QU]@/X$^E[^T-\&_HG2K\*XRECN//%NKEE',<O\ #_))_5*&
M H8Z&(_LW'\7<1UJ-7!9'@<1+#U*L,%A*6:9_BZ%&;H9?@XU:6(?]S_12^@+
MXP?2B5#B7"+#<"^%D,=4PF+X\SVFZU3,)X2I1CC\+PGD%.=+&Y[BZ'M52EBZ
M\\MR+#UYQ]KF.-=*KAR/$2()'/G'D".,]^?ON?D R0=J%FQP2IJ6+?)<6Q8
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M0J5)U9<T]6[MN[<I2DVY2E)WDW)MN3<FW*[;;&J" <FER/4?F*1C_#ZY&2<
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M-52P52:;=Y44G4I5%U4Z6L7ZKEDM7&:Z_P"EK\'OC;\)_P!H#P/I?Q)^"_Q
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MYTR]_LZ^N[VR2/5-(NV:ZTO44GTZZE2T:2YMKW3I-.U?3-0OM*U.RO)>HN/
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MQRS#%6I8FEP)DN)E#+J$TJ<XTN(<\H2A6S"4&DJN7Y,\-@VTZ=;,Z\>:$O\
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MG\::G?\ B^^ATX:=;6>G6FAVU]KEQ;Z!IFGVT5AI&B1:?I=F#;6<3M[97T>
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MC]Y96@L=*+*8Y7U6U?#_ *9Z9I5AI%C:Z7IEC8Z7I=A"MM8:7IEI!8Z=86R
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M.LKZW\F]L+E8[JRN+>YBCE7^=&Z_X]I_^N3_ /H)K^F;PK_R+GAS_L7M&_\
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MBBB@ HHHH **** "BBB@"K8_\>=K_P!>\/\ Z+6K55;'_CSM?^O>'_T6M6J
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M'?Q7\7_#S1_A]XM\6V'CW7O"/PQ^'/BWQ[KG@;X+:)=>-])T?Q;;VGP>\/\
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MAK@T[4HO$GVK1-$ET['T#]@C]F+P[H_PUT2#PEXYUZ'X1_'RU_:?\":KX_\
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M!J_PGO==U3QOX0\ :E:^;X?\#V3W=_-=?I=\(_A;X-^!_P +/AS\&OAWIO\
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M?IKQZ;INLZ3J\MY=_8(;>:%SJ%LUOTOTOJK_ 'KIM?\ .PR]\)=$\<_!S0/
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M/X$^G7_N?AC_ -AG%J_\M<@9T5%%%?ZN'^>9_GS?\'0'_*23PO\ ]FK?"_\
M]3SXO5\2_P#!*&T\4:M\6?B7HNA>,_VD/A_IFI>!Q+XA\6_LZ_M=?#C]DV_T
MXZ/IWBC6_#5AXNO_ (@Z#K:>/K#Q'XBL+'POHNF:/]EF\,ZKK;:[J#S61,1^
MV?\ @Z!./^"DGA?G!_X95^%Q'(!R?'WQ?48SZ'!]^G'6OB;_ ();>-OB3X2G
M_:5@^%WB;X'^"?$%K\,K?XC^(_%OQO\ $FL>'],T+X9_#?P]\2V\;:E9-I'P
MD^*KRV^@R>)]!\::E)<1^'Q'>>$="LX)-6DU,VMO_3&!<_\ B'F60IJDYSR?
M!1O5=J<%+$5(^TFU3K+]VY0=G2J)N24HM7<?RO&1;XCQ32E+EQDVE!*4F_9J
MRY7.G=7LI>]>SV:31\9_M>^,?$?Q _:>^/?CCQ;H>I>%_%7B?XF>(-6\0:!J
M_B[P[X]UC2-5FGAAO+/5O&_A&VLO"_BW54DC9M1\0Z#:6^EZK>23WEK#%'*$
M7]S?^#5QF/\ P4$^,X9BP'['?C<C/."?C/\  L?RK\3/VXF\1']KS]HX>+].
M\.:3XK'Q1UG_ (2*P\(ZH=:\,+JY6Q-]=:!JQT#PJ=0TO4I]VIVMP?#>B,RW
MI5].MG1DK]LO^#5O_E()\:/^S.O&W_JY_@76O$ZC_J+F7+",(K(\.HQC)348
MI9:DHSLN:*L^65E>/*VD[I992W_;F&NY-O,*C;E>[;>*=VGWNG^%VU=_WYT4
M45_,*V7HOR1^LATKR6\^/OP)T[XH1?!#4/C5\);'XT3Z//XA@^$-Y\1_!UK\
M4)M MM.N-8N=<B\ 3ZRGBN31[?2+6ZU6?4TTEK*+3K:XOI)UMH9)5]9/0]^#
M7\_\'_!)GXOVW[9WBSXF:SKGPT^(G[/GC/\ ;AT3]NJ/7-7^)WQ+\$?&SP)X
M[T);#5M$\*Z?X'\/_#37/"WCFW\(:_HFEZ%X2\1ZI\8O"=BGPQN-4\%ZOX&O
MHIDN*8'I>M_\%Y?V/;#1_&>N:!H7C#QE8Z5\=H_V?_AH=&^)W[)&DR_'#Q%;
M7'CNW\1^/?!\7C+]ICPN_@'X)^&!X$DN[GXO_'T?!_P7XAT_Q9X(NO!6H^)Q
MX@$=K]W^!OVT_A=>?#_XG_$OXXZS\.?V9_"'PW_:"^)/P ?7OB?^T#\ [_P[
MJNK> =<FT:TOKWQ5X/\ B)KWAGP;XBU\VUX;GX6>,=6T?XF>%+[3[_3O$7AR
MU,5O<W?YG>"?^"1OB[0/!G[+7A_6_#?[,%[?_"'_ (*4_&[]JOXER6NEWUS:
M>)?V=_B#JG[1%UX-^&^D277PGMIM;\0Z+9?$[X?VMYX*U^#1O NE#PS/!I7B
M>]A\/^'VO.:G_P""5?[3GACQSI?QO\*O^R;\4/'7@7]O3_@HW^T=X5^"_P ;
M[WXA3?!KQA\*_P!N7Q!HM_X<U/Q+XJTSX9>(-8\&?&[X7:;X;M4AM]/^&_CW
MPTZ^)?%.D6'BP0S0:O* ?M5JO[3_ .S3H7B3X?\ @W6_VA_@9H_B_P"+.FZ'
MK/PK\*ZK\6O .G^)/B7H_B:3RO#>J_#_ $.[\00ZGXRTWQ!+^[T.^\.6NI6N
MK2?)82W#<58\4?M*_LY^!_',GPP\:_'[X*>#_B7#X=U#Q?-\//%/Q4\"^'_'
M47A/2=)O=?U7Q/+X2U;7K37X_#VF:%IFI:UJ&M/IXTVRTG3[W4;FYCL[2>:/
M\%/VP/\ @E)^W%^T%\.C\-/"&K_L1^$/"VI?LS? ;X=Z1X0^&^E>(?V</A=\
M$?BQ\*_'FM_$'Q7%X(\&>&_@'\8O''Q&^%NLZGJ,5O\ #2/7_C%\/?\ A4EW
M<:UXBTSP#K6I:UK5OK'T;IG["OQL^!'[1G[0/Q:?X>_L:_'_ /9[^*'[4FL_
MMK>+?'OQ;^%7Q%^+7[:?@B&T^'\.GZC\'_@EX#\/^$]0TCQ-K7AUM!CTGX#>
M)[7Q[::MX0TWQ#K>AVGPR\67^I06TP!^Q%A\6OA5JMW\.K#3/B9\/M1OOB_X
M;U#QE\);*P\9^'+R[^*/A#2=-T36-5\5_#JWM]2DF\;>&],TCQ+X<U34-=\-
M)J>EV6G:_HM[<W45MJMC+/Z#7X$?\$;OV4_&O@OQ9\6/CCXYTSXFZ5\*_AO:
M>*_V1_\ @GIX:^-'@3QE\,OB;X2_8S@^*_B+XR3ZKXC\#>/+;2_%ND7'BK7?
M$'@?X<:3<>*_#?A7Q'?^"/V??!UX^AVVBWFCS7/[[T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5;'_CSM?^O>'_ -%K5JJMC_QYVO\
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MJ6EZIIMU!?:=J6G7T"75EJ&GWMJ\MM>65Y;2Q7%I=V\LD%S!)'-#(\;JQNT
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MV@?&WQ>U[P_8WWACP]'\;+;Q]I^K7]CJ7Q6T[Q#^SI\3_#L_B/X4>*=3NO\
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M7PVLO%=KJXU3P/#I$EC'\*I- \5Z;JEUI_,:!\%_C]\,/#'BK7_!-C\0-?\
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MR0/XATWP\;W^UK[0EFAFA;5K6TET]9(94-P#&P&=K7Q7^%_ANV\07OB/XC^
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M1-!LI]3M+Z'0[G68=.U"XM>QT+XE_#KQ5H3>*/#'CSP9XE\,IH__  D3^(M
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M^'5SI>AK,B,?'7B73IYK$_U8_L:?L#?LF_L!_#E/AI^RQ\'?#?PWTRZBLO\
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MXT\'^&_%OBSQ#!$MG::4_B#P!XFBU2*R_M#5=$T;3KWQ?J^FV7@W2-?\0:0
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ME19(I%9)(W4.DD; J\;HV5='4E65@5920002*?11^'FM'\GT]>G2SLT'P?\
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MK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\
MR+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VN
MC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z
M=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z
M-BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW
M_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B_
M_:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M
M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]
MKH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO
M^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\
MR+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL
M?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(
MO_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/
M[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW
M_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V
M**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_
M ,B__:Z -BBL?^UO^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]
MKH_M;_IW_P#(O_VN@#8HK'_M;_IW_P#(O_VNC^UO^G?_ ,B__:Z -BBL?^UO
M^G?_ ,B__:Z/[6_Z=_\ R+_]KH V**Q_[6_Z=_\ R+_]KH_M;_IW_P#(O_VN
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &^ < # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HI"0!DG '>H6GQC@+QG#'GVZ=._7^AH GHJH9@3][' X4\=3SS^7X
M4WS6[;R.QW+S0!=HJEYK=RX'KN6GK+GHY[?> /\ +I[YH M45 )2!EAN[Y!
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M^%M!&J>*[/39?"WBN^N/$#QW^HZH/$6HS7+7;6VC75CHFG>?_ ?_ ()$:O\
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MK5R=IR3DC!/IA%([<Y;GT*CBD4;*G*@GN ?S%+4<>=IZXS@9],#IZC.<&I*
M"BBHIYHK>&:>:2.&&&*2:66618HXHHT+R222N52.-%!9Y'8*B@LQ !- $M%9
MVEW]IJMC9:GIU_:ZGIVH6MM>V.H6$\%U8:A97D"W-IJ%E=02SPW%E>0217%I
M+#*\<D$B.LDB,KUHT %%&1ZCIG\/7Z49'K[?CZ4 %%%0S$@*%SDD\ [2<8[^
M@SR/IDBDVHIR=[)-NRN[+>R6K[V7G\S3KMY)O\(IM_)?@3452:8AE0M\S,5
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M'OQR>F.G;G ]$WNULN^M@W:L]=;+I+35/T6OJ*YW+M)P21D ?,-K!LKD$9
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M3M2CU/1M-\>31S^*]%T1;S5+FUT;0]4EB>Y.@:9;6VB6<US=S:;96C7M\;D
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M< W S_ CXMP@KUS)X \1+A!_>^;/OQZ5[L"& 92"& ((Z$$9!'L1S0 M%%%
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M#UZG'Z4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV0!" 1L+;<J PWMDE3@\D$JV #M9N0"<7@%;+8SVSGJ!R",'WZ]2/:@+&
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MX)]<=.@RQ)(S^6<'@5>BDC)'3/RC((&,]2N3G)[<$\ \Y% $=OIT:$ #:,]
M!C.5'8 !NQ')!(.<5N6]DO!R3R#@<YQ@\=<#[IP<8Z,>0:9"\>0%PW.>.!V
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M2,D<]P2/7&<?K@_A7AW[/9Q\-8(!G%OXU^)UJ3[V_P 2/%&W_P =7:!V_#%
M'N=%%% !1110 54ED(SD@8WJN.HYP6.3CC ^N<58<D*<'!R.G7J,_IFLN>3
M;)SDOWZ8;(QVR<;N<YQ[T 9%_<# )*CY, 9/0>HYSZ]B.!QU-#1;(7UV]W*,
M6]J=J@@E)9FP1][.408W $$-GY@,U3U&9GPB*'DD 6,=<R/)A1@<@-N)QR<#
MYN]=SI]G'86<-LAZ#,A;G<Y&96XQU;.6/KSDD"@"\%QW)YSSZ]ST'7TZ>@%1
M7$@B7>Q554.SL[!%540NQ9V(55"J=S-P!SVP9Z^//VY?B???#3X"ZV=%N9K/
MQ!XSU"P\':7=P2312V,&HNUSK5\LD#1R(R:+9WUI RRH1=WMMQ*,Q/W99EM?
M-\QP.5X:*E7QV*H8>G>[47.I'FJ/EUM2@IU7LOW>K29SXO$PP>&KXJH[0H4I
MU'JE=J+Y8IMI7E-QBO-H^$OVLOVV/$7BG6=;^'7PEU-M$\&:;=3:7JGC32KI
MSJGBN:UDEANAI&IVC/%IOA<W VQ7UA,-1U:-3*DUM9RQ>;^;C,6=Y'8R/+(T
M\KRL&DGED;>\DTA9FF9G^8F5G#'DY/)C 2(97;$B*#ND 1HECC+;F#",*FP$
MRR2QPH% 8QDDL_F=_P#&GX2Z7>OIM]\0- %VDKQ21VT]Q?QQRH^QTFN]/M+N
MTC=""KB2ZMMI_P"62 !1_9W#?"N&R3!4LOR3 U*KI*^*Q:HN>(Q>)IVIU*U6
MI%Q5E+F4(1J.$$M(19^ YIGE7'XB>(S#$TZ?M>=PHU.65.C1YVH+EE-14WHG
M*-[QW;N>FE%92I V,K*R\/D.<MUS@'[NU?E(XV5]'? O]I_XF? ;484T74!K
MO@V2>/\ M7P/KD]S-I-S"\EI'/<:,R7$<FD:Y%86JVUE<0>;9QP01O=Z9J$=
MJ(G^8-(UO1?$&GQ:KX?U;2];TV9F6/4-*OH+ZT>2,%'B2:WG>-)$(836Q5KA
M) 7D(16-:?W2!TYX+9VH2IRSL#\NY2RY&,@D#[QSU9KE6#S+#UL#F^"HXRC*
M$_:X;%TI04)N+BJGM+RJQE1;YZ;IS7O7VNVXP>+Q&$J4,5@\34P]IIPGAN2,
M<3&Z?L:D(RE%P;W=N9W=U9*_]2/PS^)'A?XJ^#-$\<>#K^.^T76[=I57_EZT
M^_A<Q:CI%_#O+P:CI=V);:\MV  >,20O+;RPROZ$IR ?4 _F*_!K]FGX_P!_
M^S'X)\67WB2V&LVWCI=.U?P/X %ZEKK=S>Q"YM+SQ=J#;)I= \+7=G%%9V][
M):W%QK%SI[QV-KY-I-<IS7C+]O+]HWQ=.YLO$VE>!K R*T&E^$='@MWCB$SB
M/S-4UJ75=5NY#%M69HKFRM96!>*",%47^;*GA5GF)S;,:&5JF\FPM:3HYIBI
M.,)4).+C%4Z<95JU2E*<J,G2CR-TDU-M34?U:GQGE]+ 4*N+C)8YTH.M@J"3
MDJFJDH.;246N62YM??:M:S?]!=8^MZSIN@:?<:OK.H:?I.DV$,UUJ&JZK?6N
MF:;I]M"N^2YO;^]EAM;6",#+RS2*B@$D@ D?SQ:!^V;^TKH4T$\/Q2U'5$CF
M>9X-?L]&UJUE,A.^"X:XLO.B@6-G'EQW"26V!)&_F1#/4?$WX^^)_P!J?3-)
MT#Q9XIM/!.M:0D4^G^$EBN-/^&GC+6(H@MN8+^6:[U;1?%M_>RSQ:7%XEUC5
M/#<-G'#%;ZGIFH3WLSZU/"+/L-BJ2Q>*PBRSF7UO,<-&K5>&A>U_JE6,:M3F
MDX0YE>%-3=2HE"$FICQQE]6C-T,/5EBK/V6$Q%2%)5)=4ZM-OEY8\T[6NW%1
M5^8_1_QE_P %"/@#X8N'M-'N_$7CFXCD='D\.Z/+!IZ!))HG*WVMMIJW/,:O
M$]M%)#=12QS6TLB$D<OH/_!23X+:A-%#K7AWQWX<1Y&26ZET^PUF"U4!]DUP
M-(O;B=8I=L(3]SYA:YB79YCHDGXE7=C=Z9=W.FZA:SV.H6%Q-9WME=V[6]S:
M7EN[17,$UO,HEAEBE5TVR?O4&,[5VHD&%( (!P,#([;73CCLLC@XZ;FZ&OT.
MCX/\&/"PA[3,\0ZD/?Q<,9&FW4<4^:&&A%T5%-W49.S3MKU^3J<;9Y[:5OJU
M&,9_[M+#*:4$]%]9DU-]5>*OU/ZDO ?Q*\#_ !,TJWU[P%XIT/Q7I$K;)+G2
M+^&>:RE:$SK:ZE8%DO\ 2;Y$9!/I^IVUI?0N3YMN@(-=^1D$9(R",CK@]>N?
M\]*_EF^'OQ)\:?"?Q3;>,_ 6M2:)KUM#);M*8OM5CJ%F[122:9JNGDJFH:=<
M/#&9+4E61T6:U>&Y1)1_13\ ?C5H?QV^'NE^--'5[*]#G3/$VB3.'GT3Q!:Q
M0M?VBR':;FQ?SDNM+OO+1;W3Y8I]J2>;#%^2<:\ 8SA+V6+H59X_)ZU1T?K3
MI1I3P=:2E.AA\5&%X2=>G";I5J;Y92A*$U&;@I?<\/<2T<Z4Z-2E#"XRG'F]
MFJKG&O&RO.FYVDGS<R<+622:;UMZ'XDL H34H1AX5\NY"@$FW8\RX W$QD8Z
MD'=T.,&KIUT&P2W.5YR,\A<G.<9Z[CC'4 * :[$H)8V1OF5BRMN&<@J1CGJH
M8@XY'%>>1Q26%Y+9.?\ 43 (PX\R)MSQ$YS\WEJN.@ P>.WY\FVDVK7Z/=?T
MK/RO9ZIGU'KIY'=029&05W;B0#D#[H'3))(7J.Q/)XP;ZG*@GN ?S%8=E(65
M<Y^\""<8P>2?;<-V0<]L\D5LQ'((SD X'.<# P/IUI@24444 %%%% !1110
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M.]Q,MSJ,F28+'2+4PS:C>74ZI+%!$D,B0Q-(29;N>TMHUDN+@V\7]"'[5/\
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M5J-;>$([+I"6@TT2L)IKJXC(@7]/XHU0*B;5C"HJA55<(BJB@!<*$ 7Y=N%
M.  !7\S^)?B%A,UPD\@R3$QJX*4W_:6:IUHT\5%U?:*AAG7A%RA*HH\TXI0F
MH4E"]IN7ZYPCPO7P-2./Q\/9U(0A'#8>=I3H\BO"I5:M>NE.<;W<;6O$MQC
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M_:&3X/#X+,G.KBY9C0C^AT3LZ;FQG)' 9<8]0WS _7KP1P0:DKA_AK-XSN/
MOAJ;XB6VFVGC=],A_P"$EM](8OIR:DI97:W;++^^C$4TJQ,T*3R2I WDJF.X
MK_1'+,;',LMR_,8X;&8*.88'!XZ.#S"@\+C\(L9A</BOJN.PTG*6'QF&^L>P
MQ5"4I.CB*-:FVW"[_F+$X=X3$8C"NK1KO#5ZV'=?#5HXC#UW0JU*+K8>O%1C
M7H5O9^UH5HQC&K1J4JB24TD4445W&(4444 %%%% !1110 4444 %%%% !111
M0 5X1\&B4\1?'^UQQ#\=-1# CD?;/AA\+M4'M\WV_=WX8=#P/=Z\%^$<R_\
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M*]\5?%.?X;V\_B'PSX)34/$>D^'7\42-;Z7I_B3Q#X=MKZ6<7\5C=@'11_\
M!8G]C>#X':/\=?$I^/'A"RN_VD=*_9"\3?"7Q#^S]\37_:,^''[1&MZ%J'B?
M1?ASXY^!6@Z'KOQ#M=:UG0;*WU?1QX<T7Q&NLVVOZ(=+-PTTZV]/Q=_P6%_9
MJ\%:5I]]JOPE_;3GO=/^&Y^,OQH\)Z?^R'\89_'?[*_P@E\4^+O#.E_$3]I_
MP3)HMIXF^%.G>)'\">,?$_ACP[<:?JGCOQ)X!\/:K\1-'\(7/@VU;5X?&-!_
MX):?'/6KOP/\7/BK\9?ACJW[0OB7_@J1\(?^"B/[04G@WPWXKTKX5VV@_!_X
M/:C\#?#'P:^#EGJU[?\ B=VTKP+8^#H3XM\:7*R:]J=OKU_=:=I4-QI]E!W/
M[4O["_[7NN_&_P#:L^)7[(GQ;^ ?A?0?V\/V>_ _P!^/5C\>_"WQ"US6?A??
M_#C2/'O@OP]\6_@L? 6K:58>)=6F\"?$GQ'8ZMX!\:-I&GS^)=$\):Y;>*[;
M3(=;T/50#%^,_P#P4@\6>$/B+^VF/!GCOX+P_!?X*?LG_P#!/CX__!SXEZKX
M(\7?%3P]J[_M9_%[XT^"-=UK5+;X?>/?"VL>-?"^N^&_!G@R7P-<>'-7T:+2
M;O5&\0ZC>:SI4ILQY[=?\%1O'NE_MZ?MD>&OBE>ZO\!OV&OV!["WTWXG^(O$
MG[)?Q$\2CXAZWJ/PKTKQQ>ZY>?M$6OQ1M]$\!M>ZUXP\)VWP5^'WAWX1>-/%
M'Q<L;B,V,L<GB#14AM^,_P#@C=K\'PV^/7P?^%7Q6T&Q\$^-?V(_^":7['/P
MJNO'=GJFI>(M%T_]@/XA>//$-SXC\>RZ):6.GZE+XU\,>)-&LK;^PK6T,>MV
MFHS36MC92PJ_K7QY_P""66H?M">%O^"I'@CQ;\3-$T32/V]O'7P.\?\ P[U+
M3?#5WKEQ\-=;^!WPK^%/AC0V\=:#J=U:Z5XQTJ^\<?#*VU#6-#LKK3[?5_!V
MH7&CS7=IJ$CWL8!V=I_P6"_90L?AU^T+\1?BEX<_:/\ V?9_V7_"_P -?B%\
M6_AE\>_@#XW^''Q;L/A9\7O$EQX4^'_Q0\.^ +V"]U3Q?X.UKQ%8ZCI-XWAU
M[_Q%X9UG2+S0/%6@Z'K\EIH]Y<\2_P#!5+X<>'?!>G^/[?\ 9(_X*3>(O"M]
M)XZN;J[L_P!A3XX^';W0_#7@1M-:_P#&?B'1OB-IG@G7;'0-;L=3;5_"E@UA
M+XL\4Z9IVJ7&D^&7DTB\B'Q1I?\ P2/^-_B+X*?M(?#SQ%X#_P"";G[/_C+X
MO^%?@5X:T+QO^RE\,?C9IVN:K+\,_C9X6^+'BEO'_B;XA^*-3OXO!FIKX;_X
MHOX>:!I5U+X:U[4)]1U7QMX@ A>/W+_@HK_P3?\ CE^UC^TAX!^-7@35_P!E
MGXD^"=$^ _B?X*3_  *_;1\$?$[Q_P#"KX>>*?$'B\>(I?VA?ASX3^'OBGP[
MI?B3XE7&D)#X-U/3_%:Z=<KH-A:QZ'XST*"]U*UN@#I[[_@K%X9O_P!LG]E[
MX&?#3X0?%GXW_ G]J?\ 8RM_VI_ GQF^%'PJ\;^*KQK7Q=\5O@[X+\$:U>69
MATRW\/\ PNT_PE\2Y_$/Q8\0:[IUCJ/P[U.?PE8:U;V\VK&V3:\*_P#!4?X>
M>&?@M\./%GQ$GUSX]?%SXS?'#]ISX5_"'X1_LC_ 3XB:EX_^(5I^S?\ %3Q?
MX-\=7N@_"WQ-XN\1ZW!I7PLTC0],M_B;\2]:\6Z-X$GU?4-)U'3$T-?&7AKP
MU+Y7\%_^";G[3_[,&J?\$V/&_P &?B9\ _$7C3]D[]AZR_8%^/FF?%#1OB.G
MACQI\+]2\8? /QGXC\>?"'4/#%[%JFD>/=/U'X,W$&@Z=XQL+OP[J-IK<4-\
MNE-;K+%A>'/^"8G[3WP-M?V6OBM\ ?B]\%]4_:$_9D^+O_!0S6(_#GQ5TCQO
M;_!/XF_!G]OKXW7_ ,7=<\+ZWJ?A2"7QSX6\?> [C0OAS<Z+XEL+'5M%O=5T
MSQ-9ZIH]_8ZII5UI8!]$^*/^"O\ ^R5I/AC]GO6O">A_M%_&'7_VH=/^.Q^%
MOPI^#'[.WQ*\=_&4^*/V:M9\*>'OCG\.?'OPWMM*LO$'PN\<?#C7_&-GHOB;
M3OB!%X>TW1;_ $[63?ZS8VMO:7&H?</[-?[0_P -_P!JSX,^"OCS\)I]=G\$
M^.(]86WLO%?A_5?"'B_PWKGAC7]6\)>+O!WC+PEK20ZIX7\8>#O%VAZSX8\4
M:%?PK+9:QI=U"K2QQQRO^9W[,7_!+;XC? _XV?L@_'?Q;\7_  CXT\:_"_5?
M^"E?Q4_:2ETGPUK/A_2?''QO_P""BOQ!^$OQ+\02?";1KV[UBY\.?#OP)KO@
M+5](TZT\4:YJ7B"^TF32KV>[DNKJ_@MOM_\ 85_9C\1?LG?!?Q3\,?$_B71/
M%6HZ]^T=^U-\:[?4M!MKZUL;;1_C[^T+\1_C)H6B20WZ12_VCH&C^-;+1M5E
MAC6RFU*RN9K)3:O$2 7/V[ &_9P\4@LR ZUX0RRC+<>)-/) '.<XP1CH37MO
MPB;_ (M3\,,'&_X=>",, "A)\,:6<AAD$LO0YP1T)&,:'Q5^&7AWXO\ @G5/
M ?BE]0BTC59+*:6;2KJ.SU""?3[N*]M9K:>:VO(%9)X4W+-:SQNA96C.01TG
MA_P]:^&]%TC0-.41Z9H6EZ?HNFPN[RO%I^E6L-E8))(^#)+';PJDDNT&3T
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MN'H#]!TH WH;H$<E=H&2,?4XQC/7&<#J.^&JWOW88%05^[M((PW#9SC&!ZD
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MH);BX:XN"SS2REI&.%!8MG"#C"*"$4'&<'' R>LM( H4<C  7/3A5/.!G&X
MCG\CD&M:6JH%)!)S\W!ZC!P ,8R#\H&" 3D#'&Y'&.<9''&?7' R!@JO7C()
M(SD4#)(DP,GM]W\1DMU_BR?ITP.:FI%& !Z #\A2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !114<AP!AL<\\C.,'U]Z &R2
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MDAB7;'"HB1<8VA !UQDEL;B23DF@"5<@'(&<\X& >!@CD]L#Z@TX]#CTHHH
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M,H#QR($=3_$ .,^F.Q'/0DDB@#D["[!7[P(SCN#\H8Y Q[\,!M/3IG/11%7
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MB+P3%=S?\()'HZRN\4?AM_"[6$NE+9;+";S;FYBC6>XN<_UZ?\$3=0^+=_\
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M9XDL=)O8?"NBQPBS\(>)K."_AO\ PS=^$H=+MH-0AL+&]L[O1)-5T*Z_O(@
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MXR2IQP>2,=<>DG_]6?7M7GE\PCUW41MSA[8G!Q]^T@=CSZGK^'X '56KJRJ
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M79TZU=UN+W[);-]INS;QR+:P8FG9(COJ\9UXX))_A )8 [L$J!E00K8+[ 6
M0$LRY )Z*A\[_8.><@')!SQR/E/ );#<$%!N8J&!+D#Y2,\]<@#(&>F[."6
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M>+M#UBUTG6K;XRDL[65Q)+;P2.IRKR0Q.ZGY>0S(6!^5>_\ "O<#%@@'KD\
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M3GC8QVHN>3@;#M'3[P_B&0#\L_\ @N%X \+?%G_@GCK_ ,*?'-K/?^"?B?\
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MA";Q&HUDZ!)=MIW]IL]TMN)I'9@#^9/X#_M]?\%9_!/P=U;]L/XM>';WXX_
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M#3]8M9/[0TE%C9[:WY/Q$T;?\%"O 8*H6'PPNSNPA=5;P]XV '0KM97;+9X
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M<R7.I>&-:NIH=*U31BVG_:UU'3;JSMP#\AJ*:&! .0<@=#G.>!@C@Y/ QU/
MI<CU''7VZ'G\"#]"#TH 6BDR.F>>F.^>F,=<YXQUSQ1D$X!R>F!R<\G&!GG
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M4CJ3N')'1B 3TZG/U.<<T 3HN/F.02, >@..H]>.?KCM4E%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-<$J0!DY!QTZ$'O3J* ,V6)6&>@Y!//'(YP><''
M0YQZ8W5SU]9EE?;P22 20P(P3CG) (Q[],#+$5USIG)&?<#'/OSQD=_4<&J4
MT(<'@8SR,'*GG=TZCJ.^"?3B@#C;.^N=(E92ADM'/SP[@3&22K21L6X^4?,J
MG/RCJ3STNIZ=H7B[1-1T?5].TWQ!X>URQN=,UC1]6L[?4-+U73KV%H+W3]3T
MZ\BEM[JTN;9WMKBUO+=DEB8HR,KG=GW5D&'W06SP>?\ :8=200,$Y)P1@>M8
MJK=:=-YUG(5;?RC$F)AW#1YP3QC)&X'D$#D 'P-X_P#^"-__  3D^(_B&Y\3
MZS^S7I>BZQ>3-/=K\/\ QY\4/AMHEP)+N\OI?^*5\#^,]"\(P33W5_/)<75G
MHMK?/'%96WVI;2SM8(?R*_;-_P"#?'7[?5I_&/[#^O:?-H4PCDNO@Q\3?%%T
M-1TNZEU&XED/@GQ]J5K<PZAI%C9RVL=MI7CR637U,%W<MXZNYIH;8_U(V'B2
MUFV1WBFRF("8;=Y#,,_=8@[ ,8!8_4XQ71)(CJ'5@R$;@ZL&0@?[2DCI@_3Z
M' !_!KX;_P""'W_!2K7M;AT;4/@=X:\$V+W26C>*?%?QC^%MUX:MHG2:0ZC)
M#X+\5^,_%LEA&85@N5A\+OJ+O=VTD&ERQQSFU^Q_$?\ P;A_M#VVE:'<>%/C
MY\(M7UB;0XY?$FE:YI/B_1=/L?$6R62XT[1]6M(-;DU71'*6=K;ZA?Z3I]XA
M-Y<W%A<1S"VK^P8'/3IV/KD Y'MS^>:6@#^33X)?\&XGCJYUS2[[]HWX\^&;
M#PO!.'U?PS\']/U:^U_4;>*[E!M;3Q;XJLM-L=+-]9%&DOY?#.K7%E<2,\$#
MRQ27%Y_3I\%/@I\,_P!GGX<^'?A+\(/".G>"? 'A6U-MHVAZ<9IB'D=IKO4-
M2U"\EN-2U?6M2N'>ZU76-4O+[4-1NF>>YNG8@5ZO10 44TL >< 'OGOZ8Z_C
M33( I8X  /+':O!QC<>/\D=0: )"<=?\>IQV[>IZ <G JK<W,%O$9II!&B G
M<<DD8!(1,$N2"!PK8^M8U]XCM( \=J!>3KC<L>XPH<C.Z4#:P'HI.3@=\5RT
MGVS4Y3+>.9 #\L>TK'&IP=L:*0#CJ2VYCCJ3D4 6M1U"XU>0*@:&R0@QQ_*&
MF.[[\V3C81C"C.-ISRU:%E9B//"D$+R<GH>#GKW4X'4<=0:=:V(48*D\X7.>
M!A=H !!QG.<9/)SCFMR"!1VSPH !/4#/7..A).#CG()YR .@BP.A)X(&1R1N
MR#ST4\DG&6]1@5H*NT8[]2?4]S_A[4V--F>G0 8SP!GUSZU)0 4444 %%%%
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'Y IX# 2(  A$! Q$!_\0
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M (6:#=WL>G6>L_$3QAH'@_2[N]E.$M;>^UN_L[::X8E0D*MYC9 P,YK\L_\
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MR_V.?B+\%-"U"?X1W'PVUS1?BYX?U_681:%+8RSVRZ-JND[IWEL8WA83.(Y
MK,NP@GW.'Y454S*C7Q.&PGUO)<9AZ-7%U50H.M-KEA.K).,')Z+FT;M%:R1X
M.>QJ\F7UZ5"MB/J>;X;$5J5"'/6]E&,^:<8:<R2DKZZ*[Z,_;S&<'IP#^H/]
M*^!_V.?VKO%7[2'Q#_:D\(>(_"VE>'+3X%?$^#P1H=YIU[/=R:Y97%G<7+WE
MW#*BK:RJUO$H5))5;);(KS#_ ()1_M5_'']JWX">/O$O[04/@Q/B-\-OC9XJ
M^%6H77@2RO--\/ZG#X>T?PU>K>QVM]J&IW"-)=:O=@EKMMT$48*(^<]'^PU^
MS3\3?@)\2_VOO%?Q!ATN'2OC)\6[3QCX*DL+F"YNI]&@L;BVD-_Y,SO#(DDL
M8"2P6S9>3 8\#Q,QP6+R[,XX"HZ<WAJTZ=>=":J4INE2H*$Z<U;FA/GYHMI-
M*Z:3/M>'L1DV8<-9_C:L;8V>'RMY''$\]"L\3_;%6.*ITZ;=IR6'A4<WJH)1
MU]]'Z4H "^,]1U].2,?7/YYJ2HHCG)&<'&!V'!! [CITY[<FI:5K7]6_O;?Z
MZ^=SQU:RL^96T=K::VTTVV\[7ZA1110,***,@]"#_G_ZQ_*@ HHHH **** "
MBBB@ HI,C&<C'KGBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***,@=30 449'3/(ZCTSTI,CID9],_C_+F@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***3(]1P,GGH/7Z>] "T4@(/0@_0Y
MZ\C\QS2T %1_\M?^V?\ [-4E1_\ +7_MG_[-0!)1110 4444 %%%% !1110
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M\Y QA<Y(R.K8Y!]>.^*^*_VL/@9^T7\8[/PG;_ C]I&[^ -SH=Y<S^(+FVT
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M8O[$O_)H7[-8Y!'P6^'P(((((\.6(.0<$<@U\0?MC?M(?M=Z3\-/C'X9T?\
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M13#GCW\^NYK[5QC:,#H,# _"DV)TVKCDXVCJ>IZ=^_K63]NU+_H$M_X$I_\
M$4?;M2_Z!+?^!*?_ !%'ET[ Y1>[OONK[[[I[]>_6YK[5Z;1CKC Z^M&U?[H
M_(5D?;M2_P"@2W_@2G_Q%'V[4O\ H$M_X$I_\12LNR^Y?Y!S1TUVVTV]--/E
M8URJD8*@CT(&/RI-B<?(O'3Y1Q].*R?MVI?] EO_  )3_P"(H^W:E_T"6_\
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MP#7"J.BJ/H .G2C:O7 SZX'^>PK(^W:E_P! EO\ P)3_ .(H^W:E_P! EO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:/X3EO8+BY@\(? #Q)X>TSQ)9RSZ:+JUM+C^W)C"LB2L9,"23]P_VO?@!?\
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M='_Y$.=?RR_KY&SO'H?T_P :-X]#^G^-8WVK5O\ H'_^1_\ ZU'VK5O^@?\
M^1__ *U'+4_EI_\ @Z/_ ,B'.OY9?U\C9WCT/Z?XT;QZ']/\:QOM6K?] _\
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M /(ASK^67]?(V=X]#^G^-&\>A_3_ !K&^U:M_P! _P#\C_\ UJ/M6K?] _\
M\C__ %J.6I_+3_\ !T?_ )$.=?RR_KY&SO'H?T_QHWCT/Z?XUC?:M6_Z!_\
MY'_^M1]JU;_H'_\ D?\ ^M1RU/Y:?_@Z/_R(<Z_EE_7R-G>/0_I_C1O'H?T_
MQK&^U:M_T#__ "/_ /6H^U:M_P! _P#\C_\ UJ.6I_+3_P#!T?\ Y$.=?RR_
MKY&SO'H?T_QHWCT/Z?XUC?:M6_Z!_P#Y'_\ K4?:M6_Z!_\ Y'_^M1RU/Y:?
M_@Z/_P B'.OY9?U\C9WCT/Z?XT;QZ']/\:QOM6K?] __ ,C_ /UJ/M6K?] _
M_P C_P#UJ.6I_+3_ /!T?_D0YU_++^OD;.\>A_3_ !HWCT/Z?XUC?:M6_P"@
M?_Y'_P#K4?:M6_Z!_P#Y'_\ K4<M3^6G_P"#H_\ R(<Z_EE_7R-L,&SC/'K2
MUA&[U<#Y=.!/O*#_ /J_Q[5I6\L[Q![B(0ONPRDDX7GG([\#MCGKWI6:T:2?
M5)\R^])7_I#3OKJO4MU'_P M?^V?_LU25'_RU_[9_P#LU R2BBB@ HHHH **
M** "BBB@ HHHH ^1_P!N+XG>*_@Q^R9\?OBCX'U6/0?%'@?X8^+/$6DZ_<:2
M=>M_#]UIND7=Q%K\^DF6$:C#HSP_;IK5IX6E2(JLL;%6K\@?@]\#/^">GQS\
M,?#?XE?M??MSZ'^VWXCUF'P[XQT_P]\4/BCI$OP=TSQ)<&ROK:/PW\);C6M8
MLM&O=+U=K>".!]3GN8KNTA39#(K(/W*_:!\(:QX]^#?Q*\&Z!X9\'^,=8\1^
M#]=T:Q\*^/SJ0\%:_<W]A<PPZ7XF&D3V^H'1[]I/(OTM)HIWMVD5)%;YA_,S
M\;/V3?C_ /LP?#Z/XP^(/^">?_!._4_!O@O7_"=UXGA\(Z_\6M(O/#VCWWBC
M1M-N=>T^VU'QS#9/_9$E^;Y(5AEN)C;)_HD[G+XX?_>*LI24;SP$83DG+EE*
MG4NXZ3DFU9\T4O>LY.Z5MJBOA80C;GM5<DK)M*#:4K-)[65VU?Y']7.C6VF0
MZ1ID.AK:Q:+#I]K#I,-BJ"QCTZ.%4LX[0(0@M4MQ&( OR>4$VY %?+W[77[)
M7@S]KKX?:7X3\0:WXC\#>*?"FO6'BSX;?$OPE<2V/BGP%XKT^ZL[F/5M+FCD
MMY6AO(;7^SM6T_[3:#4;":XM/M"+*S#Z ^'&J:?JO@#P1JFE"R&F:GX5T&^T
M\:<+A-/%G=Z9:3VPLENQ]I%J(9%$!G_>M'M9_F-=R>W3KW_I[UI4@U4JQN[J
MM*:G=WO=JZ::DI;N]TW=NZ;.>E)J,)?].U%QMI:46FK62=U=2Z-73NG8_-;X
M2_\ !/F3X8>!/CN]Q\>_B'XE_:+_ &A-,L=.\:_M+W@E@\9::FC0BST&'PII
M[ZK=2>'].TFU9XEL+?7)!+NCF\]G0$4_C=_P3P?XH:I\,?B;X)^/GQ#^$G[2
M/PW\&Q_#Z;XZ>'XYKK5O&_A)OM N--\::)'K6GG6/(DU"_N])EDU57TZ_E6X
M?[285C'Z9,A8D_+VP,'MZ^O..,=.*"K$=1VR>YP2?3N,>^12DY2Y$XNT'S0L
ME%0<(RHJ*2M:-2%:I*<5:-1)J:G>S<8Q7/91_>6YU**DI6::<DTT^7EBX73Y
M'&+ARN,6ORRU#_@E5\&1^SAX2^!_ACQ9XZ\*>-? ?Q&N_C7X6^/>GZG*?B79
M_&B^37A=^-[O5(Y+:[O5>3Q1K4<.E27Z0065PEM'*/*$B^W_ +(O[&.C_LQ3
M>/\ QEKOCOQ1\9?C9\6+ZRNOB5\7?%XGBU;7;;2GE.A:%IFGS7VJ/HOAW1/M
M5U]@TQ=0NXXVNI6:6-5$:?;Y4G//4Y_G_C^E*-P/.,9/KGDDU:DU.M/[5>*B
M[I.,(QC&-H*S4%/EBY*"@IJ$5/FY59-.48QDVWSN4I-MRFT_<YY-MS<=.7FE
M+EM[O+96^>OVI4"_LY?&7Y=O_% ^).,;>#ILV,#V;D'VK#_8E11^R#^S2 H
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M?C<]AJW]?\.+1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX?'DDGGP[8GJ<D]<<D]*Z#]JLC_AG/XR<C_D0/$??_J'3U@?L2_\FA?LU?\
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MI!Q@[A@YQCG/?(QZY&.HIU+_ (;Y]O4/(**** "BBB@ HHHH **** "BBB@
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M7/\ K\]L=US4R4K+E:33W:NMFG^#>O\ F#:>DH2:TNK=M5U[I'Y?_P#!0_\
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MEKZ'_OIO\:/+7T/_ 'TW^-/HH"\OYG]W_!&>6OH?^^F_QH\M?0_]]-_C3Z*
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MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"?$<"E;7Q#X8U*XM+^"SU2V7*I+/9W,91F5HR#Q]';5]'_\ (G_Q%&U?1_\
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MT5)1VM96T9,$X)13]Q3E4BM7+VDH>RE.3ZR=)\C>[WVT/SO_ &>_^"</P@^
MGQ%TKXI7OC_XP?&_QQX8\.R>#OA]K7QK\3Z1XHD^''A>8PN^D>$(],\/:)]B
M@Q!'#'->M>7,<0 6;>J,/T0A PS GY\$CCJ 5[9/0 <GL#CDDORO]S_QQO\
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M^&%_^"IG_21SPU_X;K6O_EI7[:?\3O\ YX6'_?R7_&C_ (G?_/"P_P"_DO\
MC1_K'F7_ #[RO_PVX'_Y4']@9=_/FO\ X<,9_P#+C\2_^&%_^"IG_21SPU_X
M;K6O_EI1_P ,+_\ !4S_ *2.>&O_  W6M?\ RTK]M/\ B=_\\+#_ +^2_P"-
M'_$[_P">%A_W\E_QH_UCS+_GWE?_ (;<#_\ *@_L#+OY\U_\.&,_^7'XE_\
M#"__  5,_P"DCGAK_P -UK7_ ,M*/^&%_P#@J9_TD<\-?^&ZUK_Y:5^VG_$[
M_P">%A_W\E_QH_XG?_/"P_[^2_XT?ZQYE_S[RO\ \-N!_P#E0?V!EW\^:_\
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M\X.\4OY5Z;6Z:(]E35E>,U;2T_B]7?5WZ/J;>1ZC\Q1D>H_,5B8UK_GWT_\
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MYQDAY.@SZDC/X'^5:5NUSL_TD1>;AB!$3M.#D8)'3&!D@<]NM!2=U=%JH_\
MEK_VS_\ 9JDJ/_EK_P!L_P#V:@9)1110 4444 %%%% !1110 4444 %%%%
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M?3C6;L!Y6DU$J JX1510JJH QSEVT;[;@?H3_P -,?L^?]%E^'7_ (5.E?\
MR11_PTQ^SY_T67X=?^%3I7_R17GI_8=_95!Q_P *<\-?C+JV?TO\4G_##W[*
MO_1'/#/_ ']U?_Y/I"YDNJ^]'H?_  TQ^SY_T67X=?\ A4Z5_P#)%'_#3'[/
MG_19?AU_X5.E?_)%>>?\,/?LJ_\ 1'/#/_?W5_\ Y/H_X8>_95_Z(YX9_P"_
MNK__ "?0+F7=?>CT/_AIC]GS_HLOPZ_\*G2O_DBC_AIC]GS_ *++\.O_  J=
M*_\ DBO//^&'OV5?^B.>&?\ O[J__P GT?\ ##W[*O\ T1SPS_W]U?\ ^3Z
MYEW7WH]#_P"&F/V?/^BR_#K_ ,*G2O\ Y(H_X:8_9\_Z++\.O_"ITK_Y(KSS
M_AA[]E7_ *(YX9_[^ZO_ /)]*/V'?V53Q_PISPU^$VK#^=^?TYH;2U;LN['S
M+NODT_P/0O\ AIC]GS_HLOPZ_P#"ITK_ .2*/^&F/V?/^BR_#K_PJ=*_^2*\
M_P#^&&_V5/\ HCOAS_O[JG_R?47_  P_^RM@$?!GPTW4']_JG4 D8_T\9SWQ
MG;_%C!I77RM>^B7WO2[Z+=]!_P!>?W=N_8]%_P"&F/V?/^BR_#K_ ,*G2O\
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M5AC/P9\-@DC_ ):ZL1@YQM(U#!(XS@MCDD*HS2?\,0?LL <_!GPW@8.[SM5
MY.!G_3_P/0]/>DYQ6]]I26E^:,>6[CW5Y):;N_9C6OW7]/)]I>6]M=CT?_AI
MC]GS_HLOPZ_\*G2O_DBC_AIC]GS_ *++\.O_  J=*_\ DBO.Q^P]^RL5!_X4
MUX<!.<CSM4P,<8S]O..QR>,=/95_8=_958X/P;\-J0,\2ZJ0>G0F^P0,CD8Y
M/2JOKR];-V[).VO;R[K5"3O>W1VOT?IW7FMCT/\ X:8_9\_Z++\.O_"ITK_Y
M(H_X:9_9\'7XS?#D#U/BK2@![DFX  ^IKS__ (8;_95_Z([X<_[^ZI_\GTC?
ML-_LJ!6)^#GALC:>#+JF#Q[7X/Z^QR,B@9[KX/\ BE\.?B"UTG@?QKX;\6/9
M!6O$T'5;346ME8 JTRV\CF-2",,V!R.>17> A@".A_\ U5^5'P-^&'@3X4?\
M% /BSX>^'>@1>%=%N?AUHMU/IEA=WTEB\[6^BS/(MK=W-Q%&S%W4LBARK'YM
MV"/U74;0!DG'<]3^5 "U'_RU_P"V?_LU25'_ ,M?^V?_ +-0!)1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S[^U4RG]G/XRX8'_B@/$1Z
MCOIT^._?L.IK _8E(/[(7[-6/^B*_#T_@?#=ABN _;U3XXM^SSX]7X-S>!88
MU\*>(W\8#QE:ZK=2R: FE7!N(]%.EWMJD5^$$C1M/!<P@B/?&5!6N]_8C '[
M(7[-8&!CX+?#[@'( _X1VRQCY(_EZ[1L4@#!% 'U'1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!SWBK_D6_$7_8"U3_T@NZ^&O^"=EU!9_LWO>7=P
M+>VM?%WC">>>5P(H(8-7OI)9)"QXC1%9FQG@9"D#%?<OBK_D6_$7_8"U3_T@
MNZ^&/^"=EI;W_P"S?+97<*7%K=^+O&%O<03#='+#-J]]'+&R\':Z,5/.>>.@
M)<5[T;IN":YY)Q5HW6U]Y/HMNY,I))Q4HJHXMTU)/EDU_,UJDG:]M>QV-_\
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M#3+6\ROVQ+;SG!N/)A#,68J"YSH?\$ZC\?O#?P1U[X'?'WP7'X=\3?!F]O\
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M$Q?V(=;U/4M8U/X&Z3=ZCJVH7>J:C<OK'B%7N+V]F:XNYRB:H$02S2/(RJ%
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MKZ\_X:C_ &=<[O\ A;O@'< 0&.NZ46 /7!-WD9[X(SWH_P"&H_V=<$?\+=\
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M ,J:^]H+&RC585M+8)%&B(/(A(5$1(XP&V#=E$&2!@8"YP *L?8K/_GTMO\
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M$-!$66*%%CC4DQ@D[5&<CKD\9J?[%9_\^EM_WXB_^(H ^ ?^'DW[.'IX[_\
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M9_\ /I;?]^(O_B*/L5G_ ,^EM_WXB_\ B* /QE_X6Y_P38_Z)+K?_A#^/_\
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M[1CTPJ@8J7[%9_\ /I;?]^(O_B* /QE_X6Y_P38_Z)+K?_A#^/\ _P",4?\
M"W/^";'_ $276_\ PA_'_P#\8K]FOL5G_P ^EM_WXB_^(H^Q6?\ SZ6W_?B+
M_P"(H _&7_A;?_!-AN!\)-<8X.%7P/\ $$$X!.!L@#=L\$<9S\N:YS0/VB/^
M"6/B@ZB/#?P^N]8_LF]DT[4_L7A/Q[<&RO(L>9;S@JYCE0,K-&0K@,-P]/VZ
MDL[3RWQ:VX)4@$019RPQ_<[YQ7Q7^Q]\!M:^#+_&1O$>E6%L?''Q+U3Q/IYB
M2&4S6-ZW[LLQ0LNW+'RR=H!VC!48 /CL?%W_ ()KD _\*EUOD _\B/X_[@$?
M\L/0BE_X6Y_P38_Z)+K?_A#^/_\ XQ7[,K9VA52;6V)*CDP1>@_V.W0>U+]B
ML_\ GTMO^_$7_P 10!^,O_"W/^";'_1)=;_\(?Q__P#&*/\ A;G_  38ZCX3
M:X""",>"/'XY!SC/V<\'H>.F:_9K[%9_\^EM_P!^(O\ XBC[%9_\^EM_WXB_
M^(H _*KX>?M:_L,?"6?4+OX=>!_$7A>ZU-$34+K3_A]XQ^UWB)@I'+-<:?/(
MR@1J0@<*!$!R<!OT/^%GQ3\+_%_PC9>,?"7]I'1;XLL']I:?=Z7>?(P!WVE]
M#;W" *RL0\2<G:N[&3Z,;*S((-I;8/4>1$1[<%,<>]2)!%&H1$5%  "HJH@P
M5(^1%5!RHZ+[=,  $M1_\M?^V?\ [-4E1_\ +7_MG_[-0!)1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% #),[>.YQ_/UXXZUY[\2OB!X6^%
M'@#QA\2_&^I1Z1X1\">'-5\4>(=3FW>79Z5I%L]W=SMM#'*)"1'A&;>WW<LN
M?0VS@8Q]X9SW&>GYX]?I7P'_ ,%0_"^O^,_^"?'[77ACPS:7>I:[JGP+\<6]
MAIUD'-UJ$C6)D^QQ!#N8S11RQM'AMR\D# SA5E*-G"7++VM"G=*]H5I6DVE>
MRCO=Z))ZCA'FERNS@[2:>GOPU@D_[ST?1.S>AXM\$_\ @IK'\0/B3\(_"WQ(
M^!OC7X.>"/VBKW7;7]GGXC>);VQET?XCRZ+9ZCJKQ&SLI)KG1)[O2M)^V6D>
MNQZ?-/%=PO J^9&LGZQHP)XSSDGDGG...QZ>_7WY_F^^.OQ'\$_'CP9_P2#\
M _"'6M/\2>-+GQKX3NK>QT>;-YX<MO WPTAM_%LNH&$J=/2)]$UC39_->(LT
M4MO*@+&OZ.+7=EMQ_O8&<X *@G\6#=NW4]NN4(J+DERRAC,;A%'F4G*EA:>%
MG"K[K:M.5>;6U[][HR4W*K%-656C.L]VHSC6E3Y+Z_"D]=G9-:-7NT445F:!
M1110 F!UP,],X[>E+110 4444 ?GG^W;_P %&/@A^P9H/AN\^(QU#7_%?C37
MM-T+PSX+T**>?5;QM1N/LZW]U-#;7%MI^G0R!EDNKWR8D.,S#Y =;]I_]LN\
M^!_BSX8?"CX<?";Q3\<OC1\6+34=2\,^!/#<]MI2Q:3H^G'4=2U'4]?U<V6A
M6%ND4;>6;S4+61W9A&K8*U\B?\%P_!'@MOV//%_CN7PAX>N?'%OK_A+2[/Q9
M)HEC-XFL=.EU:)Y;/3]8>$WEO!*ZH\ENLWDO*HE,1E5'7U_]N7]M3P'^RN?A
M=X7\,^&/#7C;]K?XQV!\,_!C0+NSM8=0AB;3@VI:[K>O^0UUI'A72(RU]J9-
MTD$EM!,&#$*IQ3OAI3E!N<,TQ."@D_?K48X"EBH4U&]U>K6Y5+1>Z^B=NATX
MI4I1A+DJT*M26CM2J49Q@ZC:W33<E%-NS6ESZ _8^_:_\-_M7^&_&[VWA?6?
M 7Q$^%OBI_!GQ1^'6NLDNJ^$O$$EN]W907%W!&;*]@U*P$=[#/927,'E31[I
MLAE'V@GW5YS\HY/4\#D\#^0^E?G+_P $\/V>++X'_#OQQKFN?$;2?BK\</C%
MXO?Q[\=?&.C7EO?Z=)XJN+>6+2="L'MF=6LO#.CRP:):3-AKJ*U$_E1!A&OZ
M-*,*H/4* ?P%=,XJ+OR2ISJ0HSJ0DG>-14(0FDW=-*2=K:-:K1HXZ4G*,]>:
M*JS5%V:YJ*TC*SU5W=6DDU;5#J***@T"BBB@ HHHH @D.=RYP=P/4]/+X]NO
M7%?F!\<?^"AGB+P%\6?B-\,/A%^SIX]^."_!'18O$/QH\2:'?V.A:1X*T]M.
ML-;=8WUJ2W&O7$6CW27S0:,;JX>-701%XIDC_3Y\;SR0<KT'MZXQW[YST'I7
MXD?MD?M96WBSXO>+OV$/V5;KP1X;^,WC/3H9OVCOBQJ0LM#TSX8^#M6T^TT^
MZU/6-4$=N-<\4R:#J-M#IMM<W4SI;S(8Y(FM]K<[<O:04-Y*K&%+9^TYE>JV
M]%%I3U;LN;5K0M*/(^9\L5=REJ^6*U;LM7K;1)ORLF?=-O\ MQ?!";]D*/\
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M7%%*,5%:)=/U]=0HHHJAA1110 5'_P M?^V?_LU25'_RU_[9_P#LU $E%%%
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MVP?AY\>'^#&K_MB_!'P3X!US2?%W[/O@_P 1/:>)/!NJ:Q:Z=;Z=XON/#_\
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M;5*M[.4:3>E1J48MM6%43H5*JK:)5IJC&]G.E*5",'9ZZ*HY]+1?,[I'UO\
M$;]H+X,_"2\LM/\ B3\3/!_@J^OXFFL[3Q#K-CIMQ<Q1J[O)%'=SQ,5"QN2P
MR%5&8\ UK_#WXR?#'XL6ES??#;QYX6\:VUDY2[D\/ZM9ZDL#*YC83&UGD*#=
M@JP4IAD+,/,6OYW/^"@7B'P)H/\ P54^#4_Q%^!/BK]H31%^#?B25?!GAE7O
MVM9XM,UICJ$FFMJME%*L21Q[CL8AT;@J>>)_9'^*_@>\_:&^.W[;_P"S_P#"
M[Q-\"/V>_@=\%_$W@WXE_#/Q!J=V+[Q-\0[74=!N[*7_ (1F?4]4@TT1VNFW
M>Z_MDLW$1?YY!.C'GPTU5IQE5O!3>.J<T;^Y2PF)E13G:_*IOEC=V3;23NU>
MJ\)4YSA3]Z4'AH1YGI4EBHN47%NW-RZKW;[=S^J'S6'7GWVX]><9X&!ZDCOV
MRGFN,="3@\C QD C(SUW#'K@D<5_+/\ !;_@L9\:M:UOX-_%3Q#KO@_QUX!^
M-'B72-/O/A#X2T'Q(_BOX?\ AS7-5%@NKW=W<:%IVG.VE1EKB[<ZS>6ZK&#$
M[JSL?>?&O[9_[?GC_P"'/QJ_:R^ I^%]C\$_AOXKF\->%/A]XB>_'BGQ-I>E
MWT.G:YJ]S)!H6H6\$]I?K>BVC.H1[XHH_-P58)34X*<ZCY8TU&5?6T:4)N,:
M4K_94YSIQDY.WOOT(;2<4W&[DUNO>Y%-U.777E4)-\M[6[(_?ZV\7Z#>:[>^
M&+76=,G\0:=!!<ZAI$5Q&]_96]R&,$T]LLC2QQRJCLK.J@A#R 0:Z"YNH;6W
MDNKB:&W@A0R33S.$BAC4$O)(Y^5$7@EV(55RS$8K^<6Y_;2^*OAO4_C=\7?!
M7PSTCQ'\3;;]E3X4?$0SVEQJMW+<:KXA\/\ B&_N'N-,17@&GZ:UF2K6=J\S
M&78T)?Y!C:)^U%^TM^T#^RK^TW80?'[X0>*+H_!^;7M/UCP])JVD>,/!6MRV
MIN-6T/4-'O=!TJXB%G#&]FUS':73"Z7 EB!DRZEXTZL]Y8>#JU8QNTXJHX6B
ME?F2=U.S=I1<79JQ-%>TC2ES-0Q$Z5*C*>DN9X>$YN=[<O[SF2NEJI+6SM_2
M99ZA!?6\5W:7-O=VES&)K:YMG66":%P&BDBD!"R*R$$.IV/]Y<#@6#,0H/&<
M@'ID<\Y&?0Y'3MDC-?S*? ?XX_M[^'-'_P"">/[+?@SQU\.-5U/XO?  >.O$
MWQ!ULWDLMAHVE:7H,UG#$?[#N)KW4Q;3[':5?+>1I=SEQ\WHO[6_[;G[8'P0
MOOB5XIF^*/P)\$Z3\&(ECLO 6JWM[?>)OB8=-B2>\U 0:=X?U&WL8-2C,\-J
MMU+9RI-;QM+%$LA8E162G&;<:CK<B;TC]4A153IM*IBZ47_>BEOHW"=^:Z3]
ME2IU9\NO\6=>$*>C?OSC0G4A'XI*+<4TFU_0G=:_IEE/):W>I6-O=PV4NH2V
MTL\:3I8P'9+>&)G$GV9)'C5YMOEIN&YN:CT'Q+HWBG2+37/#VIV6L:3?QM+9
M:EI\\=Q9W489E#0S1LR.&*."02%*L" 00/YG]/\ B+^T1\9?V^O 7QMT_P <
M:)IGP^\8_P#!/O6_B/J?PVNY[PP"SFG\&W.K6$45O9,!=M?7V;6\#PRV]GY[
M-("P4=Q^SU^UK^T7\7?!'[-W[,G[+&E^!/AEXPUKX8ZA\1?&WB7Q/=ZMJ&B>
M&M'CN;Q-/TW2V>RUC4+RYU&[$D4C7%J@1'WJ1P*VJ4'"E*4I34VYI1BG>,88
MBHI3M9OEC3@^:3TC%7;LKB4H\DYPES4Z"PRJ59M*%Z]&G:$IZ14U7FJ5G)2]
MK)0MSM1/Z0-\GJO7'3IDC!__ %]OT<#(>F",X.0!Z=,]>_MT]*_G!\<_\%(_
MVP]&\'7OPETG1?  _:8\ _M ^%O@OXMU622Z?P1K6G^+-&DUG3O$&GRQ:8;K
M;;6=U8&\272;?]\MRODR)Y1?[>_9+_:&_:8L_P!JWXM_LF?M,7?A#Q;J_AGP
MGH'CKPCXV\$K=I97%GJZWTUWIE]!=:;I3))9I;V\<)6TV%P^Y]Q8TH49U+NF
M[P<*E2$WHIQHPA.3@WI)2C--<K=U>S*FY0;YX--2Y:ED_P!RW4]DE4W]F_:W
MI+GY7[3]W9S]T_649P,]<#/U[TM-3[B?[J_R%.K.+YDGM=)V]4G^HPHHHI@%
M%%% !1110 4444 %%%% !1110 4444 %1_\ +7_MG_[-4E1_\M?^V?\ [-0!
M)15:>X2VMKBZE;;';P23R$]%2&-I';@$XVJ2< GCC/%>#? 3]IGX,_M-^%]<
M\8_!/Q[I/CG0/#GB;4_!VMW>E2K(=+\1:*(CJ.FW<3!9H98Q)$0)40L9CLRH
M!$\ZY92>B@I2G?[,(IR=1]>1)7ND]TM] ULY6=E;7IS._N_XM-O\F?05%>1_
M"+XS_#[X[>#X_'GPN\3VOBCPM)K?B+PZNK6*G[.=8\(:_JGAKQ!:'>,AK+6=
M(O["7TEMR>,@'TYIF7:-_+.JJ,KEOO9VY&6!P,X!P/<YIQ;;4;.+:BTI+E]V
M=.-6G)IZVJ4YJ4>ZWL).[22NW;;O:;M\N1I^=NE[7J*X0_$+PE_PGA^&0\1:
M=_PG?_"-)XO/AD7,1U5?#;:@^D_VR;//FBS;4$>V\XKL611U&<]D[E4)+[0"
M,\J"N6(Y)XQCNV!C!Q24T[.S46DU)_"_>J1=G_==.3EY- _=2;36G,UI>*LF
MF_)WT?77H6:*\L\-?%OP7XL\:>,_A]HFLB[\4^ &MD\3Z;Y+H]DUXB36^)6C
M"R;U?:?++!<'/.,V?BC\4_!7P:^'WBKXI?$77[?P[X'\'6#:IX@URZ&;73K)
M;B*T,L@4;B%N9(HB1GYIU!(P<.H_91YIII-1DMM82<5":O9<LN9.+ZI/L#=I
M23TY93C)]%R*+;[V:DK:'I5%8UAJ<&IV5E?V%RMS:7UK%>6MPF"EQ;SQAHI8
MP5!V-YBL,C. H.,UR7Q#^)?A#X5^'9/%/CKQ!:Z#HHO['3(KBZ9%>YU#4KF.
MULK.SAPTMU<SS2J%AA5GV@M@@&B;<$[QDW>245;F;C4A2:2;5[N3DO[L)/=)
M,3O:RO=1EZ1GSV;[*T&WY2CWT]&HK\]_B;_P4T_9*^$WQ)\4?"7Q9\0[P^/?
M!#6"^+-$TCPYKNKR:(]^9/(COY=/TVYA@:4P2*JRRH<Y4 O@5]*? ?X__#O]
MHWP?)X[^&&L7NK>'5O&TXW-_I.H:/*+I!F15M=2M;2<J/N[MA!*D@Y.*2=X.
MI%.<$IRYE9*T*D:=TI.,FI2D^5I--1D[K2Y)\DXTY^[.:J<L7J_W3@I)N/-%
M.TXR2;3:OUT/=**KCS!CYP3WR5R> 2,8!)&>G;CCFD9SRP; S@ ,.H R.G^2
M0,<T*2=^EFU=[.TI1T]>6Z_NM/J/K9*[[(LT52>=EW,9%58T\R094E5&\[B,
M?*IP26)Z*0.0:XSP;\1O"'Q"M]9O/!?B73O$-IX>UVZ\-:Q-IDT5U'8ZYIR0
M2WVF3/%G;<P17,$DJMPJN#ZDG,KN*3;C&$Y)6]V$ZDJ4)RUTC*HE!;^]**=K
M@U)*4N67+&<(2DE=*<X2G&+MUM%KU:Z7:] HKS_X@_$3PO\ ##PKJ/C;QGJT
M>C>&=(,!U+5)@6@M([BX2WCED*JV(S*Z1EB0HW'D'%=E87MM?VEO?6MW%=VM
MW$L]M<0.LD$\$H#Q2Q/&2C(\95E8$Y##))/)S1M>ZMU?\K=^52[<W+)Q>S47
MKM<VWTO.I!7ZRI<G-;Y5(M?.]B]11133NKVTZ>:[^C\]0"BBBF 4444 %%%%
M !1110 4444 %%%% !1110!\<_MU?LR7G[7'P UGX,6/B./PK=:KXB\&:ZFK
MRVKW:1KX4\6Z)XD>'RDEB.ZY72S;B3)V>:6]0WR[;_\ !-:"W_;KU']K4>.T
M?PCJ?PPMO#3_  N:PN&L8?B%INF-:V'C]9_MA@%W!=27%W'&84<22%=WR!C^
MLS(KXW#..G)'<'L1W _*FF&-L@KU]&8>V<@@Y(X)ZGUJ%#E<W'3GFJK_ .OB
MA[-/;;DT;W%.\U%2LU&+IKK^ZEB*.(E'U<J3\M4GW7X>^'/^"5WQ$^%OPZ^
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MW/6]5U_^XCDY-V]6?F+^TG^Q?\9M;^/=E^U+^RG\;T^$OQ6N?#D7A+QQX?\
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M+>K2;DCI<X*O&K;FBL16O3W=6#IQC.+V3:J1NGIRJ^CT/G#_ ()1_M&_%/\
M;"\;_%;XL_$C5M8^%$/PPL]/^$GA?]DS5[>2R\1>%]$T6SLVL_B?XJCGDMIY
M9/$[W=WI]A VE)%:_86F6]E,^RO2_P!L[7K[Q_\ \%#OV!/V<]28#P)8S>)_
MVB=8T^<#^S_$6M>"VNO!^D:-J%O(RP7]M;G7GU&.RG$R--;)<^07C0U]GZ/^
MR!\-O#G[2&E?M.^%)=3\-^/C\-K/X4^,[72VM[72/'_AG1_M4^@/XFLXD$5S
MJ&C7ES/>6]T!]J9B@E:41J*\N_;._9Y\6>,O'?[.?[1_PJTZ&Z^*/[/7Q%M=
M4N[%Y1#+XN^&VLV>H:=XC\(/*TD3F)[V_M-;ACW-(9K%<)N7!Z:E1/$X*HXM
M0H8E.K![SIVQM!ROU4ZN)P]2*>W+JWRJW/2BXT\;!7BZN'J3H-J[YYTL'.G3
MC>W+[-QQ,+;>]%K2]_QQ^$'B/X\Z'_P4?_X*=O\ !W]EKP)^T%97GC/X>R:U
MJWBS4[+3[O2KE9-?*6%NEWHVJR3Q/)'/B-7A :#S=K>5BONC]H[XP?M&_ GX
M-_LK?M,ZO\/]#^!.A_#[XY6D'[3GPC\)SPWOA^^^'?C,2>"M)N6O;*RTR%)-
M/UW5--U*6<::VV/?OVL$8^\:Y_P3=LU^-?Q<^.WPL^.?Q,^#OB+XZ7&C:CX_
MTSPE)IRZ?J-_I"S&VGQ<Z?<RH\<MW=ODMNW3R'*YX]VLOV1M.UWX _$?]GWX
MS?$'Q=\:O#GQ+LKS3M9UCQBUG+JUK:7$"10K9R6UM J2V%U%!?VCDF6*[@62
M)XV"XP:J1P5&$7%XK#8# 8>,ZBYD\125=XES2:4U*<XIWZ*-G=.3Z5*E]<E4
M:DL-/%5*LHQ>OL*U*,9J-U)IJI&+CK9:Z-6M^'G[3'_!07]HWPOX1_:2^-WP
MXU[5[[P'\5/VM_AK^QQ^S\OA_27UZ?P[;:'K?B;0?B%X\\/Z7'=PKKDVIN^A
M7FFQB*U\R%)%>YD!++)\-_VE/VQOAS;_ +1_AB&/XXZO\*K?]F#QGXYT3XF_
M&7P/?^#M6\#?%W1=&\0WD2V*76HZP^HZ/=1Z=IKPHMS8V]NUP-A?837[%6G_
M  3H_9VMOV3_  -^R-)HU[+X#^'K:-K7AG7))4'BBP\<:(/-L/B$+V16$GBE
M+LO=M?31O*UP[-("<J*?A[]@OPY#HGQ$TSXB_%;XE?%:\^(/P^U'X72W_BN^
MM%31O!^H13V;VNGV5E!;VKW30W<JS7=PLLLB!4!0*#6Z]FYUJ<5^[]K!T7-I
MR<(X?#THW=E>]:&(E.R5[QO9K7*G=K"\VCY5"NUH^>I7Q%W#^5*C'#V5I-2Y
MY7?-:/Y2_"OQ9^US\(K+_@E[\8?'7[2FJ_%)/VTS\*_AU\5_!VHZ*VGZ-IY^
M)OP_N/$G]O:!(VM:E#%=Z,]JMN5MK*&>\DFWFX1-NSY7_9R\*?M2_!']BO\
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M'D >^*-Y!.0,<8(R>O\ >'\.#]: )**0$D GJ0"<=,TM !111_G_ !_S_.@
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MK6<6KV:>)JRCVWIRBUV3LDMCVR0*%S@ Y R 0>>"!M^;)R0,<Y-?D?\ M/\
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M^$C\0> [.#5+W7DE21USXAGU6RTQ9T0E?*?:V(RM>$_\$_?VC/VOOBU\8/\
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M1TJ3Q-2&&6&K7C[_ +.FHUHM.T;MOEO[Q_4TAP77)R!@9)))!8L<Y/KGMC(
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M?!OC+2+33O$+?#_0=&U37+W7-'M!J,XOK=+'2[UI6:2%8GCC4X#,%\>\/_\
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M-'\7_$5SYQM=+L;/5+NXBANXX3>+,[S7$D=OQ\)?$S]G3XK_ +*?QA_X(O\
MP"^ GB'PMK'Q4\*ZK^T-=7&O>)3'=>';S5M>^$_C_7O$WE1LYVVR17^H6]L(
MR3OBC9!\IK./*Y4N6?-3JYC#"4*TFUAZU6DL14Q-"E)*ZHT*=-WK->_4Y*?*
MN:ZI0E*E*4OW=3^SZN(6&D[5Z;J8?#2H5:T=%2E*55U(T[S4E3:;C?F?[*_
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MI1TWM?2Y/55E7'#DY(QG &2>N<CD=0!U., FK5%$H\UD]MI+^:+WCY7LM?P
M\-\0:!\+/A+JGQ$_:#U6TL_#^H/X-0^._$:$1+=>'O"Z7>IH;B-O+1[B!3/(
MKF02MD*'90-OGGC/]L;X(_#;]GJ']IKXB>)U\&?#2[TN35M.O=:"P7U];&=X
M;*.TM2X::74EB6X@1246*0-+*JDM7R?_ ,%EO$FL:'^R=X6TC3+B:TL/B%^T
ME^SY\,_%DT3%5;P;XY\>VNA^)+:X92I%K=:=<RPW)+;1$6R.<UK?\%'/V=_A
M)XR_8D\:/XH\.6^M6?PB^%MQ+X(LYYG73+*71M*CM-.NC!$0DWDP11(A=0"
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M7+>3J***19YC\6-8\">'_AYXMUCXF26$/@.QTBXE\3-J81K'^S#L1XYED*H
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MVFM>'/$%A/INLZ1?1+-:7]C< ":WGC8X9'"KSP590ZE6 -?#?P,_X)K?LX?
MCQ_HWQ \.V&MZYJ7A""_@^'NG^)-9U'5]+\!6^H[ENE\/65[?7,,#-'*T2R^
M6&C4KL*D+7Z$]:0*%S@8SUHC[LI2CI*22;ZZ*RM>]FELU9^8/51BVVHN<DKN
MR<XJ,WY\T8Q33NK)::7$4%1@G)R>>G&>!^ P,]3C)Y)IU%%)))M]]7JWK\V
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M08Z=*44HRE..DI*SE=WM:VFKMII=6=NH2]Z/)+6-T[=+K5?EWL-5"ISN)X(
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0Z?U%+;_?'_7,_P TH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #K IX# 2(  A$! Q$!_\0
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M<?\ -'OCU_ZG?[,->GT!R+N_P/IK_A;?A+UU3_P /_QVC_A;?A+UU3_P /\
M\=KYEHH#D7=_A_D?37_"V_"7KJG_ ( '_P".T?\ "V_"7KJG_@ ?_CM?,M%
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MPEZZI_X '_X[7S+10'(N[_#_ "/IK_A;?A+UU3_P /\ \=H_X6WX2]=4_P#
M _\ QVOF6B@.1=W^'^1]-?\ "V_"7KJG_@ ?_CM'_"V_"7KJG_@ ?_CM?,M%
M <B[O\/\CZ:_X6WX2]=4_P#  _\ QVC_ (6WX2]=4_\   __ !VOF6B@.1=W
M^'^1]-?\+;\)>NJ?^ !_^.T?\+;\)>NJ?^ !_P#CM?,M% <B[O\ #_(^FO\
MA;?A+UU3_P  #_\ ':/^%M^$O75/_  __':^9:* Y%W?X?Y'TW_PMKPD<?-J
M>20,?8&ZDX_YZ?Y[5Z8.0*^&D \R,X&?,CY[_?6ON:@B4>5^H4444$A1110
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M0T_P%H7BOXK>*-5T.XUBV_03]AS]A7XJ_LP?%NQ^(GC[QK\/?%-A!_P3A_8
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M^,/V;=/\#Z)X(\8_!OX<ZI^WY\1OCSIO[4.N>*_C-\1OCE\>OVOO@EH7P_\
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M5O)%_9QT=]5N[]H-)L;&ZU6ZM;*9/ /QR^#OQ1\"^$?B9X!^)O@KQ'X&\=^
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MH ]KHKQ3_A:?CO\ Z-M^-/\ X//V=?\ Y_U'_"T_'?\ T;;\:?\ P>?LZ_\
MS_J /:Z*\4_X6GX[_P"C;?C3_P"#S]G7_P"?]1_PM/QW_P!&V_&G_P 'G[.O
M_P _Z@#VNBO%/^%I^._^C;?C3_X//V=?_G_4?\+3\=_]&V_&G_P>?LZ__/\
MJ /:Z*\4_P"%I^._^C;?C3_X//V=?_G_ %'_  M/QW_T;;\:?_!Y^SK_ //^
MH ]KHKQ3_A:?CO\ Z-M^-/\ X//V=?\ Y_U'_"T_'?\ T;;\:?\ P>?LZ_\
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M]6W^=S2HK-^Q_%G_ *-Y^+7_ (/OV>/_ )_M'V/XL_\ 1O/Q:_\ !]^SQ_\
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MU'X)V]SK%CX=MI_BW8W?BN&Z^'$%QXAU/3] AE\8PZ,LNM7]EI<9:]N[>"0
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M$K\O"7_S2U^0&![_ )G_ !HP/?\ ,_XT?\3K>/O_ $/>'/\ Q#LF_P#FD/\
MB5'P9_Z%?$/_ (E69?\ S$?K_P#\/(_AA_T3WXE?EX2_^:6C_AY'\,/^B>_$
MK\O"7_S2U^0&![_F?\:,#W_,_P"-'_$ZWC[_ -#WAS_Q#LF_^:0_XE0\&?\
MH5\0_P#B59E_\QGZ_P#_  \C^&'_ $3WXE?EX2_^:6C_ (>1_##_ *)[\2OR
M\)?_ #2U^0&![_F?\:,#W_,_XT?\3K>/O_0]X<_\0[)O_FD/^)4/!G_H5\0_
M^)5F7_S&?KX__!2+X9L#L^'_ ,21@$MD>$^@[KCQ(06'/RDJ#Q\PQS];:-\;
MO!?B+P5HWQ \.W&HZ_X6UHF%;W3;:WDDTB^0A9M+UZWFNX9]+U*WD?R)[>:-
MD655*3.D]I)/_.;M!ZC/UY_GG_\ 7SVKVOX'?'+Q#\$?$D]Y:PC7?!VN^5;>
M-O!=W(/L6O6.#"+JV,H:*RUVRB9OL&H8VRH&L+T-:2!H/T'PW^F[QW#/U@O$
MK&93B,@S*DL)#.,NX<PV'Q'#F-E5C*CFE? 8'%IYQEC_ (&:812IYA1PE\=E
M+K8S#5,!F'Q''GT3.$?[&>+X"H9K3SC 5'B)Y5C\]Q&(HY[AE!JKE^'Q>)PT
M/[,S%_Q,NQ#4L'6Q*C@\Q5+#XB.,PG[BCXY>$O\ GUU_\;&R_P#EB?\ /8=*
M\J^#?Q<\-:+X0UBSNK?66DF^+7Q_U-3!:6KIY&L?'KXE:I:AFDO8V$JVUY$)
MD"E4E#HKNJAVX"1/#GB'P[IOQ!^'NI?V[X!UW<+:Y)_T_0+]2JW'A_7K9LSV
M=_9SM]G(N"'#[$DDDWV]Q=>;> ,?V!?@@9'CWXM9!Z@_\+9\<8!SZ=/T%?V!
MB/%;C/#.G^_R'$4*]"AB\'C,)@:&*P.88'%4XUL)F& Q='&2H8O XRC-5\-B
M*,I0J4VTU2JTJ^'P_P#,E#P^X7K\R]EF]&M2K5\-B\+B<76P^+P6,PTY4L3@
ML9AJF%C5PV+PU6+IXBA4@I0ERRBZE&K0K5OMW_A>?A+_ )]=?_\  &R_^6-'
M_"\_"7_/KK__ ( V7_RQKY7P/0?D*,#T'Y"N;_B+_&/\V4?^&N'_ ,V'3_Q#
M3AG^7,O_  XS_P#F8^JX_CAX/>2-'AUV%7=4:5[&VV1AF +N(KZ20H@)9A''
M(Y4'8CMM4^N6=U!>017-M-'<6\\:S0W$3K)%-$X#))%(C,KQNI#*P)SGVK\]
MR ,8 ZX[#J"/2O3?AY\0[GPG.--U"1[CP]<R,2 "\VE2ROEKFV4?,]N[,QNK
M4*2Y_?P8N!+'>?4<*>+N*KYBL+Q0\)2PF(Y(TL=A,/\ 5HX.LY63QE-5:RG@
MZJDHSQ$?>PDXJI4C]7=6=+Y[B+PWH4<']9X?>)J8B@I3JX+$5_;RQ-/5M8:;
MITG#$0C'FC1G>&(3<82C5C&-3[%HJG8W,-W;Q75O/%<6]Q%'-!/#()(9H9!N
MCEBD!*M'(K!E*D\'DGAC<K]^C)3C&<6G&24HM-23C)*46G%RBTXRBTU)IIIJ
M4DXRE^0M--IIQ:;3C).,DTVFI1DDXR334HM7333V"OG_ /:>_P"207O_ &/W
MP5_]75\/:^@*^?\ ]I[_ ))!>_\ 8_?!7_U=7P]JA'T!1110 4444 %%%% !
M1110!\^S?\G5:=_V;[K7_JQM KUMO&W@Y/$P\%-XK\-KXR:T.H+X2.O:4/$S
M6 B,QOET WG]K&S$2M(;D6GDB-6D+[ 6KR2;_DZK3O\ LWW6O_5C:!7X;?M3
M_L<_'W6OV]_B]^U?8_ [PQX]^#'P[_:B_P""??QCUBV\.?!W1KW]L7QEX4^!
M?@>PO=6\1_LJ_'75O$VIP6/A_P"'_CZTT%/CG\!;#X8Z?XZ^-_P=C^+OP^^'
MWQ7T_P 2>,=-\#^* #^DI2& 8=",\]?QI:_EVTCPM_P53LI_VC+K7O'O[6UW
M\4KN\\;#XQ>"?A]\.?$UMX0\2?".Z_;I^#MV=8_8X^,GQ:_:7\5? 'PW\5]
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MX5\<?\$Z?AY\-+W5/A##\1/AG_P3+N?'G[,_[8^NV_B7XU^,_!?[8O[0EC\
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M3P?J%Q\%?%GB_P 7?&;X<ZA!JQ^)>N0WGB&P\,^&OWBH *\=^!?_ "3/3/\
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M".M_&;4?"O[/ENWCSX>>#/%VES_!C2?A_KO@?5O#.DS>$-0\.P6%O#%T6O\
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M)?>(5/PUAU_Q)\1[/3=<\3Z)X'^'.I:[I?PJTO[I_9?_ &+?V8OV0+WQ3=_
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M\,_\%$/#OB;]IFV_9W/P#^-NC>']2_:&^(O[)VB?M ZG=_!IOA9KW[0/PV^
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M)=&^5OV=?V9?V ?VB/V4O"'@/]GK7?VP-+_9O^%?B[XE_#3PU8+^TY_P4P^
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MX)\2ZGKWBGQ'\4/%Y\-ZM^T!\>=3^!TGB[]H7P9XG^'GQ=\3:%^SS??%.?X
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M?W/@!M=\*);7R>?^"/V9/V%?B)J?Q^^"VCP>._B=XF\*^#/@3\#/V@+OQ_\
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M#PMHNEZ=;)X@;2'LKR;1]%M;2RENX[N+3C!;O;2?.OQ'^"OQV_:*TWX7:?\
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M*_B?JVH7TNM+X2T37_J"O@G]H/\ 9'\6?%;XZ)\1O!_Q%OOA_P"%OBO^RO\
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M>!D <D#\/0?BF<?%;XK#*_\ )4?B-_%V_P"$SUO'0'GCD=0>*X7=_N_]]?\
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MW@\0:] 5T2,K)8V$ORMJ[*<K-,N"1IJD?*I(^WGTM@'F^J(D\M @5550%54
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M\/>#[[X$/!_PCOPI^+GB^R^(7AUE_: T+P7JOAS1-*\23^"(_B-K?B80_P!
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M_P"'8^'?BB;6=)\%V.C_ !-^(T4%E8V]A_4I@>@__6<G]>?K2  = !GK@8H
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M]G3_ .<%0![917B?_"K?'?\ T<C\:O\ P1_LZ?\ S@J/^%6^._\ HY'XU?\
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M"'_HUOAY_P"(;P]_\[B_^(F>(_\ T<#C;_Q*L]_^>!YQ_P ,.?LP?]$WG_\
M"[^)7_S8T?\ ##G[,'_1-Y__  N_B5_\V->C_P#"K?'?_1R/QJ_\$?[.G_S@
MJ/\ A5OCO_HY'XU?^"/]G3_YP5'_ !!GPA_Z-;X>?^(;P]_\[@_XB9XC_P#1
MP.-O_$JSW_YX'G'_  PY^S!_T3>?_P +OXE?_-C1_P ,.?LP?]$WG_\ "[^)
M7_S8UZ/_ ,*M\=_]'(_&K_P1_LZ?_."H_P"%6^._^CD?C5_X(_V=/_G!4?\
M$&?"'_HUOAY_XAO#W_SN#_B)GB/_ -' XV_\2K/?_G@?-.K?L?\ [/-K\:/
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M2& DBEU)XI8R0 \4J/'(N4=65B#Z)'$L054"JB(L:(JA51% "JJC"JJ@ !5
M    P *\7_X5;X[_ .CD?C5_X(_V=/\ YP5'_"K?'?\ T<C\:O\ P1_LZ?\
MS@J]# Y5E>6>T_LW+<!E_MG%U?J6$P^%]JX)J'M/8TH.?*F^52;4;MI*3<CC
MQ6/Q^.<'C<=C,8Z2DJ?UK%5\1[-2LY<GM:DU'FLN;E2<DDFVDDO;**\3_P"%
M6^._^CD?C5_X(_V=/_G!4?\ "K?'?_1R/QJ_\$?[.G_S@J[SD/;*^?\ ]I[_
M ))!>_\ 8_?!7_U=7P]K4_X5;X[_ .CD?C5_X(_V=/\ YP5>%?M'_#;QM:?"
MFZGG_:%^,=_&OCOX-*;:YT3]GD1,TGQG^'\:N3!\!X7WPLPECRS1ET DCD7*
M$ ^X:*\4/PM\=Y./VD?C5C/'_$C_ &=/Z_ (G\Z3_A5OCO\ Z.1^-7_@C_9T
M_P#G!4 >V45XG_PJWQW_ -'(_&K_ ,$?[.G_ ,X*C_A5OCO_ *.1^-7_ ((_
MV=/_ )P5 'ME%>)_\*M\=_\ 1R/QJ_\ !'^SI_\ ."H_X5;X[_Z.1^-7_@C_
M &=/_G!4 >V45XG_ ,*M\=_]'(_&K_P1_LZ?_."H_P"%6^._^CD?C5_X(_V=
M/_G!4 9,W_)U6G?]F^ZU_P"K&T"OH*OAZ?X:^-?^&FM-M!^T+\8C<?\ "A];
MG-__ &+^ST+D1?\ "P_#T8M=O_"AO(\D$-*"(M^XL&;[A7W7_A5OCO\ Z.1^
M-7_@C_9T_P#G!4 >V45XG_PJWQW_ -'(_&K_ ,$?[.G_ ,X*C_A5OCO_ *.1
M^-7_ ((_V=/_ )P5 'ME%>)_\*M\=_\ 1R/QJ_\ !'^SI_\ ."H_X5;X[_Z.
M1^-7_@C_ &=/_G!4 >V45XG_ ,*M\=_]'(_&K_P1_LZ?_."H_P"%6^._^CD?
MC5_X(_V=/_G!4 >V45XG_P *M\=_]'(_&K_P1_LZ?_."H_X5;X[_ .CD?C5_
MX(_V=/\ YP5 'ME%>)_\*M\=_P#1R/QJ_P#!'^SI_P#."H_X5;X[_P"CD?C5
M_P""/]G3_P"<%0![917B?_"K?'?_ $<C\:O_  1_LZ?_ #@J/^%6^._^CD?C
M5_X(_P!G3_YP5 'ME%>)_P#"K?'?_1R/QJ_\$?[.G_S@J/\ A5OCO_HY'XU?
M^"/]G3_YP5 'ME%>)_\ "K?'?_1R/QJ_\$?[.G_S@J/^%6^._P#HY'XU?^"/
M]G3_ .<%0![917B?_"K?'?\ T<C\:O\ P1_LZ?\ S@J/^%6^._\ HY'XU?\
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MLA>&_@SJ7CCQU^T=\/?V6XOVRKCPA\2],\0:[)KT/Q[^%6C_ !1\(?%;PQ\
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M5]/]>T %>-? W/\ PK72_FVK_P )!\0<X)!_Y*'XJ.1@\\@#IWP>O'LM>._
MS_DF>F?]C!\0?_5B^**3Z?XHW]&TFOG>WX[I"E\+]'9K1II-I_>ONNNNGY5>
M//VTOVA-!\>^/- T[Q-H<.FZ!XX\8:%IL4OA?3'ECT[1O$>IZ;81RRR;GFDC
MM+6%'G;#3LIF<>8[FN5_X;G_ &D/^AJT#_PE=)_^)KY_^*87_A:OQ5)_Z*C\
M11W_ .ASUL]OQKA<)_7J?\_7T[U_@[Q'XW^,F'XCXBP]#Q2X^HT*'$/$-"A1
MI<4YG3IT</A^(,_H4*5.G%<L*5&A0H4:<5[L:=&G&_NW/]>\@\(?"[$9!D.(
MK^'O!]6O7R+(Z]:K4R#!RG5KU\ER:O6JSDZMY5*M:M6JSD]93J3DU=L^NO\
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MW/\ M(?]#5H'_A*Z3_\ $U\BX3_]6XT83T_]"Y^GK^%'_$=/&G_HZWB#I?\
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M .T]_P D@O?^Q^^"O_JZOA[0!] 4444 %%%% !1110 4444 ?/LW_)U6G?\
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MQOJ5Q>A4:_W:_J%Y:6=W("[Z9:6,?RQQHB_1&<_K^G^?YU^29I0P>$S+'X3
M8W^T,%A<9BL-A<P=+V"QU##UJE&&,A1YZGLZ6)]C.O0BYN?U>IAIS49U9PI?
MT)D.,S',<DRC,,WRU9-FF/RS!8W,,H6(^MO*\5B\-2Q-7+IXGDI*O6P/MZ>%
MQ-2-.--XNAC(TN:E2I3JK7Y9_MR:#_P31/Q4\$:A^US\,7^)WQH\0_#77+/3
M/"7P\^"_[0/Q[^)7C/X"^!O$,-[XAT_XI_"K]FGP=X\\1^.OV<_#OBSQV8M3
MT_XQ^$]:^#EMXB\=7VE30'4_%M]9ZE^IE?G-\8?@M^U+X)_:^U#]K?\ 9?\
M"WP ^+,GQ&_9N\"_LX_$WX7?'SXM^/?@(= 3X/?%/XF?$WX9_$'X??$WX?\
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M8^-M]\;)/!?P.\56:6>HVW[07P"^*_PJ^).J_"CXF^)/$7Q2_9A^'MAX_P#
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MA[^PO\._'O@CP+K-QXAO_BE\4[_XP^/]:/A#P%X TN^\97G@?P'\.8_^$?\
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M%/%6IU,MP+XIQ&(PRR_ZI6C5Q^(S+&T*^459U:5/'8W),3P[7A&GFU''T?\
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MXH>,_#.A^*_&'A[3_%'PZM-*U:/QAX7^''C;PVEWKFF>"]/OM4^*-]8^ ;L
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MX*.?#/P%X?TSXE_';]I_5O!WCGX8?\$R/BA\9?VE!^R1\(];^,/[,H^/]O\
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MQ(.O'PG8VUTOB-+2;\4(_P#@J5^T[\&/V7?@J?V9OC7\%?CAH?@3_@D#J/\
MP46^+/Q,_:-E^(/[0_Q"^(_Q-\'_ !WT_P !_'#X56?Q&T#XR^#8]#30O&NN
M^)_ %H=7L/$S?#FX\)2>#6L6;2K>+2OZ]2!C&!CN",C'TINT^H]#\H(QZ=N.
MO'3OC->K@LQH86@J-; 4L:EBIXBU=TU3:GA:.'5-I456:BZ=6HE*O*FJE93C
M24J:D^+$8:K5JNI3Q%2A^YA2_=\ZD^6M4JMI\_LU?FA%_NN;E@TYM.R_F:U[
M_@JI^V_X2D^/?PNU6\_91O\ XP?#_P#;>_X)L_ #PAXTM?AI\2K/X;VW@/\
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M-I(_X2#X@9(SQGXB>*>V.G')S@#KCC*?3_%'_P!*B3+X7Z/\I?YH_ 3XI?\
M)5?BM_V5'XB_^IGK=<-7I/Q1T77F^*?Q3DCT'7)(I/B?\1)(I8]&U.2.6)_&
M6M-'+'(EJ4>.1"KHZ%D96#*S*03PW]B>(?\ H7M>_P#!'JO_ ,BU_P Z_$^
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M$\0_]"]KW_@CU7_Y%H_L3Q#_ -"]KW_@CU7_ .1:/[/S#_H7YA_X08__ .8
M_M#+_P#H89?_ .'# ?\ S>9],9]O8DY"@ $LSL0$55'+,Q( 4#+'A<GBM/\
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M_"Q_ >3G _X2_P /9..N/^)CSCOCIWH_X6G\,?\ HH_@/_PK_#W_ ,L:UO\
MA"O!N0?^$3\,\9Q_Q(=*X!QD#_1,@''.#SWH_P"$*\&_]"EX9_\ !#I7_P B
M4 9/_"T_AC_T4?P'_P"%?X>_^6-'_"T_AC_T4?P'_P"%?X>_^6-:W_"%>#?^
MA2\,_P#@ATK_ .1*/^$*\&_]"EX9_P#!#I7_ ,B4 9/_  M/X8_]%'\!_P#A
M7^'O_EC1_P +3^&/_11_ ?\ X5_A[_Y8UK?\(5X-_P"A2\,_^"'2O_D2C_A"
MO!O_ $*7AG_P0Z5_\B4 9/\ PM/X8_\ 11_ ?_A7^'O_ )8T?\+3^&/_ $4?
MP'_X5_A[_P"6-:W_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E
M&3_PM/X8_P#11_ ?_A7^'O\ Y8T?\+3^&/\ T4?P'_X5_A[_ .6-:W_"%>#?
M^A2\,_\ @ATK_P"1*/\ A"O!O_0I>&?_  0Z5_\ (E &3_PM/X8_]%'\!_\
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M7?\ 0PP'_A=@?_FT/JF+_P"@3%_^$F*_^936_P"%I_#'_HH_@/\ \*_P]_\
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MPA7@W_H4O#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")0!\W3?$OX<?\
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M(5X-_P"A2\,_^"'2O_D2C_A"O!O_ $*7AG_P0Z5_\B4 9/\ PM/X8_\ 11_
M?_A7^'O_ )8T?\+3^&/_ $4?P'_X5_A[_P"6-:W_  A7@W_H4O#/_@ATK_Y$
MH_X0KP;_ -"EX9_\$.E?_(E &3_PM/X8_P#11_ ?_A7^'O\ Y8T?\+3^&/\
MT4?P'_X5_A[_ .6-:W_"%>#?^A2\,_\ @ATK_P"1*/\ A"O!O_0I>&?_  0Z
M5_\ (E &3_PM/X8_]%'\!_\ A7^'O_EC1_PM/X8_]%'\!_\ A7^'O_EC6M_P
MA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\ P0Z5_P#(E &3_P +3^&/_11_
M ?\ X5_A[_Y8T?\ "T_AC_T4?P'_ .%?X>_^6-:W_"%>#?\ H4O#/_@ATK_Y
M$H_X0KP;_P!"EX9_\$.E?_(E &3_ ,+3^&/_ $4?P'_X5_A[_P"6-'_"T_AC
M_P!%'\!_^%?X>_\ EC6M_P (5X-_Z%+PS_X(=*_^1*/^$*\&_P#0I>&?_!#I
M7_R)0!D_\+3^&/\ T4?P'_X5_A[_ .6-'_"T_AC_ -%'\!_^%?X>_P#EC6M_
MPA7@W_H4O#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")0!D_\+3^&/_11
MO ?_ (5_A_\ ^6-=V"& 92"I ((.00>001P01R".".1Q7-CP7X.!!'A/PT""
M""-"TL$$$$$'[)P00"#V(!KI ,#&2?<DD]<]3_GM0 M%(WW6^A_E7GI^(WAQ
M_B/-\+ UZ/%4?@J+Q\P^RD:;_P (_+KI\/JPU N4^W?V@C*UH(]WD?O=XSM/
M%C,PP>7O!K&8FAAGF&/P^68)5ZL:;Q>88N.(EA<%A^;^)BL1'"8IT*2LZGU>
MLE).&N]#"XK%+$/#8>MB(X/"5\?BW1A*?U;!89T%B,76M\&'H/$X?VM1NT/;
M4VTU(]#HKYOT3]ICX:ZWXYB\ 6J^+K;5[KQ5XF\#6&H:CX7U&'PYJ/BOPG%+
M/K>C6.NH)K*2ZMK>(3B.1H\02VSML%Q'N[[XG_%;PA\'/"DWC'QM=7MKI,4T
M=JJZ=IUYJ=[<7<D3R);PVUJCA"T<$\IN+J6VM(TCVR7*/)$DG@X;CGA#&91G
M&?X?B3):N2\/3Q-//<TCCX1P&4SPD'4Q/U[$5J-".'A1IJ55U)QG3G37M*%7
M$P4JB]?$<+<2X7,LMR?$9#FE+-<YA1GE&7SPD_K>91Q,U3H/!485*CK^TFU3
M48SC4A4<85:5'FBWZE17S[\1/VBOAY\,[W3++Q$WB*YNK_PROC2ZBT#P[J.N
MR>'O!HNX;&3Q5XF%G%C2M%CO;A;4S-Y\QN$E2.%O+YKWW[2OPLT_QS:>!I=1
MU>YO+G4_#&@2^([+1-0NO!FG:]XTL$U/PEH>I>)8HA90ZEK^GR)=V"();54D
MQ=75J\5R(>7$^(W >#Q>(P&+XOX>PV-PN-P66XG"ULTHTZ]#'YC&G+!X6K!T
MGRU*BJTE4UE3P<JM..8XC+)5*<*FV'X-XNQ>'HXO#<-9S7PF(PF,Q]#$TL%.
M5*K@L#SK$XF,O:Q_=TW3J6YE"IB%3J/ T,QC3G.G]%45'$<QKP!U! [$,01W
MY!X/)YSR>M25]K\FO)VNO6S:^YL^;_K^OZ_,**** "BBB@ HHHH ***^0?CW
M^VE\-?@'XVTCX83^"_C1\8_BGJ?@K4OBE??#/]GKX7:_\6_&WA;X3:/JAT2^
M^)7BO2=$6"/2M"N]:2YT7PCH:75WX]^)NLZ7X@TCX6>#O&VI^&/$EKI0!]?4
M5X-\/_VH/V>OBG\/?#_Q6\ ?&;X;^(?A]XFC^$9TGQ*GBW2-.MOMGQ]T_P #
M:K\$M#U6TU:XL-2\/>*OBK9?$[X=-X$\(>(++2_%'B2X\=>$[+3-(N+W7M-@
MN<;PE^V1^R1X_P##GC+QEX#_ &I/V<?&WA#X<^*-"\$?$/Q5X2^.?PP\1^&_
M 7C/Q/K5IX;\-^$?&>N:-XHO=,\,>)_$'B&_L=!T/0-;NK'5M6UJ]M-*L+2X
MOKB&!P#Z2HKXV'_!0;]C"TTR[\1>)_VFO@)X"\&R^/\ P]\-O!GCSQW\;OA%
MX:\#_%CQ%XK^$7PP^-WAX_";Q/>>-SI?CBTUCP%\7/!^HZ8NG3)J6H+<27UG
MIL^A7&D:QJOKDO[2G[/$'QBL_P!GB?X\?!>#X_ZB;[^S_@;-\5/ L?QBOQIG
MABS\;:DUG\,FUT>-KH:?X+U#3_&%[Y&B2?9?"U]9^(+CR])NH;MP#VVBODKX
M]_ME?#;X#>./#GPI;PA\8/C+\8?$OA#5_B1!\)?@#\.-4^)?CC1OAAH&IVNB
M:M\1O%4-M-IN@^%?#!UR\BT/PY%KNO6/B+X@ZW;ZOH_PWT#Q?J7ASQ';:3B:
M9_P4!_98_P"$7^+/CKXA?$S2/V?/ WP8^(/PX^&/C3Q?^T_>:=^SEI%KXQ^*
MOP!^#G[2'A#1)H_B]?\ A35= UJ;P!\</"%AJGA;QIIGA;QEH_C*Q\3^&-0\
M.07>ARR3 'VA17A]K^TS^SI??%^#]GRR^/GP3O/CW=>'HO%MK\$+7XK^ [CX
MOW/A6?3DUBW\30?#2+76\:2^'KC1I$UB'6X]%?3)-+=+];HVKK*4\/?M-?LZ
M>+O /CWXJ^$?CS\&O%WPS^%NCW'B#XD>/_"7Q.\&>*?!W@/1+7P58?$F?5/&
M'B+P_K.HZ5X=LD^'FK:3X[$^JW5LC^#]5TSQ(A;2+^TNY0#W&BOA_P"&7[?O
MP8^(6D^)O%_B#PK\;?@+\+?#WPY;XQ6OQL_:9^$?BCX$?!C7_A0ES96[>-H_
MB/X[BT[P]X+58M3TW4V\&_%FY^'7Q)70;J3Q ?!0T;3M6OK"GXM_X*,?LQ^&
MM8\(Z?H_BBY^)VB^/=!_9V\3^#?'WPDN?"WC_P"'/B?0OVG_ -J?P7^R!\,]
M3T#QEI'B@Z3K5E_PM?QWHUUK]WI<EY:V'A&'4=7LIM3O[>+1[@ ^[*\;^!BJ
M?AIIA(Y_X2#X@\\_]%$\4?J,\'J.U>R?7_/\J\=^!?\ R3/3/^Q@^(/_ *L3
MQ11V]8_^E1)E\+]'_P"DR/Y^_BI:VK_%;XK,]M;LW_"T?B*,M#&3@>,M: Y*
MYX%<)]BL_P#GTMO^_$7_ ,17H/Q3('Q5^*V3C_BZ/Q%_7QGK>*X;</7VQ@YS
MDC!'4<@CGN#Z5_SC\44:+XIXH_<4&WQ-Q-)WH8=O7B;B1<SOAVW>3M=WO)VN
MY.S_ -PN&IU%PWPY^\J+_C'>'K?O*BT_L#(?^GJT^5BO]BL_^?2V_P"_$7_Q
M%'V*S_Y]+;_OQ%_\15C(Z]OH?;V]Q^) [C)N'7/K^E>'["C_ ,^*&NJ_V?#Z
MKNO]FU7FKGM>TGM[6=]=/:SZ;_\ +[IU[=;%?[%9_P#/I;?]^(O_ (BC[%9_
M\^EM_P!^(O\ XBK!8#@G!]""/J>>P[GH.])N7U_GCUZ].@)^@S2]A0>BH4&^
MRP^';_##,/:3T_>SU=E^]GJ^R_?:OR5WY$'V*S_Y]+;_ +\1?_$4?8K/_GTM
MO^_$7_Q%6-P'4X_ Y_+K^-&X?KCH>I_#FFZ%%;X>@O7#8==6NN&75->J:W32
M/:3>U6;OJK5:CT[_ ,;;SV\RO]CM,8^RV^,@D>1%@D9 )&WD@$@>F31]BL_^
M?2V_[\1?_$5/N7U'?ISR.HX[CN.HI=R]001SR.1QP>1Z=_2E[&A9OV&'LMW]
M7P]E=V5W]7LKO17:N]%=Z![2?_/RI_X,J?\ RU?C^FE?[%9_\^EM_P!^(O\
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MRI_\L*WV*S_Y]+;_ +\1?_$4?8K/_GTMO^_$7_Q%6:*7L*'_ #XH?^$^'_\
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MZ HHHH **** "BBB@ HHHH ^?9O^3JM._P"S?=:_]6-H%?05?/LW_)U6G?\
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M]%)QG]JG3@>_[/NM=/\ LH^@5YW\1OV#?V<_BS\1OBU\4?'VD?$'7?$?QO\
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MZK_\S%'_ !+MXZ_]&HXU_P##70_^>X?\1S\'O^CC\*_^%V(_^=1\445]K_\
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M (47P/\ _GO5[#10!X]_PLCQW_T;[\4?_"B^!_\ \]ZC_A9'CO\ Z-]^*/\
MX47P/_\ GO5[#10!X]_PLCQW_P!&^_%'_P *+X'_ /SWJ/\ A9'CO_HWWXH_
M^%%\#_\ Y[U>PT4 >/?\+(\=_P#1OOQ1_P#"B^!__P ]ZC_A9'CO_HWWXH_^
M%%\#_P#Y[U>PT4 >/?\ "R/'?_1OOQ1_\*+X'_\ SWJ/^%D>._\ HWWXH_\
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M;[Z^IXXOQ&\=+P/V??BC_P"%%\#OZ?%T?Y_&G?\ "R/'?_1OOQ1_\*+X'_\
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>Y;8CO@':C-A3Z^#D9/\ +'XX/(SUP>1WI:* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>lixt-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSKubP9z5Z86ekhvWB6bblKjyct91Mk4SDabwP2cb4K -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:LIXT="http://lixte.com/20231231" elementFormDefault="qualified" targetNamespace="http://lixte.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
          <link:definition>995513 - Disclosure - Organization and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>995514 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" id="ResearchAndDevelopmentCosts">
          <link:definition>995515 - Disclosure - Research and Development Costs</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>995516 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>995517 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>995518 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>995519 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995520 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>995521 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>995522 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>995523 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" id="ResearchAndDevelopmentCostsTables">
          <link:definition>995524 - Disclosure - Research and Development Costs (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>995525 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>995526 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>995527 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>995528 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>995529 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
          <link:definition>995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" id="ScheduleOfResearchAndDevelopmentCostsDetails">
          <link:definition>995533 - Disclosure - Schedule of Research and Development Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>995534 - Disclosure - Schedule of Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>995536 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" id="SummaryOfRelatedPartyCostsDetails">
          <link:definition>995537 - Disclosure - Summary of Related Party Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>995538 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" id="ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails">
          <link:definition>995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" id="SummaryOfStock-basedCompensationCostsDetails">
          <link:definition>995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" id="SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails">
          <link:definition>995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails">
          <link:definition>995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>995543 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
          <link:definition>995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>995546 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" id="ScheduleOfContractualClinicalTrialsDetails">
          <link:definition>995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995548 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>995549 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LegalFirmsAndOtherVendorsMember" name="LegalFirmsAndOtherVendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DirectorsAndCorporateOfficersMember" name="DirectorsAndCorporateOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantOneMember" name="VendorAndConsultantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantTwoMember" name="VendorAndConsultantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantThreeMember" name="VendorAndConsultantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantFourMember" name="VendorAndConsultantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrKovachMember" name="DrKovachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesSMiserMember" name="DrJamesSMiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EricJFormanMember" name="EricJFormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RobertNWeingartenMember" name="RobertNWeingartenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BasvanderBaanMember" name="BasvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrReneBernardsMember" name="DrReneBernardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfAuditCommitteeMember" name="ChairmanOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfOtherCommitteesMember" name="ChairmanOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfAuditCommitteeMember" name="MemberOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfOtherCommitteesMember" name="MemberOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AppointmentGrantsOfOptionsMember" name="AppointmentGrantsOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualGrantOfOptionsMember" name="AnnualGrantOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonOfficerDirectorsMember" name="NonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrSchwartbergMember" name="MrSchwartbergMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MsReginaBrownMember" name="MsReginaBrownMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsMember" name="FiveNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsOneMember" name="FiveNonOfficerDirectorsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourOfficersMember" name="FourOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BioPharmaWorksLLCMember" name="BioPharmaWorksLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficerDirectorsMember" name="FourNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrVanderBaanMember" name="MrVanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsMember" name="ClinicalTrialAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CityOfHopeNationalMedicalCenterMember" name="CityOfHopeNationalMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalResearchSupportAgreementMember" name="ClinicalResearchSupportAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" name="GrupoEspanolDeInvestigacionEnSarcomasMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchAgreementMember" name="ClinicalTrialResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementMember" name="WorkOrderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" name="MoffittCancerCenterandResearchInstituteHospitalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TheradexSystemsIncMember" name="TheradexSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BastiaanVanDerBaanMember" name="BastiaanVanDerBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NDAConsultingCorpMember" name="NDAConsultingCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DevelopmentCollaborationAgreementMember" name="DevelopmentCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NetherlandsCancerInstituteMember" name="NetherlandsCancerInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MRIGlobalMember" name="MRIGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bMember" name="ClinicalTrialPhase1bMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bTwoMember" name="ClinicalTrialPhase1bTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" name="ClinicalTrialPhaseZeroPharmacologyStudyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialRandomizedPhaseTwoMember" name="ClinicalTrialRandomizedPhaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase2Member" name="ClinicalTrialPhase2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DueWithinSixtyDaysMember" name="DueWithinSixtyDaysMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DueEachJanuaryOneMember" name="DueEachJanuaryOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvancesOnResearchAndDevelopmentContractServices" name="AdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" name="ResearchAndDevelopmentContractLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" name="ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" name="ShareBasedCompensationIncludedInResearchAndDevelopmentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PrepaidInsurancePolicyTextBlock" name="PrepaidInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" name="ScheduleOfResearchAndDevelopmentCostsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ManagementFeePayableQuarterly" name="ManagementFeePayableQuarterly" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FairValueOfStockOptions" name="FairValueOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" name="EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialDescription" name="ClinicalTrialDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodStartDate" name="ContractualClinicalTrialPeriodStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodEndDate" name="ContractualClinicalTrialPeriodEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfPatientInTrial" name="NumberOfPatientInTrial" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EstimatedAdditionalCommitment" name="EstimatedAdditionalCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AmountRelatedToMilestonePayment" name="AmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EstimatedWorkCost" name="EstimatedWorkCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentinServices" name="ExpectedPaymentinServices" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentThroughSoftware" name="ExpectedPaymentThroughSoftware" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonRefundableLicenseIssueFee" name="NonRefundableLicenseIssueFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PaymentsOnNonrefundableMilestone" name="PaymentsOnNonrefundableMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultingAndAdvisoryCashFee" name="ConsultingAndAdvisoryCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ReimbursementExpense" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractPrice" name="ContractPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyaltyPayable" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyatiesPercentage" name="RoyatiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>lixt-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20231231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20231231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995514 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995515 - Disclosure - Research and Development Costs" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995516 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995517 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995518 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995519 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995520 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995521 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995522 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995524 - Disclosure - Research and Development Costs (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995525 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995526 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995527 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="995528 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995533 - Disclosure - Schedule of Research and Development Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995534 - Disclosure - Schedule of Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995536 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995537 - Disclosure - Summary of Related Party Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995538 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995543 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="995546 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995548 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="995549 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>lixt-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20231231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20231231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="62" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultantMember" xlink:label="loc_LIXTConsultantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTConsultantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995514 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995515 - Disclosure - Research and Development Costs" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995516 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995517 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995518 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995519 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995520 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995521 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995522 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995524 - Disclosure - Research and Development Costs (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995525 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995526 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995527 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="995528 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LegalFirmsAndOtherVendorsMember" xlink:label="loc_LIXTLegalFirmsAndOtherVendorsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTLegalFirmsAndOtherVendorsMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1_160" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995533 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR" xlink:label="loc_countryFR_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryFR_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995534 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995536 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPlacementAgentsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaapPreferredStockDividendPaymentTerms_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentTerms_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_320" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_320" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_320" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_320" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_320" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_320" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995537 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995538 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrReneBernardsMember" xlink:label="loc_LIXTDrReneBernardsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrReneBernardsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_350" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable_350" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly_350" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_350" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_350" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_350" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_350" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_280" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995543 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesSMiserMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrSchwartbergMember" xlink:label="loc_LIXTMrSchwartbergMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrSchwartbergMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrVanderBaanMember_550" xlink:type="arc" order="551" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_600" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_600" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_600" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_600" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_600" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_600" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_600" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions_600" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_600" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_600" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_600" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_600" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_600" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_600" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_600" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_600" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_600" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_600" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_600" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="995546 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:label="loc_LIXTClinicalTrialPhaseZeroPharmacologyStudyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseZeroPharmacologyStudyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase2Member" xlink:label="loc_LIXTClinicalTrialPhase2Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase2Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995548 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="loc_LIXTBastiaanVanDerBaanMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBastiaanVanDerBaanMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_490" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_490" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDeferredCosts_490" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitment_490" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedAdditionalCommitment" xlink:label="loc_LIXTEstimatedAdditionalCommitment_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTEstimatedAdditionalCommitment_490" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_490" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment_490" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTEstimatedWorkCost_490" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTExpectedPaymentinServices_490" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware_490" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee_490" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee_490" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone_490" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses_490" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_490" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOfficersCompensation_490" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_490" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee_490" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTReimbursementExpense_490" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTContractPrice_490" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="995549 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueWithinSixtyDaysMember" xlink:label="loc_LIXTDueWithinSixtyDaysMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueWithinSixtyDaysMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRoyaltyExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTRoyaltyPayable_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTRoyatiesPercentage_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>lixt-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultantMember" xlink:label="LIXT_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultantMember" xlink:to="LIXT_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LegalFirmsAndOtherVendorsMember" xlink:label="LIXT_LegalFirmsAndOtherVendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFirmsAndOtherVendorsMember" xlink:to="LIXT_LegalFirmsAndOtherVendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LegalFirmsAndOtherVendorsMember_lbl" xml:lang="en-US">Legal Firms and Other Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="LIXT_DirectorsAndCorporateOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_lbl" xml:lang="en-US">Directors and Corporate Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="LIXT_VendorAndConsultantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantOneMember_lbl" xml:lang="en-US">Vendor and Consultant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="LIXT_VendorAndConsultantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantTwoMember_lbl" xml:lang="en-US">Vendor and Consultant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="LIXT_VendorAndConsultantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantThreeMember_lbl" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="LIXT_VendorAndConsultantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantFourMember_lbl" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="LIXT_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockOptionsMember" xlink:label="LIXT_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="country_ES" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US">SPAIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR" xlink:label="country_FR" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_FR" xlink:to="country_FR_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_FR_lbl" xml:lang="en-US">FRANCE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="LIXT_UndesignatedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_UndesignatedPreferredStockMember_lbl" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PlacementAgentsMember" xlink:label="LIXT_PlacementAgentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PreFundedWarrantsMember" xlink:label="LIXT_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreFundedWarrantsMember" xlink:to="LIXT_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceOneMember" xlink:label="LIXT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="LIXT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="LIXT_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFourMember" xlink:label="LIXT_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="LIXT_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="LIXT_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrKovachMember" xlink:label="LIXT_DrKovachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrKovachMember_lbl" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrJamesSMiserMember" xlink:label="LIXT_DrJamesSMiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesSMiserMember_lbl" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="LIXT_EricJFormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EricJFormanMember_lbl" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RobertNWeingartenMember" xlink:label="LIXT_RobertNWeingartenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RobertNWeingartenMember_lbl" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="LIXT_BasvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BasvanderBaanMember_lbl" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrReneBernardsMember" xlink:label="LIXT_DrReneBernardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrReneBernardsMember" xlink:to="LIXT_DrReneBernardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrReneBernardsMember_lbl" xml:lang="en-US">Dr Rene Bernards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="LIXT_ChairmanOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_lbl" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="LIXT_ChairmanOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_lbl" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="LIXT_MemberOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfAuditCommitteeMember_lbl" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="LIXT_MemberOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfOtherCommitteesMember_lbl" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="LIXT_AppointmentGrantsOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_lbl" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="LIXT_AnnualGrantOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualGrantOfOptionsMember_lbl" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="LIXT_NonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonOfficerDirectorsMember_lbl" xml:lang="en-US">Non-officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrSchwartbergMember" xlink:label="LIXT_MrSchwartbergMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrSchwartbergMember" xlink:to="LIXT_MrSchwartbergMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrSchwartbergMember_lbl" xml:lang="en-US">Mr Schwartberg [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MsReginaBrownMember" xlink:label="LIXT_MsReginaBrownMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MsReginaBrownMember_lbl" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="LIXT_FiveNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsMember_lbl" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourOfficersMember" xlink:label="LIXT_FourOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourOfficersMember_lbl" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="LIXT_BioPharmaWorksLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BioPharmaWorksLLCMember_lbl" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="LIXT_FourNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficerDirectorsMember_lbl" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrVanderBaanMember" xlink:label="LIXT_MrVanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrVanderBaanMember" xlink:to="LIXT_MrVanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrVanderBaanMember_lbl" xml:lang="en-US">Mr Van der Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSixMember" xlink:label="LIXT_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="LIXT_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceEightMember" xlink:label="LIXT_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceNineMember" xlink:label="LIXT_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTenMember" xlink:label="LIXT_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="LIXT_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="LIXT_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="LIXT_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="LIXT_ClinicalResearchSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_lbl" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CollaborationAgreementMember" xlink:label="LIXT_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xml:lang="en-US">GEIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="LIXT_ClinicalTrialResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_lbl" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="LIXT_WorkOrderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementMember_lbl" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="LIXT_TheradexSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TheradexSystemsIncMember_lbl" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="LIXT_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExecutiveOfficersMember" xlink:label="LIXT_ExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExecutiveOfficersMember_lbl" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="LIXT_BastiaanVanDerBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BastiaanVanDerBaanMember" xlink:to="LIXT_BastiaanVanDerBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BastiaanVanDerBaanMember_lbl" xml:lang="en-US">Bastiaan Van Der Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="LIXT_NDAConsultingCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NDAConsultingCorpMember_lbl" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="LIXT_DevelopmentCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_lbl" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="LIXT_NetherlandsCancerInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NetherlandsCancerInstituteMember_lbl" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MRIGlobalMember" xlink:label="LIXT_MRIGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MRIGlobalMember_lbl" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="LIXT_ClinicalTrialPhase1bMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bMember_lbl" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xml:lang="en-US">Phase 1b Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:label="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:to="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember_lbl" xml:lang="en-US">Phase 0 Pharmacology Study [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase2Member" xlink:label="LIXT_ClinicalTrialPhase2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase2Member" xlink:to="LIXT_ClinicalTrialPhase2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase2Member_lbl" xml:lang="en-US">Phase 1b/2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LicenseAgreementMember" xlink:label="LIXT_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueWithinSixtyDaysMember" xlink:label="LIXT_DueWithinSixtyDaysMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueWithinSixtyDaysMember" xlink:to="LIXT_DueWithinSixtyDaysMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DueWithinSixtyDaysMember_lbl" xml:lang="en-US">Due Within 60 Days [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="LIXT_DueEachJanuaryOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DueEachJanuaryOneMember_lbl" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, issuable upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Compensation to related parties, including stock-based compensation of $773,203 and $1,502,776 for the years ended December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs, including $0 and $43,264 of stock-based compensation costs to a consultant for the years ended December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct equity offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation expense included in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Award Underlying Securities Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Award Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Award Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="LIXT_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:to="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Summary of Related Party Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Each Option Award Estimated Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Summary of Stock-based Compensation Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash used in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="LIXT_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash SIPC insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Patent and licensing legal and filing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Foreign currency average rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Warrants Outstanding Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="us-gaap_PreferredStockDividendPaymentTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentTerms" xlink:to="us-gaap_PreferredStockDividendPaymentTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPaymentTerms_lbl" xml:lang="en-US">Preferred stock, dividend payment terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock, conversion description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds from sale of transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares issued upon exercise of stock option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Shares issued upon exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock shares issued during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Cash-based</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock-based</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Related party costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_2_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Paid office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Cash fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="LIXT_ManagementFeePayableQuarterly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ManagementFeePayableQuarterly_lbl" xml:lang="en-US">Cash board fee payable quarterly</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Cash board compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Options exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Options vesting term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xml:lang="en-US">Total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of common shares issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares were available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2_lbl" xml:lang="en-US">Option exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options are exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FairValueOfStockOptions" xlink:label="LIXT_FairValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FairValueOfStockOptions_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock options fully vested amount, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Deferred compensation expense for unvested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average recognition period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair market value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Outstanding stock options to acquire shares of common stock not vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U. S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Expirations related to stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Adjustment to deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Operating loss carryforwards, federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Operating loss carryforwards, state</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Prior net operating loss conversion utilization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialDescription" xlink:label="LIXT_ClinicalTrialDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialDescription_lbl" xml:lang="en-US">Clinical trial, description</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xml:lang="en-US">Estimated Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xml:lang="en-US">Estimated End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="LIXT_NumberOfPatientInTrial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfPatientInTrial_lbl" xml:lang="en-US">Number of Patients in Trial</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Remaining financial contractual commitment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_2_lbl" xml:lang="en-US">Contractual commitment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and developments costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Total costs incurred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitment_2_lbl" xml:lang="en-US">Aggregate commitments expected</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedAdditionalCommitment" xlink:label="LIXT_EstimatedAdditionalCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedAdditionalCommitment" xlink:to="LIXT_EstimatedAdditionalCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EstimatedAdditionalCommitment_lbl" xml:lang="en-US">Estimated additional commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:to="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xml:lang="en-US">Inventory costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="LIXT_AmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedWorkCost" xlink:label="LIXT_EstimatedWorkCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EstimatedWorkCost_lbl" xml:lang="en-US">Work cost</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="LIXT_ExpectedPaymentinServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentinServices_lbl" xml:lang="en-US">Percentage of payment through services</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="LIXT_ExpectedPaymentThroughSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentThroughSoftware_lbl" xml:lang="en-US">Percentage of payment through software</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="LIXT_NonRefundableLicenseIssueFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonRefundableLicenseIssueFee_lbl" xml:lang="en-US">Non refundable license issue fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="LIXT_AnnualLicenseMaintenanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="LIXT_PaymentsOnNonrefundableMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_lbl" xml:lang="en-US">Payment on non refundable milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Operating costs and expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Annual compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRent_2_lbl" xml:lang="en-US">Payment of office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="LIXT_ConsultingAndAdvisoryCashFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_lbl" xml:lang="en-US">Consulting and advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ReimbursementExpense" xlink:label="LIXT_ReimbursementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ReimbursementExpense_lbl" xml:lang="en-US">Reimbursed expense</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractPrice" xlink:label="LIXT_ContractPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractPrice_lbl" xml:lang="en-US">Contract price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Non refundable license issue royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyaltyPayable" xlink:label="LIXT_RoyaltyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyaltyPayable_lbl" xml:lang="en-US">Minimum annual royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payment for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyatiesPercentage" xlink:label="LIXT_RoyatiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyatiesPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Common Stock, par value $0.0001 per share [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xml:lang="en-US">Research and development contract liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash SIPC insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_doc" xml:lang="en-US">Prepaid Insurance [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EricJFormanMember_doc" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FairValueOfStockOptions_doc" xml:lang="en-US">Fair value of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantOneMember_doc" xml:lang="en-US">Vendor and Consultant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantTwoMember_doc" xml:lang="en-US">Vendor and Consultant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantThreeMember_doc" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantFourMember" xlink:to="LIXT_VendorAndConsultantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantFourMember_doc" xml:lang="en-US">Vendor and Consultant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RobertNWeingartenMember_doc" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrSchwartbergMember" xlink:to="LIXT_MrSchwartbergMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrSchwartbergMember_doc" xml:lang="en-US">Mr Schwartberg [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MsReginaBrownMember_doc" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsMember_doc" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BasvanderBaanMember_doc" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultantMember" xlink:to="LIXT_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourOfficersMember_doc" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrVanderBaanMember" xlink:to="LIXT_MrVanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrVanderBaanMember_doc" xml:lang="en-US">Mr Van der Baan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xml:lang="en-US">Stock based compensation expense included in research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xml:lang="en-US">Stock based compensation expense included in general and administrative costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Increase decrease in advances on research and development contract services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Increase decrease in research and development contract liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_UndesignatedPreferredStockMember_doc" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsMember_doc" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_doc" xml:lang="en-US">Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">ClinicalTrialMonitoringAgreementsMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialDescription_doc" xml:lang="en-US">Clinical trial description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bMember_doc" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_doc" xml:lang="en-US">Phase 1b&#9;Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xml:lang="en-US">Contractual clinical trial period start date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:to="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember_doc" xml:lang="en-US">Phase 0 Pharmacology Study [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase2Member" xlink:to="LIXT_ClinicalTrialPhase2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase2Member_doc" xml:lang="en-US">Phase 1b/2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xml:lang="en-US">Contractual clinical trial period end date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfPatientInTrial_doc" xml:lang="en-US">Number of patient in trial.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_doc" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xml:lang="en-US">GEIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AmountRelatedToMilestonePayment_doc" xml:lang="en-US">Amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrKovachMember_doc" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_doc" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementMember_doc" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EstimatedWorkCost_doc" xml:lang="en-US">Estimated work cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TheradexSystemsIncMember_doc" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentinServices_doc" xml:lang="en-US">Expected payment in services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentThroughSoftware_doc" xml:lang="en-US">Percentage of expected paymen through software.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ManagementFeePayableQuarterly_doc" xml:lang="en-US">Management fee payable quarterly.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonRefundableLicenseIssueFee_doc" xml:lang="en-US">Company is obligated to pay non refundable license issue fee..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualLicenseMaintenanceFee_doc" xml:lang="en-US">Company is obligated to pay annual license maintenance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_doc" xml:lang="en-US">Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExecutiveOfficersMember_doc" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_doc" xml:lang="en-US">Consulting and advisory quarterly cash fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NDAConsultingCorpMember_doc" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BioPharmaWorksLLCMember_doc" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ReimbursementExpense_doc" xml:lang="en-US">Reimbursement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_doc" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NetherlandsCancerInstituteMember_doc" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractPrice_doc" xml:lang="en-US">Contract price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MRIGlobalMember_doc" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_doc" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_doc" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfAuditCommitteeMember_doc" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfOtherCommitteesMember_doc" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualGrantOfOptionsMember_doc" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyatiesPercentage_doc" xml:lang="en-US">Royaties percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrReneBernardsMember" xlink:to="LIXT_DrReneBernardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrReneBernardsMember_doc" xml:lang="en-US">Dr Rene Bernards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_doc" xml:lang="en-US">Directors and Corporate Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:to="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock_doc" xml:lang="en-US">Schedule Of Research And Development Costs [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreFundedWarrantsMember" xlink:to="LIXT_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_doc" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficerDirectorsMember_doc" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueWithinSixtyDaysMember" xlink:to="LIXT_DueWithinSixtyDaysMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DueWithinSixtyDaysMember_doc" xml:lang="en-US">Due Within 60 Days [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DueEachJanuaryOneMember_doc" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_doc" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedAdditionalCommitment" xlink:to="LIXT_EstimatedAdditionalCommitment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EstimatedAdditionalCommitment_doc" xml:lang="en-US">Estimated additional commitment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesSMiserMember_doc" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockOptionsMember_doc" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFirmsAndOtherVendorsMember" xlink:to="LIXT_LegalFirmsAndOtherVendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LegalFirmsAndOtherVendorsMember_doc" xml:lang="en-US">Legal Firms and Other Vendors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyaltyPayable_doc" xml:lang="en-US">Royalty payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonOfficerDirectorsMember_doc" xml:lang="en-US">Non-officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xml:lang="en-US">IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_3_lbl" xml:lang="en-US">Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>lixt-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20231231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20231231.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20231231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20231231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20231231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultantMember" xlink:label="loc_LIXTConsultantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaapShareBasedCompensationAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="995513 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995514 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="995515 - Disclosure - Research and Development Costs">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="995516 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="995517 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="995518 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="995519 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="995520 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="995521 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995522 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="loc_LIXTPrepaidInsurancePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTPrepaidInsurancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="loc_LIXTWarrantsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995523 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="995524 - Disclosure - Research and Development Costs (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:label="loc_LIXTScheduleOfResearchAndDevelopmentCostsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_LIXTScheduleOfResearchAndDevelopmentCostsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="995525 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="995526 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="995527 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="995528 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="995529 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LegalFirmsAndOtherVendorsMember" xlink:label="loc_LIXTLegalFirmsAndOtherVendorsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTLegalFirmsAndOtherVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_VendorAndConsultantFourMember" xlink:label="loc_LIXTVendorAndConsultantFourMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="995533 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR" xlink:label="loc_countryFR" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryFR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="995534 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="995536 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PreFundedWarrantsMember" xlink:label="loc_LIXTPreFundedWarrantsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaapPreferredStockDividendPaymentTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="995537 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995538 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrReneBernardsMember" xlink:label="loc_LIXTDrReneBernardsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrReneBernardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995543 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesSMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrSchwartbergMember" xlink:label="loc_LIXTMrSchwartbergMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrSchwartbergMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MrVanderBaanMember" xlink:label="loc_LIXTMrVanderBaanMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrVanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="995546 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:label="loc_LIXTClinicalTrialPhaseZeroPharmacologyStudyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseZeroPharmacologyStudyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialPhase2Member" xlink:label="loc_LIXTClinicalTrialPhase2Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995548 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_BastiaanVanDerBaanMember" xlink:label="loc_LIXTBastiaanVanDerBaanMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBastiaanVanDerBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedAdditionalCommitment" xlink:label="loc_LIXTEstimatedAdditionalCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTEstimatedAdditionalCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTEstimatedWorkCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTExpectedPaymentinServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTReimbursementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTContractPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="995549 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueWithinSixtyDaysMember" xlink:label="loc_LIXTDueWithinSixtyDaysMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueWithinSixtyDaysMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTRoyaltyPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20231231.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTRoyatiesPercentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166723994256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
    East Colorado Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Weinberg & Company, P.A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los
Angeles, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725740144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 4,203,488<span></span>
</td>
<td class="nump">$ 5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">78,016<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">17,116<span></span>
</td>
<td class="nump">49,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">11,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,308,620<span></span>
</td>
<td class="nump">5,560,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,308,620<span></span>
</td>
<td class="nump">5,560,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">156,758<span></span>
</td>
<td class="nump">230,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent', window );">Research and development contract liabilities</a></td>
<td class="nump">157,100<span></span>
</td>
<td class="nump">165,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">313,858<span></span>
</td>
<td class="nump">395,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">48,976,265<span></span>
</td>
<td class="nump">45,059,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(48,481,728)<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,994,762<span></span>
</td>
<td class="nump">5,165,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 4,308,620<span></span>
</td>
<td class="nump">$ 5,560,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166819052016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 156,758<span></span>
</td>
<td class="nump">$ 230,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 36,250<span></span>
</td>
<td class="nump">$ 46,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725996208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Compensation to related parties, including stock-based compensation of $773,203 and $1,502,776 for the years ended December 31, 2023 and 2022, respectively</a></td>
<td class="nump">1,718,180<span></span>
</td>
<td class="nump">2,547,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">978,244<span></span>
</td>
<td class="nump">1,268,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses</a></td>
<td class="nump">1,495,712<span></span>
</td>
<td class="nump">1,146,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs, including $0 and $43,264 of stock-based compensation costs to a consultant for the years ended December 31, 2023 and 2022, respectively</a></td>
<td class="nump">898,100<span></span>
</td>
<td class="nump">1,349,269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">5,090,236<span></span>
</td>
<td class="nump">6,311,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,090,236)<span></span>
</td>
<td class="num">(6,311,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">17,486<span></span>
</td>
<td class="nump">11,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(16,233)<span></span>
</td>
<td class="num">(8,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="nump">1,954<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,087,029)<span></span>
</td>
<td class="num">$ (6,312,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share basic</a></td>
<td class="num">$ (2.66)<span></span>
</td>
<td class="num">$ (3.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share diluted</a></td>
<td class="num">$ (2.66)<span></span>
</td>
<td class="num">$ (3.99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">1,915,838<span></span>
</td>
<td class="nump">1,582,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">1,915,838<span></span>
</td>
<td class="nump">1,582,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166819122320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 773,203<span></span>
</td>
<td class="nump">$ 1,546,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 773,203<span></span>
</td>
<td class="nump">$ 1,502,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725375632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 38,372,365<span></span>
</td>
<td class="num">$ (37,082,164)<span></span>
</td>
<td class="nump">$ 4,790,338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,374,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">5,141,355<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,546,040<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,546,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,312,535)<span></span>
</td>
<td class="num">$ (6,312,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">45,059,760<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
<td class="nump">$ 5,165,227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,137,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock in direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">773,203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">773,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,087,029)<span></span>
</td>
<td class="num">(5,087,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Exercise of pre-funded common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 48,976,265<span></span>
</td>
<td class="num">$ (48,481,728)<span></span>
</td>
<td class="nump">$ 3,994,762<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166838725952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,087,029)<span></span>
</td>
<td class="num">$ (6,312,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense included in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost', window );">General and administrative costs</a></td>
<td class="nump">773,203<span></span>
</td>
<td class="nump">1,502,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost', window );">Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">69,001<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">32,108<span></span>
</td>
<td class="nump">59,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Other prepaid expenses</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(73,976)<span></span>
</td>
<td class="nump">2,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
<td class="num">(7,922)<span></span>
</td>
<td class="nump">88,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,293,265)<span></span>
</td>
<td class="num">(4,611,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="nump">3,137,039<span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="nump">41<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,143,361<span></span>
</td>
<td class="nump">5,141,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease)</a></td>
<td class="num">(1,149,904)<span></span>
</td>
<td class="nump">529,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of period</a></td>
<td class="nump">5,353,392<span></span>
</td>
<td class="nump">4,823,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of period</a></td>
<td class="nump">4,203,488<span></span>
</td>
<td class="nump">5,353,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">16,233<span></span>
</td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in advances on research and development contract services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166838675696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (5,087,029)<span></span>
</td>
<td class="num">$ (6,312,535)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166819137056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166722727360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqbb4r9tV0m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82A_z9T7lfLXYdwg">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company dedicated to improving patients&#8217; lives by developing
a drug class called Protein Phosphatase 2A inhibitors. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents
and/or x-ray, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have
significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein
phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little
or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>President
and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#8217;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors.&#160; Dr. Kovach was also the Company&#8217;s Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Listing and Reverse Stock Split </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbols &#8220;LIXT&#8221;
and &#8220;LIXTW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zubUZhj3yay7" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. No fractional shares were issued in connection with the reverse split,
with any fractional shares resulting from the reverse split being rounded up to the next whole share. All share and per share amounts
and information presented herein have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement
of Nasdaq over time, or that it will be successful in maintaining compliance with any of the other continued listing requirements of
Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, the Company recorded a net loss of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zKsABCY8g5kc" title="Net loss">5,087,029 </span>and used cash in operations of $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zN6OfrgYrrll" title="Cash used in operations">4,293,265</span>. At December
31, 2023, the Company had cash of $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_z4garxt3CCKg" title="Cash">4,203,488</span> available to fund its operations. Because the Company is currently engaged in various early-stage
clinical trials, it is expected that it will take a significant amount of time and resources to develop any product or intellectual property
capable of generating sustainable revenues. Accordingly, the Company&#8217;s business is unlikely to generate any sustainable operating
revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its technology,
product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive
earnings and operating cash flows. At December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to
clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated approximately $<span id="xdx_909_eus-gaap--ContractualObligation_iI_pp0p0_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z3W8udyd28W4" title="Contractual obligation">6,344,000</span> (see Note 8),
which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2023. The Company&#8217;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound
LB-100 through approximately &#160;September 30, 2024. However, existing cash resources will not be sufficient to complete the development
of and obtain regulatory approval for the Company&#8217;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able to proactively
manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#8217;s operating plans may change
as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed
sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
comparative amounts in 2022 have been reclassified to conform to the current year&#8217;s presentation. Such reclassifications, individually
and in the aggregate, were not material to the results of operations or financial condition of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724709632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zAzGVenIrdJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zhR1kFO9agwi">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zduPhxVq9TPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoc7VDIezOXf">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles
(&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte
Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zXbngsCHDJR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zIj57lMpFsei">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_z9Jlo11H6Yrh" title="Number of operating segments"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20230101__20231231_zZ0IEoAjhbfj" title="Number of reportable segments">one</span></span> segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zEPrXuicGeV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z0nO8pvLp7pf">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaA2Y0Cmm8k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zSQq5L65qaTl">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231_ziGNzxUsSxP" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20231231_z3Dq2PrmJxXa" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0aYpeETTS95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBhP75WcwqQ1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--PrepaidInsurancePolicyTextBlock_z8TAnVgnsPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z4CV9JesYIM7">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkjQNNqrz7Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zobfBdlcAuBi">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zJZYksx9bD8" title="Legal fees">978,244</span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20221231_zmHFSR6xk1Ge" title="Patent and licensing legal and filing fees">1,268,308</span> for the years ended December 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI0DaF9ATAd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmwYy0kjFPU4">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zDhOXPncSCxd" title="Concentration of risk, percentage">23.3</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zJMnYwHwJItj" title="Concentration of risk, percentage">25.6</span>% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxUPoerTkMr6" title="Concentration of risk, percentage">18.4</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zphZp5lrDwob" title="Concentration of risk, percentage">30.3</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNTceUgFQ3yj" title="Concentration of risk, percentage">29.9</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcHlgkCXEct" title="Concentration of risk, percentage">25.2</span>%
and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpi6KeYmITMe" title="Concentration of risk, percentage">13.7</span>%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyYKGW0GeSmd" title="Concentration of risk, percentage">21.0%</span>, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6jJLH7sRfMg" title="Concentration of risk, percentage">19.3%</span>, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUipF1eskioc" title="Concentration of risk, percentage">15.1%</span> and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0jsSDHU2ETh" title="Concentration risk, percentage">12.1%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z1r7XuiboyKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaVrDHWpRtp6">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2023 and
2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2023 or 2022.
Subsequent to December 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaRwnM7sC344" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyUGyP3lGbZj">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_z9ZNXjnSFTXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6kX7VOtHIY5">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zTmObsInfUOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zLJnKOfudIFl">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zLagUHXv6Kr8" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">552,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A9_zsquuEIHR6Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z6PnzSAKnH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zJsbAmWqz2rj">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations. During the years ended December 31,
2023 and 2022, the Company incurred various costs and expenses denominated in Euros, which were converted into United States dollars
at the average rate of <span id="xdx_909_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20231231_zBMa2lYyC0Yj" title="Foreign currency average rate">1.0824</span> and <span id="xdx_907_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20221231_zlmwdoeIgGq3" title="Foreign currency average rate">1.0538</span>, respectively. As of December 31, 2023 and 2022, the Company did not hold any currencies other
than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zAc4lmM3qhO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zhHBMFQBT6Gc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZy8jlZGlQq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zIEp5H0oXVi4">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation
(Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 &#8212; General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company&#8217;s consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p id="xdx_856_zJclNHr2s8ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724510032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_804_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z0iLvldCdnG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82D_z5LCav1nyiV5">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--ScheduleOfResearchAndDevelopmentCostsTableTextBlock_zgQC8oWLcvC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials
involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical regions where
such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zCzvrQhSvuq1" style="display: none">Schedule
of Research and Development Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoukKhcaDt6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zV8Mp80Audbh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zKFQhmg7EOs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">359,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,618</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zUiHa81jyMi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">626,366</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--FR_zaBG9zPoIS1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">France</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,532</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zXjM0heYEhgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,595</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z3TBAtIvBzZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zQlulZwPy08e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,349,269</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPqfj8riFPW6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">898,100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,349,269</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8A1_zXK7qWiQpx68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721652416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zeK65tJL6vEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82F_zFWVaeJrtW2f">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zWvSCSMWlLV1" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock, par value $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zQqwXfVUmHth" title="Preferred stock, par value">0.0001</span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKoo3m3SGDQ2" title="Preferred stock, shares authorized">350,000</span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. <span id="xdx_903_eus-gaap--PreferredStockDividendPaymentTerms_pid_c20150317__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ze5MuyRlP4e2" title="Preferred stock, dividend payment terms">The
holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed</span>. As of December 31, 2023 and 2022, the
Company had <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zrKwew4rXu4c" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zX3eVFDlTKC9" title="Preferred stock, shares authorized">9,650,000</span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board of Directors
may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbWNonnBVxs2" title="Preferred stock, conversion description">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfHjRvYZhXj" title="Preferred stock convertible into common stock">0.20833</span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQZueNHIfi33" title="Gross proceeds from sale of transaction">21,875,000</span></span>. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzGKy3DFcVg2" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQITNxj4L7D8" title="Preferred stock, shares outstanding">350,000</span></span> outstanding shares
of Series A Convertible Preferred Stock would convert into <span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4HWiLUaKk95" title="Preferred stock convertible into common stock"><span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYod8fbPnc1k" title="Preferred stock convertible into common stock">72,917</span></span> shares of common stock at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zpeyUJE9fKR7" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zlcbkqFUBQ4f" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zCLyRzz0J2A8" title="Common stock, par or stated value per share"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zRoLF9BT21ek" title="Common stock, par value">0.0001</span></span> per share. As of December 31, 2023 and
2022, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zgEyn6NWtOF7" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zStiUdtJgYbh" title="Common stock, shares outstanding">2,249,290</span></span> shares and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zlGX2Zx74yl4" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zp9n1uTEJ3Q6" title="Common stock, shares outstanding">1,664,706</span></span> shares, respectively, of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLV6dHaygyN4" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized number of shares of common stock and the par value per share were not affected by the reverse stock split. No fractional shares
were issued in connection with the reverse stock split, as all fractional shares were rounded up to the next whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTUnTSrdnqy9" title="Shares issued upon exercise of stock option">1,250</span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zniv5KTadGd7" title="Warrants exercised">1,250</span> shares exercisable at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuI2xvJfcE" title="Warrant exercise price">5.025</span> per share for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCz6Zgvio5gf" title="Proceeds from warrant exercises">6,281</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">April
12, 2022 Sale of Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMRdaxqMm15b" title="Number of common stock shares issued during period">290,000</span> shares of common stock at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKfDzIhoApO2" title="Sale of stock price per share">20.00</span> per share in a registered direct
offering, generating gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7eB3NJMBrl" title="Proceeds from sale of shares">5,800,000</span>. The total cash costs of this offering were $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2xhfCegf6Y2" title="Costs of public offering">658,616</span>, resulting in net proceeds of
$<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9JXifmaGgLi" title="Net proceeds from issuance of stock">5,141,384</span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_z92GGFusENT1" title="Warrants to purchase shares">29,000</span>
shares of common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_zVvbf4RvzUv8" title="Warrant exercise price">20.00</span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July
20, 2023 Sale of Common Stock and Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDpwCZUmr10d" title="Number of common stock shares issued during period">180,000</span> shares of common stock at a price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6KCsx7vkqad" title="Sale of stock price per share">6.00</span> per share and pre-funded warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zLkAW4UPZ3Ti" title="Warrants to purchase shares">403,334</span>
shares of common stock at a price of $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z77bVc2EGhDg" title="Common Stock, Par or Stated Value Per Share">5.9999</span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcwMnjz3QSHa" title="Warrant exercise price">0.0001</span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zT2e8Cv9m2Xl" title="Warrants to purchase shares">403,334</span> pre-funded warrants, exercisable at $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zsQ4Av4Ene1h" title="Common Stock, Par or Stated Value Per Share">0.0001</span> per common share, were
exercised for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zY5RROjYe7z1" title="Proceeds from exercise of warrants">41</span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxU61230hVwe" title="Shares issued upon exercise of warrants">403,334</span> shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEF23643iTCe" title="Warrants to purchase shares">583,334</span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Oqe9a86D4l" title="Warrant exercise price">6.00</span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaMM9zF6h6ei" title="Warrants term">five years</span>
thereafter on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9QeBHeYG6ng" title="Warrant expiration date">July 20, 2028</span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZz6sizVHom7" title="Proceeds from issuance initial public offering">3,499,964</span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIM88Pjg0Hd1" title="Costs of public offering">362,925</span>, resulting in net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwnamlXqQqNe" title="Net proceeds from private placement">3,137,039</span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z44RKYKRS9zf" title="Warrants to purchase shares">35,000</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWdnphWJu7n9" title="Warrant exercise price">6.60</span> per share and
expiring on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zHUHgDrAVFSi" title="Warrant expiration date">July 20, 2028</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zm3FXY03nsqj" title="Warrant exercise price">6.00</span> per share) and to the placement agent (exercisable
at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWHVepD6Uf0i" title="Warrant exercise price">6.60</span> per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional investor contain
a &#8220;fundamental transaction&#8221; provision whereby in the event of a fundamental transaction (a sale or transfer of assets or
ownership of the Company as defined in the warrant agreement) within the Company&#8217;s control, the holder of the unexercised common
stock warrants would be entitled to receive, in exchange for extinguishment of such warrants, cash consideration equal to a Black-Scholes
valuation, as defined in the warrant agreement. If such fundamental transaction is not within the Company&#8217;s control, the warrant
holder would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#8217;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash payment
for a warrant redemption as a distribution from stockholders&#8217; equity, as and when such cash payment is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsUZvjzFjOoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2023 and 2022 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zDqLPxAqnOT3" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Warrants outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ziuZ25V42jz9" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">311,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpfop4SYsGh3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">57.720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMPcOrdOu7A6" style="text-align: right" title="Number of Shares, Issued">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxmoqpNrfPr9" style="text-align: right" title="Weighted Average Exercise Price, Issued">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0PJTORZgZc" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEEzhRKHWGxg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvOcIHvLYBdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired">(150,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHBShZqPwLWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">60.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztwbjoJ0GYf1" style="text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTlLmO3UyNg7" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlsxvt9qJ35l" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaQOndTeeM9d" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjs4Vjx78Zae" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS2JDRMic5j" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZpegNnuXEk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVn24AL1OWo7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJcyq2t1laBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zk3z2IZQKWDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWngRgbiF2Z8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">3.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcBMNbidNv04" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">190,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBHWJsEgkl0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">50.161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztRuwimAmhk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZcVMAUOaFl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2kd7kcYSxPe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">3.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zXB2QmlpJXo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zHCdrGKKPNI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z6TB8k2oC2xi" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3qWYGq2AwX8" title="Exercise Prices">6.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaYnQqKahfc8" style="width: 48%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z88RxNZdljD4" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8BD11CMmA2k" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQVqTnzEtcnk" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpKAaCkzXvm8" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqOgjc8Y5Pve" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zT9bmTbBiKgf" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAMfzu0vpsob" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuvCd21XPysc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231_zIuK0iOOHQwl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zMAkGxvcCTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5MtsnC1APic" title="Warrants exercisable">57.00</span> per share at December 31, 2023 consist of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwzCgsTAfoY9" title="Warrants outstanding">1,497,000</span> publicly-traded warrants pre-split <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPMvHqXizbGa" title="Reverse stock split">1-for-10</span> that were
issued as part of the Company&#8217;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTV4tY7bNks5" title="Exercise price">5.70</span> per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHA59smDsB" title="Warrants exercisable">5.70</span>, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXMUnxLvhYWi" title="Warrants and rights outstanding">57.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdrlvQepPRM1" title="Fair market value of stock">2.35 </span>per share on December 31, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721646192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZWbPdgQqE97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82F_zRyI2U6dpUz1">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors, and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zrJFA5Ku7CM7" title="Annual salary">250,000</span>.
During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztaJjLFKgH2e" title="Compensation">190,860</span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBZ4FCtyjWOd" title="Compensation">250,000</span>, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zJeAF7MSCCRe" title="Annual salary">150,000</span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgUbnZQZjDT8" title="Increase in annual salary">175,000</span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the years ended December
31, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zONiQmgNIYNb" title="Compensation">175,000</span> and $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3QXwxJOAPM" title="Compensation">175,000</span>, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#8217;s consolidated statements of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zUICFMADDaD3" title="Annual salary">120,000</span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z01Wnixvczc1" title="Increase in annual salary">175,000</span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ze68UpK9odyk" title="Compensation">200,000</span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which the Company paid $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zc6WKkehCJw4" title="Paid office rent">15,571</span> and $<span id="xdx_903_eus-gaap--PaymentsForRent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zXopDSprRZye" title="Paid office rent">937</span>, respectively, on Mr. Forman&#8217;s behalf for the years ended December 31, 2023
and 2022. During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVXAuptS4kVj" title="Compensation">200,000</span> and $<span id="xdx_902_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zlsk2CDDfTM4" title="Compensation">178,819</span>, respectively, to Mr. Forman under
this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zkujrcc5uiU2" title="Annual salary">120,000</span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zDexGD0ZRBne" title="Increase in annual salary">175,000</span>. During the years ended December 31, 2023 and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVe50L9PnxQ1" title="Compensation">175,000 </span>and $<span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXvycoFS2S4j" title="Compensation">175,000</span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zp0wAVjKlOaa" title="Annual salary">150,000</span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#8217;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will
be eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement
is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early
termination provisions as described in the employment agreement. During the year ended December 31, 2023, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbT44YZcqV4d" title="Compensation">40,639</span> to
Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations for such period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_zCa7Ij7F3Evb" title="Cash board fee payable">100,000</span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_90B_ecustom--ManagementFeePayableQuarterly_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_ztWsXJT0Hke4" title="Cash board fee payable quarterly">40,000</span>, payable quarterly. During the years ended December 31,
2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuH3xUfOjSb1" title="cash board compensation">62,500</span>
and $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqX5khH4yg5c" title="Cash board compensation">133,873</span>, respectively, with respect to his cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zoWo8fqJ6Png" title="Compensation">20,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_906_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zuGEbTrANgm1" title="Compensation">10,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zsx8qu4yEiK5" title="Compensation">5,000 </span>per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zBPcxliY4I9d" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zuYabsm4TECd" title="Compensation">2,500</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zJ9BWB7gqBf9" title="Options, grants in period, gross">25,000</span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zTiDf3UnL6L2" title="Options exercisable period">five years</span>,
at the closing market price on the date of grant, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zaqx4NUUnkHb" title="Options vesting term">vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service</span>. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90B_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zuHSSysIOvEb" title="Cash fee payable">100,000</span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zlt1lIdZQZ9e" title="Options, grants in period, gross">10,000</span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zuCeIKXSJ2c9" title="Options exercisable period">five years</span>, at the closing market price on the date of grant, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zwsGMMAR9i6" title="Options vesting term">vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director</span>. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zWoHXc6cKNCg" title="Cash fee payable">40,000</span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_zjBm4kyeOpPk" title="Stock based compensation">163,479</span> and $<span id="xdx_906_eus-gaap--SalariesAndWages_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_z38adBrazz7h" title="Stock based compensation">266,020</span>, respectively, for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zpSmtHiyZMPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zPxp7rYaMom1" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJYpwB9sh2b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zilBvtTqTHJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OfficersCompensation_zxY587gtQA2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,044,839</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zXWkfEGt3Lhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">773,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,502,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zNrpgk7VYNFb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,547,615</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_zWyT1z4sMuM9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,547,615</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zelEUnGjLmO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721801424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zN0jlIZJ5qi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_823_zKfP6XOA1ANk">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAIV13jsyRq8" title="Common shares avaliable for issuable">233,333</span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221006__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuc36anq7Ohg" title="Common shares avaliable for issuable">180,000</span> shares, to a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUOoYv851l06" title="Number of common shares issuable">413,333</span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231126__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAJpIr2wZoB" title="Common shares avaliable for issuable">336,667</span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zClHQvCXLHp2" title="Number of common shares issuable">750,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, unexpired stock options for <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWlPBRdj86ud" title="Shares outstanding">495,000</span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zM0DAsFRPnBg" title="Shares were available for issuance">255,000</span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zts1CO8ZeUT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhweWedzOTod" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231_z7a5eJuqSdy8" title="Risk-free interest rate">4.843</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zZEWVvi5R8oj" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zTUsUmQ6wPZe" title="Expected volatility">138.05</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zJ2Ao391EqS" title="Expected life">4.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20220101__20221231_zFP0jPpHHLt8" title="Risk-free interest rate, minimum">3.03</span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20220101__20221231_zDTD84iiN9bk" title="Risk-free interest rate, maximum">3.63</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zF5WOiwXBe4c" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20220101__20221231_zK7PmrqPVWEk" title="Expected volatility, minimum">128.03</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20220101__20221231_zDs6gylt4lxg" title="Expected volatility, maximum">153.17</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zlDrN4yCin21" title="Expected life">3.5</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zibY8JCgQwy3" title="Expected life">5</span> years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zXKnZ3xpsUo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zu64vgFxzDu8" title="Stock options granted to purchase common stock, issued">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zYyTglmsShV5" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC9UxaqUcAhj" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfgfysHE5Il6" title="Stock option vested exercisable term">The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5PCh2G7LNy3" title="Fair value of stock options">400,855</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPikHhfXho69" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0sQZ24Ncy9b" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy87pHHjD803" title="Stock based compensation">61,501</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zh8AJUuTM2T" title="Stock based compensation">100,213</span> for the years ended December 31, 2023 and
2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIzMww3N3Ti5" title="Stock options granted to purchase common stock, issued">8,333</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKMIMgCS3JXk" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zFAOsILpKIb7" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zOfcFf0rqD9l" title="Stock options description">The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zq0XQBePW8Eb" title="Fair value of stock options">572,650</span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7tWuAgrdrR8" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zeGXCN1y2ifi" title="Stock options fully vested amount, fair value">143,163</span> was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjtpezggaflb" title="Stock based compensation">83,544</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKVWM0OeW5ub" title="Stock based compensation">143,163</span> for the years ended December 31, 2023 and 2022,
respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_zphFy8RWYTKe" title="Number of fully vested option exercisable">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7ULeA3KwV01" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_ziGYCDhRyfP5" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zxwO14GPDql8" title="Stock options description">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zWhlbjafmEY4" title="Fair value of stock options">400,855</span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjh1JCXr2Q" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJzNCLKbH6Ri" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock options fully vested on August 12,
2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was
charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLxKnBcMNje7" title="Stock based compensation">61,501</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZWCMPhfPeaj" title="Stock based compensation">100,213</span> for the years ended December 31, 2023 and 2022, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zogYvlcKIc84" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s
common stock, exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHv3jT1boV6" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_ztFMRkydEnUc" title="Stock options are exercisable price per share">32.00</span> per share (the closing market price on the grant
date), <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmutyFMMqFQ5" title="Stock options description">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zJqOs1Dy1N8j" title="Fair value of stock options">753,611</span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1YOlqjTXAL6" title="Stock price per share">30.144</span> per share), of which $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7JYhy3nwM97" title="Stock options fully vested amount, fair value">376,800</span> was attributable to the portion of the stock options fully vested on April 9, 2021 and
was therefore charged to operations on that date. Although the remaining unvested portion of the fair value of the stock options was
being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options terminated on October
30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and administrative costs
in the consolidated statement of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zDRCugkODlci" title="Stock based compensation">126,684</span> for the year ended December 31, 2022 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zb7YnFTDFnX8" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmEtTyWM5gvl" title="Stock option vested exercisable term">five year</span>s
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zksCQFX8knui" title="Stock options are exercisable price per share">28.00</span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zbFTgWyXbBIc" title="Stock options description">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</span>. The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z7zeFgkdVxJb" title="Fair value of stock options">658,363</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zYYsKuYm3Vyf" title="Stock price per share">26.335</span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z6iijqUQrRcf" title="Stock options fully vested amount, fair value">329,188</span> was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zYCWuOIFdfp7" title="Stock based compensation">76,388</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2L7T45oQBOi" title="Stock based compensation">154,042</span> for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zZqJjf6Xh6sd" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zWGDoyJId69b" title="Number of fully vested option exercisable">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPkaFO7548h8" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zBrxnT4nsTyc" title="Stock options are exercisable price per share">30.30</span> per share
(the closing market price on the grant date), <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zUeIn9ikXQli" title="Stock options description">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</span>.
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z7niMfKEGSE5" title="Fair value of stock options">1,421,095</span>
($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8pSPXynF0C6" title="Stock price per share">28.423</span> per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to
general and administrative costs in the consolidated statement of operations of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPJBVOvkKdzf" title="Stock based compensation">211,413</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrujbsuwQgld" title="Stock based compensation">638,915</span> for the years ended December 31,
2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIKCHF1nrBxb" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zu6zHiAtcjje" title="Stock option vested exercisable term">five years</span>
at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGpFMtV78sEb" title="Stock options are exercisable price per share">7.40</span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZY487Hv5589" title="Stock options description">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service</span>. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsEN8xk5J8r" title="Fair value of stock options">158,525</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zdH129z46FWh" title="Stock price per share">6.341</span> per share),
of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjIjKIy85IU9" title="Stock options granted to purchase common stock, issued">79,263</span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zveU02Pr37P1" title="Stock based compensation">38,885</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zFOxkAh9lFZb" title="Stock based compensation">100,249</span> for the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zT87nCDWBNga" title="Fair value of stock options">10,000</span> shares (a total
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zyV2Kn7lO3Ab" title="Stock price per share">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zMyTKttTPNLk" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z1ZT4rosmLV6" title="Stock options are exercisable price per share">7.40</span> per share
(the closing market price on the grant date), <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_ze3hN3FJIAIa" title="Stock options description">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zqoCyyA5BVdf" title="Fair value of stock options">316,700</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zJSBCsF0X77g" title="Stock price per share">6.334</span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zlj3Xxmr9JBg" title="Stock based compensation">94,881</span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zzRKnFgxwki1" title="Stock based compensation">63,777</span> for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHGlgs0tdYpg" title="Number of fully vested option exercisable">20,000</span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zEYrIejNSNkd" title="Number of fully vested option exercisable">80,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zrxWaiOtdlql">five years</span> at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zAjjbzcJZXua" title="Share price">20.00</span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziwz06Zd9OBk" title="Stock options description">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service</span>. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zY90e42iPLQ1" title="Stock options granted to purchase common stock, issued">80,000</span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zfixxaSlXtxh" title="Fair value of stock options">262,560</span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ztCRCbbOj449" title="Stock price per share">3.282</span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkX8KFyLh88d" title="Stock based compensation">61,448</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNNpYsC1cUn1" title="Stock based compensation">75,520</span> for the
years ended December 31, 2023 and 2022, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPCixXgqzqgd" title="Number of fully vested option exercisable">10,000</span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zapUYn9LEfy">five years</span> at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPIZBCH59N6i" title="Stock options are exercisable price per share">5.025</span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_z62IKo2uhp8g" title="Fair value of stock options">43,264</span> ($<span id="xdx_90D_eus-gaap--SharePrice_iI_pp5d_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zB1ZObFeO17h" title="Stock price per share">4.326</span> per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdFjx1cOYqJ5" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zSyp6k8q6rGj" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zXdgyO3P6Mn6" title="Number of fully vested option exercisable">five years</span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zhtZcQdeW8kf" title="Exercise price">5.88</span> per share
(the closing market price on the grant date), <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zS5gcyomY9Na" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</span>. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zNAksO0Qgov9" title="Fair value of stock options">192,593</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLIQVGjp8eEe" title="Stock price per share">4.8131</span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ze8cao2JlpQh" title="Stock based compensation">48,464</span> for the
year ended December 31, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zQbD61Hl1kIl" title="Options, grants in period, gross">250,000</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJBiGG46a7X6" title="Option exercisable period">five years</span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjFBi9mhE2g5" title="Stock options are exercisable price per share">1.95</span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2o891JpZz8b" title="Options vesting term">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service</span>. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEyzR4sZfwsd" title="Fair value of stock options">403,066</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRiNuWNDQKkf" title="Stock price per share">1.612</span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz3wVVOMbdZ4" title="Stock based compensation">35,178</span> for the year ended December 31, 2023 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each such person ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each such person contractually expired one year from the respective dates that each of their services to the Company terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zSC9zzCCuwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvAPnVh1JgPg" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zS7sHAf62vkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zoKqAlRJe31c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwk17zItPW2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">773,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,502,776</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zcxZR7OKlTtj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zte0Q5Ns2CBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">773,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,546,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zTVL8TCwBUe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrM4TFyYWthe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2023 and 2022
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zUwm2Z22xu26" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Stock options outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zSN23ldJK207" style="width: 12%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">266,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zAkNGGuWygNb" style="width: 12%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">37.380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zXucU1LYjXK8" style="text-align: right" title="Number of shares, granted">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zAo5fnLSGNw3" style="text-align: right" title="Weighted average exercise price, granted">13.370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zUjONXbGyT25" style="text-align: right" title="Number of shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z8tkTxPvqqXg" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231_z2eCYcoZ8kR5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired">(42,188</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEazcrjFExjg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">19.160</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zPKfSZCNAHK7" style="text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zelJDPkQeHm6" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zTtB0hSpy6Wb" style="text-align: right" title="Number of shares, granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zAkrIHec4xT" style="text-align: right" title="Weighted average exercise price, granted">2.492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_z7r96UwRPvRg" style="text-align: right" title="Number of shares, exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zjpvkTFgrMT8" style="text-align: right" title="Weighted average exercise price, exercised">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvQCSdvaCO6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, expired">(126,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zdBuzk8Ddun5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">28.687</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zVjyZSjSfXSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">552,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_za5UIoLoxQH" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">15.330</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu3K38b1ry9" title="Weighted average remaining contractual life (in years), stock options outstanding">3.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zAsMNZABJiFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">281,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z98r6c3kYTql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">32.834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z3TsDk2fFqhd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zSNg0pg1CEF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">28.387</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_ziqL2vvQSYke" title="Weighted average remaining contractual life (in years), stock options exercisable">2.89</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zSsE4Xm8WJs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20231231_zlwVt4pmSYb6" title="Deferred compensation expense for unvested stock options">670,000</span> at December 31, 2023, which
will be recognized subsequent to December 31, 2023 over a weighted-average period of approximately <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20231231_zGiRoN4QN2Yf" title="Weighted-average recognition period">26</span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zaVbuJjQ1Awa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding common stock options,, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zaTHki3lO4if" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                                                                                                                                                                                                                                                          (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zsOVqVl1W8yg" style="width: 30%; text-align: right" title="Exercise Prices">1.950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrTFMhenCA0k" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOFr8bFgKj7j" style="width: 30%; text-align: right" title="Options Exercisable (Shares)">20,833</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmG74Svv61Zi" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8eyyW1MGutk" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlW3WgZ1zwx" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zG3Y24X54r92" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zChzWjLkFQfd" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWbt32QTpC" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpAu8ssEk42f" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbTSCiehNDS1" style="text-align: right" title="Options Outstanding (Shares)">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqEaJnX2jzck" style="text-align: right" title="Options Exercisable (Shares)">44,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIxxkRT7nSGf" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVpaEjQjKLEh" style="text-align: right" title="Options Outstanding (Shares)">65,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWtnnhg1v1Z6" style="text-align: right" title="Options Exercisable (Shares)">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z3VQUTFWRira" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVuOOT3HEYl" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z10zP4OpP6Rg" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zX5xiBpdvXf1" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zV6r3sazVpt3" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_ziVJDDvxr6q5" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z110Sw13H9ac" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbt91km4mvHh" style="text-align: right" title="Options Outstanding (Shares)">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0GaP5FPb2t" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlQTaFGFabI6" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zvcpJKZwvx1d" style="text-align: right" title="Options Outstanding (Shares)">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zpKXtRoGOIeb" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z62SuWmemyr5" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVLH8Zt4qcC8" style="text-align: right" title="Options Outstanding (Shares)">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbEDizTmLd12" style="text-align: right" title="Options Exercisable (Shares)">16,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zyX7mW3f6Bcj" style="text-align: right" title="Exercise Prices">66.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0JIKDTbWzr9" style="text-align: right" title="Options Outstanding (Shares)">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxfNEcRsC3Ab" style="text-align: right" title="Options Exercisable (Shares)">3,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zdPPdgQja3Bi" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zR9IrHmBaSMb" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zDm5x3jpqur6" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zdRaM6sQryx4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zyyKTSlOmXy8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">8,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zeXRwZvBnlz5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">8,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zdeeRb8UEaa6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">552,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_z2qehMfT1TI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z9qBfhAIsidb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20231231_zRoppz8aQ2Ga" title="Fair market value, per share">2.35</span> per share on December 31, 2023, the intrinsic value attributed to exercisable but unexercised common
stock options was approximately $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_zVlS68weT1q6" title="Intrinsic value">8,000</span> at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20231231_zYDJzxxZsf6f" title="Outstanding stock options to acquire shares of common stock not vested">299,791</span> shares of the Company&#8217;s common stock had not vested at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724474928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zMhXDgaRhSo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_821_zAP1WRUS39i3">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as
of December 31, 2023 and 2022 are as follows:</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9mvvZNffDAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zH8ndxbWNeX9" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zDYYnNYHG7bh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zma1HyE6kpJ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_za1o89028jIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">612,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">574,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zaMh0fAWNnB5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_zPgW0YCOKjOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zEh9c2FvEaJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,601,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,135,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_zT7SZsuVpP5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,688,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,846,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_ztB060NVs70g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,688,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,846,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zirtavUmVtIc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zduRiwKJXMw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2023 and 2022, management
was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwtdaRqYtmib"><span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z8UkT5IppYZ7">No</span></span>
federal tax provision has been provided for the years ended December 31, 2023 and 2022 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2023 and 2022.</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbGdSjPx7H8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8BB_zj9diyxYUj1" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zwTuNL0UIy8b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zDvQCnh1zpLc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zgBpjzegXLel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.
    S. federal statutory tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_ze3hZVnUtkf7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income taxes, net of federal tax benefit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_zNzF3F1CR3I" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expirations
    related to stock-based compensation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_zxEdgZmUP7U3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
    to deferred tax asset</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zUn3s9LEl5f5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_zdA9231C6Fv9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p id="xdx_8A3_zAKTiw3Imql7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20231231_z7msXVWLyOx9" title="Operating loss carryforwards, federal">28,111,000</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231_zvRJKckRK7x" title="Operating loss carryforwards, state">32,617,000</span>, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zntpcYonTU02" title="Net operating loss carryovers">19,141,000</span> that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. <span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zovH0B1EvJKf" title="Prior net operating loss conversion utilization">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</span> The state net
operating loss carryovers also include approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zR6Xjd05F2Zb" title="Operating loss carryforwards, state">13,476,000</span> that was incurred in the State of California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change&#8221;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company&#8217;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721755728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcvXxpRiKx1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_829_zjnGezmfzZU6">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2023 and
2022, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20231231_zSCH6kszsCT" title="Clinical trial contractual commitment">6,412,000</span>, including clinical trial agreements of $<span id="xdx_909_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_z6Lnq9l7o5yb" title="Contractual commitment">6,013,000</span>
and clinical trial monitoring agreements of $<span id="xdx_901_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zAyeISpIsMg3" title="Contractual commitment">399,000</span>, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified, suspended
or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein should be
considered as estimates only based on current clinical assumptions and conditions and are typically subject to significant modifications
and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zlVIDKd4qdB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z18PItiuPbNj" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Description
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Type
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Institution</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Start
    Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated
    End Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of Patients</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>in
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Study
                                            Objective</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Update</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>NCT
    No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Financial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Contractual</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Commitment</b></span></p></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zKqLsxKkxJm6" title="Clinical trial, description">LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">City
    of Hope and Sarah Cannon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zFj003DVZP38" title="Estimated Start Date">March
    2021</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zzC4w2NuVqAe" title="Estimated End Date">March
    2026</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zWpRthhGing2" title="Number of Patients in Trial">14</span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zzr4OX51iE1b" title="Number of Patients in Trial">36</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Three
    patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT04560972</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 9pt">$</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
    <p id="xdx_98B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztAtIZWzhOsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">2,433,000</span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zxNJdmnGYtzf" title="Clinical trial, description">LB-100
    combined with doxorubicin in sarcoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zrF7qrWYgnSg" title="Estimated Start Date">June
    2023</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zevffWxihBh" title="Estimated End Date">June
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zBmFB9LvJPgh" title="Number of Patients in Trial">9</span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zKHo6fCyXfc3" title="Number of Patients in Trial">18</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    MTD and RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">One
    patient entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p id="xdx_98E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z0OO1AfG3CK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">3,580,000</span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zw5vzSmBCCfh" title="Clinical trial, description">LB-100
    in high grade gliomas</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    0 pharmacology study</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">National
    Cancer Institute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zTiIV1t65IAb" title="Estimated Start Date">January
    2019</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zsr0VwnkuAh8" title="Estimated End Date">August
    2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zj8ceD9m0Vk9" title="Number of Patients in Trial">7</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Closed.
    No or minimal penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT03027388</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaWwQbf2nJf5" title="Clinical trial, description">Doxorubicin
    with or without LB-100 in sarcoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Randomized
    Phase 2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zoqYwLNBG0p6" title="Estimated Start Date">July
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zuZb7uGuUWu" title="Estimated End Date">June
    2026</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaYRwN5QFTV4" title="Number of Patients in Trial">150</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    efficacy: PFS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(1)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zcKzEyBN7Iu6" title="Clinical trial, description">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b/2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">MD
    Anderson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zvabHACetB59" title="Estimated Start Date">March
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_z5l6cWHN5KYg" title="Estimated End Date">December
    2025</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zzgPI8fkWvA6" title="Number of Patients in Trial">21</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the survival of patients with ovarian clear cell carcinoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">No
    patients entered at December 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT06065462</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td>
    <td id="xdx_989_eus-gaap--OtherCommitment_iI_c20231231_zedGZLrQIZ6k" style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">6,013,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt; width: 0.25in"><span id="xdx_F01_zRzkG6rSBs18" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F14_zaauqrobGOth" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F09_ziSh4RFXLjA1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F1B_zpeuWm5pbeYc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no remaining financial contractual commitment associated
with this clinical trial.</span></td></tr>
</table>


<p id="xdx_8AA_zGAIIpKMHZY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated
ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase
2 dose (&#8220;RP2D&#8221;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the
safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration of overall
response, progression-free survival and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#8220;SCRI&#8221;), Nashville, Tennessee, joined the City of Hope&#8217;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability,
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8ZCbmkiikU1" title="Research and development expense">69,001</span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zB3P6C7M7bFa" title="Research and development expense">0</span>, respectively, pursuant to this agreement, which
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December 31, 2023,
total costs of $<span id="xdx_909_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2JT43J4bAl6" title="Total costs">447,512</span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zXq46MUq8lE3" title="Aggregate commitments expected">2,433,000</span>
as of December 31, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$<span id="xdx_908_ecustom--EstimatedAdditionalCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zwFE9eDkOOWc" title="Estimated additional commitment amount">800,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_906_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zzNddjiGs9K5" title="Inventory costs">1,144,000</span>. Although the production of new inventory
has been completed, nominal trailing costs subsequent to December 31, 2023 may be incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b portion of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zn7ggzuvtuIc" title="Research and development costs">268,829</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zTtllrZQdws2" title="Research and development costs">260,770</span>, respectively, pursuant to this
agreement. Such costs, when incurred, are included in research and development costs in the Company&#8217;s consolidated statements of
operations. Through December 31, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_903_ecustom--AmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTRDt66xc1pc" title="Amount related to milestone payment">684,652</span> for work done under this agreement through
the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zWsYmLT6OVDc" title="Aggregate commitments expected">3,580,000</span>
as of December 31, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The clinical trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)
and is being conducted at The University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly
and financial support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical
trial. The Company currently expects that this clinical trial will be completed by July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years, unless terminated earlier by the
Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a
Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound
LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally
well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent
in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. In this clinical trial, single agent LB-100 was used on a new schedule of
days 1, 3, and 5 every 3 weeks. Although MTD was not achieved, there was no dose-limiting toxicity on this schedule at doses that were
greater than the MTD in the Phase 1 clinical trial of LB-100 on the Monday, Tuesday, Wednesday schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z3qMxlqgaRu7" title="Research and development process costs">16,165</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zQyu1JmrpCcj" title="Research and development process costs">26,397</span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of December
31, 2023, total costs of $<span id="xdx_900_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zAv0ZLz4T8y" title="Research and development costs">147,239</span> have been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#8220;Patent and License
Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the years ended December 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_z0StsgANnSu7" title="Research and development costs">20,884</span> and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zwpKupI9CFQi" title="Research and development costs">35,403</span>,
respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zGLGsIOxn9yk" title="Research and development costs">148,172</span> have been incurred pursuant to this work
order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Company&#8217;s Clinical Trial Research Agreement with Moffitt during the year ended December 31, 2023
(see &#8220;Clinical Trial Agreements &#8211; Moffitt&#8221; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to December 31, 2023
are expected to be incurred relating to the closure of the Moffitt study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zL62WkZJJRSh" title="Research and development costs">335,000</span>. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zRvc9O8r5DGc" title="Advance amount related to milestone payment">20,240</span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgM4wdKq05Sb" title="Advance amount related to milestone payment">33,815</span>, respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGJeMthhviWi" title="Cost incurred total">78,681</span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zsGZtE0lPTPg" title="Aggregate commitments expected">258,000</span> as of December 31, 2023, which is expected to be incurred through March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas. The study
is expected to be completed by June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zMlopiGEA6u4" title="Work cost">153,000</span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zoAGXguiJZY6" title="Percentage of payment through services">72</span>% to Theradex for services and approximately <span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9j1B0Dd2ZQ9" title="Percentage of payment through software">28</span>% for payments for pass-through software costs. During the year ended December 31, 2023,
the Company incurred costs of $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z0f0ehl2MJek" title="Research and development costs">14,862</span>, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_907_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z4ksR7aax2S6" title="Total costs">14,862</span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAGJvhyQENVa" title="Aggregate commitments expected">141,000</span> as of December 31, 2023, which is expected to be incurred through June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zJ9tGSljC0o4" title="Non refundable license issue fee">25,000</span> after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $<span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zFLmbiY9Dl5d" title="Maintenance fee">25,000</span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $<span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zVxLqJqnxnq8" title="Payment on non refundable milestone">1,897,000</span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $<span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z6QMIb0GnsVe" title="Operating costs and expenses">9,109</span>, representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement. During the year ended December 31, 2022, the Company recorded charges to operations
of $<span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zfNZKLc4L416" title="Operating costs and expenses">25,000</span>, in connection with its obligations under the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zIA4dJmidx6d" title="Salary and compensation">640,000</span>, payable monthly (see Note 5). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210501__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zNavkSvYyYPl" title="Annual compensation">775,000</span>, effective May 1,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zmRyT0OgmGBk" title="Compensation">200,000</span>. In addition,
Mr. Forman is being provided an office allowance of approximately $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zIrrB8gzMuUc" title="Payment of office rent">1,500</span> per month through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $<span id="xdx_907_eus-gaap--OfficersCompensation_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_ziydiDSQpjg1" title="Compensation">150,000</span>. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#8217;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined at the sole discretion of the Board of Directors. Mr. van der Baan was appointed as Chairman of
the Board of Directors upon the death of Dr. Kovach, who died on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate annual cash compensation for all officers was $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember_z1vz99lGrBjb" title="Compensation">700,000</span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zkGkC8GEqLfe" title="Consulting and advisory fee">4,000</span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOmZNk05bq1b" title="Consulting and advisory fee">16,000</span> and $<span id="xdx_90D_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zwXOHPNYb3Mg" title="Consulting and advisory fee">16,000</span> for the years
ended December 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zjnvRLQ3UHx8" title="Consulting and advisory fee">10,000</span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 6). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_903_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDXqRHZ6t8ml" title="Reimbursed expense">120,000</span> and $<span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zn0ukr3Zmww1" title="Reimbursed expense">120,000</span> for the years ended December 31, 2023 and 2022,
respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zBkw1k2RH0G3" title="Aggregate commitments expected">391,000</span> Euros and
provide a sufficient supply of LB-100 to conduct the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
<span id="xdx_907_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQOlTbUv7rP7" title="Aggregate commitments expected">500,000</span> Euros (approximately $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQIceSAZqBY7" title="Aggregate commitments expected">526,000</span> at October 3, 2023) to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company incurred charges in the amount of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZpc1uW8wiLi" title="Advance amount related to milestone payment">226,150</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zfnxcAj7qss5" title="Advance amount related to milestone payment">204,158</span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2023, total costs of $<span id="xdx_901_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zDARE2RFxlKe" title="Research and development costs">485,556</span> have been incurred pursuant to this agreement, as amended. The Company&#8217;s aggregate
commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zkru21Oz2dy3" title="Aggregate commitments expected">595,000</span> as of December
31, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros,
final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zxcsDkx3E23b" title="Contract price">273,980</span> for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$<span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zyMtECBpFl25" title="Contract price">326,274</span> for services to be rendered through April 30, 2024. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z18kwnAj6wtf" title="Advance amount related to milestone payment">32,307</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgJ9YYCrzQ2f" title="Research and developments costs">27,702</span>, respectively, pursuant to this work order. As of December 31, 2023, total costs of $<span id="xdx_904_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zqVTNug3zUFi" title="Total costs incurred">248,298</span> have been incurred
pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zNNfDOQkcit8" title="Aggregate commitments expected">78,000</span> as
of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates has had a material effect on its
operations to date, other than its impact on the general economy. However, there is a risk that the Company&#8217;s operating costs could
become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital may all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166723532272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zNwA8ZEEixYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82F_zxvDojBQeNAh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than those matters described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures
in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with the National Institute
of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;), each an institute or
center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has licensed exclusively
NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) subject invention
co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination
with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for
the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis,
until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed
territory, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6N1FIZy3DU8" title="Non refundable license issue royalty">50,000</span> and a first minimum annual royalty
of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueWithinSixtyDaysMember_z1uCnYQRHCuf" title="Non refundable license issue royalty">30,000</span>, within sixty days from the effective date of the Agreement. The first minimum annual royalty may be prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90B_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zmOGlURMzAKc" title="Minimum annual royalty payable">30,000</span> is due each January
1 and may be credited against any earned royalties due for sales made in that year.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively,
each with a different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 31, 2024
benchmark is defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The total of all such benchmark payments is $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzpnbkgb6tm7" title="Payment for royalties">1,225,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_906_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zS8a1cDyQdwl" title="Royalty percentage">5</span>% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725823536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zduPhxVq9TPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zoc7VDIezOXf">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles
(&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte
Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zXbngsCHDJR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zIj57lMpFsei">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_z9Jlo11H6Yrh" title="Number of operating segments"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20230101__20231231_zZ0IEoAjhbfj" title="Number of reportable segments">one</span></span> segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#8217;s Chief Operating Decision Maker, which is the Company&#8217;s
President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zEPrXuicGeV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z0nO8pvLp7pf">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaA2Y0Cmm8k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zSQq5L65qaTl">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231_ziGNzxUsSxP" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20231231_z3Dq2PrmJxXa" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0aYpeETTS95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBhP75WcwqQ1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PrepaidInsurancePolicyTextBlock', window );">Prepaid Insurance</a></td>
<td class="text"><p id="xdx_849_ecustom--PrepaidInsurancePolicyTextBlock_z8TAnVgnsPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z4CV9JesYIM7">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkjQNNqrz7Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zobfBdlcAuBi">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zJZYksx9bD8" title="Legal fees">978,244</span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20221231_zmHFSR6xk1Ge" title="Patent and licensing legal and filing fees">1,268,308</span> for the years ended December 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI0DaF9ATAd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zmwYy0kjFPU4">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zDhOXPncSCxd" title="Concentration of risk, percentage">23.3</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zJMnYwHwJItj" title="Concentration of risk, percentage">25.6</span>% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxUPoerTkMr6" title="Concentration of risk, percentage">18.4</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zphZp5lrDwob" title="Concentration of risk, percentage">30.3</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNTceUgFQ3yj" title="Concentration of risk, percentage">29.9</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcHlgkCXEct" title="Concentration of risk, percentage">25.2</span>%
and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpi6KeYmITMe" title="Concentration of risk, percentage">13.7</span>%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyYKGW0GeSmd" title="Concentration of risk, percentage">21.0%</span>, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6jJLH7sRfMg" title="Concentration of risk, percentage">19.3%</span>, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUipF1eskioc" title="Concentration of risk, percentage">15.1%</span> and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0jsSDHU2ETh" title="Concentration risk, percentage">12.1%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z1r7XuiboyKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaVrDHWpRtp6">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2023 and
2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2023 or 2022.
Subsequent to December 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaRwnM7sC344" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyUGyP3lGbZj">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_z9ZNXjnSFTXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6kX7VOtHIY5">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zTmObsInfUOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zLJnKOfudIFl">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zLagUHXv6Kr8" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">552,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A9_zsquuEIHR6Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z6PnzSAKnH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zJsbAmWqz2rj">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations. During the years ended December 31,
2023 and 2022, the Company incurred various costs and expenses denominated in Euros, which were converted into United States dollars
at the average rate of <span id="xdx_909_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20231231_zBMa2lYyC0Yj" title="Foreign currency average rate">1.0824</span> and <span id="xdx_907_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20221231_zlmwdoeIgGq3" title="Foreign currency average rate">1.0538</span>, respectively. As of December 31, 2023 and 2022, the Company did not hold any currencies other
than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zAc4lmM3qhO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zhHBMFQBT6Gc">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZy8jlZGlQq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zIEp5H0oXVi4">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation
(Topic 718) Presentation of Financial Statements (&#8220;ASU 2023-03&#8221;). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 &#8212; General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company&#8217;s consolidated financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PrepaidInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Insurance [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PrepaidInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166820403152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zLagUHXv6Kr8" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,031</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">552,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">652,427</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724849648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock', window );">Schedule of Research and Development Costs</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfResearchAndDevelopmentCostsTableTextBlock_zgQC8oWLcvC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials
involving the Company&#8217;s lead clinical compound LB-100, are summarized below based on the respective geographical regions where
such costs have been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zCzvrQhSvuq1" style="display: none">Schedule
of Research and Development Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoukKhcaDt6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zV8Mp80Audbh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zKFQhmg7EOs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">359,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,618</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zUiHa81jyMi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">626,366</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--FR_zaBG9zPoIS1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">France</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,532</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zXjM0heYEhgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,595</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z3TBAtIvBzZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zQlulZwPy08e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,349,269</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPqfj8riFPW6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">898,100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,349,269</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Research And Development Costs [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166722695296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsUZvjzFjOoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2023 and 2022 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zDqLPxAqnOT3" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Warrants outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ziuZ25V42jz9" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">311,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpfop4SYsGh3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">57.720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMPcOrdOu7A6" style="text-align: right" title="Number of Shares, Issued">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxmoqpNrfPr9" style="text-align: right" title="Weighted Average Exercise Price, Issued">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0PJTORZgZc" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEEzhRKHWGxg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvOcIHvLYBdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired">(150,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHBShZqPwLWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">60.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztwbjoJ0GYf1" style="text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTlLmO3UyNg7" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlsxvt9qJ35l" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaQOndTeeM9d" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjs4Vjx78Zae" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS2JDRMic5j" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZpegNnuXEk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVn24AL1OWo7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJcyq2t1laBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zk3z2IZQKWDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWngRgbiF2Z8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">3.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcBMNbidNv04" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">190,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBHWJsEgkl0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">50.161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztRuwimAmhk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZcVMAUOaFl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2kd7kcYSxPe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">3.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zHCdrGKKPNI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z6TB8k2oC2xi" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3qWYGq2AwX8" title="Exercise Prices">6.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaYnQqKahfc8" style="width: 48%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z88RxNZdljD4" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8BD11CMmA2k" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQVqTnzEtcnk" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpKAaCkzXvm8" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqOgjc8Y5Pve" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zT9bmTbBiKgf" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAMfzu0vpsob" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuvCd21XPysc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231_zIuK0iOOHQwl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724750544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Related Party Costs</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zpSmtHiyZMPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2023 and 2022, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zPxp7rYaMom1" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJYpwB9sh2b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zilBvtTqTHJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OfficersCompensation_zxY587gtQA2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,044,839</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zXWkfEGt3Lhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">773,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,502,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zNrpgk7VYNFb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,547,615</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_zWyT1z4sMuM9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,547,615</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724701856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Award Estimated Assumption</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zts1CO8ZeUT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhweWedzOTod" style="display: none">Schedule of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231_z7a5eJuqSdy8" title="Risk-free interest rate">4.843</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zZEWVvi5R8oj" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zTUsUmQ6wPZe" title="Expected volatility">138.05</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zJ2Ao391EqS" title="Expected life">4.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20220101__20221231_zFP0jPpHHLt8" title="Risk-free interest rate, minimum">3.03</span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20220101__20221231_zDTD84iiN9bk" title="Risk-free interest rate, maximum">3.63</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zF5WOiwXBe4c" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20220101__20221231_zK7PmrqPVWEk" title="Expected volatility, minimum">128.03</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20220101__20221231_zDs6gylt4lxg" title="Expected volatility, maximum">153.17</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zlDrN4yCin21" title="Expected life">3.5</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zibY8JCgQwy3" title="Expected life">5</span> years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock-based Compensation Costs</a></td>
<td class="text"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zSC9zzCCuwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zvAPnVh1JgPg" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zS7sHAf62vkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zoKqAlRJe31c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwk17zItPW2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">773,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,502,776</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zcxZR7OKlTtj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zte0Q5Ns2CBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">773,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,546,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrM4TFyYWthe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2023 and 2022
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zUwm2Z22xu26" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Stock options outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zSN23ldJK207" style="width: 12%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">266,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zAkNGGuWygNb" style="width: 12%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">37.380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zXucU1LYjXK8" style="text-align: right" title="Number of shares, granted">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zAo5fnLSGNw3" style="text-align: right" title="Weighted average exercise price, granted">13.370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zUjONXbGyT25" style="text-align: right" title="Number of shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z8tkTxPvqqXg" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231_z2eCYcoZ8kR5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired">(42,188</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEazcrjFExjg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">19.160</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zPKfSZCNAHK7" style="text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zelJDPkQeHm6" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zTtB0hSpy6Wb" style="text-align: right" title="Number of shares, granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zAkrIHec4xT" style="text-align: right" title="Weighted average exercise price, granted">2.492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_z7r96UwRPvRg" style="text-align: right" title="Number of shares, exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zjpvkTFgrMT8" style="text-align: right" title="Weighted average exercise price, exercised">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvQCSdvaCO6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, expired">(126,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zdBuzk8Ddun5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">28.687</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zVjyZSjSfXSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">552,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_za5UIoLoxQH" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">15.330</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu3K38b1ry9" title="Weighted average remaining contractual life (in years), stock options outstanding">3.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zAsMNZABJiFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">281,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z98r6c3kYTql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">32.834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z3TsDk2fFqhd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zSNg0pg1CEF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">28.387</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_ziqL2vvQSYke" title="Weighted average remaining contractual life (in years), stock options exercisable">2.89</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zaVbuJjQ1Awa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the outstanding common stock options,, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zaTHki3lO4if" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                 Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
<br/>
Outstanding (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable
                                                                                                                                                                                                                                                                          (Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zsOVqVl1W8yg" style="width: 30%; text-align: right" title="Exercise Prices">1.950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrTFMhenCA0k" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOFr8bFgKj7j" style="width: 30%; text-align: right" title="Options Exercisable (Shares)">20,833</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmG74Svv61Zi" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8eyyW1MGutk" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlW3WgZ1zwx" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zG3Y24X54r92" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zChzWjLkFQfd" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWbt32QTpC" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpAu8ssEk42f" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbTSCiehNDS1" style="text-align: right" title="Options Outstanding (Shares)">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqEaJnX2jzck" style="text-align: right" title="Options Exercisable (Shares)">44,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIxxkRT7nSGf" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVpaEjQjKLEh" style="text-align: right" title="Options Outstanding (Shares)">65,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWtnnhg1v1Z6" style="text-align: right" title="Options Exercisable (Shares)">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z3VQUTFWRira" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVuOOT3HEYl" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z10zP4OpP6Rg" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zX5xiBpdvXf1" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zV6r3sazVpt3" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_ziVJDDvxr6q5" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z110Sw13H9ac" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbt91km4mvHh" style="text-align: right" title="Options Outstanding (Shares)">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0GaP5FPb2t" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlQTaFGFabI6" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zvcpJKZwvx1d" style="text-align: right" title="Options Outstanding (Shares)">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zpKXtRoGOIeb" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z62SuWmemyr5" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVLH8Zt4qcC8" style="text-align: right" title="Options Outstanding (Shares)">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbEDizTmLd12" style="text-align: right" title="Options Exercisable (Shares)">16,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zyX7mW3f6Bcj" style="text-align: right" title="Exercise Prices">66.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0JIKDTbWzr9" style="text-align: right" title="Options Outstanding (Shares)">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxfNEcRsC3Ab" style="text-align: right" title="Options Exercisable (Shares)">3,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zdPPdgQja3Bi" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zR9IrHmBaSMb" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zDm5x3jpqur6" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zdRaM6sQryx4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zyyKTSlOmXy8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">8,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zeXRwZvBnlz5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">8,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zdeeRb8UEaa6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">552,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_z2qehMfT1TI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721801424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9mvvZNffDAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zH8ndxbWNeX9" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zDYYnNYHG7bh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zma1HyE6kpJ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_za1o89028jIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">612,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">574,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zaMh0fAWNnB5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_zPgW0YCOKjOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zEh9c2FvEaJ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,601,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,135,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_zT7SZsuVpP5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,688,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,846,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_ztB060NVs70g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,688,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,846,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zirtavUmVtIc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbGdSjPx7H8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span id="xdx_8BB_zj9diyxYUj1" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zwTuNL0UIy8b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20220101__20221231_zDvQCnh1zpLc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zgBpjzegXLel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.
    S. federal statutory tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_ze3hZVnUtkf7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income taxes, net of federal tax benefit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_zNzF3F1CR3I" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expirations
    related to stock-based compensation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_zxEdgZmUP7U3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
    to deferred tax asset</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zUn3s9LEl5f5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_zdA9231C6Fv9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166721877824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Clinical Trials</a></td>
<td class="text"><p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zlVIDKd4qdB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_z18PItiuPbNj" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Description
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Type
                                            of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Institution</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Start
    Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Estimated
    End Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Number
    of Patients</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>in
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Study
                                            Objective</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Clinical
    Update</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>NCT
    No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Financial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Contractual</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Commitment</b></span></p></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zKqLsxKkxJm6" title="Clinical trial, description">LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">City
    of Hope and Sarah Cannon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zFj003DVZP38" title="Estimated Start Date">March
    2021</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zzC4w2NuVqAe" title="Estimated End Date">March
    2026</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zWpRthhGing2" title="Number of Patients in Trial">14</span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zzr4OX51iE1b" title="Number of Patients in Trial">36</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Three
    patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT04560972</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 9pt">$</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
    <p id="xdx_98B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztAtIZWzhOsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">2,433,000</span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zxNJdmnGYtzf" title="Clinical trial, description">LB-100
    combined with doxorubicin in sarcoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zrF7qrWYgnSg" title="Estimated Start Date">June
    2023</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zevffWxihBh" title="Estimated End Date">June
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zBmFB9LvJPgh" title="Number of Patients in Trial">9</span>
    to <span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zKHo6fCyXfc3" title="Number of Patients in Trial">18</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    MTD and RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">One
    patient entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p id="xdx_98E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z0OO1AfG3CK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">3,580,000</span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zw5vzSmBCCfh" title="Clinical trial, description">LB-100
    in high grade gliomas</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    0 pharmacology study</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">National
    Cancer Institute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zTiIV1t65IAb" title="Estimated Start Date">January
    2019</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zsr0VwnkuAh8" title="Estimated End Date">August
    2022</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zj8ceD9m0Vk9" title="Number of Patients in Trial">7</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Closed.
    No or minimal penetration of LB-100 into high grade gliomas after IV injection</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT03027388</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaWwQbf2nJf5" title="Clinical trial, description">Doxorubicin
    with or without LB-100 in sarcoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Randomized
    Phase 2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zoqYwLNBG0p6" title="Estimated Start Date">July
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zuZb7uGuUWu" title="Estimated End Date">June
    2026</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaYRwN5QFTV4" title="Number of Patients in Trial">150</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    efficacy: PFS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(1)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zcKzEyBN7Iu6" title="Clinical trial, description">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Phase
    1b/2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">MD
    Anderson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zvabHACetB59" title="Estimated Start Date">March
    2024</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_z5l6cWHN5KYg" title="Estimated End Date">December
    2025</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zzgPI8fkWvA6" title="Number of Patients in Trial">21</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Determine
    the survival of patients with ovarian clear cell carcinoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">No
    patients entered at December 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">NCT06065462</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 9pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td>
    <td id="xdx_989_eus-gaap--OtherCommitment_iI_c20231231_zedGZLrQIZ6k" style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Remaining financial contractual commitment"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">6,013,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt; width: 0.25in"><span id="xdx_F01_zRzkG6rSBs18" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F14_zaauqrobGOth" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F09_ziSh4RFXLjA1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
  <td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"><span id="xdx_F1B_zpeuWm5pbeYc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no remaining financial contractual commitment associated
with this clinical trial.</span></td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725689872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,087,029<span></span>
</td>
<td class="nump">$ 6,312,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,293,265<span></span>
</td>
<td class="nump">4,611,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,203,488<span></span>
</td>
<td class="nump">5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725406496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,433,365<span></span>
</td>
<td class="nump">652,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">190,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">552,083<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725108736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashSIPCInsuredAmount', window );">Cash SIPC insurance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Patent and licensing legal and filing fees</a></td>
<td class="nump">$ 978,244<span></span>
</td>
<td class="nump">$ 1,268,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency average rate</a></td>
<td class="nump">1.0824<span></span>
</td>
<td class="nump">1.0538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | General and Administrative Expense [Member] | Legal Firms and Other Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.30%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | General and Administrative Expense [Member] | Directors and Corporate Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">30.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Research and Development Expense [Member] | Vendor and Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.90%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Research and Development Expense [Member] | Vendor and Consultant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.20%<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Research and Development Expense [Member] | Vendor and Consultant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Research and Development Expense [Member] | Vendor and Consultant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash SIPC insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_LegalFirmsAndOtherVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_LegalFirmsAndOtherVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_DirectorsAndCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_DirectorsAndCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166820410096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 898,100<span></span>
</td>
<td class="nump">$ 1,349,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">359,589<span></span>
</td>
<td class="nump">350,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">295,163<span></span>
</td>
<td class="nump">626,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">FRANCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">17,198<span></span>
</td>
<td class="nump">76,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 226,150<span></span>
</td>
<td class="nump">$ 204,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725247920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">190,031<span></span>
</td>
<td class="nump">311,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Beginning</a></td>
<td class="nump">$ 50.161<span></span>
</td>
<td class="nump">$ 57.720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Issued</a></td>
<td class="nump">618,334<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">$ 6.034<span></span>
</td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 60.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">190,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 50.161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Outstanding</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants exercisable</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">190,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable', window );">Weighted Average Exercise Price, Warrants exercisable</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 50.161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Exercisable</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725416384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">583,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 37.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">11,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 57.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">149,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166719990096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="nump">$ 5,141,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember', window );">Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of warrants</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,141,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentTerms', window );">Preferred stock, dividend payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725959280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Related Party Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">$ 773,203<span></span>
</td>
<td class="nump">$ 1,546,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Related party costs</a></td>
<td class="nump">1,718,180<span></span>
</td>
<td class="nump">2,547,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Cash-based</a></td>
<td class="nump">944,977<span></span>
</td>
<td class="nump">1,044,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">773,203<span></span>
</td>
<td class="nump">1,502,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Related party costs</a></td>
<td class="nump">$ 1,718,180<span></span>
</td>
<td class="nump">$ 2,547,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166714195088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrReneBernardsMember', window );">Dr Rene Bernards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ManagementFeePayableQuarterly', window );">Cash board fee payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonOfficerDirectorsMember', window );">Non-officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,479<span></span>
</td>
<td class="nump">$ 266,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Dr Rene Bernards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Cash board compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">133,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Appointment Grants of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember', window );">Chairman of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember', window );">Chairman of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember', window );">Member of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember', window );">Member of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,860<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,571<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">178,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Stock based compensation</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ManagementFeePayableQuarterly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee payable quarterly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ManagementFeePayableQuarterly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee payable for management of fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrReneBernardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrReneBernardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_AnnualGrantOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_AnnualGrantOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrKovachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrKovachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166820386464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.843%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">138.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.17%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724109520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-based Compensation Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 773,203<span></span>
</td>
<td class="nump">$ 1,546,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">773,203<span></span>
</td>
<td class="nump">1,502,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166724993792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity Including Options Form of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the beginning</a></td>
<td class="nump">389,479<span></span>
</td>
<td class="nump">266,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the beginning</a></td>
<td class="nump">$ 29.183<span></span>
</td>
<td class="nump">$ 37.380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.492<span></span>
</td>
<td class="nump">$ 13.370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, expired</a></td>
<td class="num">(126,146)<span></span>
</td>
<td class="num">(42,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 28.687<span></span>
</td>
<td class="nump">$ 19.160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end</a></td>
<td class="nump">552,083<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the end</a></td>
<td class="nump">$ 15.330<span></span>
</td>
<td class="nump">$ 29.183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), stock options outstanding</a></td>
<td class="text">3 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, stock options exercisable</a></td>
<td class="nump">252,292<span></span>
</td>
<td class="nump">281,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable</a></td>
<td class="nump">$ 28.387<span></span>
</td>
<td class="nump">$ 32.834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">2 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166723289456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">552,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">252,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 7.400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">44,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 28.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 30.300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 32.100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 60.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 66.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 71.400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember', window );">Exercise PriceThirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 120.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166707480144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 27, 2023</div></th>
<th class="th"><div>Nov. 26, 2023</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Oct. 06, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,083<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,292<span></span>
</td>
<td class="nump">281,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred compensation expense for unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding stock options to acquire shares of common stock not vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember', window );">Five Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,413<span></span>
</td>
<td class="nump">$ 638,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,885<span></span>
</td>
<td class="nump">100,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember', window );">Five Non-Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,881<span></span>
</td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember', window );">Four Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,448<span></span>
</td>
<td class="nump">75,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember', window );">Four Non-officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501<span></span>
</td>
<td class="nump">100,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember', window );">Dr.James S. Miser [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,544<span></span>
</td>
<td class="nump">143,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,501<span></span>
</td>
<td class="nump">100,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember', window );">Mr Schwartberg [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 753,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember', window );">Ms.Regina Brown [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 658,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,388<span></span>
</td>
<td class="nump">$ 154,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember', window );">Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="nump">$ 403,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="nump">$ 1.612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember', window );">Mr Van der Baan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting term</a></td>
<td class="text">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">336,667<span></span>
</td>
<td class="nump">413,333<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_FairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_FairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrSchwartbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrVanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725402320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">$ 612,000<span></span>
</td>
<td class="nump">$ 574,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">844,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,631,000<span></span>
</td>
<td class="nump">2,137,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">8,601,000<span></span>
</td>
<td class="nump">8,135,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">11,688,000<span></span>
</td>
<td class="nump">10,846,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,688,000)<span></span>
</td>
<td class="num">(10,846,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725052544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U. S. federal statutory tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Expirations related to stock-based compensation</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset', window );">Adjustment to deferred tax asset</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">17.40%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166725696864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, federal</a></td>
<td class="nump">$ 28,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="nump">$ 32,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember', window );">New York State Division of Taxation and Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Prior net operating loss conversion utilization</a></td>
<td class="text">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="nump">$ 13,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166820434944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Contractual Clinical Trials (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="nump">$ 6,013,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">March
    2021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">March
    2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="nump">$ 2,433,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember', window );">Phase 1b [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100
    combined with doxorubicin in sarcoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">June
    2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">June
    2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="nump">$ 3,580,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember', window );">Phase 1b Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember', window );">Phase 0 Pharmacology Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100
    in high grade gliomas<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">January
    2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">August
    2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember', window );">Randomized Phase 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">Doxorubicin
    with or without LB-100 in sarcoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">July
    2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">June
    2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase2Member', window );">Phase 1b/2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">March
    2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December
    2025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial</a></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">There is no remaining financial contractual commitment associated
with this clinical trial.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClinicalTrialDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClinicalTrialDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period end date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfPatientInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patient in trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfPatientInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166713548448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,100<span></span>
</td>
<td class="nump">$ 1,349,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment of office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember', window );">GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AmountRelatedToMilestonePayment', window );">Amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember', window );">NDA Consulting Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember', window );">Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EstimatedAdditionalCommitment', window );">Estimated additional commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,829<span></span>
</td>
<td class="nump">260,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPartsAndComponentsNetOfReserves', window );">Inventory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ReimbursementExpense', window );">Reimbursed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember', window );">Clinical Trial Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,165<span></span>
</td>
<td class="nump">26,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,240<span></span>
</td>
<td class="nump">33,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,884<span></span>
</td>
<td class="nump">35,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EstimatedWorkCost', window );">Work cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentinServices', window );">Percentage of payment through services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentThroughSoftware', window );">Percentage of payment through software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NonRefundableLicenseIssueFee', window );">Non refundable license issue fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualLicenseMaintenanceFee', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PaymentsOnNonrefundableMilestone', window );">Payment on non refundable milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,109<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment of office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,571<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Bastiaan Van Der Baan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,150<span></span>
</td>
<td class="nump">204,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="nump">&#8364; 391,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember', window );">MRI Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and developments costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,307<span></span>
</td>
<td class="nump">$ 27,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractPrice', window );">Contract price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConsultingAndAdvisoryCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory quarterly cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConsultingAndAdvisoryCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EstimatedAdditionalCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EstimatedAdditionalCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EstimatedWorkCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated work cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EstimatedWorkCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentThroughSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected paymen through software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentThroughSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentinServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected payment in services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentinServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NonRefundableLicenseIssueFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay non refundable license issue fee..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NonRefundableLicenseIssueFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PaymentsOnNonrefundableMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PaymentsOnNonrefundableMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPartsAndComponentsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPartsAndComponentsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140166723847888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Subsequent Event [Member] - License Agreement [Member]<br></strong></div></th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non refundable license issue royalty</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="nump">$ 1,225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyatiesPercentage', window );">Royalty percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Due Within 60 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Due Each January 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyatiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royaties percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyatiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=LIXT_DueWithinSixtyDaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=LIXT_DueWithinSixtyDaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX>L"]3(]3X1)_C]Y69U[2EO$2Q,EHG4PW$$4Q*N_['4-8B?@Y+0B@*X#Z+L
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M+QG,SP+9+'CHQ#^#@HF-BJ U+5MV@6BK5T+R?\#(I@=?(.Q[8&4^2*TH +M
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MHI+-!X#F08NEG:$?A<:)W-XN@.<@C0#^/Q-"OSZ8!=K/,--_ %!+ P04
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MGDM4G9&>^YLUDF=#O?U* V^(\P6I/DS2P23N@D@2<3 S1L6^L6W.FWZ4)/+
M7T!-1GCF$5U>-)DS[K$<H3B>P-WQ/':2J*L9G8LWS]@VRVO&M^*G%OQ+,X3T
MX8_%XM@+\03^CJ7QRS2=F&'EH!JVLTTJ5MS^&+=/EM /@R%TFV2(<42C"?0=
MC6,WCP_'K%U6PC;\CC$+7Y6_KV6M'X6.P;&;PN^E2#A/SS%0#'8/3.J*)P=9
M1\"D5?)'('8N(<EI)N&X!"([+B%4KU')S5O[89I'\9C1*::11X=SFT4PP#ZF
M\53+[;@?N\G__1.72:9J#R&8\]W!'"#,$%< E2@SUZ$3D]"-)URP</B0+-P0
MOFM>Z'O7C0+82;H][WHNB<J,IW:/XC$#DGCDT_]@>Z=/'=-C-]6W'::2XIB9
M9&V_63>JU3D+<6.?TG#DWUC067&D(WGBO=ACK#V$.(>#'^TAU[+6][(;$XA[
M3#!9RL:3J-7O\00PQ]A?+CU_D!2+9$"6H3_1]TDW+1#WM'#'<C-N(:;1%AI;
M69I*,AT!&IA(K:#'] ^G2$J70Z*U"/HQH9$_,8F1;E0@[E'A C2'8<$-=TSW
M/ARP_'@X-EH$AW[UX7:3 ?'=9^1#5>7UQ0^<#M-,)7":/TA>WP(ES[P+-=/<
M&D)WLF\2Y_CQPYOD2M;Z(>G&#>(D<CBJ&095VNIH,)Z+0T*'9V*+6!Q'4[75
MC0#$/0+ (5(4'&GV9.^C;O4?. )?P5#CXN+B>K+@\K&^M56H/@4TUW[MU_9F
M^&U]'SKX?H=O-LW];F>FN6[^Q"3T!H5RO@.3WIL(HBZ;&]SF18NJO@3="JU%
M43_N.4NY- +P_YT0^OG%+-#>HZ__ U!+ P04    " #50W-8A/B;L%H"  "X
M!0  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*V4;6_3,!#'OXH5$-HD
MMCRUW2AII#Z F,10M3)X@7CA)M?&FF,'^])NWQ[;24,WM15"O$E\]OU_OKOD
M+ME*]: + "2/)1=ZY!6(U=#W=59 2?6EK$"8DY54)45CJK6O*P4T=Z*2^U$0
M#/R2,N&EB=N;JS21-7(F8*Z(KLN2JJ<)<+D=>:&WV[ACZP+MAI\F%5W# O"^
MFBMC^1TE9R4(S:0@"E8C;QP.ISWK[QR^,=CJO36QF2RE?+#&33[R AL0<,C0
M$JAY;6 *G%N0">-7R_2Z*ZUP?[VC?W2YFUR65,-4\N\LQV+D77LDAQ6M.=[)
M[2=H\^E;7B:Y=D^R;7Q[YL:LUBC+5FSLDHGF31_;.NP)PL$10=0*HI>"WA%!
MW IBEV@3F4MK1I&FB9);HJRWH=F%JXU3FVR8L%]Q@<J<,J/#=$Z?R$:3.2CW
M1X@,R(SIC$M=*R 7Y'XQ(V>OSQ,?S656XF<M>-* HR/@,"*W4F"AR0>10_X<
MX)LHNU"C7:B3Z"1Q!MDEB<.W) JB^$! T[^71R?"B;O*Q8XW^*?*_?A*EQQ^
M'JI;@XT/8VW7#G5%,QAYIBTUJ UXZ9M7X2!X?RCG_P1[5H%>5X'>*7KZQ0R9
M&Y')$LC99ZGU.1DC*K:LT>9.4)(Y52#P4!$:<L^1[:39I!?]X/HJB-XE_F8_
MP0..@SB,^G&_<VR"]_>:H 2U=K-!DTS6 IN?K-OMQL_8==V+_8D92\T4^8-I
M9MHM56LF-.&P,LC@\JKO$=7,B<9 6;E66THTC>N6A1FMH*R#.5])B3O#7M -
MZ_0W4$L#!!0    ( -5#<UAH?+JR0P(  ) &   8    >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&ULG95=;YLP%(;_BN5)NUK+5SZF+" E[:9%6J<H[;:+:1<.
M',"JL9EM2OOO9QO"LBFA4F[ '^=]_9R#?%BV0CZJ$D"CYXIQ%>-2ZWKA>2HM
MH2+J6M3 S4XN9$6TF<K"4[4$DCE1Q;S0]V=>12C'R=*M;66R%(UFE,-6(M54
M%9$O:V"BC7& #PL[6I3:+GC)LB8%W(/^5F^EF7F#2T8KX(H*CB3D,5X%B_7<
MQKN [Q1:=31&-I.]$(]VLLEB[%L@8)!JZT#,ZPEN@#%K9#!^]YYX.-(*C\<'
M]T\N=Y/+GBBX$>P'S709X_<899"3ANF=:#]#G\_4^J6"*?=$;1<["3%*&Z5%
MU8L-045Y]R;/?1V.!,;GM"#L!:'C[@YRE+=$DV0I18NDC39N=N!2=6H#1[G]
M*/=:FEUJ=#K9F/)F(-&#)!GE!5I)27@!INQ:+3UM3K!Q7MJ[K3NW\(Q;A.X$
MUZ5"'WD&V;]ZSY ->.$!;QV.&MY">HVBX!T*_3 :\8N&="/G-[L@7?3SBXE&
M&PV5^G4J]\XZ.FUM;\]"U22%&)OKH4 ^ 4[>O@EF_H<1\,D /AES3W8- Q3X
M^^E5< R-5IFH]?^E[G#'#7/"%(R 30>PZ:C/5\&O+H ;-WT-;C; S2ZJV@-(
M<Y?(&;9QS]?8Y@/;_.+"C?.-^Y[E\XZZ1 6R<+U0H50T7'<-8U@=VNVJZS)_
MP[M>?4=D0;E"#'(C]:_GYG/*KO]U$RUJUW/V0IL.YH:E^66 M %F/Q="'R;V
M@.$GE/P!4$L#!!0    ( -5#<UA#&ZMAQ@L  )0=   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;*59;7/;-A+^SE^!43N=WHPLR[+STB;Q3)RTU_:2
M2R;N76_FYCZ )"0B)@$6 "WK?OT]NP I4I:=S-P76Q+QLOM@]]EGP9=;ZVY\
MI500=TUM_*M9%4+[X^FI+RK52+^PK3)XLK:ND0%?W>;4MT[)DB<U]>EJN7QZ
MVDAM9I<O^;>/[O*E[4*MC?KHA.^:1KK=E:KM]M7L;-;_\$EOJD _G%Z^;.5&
M7:OPC_:CP[?38952-\IX;8UP:OUJ]OKLQZL+&L\#_JG5UH\^"_(DM_:&OOQ:
MOIHMR2!5JR+0"A+_;M4;5=>T$,SX,ZTY&[:DB>//_>H_L^_P)9=>O;'U'[H,
MU:O9\YDHU5IV=?ADM[^HY,\36J^PM>>_8IO&+F>BZ'RP39H,"QIMXG]YEW#X
MF@FK-&'%=L>-V,JW,LC+E\YNA:/16(T^L*L\&\9I0X=R'1R>:LP+EQ_<1AK]
M7QDA,J6XDEY[8=?BHU->F<!/7IX&[$4S3HNT[E5<=_7 NF<K\=Z:4'GQDRE5
M.5W@%$8.EJYZ2Z]6CZ[X5A4+<7XV%ZOEZOR1]<X'S\]YO:=?X?E<O+'&VUJ7
M>R#&_A,>/VLC3:%E+:[QHT)@!B_^_3KWP2&T_G,,HFC ^7$#*-U^]*TLU*M9
M2WNY6S6[_.Z;LZ?+%X^X=S&X=_'8ZO_'P3ZZ[G&KSQ;9U^TGWNF[H+(K;8,J
M*F-KN]F)7VQ=:K/Q<_&K*19S(<5;5<NM=$H4UK76I3/2IJ@[&BDTH-]6MJYW
M)W9K5+F?X+O<ZU*#7^9Q+S'9*VXAOD?:,"_<JGHWST*EQ'??/%^MEB_>V*:5
M9L??SE[\!9MZV%, !5W(^L0',)7(M6TK"4XH5!?H=]C)T\ ');X'6!2LT$WK
M["W9V\(#BA=:]NS9"U%C8R]R&@\+;(LQF12EZS;82GHOL&:M* 9ANS;B8V4]
M=@R@'[%Z#2 JG>M@G5^(WV'[R&BL[@?4%.!?ZT*1$[6-=M%JTLM2&8FHE[4&
ML1LM>:'L<"'87W9%$*UN%04"+=0Z#?K6]4ZL+0@*2^)8]Q;1B;?)['9B]ESP
M:/P.M')D$P?$5H=*%+M@@[W3A0"\P"E# )U:)^Y.G,29Z:;IL#D*4G'36FV"
MR.'.C<)N%&D6Y^< F2GPCS[+5JLI-"*'_8I #[#GR^9Z4<E;E7F],1H(2FP9
M%^8#%RTFF$!< /00'[FSLA1.F@U!GDPYL #0,6 4#_";8JX/JSX,B%-HOA2^
M505MW-N6C:$<K)]3653.Q7"37KR[.CE;+N?(#5U4< $QII01OD*6T!!R:K\K
MO-(G"3:NCCKL!- IK>^!B@&@$+ AU"J#L\8*/BF,/1XS:26<@$@)^1F91KN/
MT73:W\33ZVC_ /E 4\9)3@@9!=\8X[+4%"^4:SC>(.L)NAGY:FP0.^@8A!>0
M+#"3<'? UG3J!(&EB$D(_E9%3L%^I55Q)F/36J^)%;")K\0:D@6GYFPSF>(H
MECP=(LIS<7-"JJ!D"H!8X4%9# LBHR!CH" A^TJBFK:V.Z78_0)+0D$0)N,5
MYOP0,5,J_%9R8"!"E=,6# .4UAWI(HY?]6=')Y=P(:37'4U&'B6SX;.C42Z6
MK05SLJ95*=/$FTJKM?CI3A4=._^!6<.)G];K2)+9M6I1\G+\MGH:*_"<"%[<
M2@,+'3Y+,EF4V*) 9))9813\B'I$T6^4Q6?/>($5X=C6DHXI'.&PM84/"B'^
MUBW$;[8RXGJ1_<W>RJ*:4Z@/'HA'/%CP[#@+).SIG% G=H3E!]A)#CV)_BSV
MW@Z/!E??8Y6QJ]D6%LB6N8B6]#! :A0$TSM^9:4KZ<O;A(B?V,+S:V^/NAZ=
MN2ZH9# )#-[\7?I2_IF]TY[/E#S_A/!V((5K"D5QW2)3CZ8E)44?L3R1=D;)
M!&F%F*G0,65D<WH4MT*%B$'U7KH;I-;WJ4S&IWV5%'Q4/,WOFAR2M"^G[W[]
MU^]I%$?:Z.<_TN\4!T1WL1@OQ >3<9RL>O#'<:3XC AR<7:") /=03YL"0,N
MXR09< BY(I[">7>.Z"V1V7BAK:YK&B;S6E'&(#- 0:DX 42:%FL3S?KV;+%<
MDOS63=> 0"VS>*Y+JH88.$JN#&>>L+.W! I:F+FP+A6>,.SLNP*6^757TZZT
M.Y$@K7MH =F;PBJ5.BAK#4XKP<O^7G9C;!8M6(B_6I(6$+<('R/0Q[#6V2GI
M!+$*":<BYG6OK*=X(W:M*QEO@^.'X\PXWR)KEL^?S9>K'\3%?/7#^7SU] E]
M6I[/+YX_1^*<7US,E\#L>"CV6IO(?9#5?B^KF8NY=+51/.[C,F=9.0&SAX/R
M4(J-C1BRRWTII"%$N]C!,P1H8.M>K5+%!36$6(^(?_U:%OTCG$2NZUC0=+3!
M4#](^W:4>1B34UG'84XK?JQ)A&'G'!GE,:'@":DH<4[0,'5'U!Z+EE$;R32T
M)^]1-8I,2G]:LO#^CA%054:1C)8X+A#3>!(GH7*VVU0)C\%(6;.)-#U5%D\/
M&8$%L;XJLW08R$#%>,\1P ;:C14,64'XHXXSN<?4<ZP>QR6QM%T.^LYM%X[R
M8,1]1^GYR!%GE",X&&M28,MU2&1$$;9/_2^'';%@KKC! '6H<H%N85 >2.+.
M ?A]08;O2#]%\JOM\EH7F2P0$X:/;(URP$CH'@CP$HZY!DXH!SN4(R<W4)15
MBBKMJ"!")<2D3Z1(SL,]/Y))N^@2[45XL12!91*J*:ARXF9VW$W.80J]M8U
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M: ">KZT-_1?:8'@1>_D_4$L#!!0    ( -5#<U@A=S5AJQT  %E;   9
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MTG)CL.^\I9X( MW9+LSFD+-D===5A)&+-;FE-NJ!SE ]8>7EJ-($*]*@BP,
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M@/?SING<#]S ?TW[[?\"4$L#!!0    ( -5#<UCDH-O9/P,  #P'   9
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MXXQQNZ7SA1PP2%Y3PJ\3A_8CUVW?; B+)H\1WX6-VB5&&"RMS8Y)N&<U!7G
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M/,EI)IDE8;:<D>21X"]]_1"D/J'349GR?V:2>)C6XA"BT83T9"D4[4%(ECX
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ME@6D9IG"4<++P40S6)W<(: B+$2//,\3B$("[)WH,Q#@B$CP(JY?ZM,I?Y/
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M4IE<A+:NM[A.H2M'L4BIZ4,()%N2ES97E!*2.I&Y:_%_,D#51XCJS7_N6US
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M9H(1D?E,-%8]9Z)<%O5*B,;&W$HI"\MMM1X##7R15VW#,)66&L(=]K:R?NA
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M%&-'KT[DUDQEQ_Y3L]%:/ZG6]"=$L 4]C%'"NGN$.)SYDXJPO](^,"NZ5 4
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MIPWZ<'4R![:,K ;@H5 P*-0)4(5PBCUJ7>R'-88H!GB1O.W G&I0;_ %R.9
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M*C4U]ZSQTKY:FB6)0^!ARNNHAJ8M.>%LC:MT_6D[<]"ED(1; ZJ+%VY3IAA
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M_*!V ?1]HY0]3ER"TS]R_C=02P,$%     @ U4-S6#E-<]S/ P  KPD  !D
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M1H$_O(:[;Q77+W#Q.UMEJ"XGKJ9$QMV-=Z W-6AP!-0/X+,H=*K@KD@P^1[
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MR@+(7TAIM@N;8/>7FOX#4$L#!!0    ( -5#<UBBM:'-R 4  !X2   9
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M!M(R$(>[4>10OF6&37>57"%EJ4&:_>%,==P 3M0V**=&P:D /C,]-3*_>'T
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MX);E]4*)W!)4LN"VR,R\T21+Z$L.=^\DO8/^KI^]$Z$O7L\4YTC4AH/C#%)
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MW>7KMG=ZJ\/"_*X-F.7:E+EG<HA(DOA)DD)*T32@&?;>6[B@-4QB'V,,-U9
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M]W/.6<&5)8#SF92F6U@%_2>AZ5]02P,$%     @ U4-S6#JK*CR8 P  = @
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M8YS4KW2BQR0?CC15EN@6\XQ0@0K8*$KG<JIV %XE7JJ"9%N3BE@S*5EI'G/
M*7#=0;5O&)-/!3U D_Z*_@-02P,$%     @ U4-S6!SLB^E; P  L X  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULS5==;]HP%/TK5B9-F[0V7Y!
M!Y& ;EJE54-%6Q^J/9CD E:3.+,=Z/[];"<$PD=6I#ST!6+']_C<<T\LW\&&
MLF>^ A#H)8E3/C160F0WILG#%2287],,4OEF05F"A1RRI<DS!CC204EL.I;E
MF0DFJ1$,]-R4!0.:BYBD,&6(YTF"V=\QQ'0S-&QC._% EBNA)LQ@D.$ES$#\
MS*9,CLP*)2()I)S0%#%8#(V1?3.Q716@5_PBL.%[STBE,J?T60WNHJ%A*480
M0R@4!)9_:YA '"LDR>-/"6I4>ZK _><M^E>=O$QFCCE,:/Q((K$:&CT#1;#
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M ?K[.>?JX<9T4!X>COX'4$L#!!0    ( -5#<U@0]V,T. ,  -,,   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*U788^:,!C^*PU;EENR';0(PDU-
M//5R)CMCU-L^]Z *.:"NK7K[]VL!$13)3/@B;7G?I\_S/D)?>@?*WGE B  ?
M<93POA8(L7W0=>X%),;\GFY)(N^L*8NQD%.VT?F6$>RG27&D(\.P]1B'B3;H
MI6MS-NC1G8C"A,P9X+LXQNSO(XGHH:]![;BP"#>!4 OZH+?%&[(DXG4[9W*F
M%RA^&).$AS0!C*S[VA ^C*"I$M*(7R$Y\-(8*"EOE+ZKR=3O:X9B1"+B"06!
MY65/1B2*%)+D\2<'U8H]56)Y?$1_2L5+,6^8DQ&-?H>^"/J:HP&?K/$N$@MZ
M>":Y($OA>33BZ2\X9+&VJ0%OQP6-\V3)( Z3[(H_\D*4$J!])0'E">@\H7,E
MP<P3TLKI&;-4UA@+/.@Q>@!,14LT-4AKDV9+-6&B;%P*)N^&,D\,EO)_X>\B
M N@:+ @GF'D!P(D/QF0O/=Y*QP0842XXN!L3@<.(?P7?P>MR#.X^?^WI0G)0
M2+J7[_>8[8>N[ <1>*&)"#B8)#[QJP"Z)%\H0$<%CZ@1<4R\>V#";P 9R*PA
M-/K_=-1 QRP*:J9XYA6\2A']4A$]5<2Z@F5XG11//77[@>,ZT#!Z^KXLXS(,
MFAT7V6X15^';*?AV&OF^SJ:KR1@L5\/59%E'KS%=O64>^!9[I*_)UP@G;$^T
MP9=/T#9^U'G1$EA%J54HM5IV)L.S2B4W+==RW#-GZL(,&SKUQM@%7;N1[G(^
MG,[J6#6FW6I(2V 5A=U"8;=E0[H7E4:N!6WSS)#+,!O9IFW7&^(4=)U&ND^+
MX6PTJ:/5F'>K(RV!522ZA42W94<:\>K9@CK5[H5E+K1,5.\8-$ZGF]$H:/0\
MG0UK3ZG&O%L]:PNMJK)TAL.6;<L!R_6&7>@Z9P]235C7EJ_ *[:@$V'42'@V
M63U/%C^'LW'MD=.<?;,Y+:%5M9[Z =AV0P OCWJ$;&B==P1U<48'6N<'CUYJ
M#V/"-FG7S.7^NT1D?5:Q6G3FP[0?/5M_5!U[VG:>8+)V_P6S39AP$)&UA#3N
MN_(OP[(..IL(NDV;T#<J9$N;#@/YU4&8"I#WUY2*XT1M4'S'#/X!4$L#!!0
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M970S,BYX;6S%6&MOFS 4_2L6FZ9-Z@HV(8\N0>ICU2IM:M3N\6':!P=N$E3
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M[*.,(X@ND6-]1#:VG19!P[?#[2-RG":)CN;S#_!M9^X;(P4G594^?I6FZ%9
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M<WM)8 N2E>:</6=2G=K-8PHD :X;J/=+QN1;07=07=6,_P902P,$%     @
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MJSA1A65>8B$=6#!!7UDNUP+]DL<07QIP%+&:'3FRFY->BP\0V<C#-XBXQ#,
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M!DG'\7<):E4^C>'N]3/Z34Y>DYD1B6,>_T%#%0VLG@4ASDD6JZ]\]1N6A/(
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MF79;C6G"M#*L=U8&K"+!LT6DHVXYS6,KIG9:WIDQKK-MI9S::1^3F.H98)3
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MYJ":BVH>JOFH%J!:B&H1JDE4BU$M0;44U3)*4R.VZ_],IR\^@T?[0ZAFHYI
M-0?57%3S4,U'M0#50E2+4$VB6HQJ":JEJ)91FIJY7<UHJJ\973ZW[-[3%AD?
M+DA>ZH<Y.0K1IA"J.:CFHIJ':CZJ!:@6HEJ$:A+58E1+4"U%M8S2U"CLZD13
M?9W([FY_\?2HLESW3_CCHCT(73:'IIL?EZKK+DNGG?>C-214LU%-H)J#:BZJ
M>:CFHUJ :B&J1:@F42U&M0354E3+*$T)WEG7:IH-7GK>/T.;3JAFHYI -0?5
M7%3S4,U'M0#50E2+4$VB6HQJ":JEJ)91FIJY7=-IIK^WT<?BY!N_Z<63,Q1M
M+J&:0#4'U5Q4\U#-1[4 U4)4BU!-[C2E&&]-S/'>2;:X[WF#D3G>N[M#@NY=
MBFH9I:FY9W6YIV\;_5;6V[)1>[V0Q7I^7U7%56_8H74C5+-13:":@VHNJGFH
MYJ-:@&HAJD6H)G?:TQ ;S<;C\60_[-!2$JJEJ)91FAJ)72FI>:B+Q/<W-U5Q
MD]=%V\%<+>J'P\#V0DKS^B?AJ 5/#D=2LU%-H)J#:BZJ>:CFHUJ :B&J1:@F
M=]K3<!Q?'/9K8W349*<]7>0=6Y.#4=/=\TQE]P:'J\%9WQ.'%^;3)ZIAU;5\
M9OI[",F/ON$NR\_-09QNC46OG)Q0:%,'U02J.:CFHIJ':CZJ!:@6HEJ$:A+5
M8E1+4"U%M8S2U-SLFCJS%[_;SPRM^*":C6H"U1Q4<U'-0S4?U0)4"U$M0C6)
M:C&J):B6HEI&:6KF=I6AF;XR]"MK+&@G"-5L5!.HYJ":BVH>JOFH%J!:B&H1
MJLF=ILQ(K>%@NC^Q[KF7TG0ZL/976- 6#ZIEE*:F7M?BF>GOXG/T"@M:Q4$U
M&]4$JCFHYJ*:AVH^J@6H%J):A&IRUG,+I-',NICM9QU:LD&U%-4R2E,CL2O9
MS/0EFU]884%OXX-J-JH)5'-0S44U#]5\5 M0+42U"-7D[+#0-IWU++"@K1M4
M2U$MHS0U&[O6S4S?NKDLUW65SVOCKEK,>V]II@=.SD*T+[/3GOXV#:V)-1VI
MOTX"'=7I&=6:#B]F>[_$+CJJAVH^J@6H%J):A&H2U6)42U M1;6,TAYB[GQS
M6Q2UG=?YNS>KHKHI+HOELCVO=[^NVT&>?+>]=6,3@^;K]];9^<'WI?DZ-GN^
MGYBOT^WWSSO^W9N[_*:0>76S6&^,97'=##5XU5X7J5K<W#Y^49=W;\_,,^-S
M6=?E:OOPMLBOBJI]0O/WUV59__BB'>!K6?VQ?3GO_@]02P,$%     @ U4-S
M6!'(([3/ @  '0D  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULM59;
M3]LP%/XK1]DT@;0UEUYA;22@H#$!JD",![0'-SUM+!P[V$Y+__WL),VZD88)
M=7E([-CG^[YS\66X$O))Q8@:7A+&U<B)M4Z/75=%,29$M42*W(S,A4R(-EVY
M<%4JD<QRHX2Y@>?UW(10[H3#_-]$AD.1:48Y3B2H+$F(7)\B$ZN1XSN;'[=T
M$6O[PPV'*5G@'>K[=")-SZU09C1!KJC@('$^<D[\XU,_-\AG_*"X4EMML*Y,
MA7BRG<O9R/&L(F08:0M!S&>)9\B813(ZGDM0I^*TAMOM#?I%[KQQ9DH4G@GV
M0&<Z'CD#!V8X)QG3MV+U#4N'NA8O$DSE;UB5<ST'HDQID93&1D%">?$E+V4@
MM@R"8(=!4!H$N>Z"*%<Y)IJ$0RE6(.UL@V8;N:NYM1%'N<W*G99FE!H['=YE
M4X7/&7(-YTOS5G P1DTH4W!#I"0V9H?P!?Z>!X_7F$Q1_C1C5S0R:4(X64C$
M9'MPZ&JCT3*Y4:GGM- 3[-!S@=,6!.W/$'A!!^[OQG#P\?!/&->X6/D95'X&
M.6[O'_V$QRLS RXU)JI69@'7KH>S:^58I23"D6,6@T*Y1"?\],'O>5\;Q+8K
ML>TF]/"FJ/B,S\B4(; ROE2I#$&*-6%Z7:>Y0.WDJ'8Y+L.N9YZANZP1TZG$
M=!K%3,@ZSZG9 4INBJJ.O?.*W0^"[D[^;L7?;>2_+?R%%*4)@S9;11UY@>'[
M6^Q>R^O64_<JZEXC]=B$^X'JF'+H>3 F:]58V8U@[RR9?B6UO]_Z[O\'L8-*
M[* QKM>4TR1+@'">$;:I:$C)VM9[G=K!J]IJ[Z[LHTK&T9OI/2=1#-^)T2'7
MX#>FMQ'LG1'SO=_[M+??!)=X>]:[=:[X>\YQ"?A6DMVMP\Y>'*Z)7%"N@.'<
MV'FMOMD*9'$6%QTMTOS\FPIM3M.\&9O["TH[P8S/A=";CCU2JQM1^ M02P,$
M%     @ U4-S6( @T2ES P  ^Q8   T   !X;"]S='EL97,N>&UL[5C1;MHP
M%/V5*%VG5IH:(&L@*R!M2)4F;5.E]F%OE2$.6'+LS#$=[''?LZ_:E\PW#B10
M7T:WA\*T((A]3^ZYQ]?7B4._T$M.;V>4:F^1<5$,_)G6^9L@*"8SFI'B0N94
M&"25*B/:=-4T*')%25* 4\:#3JL5!1EAPA_VQ3R[SG3A3>1<Z('?;JUMGCV]
M3XPU>NU[EF\D$SKP[\]>?IE+??7"L^>35R<GK?OSJVW[60F<^X&3]'(/THN6
M.5#F$L7HH_WH=Y%CU-U-Z@VE>RCKN=U/F]ZGF'/L<*X],;=N:\]D[\PU1M[&
M\K&5$)2@@Q!LI 0?7.@>W,_O/Y "K9%&B0;58ACV4RGJ-1'ZUF BDXQZ#X0/
M_!'A;*P8>*4D8WQIS1TP3"27RM-F,1HI;; 4WRS<MCU8IQ5/QH1496P;P?Z.
MJ\NW@%4/!#+.UP([OC4,^SG1FBIQ;3KEQ:7Q$>15[;ME;A1.%5FV.Y=^[5">
M3)"Q5 E5];W!7YF&?4Y3D*/8= 9G+?, 0*UE9AH)(U,I2*EAY5$U#.V$<GX+
M-['/Z0;W(FW,:5FN8MTT@JJFI;$=X&^R6>XF;?1'O%[.'J1^-S?#$64?*H7>
M*)JR1=E?I&L!&'L;9R=YSI=O.9N*C-K![QUPV"<K/V\F%?MFHD&I3(R!*M][
MH$JS2=/R59'\CB[TJIP6*:ZY\U_S;S1/J:"*\*9H4_M[**X>H<^AN5RDVXJ=
M(L/NX6M\MB7V%U-_>?AIK;9+AR[R" JTVMX=NLCX"$1VG^T^_Q21[6,0V3D&
MD>%!B@RJ365CY[JQ;UU;/7@_&/B?X$V$UT&]\9QQS435F[$DH>+1]M70:S(V
M;_8;_.;ZA*9DSO7=&ASX=?LC3=@\B]=7W4 BJJOJ]@<8GMD+KUY.3"PF$KJ@
MR:CJJNFX;'JF8:)6!SAL(]?EX48P'XNY$<"P.)@"S,=Z87'^I?'TT/%8#-/6
M<R(]U*>'^E@O%S(J/U@<MT]L#O=(XS@,HPC+Z&CD5##"\A9%\'6S8=K  XL#
MD9Z6:WRV\0K970?8G.ZJ$&RD>"5B(\5S#8@[;^ 1Q^[9QN* !S8+6.U ?'<<
MJ"FW3QC"K&+:L!6,(W&,(5"+[AJ-(B0[$7S<\X.MDC",8S<"F%M!&&((K$8<
MP12 !@P)P_(YN/4\"E;/J:#^NWOX"U!+ P04    " #50W-8EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( -5#<UA'
MK/3\2@0  !T?   /    >&PO=V]R:V)O;VLN>&ULQ9E+;]LX$(#_"J%3]M"U
M]4C:!G6!U$YW RQJ(PZRQX*61C81BG1)RGG\^B7I=3MJDT$OC$^V*$OZ-#3G
M&Y(?[K6Y6VE]QQXZJ>PDVSBW/1^-;+V!CML_]1:4/]-JTW'G#\UZ9+<&>&,W
M *Z3HV(\/AMU7*CLXX?#O19FA ^T@]H)K7QC:+@5<&]_G ^';">L6 DIW.,D
MB]\E9*P32G3B"9I)-LZ8W>C[O[413UHY+I>UT5).LGQ_XA:,$_4OS<L ><-7
M-K8XOKKF'F22G8W]#5MAK(N_B/?GGG$'_L?[H][IST(Z,#/NX"^C^ZU0ZW ;
M_Q8C]!HQ#H?/?1#/S>^$4;>MJ&&FZ[X#Y?9Q-" #H+(;L;494[R#23;5.S#A
M??P#KIK]NSD/A2)ESH4_8:Z:B)<215DM1>.?WK!/7')5 XLAM BP( "+HP&R
MDP5'D"4!6;XBY#) A LLTRV;;P==71&0U1$AOQ8(\I2 /#T:Y-+I&D&>$9!G
M1X.<<KM!D&\)R+=I(1?\D>TL6X")EX=A,Q.VEMKV!A#B.P+Q75K$*V5% X;=
M&-[X7,PNC.%JO0\F(GQ/$+Y/2S@W:Z[$4SS!N H9R(K8T0L#%H<Q'U-)?)P6
M<]EW'3>/<92(M1+^,JX<NZAKW2LG,";IFL2RN?8AXZ;>Q$C.8 =2;\,E;*KM
MH,=S2CAY8N.$/'.WT=+_,^U7=OFM]S4,9J,\DR<6S75H]$EGP8U[#.-&61XK
ML4'T*,GDB2T3H_?&#Q-/.=6=OY.-/\)\E%_RQ(*Y4K7N@-WP!QC$C-))GMPG
M72?<WB%A:'B_.)\/0=5B"$GI)$_LDV6_LO"M#\/U<O=3ALXIB>2)+4(FOT%=
MDU,FR1.KA,8L<;5-J:1(K!(Z1S.,2:FD2*R2YY(T._%S/0GV#PQ)3ET2F^3E
M;!U1,28EE2*Q5%Y*V?_'$V-29BD2FP5G[F>[FM)*D7S>0J1P=H(Q*=,4B4U#
MUK.#7%E0KBE2N\;?H^DE!+ +'\@WC9!]6,QA2ZA[/)\N*/,41S5/A3$I\Q2I
MS8.B^4QZQTLHE'G*U),8A/DO#U-!/Y;FO?- RD\/,29EGC*U>2C,P1 J*?>4
M1YC%L),9."ZD95\P)KEPEMH]/X;0T):_E!LEY9XRL7LHD_N88DS*0F5B"^'_
MYF<N#+OELH]'E]R/>8Q)6:A,;"&<-V/ML1K4'AB3LE"9?,8SQ&3S;?3F1=A7
M$(-.IRQ4IK80ZO3+!S"UL.!U[B^.8L>8E(7*U!9ZL<J,20FOD5,6JE[10@%3
MJ\/2[@S:X5(^9:'J%2UTV;80M[K8]Q(98U(6JA);:%BS?[=/T&8 QIB4A:K4
M%AITNG+&)_>>2S:50OF:#F.2&SC)=W"(2<:@]*@H"U6I+?3S2M&PYS$F9:$J
M6FATV(YMH!4*FB_^$=:WUUS6"\/"QW[%N#H-RSMM+^74M\W5/YHWA]W=P\[T
MQ_\ 4$L#!!0    ( -5#<UC]+-6EK@$  ,$;   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'/-V;MNPD 0A>%707X EIE9;A%0I:&-> $+EHLPV/)N
M%'C[("C@6"G2H#V5M;8\_AM_LM:SKU"5Z5"?X_[0Q-[E5)WCO-BGU'PX%]?[
M<"ICOV["^79E6[>G,MV6[<XUY?I8[H+3P6#DVM<9Q6+V.K.WNC;A/Q/K[?:P
M#I_U^OL4SNF/P>ZG;H]Q'T(J>JNRW84T+]RE>IZ.[GZ0_FURT5MNYD6[W$CA
M<@<I!&G^((,@RQ_D(<CG#QI"T#!_T B"1OF#QA TSA\T@:!)_J I!$WS!\D
M91P0)'6P)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0
M;R'06U%O)=!;46\ET%L[']L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HK
MZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6V>SA$!O0[V-0&]#O8U ;T.]C4!O
M0[V-0&]#O8U ;T.]C4!OCWI[ KT]ZNT)]/:HMR?0VZ/>GD!OW]GL)M#;H]Z>
M0&^/>OMWZAW3M0KQV?-8X_/?276ZW1N>C[\O'R<[[_@=9P=_[!:_4$L#!!0
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M4$L! A0#%     @ U4-S6/W6*CZ7 P  UPT  !@              ("!*A8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -5#<U@TR[5#
MZ 0  )(1   8              " @?<9  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #50W-8#',']0$#   ="P  &
M@($5'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ U4-S
M6#^\QO7(!0  '",  !@              ("!3"(  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( -5#<UC$.V(OI 4  %,7   8
M      " @4HH  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #50W-8A/B;L%H"  "X!0  &               @($D+@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ U4-S6&A\NK)# @  D 8  !@
M             ("!M#   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( -5#<UA#&ZMAQ@L  )0=   9              " @2TS  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ U4-S6"%W-6&K'0
M65L  !D              ("!*C\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #50W-8Y*#;V3\#   \!P  &0              @($,
M70  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -5#<UAN
M&"Q[2@<  $L2   9              " @8)@  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ U4-S6$*&;J.("0  51H  !D
M     ("! V@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -5#<U@:D+U_ZQX  /9C   9              "
M@5"I  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ U4-S
M6. +DF-4 P  <P<  !D              ("!<L@  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #50W-8UQP_ADD#   O!P  &0
M        @(']RP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( -5#<U@Y37/<SP,  *\)   9              " @7W/  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ U4-S6+&FY.OV @  L08
M !D              ("!@],  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #50W-8HK6AS<@%   >$@  &0              @(&PU@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -5#<U@ZJRH\
MF ,  '0(   9              " @:_<  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ U4-S6#;S=9T*!0  K L  !D
M ("!?N   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #5
M0W-8%_I*B.4#   *$P  &0              @(&_Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -5#<U@<[(OI6P,  + .   9
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M970S,BYX;6Q02P$"% ,4    " #50W-8_4J6E/4/  #WQP  &0
M    @(&%_@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M -5#<UAN$(/M] (  "0*   9              " @;$. 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ U4-S6!7J-XP1%0  F'\! !D
M             ("!W!$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #50W-8;Q8)8<D#  "V$0  &0              @($D)P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -5#<U@.48QH^0(
M %D+   9              " @20K 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ U4-S6!_IJTHT!   \!   !D              ("!
M5"X! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #50W-8
M%MQFPOD%  "'+@  &0              @(&_,@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -5#<UC6[T^KM2@  *=" P 9
M      " @>\X 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ U4-S6,@U"" 2 P  @@D  !D              ("!VV$! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #50W-8M@@RNR\#  "6"0
M&0              @($D90$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( -5#<UC5>BG+7@0  *T1   9              " @8IH 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ U4-S6 .-5"UU
M!@  ?"0  !D              ("!'VT! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #50W-8\J.P5:X8  !LSP$ &0
M@('+<P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -5#
M<U@1R".TSP(  !T)   9              " @;", 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ U4-S6( @T2ES P  ^Q8   T
M         ( !MH\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #50W-8EXJ[
M',     3 @  "P              @ %4DP$ 7W)E;',O+G)E;'-02P$"% ,4
M    " #50W-81ZST_$H$   ='P  #P              @ $]E $ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ U4-S6/TLU:6N 0  P1L  !H
M     ( !M)@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ U4-S6";ZAZ>U 0  W!L  !,              ( !FIH! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #8 -@"Q#@  @)P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>282</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995514 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Research and Development Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCosts</Role>
      <ShortName>Research and Development Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995516 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995518 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995519 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995520 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995521 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995522 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995524 - Disclosure - Research and Development Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCostsTables</Role>
      <ShortName>Research and Development Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/ResearchAndDevelopmentCosts</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995526 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995528 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995529 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails</Role>
      <ShortName>Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995534 - Disclosure - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995536 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquityTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Summary of Related Party Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfRelatedPartyCostsDetails</Role>
      <ShortName>Summary of Related Party Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995538 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails</Role>
      <ShortName>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails</Role>
      <ShortName>Summary of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Summary of Stock Option Activity Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995546 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails</Role>
      <ShortName>Schedule of Contractual Clinical Trials (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995548 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995549 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>lixt-20231231.xsd</File>
    <File>lixt-20231231_cal.xml</File>
    <File>lixt-20231231_def.xml</File>
    <File>lixt-20231231_lab.xml</File>
    <File>lixt-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="657">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "lixt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lixt-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 226,
   "keyCustom": 40,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 77,
   "hidden": {
    "total": 46,
    "http://lixte.com/20231231": 4,
    "http://fasb.org/us-gaap/2023": 39,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 282,
   "entityCount": 1,
   "segmentCount": 111,
   "elementCount": 569,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 657,
    "http://xbrl.sec.gov/dei/2023": 42,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://lixte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lixte.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "LIXT:AdvancesOnResearchAndDevelopmentContractServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lixte.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lixte.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OtherCostAndExpenseOperating",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://lixte.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ConsultantMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://lixte.com/role/StatementsOfStockholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://lixte.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentation",
     "longName": "995513 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995514 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lixte.com/role/ResearchAndDevelopmentCosts",
     "longName": "995515 - Disclosure - Research and Development Costs",
     "shortName": "Research and Development Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lixte.com/role/StockholdersEquity",
     "longName": "995516 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lixte.com/role/RelatedPartyTransactions",
     "longName": "995517 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lixte.com/role/Stock-basedCompensation",
     "longName": "995518 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lixte.com/role/IncomeTaxes",
     "longName": "995519 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lixte.com/role/CommitmentsAndContingencies",
     "longName": "995520 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lixte.com/role/SubsequentEvents",
     "longName": "995521 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995522 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995523 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lixte.com/role/ResearchAndDevelopmentCostsTables",
     "longName": "995524 - Disclosure - Research and Development Costs (Tables)",
     "shortName": "Research and Development Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lixte.com/role/StockholdersEquityTables",
     "longName": "995525 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsTables",
     "longName": "995526 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lixte.com/role/Stock-basedCompensationTables",
     "longName": "995527 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lixte.com/role/IncomeTaxesTables",
     "longName": "995528 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesTables",
     "longName": "995529 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "longName": "995530 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "995531 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995532 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
     "longName": "995533 - Disclosure - Schedule of Research and Development Costs (Details)",
     "shortName": "Schedule of Research and Development Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_country_US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "995534 - Disclosure - Schedule of Warrants Outstanding (Details)",
     "shortName": "Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "995535 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ExercisePriceOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://lixte.com/role/StockholdersEquityDetailsNarrative",
     "longName": "995536 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-192023-07-20_us-gaap_PrivatePlacementMember",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
     "longName": "995537 - Disclosure - Summary of Related Party Costs (Details)",
     "shortName": "Summary of Related Party Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_RelatedPartyMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995538 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2022-06-15_custom_DrReneBernardsMember",
      "name": "us-gaap:ManagementFeePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-15_custom_DrReneBernardsMember",
      "name": "us-gaap:ManagementFeePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
     "longName": "995539 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "shortName": "Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails",
     "longName": "995540 - Disclosure - Summary of Stock-based Compensation Costs (Details)",
     "shortName": "Summary of Stock-based Compensation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
     "longName": "995541 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "shortName": "Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
     "longName": "995542 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "shortName": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "995543 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "995544 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)",
     "shortName": "Schedule of Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "longName": "995545 - Disclosure - Schedule of Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lixte.com/role/IncomeTaxesDetailsNarrative",
     "longName": "995546 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
     "longName": "995547 - Disclosure - Schedule of Contractual Clinical Trials (Details)",
     "shortName": "Schedule of Contractual Clinical Trials (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember",
      "name": "LIXT:ClinicalTrialDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995548 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_srt_OfficerMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://lixte.com/role/SubsequentEventsDetailsNarrative",
     "longName": "995549 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively",
        "verboseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r540",
      "r702"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r417",
      "r660",
      "r661",
      "r662",
      "r682",
      "r704"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r257"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "AdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on research and development contract services",
        "documentation": "Advances on research and development contract services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r583",
      "r593",
      "r619"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r586",
      "r596",
      "r622"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r578",
      "r587",
      "r597",
      "r614",
      "r623",
      "r627",
      "r635"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation costs",
        "verboseLabel": "Stock-based",
        "terseLabel": "Total stock-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r300"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "AmountRelatedToMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount related to milestone payment",
        "documentation": "Amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AnnualGrantOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "AnnualGrantOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Grant of Options [Member]",
        "documentation": "Annual Grant of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "LIXT_AnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "AnnualLicenseMaintenanceFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintenance fee",
        "documentation": "Company is obligated to pay annual license maintenance fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "LIXT_AppointmentGrantsOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "AppointmentGrantsOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appointment Grants of Options [Member]",
        "documentation": "Appointment Grants of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r135",
      "r155",
      "r186",
      "r199",
      "r203",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r326",
      "r328",
      "r340",
      "r387",
      "r454",
      "r540",
      "r552",
      "r671",
      "r672",
      "r689"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r139",
      "r155",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r326",
      "r328",
      "r340",
      "r540",
      "r671",
      "r672",
      "r689"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "LIXT_BastiaanVanDerBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "BastiaanVanDerBaanMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bastiaan Van Der Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BasvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "BasvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasvanderBaan [Member]",
        "documentation": "BasvanderBaan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BioPharmaWorksLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "BioPharmaWorksLLCMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Pharma Works LLC [Member]",
        "documentation": "Bio Pharma Works LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r134",
      "r525"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r88",
      "r152"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease)",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r88"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insurance",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CashSIPCInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CashSIPCInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash SIPC insurance",
        "documentation": "Cash SIPC insured amount."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ChairmanOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Audit Committee [Member]",
        "documentation": "Chairman of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ChairmanOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Other Committees [Member]",
        "documentation": "Chairman of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "documentation": "Person with designation of chief operating officer."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r687"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CityOfHopeNationalMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CityOfHopeNationalMedicalCenterMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City of Hope [Member]",
        "documentation": "City of Hope [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r136",
      "r137",
      "r138",
      "r155",
      "r175",
      "r176",
      "r178",
      "r180",
      "r184",
      "r185",
      "r210",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r231",
      "r232",
      "r235",
      "r238",
      "r246",
      "r340",
      "r408",
      "r409",
      "r410",
      "r411",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r442",
      "r463",
      "r487",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r644",
      "r654",
      "r664"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r184",
      "r231",
      "r232",
      "r233",
      "r235",
      "r238",
      "r244",
      "r246",
      "r408",
      "r409",
      "r410",
      "r411",
      "r534",
      "r644",
      "r654"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalResearchSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalResearchSupportAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Research Support Agreement [Member]",
        "documentation": "Clinical Research Support Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]",
        "documentation": "Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements [Member]",
        "documentation": "Clinical Trial Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialDescription",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial, description",
        "documentation": "Clinical trial description."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Monitoring Agreements [Member]",
        "documentation": "ClinicalTrialMonitoringAgreementsMember"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialPhase1bMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b [Member]",
        "documentation": "Phase 1b [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialPhase1bTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b Two [Member]",
        "documentation": "Phase 1b\tTwo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialPhase2Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b/2 [Member]",
        "documentation": "Phase 1b/2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialPhaseZeroPharmacologyStudyMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 0 Pharmacology Study [Member]",
        "documentation": "Phase 0 Pharmacology Study [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialRandomizedPhaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialRandomizedPhaseTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Randomized Phase 2 [Member]",
        "documentation": "Randomized Phase 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ClinicalTrialResearchAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research Agreement [Member]",
        "documentation": "Clinical Trial Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "LIXT_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r388",
      "r441"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r215",
      "r216",
      "r512",
      "r670"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares were available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r660",
      "r661",
      "r682",
      "r700",
      "r704"
     ]
    },
    "LIXT_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]",
        "documentation": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share [Member]",
        "documentation": "Common Stock, par value $0.0001 per share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r442"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r77",
      "r442",
      "r460",
      "r704",
      "r705"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; authorized \u2013 100,000,000 shares; issued and outstanding \u2013 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r390",
      "r540"
     ]
    },
    "LIXT_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r67",
      "r68",
      "r208",
      "r511"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r67",
      "r68",
      "r208",
      "r403",
      "r511"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r67",
      "r68",
      "r208",
      "r511",
      "r648"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r115"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r67",
      "r68",
      "r208"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r67",
      "r68",
      "r208",
      "r511"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r527"
     ]
    },
    "LIXT_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ConsultantMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ConsultingAndAdvisoryCashFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ConsultingAndAdvisoryCashFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and advisory fee",
        "documentation": "Consulting and advisory quarterly cash fee."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ContractPrice",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract price",
        "documentation": "Contract price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodEndDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ContractualClinicalTrialPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated End Date",
        "documentation": "Contractual clinical trial period end date"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodStartDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ContractualClinicalTrialPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Start Date",
        "documentation": "Contractual clinical trial period start date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "verboseLabel": "Contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contractual Clinical Trials",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock convertible into common stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issuable upon conversion",
        "verboseLabel": "Preferred stock convertible into common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r76",
      "r96",
      "r241"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation expense for unvested stock options",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r100"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total costs incurred",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r649"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards, federal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards, state",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DevelopmentCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DevelopmentCollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Collaboration Agreement [Member]",
        "documentation": "Development Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r701"
     ]
    },
    "LIXT_DirectorsAndCorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DirectorsAndCorporateOfficersMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors and Corporate Officers [Member]",
        "documentation": "Directors and Corporate Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r259",
      "r290",
      "r291",
      "r292",
      "r538"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock-based Compensation Costs",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r54"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579",
      "r615"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrJamesSMiserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DrJamesSMiserMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr.James S. Miser [Member]",
        "documentation": "Dr.James S. Miser [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrKovachMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DrKovachMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Kovach [Member]",
        "documentation": "Dr. Kovach [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrReneBernardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DrReneBernardsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Rene Bernards [Member]",
        "documentation": "Dr Rene Bernards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DueEachJanuaryOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DueEachJanuaryOneMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Each January 1 [Member]",
        "documentation": "Due Each January 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DueWithinSixtyDaysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "DueWithinSixtyDaysMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Within 60 Days [Member]",
        "documentation": "Due Within 60 Days [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_ES": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "ES",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r175",
      "r178",
      "r179",
      "r180",
      "r182",
      "r338",
      "r339",
      "r386",
      "r394",
      "r529"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r175",
      "r178",
      "r179",
      "r180",
      "r182",
      "r338",
      "r339",
      "r386",
      "r394",
      "r529"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustment to deferred tax asset",
        "documentation": "Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.",
        "label": "Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "U. S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r308",
      "r321"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r681"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expirations related to stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r681"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash board compensation",
        "verboseLabel": "Annual compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r130",
      "r143",
      "r144",
      "r145",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r183",
      "r211",
      "r212",
      "r248",
      "r293",
      "r294",
      "r295",
      "r317",
      "r318",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r355",
      "r398",
      "r399",
      "r400",
      "r417",
      "r487"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "LIXT_EricJFormanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "EricJFormanMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric J. Forman [Member]",
        "documentation": "Eric J. Forman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r583",
      "r593",
      "r619"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r568",
      "r580",
      "r590",
      "r616"
     ]
    },
    "LIXT_EstimatedAdditionalCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "EstimatedAdditionalCommitment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated additional commitment amount",
        "documentation": "Estimated additional commitment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_EstimatedWorkCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "EstimatedWorkCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work cost",
        "documentation": "Estimated work cost."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "LIXT_ExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExecutiveOfficersMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officers [Member]",
        "documentation": "Executive Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eight [Member]",
        "documentation": "Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceElevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eleven [Member]",
        "documentation": "Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Nine [Member]",
        "documentation": "Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seven [Member]",
        "documentation": "Exercise Price Seven [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "documentation": "Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Ten [Member]",
        "documentation": "Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceThirteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise PriceThirteen [Member]",
        "documentation": "Exercise PriceThirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceTwelveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Twelve [Member]",
        "documentation": "Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentThroughSoftware": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExpectedPaymentThroughSoftware",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through software",
        "documentation": "Percentage of expected paymen through software."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentinServices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ExpectedPaymentinServices",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through services",
        "documentation": "Expected payment in services."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "FR",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17"
     ]
    },
    "LIXT_FairValueOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "FairValueOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock options",
        "documentation": "Fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FiveNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "FiveNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non Officer Directors [Member]",
        "documentation": "Five Non Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FiveNonOfficerDirectorsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "FiveNonOfficerDirectorsOneMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non-Officer Directors [Member]",
        "documentation": "Five Non-Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency average rate",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r484"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r587",
      "r597",
      "r623"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r587",
      "r597",
      "r623"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r587",
      "r597",
      "r623"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r587",
      "r597",
      "r623"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r587",
      "r597",
      "r623"
     ]
    },
    "LIXT_FourNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "FourNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non-officer Directors [Member]",
        "documentation": "Four Non-officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FourOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "FourOfficersMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Officers [Member]",
        "documentation": "Four Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation to related parties, including stock-based compensation of $773,203 and $1,502,776 for the years ended December 31, 2023 and 2022, respectively",
        "verboseLabel": "Related party costs",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r465"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "GrupoEspanolDeInvestigacionEnSarcomasMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEIS [Member]",
        "documentation": "GEIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r579"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r470"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r470"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r304",
      "r309",
      "r310",
      "r315",
      "r319",
      "r322",
      "r323",
      "r324",
      "r413"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r118",
      "r170",
      "r171",
      "r190",
      "r307",
      "r320",
      "r396"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r305",
      "r306",
      "r310",
      "r311",
      "r314",
      "r316",
      "r407"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances on research and development contract services",
        "documentation": "Increase decrease in advances on research and development contract services",
        "label": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidInsurance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid insurance",
        "label": "Increase (Decrease) in Prepaid Insurance",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development contract liabilities",
        "documentation": "Increase decrease in research and development contract liabilities",
        "label": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r587",
      "r597",
      "r614",
      "r623",
      "r627",
      "r635"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r639"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r639"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r639"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Licensing Legal and Filing Fees and Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r369",
      "r370",
      "r371",
      "r373",
      "r528"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r110",
      "r146",
      "r189",
      "r354",
      "r471",
      "r550",
      "r703"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r151"
     ]
    },
    "us-gaap_InventoryPartsAndComponentsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPartsAndComponentsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory costs",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r650"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and licensing legal and filing fees and costs",
        "verboseLabel": "Patent and licensing legal and filing fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "LIXT_LegalFirmsAndOtherVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "LegalFirmsAndOtherVendorsMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Firms and Other Vendors [Member]",
        "documentation": "Legal Firms and Other Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r108",
      "r392",
      "r540",
      "r655",
      "r667",
      "r684"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r133",
      "r155",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r327",
      "r328",
      "r329",
      "r340",
      "r540",
      "r671",
      "r689",
      "r690"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MRIGlobalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MRIGlobalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MRI Global [Member]",
        "documentation": "MRI Global [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r536",
      "r675",
      "r698",
      "r699"
     ]
    },
    "us-gaap_ManagementFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee payable",
        "documentation": "Amount of fee payable for management of fund or trust."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "LIXT_ManagementFeePayableQuarterly": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ManagementFeePayableQuarterly",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash board fee payable quarterly",
        "documentation": "Management fee payable quarterly."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r253",
      "r368",
      "r397",
      "r432",
      "r433",
      "r495",
      "r497",
      "r499",
      "r500",
      "r502",
      "r522",
      "r523",
      "r532",
      "r534",
      "r537",
      "r541",
      "r673",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "LIXT_MemberOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MemberOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Audit Committee [Member]",
        "documentation": "Member of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MemberOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MemberOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Other Committees [Member]",
        "documentation": "Member of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r253",
      "r368",
      "r397",
      "r432",
      "r433",
      "r495",
      "r497",
      "r499",
      "r500",
      "r502",
      "r522",
      "r523",
      "r532",
      "r534",
      "r537",
      "r541",
      "r673",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MoffittCancerCenterandResearchInstituteHospitalIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]",
        "documentation": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MrSchwartbergMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MrSchwartbergMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Schwartberg [Member]",
        "documentation": "Mr Schwartberg [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MrVanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MrVanderBaanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Van der Baan [Member]",
        "documentation": "Mr Van der Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MsReginaBrownMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "MsReginaBrownMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms.Regina Brown [Member]",
        "documentation": "Ms.Regina Brown [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "LIXT_NDAConsultingCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "NDAConsultingCorpMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NDA Consulting Corp [Member]",
        "documentation": "NDA Consulting Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "NL",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r536",
      "r675",
      "r698",
      "r699"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash used in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r90",
      "r109",
      "r131",
      "r140",
      "r141",
      "r145",
      "r155",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r177",
      "r186",
      "r198",
      "r202",
      "r204",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r339",
      "r340",
      "r393",
      "r462",
      "r485",
      "r486",
      "r530",
      "r550",
      "r671"
     ]
    },
    "LIXT_NetherlandsCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "NetherlandsCancerInstituteMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands Cancer Institute [Member]",
        "documentation": "Netherlands Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New York State Division of Taxation and Finance [Member]",
        "documentation": "Designated tax department of the government of the state of New York."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "LIXT_NonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "NonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-officer Directors [Member]",
        "documentation": "Non-officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "LIXT_NonRefundableLicenseIssueFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "NonRefundableLicenseIssueFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable license issue fee",
        "documentation": "Company is obligated to pay non refundable license issue fee.."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r657"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "LIXT_NumberOfPatientInTrial": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "NumberOfPatientInTrial",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Patients in Trial",
        "documentation": "Number of patient in trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficerMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "documentation": "Person with designation of officer."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r701"
     ]
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash-based",
        "verboseLabel": "Compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs and expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r198",
      "r202",
      "r204",
      "r530"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior net operating loss conversion utilization",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r105",
      "r404",
      "r405"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining financial contractual commitment",
        "verboseLabel": "Aggregate commitments expected",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other costs and expenses",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r395"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r668"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r585",
      "r595",
      "r621"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r588",
      "r598",
      "r624"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r588",
      "r598",
      "r624"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid office rent",
        "verboseLabel": "Payment of office rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs of public offering",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "LIXT_PaymentsOnNonrefundableMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "PaymentsOnNonrefundableMilestone",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment on non refundable milestone",
        "documentation": "Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "LIXT_PlacementAgentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "PlacementAgentsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents [Member]",
        "documentation": "Placement Agents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "LIXT_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, conversion description",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r76"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendPaymentTerms",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, dividend payment terms",
        "documentation": "Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r76"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r76",
      "r654",
      "r674"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r700",
      "r704"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r231"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r442"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r231"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r442",
      "r460",
      "r704",
      "r705"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value; authorized \u2013 10,000,000 shares; issued and outstanding \u2013 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares \u2013 72,917 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r389",
      "r540"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r533",
      "r668"
     ]
    },
    "LIXT_PrepaidInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "PrepaidInsurancePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "documentation": "Prepaid Insurance [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct offering, net of offering costs",
        "verboseLabel": "Proceeds from issuance initial public offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of transaction",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of common stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of pre-funded common stock warrants",
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r251",
      "r253",
      "r285",
      "r286",
      "r287",
      "r367",
      "r368",
      "r397",
      "r432",
      "r433",
      "r495",
      "r497",
      "r499",
      "r500",
      "r502",
      "r522",
      "r523",
      "r532",
      "r534",
      "r537",
      "r541",
      "r544",
      "r669",
      "r673",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r251",
      "r253",
      "r285",
      "r286",
      "r287",
      "r367",
      "r368",
      "r397",
      "r432",
      "r433",
      "r495",
      "r497",
      "r499",
      "r500",
      "r502",
      "r522",
      "r523",
      "r532",
      "r534",
      "r537",
      "r541",
      "r544",
      "r669",
      "r673",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r568",
      "r580",
      "r590",
      "r616"
     ]
    },
    "LIXT_ReimbursementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ReimbursementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursed expense",
        "documentation": "Reimbursement expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r359",
      "r360",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r459",
      "r461",
      "r494"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r359",
      "r360",
      "r361",
      "r362",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r459",
      "r461",
      "r494"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467",
      "r470"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r359",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r459",
      "r461",
      "r494",
      "r688"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r363",
      "r414",
      "r415",
      "r416",
      "r468",
      "r469",
      "r470",
      "r491",
      "r493"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ResearchAndDevelopmentContractLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contract liabilities",
        "documentation": "Research and development contract liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs, including $0 and $43,264 of stock-based compensation costs to a consultant for the years ended December 31, 2023 and 2022, respectively",
        "verboseLabel": "Research and development costs",
        "terseLabel": "Research and developments costs",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r302",
      "r697"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r303"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r581",
      "r591",
      "r617"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r570",
      "r582",
      "r592",
      "r618"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r589",
      "r599",
      "r625"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r98",
      "r391",
      "r401",
      "r402",
      "r412",
      "r443",
      "r540"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r211",
      "r212",
      "r293",
      "r294",
      "r295",
      "r317",
      "r318",
      "r330",
      "r332",
      "r333",
      "r335",
      "r337",
      "r398",
      "r400",
      "r417",
      "r704"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r197",
      "r200",
      "r201",
      "r205",
      "r206",
      "r208",
      "r249",
      "r250",
      "r372"
     ]
    },
    "LIXT_RobertNWeingartenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "RobertNWeingartenMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert N. Weingarten [Member]",
        "documentation": "Robert N. Weingarten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable license issue royalty",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "LIXT_RoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "RoyaltyPayable",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum annual royalty payable",
        "documentation": "Royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_RoyatiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "RoyatiesPercentage",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royaties percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares issued during period",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r254",
      "r645",
      "r663"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Information [Table]",
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r466",
      "r467",
      "r470"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Related Party Costs",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ScheduleOfResearchAndDevelopmentCostsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Costs",
        "documentation": "Schedule Of Research And Development Costs [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock Option Activity Including Options Form of Warrants",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Each Option Award Estimated Assumption",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r95",
      "r97",
      "r98",
      "r136",
      "r137",
      "r138",
      "r184",
      "r231",
      "r232",
      "r233",
      "r235",
      "r238",
      "r244",
      "r246",
      "r408",
      "r409",
      "r410",
      "r411",
      "r534",
      "r644",
      "r654"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule Of Warrants Outstanding And Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r206",
      "r207",
      "r429",
      "r430",
      "r431",
      "r496",
      "r498",
      "r501",
      "r503",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r535",
      "r544",
      "r675",
      "r698"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r206",
      "r531"
     ]
    },
    "LIXT_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense included in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vesting term",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Warrants Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "label": "Warrants Outstanding Shares",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.",
        "label": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common shares issuable",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, stock options exercisable",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, stock options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, grants in period, gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value, per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, stock options outstanding, at the beginning",
        "periodEndLabel": "Number of shares, stock options outstanding, at the end",
        "label": "Shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted to purchase common stock, issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted to purchase common stock, issued",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, stock options outstanding, at the beginning",
        "periodEndLabel": "Weighted average exercise price, stock options outstanding, at the end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options are exercisable price per share",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs",
        "documentation": "Stock based compensation expense included in research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Stock based compensation expense included in general and administrative costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r263",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value of stock",
        "verboseLabel": "Stock price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable period",
        "verboseLabel": "Option exercisable period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding stock options to acquire shares of common stock not vested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average recognition period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options fully vested amount, fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r153"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r136",
      "r137",
      "r138",
      "r155",
      "r175",
      "r176",
      "r178",
      "r180",
      "r184",
      "r185",
      "r210",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r231",
      "r232",
      "r235",
      "r238",
      "r246",
      "r340",
      "r408",
      "r409",
      "r410",
      "r411",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r442",
      "r463",
      "r487",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r644",
      "r654",
      "r664"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r130",
      "r143",
      "r144",
      "r145",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r183",
      "r211",
      "r212",
      "r248",
      "r293",
      "r294",
      "r295",
      "r317",
      "r318",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r355",
      "r398",
      "r399",
      "r400",
      "r417",
      "r487"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r129",
      "r206",
      "r207",
      "r429",
      "r430",
      "r431",
      "r496",
      "r498",
      "r501",
      "r503",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r535",
      "r544",
      "r675",
      "r698"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r183",
      "r372",
      "r406",
      "r428",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r465",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r487",
      "r545"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r254",
      "r645",
      "r646",
      "r663"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r183",
      "r372",
      "r406",
      "r428",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r464",
      "r465",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r487",
      "r545"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r584",
      "r594",
      "r620"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock in direct equity offering, net of offering costs, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r76",
      "r77",
      "r98",
      "r408",
      "r487",
      "r505"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded common stock warrants, shares",
        "verboseLabel": "Shares issued upon exercise of warrants",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, shares",
        "verboseLabel": "Shares issued upon exercise of stock option",
        "negatedLabel": "Number of shares, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r76",
      "r77",
      "r98",
      "r269"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct equity offering, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r76",
      "r77",
      "r98",
      "r417",
      "r487",
      "r505",
      "r551"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded common stock warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r98"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r92",
      "r444",
      "r460",
      "r488",
      "r489",
      "r540",
      "r552",
      "r655",
      "r667",
      "r684",
      "r704"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r154",
      "r230",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r245",
      "r248",
      "r336",
      "r490",
      "r492",
      "r509"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lixte.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r366"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for -",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "LIXT_TheradexSystemsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "TheradexSystemsIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theradex Systems, Inc. [Member]",
        "documentation": "Theradex Systems, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r687"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/StatementsOfOperationsParenthetical",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "LIXT_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r113",
      "r114",
      "r116",
      "r117"
     ]
    },
    "LIXT_VendorAndConsultantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "VendorAndConsultantFourMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Four [Member]",
        "documentation": "Vendor and Consultant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "VendorAndConsultantOneMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant One [Member]",
        "documentation": "Vendor and Consultant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "VendorAndConsultantThreeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Three [Member]",
        "documentation": "Vendor and Consultant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "VendorAndConsultantTwoMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Two [Member]",
        "documentation": "Vendor and Consultant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "LIXT_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share [Member]",
        "documentation": "Warrants to Purchase Common Stock, par value $0.0001 per share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r180"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r180"
     ]
    },
    "LIXT_WorkOrderAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20231231",
     "localname": "WorkOrderAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work Order Agreement [Member]",
        "documentation": "Work Order Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001493152-24-010427-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-010427-xbrl.zip
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MH$CX0"JO93Z&]R.2P=V=0Y0F%*VCK]&8IR/!^E'>8Q=%(O#;K=T>.^4FYE]
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M\12D&2/[M5!V&S! 7D/AF(GM=F&/NX/MQ_^?K2WV7HHD?L/.^4CLP2!?"I1
MF&N/G67DJ;[!R9Q)NL?^Y$F!7[.M+9=_L7]X_*>'T\Z^-5!YKB9OV.L,>&<
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M;SR"NBZ5=9<HTYE,C=3[YO[(3VH=H9RA;=0L9F$:N+_7B8+X0E.(F$J][#$
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M3=N0Z$^,'92+\,E -O&$$@O&8 ^W9!'*!,G*!0\* _0VF(TA 4V8VF"HZ0;
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M/)D:27Q1X>K =R>U)+N@,@MZYLPG3+>TR9S)$YX:C#3/QK=0Z$[7$G<G!#_
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M9Z)RV"BB:(+Q&>#5N9 );*PNO+@4+;!MV^KU3P>GIR^;]9!],/3:MM_T@/
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MWSV%6V"-?1>U]2M6^<ZE7\V^ U!+ P04    " #80W-8(_^=5"$(  #Y+P
M"@   &5X,S$M,2YH=&WM6N]/(LD6_4["_U#/9">:@(B.+WG"FH"T*WDN&F0G
M.Q^+[FJH9W<7TU4-\O[Z=VY5-Z PCKY%1S=.@DQ7UX][J\X]]U11S8O![Y>G
MY5+SPFMU\,WH7W/0'5QZI\V:^\;;6OZZV;[J?&4W@Z^7WJ\[H4K,":L?3 P;
MR%AHUA,SUE<Q3RJNH,)N1"K#'31$T^OGMFNPF*<CF9PPJKKX-)@1=Z;*(SG"
MJ_]DVLAPOG/:/+_J#5:'J(8\EM'\Y$>#V+I:_E<XF]!3^_13,M231K/6QB10
MO_BZ?DDO4CD:FRW[\+ZM]^[&<BA-N714WZ]OU96J41/KSJ)@J(Q1<5ZVZI@O
M$B/2G04<7G06B\&V.HUG7G_0/>^>M0;=J]Y-N71US@87'CN[Z'KGS/O3._MC
MT/WBL:MSU/'ZKP>9%W'VCU['ZY=+-]X9><N.#@Y9[N]-J]]N];R;ZM6?E]Y7
MUCH;T)O#@X/#GPVM[4U  =+76+Z<=?-"F02".C_8/Y;)-EWJ5LJE-L=0G"=L
MBD\@4M;FU/)L+$7(O#OA9T9.!;L*0^GCK0K9I;PS@K6E,L(?)RI2HSF[4%$@
MDQ'&ZB;^/MLU8\$^1<&W3#7Z8B2U27EB/J6V8*^"U4G)/V;&W)R\ZI2^<T1L
MT_SZ?KG496..U4W%5(J9"+ @4K-6DF0\8GTQ4:EA*F'G*HW1J/IO=)(R6MM0
M:A]5YH*G3 "> >L(7\1#(.2H7D'D'QX] RKE4HZ5>R,7<'F_,_S. 7*X;^D!
MBPL,Q'-VFZA9)(*1J&S"2:#0>:(,\]$/EPGCR9QEB4DSP;3A1L0@,0(%ASO@
M9HFF(?=1!%:)I6%&N7IK%1) 2VN>SLLEU(GYK; 87'2J41; *(P9D52B0:B"
M+U,_BU$M07N80NPV&TM_S'1&?Y;M9R(5>2?D02QU)#BAE,VD&2,\]$3XUD*+
MU@F,4P$<G:)=P(;S#?/Q?I?]G:/VZ#'4$G,EP -A:[G^%6 5U?$Z77DO$[ =
MD"C1CTS\*".: \;6U[H"G,HTFK,)D$(H)_1'4;FTP'&.(/W !(1*(&F "M7(
M(E0 =A7P98?5UBZ?ZS$+(S73!;"7*95Q*G3VPUKGHH.G+JP10;FTT>SWN\;O
M'**?;>;EL84%EED.(V%3JP FAY'48Z(>6M,81$ID2L\!<FZD= :J(HI-5>3P
M,4F5+P(4:[8+. 0"^')(]>[\,4]&@K5 7OTL0HWZ$:_6CW?%'C4ME^K'@7NT
MSV@#O"8.F#0 (X9;P6MJ<4/&/'FDT/6<#Q1BH$)#+%%<+E$5IT4^Y. ;VB#L
M\KURJ2,TQL0ZVZSY8Q16**/[/--/;T*9=2@ J'PDEZM!WCH#F4VE)HJTV5\D
MMA_:."Q5PBI3IR+B%J$N6:^@K)*S.+V48%K8HE4D _1"A@ZU#"1/)3D@G:2P
MN2.AGF)!6=YF"%TND2BPC*JT@$4&%$ZM)ARQX6<1IU0 OZP5"SZF,''J8X-X
M0L%04'UP-KH1P?LEM[]C& S7PN#)3+D6#4_GV$U! 4UQ/RJH%@)I*@/:QG&M
M$D[9A&O$"0E?%(YX&A181'A(/I21-'-2$YN&I="TL+50=%%UK^I2.)5+-FO=
MY1Y-LG2"D-!6__B^2@-K@=70(Y% U42(#+P1$XHYJH(-@H,]8E-.D#<^@/^6
M@.\#^-Z41YDE24*%"$,(63G%<NH-@O13JFG3KI]"^NXQUZB;E37E #0';1/8
M@3<^5)GYOB%/R4Y\45N0Z@]7.?K1+1T;YMN*<LE&LG 3 \,:-,@'<-\0< -B
M; >&%6PYDK,G$[E>M6\V O@9/$UB1/E^EA)T5A+_>J^@;Z4-VM+Y='&*]BV#
M<$#?N]^Q)%19"@9]4#NW'+M#84]5Z,#%@M49MN?,&G.]T$G$O39H1  Q!>*V
M,Y*GC#F+Y*W ESUB>="@\I<GZ2-"?J+YQ\N3WJ"(B<J"S8AC5U&YI#7"U3.$
MSIKB7L"$0W4;1=*Y$!>V!'W&L31&B$<225M!OM#[CH2!U O;!79!V)I.2/!-
MXK\(.?$MD[#?1E>6^/849>]C3_F6J)GVE*T(,A*CRE#Z=(Q%1PF^%(!4K@L6
M>[N9X+>4X9VJM#G>"F)[;%P<E#T+J/DN#+NL<FDC_?$ +;58L-]W49WK:#0!
M,J%V*TYG:'BOLQA3#K>M-WG>V7BVV+!!\8'0-X10VNZUH!'"%#15 5Z$/1H&
MXNRO SDT*R[#RF2JHJF@-)OP4?XK1YJ?)HMX$JFYP-O96#D&YO> #Z ^(D+H
MX/:)J-[_FR%HT&I?>NS,N[R\N6Z==7N__;ISL&.?KUN=3O'\;!=G,C!CJGKP
M2X,-$;,BK?HJBOA$PZ#B?SOVJE9ST'_^ %/Z:1LZK9@PHR8[^<6OYJ#S?QM\
M?/#+-N>\ PR?.*M^YRG8L/XO^ZOMY\4R##K;L'JK1K?G)X^:ER]G<2>D'7'_
MEM7WCV&N/>AS73[+@<_;]:#9/:WIFC.\W;H9=%NM'ON"3\?KHZ#5:]:ZIZL^
MXD__K6#Q!6/^KX!MFV;U>%R$Q9NSS4U9<5W'F;1Z9^<#-C_-K($TD7B<FW[>
M;%VGT,NDE)Q-)$>_<[EK,X)J-A.?OO3MUE>Y QJ)D%BX&.0?U2H[ER(*3M@U
MI%L#/7W+L FA&6RPJXG=/9ZP2\0<JU:+1>UTOQ3&/;B%^$^ZA?BC+(3QE]IF
M5<L\U#KWL]JZ2'D@9M:3S3+V-T3TQHE9XG6EZ^7:%+@H,-&L82Z*:5F9S!K-
MIINQEU[*5[Z5OC!L#; UNKKO[O+3E?__ 5!+ P04    " #80W-847#Q- <(
M  ",+@  "@   &5X,S$M,BYH=&WM6FUO(K<:_8[$?W C=95($/*RJ52@D2!,
M;M"E$!':>_>CF?& ;V;&[-@#H;^^Y[%G@"0D36ZSV:3*2KLLX[=C^SSG.3;3
MO!C]VCLMEYH77JN#3T9_FJ/NJ.>=-FON$Z6UO+C9'G2^L*O1EY[WRTZH$E-G
MAP<SPT8R%IKUQ8(-5<R3BGM085<BE>$.-;Q\;JL&BWDZD4F=4=75WP8SXL94
M>20G*/I?IHT,ESNGS?-!?[0Y1#7DL8R6];\:Q-;5\@_A,*&G]NFG9*QGC6:M
MC26@?O%QB3F\LUF\'OY43J;FA=%[-U,YEJ9<.C[</WKUJ10,^*9C^2(Q(GWA
M=3OSAJ/N>?>L->H.^E?ETN"<C2X\=G;1]<[9>;??ZI]U6STV.$<=;_AZ"_M-
M)OM;O^,-RZ4K[XQFRXX/CE@^WZO6L-WJ>U?5P7][WA?6.AM1R='!P2MRZ1N$
M=<'+5X2?/Y1)(*CS@_T3F;SDE+J5<FFHQB(UK+_/_B-D,N&I$6AX-I4B9.<R
MX8DO><0&82A]D3(5LIZ\,8*UI3+"GR8J4I,ENU!1@,88JIOX^VS73 7[% 5?
M,]48BHG4)N6)^93:!WL5$#*EZ3$SY:;^08CO _]POUSJLBF?"Y:*N10+$6!#
MI&:M),FPY4,Q4R"&2MBY2F,TJOX;G:2,]C:4VD>5I> I$V!GP#K"%S&8Q(X/
M*XCUH^-G4*5<RKER:^2"+N]WA=\Y08Y D#;7V%QP(%ZRZT0M(A%,1&4;3P*%
MSA-EF(]^N$P83Y8L2TR:":8--R*&AA$I.*:#=$2J$G(?CZ JL33,*%?O7H4$
MU-*:I\MR"75B?BTL!U>=:CP+  IC1F0A:!"JX,O4SV)42] >4 *P<S&5_I3I
MC/Y9MU^(5.2=T QBJ2/!B:5L(<T4X:%GPK<(+5MG *<"3'2.=@$;+[>LQ_O=
M]G?.VN/'6$O*5:2T]?Y7P%541W&Z42X3J!V8*-&/3/PH(YD#Q^[O=04\E6FT
M9#,PA5A.[(^B<FG%XYQ!^@X$A$H@:8 *U<@B5 !W%?AEA]46E\_UE(616NB"
MV.N4RC@]=/B!UDW1T5,7:$10+FV%_7[W^)U3]+/-O#RVM, VRW$D;&H5X.0X
MDGI*TD-[&D-(24SI>X"<&RF=0:I(8E,5.7[,4N6+ (\UVP4= @%^.:9Z-_Z4
M)Q/!6A"O81:AQN$QKQZ>[(H]:EHN'9X$[JO]CC;@:^*(20,P4K@-OJ:6-P3F
MR2.%KN=\H! #%1YBS>)RB:HX+_)A!]_0^6"7[Y5+':$Q)O;99LV_9F&%,KK/
M,_WT)I19QP*$RD=RN1KBK3.(V5QJDDB;_45B^Z&#P]HE;"IU*B)N&>J2]0;+
M*KF*4Z&$T@*+5I$,T L!'6L92)Y*FH!TEL+FCH1ZB@5E>9LA=+E$IL JJM("
MB PDG%K-<':2?A9Q2@68ET6QTF,*$^<^MI@G/!C3Z8LT&]V(X/V*VS\Q#,;W
MPN#)2GDO&IZNL=N" I[B=E10+0327 9TC.-:)9RR"=>($S*^>(@S?5!P$>$A
M^5A&TBS)36P;ED+3TM92T475K:IKXU0NV:QUD\]HEJ4SA(2V_L?W51I8!-9#
M3T0"5Q,A,E B9A1S5 4'!$=[Q*:<(6]\$/\M$=\'\;TYCS(KDL0*$88PLG*.
M[=1;#.FG5-.A73]%]-W7W*-N=]:4 ] <LDUD!]_X6&7F82!/R4Y\55N0ZP\W
M-?K1(QT;Y\>*<LE&LG + V -&N2#N&^(N $IMB/#!K><R-F;B=ROVI*M!'Z&
M3I,94;Z?I42=C<1_OU?(M](&;>E*OKA%^YK1I6OJ;DVW( E5ED)![]3.D>-T
M*.RM"EVX6+(Z8'L.UI3KE4\B[;5!(P*8*0BW79$\92Q9)*\%/NP5RYT&E;^]
M2!\1\AWAGZQO>H,B)BHK-2.-W63E6M:(5\\P.O<<]XHF'*[;*++.A;FP3]!G
M'$MCA'@DD;05[ N5=R0 4B]L%]R%8&NZ(<$GF?\BY,373 *_C:XL\>TMRM['
MF?(M23.=*5L1;"1&E:'TZ1J+KA)\*4"IW!>LSG8+P:\IPSM7:7.\-<3VVKBX
M*'L64?-3&$Y9Y=)6^>,!6FJQ4K\'69W[:#0!,^%V*\YG:,Q>9S&6'-.VL\GS
MSM:[Q88-B@^&OB&&TG&O!8\0II"I"O@B[-4P&&=_'<BI67$95B9S%<T%I=F$
M3_)?.=+\-EG$LT@M!4H74^44F-\B/HCZB FAB]LGLGK_'\:@4:O=\]B9U^M=
M7;;.NOU__;)SL&._7[8ZG>+[LZ>XD(&94M6#'QMLC)@5:=574<1G&H"*_^W8
MM[&:H^'S!YC33]OP:<6"&37;R=_M:HXZ_S?@DX,?7W+-.^!PW:'ZE:=0P\.?
M[:^VGU?;,.J\!.H7!=U>UA^%EV_G6!FCXCIK1]R_9H?[)X!K+_I<E\^:P.>7
MG4&S>UK3-0=\.&A[PY%][\(#G5LCK]^L=4\W9XA_AF^%B=\PXO\.U5X25I_'
M15"\.6QNR=R[.@[0K1=V/ECSW6"-I(G$X\+T_5;K=^D+!^<RA6TFPV0-Z0.O
M=VVG4<WFXCNN8N45'GYA<Z/*JO"':A7#BBBHLTNXI0;P?\W@^PEW@PUF]L!6
M9SV.\VBU6BQEI_O[[4Y7(O_3S*SR^(/"C_'7=F+3/MRU%[<3R7U?<,<_W-?W
M=<1MB:/;3BH2H6VQ8LE&U^LU+3:BV(1F#6M1+,O&8M9H-=V*/6V7:O0VN7N]
MG-Y"_Q-02P,$%     @ V$-S6'5GODK0!   81D   H   !E>#,R+3$N:'1M
M[5EM;]I($/Z.Q'^80VJ42+SFI;J"&\D&TUA' 8$;-1\7>PU[9^^ZZR4)]^MO
MUL8&TMXUN2/)43520MB=G7EFYIG9,1A7[L?!9;ED7-EF#U]!_QBNXP[L2Z.1
MO>)N8[UM6*/>#4S=FX']OA((KMK0:L8*7!;1!(;T#B8B(KR:+51A2B4+*G@0
MCXZ?>JX#$9%SQMN@18O?#BAZKVHD9'/<^GV9*!:L*I=&?S1TMTW4 A*Q<-7^
MGI%4-F%_T@P3:K(NC_@LB3M&P\(@:+WX,GY.+R2;+]2>?3AL]/;]@LV8*I?.
M3NNMEW/%HUQ1>>!L>A8GNO;$=?I.UW2=T7!:+HWZX%[9T+UR[#[8G^WN)]>Y
MMF'41QE[<N#.?AKV[$FY-+6[VEMXUWP+:W^GYL0RA_:T-OH\L&_ [+IZY[39
M/'TYEY^AY^44?4'XZT7&?:J5-^L7C._3)8>72Y[@G'J*"0YW3"U +2@$+&1\
M#K,5#-B]HF QH:BWX"(4\Q5<B=#';=3K<*\.Q_K$4>A_68K.A,Y9HB3AZDBF
M"R<@ F J 9/S)0EA0F,A%:"QOI 1PJC]AK!DN92933R465$B@:+//O2H1Z,9
ME7#6JB*#3L]VK.WH+ P67DRIMY1,,0P)X3[8]]Z"\#F%KH@BEB3H,7I0!8M@
MK GA<$LP'#X:LXB.G4>ESD$5XJ5,EN@2* &M7^%3?5KOUK7V-&BMLXMF%0C:
M\$6L$/.V>"ZDJP,#D:(B<D8X36JC^Y"NP/24WM'54<5]HMH_"^1UX!^SDW+)
MQ0SM4C58AN$*/!'%H692P2Y)ORR9I!%69J(SN.'#,4'6R\W"Q;%_DC$D1AT>
MF86T6K!AP]&"GTB)<@GW6^_.SK-S45H-'4WC@PWOP;,CIP?CV+ BDN86FZ<B
MC&/5,Y[F\P%W")-(GEC21-.DJJ5(&*(+>!\SE,.-&&F25-=MEQ/NZ774Z[/4
M@NY<*+4,,Y:)F,K4=))21)_:]-SZP4;W![Q;S7(I07M(#8'#/V8VS&J>80_!
MBE>40Z*0![J!Y,W$UU?N]IVQP.J?412-I;AE^D;$2V4WZ2E#[ABR:J:;TIJ.
MJ&=7K%S2<L%2<I8L-GJ^?T?J5J8O< 0;!+",<46CI<D/1S?7M 8XK=N#P71L
M=IWAA_>59B5]/S9[O?S]DUV\8[Y::-'FFP[,A,0)H^:),"1Q@H#R_RKI)PN&
M.WFZ@5L]J.#@E =,B;BR_IS"<'O_&O!%\\W^8]Y#QK<S;!^)]!9XR:6#W7F1
M#+>W#^Q[A6ZMUI#_$>0ZM3.AE(C:8(7$^P-:]0L$G8B0^9GB)[EQOE\_#.>R
MD30L<^HZICG,'+@VAX /<F#ABM%P+K==Q#^3_PLMG['\_POC]@EKB'->.\/V
M"+J]!L+\42D#@\]+D#\N_:3-J\%RF0KI8QK4:X ;X^S*](25H=$S1G?!:("3
M!DX>BMU2& 4!PV?M;S.HD5[*#\:+8FC8Y.3A!+(E4FS^4JM!G]'0;\.8S&D'
M0>,<PST-M@.C.!VKVS! DD.MEL>OYUSO*BTZ_-M8%1?ZWW9]M+^9*[;GB(=S
MQNXM\O6 \&"0^+JY;XKM&R6T.U*%-$A/%-384KV):9Z(/ E& V.1AV4KF T=
MS2QBC\M20W]%DGUGHK]:^0M02P,$%     @ V$-S6.DRT\O)!   6AD   H
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M.*P[@\%T;'?=X2]O2_52^GYL]WJ;]X]V\98%>F%$ZZ]:,!,RH++BBR@BB4)
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MTE^,T:WM5??W#ZJ'+W15O9(NZVK"U%%\58[EIVI%%<Q>EX+9N"\+@H5V\"7
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M A;_5)N;$%N^;?YV[ODCPU6$M3K"FEKFE[1*CA8MRB5 ]0)6B<*OPN\&6"3
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MXJQO\<KX+0@"+))"<T_\A822V*<5"*7D8L1*JEB, L*: D'LTZJ!<*B L!%
M.%P=$.I8V:>F.,*Z T'LTZJ!H#C"9@!AM1PA;6@H(*PO$%9]:QAJH_7XT_[L
M:B/;6+?_R4;I:NM^;%8Y?X&AA<QA@;95F\,*S@K.BW'<'#!7PG%GU)Y1$%40
MW>!"-+.+=RA@*V!OX_F, K8"]IS 7J\CH\>N'GPMU[;]0M*;NL]M7>\D3 Q
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M)CO_L<>S'6%_#HP_;X:WD[_^8LLFGTSO&=@<579.CJO5RJRXGE?LAQ!KQ^W
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M%/1FIIR%[AX/M%2(?(:1=H>LT)M]EN.L+2%W9H;CK@:@?6OR^?-E;_)E]$P
MS?O14=Y.N]"+5B6+X7V0W8W.6>-_9YG_-!;]B^'_9*%^<=%\?<*[M3+A_<W
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MGY87$Y/K. /JXXH"]?H,>@:H[X:,LH)RR'Y3?:N#^"<X6[KA.#&FTV#O,?$
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M 0]Q0D^/ FXRPP3XO0H%E7S!Y,:^G D2YYT-74.WN@O#]] TO[4#])>;)E;
MP_'AA;"6X5N!CCGIMC4K7ZG^QIAQ'I379#=CFS836PN[7,7YB%"D,#<!_1U&
M&#*L0X ["YN,=4*A>X/?HRSS0'4C"$!-P*_DQK-^GY%?$/4'#;[$-VUT%[J&
M0SS0]QS= PD/';N&:]J&D]+A*$LTAM1>92^5 ]<Q_)X!S9:O[ATV063I;ZK[
M^M?=#MZQ=E@[P(2YMT@UR2PQM4(;1ST'&' *TGW;'W'7[!CZ-M /"]BG WV+
M1FQ$EAV*<4T[8^7)9=OL^PU\TO,;R7J=.\:@6#S<WEXTSO;[=G.\G*L\9HF'
MV>/*2H>#N:7#9H!_(REVPX8+P@O)*T@.1(%\] 5S66<*N32?2OA#("// ME&
MZC3%=DTGLGCT#7]-''OV'3H-A:],S_>9K!:);FOF^W@0ZB'YW]I>%#@32?U%
MO4YS@,.IVVS<3C@*6]AN,^YM-B>(:J/PV^W^ST%GD5#EIU_C,7M\68YPJ#C"
MRP_Z$1F.VAJ1@0?*'D=R G!)CBF2(3D7GS>BH#<].DT%>>Y, IN("@L(N2BW
MRST#]3_4$)D;D.#0\,P3?J(@B;CW-!'&"D&^%HH?I ]/?89UVMPP&8+02=,\
M@Q_&UO8JN]7*6;D*C$,ID.L#OOSA8#!DCB-M%_U-03#DS+.PM^\W;&F^LT"3
M9]67WB-%!3NX,-)98/7.B^7 Y_W_M)WZE[.*[3R#PR ]IBS?G^/NS8W:JHTD
M/8S9-P8#(#%4C$8\/)SG_@CR,7EJ4$#QX["9Q)'IN+V/:@^\5J A880R?/E;
MY#*]7BGIB!V*,#/&8-#?VP >!OK/_WVX-N@U&5'GCF>$/^RV0/-!O?+CGR]_
MU^V1__OPZ[<8PN<4' (CS2,PU<I.!N"-X*K/ 7Y0KE>RH':CD>6%%C-AJ,Z.
M+CX$=,P<N39OX&OG+ OIXYV3:JE:VR_5JOL2U')<$L[;<!R_]H-&6 NFHP^-
MZ:L^][+1ADFV!B5G!%=12!XH4"(D\/8JP$A__//;OO_7_]:O?;-K/XZ\A]HM
MA.)>N8+L=DXHMB_/4V#D/:3Q6*O@Q9*EVMYQJ79<F85'GM='Y)HF]8)B/R5I
MKZ"SQDNF(HC]B^&;0[U*Q+ZG4/X,@Y:65J E9>.YQ@R6*!C&H%^_?_12U*"=
M>O=T<B/?[,+83QU 0K$6<30X.O\45&Z<WY[N5V*!:8QA$6;=V_WHT+)HK]+A
M]ZP4U94B4B;321BMLI@9;_S_E,OZN0WB^#VIO.5K S3<<OGDHV7?RGYY:^70
M&U.+LOFXJ U]EXJ!VLF\+>*AZ.W3XO(W$HW83JY@#G]C3SZ?+ WT<"+^G9K#
MN\PD-K,27&93<"H?X.V_(TZ&59H7'3Q.KW%VT3++_-@>'I _+XF/2\?#Y>/E
MLIU.![KE N*FW8;)P7K!<7EVQ1W6IS?B0];I[<AA3ZZH/!641X(<+--+YS/C
M9[G'0%3" ,>TW.G%.B@&_&8LUL(+DR:E)5+1ICB=-['2XPHK0:=);D9!U&[C
M]**E79WKS:O+;NNRV]FJFIP;&2_\*Z'!A2PFOEK\:,E7BZ^J)H'0D6=$8SWG
M^..EJ^+*I3CP*NL$YF?-&TWM(VSC,_ 0E!^IFY"66']]R0A7D)YG_ ^A]]>Q
MN5%WHO2 . >^!V(0V;;GO]?]0>]-K;)7JM6/2K7]_;=KC-"/AC[TT:3^K_&/
M2J6^<W+=N.GJ[8_OC!74L5&P76O8?AO:(5MCK"IN^BIAN4QN*A3U,MK&_(V5
M[WJ[V_I" Z[N;BYTLV*BMG-R^K73OFQU.K,$Q28C>F^=>>R+(KBQ-1"N[IS<
MM#N_Z^>-9O?J9BMAC*?%BBD_!NG3K8"T$7!,?[V\:76N+OYHG>F=;N,<'7%?
MOG!'W/8!?+^F&/4,5#>W!M2@:S2_G[9N.JWFUYMV]_M6 KFN./6CF*YM#Z-&
M-\O-U77KIMMN;2=G7B6@-YHSU[<'Q7A#1NM3XT('+#=;K;/VY2<%YM?*G?>V
M!]?[.R=?VI<MO=,X;W6_ZV?M3O/BJO/U9CM9M9@/@GP-6;7R*"N/\GHSW>?E
M30?R@$Z=T*TA<"4OW5.\5$%R/2"Y4;ST)178_>U18 ]!@6W<_-[JZN=7-_I-
MZU.[T[UI7'9%<G.'G,)7EWKK?[^VN]]+\,1%HTL>XZOF[Y^O+LY:-_J71K?;
MNNGHC<LSO=WI?(6OKK_>-#\W.JV.?G4NWM6%5VY+W1CKS<]?DEH.MH=:CG9.
MP+1KW?S1.EL?#._O*UX]&WV'VX.^8^35EXU/+3REBQDT^AR^=CIM8-+(@.&!
MB^^=-C'>\_9EX[+9;EQ@C/T9L%[Q#&#XZT67'D'/<@-_V&JF?*"8<IXLMB,\
M ^FB6MDY^=^OH+.TNX#D/UH$<?CB0OZ=\LKIC=.KKUU=J#P8U;'%L#]<B9]N
M6P3#T?800'7G)&'U'4 ]20BND'>^7E]?T-^-F^_Z6:/;4(A_38S^>'M@CN$=
MGQN7GX"-M[DB YR]\>FF)>#^K=W]K#>:S:NO ';\ M4=_F?[\A.]D)!)(A04
M/;Q2"7"\13I0'6CCZK)[<W7!V3Z=LY]M^4&D8O?3F-Z>&-7JWL[)5?=SZP:X
M_?G5S1<R4]<'S8?*[?(0#IN[2[J[:0V N+]SDJ@+Z"1OW& $$[K,6^U/E_IO
M7\&2/&LWR8^B=S\WNL!_6W^ 4@+0[5RWFMON8%D-+:A33'6*N>6GF,_+QY*(
M$!42\AJ1JQBJ@N4:PG);=-YJ97MLKT-4>6]:E/!:TEM_MII?Z2SEZOR\W93!
M'LVKF^NKFT:WI7^Z^J-U@ZZUK?2F'1ZL,U-^4<AO1Z$"@OS1SDF"\^;5E^O6
M96?-? Y'M1540U0,?2:ZMR>/L'J\<R+38O6K;Y? PC^WKS$"!+AYM]&^U$];
MERW@[7@VPG\G%I\$G(C(D9GA?^M#)<>;026;S?BW)SFQ5MDYD41 ^$9G'1!'
M)X-X-)R_ZQ@;VVEP?UY)'$%R+4EO7YZU0&2<M;94"3I6J8USD,7VY#;6JIAY
MWKYLMJ]!)"3'ZOIYJR5"2UHW?X QL$:<?T/0KOPPR@^SY7Z8YV55->G8_D/Y
MM5\A<!4_5;!<0UANC5*[/?F.M3HZ^3ZW3]LB/+H@;EKO-#^WSKY>K)-B>[RG
M7!HKA_G!]H0LU?9V3C!F#GXL_ZYWOG[YTKA9HW)X&P+G#5*(E8KQ*E4,I?D^
M*U?=!W%Q>=;Z4^]>Z5*-6".NNO81R0IMB@DJ)KAIL,PQP8.=DT[[TV6CNZW9
M1<>'2J?<!MPJ=JK8Z1K",F&GKKB)H7EUV;FZ:)]1H$%1)O_Z<-GS<C6+.7$5
M\ 9<5K_HA=FU#_K5&*^M#=YC+QUFXA\?]#\,)\*??^T^[>V[/KN<7DRYC!_T
M[F0, VCX1L\V/^B7QHCQI;[T< %KF8NCY5OX2SG!V<=?OH@;9A+C,X6Z!!3C
MDPV[S'I#KX=NNZ'O69$9>OY$:WJC$72RZAN?8\9.7]JNQ;!1NLQVLW;DF2;2
M'8(^,!AZ4:B%0SO0&ZX;&8Y^P\:>'^J>JY][_H@\RR4]'#(8C3\*="Q(5JM\
MN&,E^E3](+^)@OPW7N07? 5L; 13F.1_NK#OP[A1#3L4/S3Y\_)QP[7TU*\W
M;& 'H6^XH7P A"[S@=/IU*)^:GLA,X<N:#V#B?[9<Y#OPK*T77.WI!OZ&7.,
M.\,'MNSY8W&#>8EZH?>US/N/O8;SNQL"GYZ4O3N7 5>->H%MV88_V=TL(MY0
MQG-^=?.M<7-6OKBZ^KU]^4E+*U>*_:S31+K <[39/$=_DR%R_%T0^%L@.3<T
M;#< "/GX 1KW@1:MLN-Y/X&Z87Q&R%#F!+O8HL[NC='88:74#\ F!O */*TA
MT?9MUW!-&\8R]@*;$W,O"FR7!8&._"5DP#V0*W@P+E\?.P;T3W_W_D*5\18F
M#\/0^U$8 5?PQHSSA(#S$B,(HA%7,^GOL<\LVQ1_]Y 'BQ?'7&[J%H-%M&#$
MT7CL -^!OZ*^8<(S,.02+$$0!OBM_Y.%.&7>J(U*I([/>3XT#.T9CO/@\G2'
M+&"I;S1\:<!<&#YP,=TP.;NV@9?U)OH=Z*2P'I$YA!G)W;&!CF&H.7X.'!E&
M,S;"*4G18X[-;J>^9@"[4>IQ37P_!OX+;1G.&V?R-O\20L%VHZG&4$DTC2#,
M?R_6?>IKV,[\=R-CDA_*G>TXTR.(G*G)WQ5]&0R+OF7W8\"/_!(0A+AW 9R(
M*=WK\]4FX:O!KQQ^M"D^61/XB\VETZ[^C>EB=:$9(Z2V\M#C'7)PHK!TX"_8
M72 CZFDV6 A/H(0'GHL]E[2>$<"+0+6V"V^-J$G=N#5LAX_,TZ, ?\916-"*
M#D-G7A\I*]3O0'0:KNN%-$!H>>)%\:"#1X:-&X&D<LLTZ&5HW.*\F8O"&/8]
MY,MH4"?T:&C\A!9=Q#,-4OX(>XRD&,#T .P]1G3MPK1W05.X@V7T2V(X#R^+
M9KLX-VH%1#YR!)S^3Q>T !I]Y/+/OAW\#,0W@GN%-@,Z; !I _>!L40.M$E,
M"WB(3782#M.R^ZC7((7X-M%FW_=&,#H/1L<7AUF(D(3P:%-Q\1_DCX)9T)(0
MF&%?(FC3\XG1^C;L%FTFP8,/ T<50.NF$UF,[R>" W?3L4<VCB3T2LAC(\=
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MFZEY"&T%=5P64)RS2[(-^ 9W9CG>@,<):G$:@F/)) +8#/'MT(LS"^0YTQ:
M<JG4M7Z^IMI*?$TOY<M[2:!<W1H@8EP-%'W#YVX($P26[:*TR]I%MDL'8/S0
M913)1!,,1@#Y?%-M8-(GGD4!+=(QES@J,H$[>0X_1@);U(TE.K=ITNYI;29G
M!).K!(8;I=>8/(NDC[4ZXF-82ERPX&NP=P>8X!#YMS!8!_U&;G8F7L33?N0<
MDBADR0&T&Q8":QKSM#4\:*/P;CS<SBR)@8'F-H8M)\?467\[<'%*$TG[HE$>
M0.?F<&JLT J\("U/+=^96.>"@7.C5'&NM>=<]2SGVAHM**/->[V ^;<)?_ X
MD]&+F$Q6?T=G9UJ'S[J$XHA^Z?'@D2_(:X0*0TS$T$>>ZYD..3Y1B^AY8 A0
MC L^>GU6KB*KDG$JG(_ T+D6$^AO+IO=RD'E8'_OH/9V5S^/?*1</,!'MRV0
MK$?-<*]5KV",8V087A2 [A&YDAUDB9G[X6DIG A:X\RCE')J]QC90, ^G917
M.Q/L ^RB'Z'C&!UBL*(];TRI(26= ? ]3(X@'JM! _^ :O9/-#)Z?'I[^P>5
MXT.<'KFZ\W.0W9..Y?GB# !T+-3$\"_.09LV9WV?O3$#$S_M:X;_-HFD<$'.
M(M U64E3L6IK.9%/J$5K/+4D?8A#>R[_2!,UT$)( 8GV3^9,,B>RF'W58T(3
M0(/ESIA,V3ZQ*)0^QVT570_Z%/>53W&I/L5]Y5-< T:V?CK7WI;J7!BCB)GY
MH$H-90RLX,(!YL7S4[Y$G0)!7*M4#D2^H@%*EPBB Q/G1K:#//\L%3_;&/B,
MY\-*QU3SIG'6B%U3I'%AS['X;[LP^S#BF8R7+/*Y*T8_LP-B-CPXL@,&UD]*
M$+YL7YYU1*)D02MD=GUFL'M#_O1GG6>0?Z'QUFHE/BN*+, ))XFL()I@ S#(
M$ ,/J)83&J1\;3 P&.9E\31*T--L!Z4:+Q9!'<"2-L8^?%W%+M(7/6XN9K8*
M_&FKP7 ";U;$BB",6DP8,J2;,H@#GB\-:G!(1^7,,,&B=S*AX6 4?#YK-.VW
MN[(A&98K3X<UGLZMIR)@D-GC0'C&L0A3+8CWC>-:^]S22,>O8]D+TZ,J/%CC
MIL=$Y0F>)T\1\/GP=RT7_IZ).C& %GD9GDR _T3G\3ZF;_<HJ,_Q[I!?4#:_
MQ4+#=DIQ&!XF0"-)X?1Y^C%P$*"U<>3CR0J.):5%YH>#X\YL!OE.T#<$2Q!P
MRP)4RQ"V7Q'<"^:RR>WKDD48BP$5X[L@F(HJ"]_QRL++FZ$XI]2RYY3-Y% 1
M99G<PFU>B.W?ZA8_Z[MEVF\1,-TZ5TZ.LWXT4JQ)Y4,&/0L(W$/OIH(%/;_<
MCO5%R0)TS@)F'8IKRS\4+V7/NTM4 </P_8F.OGMYM(_!HR&F6,H:>"#BO!$L
ME:6/R3G7?M=N"X]6(@?'#HA,R[OW_*B'(9'Z;;";^9M'S*%CT/8#K-;DDKQ-
MA8'U04;Q*(* ST.,>U?#Q!T0@V,O2.IX3/O6L'!+C\KRI<N"I8O'B.(P& (!
MKYH\?CTP^N*H04R%^P*E;S U!XSE+!@F3/0L-5&;A\T/'*_']177,GR>E"1#
M#,EY&>?1/; "06$@Q:YV-K6P<1H='<$8=.I+DTHM=Z9;;) &Y=V"OK)7T2=@
MJ: *AY/FF70B39>#FLJTB0,5RG#B7A M"?)-M W<"9]G,Z&Q02E4/$&BX&$<
M0VJ1*7X1*&$4)RJ4DHTAO5*8(*D<!8WBFOD!?9PC"'-,XT\>41GCL>&GHS!Y
MC.\+9PLJ+KX<ERMP.TKM,W27A7>>_Q-AP/-/T3(@!DX;3AR0:^\8+A&( &WN
M="5]'&/)1U1;"2WYT$<W(>C?8#50#AVR$)M#43CP*4C"=;U;LOTU&:N/H5)
M:]D\6P.%!1VS4B(\<'0<NCR-X+4W4RR)QP(#)3G$AT7<K^AW!DLL@?&AW>%1
MB!&D.T*;2)XC9TPK>HL/<^#%+)6?-E X^SV5R82!5?=I2-7#2G+^(@^1<GP9
MN8MFB$1$&NF=1Y89&BS$<GB/,EHYE?:(@^,BJ<<&ACR6Q3)7/@Z).R!^PX/M
M>@6E=:U.I:88]S4P$1K-DSLM+!E 7=3XN8YH/W?NDQ%86(F9EA^LQ2#%IH4R
M2.4/*/;9& PD3&2\,J\[17:S[(JZUVK%,Z1*9)@!2WE=!H7G\$8]M]P'K"3,
M5TJ$Z_.48'=AHW!WT3.+\Q G>:E6D".#$0[X0NZM(0C)Z'V+S^_M[N/I7CB,
M$QXR*^&/9':%X<#JNMRY)48*X\ F#A]L@M0#:3)CP2W<*'B<UT[##!H\>P]"
M48,LG?D+=G$<+<^+M&'L@!W\%%GQTQ/L381PBO>O*U+H\'P2"VUR'0XP.2+C
M?0)B!5K3N(V-E0-0OE@\5 *S6G+XWZ_\2VY?M5*3A>B$*X*+^K[-CTE%XS;^
M;)A#9KTV"?/@6<V!.JM9ZEG-@3JK4:K1/)Y=*Q5-$1?QE560IZ6XJ.XHZB3H
M%A4#?T0:5U*EC,4+:%IK^%,I8_&FJO4:$6CI/I7XL&[M0'B9Y;AI?'AD06<.
M=LA3;2C33CP9D$Y&14FH=C-,!F?1,SB'%UY4L$%@F4N:'29,.RY;+3M+"I]C
M68D[JE7ITB 3O8R?^<AJI7(^N0I(F0KJL4$H2Z!K\1<\$,^PO'$H+G 0A4.%
MU9J*V!4SR9?28/<VSRF*0X_%D%^;T-FR&;9=C804(B$-2R,'S"F[0>KX9%P4
M)0(FGJT!,&:,#7.C48]1QC*T:E&![I272.,1GDYHC[%2K8%%6; " ;=E1KS:
MN:4/R+@2*;"\6!".-!Z!+-G$G2+9G-HXP80G9<AJ"=25K%M-PP@F+@;7V($@
MPX'G63EB&_OH#D OP9M/7Z[?2KKA9RN23L5!*CR/-?KI3+9QW7Y;DOX?GF4=
MVPBHQHF&@';9.)"9S)2E279*4H/% !L0MH;;.- JG1V'J%%2.FBJ+I)8;EG1
MB*&7(L@58,*\9+%T)7XT1S/78&YD#-H\-C"5&/[(B J;3L88".Z3# XX$6P6
M[=LXXGP:76BH2E.&@2:M3-I\T*6QU)IC],B-$X1X[D6F 73'XY0MO$1'5'H7
M/^CY,S]IMF.O$3<$I@U7+&6OD]O/T:!S!XO-X8[)Q:!"<EB0F;8,Z_*[W"JF
ME9Z]T/Q43_Z"W8O3\)$=BFIV!*G4?!-YIDEYAHX ;(C'/'-K2I*'J(K,0P-E
M];%\D*;BX!L]PRM7NS)##SEKM4[J42W+@/%&BHC\"[$B(M6)Q@"4+IYR+>H-
M,![L(<(W1.D!X''TI&UD3@L,/"[@L:-(!EZ@3>0;7J!WH(O0\&TO?6;0:'VY
M3C+I2,?B,/Z')(0,T7WG)R<#TK?"F7<L@$J%:HK##$M+J%MX@DM39P@E=*\$
MN7,%<G>7ENABU]Z@>^[M+@S3C2-<2H5J<%(H;"X-N,XS,7@>OX<7 84BB,+
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MPJ5X_M9P(E)>A=V*G<C+E6Q^N5(JR"J53I'>(&$IX3U.W+N4Z &IDN9) ?
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M[G9V]7.I7]'USPV!I53N'(::S;PN.KY?[C*Y.+>12D-.4U$1Z>A/)YU8J2J
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M!_H N!CEZ* $.E[0E2<1P"0G-()L>A'7'KDC#\>27$6 FE_VY!VIW<<Z?^1
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MW)VK>,U1R$M1^^)\38(DOM!<I.N1&3Z1=L%8Z/E%GF7/U\7#1;]R-YL8M9=
M-)==(B.2**;E WH2^&"US&#%B(K6A=W;09@,D9_MQ6,2%(GDE,P1USD*LEVG
M[V-*>+A(N+/=F-,+1WI^%'&H<O)ZDN3,799Q44518?I#["I_:)L,5R,]G-;0
M!%H/Q5%SN@1X-DT^#QEO)G^(:S+D6)WB$&LT$51N!(&AM.N##> E?O#\GE-H
M?*)ZI(Z:;SWG5L(WYP&8=D)SHWP$LZ<JESS>G&KLXQ4L\.Y=B8)<!C)4@&LO
MF=18'@594.H-IN#(3#,#@<PK@SJ"D.$E*I6*G6*B+OV1(6=TD6LI%SG7-F"N
M?_$S/K%<J8(DPOJ&IT<QP? (@*2>>\H]R)D(V.2@K/092Y8[33H86 $\8FP(
M N(M"B+%!CC=6A[C]>,**#;='.P0T2+F^;J*&-=S(NWL?9A3=V'&@;R\[N U
MT SIXSRO;VBSOMZZ9V9$WEM^7N*C6\1+7>(%*+6Y/VN6S./5L2EU6RL*#4[T
M/H<-Z!@Y L75*:5O<<RE&M&U#BFO^[28#<63>5Y$ERBA.T&C&)^QPS5:0_(>
MTFH,A^8CW_6]@!:!=-M %L0M/L%/V5@BNBC(7."1W8$DKT;+5A2(*Z80\=EA
M0I=<=HOP2?3$,7X7"K]:$AK JF1Q:61&=UPHHERCB7SLG7RT3[@ ^_C./L&0
MG8P[-Q==D2OK;@?I<!"2-N) \](#J!V5CFJUTMY!E2!P6#H^/BH=[Q^F'=U2
MT9(E*XI<V**$?Q%MI7WB*5=X/AH%>TID'(:X\K):A-!Z!04'(/6HE"JQ(6HX
MQ Y7K= QNPLCHB1Z<HM,B=P'^ZT=[<H;,-,Q;^)$+TC%Y/)S"5IGK6B=JY72
M?KU6JNQ72O@9>>O^T2$M>KP%BRXZG1ODEY$3LNUK\4S-9/J/+?/>/,M<[/]^
M95GS+\X*T"481PYU160VOU$.1'$<$-26P3\QZX@OR$R]'V;?+PHHXDJB//$5
MT4QVH*68BQ$;U"D*2]O-,OIBF@AG^'(*P%UDC0.HM:P1^!#%\$.<[E1\#."\
M =8MM$K:O<]BFT":]1WR@]$YWAE#>I(FABA9B:$CG^G^;MC!6UM&^!?.@)_)
M\TK]O%Y:_-C4Y!Z@V,,"2N6M:(H^UY,^FX;?\\9TR%K26Z&'XL3B40Z-D/T#
M6N<_@*'>_ 1KIAMDZ08U(]5@EH*#$9B'9;JAW8G2%)U6%]+T7,J8K.)LN@BP
M\3E]6H9I#\JPZR62Q%Y5D<2FD42#9TY,70W3%,KL_+20RV3BS=K99N,KH8,B
MH5;BAT",3K+P<$:(0'+>8"X#V)B4AX$WF6 ()$@$,&A3UJ5L9S8M$6WFI. ,
M(EI4KG5 31W28#\ST#V9)<.4?S?<GTF8<A12M;EJ]8/6<$//M?4_8,<O&(ON
MF#OTV$_]/S;["1\C.U@R?=9?B#[7+E:BJF(EEALK456Q$DK<).(&F7M7,G>>
MI3$E2#(" /<^"&/^#:3@Q8&L(K8BKS !TX6I>*+ P,B(BX-'=,"/2I8V_0[=
MA(KUBF3;> EK(G]N,?8@VRX>R[LFCD]/?^=[04C5FS/?T>U[Y@2/XQP6_<2;
MP4J:.?2!S9MZP8_DSS<Q=<69C,;#_*L/^I!V]>-2Y?"X=%P]3"7_S.TSXE>1
MI<)0;,I,6MAU4>BR> Y'A<IW>Q)M7OL>+VQ%9@]5J@JFB'.<?HB7LPK2GK9"
MCV:U4CJH'I6.*X (@.714:E^O%=*>]F.2K7:86GOL*[]DL_S0??;8AC6N#%_
M4'K,USG#PSF?CS)>3CK_FUK-8K]EM71<KY;J^WMZ"3[78(S52JTTPY]9O,P+
MNI:UE2VS]'+.N<S/HHZJ4Y&G)\_&AW1H\<T(!YD^;!>Y,(D;+AT+0*?_?)4H
M,8;RU5(%#Z::TXH,(&'K*<2\D,P40J839U4U8XN_#,S2"\9@7F-J43O)EQ7F
M,'\TE;+UE>I]RRS?KLSIW; 5V<AMO)K*>R6)G?T:,V!+*!] &ES[Z)8WTGNW
M85,NVJ>%#/KY)_:XZ7^$IC@8L0_8^MSU (T9YL^!CR2&#7K^>_W;T [9CK"!
M$]/_<:>&Z/Q@[U\R29H;[TD;XHG:O] !32L2MT<M)<L([RT^@$+O!,ZFC.L-
M"^5Z=[XQ3EP6!S#2-DJ5=Y_HSN<S RLF/^N8DZ$4C7_GI)5$BR6C0W?(DK8W
M/?K<G_G)I(=' >$[RWOY5V;D#WIO:I4]T''_?_;>ML=Q(TD7_<Y?09S=>S #
ML*N[JM^/]R[0T[9G>G<\-FS/,2XN+BXH*25QFB(U?*EJS:\_\41$)I,45=4N
M5U>1Y3S V6FK)#*8C(R,U^<AS_7ERS]Z#_?N[^0I/J/SX<7%V[>W%//\Z?G;
MIQ?/SE_<\O<73U\]A;MZ]Z_N_;OX(GGU^E7RXN+BM@_W[.DYQ#M_\^!/=\UK
M?/\W,HSGKUY=O'U^Z[=X_O3B)1[TY8,_Z-%KQ-,]?_WFS?FSV[Z%%T_/+_!P
MKQ_\X:YYB]_\$%^<7[QX^?+9[9_R[32><O@*OWD74R3]YMEM;<3KIQ?\9*\>
M_,FN>7__]4/\\M7;YV]^R_N;Y@[\^T]=FN.6PKU1.WI^ZX>[>/84V8TO^@KI
M0=_0:4$GQHO;JNJ+IQ?/\:#/I_@67>KJ]OOP!1[NML?I\Z<X9^[E+;Y\<9Z\
M>'G; ^.M/NCM%^K\-5[CVR_T&C49>?NGFX;'=OU+= 68V[^$%Y,UJ%UR^;>I
MV+0]4WG0YV_I-;Z][5YZ^Y0-ZFT]V_'GU&+Y7%,GDQ?ZV[+:M0KH"MBFXY17
M/)[RFMESAKR6RVN]FDU>Z_G#Y[5N)?.73G;9"]S\P+_JRY]U^?Z2C.;/[ON.
M7S+I=O[BXN7YLUL?_B_%@[OMF?CBZ1NXX2^^4++FY<6SM\^>WS98/Z= [S?E
MW.[NZ:YYBQ_^&E^\.'_[XK;.Y8NGSY]-\Q6*SZ9=$+=/"L/UOKCM[U\_??GE
M7R$>U+6!W#ZB16;JXO;I@K'7&+S3+ROT#\(+#L?T)T4N_1<:)9\_^<.+)]^9
M9GO(@<Y7I?2I>7+^A$=;BD/^QR>OGW0N:_S_7IQ=G)W_?_%?Q*5]<B%?_'3(
MLV7\;IFMYC6($?S6&?B P6_]O15I.1/V]NV+Y.6;VYXRK[3^=5N/"F50G.?/
M7SZF<^KZ*9:+,,5RMU,L%V&*Y??E8C4F*R*_*_'BG=^8V!MC^0[3&ZM#O<_3
M&D,:Y):MJG(7\H'!KPI^5?"KOE"_QJL7+Y^_>'';,NJY]C3<-H7S6EH%AD[5
M'1887Y\GS][>UFE\*\7Z6SN-=_AX-U887SQ_D3".U&W=VS=?X$7.VSN>OM!'
M-44W?3>S!PE.0W :@M,P"Z=!BG>O+EX]?_;ZML?%FZ?G+W_+<?-2LCFVP':G
MC;H_Q,\OWKZXN'5A4NH9MZ[[W.&CW5"[>_GRY6]H)[YX/9&G'''\W'#XK9.%
M+W^+VT</]_S+OT)M+'M%?WQYVV[4U[^Q!'N'3SKNO^N\_ZVWXF^KP9YXO+OS
M:J?NP-XQ2 0@X;]CZJW 3GT_0M.BORN:[(G,.$=?2V@0UO[!:%. _Y]GYM(#
MT]^9Y38MLGH'G Q!T.A@[,99#M9K X(.179D%"*RIE<-(_2L,G .,70XP-ST
M2T#UQT_:"G_*#Z G!@.CT/LZYNZV-F?Q7WVXZ>OH?I4E")Q[*<@,XS1>5"7]
MF'EAJG;'_-CE;J=3VU5:D2A;!E(5N6H I/ #+-N<"4WJ0]V8G= .67B&I(^
M?:U(4'?[S%8\)L?*=O1\NW)E<O[])L_*!7+M].*B'0C:P0%AE*[4_D6@]W9F
MU>:Y_R$$E@? M? 3NGC# !2?MW[,U-A;Q,@NXL[DJ2 ^]6"KA$$QK98 HSIZ
MHB$1IV$=R2[145QWKP',T#4S8W3+)- Q[HJ17%'(*?22%@YW='4="92]Q9,3
MMRB7I'XD*D#LE4=:%X4W@S+]UK0ALS5I(ZMI)MA8P+;_E"U[+Q,ZTB@A?<4%
ML7A;[HTR6ER!95+0)"V')M@)5J =\$6KS(;V++ -[?(#)Z9I=\ /.^RQFQ5T
M@JEVE+BTQXRC^/Z.E*PMTB48/SF!X<O-FA^(K![P-!3W(RLVT0^TR<)1^, X
M/Q7MX^H0;TI8SY+I;IC6CDER0/N;?C3,%&>_::VJW91@)A"6UQ^V7&#MCK*F
MRLA&Q.8RS5LIL9))8-18-3J\G]7 1;Y)D+W-W'=*1&YM>$%;/V^$SLP_XWQ;
M: 6[,K$]ZS,V4[!C94%&X1#GV4=@&M%70/&USH""QH2"!7EI2O"U[T-_T7?H
MQ52'CG.D,G4C;& ,XZ?L$&DC;'UD[(1?'+A[;E$\!J6S^"_E%=!T651AY]J3
M'<4"E!$= >E!R7Y8+%K IT(EB*4$HSA3=K>T;KE\KVR$P1'D7*UC*W9T8H#N
M2MO-S@&OKPR=%O1(J:4G XX7, )A9,T*5KD!.8L3WKY*]2;2GA'&D4)N CT>
M.T&6M(C9,P<Z<19_W=U:N E]!VC=YGQHRI(L0,*X9[RQB/E5%CA&&N6H=J?3
MUHP^=K#U#V?K?R2?A-RE+4,+?=TI?K#Z#Z=+W[85-NV0RWW@WF>=ZX]3P+?7
M2GMFK6/YD?8X;?^G[H/5H2#9EC$%516999+C7[++_Y"=F;,D!FLM,\"E$;S2
M>$\^? 8N)S6[B[PLA1C-?9.IY_!=,BQLZ4VLL9OC3VR (=O\D7\G>++JGK/[
M)]3HOOT2PE;P6@F88[0S[);$WW[]SCXC%H=LU7>@QCMVIM=IQ@R/_DHNNM-J
MU ?U3#Y8/1@I4@\4&X7R84-^MZ7&<R\EZ2ST!BLDIQFS9/D1[>>_23*L*AQS
M7")4P;_%1Z9 9PV6.E"[DTNMPY(N<A *+:P7K'M9H/;3&7-YKVR \97/"@D?
MJ:&^OL/S>>CPO-L.S^>APW/B!]P=^Q@_B)L7!?=B$A;P%PKDF )V\0\EII;S
M=&,G\<'_E#664+(^C@S>.438_) (9+"\8LZ32GJ6PJ5RP1R-.YM.B"6=FN;*
M+QLY6DP2NUW3L=,R#?Q>YJZ8C9W.]2?V9UZ$EC:I$M>6NU+!:3LZ=A:C;DD*
ME2MQIZGWU,H(F>9TCE]FM'Q\05JT<D5^2%9P[,KKH0186"9\1VA5=,%*BC87
M] L$PM_@>,[6_I^<[ B W3+!/Q"^:F$-M-^*E,S:DS+/=EFC[T7Y[DDS@+5+
MCD=;Z\-VQ/?V%GHE67RS$HKI@E^([SI)9IM6F0(U7FSWMJ+&"&<OQ_%M=6EH
M"25U6I(_4# M&NX(+Z1A[&$#TM-TZ?B\;7P7_Y6D)9\LJQELF_\.CIFL;&LD
M6XN/17G%/-QD\G?*&.K'Q0E2G'G+##+DM-%[6V9[7H%T11<D;XX):P3;>_#)
M>O +)L?)1.!U):</:7&G@B0I_>F42D;X&;F5S.)=LA>7'RQ3LGOM_A(G_"[$
M&XMY^2FHSI;NE?J*6E]W:[[+JDJO2%'Z*UP[3AI]X4E\6>9M ;8VO>+*"@;7
M-4$Z!5>L6])RQO?&0HWH;9TXC:I-]B]ZZAJ<0/]HBZ6B=H@29!UL,#(%M!%S
M5KF*U!>;D^Z2YMB;C]2'G/[Y10<QP)UI;^,MA0/XX=0')?X\6Y/E7&9P?>LN
M;TD'PS;;;'-)XO*[NC1J@=V1@+RKY6TOUYS0=(P!PH! 4>K&G,7?LPEE&D?Y
MNLL^VJN77%R$:87E^ >XOX[)%"@&Q..05W"%(B3]+XY&NHQ@QOM\!1+;]YYM
MG54[ESCH<TXRXTDAYVG$% 85GZ,<S?L5,Q%!2H%TBH'@K^(<\0:3062PR9S1
MT93!M6!A6':N2CKG@]:!CA1(1#%X ?]D50Y=F9VI-JBW<AR])!-N:23&T\U,
MZ-E[?'V1$+9O]'$:T:E)AT8GQ\(P[YJ+S"4/BW//>SUG$=ZB^935EH,-M#=[
MJ5OZ7^0;:J*C.S3T!W)(.%HU%L15/V5!2I0=Z=N+HS^#4]MR?[-CP&CCG<IA
M24MW:Q0X385WX9U.:0UB;5;(H<AT_"V-/CH[C'SH.3)QRP].:_V4">B6A@X7
MDF+,R1)GQMY?IO6=$!(MVA?O!2/LX)4CHE6&,U">)X(R\RI;"6/J JP+C<$1
M"#X$;\>&0VY"#X)X!XT$J%!4;)0ZXTJ*Q9Y36X"#JI;HP??Q)3N.: "\@6P,
MI-V!U @[28M4Z@F2-JCSBI]+9@]FI!)_VID)]=90C5%CP)T$%;,G8@<6)9E9
M<KJU58%VH A45ALRA?_2>("#&K0#V+W7VY-2SN\:!> 9T_^D&T->VR67\,I:
MKZY/4QOSD>M,;CN3A2P.XJ+Z2=0EEWU@#7EW+-H:_F1P[J;T(*3W/9W\-3H>
MFV)#BK+2>,5^04_D%'EM.J81^6LISS>=?$S;D]D=QWRHNG-Z_#A^!*O^:-0'
MO0?I(LL1*GOFC8_KNEZW7-JEHS-%'Q/9T:*E8Y<"^ABA*ZD!PD2-V?_7(UB.
MZZ>O_)S],*?_JQ^VE](_F?H?CE]][O6/YZY^M63/SBYH=>\[X!OI1_]\R4>K
M'_?].&]?O7Y[1\_SA64E.\^R(3/XY*A-TL_X6O<!I<8=67P)79T'CG@':>5+
MTQD1WROO+<?(<,1]:/7<U7A&\M^[J$&EIJE2\S.%W,*&:D(M"3GR;U>'.+U,
ML]RZ22=,XZ+2F$J245_AYT%'IZ^CP>Q-_CGGIE+S,WO.?:OWQLZ(N H_MRO;
M_K1*BL6=_>L:T#C?A1YKETMPUM"FO*4Y4#_T$DEC0Z6_.8*4__L@4<Q\(^ /
MZTA?>5O8E[Z2LD2;U?V"O8[5';G["2H,V7KD+SA/EUNOA(W"4=TDMO]_86\;
MG4I&L&KJ[!X7]UN>E?-K*8_@+<RU]OS-;I^7!Z,DMG_A\<;WZ3YKTCS^T>8"
M0U7ZX13K'0-=?\?6^1P<\1<O>/-M4PP+5L;$V&9/*,J'&[S.EJ9Z:NQ+E7QR
M(8,PX]^16<GW7,Q%:2W7NF':JU&83\P]CS:2MD&=E^N]=(RDJ--Q779UF=5(
M,_-^OTPK=!%Y5=_Z8Y;;64]4?)JL]@:)[?U19T$K#3*7:1T7!G8$W3+2&,;]
MBKT#"]?S*R#X[WYC'$S9IDHQEOM+5Z9FLRB'*'VRS?9==U.W>MK>798KJ9&J
MZ2+I,6_+LU<K UKUNC_Y&;=[[0G39C;N;ZHN:>%M8OZC.7#[?ED41BK6^-1+
M[*9-@QD VW? RT>7<<+QTZ"^2D\3]<66)]F#B;XMNLX[]#XUPD!?X8D?J=F]
MOFW\16@;O]NV\1>A;7SB)]0=>PS?DC[G;%6"6S ]MT"!"$KP7S2&X[ZU>V'V
M!)23!>/^I\]1U[6=^#-)@FC!7\:'-;GOM+O@^]L3W^LSRE.R=&@%ZJ[BM_.*
M,Z"7\*4,.G4O&_G/Z#8I>%+Y1S=E$/;TPY;V;<L.:OA>;RE\27\41/O,>?3A
MAJF0]P-0@52:'67;UTV[L@Y_45^17\P]I.3(1G20USIWLH"I*.@Y'+H  GE\
M<)4>I)>?)^ME7J!!BXD.@ YO[F;;': !KJ(0*Y7W4Q:3?*QMA#D&"1NZSD>T
MUNKC W+!FYCGB&))/Y;D@RZ+&08%<GU<@WL@ZT81:M;XYU7*'CA#&W0215(W
M**N/R(WM3;G/0T/AE!X$_=N\(=!5J),>MKFV0 LPAVHXW'2P:%&N#EU R /4
M@H8C)U.5U1^EKCZ,*/%7'A3JM[CJY,>^K,TJPLXZ=+TV%/_ET%[T"J_IXXS[
MO7DB.(GW.<:&.4:KZ2ZI&P:F/_M_W94KCC']OR-MU^'TH$.,.[9-959)Y/^4
M)X,4K8([QJ7/F:4AQSE;M=@62!3(3(Y.*/,H$9Y%CGU<:T5K5-@1I)U):YZ(
M2:R=DEP!QI;JC)S^)((30B*55\ O,@H 9H>TD:V$9Y"N: -G%M?BC-\R_ DW
M-R2_2Z3ID38]VMF?( ."GF2IY/$JV#:Z%?UAF_ ^S\@E667<!1%5!G&Q392*
M7>VT@2U+:8W+6?QS&4.L'7=,D#X(-!.O!R^ ,U^)CH!U[Q4O@QOS%^1478D>
M^F@<,N[.@$UNQ/UOI31Y<^^=9'?P)IQ!-/)BT?J=ZM@Y;L6 8QO2W8J'^-SM
MX0FJ1FF-@$?'O1<>Z>7/XN\1M>G,&-2HQAIE]5;P3G@:;E%S:%=Z"D?:P _G
M UP!SZW=RQ'E/P$D@T+"3".K@=$S$12MZX6%&)#NQI312CB:;(87]/65S789
M.S077/$)#^=Y*C'<&)+S\E!7W,!]-(I^Q3!=A6YA+'\MN K=!213U'L""^IC
MS^&?MZT $0AD$#V-?./<'<*9-NSK81:Y$<1]!>7U[\>VHH-DL, !;M(/)Y15
M'$G ,X9 .*\F]" ?BLC'E_#=.Q[;ZW8>F2**G_CX8I,MI3G-1OJ1FBO*+!E&
MR9M-<A=7^ X;KJT-9G:D"[C&^ __7X=:X0G565Z(]/URV>Y3'?']2<P&5Q!,
MFI.ZO<-P+[[W37&9525'&?3%'[K!$?>-G['-XI\$FVAIZN@] M0R[[YAP7!B
M^@O2J*F#4?K1Z.0J?[>P\@Q'.;T6?SI?BGH-%!&><MKA,$A@E^E_)7G< B>Q
MCKPG/XN_Y<$ I,]Q.&2 6I0N;5T^AJA<VI.'7(H-B5"+, B(LZ8Q=E"J&Q-F
M2]QA8?G#//1R!6S&>W&TR0=#7?M]KMZ A/8X(F#S[>FV)UM'R^!\[=3.#/BZ
MY@!-5N5>)Y+U^PE\"_TXB<9_"!G86_;G#1+O(CQQ7FDS>NY2 AY$E976G]F%
MI/IX^*O_,A[!SG^,)DP'$156R&LDZ-6?,U5YMU6UL4!PW%03U7?GBRA806W(
M,85U&IN%YJHVGY;?M'18&GJXOQ?61.QX&D(V*[E6M#JT..3*K=0^G,7OK _O
MX0FL2J/N4U&SD?6^XXO0-EMRJMGG/)Z8%!OC_Q2E."O%R&4.O^6^[L+N_IB
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MHT>72@<Q#:,OG&B(.RU/J.M/7E=G+6I0J6F*.C]3W2"_N>$)7!NTB(%6 'I
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M#Q[&J4'.G7V92X%B/6Z1UGS^KH>+VF$#<GVXK4Y?7RO/DI$3=-;,'#L])YJ
M'8PK!ZN6-D"Q9$DT'X0U;*?)J^BL10TJ-4U1YV2A/2/JANE.U"=XK&,(-#BN
MD'<V2_>@0W)OPY#<W0[)O0U#<J%\'\KWH7Q_O:QFO;9S"BQCGK;%<LOEH&YH
MD.?8;L+)]>;9$C>$F.:*[,-MMZ3/"]M,RX$)-Y<&8)_IJ\FL10TJ-4U1YV,E
M!;_,)5CZT&6?:Q,7!S<Y+2WZ.[.R#9B[MK#$-7XR)? ;SD:99RQJ4*EIBCH?
M^SCT(A5?@;S(SLV#R:O2?1:XJV?P0F<M:E"I:8HZ'WN6K6]*T&:UY]FYQH2C
MIH3/8;XFO_#8Y_/:WUD4CP#;?B&T+,Q^1\Q8U*!2TQ1U/D:66\\/UL#)]&&>
MG^@+4!Z:G43/W6C0MU^_BQD5@@SCG\MR%=L1V?@'0/$RM?8?=%;_S^]_T.G\
M/R;Q>_]'WQW5YHY__?[/WWD_5["88H5!^22NVEP;%E1FQA,0HZT]$[M28;"Z
MJ7J/0L+-/85--GG%G;6H0:6F*>I\[+;GWTHZU.'GK?R.A3I=F^8@V'RYP\T\
MX4ZOI,EK-8"B<#/@KB7M=X$G/$_$@0_KZ(K>9"F8H,+X,23V(!6HC9WX5Q@R
MNFK.?8,%8$<K[GW)<T:<7)9MOF+@SRKC]@4? G-E\O10\R\ 4]:!VT2]J>/;
ML-99&"FY/T"I,!*7 UZNVO'O%FT-3-  \GA_X">_F$@@1]:DPL#67668!6]S
MAO@R147&PL.F%7CRHZ%&[[VR LDH./"C&@'Y;2@*9^R3P2]MN'V$:Q&@3A[:
M\."Z=!\<2-CEPK1QT*$040?2$*17.E#=H_=[;2D/^1[T/ O #3"OZ*MJ9@0"
MA<P8;BA7B887%]23VH)*QXHH76FO7T?V1DM2F6759LV=R9[PHCCD6\^:J@4]
ML54$"IB^6+;H2NNV&P,T%[KC! 1&H'MOO'0DEY;R)QM^,J*RLUP*[9H^]!/O
MAG%E=LS$G'W$6;+0^]\/V%C8DR,/\AU0R>TY+XJ7<I%(4,4[(+I,-V]B+;B?
M0O5)<U);.@\P0:'/<*)18N@S/%DAIBLK.+!4B*N,G6IKVLMB4]H"BL5<'P6D
M *XR(@!@TR%'1Q<A89=:CME7F25^8#,!7,\3YUO(BDQ>:68M:E"I:8HZ'YLI
MR#U2B9;L6=^$!76;_"N<M:A!I:8IZGPL&/[MP#J*E"E7U)1I/.=1-@7=F_S[
MG+6H0:6F*>I\S)G-0?FP%GM3H>0IC"*<JP7\N?2"+$QAUJ!%N+[X*?P6@*^U
M$R#&2_AJ!)L.G+^.5X+%R) W%CO*Z6F9OG-$2*[WVD^? ?2[H(<'CH:"WSJR
M!L?19RD)._Z^F@GJF(_E$B1_FQ0M+&&K35Y]9RUJ4*EIBCH?ZPV6,O9%Q2I*
M!8(QABRD.*J^;G+%F4SI' C)P]FIYHQ%#2HU35'G8^V$QWIYL.E#G<&32@I[
MG%?IP5(<U.DN1.0S5<D9BQI4:IJBSL?*H?6'G#5T8EI#Y^C<QQJGN(%OO+P<
M-'/R;WO6H@:5FJ:H\S%V3)AG&V@TI;C*:I/6-H?H9>2"]S:#-SIK48-*35/4
M^1@TH7SW+)K?\N[<LSIK3HW%/@KLVXMG ?NVN$OLVXMG ?LV]*2'GO30DW[#
M\:.GC>!/;$LN:A=EP< 4&49,R\K.LW+Z](J<;<N8:&2&25('*!$%UVCJ[WO6
MH@:5FJ:H\S%W65VWIO; =ABW 3,T('<U:;7<DL';I$7V+\X?Q'](8XM]\^/W
M%OH&INXIV44/V/'2%"N,^7$'D38&E3F:A^1+Q[,W#X'B$,8T1Q[$S=3CC$/;
M%S>+E?0&LR93HG2+[H'/0;Y45LW8 /)?__2$G+GD6E0%GO3U$"&\IK(D8B"'
M@]*MC]&SRT R%*PMK*!YN>09:J:*DOE1$A(-'5S++-K= J@2ZU@&T'*OLTY1
M @220I\CK2-%FEH)+I]AA*F!V*+VXZQ59_$WM!\\6:VDUXLWP"T8#I SE+3T
M!0KJ=#=\C='T.B^O&&&5U$+GL)>-3%G[D"H@D;F)P5E; +-B62&Q&-F&1$L4
M379!1_9TR5S+H(Y<QWIY_;- +2P,_1[+4+)P10U*:03YZDR%.>T'!6T9'=P_
M>NL)7BW%Z+NL2-U'V+*_#H[ 7MBR2] W,-1)?OCU8_Y6DQB$!;";EG[.FR:7
MIMBF,Q^,[$&V2RCGBH.5;<2\V.M'GB(K,HA9G<4?BACQ+AY<GKI;*8]$?11S
MA"^LV 1V8\G4ZR6W\,K&I#V^VZ?9",+($2[2/TQ)9FQE06R\!1 <A5$0!>D/
MEGW'8BH"'NJA9+;>R>*(.2R7\M<E.0RRP8^0;Q+@L*0%OT*0RKN5675OU,?K
MR0]AD]\;5L[/6T,'6=WFTGQ.:MRE4YMVA:Y&TF[R^?+,'"NLQ,%T/!G@FZ05
M"8)+T%G-^D,7U$-:;W$6?W]RVT;'<"6B)+P9^2 =V8M>,WJZNF2JA:SPD\+V
M2IWWLDTO@2QU65:*'2E/3[?/@=]T!,E25DI^:<9V2P#U>>"#Z2<!UX'ZC&DO
M.WRDOL>'SZJD/T,AF#K4B"JQ"HP "N1Y=V0X>&92P11&<F5VY)@V^&.$,\OU
M"3/XI\#;T5Y@]#&O[DK7QT0%653/O\,109&5<2?K'@:5G+F6 W,9%\G 5+TM
MRKS<X*!8T4I7_9D-DJ.LC<15&SI'&O9#:[++2[LHW5%NW4'LC$3V!WQ/ ^?6
M!U*K3;-(EQ_K$62A),;Y%Z=KW*@VQF*99C6$\?:8-24G+,W)^"_LJGO=55^;
M>I^I.MNW5QF$=*03O_HUWA!*,(2?YD\_%N658P7S1]D5$DJVJ0.I@D.!:_$.
M]?9AMTG'-B.&K_BAXA,N$'U!,'>/I/:<+3Q4JF$B7:'RHM2$)[&*@__7?[15
M5O/16!84_%FQV(BPUVF](:;'B&6HWZSZX1.PM>B,ZKE+\FO9\.+681P+GU6F
MZ:Y)>WJQJ<H6"(=I?J@1@GY8B\5[4C<H-!V;2'XG\N@CAR;%XGVOTJ(YCJWI
M9X632"VLR-FMV04F4[ADG]H+E1<4H.,65@]@KJ(CDVSS#R!'%9QH#D369?4K
MW[<GX4UYAR3RTP#7A/Z>,Y*2<9:LA'RF207W=%:_;40!'_K^3>27MC8S=J M
MC'C$).-^_*7)33IM2:&*3;,]N'-7TAK*CZY)UB)NZ2RN."HKVP9ID.!;/K!>
MNI?;P&LCEP;HCN[]\;@7W:E)/QK TA[B QV+M9^N2N3EPB[H.R6U(,-@V&Z[
M%WX6?YMF.:P*KL<QM3 ['QC\4%&/HV-D%ZM#9_&?N '!9QAQ=E=.@E%#9(=V
M0=QY4S8&9RXM>V1-$JV\+L3PV.B[Q'H#/GB'4W37 6D6\;;=<<;AARJ#G"[;
MC+4X#A7C>D^W1.J5I.RJKYV8OJ]B7RC<\E%"/NM(\TG.F)'+M(:N>%>)W*.(
M,\VD QCNOC)(X-;QA[]]_<0@!<US@N6G;"DNNWI*# A:F_ZOF2] '"EW)$()
MGM"ZU^W.8I\Y-8S\["@CC-IH_##ZQ+TTOOWA*NY!(:MGX_UZA'D<H7F\ITB$
ML4[S0^3\_9.G.\Y$T=,"+:K\:"26N)3V;7_/07PCF3\DEI+XZ"'\?9CT\'TC
M\9M8O P/AV5-;MJG\O7:,\$RHF\-,85H:]VAT%HOQ3_4?;>!(]W XEDA82:R
MRSNRUF"0<['/=SIJ[;V^?JZ%]YF\1OSG:#9#4BH9.JBR7>QE?HY@ ]3W&TGM
M<#XO[W(ZW]$Z($'9VQN]8=B(W;*45X_TA:2L&0M!*QZ7I*O\5B$67:-)%2:!
MLS_BJR:*]XDLL@N1V4OB>%6]0BY!9*.9(MIBI'D[LXIJNGPMD*,9)UI/)@Z&
MB\^W*NCUTUUR+#.4 C=U^52/J</#I.T)12OFJFE>$%ZT.T/>.700.X1BZ()C
M:GH]%O1^Z&'PXY^ J!XXYC:#=2Q?Q)6[SX,[Y^1V%](DORZAK[IKHPDRL:5
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MVUI.#084^7GHUJQ%#2HU35'G;UI'G%%XEQT%+>)1K<-[33CQ^Q^_'ZL#"-"
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M>IT!9M-#VU:.@L[P*1--#&QD $JC8WY<2^^,D?A!$8HO D)Q<:<(Q1<!H3B
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MH8,69&VZ#A'7VV[Y6_4'CZ"-^OH1UA=AA/5N1UA?A!'6B9]?7\;GTP$,[8^
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MT:*A:)"U>WX)^<9LAV:;KY%/C@D,OZNS7S->IL+(<*L7H/=*<M_I5Y'T4#C
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MY!=:>O=%K>FRWFW=J[H>.0VNR*BX5D6N*QHH2I^?KTW15KKD0/1$EO::%0Y
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M"%6"&]RMXY@;\X@]@<>3SVBBHP$>"QQ]H]-\C7\,&ZJ0;_:\9>1:W;96,8]
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MR(X38P-9.?Q7,C'%;I%V'R10DL>OALV$QZ=3Z:ZU7SP:P<[D$4%$L#))>D#
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M;$+^1?([J:"SN1V19]B>DJ"</>'G(EF"PABD%B_)5XHWQ,LA38J(Q$A*&S0
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MDTYHBBQ1Y^T)F!#WPC^^?+[ /SXH_./+YPO\8S&'+@7G@J' RJPLWODRY'5
MFU4]A6;7/KO'>D!E=ZI;HFKGH':PH537$044FC(:--D6#:OEO'.2Y!%.%;I]
M-;&AA6+15K+!?,R;%)M.>@C#_9V+_D6=&R(,Q#SO0[J)PQKHK7N=(UICBL^3
M<%%4SAGG+ G $I(XV3V7CDEM*I+%3B#$=#1;1=VG&PGA./8]TF_  _^$-_GQ
M1&D-"NF+)1ER.(,^PDO;Q(OO7OJE?22X\-(O[6%" 4W8W8-IHI#ZO=FYI5GB
M<OB7PS^7PP\GG6M$3<A9P(=U0UFD7.YXC7$CX1PB:HL60;9-T!?#2,M2XW+U
MFS_KH2XB=9U#G;7N"Y!]@>ESGE)J"!#(!D8/&3X:1J9O+G)Y]7L]ZZ$N(G6=
M0YV/JE,?+P \.;>@-EW$"3.ZX)2?E\KW66SLK(>ZB-1U#G5^>FU$<<2 J3]$
M!?L\4SX_>^??GSPE3"11\^KUJ\SR,W/:PJ0>&D]0RX";>D1J18&S#(,BQ'(L
M*Z$L!Z?V"P.(C"D3\VY$!1;5/F,X=U/LZZ;NVX@VW#0%@;(R 8^F<$-\)*;X
M%5<9T1J$U?[Q0#5&?;EU_.U8+:%7M$9E+F$0;U:O$*?M*\206!BD9G,(*U ,
M$9LIV%*AOFX,APP8@M%ZK@24HB\?OC BB0FGFD JM824'WHBKZM;]?Q9M_;$
M93LJIPZ8;773,BR[&KEE*4A*<9+3(6U=SB< :;C^03,J\GN4;S=('2(HG3*+
M=(ZUQH&K]P?2,LPRTN[&6NLH!PO:\5.S.U2N11*# +[/@H(3!O\QH GCRX*7
MHL-OP8\B,P3@@P>UR9/UJ97?UY2$QRPX53;:9SA3*T/ ^"Y_1WEL[ 7%!38=
M3 I$JR-E#LKW)-69HXP7Z^2HB-_$2T8QD/B&]>#Y.&>\QQ#E%X=F,_8M#NI0
MEULJHZFT(&%<&J#5;+&^!JY/ M,3S#.M70WWY\WJ^QK.!QK1F?/PB?I8;(9P
M"E.>HV=TUS="('"DTIK.3RZZ0M(FMH.?$T =NLAF2NZ0MPP:Y4PC:.;5#WX'
M:XG0!WTH@@T1UWB;-P7>QG_OF_KD8:U_JE"0CI[0IFV$K2*@K2S!!;8E182N
MS9MUT=&%N?;=';X8;N)GM.);*I0ZP)CEY_3!&>VN+@HC)V2KEMOD>C3.'9LW
M0Y(K6[84 R!8)4$U%+$ZJVO$N-&S"0=-;5"&2OJ $GJ6X"6=D&N-BT:Q5IF>
M%@M5\4=P7CS7(S8$<0T5S38"G6J N@F'(I;)?M^O2ZD6!T7@8@G6=+D5G@*C
M%7EA" 8 (U#Y5JVEC!"BD^JAQ2O0*E2\8I#S7IQQ-4YF8%'=A<V:*/"]U,X%
MZ^,J6_8;*BVQ7&D#VH"F1<7U=,Z+G2X4%@A3@A,,SJJ%P;2(R$6=I^HT*:9@
MN#GY&:G=L1B-'\MH_*%HW[7N!Z4.J5>QL&;UFBXC L;]P+<7WC2+U?<Q+7HD
MG%'B_/90G,3NVL#[0!DWRC<X4CQ:6&SLO5BU"U_JBF?OBLV[=;YYEX%GF/=<
MG9>OL:1VREMW5!EJ+!FV1RQ=D7]/^,6>D8\-]I+"$EP0(/GPIK@MRM7)PZ^)
M/(:M3L3LP^>V^1%,!?AEXT\]%TC";XD"B0N6B8/FP-5XX(GP8,0Y\7F#^%)6
M<WPM41DJBC$HL\@R=2+X*]?@$-:ROBU:F4HL,"=^,+-T/' JTI%IN:*ZQ9*B
M?1XQH51SZ=%6#'?8XVL652EF4X6%^GADS^B64K-/;0J9XD,I#\&P2^2]N_=0
MGLK\S @@HLH!I\MK?*WQ%%O!^NZXZ<:+D]ZZ8]8S]VB:#ZSUW?1-HQ$T.3]Y
MTV"!F+)&P?FP?'UQCN:W6 S3B>,99NH,IWW447RL$O6P;NI\RWP/JI0>HX56
M4UK(!BTWS$13,"-$L#2P[B\<JV2R@3DK*-CNT-3]_A#7,Q KA&)D_!)M)D=1
M,BZ.2W@5*#+FAL;5S>I5BYN/:BW?^)X\18&=G[,5AMZ0W(9>[U=;YE0(;\,?
ME/^H0<^M04S^!?0Y3'E-O&.$Q"^IL%NCDEDLK@K6]Q0IV!C>_]!6G+BL2C@:
M)K;4*6N/%$5AW/?0!;I)%08TT"WQ'5@@3$) ;^$Z-2L[OW:@SLB,B749W J7
M]GH) $AI%[@Y]1U,;H'?+PC<3YVS7!"X#Z4P52L87? *+=__)98O55^CJF95
M#SKZ4*P+HHN8*#>V=:I$AR<7("=AWE6D&,IS4-=$=$7C:(G#HZ-<5XUL(_0O
M3C_%3M/P;*:L./:5L ID07MSI:_^E!$+A?QZ(_^F:NM-WA[XLZMW!5*4@29#
MUKT-KPC%%.[R9IO)AQH/]W_%E&*^D/GZ<+NPR6&FGI*/]7 KYJW/)*I"3T],
M&"4FV]?UEM'/=#MEO#W!: DYO$#PE&^]:OFI;934V8I(,/,V333JW?8$RR;N
MKZU]L=36?MC:VA=+;>UBA"Q&R!6-?#Y&B-Q:W!EI%#]:[<",0**ZO#BVY*'8
M5*.ED?B6/OB:/_A*P3V2_?05J)4-$7&PT\IOND-VFM*O&?E2,R;_E[Y8=7!G
MYAN32^3/@[7C.XQ&<&SN+ -2@R@Q?>#2OF3Y"&4<VSG([H_>VYX+S/6/?LN7
MOS#1C,DRANLP>;4'[$RF2\BDOF?-W(1$<F!4X07'0  ZI7V)&5$QB8[Y.\KR
MR&?(@3P**7=^6Q=;]/R%X8,,+K@$R-E<U>M20H""\:6E/%^>W0+6O/J#.^NA
M+B)UG4.=S[TU=)XYV+UZ$T@ROJ^;  =$G?QJ0UEF_15>4> UOOCZZS\'=J]_
MO/G^E>'W8B;6(Y/UAALQ7D=EH624ZB;Z]W[3=ZRDV\T!M#.JV*W7 ./9.H=*
M/*Y.(L4?D3@353CQ;<G4PJLMZZE<>8D_3^,(/CU=$[#J=,_)92!NO%*7K_J3
M3?GLB$\M7C35.?Q-'F=NG9:QIE7E&>^IZ2IA%"@+> 4ALLV-AVLT7@&T*>"9
MK?&\6X(#YT>.2@L3<MABQ +S;?:CWQPJIC[#9__=0)EH'*\5PR'?E5U_^?SY
MUV;7?_S[ZW]<V/9X<R:6SS&PV]K<(/*58H8.5P+,",R"J1'1YCN_[_,FV N$
MAMV<,2:_Z1L54GA4U1Z+MI4\2K1H8 .0 !^.44&^2&AD$1<#_A=,'I,5#!5
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M"JX-^_WE"NZHJL:$B*4\9S< WDGOH@BG UM8!4N,WY@T:3'DS#8OBE93Y]O
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M2UO&!SNNXX,=]OP/YY?G'_[G_&47)MV*I=V<PW+0Y;"L-X?EH,MAV<X<EF_
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MSYJ:.;?/Q"Z90FVP=60[R$!>WS1KA>GR[J.#>8)YD24%%\%(0UN$QT/=!\=
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MT>#5:8@%^"K/CEE/. ,EC0$E8$1A$..JK'+ET7W(<<*Y>+)YK73#* DG'*D
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M2;)1R+V;T OH_GO,PU$XQUL%\Z0CL[GD$ZP(A1:-L-QG#(D6-L(WKG"*G*;
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MFH9)HM*)0*60K[_G?P@C<7G7X:R(J4_5+'-!ASB8#S_^!==AAK%+'=7SFD5
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MHDC =KZ?TNPZ[8', IY-5%>+SU>%&E=,6+7=@O72VYPK;T=%'ZJHM:;\7RI
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M7VO"R:+F)&$'67;M4Z@(MQFKJ4L%(I%JFV<+E8#@*^:H%,(LBT4:Y8AS9L6
MQ?SY%M>Q8RI?4U/X%J&36%%K\@YCJ9LJ)4G*!4'>N^SYK_X?>V_:W+:1[0^_
MQZ?HQS?YEUP%,=RTQ3.IHF4Y41)+OI*<3.Z;*9!LDAB#  >+9.;3/V?I!AH@
MJ,V43%)==>_$DH#&Z>WLYW>TA?8.S9.>.FY&XC/F2I]6*ON0.'I>'Y_3LQQ4
MW^D9-5OF11.KO5VY659S"S"64G<-X)2#?JGRES&-$3T8L<K 8M!IUM46K5O#
M44*?@:'<HK8Y2]ANC((A89O#@&,@-28_'Z%FR"^HI-**DD\235\Y]3UE !*$
M1JR*7]A1PG6%9.XF*N"T? 5S, ^M4R6%?0R\K7#!EE32VI6K92 PW1>ME=R>
MK75DL[56FZUU9+.UGBMQZJ7=Y&V>[M5B:P\&.Z(>-DH<J)*GO#ZJ=91G_I0M
M7W2)WE&"A..0Z8K#-$21=^V@XK\L[=JM&PF_-@BB1 XIFEH+064*M+R%$+R7
MZ:QQJCU-T%6?!>@3=LB @,]VN,9H#]%UP-+OB!LI/R=&)/+#U;L\;,?)YPIY
M6/F&PXC\S+N!/_53#J4K'252Q.:?S2.6Y ) -[<SIJ9("NB8##/XG)+(&JMJ
M6<LJ_@#:<J"2S.$,9#*A?_PIAR'],__TBQ;1VSS=U?>?:.V[K?T]7<_@=HX.
M'M"$PN$H8ZG-P[=H1>$8'*72BJ+5/7#;G:--;45A[\J*D+,P:C[P\6@B9\>
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M%?Y2Z?1HW RQ)DAC4X^0"W+G1NJ[.J]@"7(#I3QGC2IST'K('<6%FH\D5#*
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M5F !CXD!1+/5EA'T>R^'5)I8.'-$X-TP#H'*YM--^D1?PG'#[4RBXF\>X2_
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M(Z6NY>D5?D =:NV)7?L#L-&DVB.UGJ1N&!/,<Y8T'P0..)##+)8,Q$!@F)A
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M]1'R"3T+/G=4<&JFXPVO*4$607_#A!P3%+,BRKQ"T$0UD7_4QO7[2A-'7*@
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MNUDL0F!-0Y3&2@G,1;%'&IAY#!SK__U&)#](4-Y_6O<3J:_NE8FSF 5^MU)
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MU68O[=OL)9N]M 8L9L65UY?9%)N".J7^#U=XB#>NCGQ+>#R9ML1F$U#C@%6
M>.[+(+K!XLJ$<!59S!L;II&[$$\&=(V0 8\1)Q*!95"+00T86-IPL1W)4@^:
M4Y-X\X2:P.8U@E@]Q=B&YO3BY/CJ_,(Y/O_P\>3LLG=U>GXFKGIO?S]YVAOY
M/.O_( 7B_K.ZGZKQ"J7F+<H%ZSJOE&PM5(J[E:5ZUK;F#!-.&ZHY@MM3^>'
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M&GLPWR0*_*&>5_[$/GV?[JL8R""8><,A;/P_7S5?T<] V$#_7/X&:#F!-TN
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M(N)$X^CQY:*@][ *@Y5?W!,VY<[I]HD&.MC;;-%Q0'W)8W$G3T[]_G(^D06
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MX>G("UAXAQWWGFT-F"T9G'Z4X,'IL=GW8!6CXXHX.3\_+^9B,1"EOM,L+[0
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M&?3>>#,<S[[7[_$2V.2AO\_B>+!35.Y,"9V%KZ$QQ/#9OJQ!I10.+B" )LK
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M;]K=/O X]PFLR[NW.7:U2*D)KW<L\Q#4($-]P%L^Z@8;5$PZ';@W>BLGGST
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MCIMJW1![H)M4A-&=,8B+E8F!\/J4%\X($<ZM7@\D0""4(N6+82ED1 9-R+3
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M'> =&K"Q=\2$-QBPJ? ]&<*.!X-0OYEZZ$BC\-1I\HK*I4'*I<%'"W"<:UC
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M[5;'WM-#C&;DJ"<='9*H+8H"J-.J2R.<HN]\I Y*31BA.2]2MHS11RVD-\L
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M?/U;>1J>#\I+28^M<1UV';>8Z=!=@HN1!]_O&Q7UZ]V7WQLO1EZRF,LQ=G>
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MW?C)6F,S5XH<0>G+?>U7ZZ/3_&<3C]9S*\86C+2#T[APNFQ25JMCNX>'-VB
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MYBB3Z!)L83 3%"-<SM RC0=4Q&%&8F1&4PJ/[8=!%/D6W#3?4G!1.839X@7
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M_+73__S\0XMN6?2HTK8,@8/_F_BV]>U7;>^PE)VZ7S%(8R%/E%3YQ:'.I83
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M 47!B25 1[S P@+]TN]WJ0C\?>HF/V*2^WE_*Z:+BF[$;\)7X4MX"J[#L%T
MCD,-Q=BSYM-1:^0W^M"&7L\633J"XI'(-)$N"3XZHI8&7;7\CKG .0@ +?[M
MPU@.-->+=QI #@2-.H2227HFLUC'H":CN'W3JIS0=+<9-2R ?X J8PPX1LC(
M;P4G12F,E/XFK^?8PVYOXEW%]^D'V,)EI%IG =Z"@%X+V \1PJ7!1G#/#NMA
MY1-P4-_6F1DDFD^:/M+@0MK/J'VF80L1@EY51(15XU\1#1IN&_ASR*O]_!G1
M'*B##C$0]>Q#]O"-,L[#_//HS!T&EPI'/\#7B3H^X%CL$4EL1#<*HXZ/W"CS
MWQ1'GK4MA%S'>PS%F&BO@QK%/M<H]E&CV <6$NUVQ+1<.%B_LY*P <F$%;("
MX2T4 ?(0Q>@!5:0CGPAF97 VQ6BU 4<"X[Y\*AD.-VC9 >O:'86C&R4N/DGB
M>"&@(FQLXIOO$7**'5Z:+()'4!0=*+?#EDM6"XGFB1]FZ%W4@)BYW&\ (EDS
M1<F<7_^:]OXG ^1[*P[6S,G:MA@7<)R .&5PM^O6&^5K\%G>@AK&CA!?!>D$
M=HTX^XH*3>J6?D9>;Q :UZ9FN9,81X5\'.,HG'V_P.#-L7;S9%U4W$:AN)V-
M]0K-\>C^X^BZ8'YL_?J]=WB+I3O[M M*>!MVR$8;N8S4$G]JQ.DW>><%62C)
MHJ59:,Z(JH1,4)R545E_8-HC1F]N&TCV6&A?UQ\-%\'8X8U]P_,87,XD.MV,
MCZZ:E.F$PCH$(&#1E7*@7HE)/$HI"X+0$"CMY%@ERXQAE33\ BP_P^VA+.46
M,RZ0#'79#9D0X:C6# Q+6B7](])*)<#.\V!?Z<VDD#M,Z@W^^/0P'SQ4W$9+
MF]D @ZXY''Q%T'0[;\\K-5'B@GT.U.7W$U@:,TQT/%+"W  J&J<UB2:)44RJ
MF@Q8I,T064]X;:C9,0<]Y UWM2<-_59!P^1T>I6XF?1$1O&AS>B=L6X2(6DO
M=1*)8I8$9YF"3908F_#1*053*,)E$ID>)F+ZBKQ 69N<$>X#-DCQ3T4-YN*"
MLB"],1KO$66A1>&B3NW%M$O".*5V>]*V6$G'XAVOSL^K\U018]^-$/=&:"2*
MVQKE#PKL[-^VL0.[*T;='X!BBC\@&Y,;B(:K:&2J<6O*Q08_0,SH&4+GH^A(
MU$?^"6,)^MW:!=!Z8#F&&R&%EY01/T,<01?A X'T(K]3^.\D;VI. +M#&X5I
M+LR+,GKDOA?,&T@&OD(OU'9=5Q]MQ XAHRIAC /EGG=I<H<H&E'Z13NKB]G#
MZ!HUU94-VS/S;0(^(YN4\\.EW37T_8$-%IB,>B9<J/Y2I+!%;!,\^TAK6M<
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MVG2=M/NUO</L 6Q\+G7G!X1M!$\>J%>60%/(5;#^!K%JPNB8'<,D,'Y$LN+
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M.2SUP(K3#RRC/AFFJ;: I1ELDP/,#URMM>EO%?8K8.:![7KBD@KS-8S0,^
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M;GQC- _^W1IZ7/\)*Z/P(<Q-JJZZ$K%I@@KD!,?,N[Q9MW$99Q8G0Z 6Y<D
M*Q5H:P F,1XUFJ1H]B,6_(3):EA(_1;C+$*//FI@NP]=_H-] GK 9_P@@*H%
M40 7E>*!8S\::%0#B5S:'E/+[Y,NXLZ5Y8$M2*%TPTR0DOJUYGBC.]ADEPL
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M"6J6T];=9>&PX-4I;;/"5BGGZ(I8"20NQ0[8,<MH@/6Y&B!59BE+ Z3XM6J
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MNM[2LY ",W+ZK1&9.@-A!$UJ)\DZ770(DQH"^-?N+XT$,WJ[I*,+\<E&KK5
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MNH%>9KC9S9+FR:M!(+"R$]!+"=49PHQ@@0O&K+QD@)05&MS#3,+GN?>E.T]
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M+=W\NNG)G4RXD-=X9L7</L?R^0H='5Z>UQ:-R+[G>%>#L) WF2[G[;.<6X2
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M4NG62<G[N<#)C([(S]<$-C,;^V@AAW-2*-:5OK^%._G)^.ZOV<6<]-''=$?
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MT^ &F#'X.*G*S\ DOX1RMC#3&GI<EJF(RU*O/5('SY6KZ8R[8!R.=!*B-+S
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MP7\7.6\%K;H\A_(60P<T%/2AAOZ6C!JHG$@M!!^.?BOJHJ"U^]@E-:2&U.M
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M^X$UU]=$<0_;<Y9I9G%^S\+=*35""_%P=">2*J8NXF<AJW//>C.)Q-"4F09
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MKE_=#_@?Z>!?('V?W:7O)YR^S^W2]W=Y[U'F=7+A#UTSPO7%N@3I"#"&\E)
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M0N>*[691#_H/^CBBK%%(R3YBZ\"B]** 5V[ VL@ )<]WI*8\?T:%0Z=SC(2
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MKJTY_(HL ]WX!;&<Z;BU#D:F?$>:0+T$(Z0%6:64V"JI.Q-8O!LXA$M(PW=
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M5B-<JN,A')_,X8PH0EC 0]&J6&RD0R,6*&+1.2/F3WQ-E6_A^6*H7Z3<==P
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M8$.Z7J8&L7B9$RG7+@R-=5:'R= ,@['EQ6/EQ\Q>%6PC0E<E+32,]R0GK28
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MC3G 469W;Y;157I%:>.DZURUO_[8^_+_-6WDC<UF%6BC.@<O$YLY[OE6,L5
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M\U!LX#,1+4X.^"? >@D"?+_Z+R;,T&GXA+-0Q# ]T\'$,3Y:<AHZ??7=[3\
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M^P%V#CY; UTCFQ1_(EW>N_JME'<C@.4E79QL0G.\4.D0\(/&['(="[M^]'K
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MY^3)]JM:>?L)@DUNX2-M3 D#R%I2^(G!J@BS/HM>/CJI>KY!C!O7/"QW.&;
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MO4E[_XR[)SQ*ZA5,IP58@^OK)2B5@TW[^@T&"SUSSW^0<@"B^:_^J>Q(]-\
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M#ID0L[C]+*G/PILA&X&V;Z<'Q1"*XA5J([JA%@7+37RF<JB._FA$HXG:['A
M4W#$U;T^<A'K3OS&+B=(QRQ .+C]TM<KE %\([TS:ZR'3:WCW(RD!N]A6"*]
MU(9O=!#+);(C F9[7$'AG0;Z%I9 >&L\,X-.OV/M*4"OAVY3,=_'W;U@3Z"P
M[%[D,R]26M=U3,J3P2J3F_AB'T,0SV8"7C8$+B-#=/PC97"JSC,=)T_V@[8_
M1=ZWK-QFJ'F3?0!,UQ[$()38B$]?$B;1-K.G,A?#C0ZSB J-1KKL2:V1!63/
M1!AMHB7N[F*UA<@=>$\7C#II:MOND1;<N5;7:"Y3MN:.:,<<Q0#B\",GY-HE
MJ%HQD]6W3J#PB*80NQ#.C^R82B9BR/*@):^I![\5MOQ@1M6$-GN1U]W@9:D;
M%_-,-I'N=&CTY:6>'8E)$5KCSY9#?Z];44N%<9"G!+7A#MB?!D<!K^VET4^9
M-,0CW"1[BL[,$0$",QFOB!4$L^B:Z#7(1XVCB'Y3I R)VMFBDQ-> ?\)^1G#
M^(BR +*O*/CN_2F/YA&CJM;MSWUF/*XGOK:\R>32D;U07B30SP[0$F?!KN6P
MKOBY0P]= >FB*<<RTREK4ZGI-"7&%LBSAV+P =X/.K0/A++<(<QCV/TE%,U/
MBY0E/1%X@6-#-4923]@WV&H93EWNO8R>:#'\70E$PBK,903*XN*AG7BVD2EW
M)3&2'"CR)94(V$UIN(TD.7; .F#J#C[49/-W?+U:M2!R/<3 8V#;0>MH?N28
M!,4*V ;>8X*3%8^]20]]P:=6V)N1,:)*FJ;V]=[.IJ*5"FI'A!D=^I.Q08(Z
M0WG/.0X*^>^+1<=FBHP@6U!&8))D+<N5H!(PM+KRKFT,5=CEQ0CNP$<2OMM"
MQW"XL5\[S5^/]S1 !PCT(MT>=>KS98_3;IJ)9 HNHS\7&()9MM(-VC3+P(,2
MU"UX/]"[[ ;>X"3$TC_F'1$W4W:2^OE3[,AU\#KLNE;96#XU?7(3B$_ [9JA
M*L9,W,"? &42R?Y 3LR]BO(4*F];Z\N1I4BEV>OTI%9=GG?C@N_;:JFJOM((
M:NK(&L_F&S>*#GO/ZIB*\R/P0?U*M$WD?9"(QTS1D85*N 3I%\H> G26%%@I
M>]%KH+ ^<ZFOSW(P/\/'U<IYQ\Q\9W0'.$? #"2[RHD>^B>68>8IV"'=I%YD
M(I>>?)W6R1Q77CX^BFR!7K?C-:D7"$DTC9IJBAEDR\?>P6G !N(7I2 Q@2(#
MQZ6QQQT2%A_Z1Q_)X@L3%W 8LBN 5(;R-@)&PI0&[-90GY7TQ8I+HQPA80RS
MG$<<[^5QTG#&(0SY;!9605F 9=.2F)M@.Y/D<QP\+Y*,@WP%<L(D  YLJ,^R
M']P%=*<(J*HD*IO NZ$PL^3]HU6__#ME#S(40CZNFG%39GCQ?Y]ZE%3.9[[[
MWVUW=Y.$5?R_A N4393_JS&._^$_-X38.2M77\?,BXNA<E_ /(/QD&>D1QR\
MU$A0(YW[Y='<"+YI'32;4IFE*C1$*HZ_L4R ?8N]&CQ] LK%C?D+H[-RV"VS
MF_,8IWY\^"U<>$ 5[$1VB+ *$M2L7C%M;D$<UM-I*-:U!12DYJ$=S'N?)WYU
M[;DWZ3CL"Q0)>S!@^/73G(1+C>$](PLQ1IZ7BLSB*]/VF,T$9_W;QLQ<^L//
M[(VX_Y_!"F(G1:'\B'ONCFMQFSLS#G6V.1PZU?O98H8E?_U]3*!)E:@VU)WE
M_.8@^R_JEU&U1BU\5M&ND:[WU5IF!Y.R@I.K'5^JW2[?=&&PX'28('2899^[
MVY5DV'^?PM$\[EJQ^?XE_'['G>F]<N0W*O>?X#Z_OGOI^X$U!P_.R_;H1@=&
MB4VE&SE"@NJ1H-@\"<J%(86U@4D]"4H#?O_WUOMKOTM0K1=5[#(NQ_U]&J6I
M^N#V\S\-GFY9PZ;\(]U %A+4E^U@/-)&WB9E1)@0D)0>:K(%RC#TMMWK^'[N
MQ(21S^$VLR'/B***(OQ 6AZBF[?^9_?^5'J75FUF;3IU9'XN1^^:O[UU+:'
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MB%W_=08Q^!#ZW:)-$(O'3+"DZ(AS6L\*\'<#K*!27!+PJQ,Q'D5VD.CL:-(
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M[9YVC"5V/>RS&D O^S2GL=1E62#G1SHW(#0I&2)[<AU@M>#E<]!,#;RW'JN
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MK2_1-/ AZ-2B'>(<A@+Y)"0/=*_P:]J 3G$Y% 1:B7@CG&5L*N$V0XFDX1]
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M;'_\;?R9K#$"KR>)&MPO"UGR[JX2DB2H(&HR4XEA"&]ZD2U%;R-/9&N6#AQ
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MX6S/$<1\(&'X*\U?Z>)>+H@&BW:#O7D@LYVQIBL\!X[>H1"PT '>@J:8^VW
MU!?)>QT ?"="2CP)N)T!C2*-(:&]H-J8GY=L2MU."H&\RJ"0X;V-@R)UZ!?+
ML44'=+SG(VB3Z0OZ<9L\',2L$Y/KP<?$/[>\Q$4PQQ"3UZB"#5B:>4A2E=
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M[TF3&S#I@-P=/<%/ A7GU1Z"]N43<V-?UH>_3(AJJH+,1H]>0O0SH/V$5!^
MF4H)Z*ZF=&B9 /YQ/I GO]#ZIS>$%< SS=TZSZ (_E,[OC5K!D\Z2$P2$H41
M3XF=8U-_#Z/(ICT2732XT!T8"SZ).HIRT:)NO3?WCTA+N'>J/4P#7*^)#MN
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M3J9,S+$D%:&TOT#KA*H96_X&K!ZO?-HK%N?(?#4X:+WFG]1\$K_^='0S^U*
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M@4A^"6Z=&&O*L8'FS#OHD[+A.*]NM,</.PSK62V=0D#0EY6S1U@M$:7=59B
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MKT+OT$#ZB17+"VI:=+&W=['YJ5#4N>"MQSV.,BO?=RV$(47+846L/$(=-:V
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M(3\>(1;:<8UL^*LLVE:Y0S\*_:H?Q5DW@3'NBWS@\.\^$E)O:M3M!]E@E%K
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MH0,;OEQ;95%5.\HZRB0$P:'>&G)XRX@.,)<9#5JTMA50L)V"W<J!-0AU>9#
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M^8_E/Y;_6/X/%NS:Q_\!4$L#!!0    ( -A#<UAQ#A5,U,P  ,33   0
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M^[^\UZCTD@2SEUA^Z'(1JC9DB\&+;$]P[4F/66*E\FXL<75>6X@0(YLLO8#
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M[HF'&$KHOQL0:*)3K_)@^>, 1M-P.<4N>2:R53&Q^'E(5&@([2K/5D)._)1
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MG_L,_=E#2ZX4/^\(O=/RB+Q!&!>T-,^QSAY>K6MLB[\T/-C!K1:\]'S7X9.
M1NWK^ZFN<=8VTINL 55)O\PK$@+SJSP"O/,+A[:MMF4[UH!=(O/U4Y!3X9O&
M#4E7'YFJWJGK&/',459+)GN5"G&S AX/.%Q/J=M9U/I[7WFKEE7<'<.M_?N\
MOJ;PM>]_GU[$F;W3Z-[)G'Q2&W0",?%NNEY<TF!!H<F."]ZY1Q2/_IN9SUC3
MS<-9RU83M/ ZS@E$%*&ORU_KY*_]@C-EW"6"U*5,Q\'WG&7,:O1]O#V745+C
M<NN.L)$_IZ#Q[R<]<I0YL<DUYB8/-M]8GXI (K_*8O;TD4:5SG(=;N)\>L<
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MZS6Q/ ZB7HM0;J_]CA#7]?1R+[>'O2.0T'W#W&9*F-*XB"#.R@ SQAJ9(Q;
M=2#[OJ,G@J6U^:'%D--W_5-0G*K)F5!%L@8B!>T]:OO=RP!DOY- P9(I&1V-
MF4P#L\&-;0M$("P>+!7MZKG>Q<_U1Q/:#4N, SX R::P1O>0"1Q_,79)B&:]
MP=(\MAJ_84A@9F:^:/A1@/6+&(O[),A<GP-D91$$*T1N863U):S_J>_9@7I:
M;QA$)E#'!RE:TW*O/GD]%(.<Y%XN=6!6LOW*D/]/.6#$%[YCS_T>NBQ["OK0
M;P51H^EH$_-O)$<A%[/2D*5K/[[3/7D[ !I@OJ0-[SI_8D6[#]DS+12,_ O-
MAK[BN$\K$%54<-$J<%0\2@#L+_V&#$L)!%]R1\W]HQ8*OL]S+'GOQ9/FOJ,J
M:!#TJKO4O5%!7_57(?)ZZBI7XZNVX@9NV\SG]9B67+G//@<^ _"5@ E1;4V(
M:_1,<40>&3>*(>?$>.\\M1Z7:^@(OSON^*/J$SP7*47>SK95TA4J1A8^7&#2
M4=]=\PSWLNH6J\4%/*>6&.>,#2M#=!A8S7O>3&[<'6%Y4V@@%U!Z^:O9$>;)
M&W=Y%VD[_[M%&=%[ H\+GL!#$LA_2]BR^++6I:S*K?KO5OJ^#6M.2DK5 N(,
M\M>D%-[LW#!]$=J1XF%;:%#\W(!_HEV5[-/=*3/U^/NGS/MCF+R=AE1YDYF&
M696*5*LY?=7AOC#(A')W9.B%]QU3"\.I#55(+W<?U6^'M47L/%3?R0AI-/S<
M+R1XP4U(9$HEW&@MO???KX1/'IWBC9,-X<DS>6;VP+Z]<=[)#=M&X^C2C<L!
MEYM:FS$M4U=;DDTFZ4O +ZOQ30EF+Q9G[3PL-K5<IE_+3I+FQ3&+<>%"I7Z?
MY>?EN(SA$:HE#QPWPSHF'*Y@)O;GUYW<9GP3QB%^Y-;1OH*K&))9-,0J][EQ
MJ4FE1]/TM(5NI0?KNY5X!GEFD^H'E4B7> ;/5$.;J?T3]?MO;M?:K<^HX;8G
M](_>*$4\LTV+^:HPTLG-&],_*LCX]/-,<4SABPS8PS2U."G$ &?FT?6O;TI6
MZ<>.V<KC*99*A)3ZE[LM.I+?? &9>1G<ZN2NC,'%T( "[STM.-HS1P:K^,TY
MNK\GSH&_CZ 8Z&=;&(=^T6_U0DKC,7E)UJ-3B<R(4",'9;CG#N=K>36^QA\O
MB+3KRL=GXY?C5)M0=IWC50>"1M[..;:Q@]^);@,H_O1MXZ5&,]4X;#OE(E <
M?G8((7*6-YNF+(9@Z5;1*I$6NT2[S'O8VO$@;8]1JS',W^[6YK&=P"I:\]II
M&6]AKS2,4'Y-\D.7]F/;KXO2$Y@E1F#^?OLD9GC.)Q%3+N[EVL_V3J4M.O)X
MT[UD&F^0.V]>V]Z<?'O2I=/(.7?$7O;6'"V[[-M_.8>^0%"E1*J/CJA'I9Q*
MAWSOS-RUA"#.N-5L5%!(E<ECO\CRW[LP0Z9%#$=PL*277/7S_>.+ZFBODOF%
M2][>HXMD!+O(QQXTK^-C":F_-EP/Z!M$7UJBWUH4ZH&'SDQ'EI%5FNQ,2D>5
M1[W5NIP+)Q=J18?O"=")??DPF$&>.IXPI5'(>E+!>$_A9_/S3.ZT?F?%I/L]
M<QSKA!KKJQ]JWDJ%1MYSDMB\;,SV,2WAYR<XC=0$AVC^JZ\,BL^LC<R8?]A(
M167XWHU23"Q\2H]2KA5)_U*UI\-P0\U_5GH$EA8E4+>&1W'?A800T.P_X1DT
MY0_<=<1F(M2+W+A_/QL/W)1G\LBQ4UX8+#*=F!TJ\\BQ.>)+R6WXG:J3IX;R
M\I;IO=O;"BA6+/Q>5,KI;MQU=("'6) ./U;9NZ-O..CB-T_4+<:KBC/&Q'S4
MQN<=^58F3-Q&QL1_O5?]>96S36WZ%)3V1,.TFELF6WF3.<@=7^;LB;?6G"@T
M2'4S*"PUK:\*FUK"Q)D:FBI,-1OC+:GOAR*,BE-&KZ^B9I6+<VSZGRAMR3TA
M6U8D'TXJ:N2WPE-L8! .Y[@A\H-VKJM9] VUF%KSDO+P>ZI:JI^?7(_T%+KL
MP$44^W.>O=E;Z)VHMB)NNG(*;NKKUP3AU#84!$N4:.)XE_ULI%?9O0:U'6">
M8KD61B&K)M<.VC/7G0_$*M\\SQ$G9*P_^]<X;WJ4.A]1)=TF:9Q$/H]P*O92
M. 5EDSXKXLRNWB<V03<O;Z8/<8:8==_4MOR.ZA!XY*M@&LISGOW[DP]D0[;U
MHLA?ZO3@#Q>7]D9VQDMJ0 ,<N_0#8-XO<U$I ?EI/S378\??CG:!8TY!=3E;
M8Z>@"VPGF#,A63:7OHTG+?5@&]33J><08TX< )B4O+S6[UF!9@%\E@VW5D]!
M](9X7$H$'0&5@+A<\$<:S.@AS!^$8@%0.#YL7Z16EV=K%<7LXT//U_9 <+A&
M'=)-?KZI'T:Z5V5K?I*+$#3^%'$?,".K'\J0F$HI; I.FT<(E:EV]^,[@/2
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MT,S.'P0+-IDJ1M$FPY)<)BFR'SR:0KBH:G6D?MR<RBGH'#S,79AT=-AV4M>
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M"#S:P]%5A4H,0).=6 !=_(UT3J#DP/HJ^_QZ[E.Y0O-IC'89V?U?F";HRWR
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MU4HWJ[VLRHT<YE.4U"\[2(=Z<;D;I&QK\BVB9Q 64*WS\N2Q4+AXT\#IYRN
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M?P!/2=BI/$8C!T,=L^3 :=HM@,>6[8 ".Q)K$?C)>$C45VZ*98218B45"P
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M]!ZG5Z/S\;ZWTU-"*E_1RG.8%VG<RV;.^"-_!3 4HQQ,E>!;P#,47"Q9U2D
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M[,&U1OO'XLVJG%L?>LET^CRJ+=T$LN/6/L?/XL"HEM:J3?%%Z^^TW+C=GO;
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MJ2?S;L=XF7]V"SX"1Q%J.BVJN_2Q&YNS(S.7C>-HR+R, M^<YZEZ:A\B]C7
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MN'WCX@$SMIGN+E1]BR[B]O4(&1*!4!=TZV J4]BS8AO",=X/*XND0_EA[ =
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MB&X8=F7-Q3)XDB3;J_S8O4Y8/_?#'YG&?E\!ZO8X#=6NUVC1YS/VW"2M\/C
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M2C?5+-PXE)H#WV^9Y#=,I=_C6*%M?3E_UP^.^4-Y.))H!MR3Z=_2XOKS>3)
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M</J^0MW_Z)/M6R:LC_K0")V#8-V*P,PYZ++::69J:JLZ'I:PR%^?9:&8S\C
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MOY(X\DOO>;A4#[\[4*GF3U0<C3X'?;;_:TJ\)!@?5'"YW;D@TI[A1=O-M0S
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M>&AP,_$@Z\O'16L]Z6\NA0MRMJY3S:N';QK>!-(KFS'-C3*T=+XC"9[1])Z
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M_@OX;PR)%:^<TB8#WSET!R3QHZ\$V30H*A"2P!M"53#N**Y>D 5Q&PBL=N5
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M=[_[['&_>^ZX?^QDK#&>E;GF6NLWVYKS29[@9_'+@)NJ2BI*  (" L#+JS<
M/P]X\KOWO_7Z/<G_[AP$^'8 S0V"\VM9A 3W -=H" AI"/#= "  0$#\'P,
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MEU[&>'BP2"4*+03;:5#-;+$])"1A7?].1!&]G.&]JW'\:(2^G@E'I:3,L3G
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MD&.'COC MBQQ9*,(X'):ES +M /DJ1D&O8%C]>'0;[BL:&5\Y%:$-NV 4T5
MQ8&(1+NX#77/@MD.\:)- -K;-7M3QHD9%S[0_9ZD"'#6W]?J%[DW\KV>YXGP
M'Z^!)B'R Z]V1E)%2_GU8U1]"C3R=B9BI(=5/5]\.;\WZ7P;QC(T.E!B*8-L
M<)$TLM<?NON^@+E>UCU7R:-XI6&[<*)(9O!SM+WTB-";_X.]]PYJ\ML6AN-/
M%!4540&I4>D@(M)K;(" ]&HH41%I M)[8@.D2U=:E%Z$2 E(C70! >D22@H@
MTA-*"*1]\;3K/>?<[SMWOOO.O'/G_+%G=I[L9^VU5U_S[+VV+;I$04W;53RW
MZ>;LOW:&ZG^H_<WFY/^')2K^0^^?#%4'DEY[AB]BK3I-B/"V_<@X.A><)? I
M>:XMV#ZF)##!G,@>,9"I'ER17N0,EA,M*9O!@.5?W[Q_K\_OR<"#V(B+J"Q(
M)(@-Y+ZFTYG#/XK"IL[RT_) CS9>I+6<'UY']GE.V4"::\G.]#-I)+:8-^H7
M" <[<@1'U'6=+NT[-R!K/M&GW[15"7]X^#G):!J$WL4>8@#B:V3X0O4):QL=
M":?(""WR32);6X9,._MA5Y*E++ETHT/U4BW6NCW [_Z]'-%H\W#?D)6>.?V0
M].N+M_@_4=D(3$EXZ*[40><AP->D*#KT::;Z, "=+..A(/?"0&Y2-%%C(-6A
MW/4;!!S$ZY&*UQ"R' ^5]CI!Z[69:O6D?1+.8/MB$CI\K#.5)>V"7L#B>)9$
M[_J95-?7*3;1]MMYX@4L&36VJ=GK+B;BN)'"E )Q _/DL>OBC<J(ZK S'BMV
M=: /=B<UP +<N@;!;C;9'M*J0WYE9>? ;&IQNM)Y\?LA:@$B[VLSL&JM'(\F
M>2QFOQ\/8H_&<--YJ)P$PW(B.YZIE.P' F5N6MN8$-FCD&IV0,-H_;=YR.I:
M_;+)-7S2^N9ZH'2Y=/O&IQSS: 4G1]8RP@RR(#+25XU/;6)T]?&V#9N;NZ$N
M?7B71!JOU#JQ,NWY^LZ$;&[OP]-7'BRRQ%K- ZEG^PQ&J$X40Z;'D-7D)O>>
M\P.&YRC1WM&%ZF*I2B4GZ$"B]$0XG7,Y1XR 3*MVD9)NIEI"A3Z.^+&IN>QJ
MB7P]_RK?F3Q4=$E+\HKKF8ZY"Y$^*1 1,1&PA8CXC)J(KK:43K]PP_<N:>WD
MTCF)MC1>OVQEA37)4M^L5%6/@>$?U2BI)O,/#? "U$&0\^!S> TL7(R8W@IY
M!>4CTB-= A\KJ-0(6'8;PW5&SSJL\C8C"SHVE^H<N8.G9EA>5UA?GGT+8:9I
MKD9/8=6:444K&'Y-4;(-;J>P,D"D,,JM8GF<"UQ8K]#DZ>4OGZWX \_6?%V>
M+)3V8U__EI>+.Y^^7 '4,?3$R&-- 5BK \B9 ?B#JO9QA*J$A?- !^E'B$YQ
M37*X%34#I1N1G?MWP'YIX<6*Z0\2)^^Z<C?8S<Q7Z9Y5')G5#IVDSKQ?^9&
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MJR-MM%#$ +S(8P"^1*K2[\(@0DZ!VZ B\E!3,'"$ZL:W!JZC,2/\31 # $Y
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M+ ;@I&JP5 *$Q  804''8-CT ,MO] D0P0RGT=]T%=:V,Y(E//R*KJWZWK2
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MJN%=#WA:/2-GA6_<=)!$VW4\%.QP=VB=.^\D=!X+[7C*SHPA7+MI')Z1TP
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M8;Z4"K3K9D#V>)*'>OE^\51BLX.T1YTZ$!NPND48(061C0JI@F3W0J,BLN6
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M5NMFMLVJ$&KS@#,O.C3/H'Q*74X\.<AW/^2L]!7+"]HG8* ,X&HS'C&9WLT
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MH_9<(+7PW\'2Q6!;;>UTNCY='O8A*)U*Z64ZB:EG3*I>ISU+AVDR844>=V(
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M2E++P+\XP*$I;"!:4KD, 6+W/*<Z1GO@A#L$)!60(G]T]*N,"E@=F:&0-*F
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M5NNIW%@-3Z&:^H3I<^XY+)[G9KB:W#CU;@MO:5\LN: #L#_]!BR 6O" MRF
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M4VB7();F=D!9V;W.S*S21CY0W/.R[Y>FK9\<"M^_'_C"1#!P+)K>J.B^IB8
M4%02==,T\3W7PY>Y.42?5L#%L7^U\N<_M=[;=0FKP*')!)7);)(>(63!,UP8
M@(OL1 EL&*T+LV/%(^6AG/Z1)AE^:4[Y+MQ#?GZJ[LPOHQG9%_CJZF;[I8-8
MJD+B@A8RC_C6CQ<GUZ&TS*3M(4D&21BB,.*(-O[V'0IIKU,;2V!,N*[FB*QG
M@K.N%^6CD[>\Z%7_&N!\V?USH4Y&E)EYP=PX/E.L7\;M;M9(\V<K\V07VS[5
MV;6DUPGL*VF256'5Z:\#L1.,X%UUX/VMN<A8& <-(.D].#J,83N8":9#$%B$
MAF6?(^<@?6>@4ZL8Q6C/YPX_*2+].5,;*J6=S[?RTE?O9^_JC01/N0@W"B/D
M<#;M6(GC]V6(,N?6[-N#NDO9W@FJPMGDH&.*9XL*21MKV)-X%MYVB42'C;0:
M)>DNZB/X"08;<SW:&8K9@K58Q0X==Y*U]"<["9^#Z .(/00QX!\K9SS3]^8K
M<@TS^<K:BX(_Z_WF?"B<FV6FSF2FXF%,;-+CRHC; F^-5HQ?YH<7AF=*$,M+
M#<Q6)B91@;EBBA)?(99FN2I#KW*5)E) ^IO8O,.I*?E<BT9-3G/'D#\G!Y[X
MM@X]6*S+E_H?)PD85A';,W^*.1(N$\\Z@P2:"'&^+/"N8+G)ZEFF#A#3<$YV
MD#FN1B"QJIP\-CSSV-KEQ.?664MI).RO=XNW6=\)>4[#\?U-!"!F* )X'B0(
MNXHS[)&)!W)+R0OI=X#HL;_QT\9=>6LG7F.^4MHFDX?>#I\?6><9U:5ZRC-9
M"DV]=?TE";T";WM!8I^O)2>J01?K89<7-A&"UIN4BR-;),NKT?:*T64^Z[[.
MV=;JX$?^D.6FBPVYO1Y5 3(2T0^TS+2A4'(]W-WP%*5O=<$OG'1[(9'%?P9?
M1^AY KN-M;_36%43^3#BZFB8J]5.'?*8Q3?/WT(GK@9? !G1$*OF.,M\M[A+
M=2%?6:.^0ZYS_E/RT:91PNE4"<XQ3]_7-?6FU;:;:UD-0DKY>D9OZR6&2XVM
M5(V+M;S"BJ9GY7Y_,/$8</%>8_U%Q*.PZ&WH DJ@N2[\$'$*=I]@C2G$.G4!
M(ZTV11N0;YLTQ!IGIS2\_.@=^_ L>JW:@<QXX\=MRQ#A]4H^[6G&(XM,4F[R
M&%99C74)E'+<3^,4+#G[1@L#217775\!TQH)EB"]('1ACG"[/5#>M<G4HQ.?
M;(EO=:E2XG>_!#KZNLDPK^VUY5@]^.565'Z?8JKQUNU$+O?\I\/SITAG? 8E
MI$E)A2KO<E7>)?G%:]YE2X?,RN5EE>=:E?,KK>OVW9Y,ER@;YW&L+RH7D50W
MFQW/2S8?OY 3(\'R;WMLYT25?]>W_68U&>U?G$$^MEAAZ $2KCE%-9W!.6$4
M.UC?0JL*$X.59-J$N&782,ZXJY%P^\\NPN='9PR^3,S:![GJ>R$?:^;.BNUK
MY J41L;;T&MB/HJ003!/M7<OFQGJ*F31+=[#KRTPVMOOB9;6_E68HUB4'>N4
M^6:;L !A8%%=A0_EO!O+_ZYR^& H G1AO)H( 6V:3,AK"'V;5#.Y&E8T<Z]@
MYO'L@W7/6[Q+T>7X.M67^'</Y_3*[/2=MI53-FH/C%P,S;?J:]SNCB2*K,"^
M6KQ,1:9*FF_5O)ZYG[%7Z32K0 74\;0QHI[16-V=86*@KKU8C=UK46Y_PO]0
M/&EZ!..()2E /(5FY[[L:PV+9;Y"BB;0=3"]T_1!??7;UEY S8#QG@1WHJZ_
M_ITQDNP".IJ[H>)S@?-T5>38]HWJ6;^'(Y<#R[3965XVO/[]5K:[_TSK+/_-
M)V!VL//06Q1',)<EZ2R!';LXSY ( @=W@T\%\\RZ[;L%GT]@L1K"^'4I/9>J
MD"/;=[UC"J]K^#J"W'9(/9G-,.*P&I#SUDOXT;/E2;BTF@#37)0AB",[HO[<
MS7%"!71\)X$QX"A^C\0+5:ZU7S;PM_V)G9-:01)LN\M3+E7Z5Y.7V?GB+.5<
M8S@M]/+U\A_TMBOF:V^,M&O4\&AE%+M6[QP'H*N;*I [QX]7BR4^4#X=Q';J
M-72J4_CAC>86-=L#0<FOFG>"AS^I]FZ9^NWV*(E/BA3:;?ZHX1=\XQ6WH_ZM
MXTG(]EQ>'DH=PMW[ZC'J58ANR"2=^NV$N0_5#V_^.1M=H!L?G\T@>+BC:K*A
M'!#?&#3WK6=.4#"L;<U_D+&-@?[!C%&RP8!F-5&N[IC%HRS8EA1$(^ZWA+ %
M<"=*D'"O#5B5EM@B[F^X<#9-N!$7B!$*'X^(_DRXV^6TM[-<RS\SI5_1[_0L
MUE=-1=!B1^1Y64S;F#/,F"8CSM_I_F@+\R,2"\$78Y@(9J,H^TOW8!3#2(R?
M;&><_=X35#!STWAW"Y-Q^=VO+OB;,SV^S,;E!\,ZHN\UXI9*",#M61QP?G);
M=AXZK8V'51*(&/#4;@_J='F-NEM7[[.S[_T69ZX=Y*7V3:N&-U4&F6B,5RQ0
M>K/"?JM]'9!S9#!M)6401!8@4,SJ]FVBY 9< .9'DU"W@(J!V^^R$>[=]3R+
MGB7<-63+.@UEGG(YVV'S-5 @7LT_9OSJ>)QS/#ZOAEVH6^M9^O5OWVK\M1J6
MLV,S+JPKCZ5)'YD]K_=-)B2Y;OF:VG/)X]K3;CS=]3//=VX?L 39ZBH.>9BY
MV:@"1X>V"HGW-8AZ)-5Z7*F_3"><U;>9QZ8%BXAN$L/XBT+NZ4_*K=VHD+9/
M6.K@:OGL:KPC*[0=J^\BR6":,B4H/EIS+$LCJTQ"R&(B%X%U,3*\20.CCXRB
MY41..&2G+1/!"R=I%)]FBO,,?RZ'8/T] REZK+-G6#S$G%8%W)9,VR_0UIGR
M9I<_&;+A$N$2G=]EO,L1.PZRE"PMW-5<V^43$QL7N6;CK;&K]S(/_[HC]:0<
MV-/0$,1KI,GUT>[/<3@=K[#LOU92TY?"GZK,C_A5U>)?':Z=YC9]& @_K$H*
M#FUA(#=1 9[(<. 7>(B:,H86M2K4G>"+%UFYG2F<V-5P.0N64E=%J[)B=_R8
MX56X])#A+=&CVRJB>J?34NBN@P,><^OT7]E]ILMG$=\9TFHR)*[J+[2?<AJ5
M "=<KZ@CZC^>I0P#.2@*P;UH]L-^]]M=TS)O*8R$)"$5(>LV"C^VO'QP2IZH
M:XR9M]Z8_FW!2L?.4K8Q#9.J#XUO.A03-\Y2*IIMT*O*='(Q+K5-$/:*M;IN
M5:?B>3]G!Z_O:A2>N=+":YX$_[X0@30:[#?/Y:U[EO'22]\&N(O89B0&B[=#
MV4DW".[8S06>Z)9;)&M"\0(36/B7/^O]L>=RQ=4H)DBAV/( >:6T5([_<:C\
M^TO.N0T6S"7&UQ5#H/>">U'5NV_A;JSAD1B9\#)YEHN+>CCN\GDJ@(O@9FHL
M#V0A-':,1LG'<R^/-5G(N(GD1&]/S:<IQ>^=3VSSC#FQS2<:!(]0 94];TF>
MB[OLP=T\("'R!SD4Y_J<2GAX89P:)% H-2T?R/"[R>^5Z/JD0EV56\1U&?[K
MN5],'SD$58!HJ4>HO*L%-_ALRTV24ETB$:Y)\,95=9V8I^ >%G.03),"ZX/'
M,39:CB:BT[%R;+'1HJDO1=)O";[M]]74'>V66UIF=#0IR+\&@I:N[+69O'7@
M'F^IR)?+6$'W"B:[(L;K!7/2\ X21Y!]\]+4^GKI#?>N6B1OC8OK1Z)T9@D"
MK[U7:&*R(^Z9XK_^ZU6A<4VUM11H&WS/M"PI,"]MMG#MW_Z"S45?4:(A%=^8
M%2UZYORM1]D,I^J'/+S>Z&17RO\E]FWTD/?R[,IOEZ,O75672>M25Q,N%8J(
MIHHK\THHJV$D5.]"?.+U7S=XTW*LWDR+E-UAU]\_(3;*HJ0T^/MC.]P]RGDW
M\8C@2_ZC'5 FT"E_]*+,6Q"WVT-G!"?)>Z&_G\D-S&*K-GIWW<FN2/=";H6^
M@(;B1W*R?9%*%('N1_20)BZ6<E[59<&0S1_:!C_;<L%_:#$Q01YZMC"1I+E0
M?L$ZZ"*Q'<2?P+<C4R%O5ZZ07>KK[NFNUCTN'3PR!TVM_;'-K[A0US$4B<9&
M$[SQF[BT!)0+6!!VD]"&G<&T5%40Z%I5;.N*UJ8]"O9<3Y:FS1+R<ZS0VNZ8
M6'>(?<RLYO=W/>'>[Z^.GQ#Q=PF=%%YR8?!ETAUR[HX<C1T(B9C5+9Q[N8O?
M=+5^H;4K;LK2EB^]_^A!J=@2=_(LDVG*CV!OR3=[A7\91X*$%%4,C#Z5#!AP
M&'A_3ILH/W]]G7LYYO,YA8P1#^B%_,&?608ZWM<'LR2DU_\ORMX[JJGN[1:-
MHB*@(-)!0:5WE28U@@(" M([41$AY V]$XA*DRY=J=(%A"B]1[J @'0)-8F(
ME$!""5M3.+R_\XUSQQWCN]^XY[_\M;/V6NMYGCGW>M:<>_O3T:HS&4&&6I/*
M;3.;*#>OQ<)Y%#F:&$10(M;K 46K*VH8#&GM\XQ_[F("@<6^_E;OAXV@SYFF
MR_;?ZO2$,@,3W\Y/_Z0QW_36+Q)"'?1'/$!VWVA8ND?G'.P;YZ(EPY"LP#CN
M*/X0R=(0^8^-FL72DMJB@YPP"TMNZ;4_][PE?%FX(+,SHI]\4C(.#L?.4V\Y
M<97P&DN4"8;Z;[:(%8I46528/UI"^UKX+&]E6_ >@T9&C INH:PSW&!^/1QY
MPNIVBA6\E?_4^!R8Z3Y[]"^7^F\=_/Y_L; H5H4?D<#ZWX,J%>OO2R+DN4N#
MFAVDH0O?C?E'+A!'^0R*TE3.*>OK6.Y:6UM+645#BHMZ".WS!A*C]M0A2/9$
M]<9[V/<_8=B4[3#*;2HO:?8S21R+[$8S!:L/"EY+6SN$L$,#;< POS"9>F<6
MI98<W)P)C[R?:J8_ .?A,(SG5N4SG?*)8EQ;^O[SI@9(#W3GBN^#W7&-Z6D+
M@UHG!S-S^\.,UI#RE< 23AI'BYT7W&HR/#T(MB[=_*LG7J+J_W55:EQ+F*I
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M"YX&'BC@;R<ZA# CC+RJYHU+2K-O]Y]A[SP(8CMM)#/5?5EOAZ_@&5-+YA*
M/ :=Y08,2&K(!4;L^F L<*N:_@-]!L&Q>M7/@!2T33EAR.R:%7$: E4P[K:
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M+W-E8RJ),+*]Z'.S:?G ?O*(Z@-HX\ I:D)43B2=.? 8Q(AT19V.^&YM4Z
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M]O+K%<$'@P]3%T\;2MV$"%]S$;ER3KSV')O)'=EQD."AZ'\=A1F+D <=_0J
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M%(_;*XU]?A]3A9%'V*[&!,NU#OW\3!.K]'H)(R[.PNIDBWN)X,<A2@V@%)G
MP0QCPXSP8_6"E]S2\WL=FMQG*'&'41,_"87=\H ?Y0=ZH<P&+QMTAQ[&(6X9
MT,^^5[^O2RV:8-""V [4X<\!#[["[S0WC_EYZ!\95(8:/:\:0\M(^2U+E84&
MLMTDV-XVN<[:?_O>/[]DKG?#U>%MF.K(;5.B*ZG^M$2-EJ)C-0VU&&C7[#QR
MN$:02=]9>C)2(^G?& &:88S-6,_UCPO])62A6;]2Y5AE4GN=DR\XT[='->R^
MG,_]4&@W_,79L".=QETHY(S^*L4&!IJ" =73PF"N/Z RLYW< Y5?_>FVI%Z"
MQJ/8;]%<&7K9_^[FZ#1*J^^5Z[#P%BJL9TROI' BA5/%DQ20E.R<*XT_7(VW
MS5(PO2&?5:S=>KOTS=8*IZ7#B+W"C_ _26 ],/C-.> YJS*7<@>3 R5H+>?P
MJ,A=WC[O8#E@._9'7E[MR)R#@<9ZO\6QK=<]%4C!.>#$# .Z"M.A0,]^G\1O
M'1+<W%NYL6>*1.0G/R\:LIQ@/7([-L2D<JQ[M+@25QH^4L\X\WCET:)6:&WG
M?_6P5B7WC,[H9W!\#FNXNO:%*-(MHR 7PN<ET8\PTW+KMM*5@V\*MI+*:P_0
M<@S.WU )=/17'""W!"]79@9E7=?3T)O,,<S/,.C(MWF;:6J@U*!5G>^7&U*;
M^*9>-41/TM<TYU/)M5&P&>I)Z7I?]\(W;;"&K=[ TUQ19VAOK/\"-G I<)M)
M="L7!XPYZ>U,(=,2O)X1+;L0/&ZS<2C\+N\F-[AI]$6 WN)+5,:<W'8Y0]\]
M$-OH+7IEFP$"9CN)N+%&>A*_Y)!?U"X:"WR-CM'$(;MGK^@\<I ?71KWVY3,
M,GQ;N6U=YE>F/_7\R]JU=9<K3@&*9[*8;L3,.8!42Z3==B*@<=EH(@:'W!8D
MI!G^]F1MWZ.KN2%H.R:/HPV7699>[3W-\O4NM^OSI=0^K7V__">.CE\5#PS7
MN$^FNW M(^2J7"JH%N3U&5DCT.4RU?MQ\:5"3T8I=,%ZY" +:/CTDG.0U-:-
MO#09QH[+UQ,^S4MJJ10G;_@^-I1+S,)C M-!BEET=;2W5QXO'SH92C"G7#7N
M^5&CNZ]M48EB=Z6/UNBP]7EQ-UF'>5M"HRHH7.6WN\&DW;J^6JWK >TBDFT=
MKD2(CV@&Y_2/N;5*_3Y LX!9?M[-&U,H80C5[IMFT76MJX_]U =(O'2'QEX+
M6K>UL#BHB1O>.B48X<Y*]29@[ 1TF\;M\:B[\;/5L@SKP?Z35@"Z_;(_;Q_%
M?7@GB878%#\H,KE/%E365@^=$$EMC>(R3D;I9^83]9F3JVO+1 [&7F_O-8Y\
M1\>< [R \2=36U,4!=@_Y S<)PL$N\V%L7,AN[A8<U\_+-.?QZMK6(>IL"3\
MZ8F9?C&KZ'3E=>N_Z"C,XG?@I<-S %:6Y$2.).QV1#S$-TA-61/^?2A7JF@S
M'^_E[X^RU=U^%Q:"EG@DM)@C&*;E@[=;TC>)]JF*5+/L6F],'M]^G35NEY_;
MDE1#"H6ZC67?2Y90X!S 2K8TI' /B1]4I8<UC6[#,!IP;O(F*>WTJX;J69\-
MHEOV\TE\]S M?&JS8-UF)>)G#*J=7WJRFB>>[3'_Y\]IXBCK3E:K)8AD<9@2
M)WKN:]]LGRA8K<Y.3#)I,Y$AE*GL@H$41X!N3-B!I>&M(,685H9-S'6J($6
MA\^W^Z3N4[I"?+>&^(B\>+.$=+7)+X:9N6_.S3%== ]Z%IH[7V-"!!G-V]N$
M_#:T<4UHDTNO<I47O;O]#)3$NBGG@&VE*7WCVJ_Z-2NFC"M57JF^>GK*/;Q%
MA3."WWQJM+T-9:R>2;EWU^U,H4 SD[$9[NOMOGKV^H8F)BFSHK2"@CG+9CZN
M-%RX]TH'@'. '7UP#$ =(/"EH.'8J#7HH$T:.280^S0%OT0=2-U$!/DLH$*2
M=Y(@_G5HS0LC.MM+BI@ NBY\J'" 6D^=L0[S0]&=\$L$M]#MY0VX^&3U*;M7
M&-VMI%=>+,NWU9FG=J;:L^\3.;8?$M=(\0VGJ6K"Q%P+,MB#(+M8B\2C^<D8
MK8=\MMW(6ZO1'5:ER_Z-%^'B A(>[- M[F*ZTT [<+DEZ8R^%V=@8P2@WB87
MO;R2UAC8X14+IR%R?)(V#I1PVX,BGT:32%KM4JGWM83'F.M>%>QI2_;!)0:)
MEB3_"]HUIIC#9,GVY50/LCWE*?5NU<_>C_,<K:/-("$+T<ZZT4++&RB0*V/E
M'RY!"4$)S1*5G]&&Q+)_D6K>G-,OLPYBS5-Z4NGS:JH^5LB5\.N%-*\;>EO$
M#-;8)>2++<S@BH>_2;\B^J5JI/O$)<;1F:VD'"6^A9% R L<RB(.44C ,;BZ
M.S9/M!M8U=M+!V>'O:FJ8V&09?T;+#[J.EF#,E*J2) ?-#-D5TS-YN*+,Z4]
M8NK0$!ZCNN"0-\AU.@&ALEU8D10T^%^]/V_\(9(0BOT,8'GVC\CB/W<2KV\[
M#M=%G]V"#BP"J:RT>-?W&H(VPG7=&&P&WK.D%!4A_7-O7>,..>EFUG=K,.ZV
M]DVII8J:1!^:4NE'QZR"@D>:BXH?%60O7<RLWN*VI: I =6)N4H.,8D=LI:M
M1C.MIX=B*P3$Q=6;8N+JEVC*]V-<>'7D4]:G.CO35<3-RM),3A8D+)K!>'!/
MGZ2H\5YH@4_)XY?FJGN&G!ONTJ#T5 ZF3]X#=L<U*?K5=CGB=>+Z9IG%>O-R
M:15F'NU"_H("CS?4R>< _@EA3OZ43/3KQ):#@PG(7D4N1L<)QT06 _:> V[#
MAY$ KPL8N,29U*LA-G6 O@;U7,79XRI:IT1NKUZ8,<\8@U;VA$! SF?>F&CR
MPN)"+- -,8,DE9 5":[XJ>XLT!+3AW. F]%5 SQT]S"YP7:7'AJA#C1I33.H
M=LU^_N8[Y4[8W??QBO]2MGP/>ZELMHO SZVJ9\.!C:[OI$?W>UJ9B-=BESQH
M#0)U>U"//O@<R;Y@D(0=75-@7G16%=_R)J+:RT27D-N.%"LJ&[EN:?C#R5$'
M$\W9L 9]/>%P2T,0VKT0I6;H=PHR2 UAEZAL^6 4Y.5["\N4MI+9P/BD@V)4
M:F!0[E@F-EA==HJTE.UZXAL=[*O)SNU=;5EC4L2E9:W<_4JF<-#T*&W"5<7;
MPN3D4*7Z--,V %:5KZRJ[ /?L9L,,#KBE[-FRT8I;\;1\;+H"?Y>7O8U*LSY
M(_A\(23S<+/^Y% #E:,6]\!DXN^AK=_!.IEI#:%QAKC_O\Y-_3\;L\7Z_WN[
M]IW0_W6L*J!XBD/<Z^J_N_VV6E*5?I0*[=$ZDVL!18)"-[\))DI-/JJVI,A:
MS]-IYB]\J/9][RJSY5Q(RT4CU0#L4HG94.34!UER#MEA_ETR]-$_E5H*V5 J
M!VO+@O4?P!.3G<B^CD.3&W U-P&"+=/,0G<V]T1S(&XA$LGE'Q_)+;R#AA1!
M%YX15F(GXZ_6?BS'EA'\)E+^O?U;*.D7W%+W1Q!4##(-_Z^.LSG0%1C!X7CY
MC=]GQ&VJWCC"#7-U@U^## $O>LB-F68\)^RD%17$%AJ]Q6!O?=J1JK%4"?TC
MOGJL^%G*95J[GFIT#@BSVC@'U"U$8Q:SZC",\*O4"_@HAM)TI_=V,]&1$3UP
MD493A9K:EK7U_0V5V)A 9AV_5"/5GWI."=EJA:]6U?Z22Q91/8[32:3!BX]9
MGPTOT,B? VY2C<@IA MY84V>XR\3B"JPJA[H7&**H>EN%4D="EIF[6:/JRKM
M<RW(&E%[9/RC9/LY1\[SR!WQ\41_B?'V)S*1E&ZKJ?;Q[BG?N/$EVNMCAGNK
M!H.S:<D]OOI9[N,XQ*L*>K,U426MD>Y>!OIHM:(&&\/<V".[NLFU[<A.#%F"
M:>MHJ8QG*66U"+)D='GS'%"UUC'GM20:#^-9DKXW9DAD@ %_^WF8VK5,R8<\
M+AR2+1OM!;6 K?/"7T&73-_]R]';##P'7/U^FEUCQ$3V[;6I>Z<A"_7%Q4?)
M^/TJT[B[H<%3970#B]TX^@UNA.>$^)\6/[6P5)RR(,A'E_97A>6NL!/3MCDH
M\O!1#6$"8ON(X@,?;W3\T,Q0[ 8D&"Y@F7 "G0LT9(F %)M9"[(KOKYFVZO+
M\J&=RM 3Z68LQ$ T [*J<I6Y2'])XP:9XXR>BV*!:%<\NP$?G,3<A+.2+7%&
M78@(C6N_/5OOS-D'-<9&?I _!1F..V,B1AG"M29D#BBTMD&XNOW<YF\N)H%)
MUCU9$SF<C17Y'U-LO-,H4NZO*MC7@1#3D(X4?K">SIR/3]7SZNH5X^1["PK*
MPYPI@?SNS?5V"BH[MU!0B/CXZ1^[EG7M^_.!CFCD?]N[>8A+K0SDQK&V/LA_
MI\1GW^/G&E6#E#Y>Y!/AL^&CZ0C>H@O*AW"G=,YC\\2+K*3J;H,X7YR9=4=8
MLD<1'<_H$10-JA)A8>L(KRX&1>&E$-5KI'6R-0HJ:Q3Y?-Q?FS"?%E*RZ3UX
MI>Z+%,MZ:N/K[VEBW/^(UB7<U[X!PQ&;\,#.W>DU/<+45@U%CFRK1XZEO*9J
M7@"[8_A/D%)M,U*/4/>^^O9O>00'5<MWC<=>IF?8K*D^FJ<>I_CY8?,4BXY7
M;X<C*]#5*/H<4(GL$2#?.P>TR;[+ODNHK2":=C2BMV_X>Z.AR;W^N-E!6P>R
MT=)I2->\V9LUCTHM1*'M[/4^57SL%UA!5;QDBHSUOFG)UTZZ)]495L$38"FM
M9P;T)OH;L?1^<YL*N^/+J/Z&\J(G)OGBH"-_8-4&_C:WX<1ZXU>8?*%Y&1^[
MN+ZYO>Y8\WC*HXS88^06NFV8++;6'A\K<%M^.(S#1C86S@O3(]Y,091#+;6(
MJRE>^;)1U:?BN#CJ.HM.Z-NQ/@_!ZW./%BM52&M8A>%9ID7M*(H>F8EDD-%S
M^VB!NSDH'_K!=JQ9UGGDSP *W,HWAAK?+5<(D#L'_*AJ]Y *V(C0D5N6A]0I
MD)$$%<H2;0^"+#$5H?: $KP #6D[!W B7 4N;VK<.\UL5L=!38TNLKI;G<&^
MH:9AHH:B6FC#6<.#9-)UJFFL]E*?$4G)EM/?/MJ-<;QRQ@V[?X$(+? .C8>$
MM$A\!=&K"XIPF]/I43GL_G=*):)TD]!_H.GNDB:6^ES_RY_'E[MYI/"6"Q\Z
M3 U6ZB"G%>:Q^(9<DW$)LYQ_MQJ"<-JYZ8$DWQ@G=$UC87N_U;1D\5?W^^D&
M^=S@GBS]I"PD88.B5\PN" ?7W$[4V3'8R7_Y4CC185X3+)(;4/L(I%:1Z^"@
MQYNH WXCY"\W--(M]$.L4[54^IWJ^E/M]E\;?]X^2'6*>?%6U37SIIZRZ/'R
MQ;_G(<EB\HX7\>[<3;8O)#^:Q75/;0<M9GA=TF&S]:<I1D:V*ELZ<L@_6SE0
MYG5X8)NBF[JVY1J@3;LCT.Y,+M;@_RM._&%P$_$)PO;! 7'SJKWHT,U;H9DT
MF94/=]KOR-6.LI7;"\R;9FEO2YB[/-'[NS(8I-4#'+C*XPLARBR;&6;9^,V:
MD)+MS2:+A,6Z4<(_4E9* _\<HN[<#'9&('M12W; +EF.6:H:02<:YA6(VDAO
MJ0OW4]>TS= ?Y1@>1X_VW$[&3G<*%2;9ZYM)&=^FUU6C]JH/^*F? X#K9CN\
MUV?^B.M.I#^+H7X/Y*(W$TN2Z)^-^WVIG<T,5I'4^-DXR61EU;NR2<_1P>7(
MVNMW7*7QQ+RQQYO2[*G]:>I7PC"5?6TQKHX8CW-L.[7%#7=C&*!K2_Q5_KG0
M>U.VA-,\Y@6[:6L0(M#WH0A*GFC3Z0KQ&7Q0A^5F87@C[5B6P%MQ'-6Q&.;[
M"YN72>V4*N40O7(Y2!W(>@YX]76*5'M:CW'WFJ7I*KM=AC-Z?R93?YJ!</UL
M+8V#2$H_?%95-]%LO,2GG!-U5R7Y"#M4E//'CDXDY4YL1X7S#<?:!S^EWVEL
M)#15'$>.U:J^+I;6CV/OES-WH3,KW#F=K=O"3Z0<K]<;U$&4A5T'WF8FEY@O
M5^;3B>4U@K:%=LOR\OD4:PX:U,U=[-XN+\>X IRS&WXM^P/\E=I$RHR?Y@XZ
MD["@XQ]'\2E;-50 8>&6FP"#!LL&DAGHIFXQ.MQY\H&LP!1'U?[XM,Z!G]!H
MO^'F*>@ES8^_^O!7N3-+[9-(%QJO;.@PJ8<L2)@E!4>2TLE1>'^":R>H1<;
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M2I2'LT6L[N'M#?<F\2>L5Y-LVP.%JW.R^%+EM<S,>RWQ0"R09$D>( POUO4
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M1&)5C%"-!P5U<,BJ<Z^+^,4XA?]>_;3),]W2]WIV]]LYAP=B>'TM)5>!T^>
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M=1VF[A(2ZLO(.-(_(M5JY39>WI$G#?]XF$?/H<0Y;".XTV\2EYBHU]HH*>E
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M!/RJ^ /D@\"!/__[/WK\N<G_Z1Y*\F9 8PDPL2!766DCL$!#25E#2=X&8 %
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MT1?D_A?GY_\PV(O_3;[I*I6-,[(FQWJKJ670+"4 >\UJPN]4=FL8N4NI>^U
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MF (-IQIWV)FQL<NI2F27#E]=B)DX"F<W<^+IRVV5X2#J)B1&? %VI)VGG'Y
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M<U=!?ZPJ'E86>5[;AJX)DUZ#L>W@T\*I%Q _L=I,/3486^EUBG>T=630D^U
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M%T?4EB9(D&KRDPC9L<P?A8P7RS'@&SF0NOI/8"\'=''"\(9H.9 WK0X*UV6
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MEK(7MJR-M76"TB;$8XC-Y7#:>Y'(N)W!([03 (H53/A)>LVQPU5%?!'B3\Y
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MT P#]&=D+Y0MV#9ORUQ2Q5<$0*W!'#I.W4SY19HIVS8F,_^&A@E!)8J/E/X
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MVI*:1J(1Y-9%7$X\1KR$;:04$K;B'4!BKM1V5HBM1PJ6R95M!E"=[ZJ(8QR
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M(+5*\<%!J6(\8XU=?U:9 PFOC<Q'N0$+?B/?4,@[7W>DE-JZ5X>V7,17,(
M&2S?V.:9I* U%J@6KH78#\56DJ=2*RAIMUR\$O6@)>'Q=S1$+EL)E2"RD XB
M&E.R".OQK@-UZ)BP/L_.LM\S:$6Q/:\MI9.A9XG2($;]$7S8\9*2)896V4('
MP7@4T!5K8[F3,Q4;!O"Q7+)!/$5#((Y&9TN-9BK6 1Z%G%IDX?4Y-N"'S6<
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M4%)WN,T[NV5\9U&Z<X]3<Z:+[NX_:W"$]M][7%V+>MJ-[8<;,3IB)^@F$'
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M\%/7J_N5F Q58F0B9-HL0(,7]K9!$: M"ZOEJH$C"GV@(Z<9*_&V8)*PK E
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M-I<(P^\"\CL1:^E;Q0Y ,[F1G4/8 >CFB=UB04PPY -Z=^P@KI4B#L\8J[8
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MKC:PX\3?NC>Y9YX_<FQM6+U/N[\3H25E(AK[EIC4RU,:+S*66!5:P#HY8O\
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M9O%^C.8\L-QO$MMHF]UJY-B4]WC"DDKL;; \+V[/7NNZHIBV*<&^.>>'OQ"
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MDW4R6#9MY,&E(X#6Q/>&RF)*C6<W;?V'*;QI5U'!U^']D$YA^7A_;%U_[L[
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MN"8@[;E-R\PNG@@]G05%B/AB<LO*7MD.BD+"NSMBABZL%#)[&3E2&CGD4$]
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MLMK:K=_M^=.!)FL>/:46K\S0-;^.WL23,T&U([8\!X=OSE1W;^8M^O:?KN\
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M&XO^ISMGQ.=;2(.65W5N"3'!AZ(EL.STWZ_HQI5^IPMZEAO)%^9&:)W(.I1
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M\/A4%[CQUM8[TX9G#)]<RX=]SXC)P?4#$_(K6E2RG3Q+Z=/]WQ7FOQ*F1(?
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M*?\9=.HL;'J^'GQ2OG11@_W_FP!02P,$%     @ V$-S6"TM_FOV$   [[X
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MWNHC)25;@>@.GP)\1GR!*/DCL/2".I=($(!CG'!=@:7!5XW<V=GKU\=R'3*
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M,.%*%> VGA$OJ@-%6S&*/:C.YSAK66G_+4$SX@;?3[KR.<?2O/ 09O-RK6O
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MBXK]=W7&UP!9;T*LJCG%*!O+:IOYQ0Z"FI;UZG&K,C9T-@B_P=AD^&TT<VV
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M0%*-!P@Y+?%A.R*G;E(*.O4)J4;&I);8,2T(R2Q)H$/_D%&P(;7$C&E!1<F
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M*V;S'T7)*(*-*MY'U,6X*=54_E+B0:NI>\'?/Y.F@E]U&7_LG^ WB8<$_]&
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M1HDB@&"'\5M+%J\QZ"2LPU//6E[0.Q0B&F#^$. ;>A35(=AN.7YK^E)WQR>
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MXT H'H?*B93Y'$;^-8G0^B?ETYLLC5WC@>QX%\2XD-U8<L_+8 M>E_T3':J
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M%Q,J3:*^4V^\W*517-V*6YEOB6D$O5D/(]#69"BE@O>[%9J4EJ&1197PR5E
M\=669VJV[\UJ1?TQP0RVXX):#@@;C. 4:3K>+(7X\7=DCW#OZ;$@"8GH[B'B
MJ:^L>;/U\G[O.EE@#V\Y:82#L\D5H;3PCZK48\=,FWV$7$'DF3E$K?FS9 M2
M"_O-%V0"/,P8I)($0Q\C/-D<"6'435-@C-$\>\8%*];(G+&03\:H ?:9,I0
MPQ EK#$S&B$XA*A.R:,")_P<'6>%.$@7?RUFV_(II^3O..&K,=H["&/,YAF(
M+U\PC4F!&>%C?,^3/YCFM5-\R>N,>+JF&LREQ_\,F$%RNKI)^?YJ822DD1 _
M;0C' )[Q'H-.TML2P0RU72&HQ8*3R8[-0H9C7E1P(8,Q(%PG&88,^B!PM1A
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M(H8&FN(*&!-$)9<\*C\*'+]=Y<_?X#BIJ1$G'2/8O_QR][Q1/1,X_,E'KZO
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M8,Q<%,&0< I:R<A5NFB>+7.ZAL'"'PI\N[PL2L+PX/$=9)V03UZI ?8)-)0
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ME/W/A=WZ_X2#3SP P1]]4 VX]D=?QWCNB;AE:(;W+M+VO8NT?>]B6;UWL<0
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M]5<Z2GW[](Z?_A)'].GCM< -^P.<&7W#Z9R9HR>2. 3):W+=#VCJ8[KN>\"
M92:"U/TTKCLX2R*9X"HH8[8MGW)*_HZ3'[($TUZ,QAUKE6)@8^]Y7_RPV6 J
M_NF:K(GN2:_3?C*\JW#<QK/[!\?Y'K2'[3S45;X%5\__0A'J=:D]FZ!:U=PN
M>_L8M7GTT0&FK[_:$6MOTI,-7OVG8<W:WNJKR^[?4T!?5Q__[9<YL'M>3H"!
MK?KZJQ_8^B8]^<"6/_UE#VQM?74#NZ< ?6 [;&@TS5"WXG-$4EZSJYR* /EC
M[Y]8/Q=^Z!ZOT8ZRPV;Y%O#!>;0*ZO?*XWR]SK-ZRQR1HMC:UK<0*14V\L=O
M2HI3[LSJZZ9\\0+6<>:YH+*8N\ZC#2FCM )YCPM,GW'"QL35MMQ2S&^S1)GV
M>&2/<GS:W;VKV1\$DPL!0_%]D6L(_!E3C*+&;*)E3BLCR!1#&L%]MDW]/MWH
M-T3$=>?IJ%53^[!?U"..M=WG#^_A9)8E;>KGG/\I[#'SH:!>A3-\U XXIIMS
M&"(PTP6(9I#FGL&Y$OOZT*9P36Y9*J_\4..2DI=26(SW[#_":ES/_W/Q2YN#
MCJT=>K=X1\UH%O4QPES <MZ;Y(*ST0'<F"-<&CUS<1'2U&=,2,?$;&]"Q)Z[
MN@;FX/!J2!YYZ 4/&*FL5W-5J"7@J:)"])][3:$?MD8[9GR'[EO!+9:G"IIG
MQN4V37?BI6<>N['.MUEYAI:M880Q/"7G8I(G L%-=7<?01IV'4HUMP11!UE6
M3^1@'7$OKAH\\RRFF E?X.I_Q4!2.1J^ONS-_?/;E*TWZ>>SP4V]_[J:K7Z=
M^0F5.=JP^CTQY?:8@@N>B1VZ5WL].=!U$)A.^4FJJ#_M&C@4N;2=!]2A..(H
M//VYD>Z[X=V<$S3CB<X5U1_]T@:P:X5//UMX&=L7>(DIU3;63Z1\FF?B<>)M
ME"K>$-#TPN'%^AR9QVJ$_L [M,S@#MB1*S(>+TVQPZ<E<*4C3CRW63TE.F\S
MOJ+=KPE[][YO41T3X.O;83MFQQQ_3^X8Z,!8%G!-HKNA]::[H17GJXP(4_6%
M'+(;<R:+'R^B$K=;I"?RNB:C>$V.^YY-?+KT_58(L$R$]WHK3SW7$?T5E]4>
M_]D7=!K7,Y=S9A5)5I#XI.=QI@^^)G_!WG GNG,]^AJLP7K**H['92L%Z>3M
M@ :XR>LESS!^_D3-K?W::QJ$EB8[Y@C4?.J+&7[F^DEAI[V[D,.,!&6.HOAO
M6T)Q<X&C=Z-#2&9Y66]W!Q^RS3;$(GJ9%04N"_8/Y^S?27D>4;I;YI2WD(CC
M9MWZ9-DC<2XEQ.[6Q"JJ-K,<BP S)/;#+3U27_^,8J$:?@M*JA9S<&D>XZ*M
M"5L47^!GG.8;/LI=6\=:3%#:.E;2R%M+&7")ZP9\S-SZ+@J_0HMHPV)FM%'2
MJ<)C,_N'YF_U'O)@0LN2CSC#2S80U:O#\[QP9OQ1/A7:F!^KL6P6_]#O0#LJ
M/&$=E:>#BK>TX0V^VPWFUXZRU75>%(-9TK45324$'2KVJAE'@%X=[K1AQ2Q%
MI>"2.?*U$DJ9%HK[:O (^SUE(%W;HQ8.2L,!8"/CA*17<I4Y<Q<FV<P^QC&9
M%KPTYFO4)[UE]((BH02/17R?J;+R:9I_-MS#=M(,RB]]58QDD]6@/4?E#GE,
MQ%8018TD/ HRT^M:<2$:E&0]L$96,3G@!JQ#J)H+(1JOR^42QR5YQO.,^9*8
MU>2>#9U[S/N1I*0:$>453M@TGCZ44;EE&'8#84WC'*5DG[P\8E/T:7R$8J$9
MS^-5:3Q,?GB+'MZB9:6)BD95C!CF1X:WM"Y5YS7&;(5WS1"DK9SV[.6P(J&-
M$%OEIPX-77FO<4Q8ZB(O])DX(D*.CP#^XD/&UU3+=H3P<?%8;22\CJ&AW.RX
M?.&[D4RAWA.YPZQ_M%O-)_@.N$&T3S--'EE3/O(JA]L>%913+[?O42**TZ@.
MQ"].M >GN6GI-.$F_[TM2KX+O\C'CNFH$8]4IK?;D<>J?GOO\= "H8R&8U9F
MS/Q.A1->7KN\BOGF_(D'+,RS_?=HCOX5:'/-'DTT=::9\ DH(^NTU9/.5D4)
MS-43P6?0=I?4;<#CWDFV%0G/<3U%3FI$=0'AAX>I8G;FJ[1A[5I-QBWY1$T!
M<);E^K.I!0\!U;2$5<LG&1VKT&>@107,4:(;3CD997-TR-700 _]+#3_+V#B
M79,,STN\UAE%)TT8!)2JXD;"5NT5$'&,=1H9N382ZN$9V5KU.NRD7N9J6D0K
M[9-Y%LA]MFE$P3#,C$^^="#V]I@XJN71U[5&^#<C)@2 7+!:%"6)#P\EZ4H"
M&MXSKNJ>83Y-,6"(NS]VO:F40W[.FIWKU\3NP;;]X<TW*@XHSY65WI/L@[)>
M(^-5%9A&>WZ4"7F9))X?K%9]M]D/VEPL4PJ XKNJ*^;JP@ZUP9!W,N0Q7>\H
MR6EUG#@B+K^Z10N^!;4M24K^#B.X^+9\PO0\7[/*\3UI\[I>+>N5D":X ^ZI
M!.'0S(!.,H!<%O6$X2S21[6P+LWU\B$Y9%Z&ZX3!<LFZY);Y=,1UMN:D]9R)
M$#;)+RB)T@M<Q)2(JZBJ@S>]K+>341O<]L13)QB<'2[HI..26AR57/X,)9W&
MJ6C1)?D98*UR@3#WD(KD'\JZN:KZ(\VTRG0<<M,#0JE)8*4C#K:^78M@#R&)
M+H[@O>]%K<LLV8]8K2(06HTJXDBJ6NLU4&H(54\H)G=*.C4)%^Z8V\XFS7DF
M(*JJHY/T1A@SU)8A:C$8E#!BTV=IKL4+?N(O-*"YR&XN7%!WV,$)#LX1,RXY
M-T2=4A M219E,>,%7XTW-D?D/:D*")08OF< ;Q]3LHK&KJ91$%Z"=C-,R>N$
MU!7JU V&',)&!<\/_):8FCO&#:PVM\HH*P7?TRH W+7JLA\S-)9-Z5HF3.;J
M'CQU&FHF ,:VJE"I+P\+%O#[%%LN'VC@[C&+@;.;.H!2"/%J146(9<]>%B(O
M=WR$?%VZ6/G&TYXEB<BN*S*)J_T:%P5_4>XNP+L0=I-T\,'I#%&_3HI:I1Y[
MZC?2@IOR>?;,T.1T=Q?1LF#3%+]ADF><WS>XO%W6;W7KK+R[NM\PG&F5&L;E
MN.D&9^:>@.7(G5K].+Z%QI;-!-OOJWM'B_P327%1,I!UQD75H+.J>+-GCN!;
MBV:1#\Z<"2"EB5!H]2^0K1M%M*DT3ST;_I337Q79S'1"_F>],4!YIFLD8#!!
M!TM*_,]^%D;B5#U<NU,U TGVP.P6B:6YQR;LK\=M@+N>UTD"88 %GA1R4=TT
MY8\_Y,MFW*/RB>;;U1,J:F4_-%E47WW(E^7GB"K/%VP:H0BC@:YCS4@<)'74
M&"?RIU8^U;E"GMWCY39+>$C'-2-J5N Y?W?L"BO98Y;W=\;@ +L[:3 (P^"-
M T+IU"'/F./1Z*"T4JK>C$-+?"J^S+)L&Z4UQ$\1R4K,][1U=#&*^W-9[: [
M=U4O"X,K=H!CJO2$3LB,VN85MQFC9L?,UI56U<6NXXTCKO!;HM@48+#%$:4T
M)]6S$#,RV=#0M"N<X)LU;:RLV"*NW_AB8\)Z,T^6#Q+3K(.M#&$>"P=GERM"
M?3Q]M6_/#W7J)QV-/O()>^1RO4GS'6XN=?%*J'/,J'K(61G>?O]TZ-(&B)B+
MG%/EG+ /&SMWE=-[S?G+2 1>?^@ :HWSDOUGR1P!9I]/MM-TGF?%-N4#EM%C
MECR3(J>[\ZAXTGA\9GF?46M6V/U@-:UP<$/KBE 1UU"K"!L;U4HG] #O,5D_
M;FF!%3$+_<JHY;Q1PP2SI81*" 85#,CDR(E:M)UB3QSL>D>)E'%))> ]>'4
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MPVN=I<,?$4[QR(L>7+5$4?=]]+BKPRXJN2:-2,1!-%M+*.]@\$ -AH/GS10
M4%(CJ;:E@NQ"=:L0;;S-4  6233H-!?SHM"[KZP!ZHE$.Y]*(K :7(M/FCGY
MFK:1#.M+TA]M<Z4L JO5M?@4+CR39(:%(J!S);/"Z3;!S!I_CS/^?J6X7;LF
M&2E*GJ7@&2M3UQU2&*R^/$)-I-E*'&8H9JOZ"BJ?<43I_)4$0U19488Y"K$U
MB2Y&9P^>Z(MZ72RQUN,@CJPJ#M:WV/LL#,B2L?\VSPX..3V\2%BL.5I]%,]K
MCUQ6QI)HKUA5&-1Q#OMSX(QS6=#),K4B3BRQ,Z,7&1DD2N4%TY@46-S_UQ_!
MJ\5@=:D1HQ2<4@LC(1W\O'V 77_2KA8#W VVT_51-X0^5A]B-QRHZP0A=X7U
M$'W<&<%/SP?X#>?F&CG G6$]*Q_U1?!#\B%ZY@L[=44K![DKQB!M7<$7 F"Z
MXH&\N/1$*P:X(\88+?W Q %U W/MM*'5&D'(72&AM'4&5VB[(\@*>5"!2[)Z
MTH9;:P0!]X>,TM(?0@'.\+@A;BN+3@YP9T@@+7W!Y>%TQ<+-3BU>@94:8[3Y
MLX%CVX8C.G6=,?J2@#M# =-FH]+!I!&\2Q:?<>KFU_8E 7>) J9U_<TU '7)
M$Z$E=K18 UG(W:(":NZ81B5HS_R0);@@JXP_5N5T:]JF *N/'-&..ZJO!NJ&
M]%T:Q;BZK<=396GZ2"D%JV-,$*4;N(TLJH3#FK+E$L?\W'">Q?D:+Z*7>\:2
M>\SU2$JJD*[DO[>%>)-TD3=/$#/!65%@Q1-V!Q8(JU^/5)LQ!2Y8645)8K3$
MB3C'+1B$K7ACDX@/H3)Z090_)QR5)26/VU+DD"QS%+5?X_^6-&.9RT?\BV&"
MU-@?2!RE"TJBM+U(JQO/1FE8_>\"58IEJW604.KN%8<=Z(.:?,HSPMC&4^=/
MZBR]'N!NLX+6=:!%.W@O7N BIF0S?H7%* BXGV24VI%5BI&5= KAK=X=3^WW
M_M%E% U$ 7>("J?DS(B,AN\?X=BV&K7^@-HH#;\[;,?538_\XS]\]Z?09]5-
M9,HV2H=5$7'V#V5$RPOFY,A=Y*8'K+,F@=8]8"'>CAK:N?I60L%+0 DK(KRU
MNX^R)%^3O[-E**>;XV#3:0'KQPF0I<O*K3BJQN$'8(;QOS#-V3_0=13G:;[:
M/93;9.=L* W:@/O0$;K:D+Y#?2TDU(#UZ0?G_OOP.OKJ@],$]TW@L64T]Y=9
MLL?,5FL!ZY\)D*?/:I@'G;("0G3AS9:SYW9YQW.V9^4\$_62^DPM!JN3C!BE
METF$</6RNA#G8<"B5P)=<6R3;S<))K1W'362L#K#!M.4/QQU.3; 70USN-O+
M[^^+%?GWHA+SK+(2/V$>[(&3V3.FT0H/SIJD7O;Y<5C$"5#SXU^LYH]C5Y>K
MT:IB,K,NM;7_7 -"484(X>8,4;S;UV7*!W3-;4KS-RV<!"+^I.]_:=S?I_(G
MI7]#[L1]!+Q2WE_E=(D)J]8MO7S9$!IL .P'Y$L;"0>UPDF'Q+)!AG+*;[9R
M;%_\Z+C\VY:4NWE6E%3T?%$W.S_3K7SQ4TP%UH]^::QWKO%A#$\DAH^LOH#!
MT]\W.!H6BS/\3"!YI4SNY>SQ;-@=O_RE<7I:M4]JNON)DL#:Z4=[8S]J&[O0
MM_8]7D<D8W_O[6@M,%VKF>X;!4#6!VH"*6/IF*BTT6^OM_.]R9*5()[?9!#>
MU'P7 V"0'^R,>RK_=)?]-?N472RR/[/_>?@GKK:.RC.ACE^B]2;%9TSJ_5__
M^=/[;R_^B7UQPZ_8BU< GSB 34XYHB6_6I\O49YAM,,1927P:WMK!NNI.!.W
M\<LFIC:)=@$SOQS6E[U9.."@FH[BBQM4>S>!<EIQG%7,D\K0-9)F%?U@#;-1
MS?RZV^6?\PV^$16.TD\XX4<:YZQN6'?SVTD+%MFF0)8VL[GSR\P:UP9Q4-HD
M37G8;KCEM;UTXZ8&K+^F8-9&U;5/Y-7J0)[$>8B?<+)-\>VR.1KI>0>S+.F9
MM87X+VU&]KU+@M7;AU9#,N=U>>AVV9T^]8I$K$S4*Q3]+(H-G?S]>[K=Y)?%
M)LKR] +/LV<>4K^*8KX3D#VP4O)UI#M(G* +J^^G Q_W]O>7\X? @1,I^RFG
ME0-CL\8&85@]XX!4/O?MJ0"QMM7CCO<XY9?%%ODGDC*&L25*[5)*'621A]5'
M;F"E)Y^%%G-&A1J_=K-N%!O'-H@[>D'_/7^.XB?-T!G^#*LCE-BD6U+T+:K$
M0/B153QHDX'/T8LT*<'JD@F(+3>>6C\2AD7[*:>_WM($4UN?Z01A]9,%I;0!
MQL21D ?2'9_RY9*4Y3G/3$JK]21S,QO.\-,;4FY+_.>\V) R2N=9K,L)OF=!
ML+KSP%I(^<6KXE!5'JH*%'N)[:ALRT1-H?RU^["WD!FB-9]<.5N5::,E"5B]
MJ(,GI4QHY-!G/BYYKN8@KL/BB=$LP2\/NZ+$ZT(_R'2"L)K?@G+<"XTXJN7/
M^ !X&SBER ;'9;MS2S)M2FRM)*PNL<&4DXE4\NU6,<G:C-2!<K4-*K!XHOEV
M]?20+\O/$95/N,WBH/M&C56Z=H$9#%;H2CS/C(?=A<JJ#%34A03ILD]1%E7'
M#U>8K^GX+M5_;/F+D33=R?Z#21I6A[E E3R!5@<ML5BHBDV[OS5J07KH)L_N
M\7*;)1S+-1O;68'G1;'%K%Y2!YF$8?6/ U)%S/\FRG:(%"A_3,FJV5I@_23.
MQVA;'DJK IDH*Y%WYMM !C%.MP5Y;BIH6TY9Y&'UH!M8>=*JM5"M!F2--<NR
M;936F#Y%A"T",KX@4(TR@RRL+K(#G3+&(E%:.[;677EBA 7)AE5-Q\5MQNQ)
M-_[;74JIZVP*L/K/$:VN$R,^LOHF\DW/1$H;L@7Z_$388C=F_9R7Z!&CF.)$
M!!Y'JXC'9B*V&L[8O])\%Z7\:8MVBGS<B4"=^L-G=5R<L,E1_,0/Q)XC2O)M
MT5UIY OL.%^O^1D9^]<63BC7%<=;GK7*\I:=1@X6;<P@%3D)*VD83]O5[QI6
MY[*SY)D4.=V=1\63RA*;A&'UB0-2S0N/?/14CU952IT_RH9J\13,]MY<S#J$
MYSG=:(:,1@Y6]YA!2K>!+V:HUSM</NS;R:1.U,#WTHKKZW--5VCD8'6%&:3T
MCC+)ZW032,@CIA"T+^XQ63]N:2%<VLOJ(3JI(U1"L'K!@%#*X-(7;=[>"W.\
MVW_A:T+(A*,>K!Z:!EHZ*>Z]6@8QJ.(&,X>2,LA)41W,M&<PNFG&H@"K\QS1
M2A-/I]:<5W5G4Q!2NZCO,@U^A=41*FBZE"P!;^I\NI]_G^://*I8?;([_!U6
M&ZO!2;NO]W-4B85E\E-$F#>1W2YG6[;ZY8E&2%EJGXPSB\/J!R>L$OEK)7Z$
M(=10JP>DGVZY36Q!:1/AF.6A]I0)K*FKA%[758&?J\=5JB6G$642AM5+#D@E
M(X>;/%*0QE)3$;>19)2&V4-31E'71:#&D.,1TFLX.9IT8 3QF$BDC&*LJB[D
M:7I"+PJK-ZPXI>#NZAQ(:(AA4M]+#+KKDN]X7KZB"[F0]UPD$5C]H,4G[;?4
M@CP#3"T9)I;^'F?X(Z89O_2MC:B7A6 UNP&A'%V/N"QJA.'$V'</+<RRY"CO
M5NQ3(JR./59UW!\KX:<THU^[TJ&\:G)!*(X9)-$0.=WP;3_;J:>##JR^=P<L
MC?%&L^K-1A?&V6AWC;6];9(E@WW@HBR<;_0ZEP&K;_>O@.D6;W<#AW7[<'.\
MX",6Q/W=PY,CF3(B]>XKRZSQ]65@7/-<[9-FH[)EDNWE%0D3S$7QU39+<&))
M::V1@\4<,T@I4ISB-TLA#B.9]6RSR4DFWLRKTB-;%[L6!5B=XXA66OAV:M7J
MMX"R_+UB;<1-3N6DM#Z,IK.,TK!ZR@7JN)NX3I65K-)"G4\7U/'>XI](^42R
M!_)2[BZBG=;;U@C"ZAD+2LFOWF)4R:/?OT-</'1G7$;QTU^B;!O1W6VF.XS0
MR('K"@-(54]P<53+H_=A31=YQHH1KN\2FP*LOG%$*]DP'H_+;=@M*!O67L:=
M)0FITIQ5QR/*1"=&:5C=Y )5?S,Y:I5$2'NE%2C!R5^B-2X>/C&W7I==3R$#
MJS/T !7Y3H0H>GB+A'3@(*CV$1NSMZP3A-4-%I3&)WD@.,77>!6E5X2N^2Z@
M.,O]$6>)WBVVR,/J'#>PTF$JUT)"3>QO5B?<M6;P [RTW-4W=96'=]W/L+I"
MB4UU:,>$FAM3H:X2.ZX07\GJ<.K*$-2B<%N\6471YI=94>"R.-]2.O*AE *_
M?/@E?4R]=<$ =]WT9ES2IHF0.D.U7-!&UK<NN&:UM&>@9KPFT2-)"8\^,!!6
ME@+4O 9P<NA1*QJ:O\*K>LK3!-.B>K1%U?"RU"^_ ]/P!G#2RDK\?(9F94G)
MX[849V]ECNZB@%W08P-SN=PZQ*8#<UR8H1I&B? I*_% G72[P?P:4[:JKZPI
M3;XD!*@;]-C&[=Y*HD8T=)O/LSA?X^N\,+=Z)P:QW17H]"U?":.ON?AO S7_
MG.<KQ(7JKJE&!%"SZY"-F[R1:[@>:AKFY^S]W/'*67@L],NW8-I;CTT9>L#\
MGIYLB#4K&V$41P6^P-7_SK-9\LQO/A:WF2[^I[JMITT'>'B1 #KTV#61!]RA
M10<SAV/@=Q1O(I+,LV)+>0W4%M*F!<IH.H/5=2OZNE'^+4\;6>NCM@!HG=>X
M.&+#<E('#C1?0R>J 4_LR*:0LVJ+%X;E-MN-WCK"P60[EP775D^O@MU(.Y<9
M:(#?X)(G/;JC^3-)</)Q]X-X?+SUJ&=Q29XE#DS7!M#K!X!6I'U O S4%,)C
M/K_^H7HF_;>H6X]T907J7P8PQC@IKMA?^R>'[4/SJFZU*@$RV^Y8Y1C/2A/Q
M%AL=D[;:L(;E%>'I'?<=E@IM0!VY!^B)P[(M*ORPY"CY__.]N><HY9>0V$Q1
M4L(34O,?9N(!A=X?>I)WXJ%Y>:Z)TVTB-JKB)QZ+?A^5^'*YQ+'R3, O D \
M"U1Q*3J#%7Q6L;57_AGJ/HTJD?KAB_X?AQH5)J1P0,6C !4RU$!#'!NJP+U&
M\K<UNB#%)B_X1>E\N^'N%2GX"ZLDV^*DGH"9)3\Z]2=^'Y#?$Z3:IZ-]1^T&
M$A*8A&8?%>I@!20\O_@XLB5Y2N*=\F+@)$5@MM4=KXH;U2U/V<:)(M#_5]VU
M];8)0^&_XL=-8C]BZ[JI4C157=J7/5G!V3Q1J,!IL_WZ^?@V X8X#H3#2TN(
M?2Z<+^;X7."'^;]<VY\7+:B>V98>(ZPX-!:1X4Z*&-CI0J)%SD!HG'"7H/;M
M)3RE[!)5_)7=2Y4,.@?S!N>106322Z0/YAX^*&+$=%42K^D2@>DGZ@[UDBMC
MC:*]>-C5.".H'UE(X5E;<2OO5=$GVG)1K6D1%]R$-!*0?676B%SE:VL\MM[Z
M$K0678GMX+H,<F0VDM7*%V?$2D.,."[01>Y7C.W;XPLW'OY=J;?#<^ XP ;]
M_7X:[>;$I\=7)<P49U1 U)47'P_B5U7SORQ_+'-6>[%FY4&U?M@/<!$>7^2^
M4QUM^#,/!N'FY(<>FA.K>:;/:A&8=99 HDAG1+'1'XABA J2\6!"#X-T TI7
M4KUP!4$)VC2^0CBZ/+-+%F:*'C9SZ'HU-VPX9+\0B#^S/:MKEF_I4?>SR -[
MSOR\6A>_S#^QDNVY:,+6Z;X >TX^B* ZJWK]-X9HPA"$([:K"X[=%X9EU@8O
M1%@MVXP,8AQX8T'CUWJ@ACT\$C,BV@)&V51-P6**)UH<-'B+HGH;*M^,F(;9
M2"/21EG,S2>. !;[?6-Q"[,<A]E"OGA1)H':D&J/R#(Z!<]?F<N]0&;^@<%4
M7G -/_&%R4T1+;X+*@ZBJO^T!H<,.0%91':?4IM>4Z.E3?XGLW1U1)M^1J@@
MA@5Q/+J3E%.W6ZX;,N9*@?!,.AV;:D<+-RY<0W8)O94!Z*0:Z<A1I)7'I8A[
MXUFS"L0$W=+;XXXUX-L:-]+HD0RC<YBL#5M)NJ4##KXP;C]Y9ZB_S\([5#^6
ML@P4]:.^8M;X_/>A44_QVE9=7Z"7C+V4(()$U+1Z]!PD2:T1?$?VYJ[6N+L:
MU_@2$D;J,>NTT_%/'3_XE%M/"\93X(EX+;M1]8]W9>*69F(6*UO'4C1+7\4T
M-T@'!7SYD ^/\UYZHTL0>?ESO" U?C9ZU(P*G0Z(8>OZIS;R2)ZVI^0?*/N0
M9_X!4$L#!!0    ( -A#<UAQW42$'U   *9,!0 5    ;&EX="TR,#(S,3(S
M,5]P<F4N>&UL[7UM<^,XDN;WB[C_H.V-V-C]4%U=U=W3T_-R&[)LUWC696EM
M=]7.?NF@24C"-$5J0%)ES:\_@*0DBB2 !$4P(9<O]J;+-@ BGR>1 !*)Q)_^
M\WD5CC:$)32._OS-NV^_^V9$(C\.:+3X\S>_/+P9/TQN;KX9):D7!5X81^3/
MWT3Q-__Y__[O_QGQ__>G?WGS9G1-21C\8709^V]NHGG\Q]&=MR)_&'T@$6%>
M&K,_CCYY829^$U_3D+#1)%ZM0Y(2_H?BPW\8_?CM^W=/HS=O .U^(E$0LU_N
M;_;M+M-TG?SA[=LO7[Y\&\4;[TO,?DN^]>,5K,&'U$NS9-_:=\_?E?^OJ/ZG
MD$:__4'\SY.7D!''*TK^\)S0/W\COEM^]LOWW\9L\?;]=]^]>_L_'V\?_"59
M>6]H)'#SR3>[6J*5MGKO?O[YY[?Y7W=%&R6?GUBX^\;W;W?=V;?,_TH5Y2L]
M2>@?DKQ[M['OI3GMVL^,I"7$3V]VQ=Z(7[UY]_[-]^^^?4Z";W;@YPBR."3W
M9#X2_^7L[;\:TN>4"+;>BK^\G<1<&WDW\SI+1N9__D:4X$V___[=^Z+A?STJ
ME&[77"L3*I3JF]';+A^]\$*!SL.2D#31?;RU<-^=F'F,1.F2I-3W0J,>M=;L
MH7MBF) 5;SJ9SJ=K,;2Y[FC!4M>RUBTC^ R:Z+G##VGL_[:,PX#;P:M_9#3=
MFO157KOG;DZ\9'D=QE^,V&Y4ZJ%34[;P(OK/G*!Q%%QX">5?FC&2\&_FO]7U
M$-Y"'QAFJY7'MIPINHCHG"M2E(Y]/\ZBE,^OLSBD/B5Z4(U:Z:';]QP,C_E+
MCL\EV9 P7@M*)W&BMXV JKWHIOFPL3A4[DG(U3[@!B/=/C(O2CP?9!MU]?I"
MZHV8FP.QZB+\&Y!1HJG60\=N^")S11Z]9[W^MQ3MH0-<KA5-<UO%E742YX.)
M+WT! Q)0M1?C\920?V3\*U<;\2F]F6@O/Y@=Z]>>6;!KL \_>D]A7T(<MV77
M-,/Z#6[ BID&8JNI9]%D0T&$U+9GO@U@U%7NUY3#.B:M8->LPSH';F"0Y>PE
M23T:)G<>$[N2#3E]>2MKL0]M]9<DR$(RG8\Y:F\"&F;B"P_$SQA-.8!7SWZ8
M!22X9O%*J&16=&DZO_)8Q&%.9H0]+/F^J^RD5L-M?7"PR<:4W]-:[95CQ4QB
M3!^\K5Y%^"P $IO5+,T=G!Q"XZ[KV[#=90[:U3-A/DV$?>I# &6+5A8&QN,
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M^]UIK<G35,-V$II.52 4T+EJ2&6P ,3W^)ER(I7VC&^B[&4J5L&W<>N3874
MJH6Q'8(=E^]-><^8Q9MH0Y+\=GLAUET<Q?JI3ET+VZ-HQBL$ 71SF3_-R+NI
MG<P:!=$]B*9LM IJ/L)^+D98Q!>7:5D6B[SKF!&ZB(H(,;\:8_[!HY$P)!=D
MSLLH_5I&C: GO3$CO0- Z"/RCJ20B:]6##W+C1DQK4*>\6RWNZ>].VV]\!+J
MR\F3%$?/:&-&HE)H]'%4[]TE#;-4=9 IK8">M.8T6FJ"HQ/SF9OD)>_0>,,7
M0PM2O(HXG3<.]S1CR+ 9]*0V9B1V LE5:DL--#B\-FX(/5-.+_3J@'+SG!N0
M+^#'+H?>;F0../=#\ =_28(L)%R[R%SDE+D@$?]'.@OY8OB2)GX8)QE7$%WZ
M +-FW+C-9C8H#47$SS?0[.:AE[?Z% 3 ZFY0V4F-:P0#!7[-8W"^%+^F.7A-
M<_":YL#A- <)2ROX\Y\.V/,??GT4R\;I_(8O>S<TR+Q08N1X64E1-P;%2;9,
M+IR=+ >FG(BHP%QOQ#!?TO5C?)4_:2VU86T"Z1I!YE'.@9XKG6AV$B2(/546
M\AUCJDR%T"R&%GG5!;MC]-L%<L0;,@[S=LO]_(67D& 2K\3Q4RZ=]L@-6A\Y
MR-AH%U)/@& $D4ON#T46R"//Q^_@GH]JD__FK>/DCZ.R9>R4B=W2P(.JOR9-
M/"EI8H?DM:]9$ZUR<GY9$_>]*A1(&. X$D8)F%*LO=HYTM(N";J?H-8MG:M
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MMH6>WKR_HSX 9N@^!]YGGY @$<^LBA@>L5KF@A_N<,O9!51%3W-^ C/U) -
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M':7FJ;C2B69GJST+/3]?N(T71#LQM)>%3KM6WN#HJ&9'DX4* O2ET$/VE-"
M>FS[X.WM@&8_)Z]R=E9-+U+%1X#$T*%'Q5/U^5N8GB\PU<9[ NHZPIE.#^N,
M 23#WNK-&-WP?>O> .CV&[+RT(6QO; DL K66%(C8&L[<NJ<8Y#NXKVU9%?F
MF"OE<62ZR:=.$0[ TFU%H.1B6_V+>OXQ:<,1XV8\(9G(6 EXPR=5-R.UE76#
M)'/55'#FRA1T$VU(PIO533WU<NA3CERG:JBW2XANZ(X/<NHA6*HU@+H><L"C
M,J:C,?E#('",*:YP4Y8?-P2?O# C,\+RGD,9D]?'#@[L3IT.$\<HO!1;=1+M
M8@Y%V@3%:@)2UZ6S?#/J5%@X1EL1@Y!P2"^\1+7^TU3#OFC3G2P) N@\'?I5
MBE78\C)HA 2JL'Y]59>"-'1\@9% YVS&8I^0(+GFXMXD2>9%XGJ -,Y'-=H,
M&\*^GV,V_CJAY "[S:55)7C>;'EY5!$[Q_>I"\P6%-#9DNI3T66A>"3X91U'
M!_.BLZB&C6&'C9C;V$YH]?P$-%I@$'R[J*R$G6G:C'6M] Z,XWT?S;>)H,K8
M298[,F:P07P!X[*P0 9C<E<!/>?P20/R6&R7!J/!^D=="STU[TD$N;CT:5Z<
MO"=BTB9%O]<A55PQ!%5&SVUKPID!'&Y05PSZRXQQI2I>$BETK7)]&/2 6X>V
MT,-MC8GM!-99SXU*L?/,NAUUHJP+U0$GG$-P,,Z:\[-*_/'."3=37YD[SD]9
MJ@ZV4L*=W$H/OZH6E'I'?%1Z /"G^DJL49YWH\SK6:[Y;Z)*/(3"H!NU@A?6
MV\6T=P#()59S&Z/W4<AK0-ERPI>D$QR=&=FQPWY#9WX<4ZD*Y<H)+Q(8BO.>
M!HOC]QTH.T$G<9*JID%E+?3K<D8T P! 'Y85NS'A6S7*\<O1O"<^H1L23(WG
M04@S4!Z=<#IU@@B=V-;U]WXB)S[?K:64)!,O#$EPL:TOQ0TW+R8-0\EWPGO5
M$XSHZK#KV#@*BIY5/*>2QY+*JOJ:4$*=\%I!@7":L8]>*A1O>^FEBJ4MO 7T
MT.>^&&P#!IW)]O5>_9Z0Z?JW61_*HA/^(3-0T#G,-U.RAXEW"X5*&?2[5$8K
MG(9PZ'BWSKNPXTYM32@W3KAAH$"@,Z8RR]WF*#A33KA@( "@)_7-5BN/;:?S
MZEVC?$>J>++PIT9.WZ(5\6)AV<XH;VB4MX3]0*'L4IL^OZ^^)G;&7]B%/7 N
M8*/FW+ZR",X;;"0S?D9A27<;Q@BLS;?NYAGNH-VP.\2W+B4C_MKO@UMC6753
M'"^S\>M-<:EHV#?%JWW2W19O*XM]O15\85PN*/JV83J?\WTG2ZH/:LA9:"^-
M?$$<.D772%%)CD[+.,S;)4'[DR=7S^*?BC4FM+Y+0\B .S-XSOH<]P.)"/-"
MOJL=!RL:4;',%F^U:%5 6Q'[BGE'[H& ]$SZH&X"V6P/>0'H]W5OP;&+H-J<
M.R\ O?H,7GT&KSZ#5Y^!JSZ#1][V=%YY:$[M'I 4?WG<201%W_17>B3. ^[B
MR#O\IBJJ;MMIW) ;'"OUM;Z6-A71TKOQJW48%R\V+AA1)R_-'ZN5E\?>U'34
MOJ.G>'5HO.:@QS:!VNST/;_#\YJ=OLGG^66GOV3_%6\\?ZFT;?5": :MGW3T
M[3);2L5\R?[JK4CR\)$F1)Z#M.A62TFTU&!]02V5WA+>5XSZ?[V.V<J+U/-U
MLQQ:LIA^L)9*CC(W3Y:4S*?K/#@^6I3.;2DCO(:R E[>D-.YT<EF=3C<Q_P;
MZ=UGPK_+EPY$/2BDI?'N&O<S-C0P6 +_PDLVGGAJ_L+36*/6DGBWV/H!72$^
MBDFZI(SXJDS@O%"]#%XH?"^&IUUD2^H^67I4S#Y\IY\%-!4W&&F:$J)^HDU3
M"2^*O9]!  /%.B-Y\HW]QS6OYNEJX46S]\V)$A9+I!0?,1HDZBIX >S]T $!
MQ#(7)L-#4P<O2+U?-JP.C1Y>]?#C%=D_BGPK/B( 5IZ#*"N](%<@1%P[3U:>
MSJ N)E)3S0T6 =H)X\J5T$A-D(ONV I8'3L""*229N$_CIG-UV!SA&!SO(<S
M7X/-;06;2[W]]]P>7! 6>2Q0+R/;BZ*G0M$'D<L[;W6I?B=>',D=ISNGAAI?
M17GH^SC6,E3 0-9*C#Z=C+]P^D5PAWK&J!5SPZKT.2G4!$1_CK(]#+T:!W*Q
M/90I,U/E0APDB8)9Z$7BX57M$\M6ON:&EK1J>%N^A-[EMS-!C=?KF$:IZ,&'
M(C71O$S+K#2F^FK0B<M:RCV;.E^URE $+4V#XRC*O##_,I Z107H1&AMM3$8
M:5K4T.?2!R_T&"4B0N^SMU#E!FZ6/,\;;S*)T:D8\!*B:S?9@+<0S^_>VB[]
MYG4LMBZJ]%KU@MA>J8Y,2@1&'UP?O<@K;/LU(;R3ZHM&[:6A\Y9CE*A$MW7
MU?+)_\Y$" P+M[(#+G4=M)#$CN #1')D:!11]H1<D(C,:1ZLW[Y DH\7@R:
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MWMG6H-HFR_GN2??;D,,&(+FGR6_7C)";*"4<=PZ(ZDV< 3Z-?#;;WVJIKP6
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M4$L! A0#%     @ V$-S6 378BQ=&P  PN0   L              ( !
M &5X,3 M,38N:'1M4$L! A0#%     @ V$-S6(&OTLB" P  H0T   H
M         ( !AAL  &5X,C,M,2YH=&U02P$"% ,4    " #80W-8(_^=5"$(
M  #Y+P  "@              @ $P'P  97@S,2TQ+FAT;5!+ 0(4 Q0    (
M -A#<UA1</$T!P@  (PN   *              "  7DG  !E>#,Q+3(N:'1M
M4$L! A0#%     @ V$-S6'5GODK0!   81D   H              ( !J"\
M &5X,S(M,2YH=&U02P$"% ,4    " #80W-8Z3+3R\D$  !:&0  "@
M        @ &@-   97@S,BTR+FAT;5!+ 0(4 Q0    ( -A#<UBI4:\! K4#
M ):^)  ,              "  9$Y  !F;W)M,3 M:RYH=&U02P$"% ,4
M" #80W-85]Z_U\/E   B\   $               @ &][@, 9F]R;3$P+6M?
M,# Q+FIP9U!+ 0(4 Q0    ( -A#<UAQ#A5,U,P  ,33   0
M  "  :[4! !F;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @ V$-S6+GQC&,H
M10$ ZVX! !               ( !L*$% &9O<FTQ,"UK7S P,RYJ<&=02P$"
M% ,4    " #80W-85_*2BK $ 0"W*0$ $               @ $&YP8 9F]R
M;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( -A#<U@M+?YK]A   .^^   1
M          "  >3K!P!L:7AT+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( -A#
M<UC+Z2,)J T  )&A   5              "  0G]!P!L:7AT+3(P,C,Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " #80W-8FEX:[YP[  #[Z , %0
M    @ 'D"@@ ;&EX="TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ V$-S
M6*@;^DFS=   M; & !4              ( !LT8( &QI>'0M,C R,S$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( -A#<UAQW42$'U   *9,!0 5
M  "  9F[" !L:7AT+3(P,C,Q,C,Q7W!R92YX;6Q02P4&     !  $ #. P
&ZPL)

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lixt-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:LegalFirmsAndOtherVendorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:LegalFirmsAndOtherVendorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-17</instant>
        </period>
    </context>
    <context id="From2015-03-172015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-17</startDate>
            <endDate>2015-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-08-07_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="From2023-07-242023-08-07_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-15_custom_DrReneBernardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrReneBernardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-14</instant>
        </period>
    </context>
    <context id="AsOf2022-10-06_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="AsOf2023-11-26_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-26</instant>
        </period>
    </context>
    <context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-27</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_DirectorMember_custom_MrSchwartbergMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrSchwartbergMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2022-11-06_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrVanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-18</startDate>
            <endDate>2018-08-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-05-01_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BastiaanVanDerBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-23</startDate>
            <endDate>2013-12-24</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-12</startDate>
            <endDate>2015-09-14</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-10</endDate>
        </period>
    </context>
    <context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-15</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseZeroPharmacologyStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueWithinSixtyDaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueWithinSixtyDaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Integer">
        <measure>LIXT:Integer</measure>
    </unit>
    <unit id="Segment">
        <measure>LIXT:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="ixv-19813">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="ixv-19814">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="ixv-19815">0001335105</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_FR"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      id="xdx2ixbrl0662"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      id="xdx2ixbrl0664"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="xdx2ixbrl0678"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="xdx2ixbrl0680"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="xdx2ixbrl0682"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="xdx2ixbrl0684"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1095"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1097"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1252"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="ixv-22167">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="ixv-22168">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-48">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-22169">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="ixv-22170">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="ixv-22171">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="ixv-22172">001-39717</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="ixv-22173">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="ixv-22174">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="ixv-22175">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="ixv-22176">680     East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="ixv-22177">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="ixv-22178">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="ixv-22179">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="ixv-22180">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="ixv-22181">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="ixv-22182">830-7092</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="ixv-22183">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="ixv-22184">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2023-01-012023-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="ixv-22185">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="ixv-22186">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="ixv-22187">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="ixv-22188">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="ixv-22189">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="ixv-22190">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="ixv-22191">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="ixv-22192">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="ixv-22193">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="ixv-22194">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="ixv-22195">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="ixv-22196">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="ixv-22197">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="ixv-22198">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="ixv-22199"
      unitRef="USD">1125215</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-01"
      decimals="INF"
      id="ixv-22200"
      unitRef="Shares">2249290</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-22201">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2023-10-012023-12-31" id="ixv-22202">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2023-10-012023-12-31" id="ixv-22203">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2023-10-012023-12-31" id="ixv-22204">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2023-10-012023-12-31" id="ixv-22205">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="ixv-22206">572</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="ixv-22207">Weinberg &amp; Company, P.A</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="ixv-22208">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22209"
      unitRef="USD">4203488</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22210"
      unitRef="USD">5353392</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22211"
      unitRef="USD">78016</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22212"
      unitRef="USD">147017</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22213"
      unitRef="USD">17116</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22214"
      unitRef="USD">49224</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22215"
      unitRef="USD">10000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22216"
      unitRef="USD">11350</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22217"
      unitRef="USD">4308620</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22218"
      unitRef="USD">5560983</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22219"
      unitRef="USD">4308620</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22220"
      unitRef="USD">5560983</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22221"
      unitRef="USD">36250</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22222"
      unitRef="USD">46982</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22223"
      unitRef="USD">156758</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22224"
      unitRef="USD">230734</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22225"
      unitRef="USD">157100</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22226"
      unitRef="USD">165022</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22227"
      unitRef="USD">313858</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22228"
      unitRef="USD">395756</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22229"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22230"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22231"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22232"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22233"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22234"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22235"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22236"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22237"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22238"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22239"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22240"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22241"
      unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22242"
      unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22243"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22244"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22245"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22246"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22247"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22248"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22249"
      unitRef="Shares">1664706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22250"
      unitRef="Shares">1664706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22251"
      unitRef="USD">225</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22252"
      unitRef="USD">166</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22253"
      unitRef="USD">48976265</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22254"
      unitRef="USD">45059760</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22255"
      unitRef="USD">-48481728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22256"
      unitRef="USD">-43394699</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22257"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22258"
      unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22259"
      unitRef="USD">4308620</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22260"
      unitRef="USD">5560983</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22261"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22262"
      unitRef="USD">1502776</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22263"
      unitRef="USD">1718180</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22264"
      unitRef="USD">2547615</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22265"
      unitRef="USD">978244</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22266"
      unitRef="USD">1268308</us-gaap:LegalFees>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22267"
      unitRef="USD">1495712</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22268"
      unitRef="USD">1146289</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_ConsultantMember"
      decimals="0"
      id="ixv-22269"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_ConsultantMember"
      decimals="0"
      id="ixv-22270"
      unitRef="USD">43264</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22271"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22272"
      unitRef="USD">1349269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22273"
      unitRef="USD">5090236</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22274"
      unitRef="USD">6311481</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22275"
      unitRef="USD">-5090236</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22276"
      unitRef="USD">-6311481</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22277"
      unitRef="USD">17486</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22278"
      unitRef="USD">11195</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22279"
      unitRef="USD">16233</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22280"
      unitRef="USD">8875</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22281"
      unitRef="USD">1954</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22282"
      unitRef="USD">-3374</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22283"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22284"
      unitRef="USD">-6312535</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22285"
      unitRef="USDPShares">-2.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22286"
      unitRef="USDPShares">-2.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22287"
      unitRef="USDPShares">-3.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22288"
      unitRef="USDPShares">-3.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22289"
      unitRef="Shares">1915838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22290"
      unitRef="Shares">1915838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22291"
      unitRef="Shares">1582029</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22292"
      unitRef="Shares">1582029</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22293"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-22294"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22295"
      unitRef="Shares">1374706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22296"
      unitRef="USD">137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22297"
      unitRef="USD">38372365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22298"
      unitRef="USD">-37082164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-22299"
      unitRef="USD">4790338</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22300"
      unitRef="Shares">290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22301"
      unitRef="USD">29</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22302"
      unitRef="USD">5141355</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22303"
      unitRef="USD">5141384</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22304"
      unitRef="USD">1546040</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22305"
      unitRef="USD">1546040</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22306"
      unitRef="USD">-6312535</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22307"
      unitRef="USD">-6312535</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22308"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-22309"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22310"
      unitRef="Shares">1664706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22311"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22312"
      unitRef="USD">45059760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22313"
      unitRef="USD">-43394699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22314"
      unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22315"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-22316"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22317"
      unitRef="Shares">1664706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22318"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22319"
      unitRef="USD">45059760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22320"
      unitRef="USD">-43394699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22321"
      unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22322"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22323"
      unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22324"
      unitRef="USD">3137021</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22325"
      unitRef="USD">3137039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22326"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22327"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22328"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22329"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22330"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22331"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22332"
      unitRef="USD">773203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22333"
      unitRef="USD">773203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22334"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22335"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22336"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-22337"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22338"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22339"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22340"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22341"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22342"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22343"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-22344"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22345"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22346"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-22347"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-22348"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22349"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22350"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22351"
      unitRef="USD">-6312535</us-gaap:NetIncomeLoss>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22352"
      unitRef="USD">773203</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22353"
      unitRef="USD">1502776</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22354"
      unitRef="USD">43264</LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22355"
      unitRef="USD">-69001</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22356"
      unitRef="USD">-3224</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22357"
      unitRef="USD">-32108</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22358"
      unitRef="USD">-59805</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22359"
      unitRef="USD">-1350</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22360"
      unitRef="USD">-1350</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22361"
      unitRef="USD">-73976</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22362"
      unitRef="USD">2318</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22363"
      unitRef="USD">-7922</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22364"
      unitRef="USD">88061</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22365"
      unitRef="USD">-4293265</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22366"
      unitRef="USD">-4611737</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22367"
      unitRef="USD">3137039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22368"
      unitRef="USD">5141384</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22369"
      unitRef="USD">41</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22370"
      unitRef="USD">6281</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22371"
      unitRef="USD">3143361</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22372"
      unitRef="USD">5141384</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22373"
      unitRef="USD">-1149904</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22374"
      unitRef="USD">529647</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22375"
      unitRef="USD">5353392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-22376"
      unitRef="USD">4823745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22377"
      unitRef="USD">4203488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22378"
      unitRef="USD">5353392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22379"
      unitRef="USD">16233</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22380"
      unitRef="USD">8875</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16024">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqbb4r9tV0m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82A_z9T7lfLXYdwg"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#x201c;Company&#x201d;), is a clinical-stage biopharmaceutical company dedicated to improving patients&#x2019; lives by developing
a drug class called Protein Phosphatase 2A inhibitors. The Company&#x2019;s corporate office is located in Pasadena, California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents
and/or x-ray, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have
significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein
phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little
or no toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;President
and Chief Executive Officer&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#x2019;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors.&#160; Dr. Kovach was also the Company&#x2019;s Chief Scientific Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Listing and Reverse Stock Split &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s common stock and the warrants are traded on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbols &#x201c;LIXT&#x201d;
and &#x201c;LIXTW&#x201d;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zubUZhj3yay7" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. No fractional shares were issued in connection with the reverse split,
with any fractional shares resulting from the reverse split being rounded up to the next whole share. All share and per share amounts
and information presented herein have been retroactively adjusted to reflect the reverse stock split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;However,
there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement
of Nasdaq over time, or that it will be successful in maintaining compliance with any of the other continued listing requirements of
Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2023, the Company recorded a net loss of $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zKsABCY8g5kc" title="Net loss"&gt;5,087,029 &lt;/span&gt;and used cash in operations of $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zN6OfrgYrrll" title="Cash used in operations"&gt;4,293,265&lt;/span&gt;. At December
31, 2023, the Company had cash of $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_z4garxt3CCKg" title="Cash"&gt;4,203,488&lt;/span&gt; available to fund its operations. Because the Company is currently engaged in various early-stage
clinical trials, it is expected that it will take a significant amount of time and resources to develop any product or intellectual property
capable of generating sustainable revenues. Accordingly, the Company&#x2019;s business is unlikely to generate any sustainable operating
revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its technology,
product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive
earnings and operating cash flows. At December 31, 2023, the Company&#x2019;s remaining financial contractual commitments pursuant to
clinical trial agreements and clinical trial monitoring agreements not yet incurred aggregated approximately $&lt;span id="xdx_909_eus-gaap--ContractualObligation_iI_pp0p0_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z3W8udyd28W4" title="Contractual obligation"&gt;6,344,000&lt;/span&gt; (see Note 8),
which are currently scheduled to be incurred through approximately December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2023. The Company&#x2019;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#x2019;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2023 will provide sufficient working
capital to fund the current clinical trial program with respect to the development of the Company&#x2019;s lead anti-cancer clinical compound
LB-100 through approximately &#160;September 30, 2024. However, existing cash resources will not be sufficient to complete the development
of and obtain regulatory approval for the Company&#x2019;s product candidate, which will require that the Company raise significant additional
capital. The Company estimates that it will need to raise additional capital to fund its operations by mid-2024 to be able to proactively
manage its current business plan during the remainder of 2024 and during 2025. In addition, the Company&#x2019;s operating plans may change
as a result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed
sooner than planned. The Company is considering various strategies and alternatives to obtain the required additional capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
market conditions present uncertainty as to the Company&#x2019;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
cash resources are insufficient to satisfy the Company&#x2019;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
comparative amounts in 2022 have been reclassified to conform to the current year&#x2019;s presentation. Such reclassifications, individually
and in the aggregate, were not material to the results of operations or financial condition of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="ixv-22381">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22382"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22383"
      unitRef="USD">-4293265</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22384"
      unitRef="USD">4203488</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ContractualObligation
      contextRef="AsOf2023-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="ixv-22385"
      unitRef="USD">6344000</us-gaap:ContractualObligation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16131">&lt;p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zAzGVenIrdJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_823_zhR1kFO9agwi"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zduPhxVq9TPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zoc7VDIezOXf"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles
(&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte
Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zXbngsCHDJR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zIj57lMpFsei"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_z9Jlo11H6Yrh" title="Number of operating segments"&gt;&lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20230101__20231231_zZ0IEoAjhbfj" title="Number of reportable segments"&gt;one&lt;/span&gt;&lt;/span&gt; segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#x2019;s Chief Operating Decision Maker, which is the Company&#x2019;s
President and Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zEPrXuicGeV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z0nO8pvLp7pf"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaA2Y0Cmm8k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zSQq5L65qaTl"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231_ziGNzxUsSxP" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20231231_z3Dq2PrmJxXa" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0aYpeETTS95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zBhP75WcwqQ1"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--PrepaidInsurancePolicyTextBlock_z8TAnVgnsPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z4CV9JesYIM7"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkjQNNqrz7Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zobfBdlcAuBi"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zJZYksx9bD8" title="Legal fees"&gt;978,244&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20221231_zmHFSR6xk1Ge" title="Patent and licensing legal and filing fees"&gt;1,268,308&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI0DaF9ATAd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zmwYy0kjFPU4"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zDhOXPncSCxd" title="Concentration of risk, percentage"&gt;23.3&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zJMnYwHwJItj" title="Concentration of risk, percentage"&gt;25.6&lt;/span&gt;% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxUPoerTkMr6" title="Concentration of risk, percentage"&gt;18.4&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zphZp5lrDwob" title="Concentration of risk, percentage"&gt;30.3&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNTceUgFQ3yj" title="Concentration of risk, percentage"&gt;29.9&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcHlgkCXEct" title="Concentration of risk, percentage"&gt;25.2&lt;/span&gt;%
and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpi6KeYmITMe" title="Concentration of risk, percentage"&gt;13.7&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyYKGW0GeSmd" title="Concentration of risk, percentage"&gt;21.0%&lt;/span&gt;, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6jJLH7sRfMg" title="Concentration of risk, percentage"&gt;19.3%&lt;/span&gt;, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUipF1eskioc" title="Concentration of risk, percentage"&gt;15.1%&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0jsSDHU2ETh" title="Concentration risk, percentage"&gt;12.1%&lt;/span&gt;, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z1r7XuiboyKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaVrDHWpRtp6"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2023 and
2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2023 or 2022.
Subsequent to December 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaRwnM7sC344" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zyUGyP3lGbZj"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_z9ZNXjnSFTXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z6kX7VOtHIY5"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of the Company&#x2019;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants are recognized as a non-cash gain or loss on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zTmObsInfUOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zLJnKOfudIFl"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zLagUHXv6Kr8" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zsquuEIHR6Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z6PnzSAKnH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zJsbAmWqz2rj"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations. During the years ended December 31,
2023 and 2022, the Company incurred various costs and expenses denominated in Euros, which were converted into United States dollars
at the average rate of &lt;span id="xdx_909_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20231231_zBMa2lYyC0Yj" title="Foreign currency average rate"&gt;1.0824&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20221231_zlmwdoeIgGq3" title="Foreign currency average rate"&gt;1.0538&lt;/span&gt;, respectively. As of December 31, 2023 and 2022, the Company did not hold any currencies other
than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or exchange contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zAc4lmM3qhO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zhHBMFQBT6Gc"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZy8jlZGlQq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zIEp5H0oXVi4"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014; Stock Compensation
(Topic 718) Presentation of Financial Statements (&#x201c;ASU 2023-03&#x201d;). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 &#x2014; General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company&#x2019;s consolidated financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_856_zJclNHr2s8ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16138">&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zduPhxVq9TPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zoc7VDIezOXf"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles
(&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte
Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16161">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zXbngsCHDJR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zIj57lMpFsei"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_z9Jlo11H6Yrh" title="Number of operating segments"&gt;&lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20230101__20231231_zZ0IEoAjhbfj" title="Number of reportable segments"&gt;one&lt;/span&gt;&lt;/span&gt; segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Company&#x2019;s Chief Operating Decision Maker, which is the Company&#x2019;s
President and Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22386"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22387"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="ixv-16175">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zEPrXuicGeV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z0nO8pvLp7pf"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16187">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaA2Y0Cmm8k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zSQq5L65qaTl"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231_ziGNzxUsSxP" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20231231_z3Dq2PrmJxXa" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22388"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <LIXT:CashSIPCInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22389"
      unitRef="USD">500000</LIXT:CashSIPCInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="ixv-16201">&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0aYpeETTS95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zBhP75WcwqQ1"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged to operations
as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States and in the
European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <LIXT:PrepaidInsurancePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16236">&lt;p id="xdx_849_ecustom--PrepaidInsurancePolicyTextBlock_z8TAnVgnsPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z4CV9JesYIM7"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:PrepaidInsurancePolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-16248">&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkjQNNqrz7Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zobfBdlcAuBi"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zJZYksx9bD8" title="Legal fees"&gt;978,244&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20221231_zmHFSR6xk1Ge" title="Patent and licensing legal and filing fees"&gt;1,268,308&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22390"
      unitRef="USD">978244</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22391"
      unitRef="USD">1268308</us-gaap:LegalFees>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="ixv-16262">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI0DaF9ATAd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zmwYy0kjFPU4"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2023 and
2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the years ended December 31, 2023 and 2022 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zDhOXPncSCxd" title="Concentration of risk, percentage"&gt;23.3&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--MajorCustomersAxis__custom--LegalFirmsAndOtherVendorsMember_zJMnYwHwJItj" title="Concentration of risk, percentage"&gt;25.6&lt;/span&gt;% of total
general and administrative costs, respectively. General and administrative costs for the years ended December 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxUPoerTkMr6" title="Concentration of risk, percentage"&gt;18.4&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--DirectorsAndCorporateOfficersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zphZp5lrDwob" title="Concentration of risk, percentage"&gt;30.3&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the year ended December 31, 2023 include charges from three vendors and consultants representing &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNTceUgFQ3yj" title="Concentration of risk, percentage"&gt;29.9&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcHlgkCXEct" title="Concentration of risk, percentage"&gt;25.2&lt;/span&gt;%
and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpi6KeYmITMe" title="Concentration of risk, percentage"&gt;13.7&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2022
include charges from four vendors and consultants representing &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyYKGW0GeSmd" title="Concentration of risk, percentage"&gt;21.0%&lt;/span&gt;, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6jJLH7sRfMg" title="Concentration of risk, percentage"&gt;19.3%&lt;/span&gt;, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUipF1eskioc" title="Concentration of risk, percentage"&gt;15.1%&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorAndConsultantFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z0jsSDHU2ETh" title="Concentration risk, percentage"&gt;12.1%&lt;/span&gt;, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember"
      decimals="INF"
      id="ixv-22392"
      unitRef="Pure">0.233</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember_custom_LegalFirmsAndOtherVendorsMember"
      decimals="INF"
      id="ixv-22393"
      unitRef="Pure">0.256</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="ixv-22394"
      unitRef="Pure">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_DirectorsAndCorporateOfficersMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="ixv-22395"
      unitRef="Pure">0.303</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22396"
      unitRef="Pure">0.299</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22397"
      unitRef="Pure">0.252</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22398"
      unitRef="Pure">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantOneMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22399"
      unitRef="Pure">0.210</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantTwoMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22400"
      unitRef="Pure">0.193</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantThreeMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22401"
      unitRef="Pure">0.151</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorAndConsultantFourMember_us-gaap_SupplierConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="ixv-22402"
      unitRef="Pure">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16293">&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z1r7XuiboyKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaVrDHWpRtp6"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2023 and
2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2023 or 2022.
Subsequent to December 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-16328">&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaRwnM7sC344" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zyUGyP3lGbZj"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and
consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards,
with the cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting
period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid
cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <LIXT:WarrantsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16352">&lt;p id="xdx_84C_ecustom--WarrantsPolicyTextBlock_z9ZNXjnSFTXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z6kX7VOtHIY5"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of the Company&#x2019;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants are recognized as a non-cash gain or loss on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</LIXT:WarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16375">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zTmObsInfUOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zLJnKOfudIFl"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zLagUHXv6Kr8" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zsquuEIHR6Pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16391">&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaOlbtrWJCP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zLagUHXv6Kr8" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zkrgVdzL0cni" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zekDQc7guUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_z8prb7GlPApc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z5M4RLwZvgFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zYvVTB8pJFi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zMJLEXtBOzxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zEK1sZjcXvSa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;652,427&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22403"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22404"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22405"
      unitRef="Shares">808365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22406"
      unitRef="Shares">190031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockOptionsMember"
      decimals="INF"
      id="ixv-22407"
      unitRef="Shares">552083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_CommonStockOptionsMember"
      decimals="INF"
      id="ixv-22408"
      unitRef="Shares">389479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22409"
      unitRef="Shares">1433365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22410"
      unitRef="Shares">652427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22411"
      unitRef="Shares">1433365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22412"
      unitRef="Shares">652427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16487">&lt;p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z6PnzSAKnH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zJsbAmWqz2rj"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations. During the years ended December 31,
2023 and 2022, the Company incurred various costs and expenses denominated in Euros, which were converted into United States dollars
at the average rate of &lt;span id="xdx_909_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20231231_zBMa2lYyC0Yj" title="Foreign currency average rate"&gt;1.0824&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_uPure_c20221231_zlmwdoeIgGq3" title="Foreign currency average rate"&gt;1.0538&lt;/span&gt;, respectively. As of December 31, 2023 and 2022, the Company did not hold any currencies other
than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or exchange contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22413"
      unitRef="Pure">1.0824</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22414"
      unitRef="Pure">1.0538</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-16516">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zAc4lmM3qhO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zhHBMFQBT6Gc"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16548">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZy8jlZGlQq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zIEp5H0oXVi4"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 was
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014; Stock Compensation
(Topic 718) Presentation of Financial Statements (&#x201c;ASU 2023-03&#x201d;). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 &#x2014; General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company&#x2019;s consolidated financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16579">&lt;p id="xdx_804_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z0iLvldCdnG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82D_z5LCav1nyiV5"&gt;Research and Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfResearchAndDevelopmentCostsTableTextBlock_zgQC8oWLcvC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials
involving the Company&#x2019;s lead clinical compound LB-100, are summarized below based on the respective geographical regions where
such costs have been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zCzvrQhSvuq1" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zoukKhcaDt6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zV8Mp80Audbh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zKFQhmg7EOs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;359,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;350,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zUiHa81jyMi8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;626,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--FR_zaBG9zPoIS1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;France&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zXjM0heYEhgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,595&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z3TBAtIvBzZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;204,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zQlulZwPy08e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,349,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPqfj8riFPW6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;898,100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,349,269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zXK7qWiQpx68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16586">&lt;p id="xdx_896_ecustom--ScheduleOfResearchAndDevelopmentCostsTableTextBlock_zgQC8oWLcvC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials
involving the Company&#x2019;s lead clinical compound LB-100, are summarized below based on the respective geographical regions where
such costs have been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zCzvrQhSvuq1" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zoukKhcaDt6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zV8Mp80Audbh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zKFQhmg7EOs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;359,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;350,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zUiHa81jyMi8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;626,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--FR_zaBG9zPoIS1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;France&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zXjM0heYEhgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,595&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z3TBAtIvBzZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;204,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zQlulZwPy08e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,349,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPqfj8riFPW6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;898,100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,349,269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</LIXT:ScheduleOfResearchAndDevelopmentCostsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="ixv-22415"
      unitRef="USD">359589</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_country_US"
      decimals="0"
      id="ixv-22416"
      unitRef="USD">350618</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_ES"
      decimals="0"
      id="ixv-22417"
      unitRef="USD">295163</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_country_ES"
      decimals="0"
      id="ixv-22418"
      unitRef="USD">626366</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_country_FR"
      decimals="0"
      id="ixv-22419"
      unitRef="USD">91532</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_CN"
      decimals="0"
      id="ixv-22420"
      unitRef="USD">17198</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_country_CN"
      decimals="0"
      id="ixv-22421"
      unitRef="USD">76595</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_NL"
      decimals="0"
      id="ixv-22422"
      unitRef="USD">226150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_country_NL"
      decimals="0"
      id="ixv-22423"
      unitRef="USD">204158</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22424"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22425"
      unitRef="USD">1349269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22426"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22427"
      unitRef="USD">1349269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16715">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zeK65tJL6vEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82F_zFWVaeJrtW2f"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zWvSCSMWlLV1" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zQqwXfVUmHth" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total of &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKoo3m3SGDQ2" title="Preferred stock, shares authorized"&gt;350,000&lt;/span&gt; shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. &lt;span id="xdx_903_eus-gaap--PreferredStockDividendPaymentTerms_pid_c20150317__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ze5MuyRlP4e2" title="Preferred stock, dividend payment terms"&gt;The
holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed&lt;/span&gt;. As of December 31, 2023 and 2022, the
Company had &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zrKwew4rXu4c" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zX3eVFDlTKC9" title="Preferred stock, shares authorized"&gt;9,650,000&lt;/span&gt;&lt;/span&gt; shares of undesignated preferred stock which may be issued with such rights and powers as the Board of Directors
may designate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbWNonnBVxs2" title="Preferred stock, conversion description"&gt;Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfHjRvYZhXj" title="Preferred stock convertible into common stock"&gt;0.20833&lt;/span&gt; shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQZueNHIfi33" title="Gross proceeds from sale of transaction"&gt;21,875,000&lt;/span&gt;&lt;/span&gt;. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. If fully converted, the &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzGKy3DFcVg2" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQITNxj4L7D8" title="Preferred stock, shares outstanding"&gt;350,000&lt;/span&gt;&lt;/span&gt; outstanding shares
of Series A Convertible Preferred Stock would convert into &lt;span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4HWiLUaKk95" title="Preferred stock convertible into common stock"&gt;&lt;span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYod8fbPnc1k" title="Preferred stock convertible into common stock"&gt;72,917&lt;/span&gt;&lt;/span&gt; shares of common stock at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zpeyUJE9fKR7" title="Common stock, shares authorized"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zlcbkqFUBQ4f" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zCLyRzz0J2A8" title="Common stock, par or stated value per share"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zRoLF9BT21ek" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of December 31, 2023 and
2022, the Company had &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zgEyn6NWtOF7" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zStiUdtJgYbh" title="Common stock, shares outstanding"&gt;2,249,290&lt;/span&gt;&lt;/span&gt; shares and &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zlGX2Zx74yl4" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zp9n1uTEJ3Q6" title="Common stock, shares outstanding"&gt;1,664,706&lt;/span&gt;&lt;/span&gt; shares, respectively, of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLV6dHaygyN4" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authorized number of shares of common stock and the par value per share were not affected by the reverse stock split. No fractional shares
were issued in connection with the reverse stock split, as all fractional shares were rounded up to the next whole share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for
all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 10, 2023, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTUnTSrdnqy9" title="Shares issued upon exercise of stock option"&gt;1,250&lt;/span&gt; shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zniv5KTadGd7" title="Warrants exercised"&gt;1,250&lt;/span&gt; shares exercisable at $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuI2xvJfcE" title="Warrant exercise price"&gt;5.025&lt;/span&gt; per share for total cash proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCz6Zgvio5gf" title="Proceeds from warrant exercises"&gt;6,281&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;April
12, 2022 Sale of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 12, 2022, the Company completed the sale of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMRdaxqMm15b" title="Number of common stock shares issued during period"&gt;290,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKfDzIhoApO2" title="Sale of stock price per share"&gt;20.00&lt;/span&gt; per share in a registered direct
offering, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7eB3NJMBrl" title="Proceeds from sale of shares"&gt;5,800,000&lt;/span&gt;. The total cash costs of this offering were $&lt;span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2xhfCegf6Y2" title="Costs of public offering"&gt;658,616&lt;/span&gt;, resulting in net proceeds of
$&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9JXifmaGgLi" title="Net proceeds from issuance of stock"&gt;5,141,384&lt;/span&gt;. Pursuant to the placement agents&#x2019; agreement, the Company granted warrants to the placement agents to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_z92GGFusENT1" title="Warrants to purchase shares"&gt;29,000&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PlacementAgentsMember_zVvbf4RvzUv8" title="Warrant exercise price"&gt;20.00&lt;/span&gt; per share exercisable through April 14, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;July
20, 2023 Sale of Common Stock and Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 20, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDpwCZUmr10d" title="Number of common stock shares issued during period"&gt;180,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6KCsx7vkqad" title="Sale of stock price per share"&gt;6.00&lt;/span&gt; per share and pre-funded warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zLkAW4UPZ3Ti" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt;
shares of common stock at a price of $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z77bVc2EGhDg" title="Common Stock, Par or Stated Value Per Share"&gt;5.9999&lt;/span&gt; per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zcwMnjz3QSHa" title="Warrant exercise price"&gt;0.0001&lt;/span&gt; per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from July 24, 2023 through August 7, 2023, the &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zT2e8Cv9m2Xl" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; pre-funded warrants, exercisable at $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zsQ4Av4Ene1h" title="Common Stock, Par or Stated Value Per Share"&gt;0.0001&lt;/span&gt; per common share, were
exercised for total cash proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zY5RROjYe7z1" title="Proceeds from exercise of warrants"&gt;41&lt;/span&gt;, resulting in the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxU61230hVwe" title="Shares issued upon exercise of warrants"&gt;403,334&lt;/span&gt; shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEF23643iTCe" title="Warrants to purchase shares"&gt;583,334&lt;/span&gt; shares of common stock.
Each common warrant had an initial exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Oqe9a86D4l" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share, was immediately exercisable upon issuance, and expires &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaMM9zF6h6ei" title="Warrants term"&gt;five years&lt;/span&gt;
thereafter on &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9QeBHeYG6ng" title="Warrant expiration date"&gt;July 20, 2028&lt;/span&gt;. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were subsequently registered for resale on a registration statement on Form S-3 declared effective by the SEC
on August 21, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
registered direct offering and the concurrent private placement generated gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZz6sizVHom7" title="Proceeds from issuance initial public offering"&gt;3,499,964&lt;/span&gt;. The total cash costs of the registered
direct offering and the private placement were $&lt;span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIM88Pjg0Hd1" title="Costs of public offering"&gt;362,925&lt;/span&gt;, resulting in net proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwnamlXqQqNe" title="Net proceeds from private placement"&gt;3,137,039&lt;/span&gt;. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z44RKYKRS9zf" title="Warrants to purchase shares"&gt;35,000&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWdnphWJu7n9" title="Warrant exercise price"&gt;6.60&lt;/span&gt; per share and
expiring on &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zHUHgDrAVFSi" title="Warrant expiration date"&gt;July 20, 2028&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of the warrants issued to the institutional investor (exercisable at $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zm3FXY03nsqj" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share) and to the placement agent (exercisable
at $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zWHVepD6Uf0i" title="Warrant exercise price"&gt;6.60&lt;/span&gt; per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#x2019;s common stock. In addition, the warrants issued to the institutional investor contain
a &#x201c;fundamental transaction&#x201d; provision whereby in the event of a fundamental transaction (a sale or transfer of assets or
ownership of the Company as defined in the warrant agreement) within the Company&#x2019;s control, the holder of the unexercised common
stock warrants would be entitled to receive, in exchange for extinguishment of such warrants, cash consideration equal to a Black-Scholes
valuation, as defined in the warrant agreement. If such fundamental transaction is not within the Company&#x2019;s control, the warrant
holder would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company&#x2019;s
common stock, hence these warrants are classified as a component of permanent equity. The Company will account for any such cash payment
for a warrant redemption as a distribution from stockholders&#x2019; equity, as and when such cash payment is made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsUZvjzFjOoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offering, during the years ended December 31, 2023 and 2022 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zDqLPxAqnOT3" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Warrants outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ziuZ25V42jz9" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;311,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpfop4SYsGh3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;57.720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMPcOrdOu7A6" style="text-align: right" title="Number of Shares, Issued"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxmoqpNrfPr9" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0PJTORZgZc" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEEzhRKHWGxg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvOcIHvLYBdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHBShZqPwLWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;60.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztwbjoJ0GYf1" style="text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTlLmO3UyNg7" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlsxvt9qJ35l" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaQOndTeeM9d" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjs4Vjx78Zae" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS2JDRMic5j" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZpegNnuXEk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0682"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVn24AL1OWo7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJcyq2t1laBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zk3z2IZQKWDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWngRgbiF2Z8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcBMNbidNv04" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;190,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBHWJsEgkl0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;50.161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztRuwimAmhk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZcVMAUOaFl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2kd7kcYSxPe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zXB2QmlpJXo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zHCdrGKKPNI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z6TB8k2oC2xi" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                 Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
&lt;br/&gt;
Outstanding (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 46%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3qWYGq2AwX8" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaYnQqKahfc8" style="width: 48%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z88RxNZdljD4" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8BD11CMmA2k" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQVqTnzEtcnk" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpKAaCkzXvm8" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqOgjc8Y5Pve" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zT9bmTbBiKgf" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAMfzu0vpsob" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuvCd21XPysc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231_zIuK0iOOHQwl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zMAkGxvcCTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants exercisable at $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5MtsnC1APic" title="Warrants exercisable"&gt;57.00&lt;/span&gt; per share at December 31, 2023 consist of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwzCgsTAfoY9" title="Warrants outstanding"&gt;1,497,000&lt;/span&gt; publicly-traded warrants pre-split &lt;span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPMvHqXizbGa" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; that were
issued as part of the Company&#x2019;s November 2020 public offering of units and are exercisable for a period of five years thereafter.
As a result of the 1-for-10 reverse split of the Company&#x2019;s common stock effective June 2, 2023, each such publicly-traded warrant
currently represents the right to purchase 1/10th of a share of common stock at the original exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTV4tY7bNks5" title="Exercise price"&gt;5.70&lt;/span&gt; per share. Accordingly,
upon exercise, 10 warrants, each exercisable at $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHA59smDsB" title="Warrants exercisable"&gt;5.70&lt;/span&gt;, will be required to acquire one share of post-split common stock, which is equivalent
to a purchase price of $&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXMUnxLvhYWi" title="Warrants and rights outstanding"&gt;57.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on a fair market value of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdrlvQepPRM1" title="Fair market value of stock"&gt;2.35 &lt;/span&gt;per share on December 31, 2023, there was no intrinsic value attributed to exercisable but unexercised
common stock warrants at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22428"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22429"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22430"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendPaymentTerms
      contextRef="From2015-03-172015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      id="ixv-22431">The
holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed</us-gaap:PreferredStockDividendPaymentTerms>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      id="ixv-22432"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      id="ixv-22433"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockConversionBasis
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171"
      id="ixv-16741">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22434"
      unitRef="Shares">0.20833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember241556171"
      decimals="0"
      id="ixv-22435"
      unitRef="USD">21875000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22436"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22437"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22438"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-22439"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22440"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22441"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22442"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22443"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22444"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22445"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22446"
      unitRef="Shares">1664706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22447"
      unitRef="Shares">1664706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="ixv-22448">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22449"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-22450"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-22451"
      unitRef="USDPShares">5.025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="0"
      id="ixv-22452"
      unitRef="USD">6281</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22453"
      unitRef="Shares">290000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22454"
      unitRef="USDPShares">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22455"
      unitRef="USD">5800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22456"
      unitRef="USD">658616</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-22457"
      unitRef="USD">5141384</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember"
      decimals="INF"
      id="ixv-22458"
      unitRef="Shares">29000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-12_us-gaap_WarrantMember_custom_PlacementAgentsMember"
      decimals="INF"
      id="ixv-22459"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22460"
      unitRef="Shares">180000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22461"
      unitRef="USDPShares">6.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="ixv-22462"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="ixv-22463"
      unitRef="USDPShares">5.9999</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="ixv-22464"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-07_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="ixv-22465"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-07_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="ixv-22466"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-242023-08-07_custom_PreFundedWarrantsMember"
      decimals="0"
      id="ixv-22467"
      unitRef="USD">41</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22468"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="ixv-22469"
      unitRef="Shares">583334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="ixv-22470"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      id="ixv-22471">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      id="ixv-22472">2028-07-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="ixv-22473"
      unitRef="USD">3499964</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="ixv-22474"
      unitRef="USD">362925</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="ixv-22475"
      unitRef="USD">3137039</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="0"
      id="ixv-22476"
      unitRef="Shares">35000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="INF"
      id="ixv-22477"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      id="ixv-22478">2028-07-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="ixv-22479"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="INF"
      id="ixv-22480"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16883">&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zsUZvjzFjOoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offering, during the years ended December 31, 2023 and 2022 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zDqLPxAqnOT3" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Warrants outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ziuZ25V42jz9" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;311,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpfop4SYsGh3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;57.720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMPcOrdOu7A6" style="text-align: right" title="Number of Shares, Issued"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxmoqpNrfPr9" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0PJTORZgZc" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEEzhRKHWGxg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvOcIHvLYBdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHBShZqPwLWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;60.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztwbjoJ0GYf1" style="text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTlLmO3UyNg7" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlsxvt9qJ35l" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaQOndTeeM9d" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjs4Vjx78Zae" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zS2JDRMic5j" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZpegNnuXEk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0682"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVn24AL1OWo7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJcyq2t1laBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zk3z2IZQKWDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWngRgbiF2Z8" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcBMNbidNv04" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;190,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBHWJsEgkl0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;50.161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztRuwimAmhk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZcVMAUOaFl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2kd7kcYSxPe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22481"
      unitRef="Shares">311031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22482"
      unitRef="USDPShares">57.720</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      decimals="INF"
      id="ixv-22483"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      decimals="INF"
      id="ixv-22484"
      unitRef="USDPShares">20.000</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      decimals="INF"
      id="ixv-22485"
      unitRef="Shares">-150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CommonStockWarrantsMember241556812"
      decimals="INF"
      id="ixv-22486"
      unitRef="USDPShares">60.000</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22487"
      unitRef="Shares">190031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22488"
      unitRef="USDPShares">50.161</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      decimals="INF"
      id="ixv-22489"
      unitRef="Shares">618334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      decimals="INF"
      id="ixv-22490"
      unitRef="USDPShares">6.034</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22491"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22492"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="ixv-22493">P3Y11M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22494"
      unitRef="Shares">190031</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22495"
      unitRef="USDPShares">50.161</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22496"
      unitRef="Shares">808365</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22497"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember241556828"
      id="ixv-22498">P3Y11M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17109">&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zHCdrGKKPNI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z6TB8k2oC2xi" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                 Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
&lt;br/&gt;
Outstanding (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 46%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3qWYGq2AwX8" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zaYnQqKahfc8" style="width: 48%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z88RxNZdljD4" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8BD11CMmA2k" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQVqTnzEtcnk" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpKAaCkzXvm8" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqOgjc8Y5Pve" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zT9bmTbBiKgf" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAMfzu0vpsob" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuvCd21XPysc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231_zIuK0iOOHQwl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="ixv-22499"
      unitRef="USDPShares">6.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="ixv-22500"
      unitRef="Shares">583334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="ixv-22501"
      unitRef="USDPShares">6.600</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="ixv-22502"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="ixv-22503"
      unitRef="USDPShares">20.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="ixv-22504"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="ixv-22505"
      unitRef="USDPShares">37.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="ixv-22506"
      unitRef="Shares">11331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="ixv-22507"
      unitRef="USDPShares">57.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="ixv-22508"
      unitRef="Shares">149700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22509"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22510"
      unitRef="USDPShares">57.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22511"
      unitRef="Shares">1497000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="ixv-22512">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-22513"
      unitRef="USDPShares">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-22514"
      unitRef="USDPShares">5.70</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-22515"
      unitRef="USD">57.00</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="ixv-22516"
      unitRef="USDPShares">2.35</us-gaap:SharePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17221">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZWbPdgQqE97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82F_zRyI2U6dpUz1"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
party transactions include transactions with the Company&#x2019;s officers, directors, and affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically
renewed for additional one-year periods in July and August 2021, 2022 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#x2019;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $&lt;span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zrJFA5Ku7CM7" title="Annual salary"&gt;250,000&lt;/span&gt;.
During the years ended December 31, 2023 and 2022, the Company paid $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztaJjLFKgH2e" title="Compensation"&gt;190,860&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zBZ4FCtyjWOd" title="Compensation"&gt;250,000&lt;/span&gt;, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations
for such periods. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#x2019;s Chief
Medical Officer, with an annual salary of $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zJeAF7MSCCRe" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective May 1, 2021, Dr. Miser&#x2019;s annual salary was increased to $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgUbnZQZjDT8" title="Increase in annual salary"&gt;175,000&lt;/span&gt;.
Dr. Miser is required to devote at least 50% of his business time to the Company&#x2019;s activities. During the years ended December
31, 2023 and 2022, the Company paid $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zONiQmgNIYNb" title="Compensation"&gt;175,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3QXwxJOAPM" title="Compensation"&gt;175,000&lt;/span&gt;, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#x2019;s consolidated statements of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#x2019;s Chief Administrative Officer, with an annual salary of $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zUICFMADDaD3" title="Annual salary"&gt;120,000&lt;/span&gt;. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#x2019;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#x2019;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#x2019;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#x2019;s
annual salary was increased to $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_z01Wnixvczc1" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ze68UpK9odyk" title="Compensation"&gt;200,000&lt;/span&gt;. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which the Company paid $&lt;span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zc6WKkehCJw4" title="Paid office rent"&gt;15,571&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--PaymentsForRent_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zXopDSprRZye" title="Paid office rent"&gt;937&lt;/span&gt;, respectively, on Mr. Forman&#x2019;s behalf for the years ended December 31, 2023
and 2022. During the years ended December 31, 2023 and 2022, the Company paid $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVXAuptS4kVj" title="Compensation"&gt;200,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zlsk2CDDfTM4" title="Compensation"&gt;178,819&lt;/span&gt;, respectively, to Mr. Forman under
this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#x2019;s Vice President
and Chief Financial Officer, with an annual salary of $&lt;span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zkujrcc5uiU2" title="Annual salary"&gt;120,000&lt;/span&gt;. Effective May 1, 2021, Mr. Weingarten&#x2019;s annual salary was increased
to $&lt;span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zDexGD0ZRBne" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. During the years ended December 31, 2023 and 2022, the Company paid $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVe50L9PnxQ1" title="Compensation"&gt;175,000 &lt;/span&gt;and $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXvycoFS2S4j" title="Compensation"&gt;175,000&lt;/span&gt;, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zp0wAVjKlOaa" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#x2019;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will
be eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement
is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early
termination provisions as described in the employment agreement. During the year ended December 31, 2023, the Company paid $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbT44YZcqV4d" title="Compensation"&gt;40,639&lt;/span&gt; to
Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s
consolidated statements of operations for such period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Appointment
of Dr. Ren&#xe9; Bernards to the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
as of June 15, 2022, Dr. Ren&#xe9; Bernards was appointed to the Company&#x2019;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $&lt;span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_zCa7Ij7F3Evb" title="Cash board fee payable"&gt;100,000&lt;/span&gt;, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $&lt;span id="xdx_90B_ecustom--ManagementFeePayableQuarterly_iI_c20220615__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember_ztWsXJT0Hke4" title="Cash board fee payable quarterly"&gt;40,000&lt;/span&gt;, payable quarterly. During the years ended December 31,
2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuH3xUfOjSb1" title="cash board compensation"&gt;62,500&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrReneBernardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqX5khH4yg5c" title="Cash board compensation"&gt;133,873&lt;/span&gt;, respectively, with respect to his cash board compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensatory
Arrangements for Members of the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
compensation for directors, payable quarterly, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Base
director compensation - $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zoWo8fqJ6Png" title="Compensation"&gt;20,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of audit committee &#x2013; additional $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zuGEbTrANgm1" title="Compensation"&gt;10,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of any other committees &#x2013; additional $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zsx8qu4yEiK5" title="Compensation"&gt;5,000 &lt;/span&gt;per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of audit committee &#x2013; additional $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zBPcxliY4I9d" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of any other committees &#x2013; additional $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zuYabsm4TECd" title="Compensation"&gt;2,500&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
compensation for directors is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Appointment
of new directors &#x2013; The Company grants options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zJ9BWB7gqBf9" title="Options, grants in period, gross"&gt;25,000&lt;/span&gt; shares of common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zTiDf3UnL6L2" title="Options exercisable period"&gt;five years&lt;/span&gt;,
at the closing market price on the date of grant, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zaqx4NUUnkHb" title="Options vesting term"&gt;vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service&lt;/span&gt;. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $&lt;span id="xdx_90B_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zuHSSysIOvEb" title="Cash fee payable"&gt;100,000&lt;/span&gt; to such director, payable upfront.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.85in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
grant of options to directors &#x2013; Effective on the last business day of the month of June, the Company grants options to purchase
&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zlt1lIdZQZ9e" title="Options, grants in period, gross"&gt;10,000&lt;/span&gt; shares of common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zuCeIKXSJ2c9" title="Options exercisable period"&gt;five years&lt;/span&gt;, at the closing market price on the date of grant, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zwsGMMAR9i6" title="Options vesting term"&gt;vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director&lt;/span&gt;. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $&lt;span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AnnualGrantOfOptionsMember_zWoHXc6cKNCg" title="Cash fee payable"&gt;40,000&lt;/span&gt; to such director, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash compensation paid to non-officer directors was $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_zjBm4kyeOpPk" title="Stock based compensation"&gt;163,479&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonOfficerDirectorsMember_z38adBrazz7h" title="Stock based compensation"&gt;266,020&lt;/span&gt;, respectively, for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation granted to members of the Company&#x2019;s Board of Directors, officers and affiliates is described at Note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zpSmtHiyZMPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2023 and 2022, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zPxp7rYaMom1" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJYpwB9sh2b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zilBvtTqTHJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OfficersCompensation_zxY587gtQA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,044,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zXWkfEGt3Lhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,502,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zNrpgk7VYNFb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,547,615&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_zWyT1z4sMuM9" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Related party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,547,615&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zelEUnGjLmO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      id="ixv-22517"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22518"
      unitRef="USD">190860</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22519"
      unitRef="USD">250000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember"
      decimals="0"
      id="ixv-22520"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22521"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22522"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22523"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22524"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22525"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      id="ixv-22526"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22527"
      unitRef="USD">15571</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22528"
      unitRef="USD">937</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22529"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22530"
      unitRef="USD">178819</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="ixv-22531"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="ixv-22532"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22533"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22534"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember"
      decimals="0"
      id="ixv-22535"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22536"
      unitRef="USD">40639</us-gaap:OfficersCompensation>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2022-06-15_custom_DrReneBernardsMember"
      decimals="0"
      id="ixv-22537"
      unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <LIXT:ManagementFeePayableQuarterly
      contextRef="AsOf2022-06-15_custom_DrReneBernardsMember"
      decimals="0"
      id="ixv-22538"
      unitRef="USD">40000</LIXT:ManagementFeePayableQuarterly>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22539"
      unitRef="USD">62500</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_DrReneBernardsMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-22540"
      unitRef="USD">133873</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="0"
      id="ixv-22541"
      unitRef="USD">20000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="0"
      id="ixv-22542"
      unitRef="USD">10000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember"
      decimals="0"
      id="ixv-22543"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember"
      decimals="0"
      id="ixv-22544"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember"
      decimals="0"
      id="ixv-22545"
      unitRef="USD">2500</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      decimals="INF"
      id="ixv-22546"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      id="ixv-22547">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      id="ixv-22548">vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2023-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      decimals="0"
      id="ixv-22549"
      unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      id="ixv-22550"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember"
      id="ixv-22551">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-01-012023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember"
      id="ixv-22552">vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2023-12-31_srt_DirectorMember_custom_AnnualGrantOfOptionsMember"
      decimals="0"
      id="ixv-22553"
      unitRef="USD">40000</us-gaap:ManagementFeePayable>
    <us-gaap:SalariesAndWages
      contextRef="From2023-01-012023-12-31_custom_NonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22554"
      unitRef="USD">163479</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-012022-12-31_custom_NonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22555"
      unitRef="USD">266020</us-gaap:SalariesAndWages>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17383">&lt;p id="xdx_895_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zpSmtHiyZMPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2023 and 2022, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zPxp7rYaMom1" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJYpwB9sh2b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zilBvtTqTHJf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OfficersCompensation_zxY587gtQA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,044,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zXWkfEGt3Lhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,502,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zNrpgk7VYNFb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,547,615&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_zWyT1z4sMuM9" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Related party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,547,615&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22556"
      unitRef="USD">944977</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22557"
      unitRef="USD">1044839</us-gaap:OfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22558"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22559"
      unitRef="USD">1502776</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22560"
      unitRef="USD">1718180</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22561"
      unitRef="USD">2547615</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22562"
      unitRef="USD">1718180</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22563"
      unitRef="USD">2547615</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17485">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zN0jlIZJ5qi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_823_zKfP6XOA1ANk"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAIV13jsyRq8" title="Common shares avaliable for issuable"&gt;233,333&lt;/span&gt; shares of the Company&#x2019;s common stock, under terms
and conditions as determined by the Company&#x2019;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221006__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuc36anq7Ohg" title="Common shares avaliable for issuable"&gt;180,000&lt;/span&gt; shares, to a total of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zUOoYv851l06" title="Number of common shares issuable"&gt;413,333&lt;/span&gt; shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231126__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zAJpIr2wZoB" title="Common shares avaliable for issuable"&gt;336,667&lt;/span&gt; shares, to a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zClHQvCXLHp2" title="Number of common shares issuable"&gt;750,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, unexpired stock options for &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWlPBRdj86ud" title="Shares outstanding"&gt;495,000&lt;/span&gt; shares were issued and outstanding under the 2020 Plan and &lt;span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zM0DAsFRPnBg" title="Shares were available for issuance"&gt;255,000&lt;/span&gt; shares were
available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#x2019;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zts1CO8ZeUT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zhweWedzOTod" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231_z7a5eJuqSdy8" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zZEWVvi5R8oj" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zTUsUmQ6wPZe" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zJ2Ao391EqS" title="Expected life"&gt;4.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20220101__20221231_zFP0jPpHHLt8" title="Risk-free interest rate, minimum"&gt;3.03&lt;/span&gt;% to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20220101__20221231_zDTD84iiN9bk" title="Risk-free interest rate, maximum"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zF5WOiwXBe4c" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20220101__20221231_zK7PmrqPVWEk" title="Expected volatility, minimum"&gt;128.03&lt;/span&gt;% to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20220101__20221231_zDs6gylt4lxg" title="Expected volatility, maximum"&gt;153.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zlDrN4yCin21" title="Expected life"&gt;3.5&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zibY8JCgQwy3" title="Expected life"&gt;5&lt;/span&gt; years &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zXKnZ3xpsUo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zu64vgFxzDu8" title="Stock options granted to purchase common stock, issued"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zYyTglmsShV5" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zC9UxaqUcAhj" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market
price of the Company&#x2019;s common stock on the grant date. &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zfgfysHE5Il6" title="Stock option vested exercisable term"&gt;The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5PCh2G7LNy3" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zPikHhfXho69" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0sQZ24Ncy9b" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock options fully
vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general
and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zy87pHHjD803" title="Stock based compensation"&gt;61,501&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zh8AJUuTM2T" title="Stock based compensation"&gt;100,213&lt;/span&gt; for the years ended December 31, 2023 and
2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2020, in connection with an employment agreement entered into with Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIzMww3N3Ti5" title="Stock options granted to purchase common stock, issued"&gt;8,333&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKMIMgCS3JXk" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zFAOsILpKIb7" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the effective date of the employment agreement. &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zOfcFf0rqD9l" title="Stock options description"&gt;The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zq0XQBePW8Eb" title="Fair value of stock options"&gt;572,650&lt;/span&gt; ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7tWuAgrdrR8" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zeGXCN1y2ifi" title="Stock options fully vested amount, fair value"&gt;143,163&lt;/span&gt; was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded charges to general and
administrative costs in the consolidated statement of operations of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjtpezggaflb" title="Stock based compensation"&gt;83,544&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKVWM0OeW5ub" title="Stock based compensation"&gt;143,163&lt;/span&gt; for the years ended December 31, 2023 and 2022,
respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember_zphFy8RWYTKe" title="Number of fully vested option exercisable"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are
exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z7ULeA3KwV01" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_ziGYCDhRyfP5" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the grant date. &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zxwO14GPDql8" title="Stock options description"&gt;The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $&lt;span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zWhlbjafmEY4" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjh1JCXr2Q" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJzNCLKbH6Ri" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock options fully vested on August 12,
2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was
charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded charges to general and administrative
costs in the consolidated statement of operations of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLxKnBcMNje7" title="Stock based compensation"&gt;61,501&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zZWCMPhfPeaj" title="Stock based compensation"&gt;100,213&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively,
with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2021, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#x2019;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zogYvlcKIc84" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, exercisable for a period of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHv3jT1boV6" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_ztFMRkydEnUc" title="Stock options are exercisable price per share"&gt;32.00&lt;/span&gt; per share (the closing market price on the grant
date), &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmutyFMMqFQ5" title="Stock options description"&gt;vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90C_ecustom--FairValueOfStockOptions_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zJqOs1Dy1N8j" title="Fair value of stock options"&gt;753,611&lt;/span&gt; ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1YOlqjTXAL6" title="Stock price per share"&gt;30.144&lt;/span&gt; per share), of which $&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210408__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7JYhy3nwM97" title="Stock options fully vested amount, fair value"&gt;376,800&lt;/span&gt; was attributable to the portion of the stock options fully vested on April 9, 2021 and
was therefore charged to operations on that date. Although the remaining unvested portion of the fair value of the stock options was
being charged to operations ratably from April 9, 2021 through June 30, 2023, the vesting of these stock options terminated on October
30, 2022 as a result of the death of Mr. Schwartzberg on that date. The Company recorded charges to general and administrative costs
in the consolidated statement of operations of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSchwartbergMember_zDRCugkODlci" title="Stock based compensation"&gt;126,684&lt;/span&gt; for the year ended December 31, 2022 with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zb7YnFTDFnX8" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zmEtTyWM5gvl" title="Stock option vested exercisable term"&gt;five year&lt;/span&gt;s
at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zksCQFX8knui" title="Stock options are exercisable price per share"&gt;28.00&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zbFTgWyXbBIc" title="Stock options description"&gt;vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested&lt;/span&gt;. The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z7zeFgkdVxJb" title="Fair value of stock options"&gt;658,363&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zYYsKuYm3Vyf" title="Stock price per share"&gt;26.335&lt;/span&gt; per share), of which $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z6iijqUQrRcf" title="Stock options fully vested amount, fair value"&gt;329,188&lt;/span&gt; was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zYCWuOIFdfp7" title="Stock based compensation"&gt;76,388&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2L7T45oQBOi" title="Stock based compensation"&gt;154,042&lt;/span&gt; for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2021, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zZqJjf6Xh6sd" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zWGDoyJId69b" title="Number of fully vested option exercisable"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPkaFO7548h8" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zBrxnT4nsTyc" title="Stock options are exercisable price per share"&gt;30.30&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zUeIn9ikXQli" title="Stock options description"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested&lt;/span&gt;.
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z7niMfKEGSE5" title="Fair value of stock options"&gt;1,421,095&lt;/span&gt;
($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8pSPXynF0C6" title="Stock price per share"&gt;28.423&lt;/span&gt; per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded charges to
general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zPJBVOvkKdzf" title="Stock based compensation"&gt;211,413&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrujbsuwQgld" title="Stock based compensation"&gt;638,915&lt;/span&gt; for the years ended December 31,
2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIKCHF1nrBxb" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220616__20220617__srt--TitleOfIndividualAxis__srt--DirectorMember_zu6zHiAtcjje" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt;
at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zGpFMtV78sEb" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zZY487Hv5589" title="Stock options description"&gt;vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service&lt;/span&gt;. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsEN8xk5J8r" title="Fair value of stock options"&gt;158,525&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zdH129z46FWh" title="Stock price per share"&gt;6.341&lt;/span&gt; per share),
of which $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zjIjKIy85IU9" title="Stock options granted to purchase common stock, issued"&gt;79,263&lt;/span&gt; was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. The Company recorded charges to general and administrative costs in the consolidated statement of operations
of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zveU02Pr37P1" title="Stock based compensation"&gt;38,885&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zFOxkAh9lFZb" title="Stock based compensation"&gt;100,249&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2022, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zT87nCDWBNga" title="Fair value of stock options"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zyV2Kn7lO3Ab" title="Stock price per share"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zMyTKttTPNLk" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z1ZT4rosmLV6" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_ze3hN3FJIAIa" title="Stock options description"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zqoCyyA5BVdf" title="Fair value of stock options"&gt;316,700&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zJSBCsF0X77g" title="Stock price per share"&gt;6.334&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
The Company recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zlj3Xxmr9JBg" title="Stock based compensation"&gt;94,881&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zzRKnFgxwki1" title="Stock based compensation"&gt;63,777&lt;/span&gt; for
the years ended December 31, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zHGlgs0tdYpg" title="Number of fully vested option exercisable"&gt;20,000&lt;/span&gt; shares
(a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zEYrIejNSNkd" title="Number of fully vested option exercisable"&gt;80,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zrxWaiOtdlql"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zAjjbzcJZXua" title="Share price"&gt;20.00&lt;/span&gt;
per share, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ziwz06Zd9OBk" title="Stock options description"&gt;vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service&lt;/span&gt;. The
total fair value of the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zY90e42iPLQ1" title="Stock options granted to purchase common stock, issued"&gt;80,000&lt;/span&gt; stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zfixxaSlXtxh" title="Fair value of stock options"&gt;262,560&lt;/span&gt; ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_ztCRCbbOj449" title="Stock price per share"&gt;3.282&lt;/span&gt; per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. The Company
recorded a total charge to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkX8KFyLh88d" title="Stock based compensation"&gt;61,448&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNNpYsC1cUn1" title="Stock based compensation"&gt;75,520&lt;/span&gt; for the
years ended December 31, 2023 and 2022, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPCixXgqzqgd" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, which was fully vested upon issuance and is exercisable for a period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_uPure_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zapUYn9LEfy"&gt;five years&lt;/span&gt; at $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPIZBCH59N6i" title="Stock options are exercisable price per share"&gt;5.025&lt;/span&gt; per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $&lt;span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_z62IKo2uhp8g" title="Fair value of stock options"&gt;43,264&lt;/span&gt; ($&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pp5d_c20221106__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zB1ZObFeO17h" title="Stock price per share"&gt;4.326&lt;/span&gt; per share) and was charged to general and administrative costs in the consolidated statement of operations on that
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2023, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdFjx1cOYqJ5" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zSyp6k8q6rGj" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zXdgyO3P6Mn6" title="Number of fully vested option exercisable"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zhtZcQdeW8kf" title="Exercise price"&gt;5.88&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zS5gcyomY9Na" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service&lt;/span&gt;. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90D_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zNAksO0Qgov9" title="Fair value of stock options"&gt;192,593&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLIQVGjp8eEe" title="Stock price per share"&gt;4.8131&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
The Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ze8cao2JlpQh" title="Stock based compensation"&gt;48,464&lt;/span&gt; for the
year ended December 31, 2023 with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zQbD61Hl1kIl" title="Options, grants in period, gross"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJBiGG46a7X6" title="Option exercisable period"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjFBi9mhE2g5" title="Stock options are exercisable price per share"&gt;1.95&lt;/span&gt; per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrVanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z2o891JpZz8b" title="Options vesting term"&gt;The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service&lt;/span&gt;. The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEyzR4sZfwsd" title="Fair value of stock options"&gt;403,066&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRiNuWNDQKkf" title="Stock price per share"&gt;1.612&lt;/span&gt; per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. The Company recorded a charge to general and administrative
costs in the consolidated statement of operations of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zz3wVVOMbdZ4" title="Stock based compensation"&gt;35,178&lt;/span&gt; for the year ended December 31, 2023 with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#x2019;s Board of Directors at the
Company&#x2019;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#x2019;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023. Accordingly, the unvested stock options for each such person ceased vesting effective
as of the respective dates that their service to the Company terminated. Furthermore, the expiration date of all vested stock options
owned by each such person contractually expired one year from the respective dates that each of their services to the Company terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zSC9zzCCuwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zvAPnVh1JgPg" style="display: none"&gt;Summary of Stock-based Compensation Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zS7sHAf62vkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zoKqAlRJe31c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwk17zItPW2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,502,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zcxZR7OKlTtj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zte0Q5Ns2CBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,546,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zTVL8TCwBUe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrM4TFyYWthe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2023 and 2022
is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zUwm2Z22xu26" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Stock options outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zSN23ldJK207" style="width: 12%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;266,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zAkNGGuWygNb" style="width: 12%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;37.380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zXucU1LYjXK8" style="text-align: right" title="Number of shares, granted"&gt;165,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zAo5fnLSGNw3" style="text-align: right" title="Weighted average exercise price, granted"&gt;13.370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zUjONXbGyT25" style="text-align: right" title="Number of shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z8tkTxPvqqXg" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231_z2eCYcoZ8kR5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;(42,188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEazcrjFExjg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;19.160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zPKfSZCNAHK7" style="text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zelJDPkQeHm6" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zTtB0hSpy6Wb" style="text-align: right" title="Number of shares, granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zAkrIHec4xT" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_z7r96UwRPvRg" style="text-align: right" title="Number of shares, exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zjpvkTFgrMT8" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvQCSdvaCO6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, expired"&gt;(126,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zdBuzk8Ddun5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;28.687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zVjyZSjSfXSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_za5UIoLoxQH" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;15.330&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu3K38b1ry9" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zAsMNZABJiFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;281,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z98r6c3kYTql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;32.834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z3TsDk2fFqhd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zSNg0pg1CEF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;28.387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_ziqL2vvQSYke" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zSsE4Xm8WJs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $&lt;span id="xdx_90D_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20231231_zlwVt4pmSYb6" title="Deferred compensation expense for unvested stock options"&gt;670,000&lt;/span&gt; at December 31, 2023, which
will be recognized subsequent to December 31, 2023 over a weighted-average period of approximately &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20231231_zGiRoN4QN2Yf" title="Weighted-average recognition period"&gt;26&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zaVbuJjQ1Awa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the outstanding common stock options,, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zaTHki3lO4if" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                 Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
&lt;br/&gt;
Outstanding (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable
                                                                                                                                                                                                                                                                          (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zsOVqVl1W8yg" style="width: 30%; text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrTFMhenCA0k" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOFr8bFgKj7j" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;20,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmG74Svv61Zi" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8eyyW1MGutk" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlW3WgZ1zwx" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zG3Y24X54r92" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zChzWjLkFQfd" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWbt32QTpC" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpAu8ssEk42f" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbTSCiehNDS1" style="text-align: right" title="Options Outstanding (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqEaJnX2jzck" style="text-align: right" title="Options Exercisable (Shares)"&gt;44,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIxxkRT7nSGf" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVpaEjQjKLEh" style="text-align: right" title="Options Outstanding (Shares)"&gt;65,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWtnnhg1v1Z6" style="text-align: right" title="Options Exercisable (Shares)"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z3VQUTFWRira" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVuOOT3HEYl" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z10zP4OpP6Rg" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zX5xiBpdvXf1" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zV6r3sazVpt3" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_ziVJDDvxr6q5" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z110Sw13H9ac" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbt91km4mvHh" style="text-align: right" title="Options Outstanding (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0GaP5FPb2t" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlQTaFGFabI6" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zvcpJKZwvx1d" style="text-align: right" title="Options Outstanding (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zpKXtRoGOIeb" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z62SuWmemyr5" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVLH8Zt4qcC8" style="text-align: right" title="Options Outstanding (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbEDizTmLd12" style="text-align: right" title="Options Exercisable (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zyX7mW3f6Bcj" style="text-align: right" title="Exercise Prices"&gt;66.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0JIKDTbWzr9" style="text-align: right" title="Options Outstanding (Shares)"&gt;3,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxfNEcRsC3Ab" style="text-align: right" title="Options Exercisable (Shares)"&gt;3,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zdPPdgQja3Bi" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zR9IrHmBaSMb" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zDm5x3jpqur6" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zdRaM6sQryx4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zyyKTSlOmXy8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zeXRwZvBnlz5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zdeeRb8UEaa6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_z2qehMfT1TI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z9qBfhAIsidb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on a fair market value of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20231231_zRoppz8aQ2Ga" title="Fair market value, per share"&gt;2.35&lt;/span&gt; per share on December 31, 2023, the intrinsic value attributed to exercisable but unexercised common
stock options was approximately $&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_zVlS68weT1q6" title="Intrinsic value"&gt;8,000&lt;/span&gt; at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
stock options to acquire &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20231231_zYDJzxxZsf6f" title="Outstanding stock options to acquire shares of common stock not vested"&gt;299,791&lt;/span&gt; shares of the Company&#x2019;s common stock had not vested at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22564"
      unitRef="Shares">233333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-06_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22565"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22566"
      unitRef="Shares">413333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-11-26_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22567"
      unitRef="Shares">336667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22568"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22569"
      unitRef="Shares">495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="ixv-22570"
      unitRef="Shares">255000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17526">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zts1CO8ZeUT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zhweWedzOTod" style="display: none"&gt;Schedule of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231_z7a5eJuqSdy8" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zZEWVvi5R8oj" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zTUsUmQ6wPZe" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zJ2Ao391EqS" title="Expected life"&gt;4.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2022, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20220101__20221231_zFP0jPpHHLt8" title="Risk-free interest rate, minimum"&gt;3.03&lt;/span&gt;% to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20220101__20221231_zDTD84iiN9bk" title="Risk-free interest rate, maximum"&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zF5WOiwXBe4c" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20220101__20221231_zK7PmrqPVWEk" title="Expected volatility, minimum"&gt;128.03&lt;/span&gt;% to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20220101__20221231_zDs6gylt4lxg" title="Expected volatility, maximum"&gt;153.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zlDrN4yCin21" title="Expected life"&gt;3.5&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zibY8JCgQwy3" title="Expected life"&gt;5&lt;/span&gt; years &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22571"
      unitRef="Pure">0.04843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22572"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22573"
      unitRef="Pure">1.3805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="ixv-22574">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22575"
      unitRef="Pure">0.0303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22576"
      unitRef="Pure">0.0363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22577"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22578"
      unitRef="Pure">1.2803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22579"
      unitRef="Pure">1.5317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      id="ixv-22580">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      id="ixv-22581">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="ixv-22582"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      id="ixv-22583">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="ixv-22584"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      id="ixv-22585">The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22586"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="ixv-22587"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22588"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22589"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22590"
      unitRef="USD">100213</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="ixv-22591"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      id="ixv-22592">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="ixv-22593"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      id="ixv-22594">The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22595"
      unitRef="USD">572650</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="ixv-22596"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22597"
      unitRef="USD">143163</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22598"
      unitRef="USD">83544</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22599"
      unitRef="USD">143163</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-08-112020-08-12_srt_DirectorMember_custom_RobertNWeingartenMember"
      decimals="INF"
      id="ixv-22600"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      id="ixv-22601">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="ixv-22602"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      id="ixv-22603">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on
August 12, 2023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22604"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="ixv-22605"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22606"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22607"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22608"
      unitRef="USD">100213</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="INF"
      id="ixv-22609"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      id="ixv-22610">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="2"
      id="ixv-22611"
      unitRef="USDPShares">32.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      id="ixv-22612">vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully
vested</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="0"
      id="ixv-22613"
      unitRef="USD">753611</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="4"
      id="ixv-22614"
      unitRef="USDPShares">30.144</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-04-082021-04-09_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="0"
      id="ixv-22615"
      unitRef="USD">376800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_srt_DirectorMember_custom_MrSchwartbergMember"
      decimals="0"
      id="ixv-22616"
      unitRef="USD">126684</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="INF"
      id="ixv-22617"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      id="ixv-22618">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="2"
      id="ixv-22619"
      unitRef="USDPShares">28.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      id="ixv-22620">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="0"
      id="ixv-22621"
      unitRef="USD">658363</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="4"
      id="ixv-22622"
      unitRef="USDPShares">26.335</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="0"
      id="ixv-22623"
      unitRef="USD">329188</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      id="ixv-22624"
      unitRef="USD">76388</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      id="ixv-22625"
      unitRef="USD">154042</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-06-282021-06-30_srt_DirectorMember"
      decimals="INF"
      id="ixv-22626"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      id="ixv-22627"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      id="ixv-22628">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      id="ixv-22629"
      unitRef="USDPShares">30.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      id="ixv-22630">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22631"
      unitRef="USD">1421095</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      id="ixv-22632"
      unitRef="USDPShares">28.423</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22633"
      unitRef="USD">211413</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22634"
      unitRef="USD">638915</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="INF"
      id="ixv-22635"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2022-06-162022-06-17_srt_DirectorMember"
      id="ixv-22636">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="2"
      id="ixv-22637"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      id="ixv-22638">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="ixv-22639"
      unitRef="USD">158525</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="4"
      id="ixv-22640"
      unitRef="USDPShares">6.341</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="ixv-22641"
      unitRef="USD">79263</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember"
      decimals="0"
      id="ixv-22642"
      unitRef="USD">38885</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_BasvanderBaanMember"
      decimals="0"
      id="ixv-22643"
      unitRef="USD">100249</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_srt_DirectorMember"
      decimals="0"
      id="ixv-22644"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="ixv-22645"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="ixv-22646">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="INF"
      id="ixv-22647"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="ixv-22648">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="ixv-22649"
      unitRef="USD">316700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="ixv-22650"
      unitRef="USDPShares">6.334</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="ixv-22651"
      unitRef="USD">94881</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="ixv-22652"
      unitRef="USD">63777</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="ixv-22653"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="ixv-22654"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="ixv-22655">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      id="ixv-22656"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="ixv-22657">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="ixv-22658"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="0"
      id="ixv-22659"
      unitRef="USD">262560</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="4"
      id="ixv-22660"
      unitRef="USDPShares">3.282</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FourOfficersMember"
      decimals="0"
      id="ixv-22661"
      unitRef="USD">61448</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_FourOfficersMember"
      decimals="0"
      id="ixv-22662"
      unitRef="USD">75520</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember"
      decimals="INF"
      id="ixv-22663"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember"
      id="ixv-22664">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-11-06_custom_BioPharmaWorksLLCMember"
      decimals="INF"
      id="ixv-22665"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="ixv-22666"
      unitRef="USD">43264</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_BioPharmaWorksLLCMember"
      decimals="5"
      id="ixv-22667"
      unitRef="USDPShares">4.326</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_srt_DirectorMember"
      decimals="INF"
      id="ixv-22668"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="ixv-22669"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="ixv-22670">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="ixv-22671"
      unitRef="USDPShares">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="ixv-22672">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22673"
      unitRef="USD">192593</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="ixv-22674"
      unitRef="USDPShares">4.8131</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="ixv-22675"
      unitRef="USD">48464</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="ixv-22676"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      id="ixv-22677">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="ixv-22678"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-09-252023-09-26_custom_MrVanderBaanMember_custom_EmploymentAgreementMember"
      id="ixv-22679">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22680"
      unitRef="USD">403066</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="ixv-22681"
      unitRef="USDPShares">1.612</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="ixv-22682"
      unitRef="USD">35178</us-gaap:ShareBasedCompensation>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17798">&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zSC9zzCCuwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zvAPnVh1JgPg" style="display: none"&gt;Summary of Stock-based Compensation Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zS7sHAf62vkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zoKqAlRJe31c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwk17zItPW2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,502,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zcxZR7OKlTtj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zte0Q5Ns2CBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,546,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22683"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-22684"
      unitRef="USD">1502776</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="ixv-22685"
      unitRef="USD">43264</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22686"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-22687"
      unitRef="USD">1546040</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-17873">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrM4TFyYWthe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2023 and 2022
is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zUwm2Z22xu26" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Stock options outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zSN23ldJK207" style="width: 12%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;266,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zAkNGGuWygNb" style="width: 12%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;37.380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231_zXucU1LYjXK8" style="text-align: right" title="Number of shares, granted"&gt;165,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zAo5fnLSGNw3" style="text-align: right" title="Weighted average exercise price, granted"&gt;13.370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zUjONXbGyT25" style="text-align: right" title="Number of shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z8tkTxPvqqXg" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231_z2eCYcoZ8kR5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;(42,188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEazcrjFExjg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;19.160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zPKfSZCNAHK7" style="text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zelJDPkQeHm6" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zTtB0hSpy6Wb" style="text-align: right" title="Number of shares, granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zAkrIHec4xT" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_z7r96UwRPvRg" style="text-align: right" title="Number of shares, exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zjpvkTFgrMT8" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvQCSdvaCO6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, expired"&gt;(126,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zdBuzk8Ddun5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;28.687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zVjyZSjSfXSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_za5UIoLoxQH" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;15.330&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu3K38b1ry9" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zAsMNZABJiFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;281,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z98r6c3kYTql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;32.834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z3TsDk2fFqhd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zSNg0pg1CEF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;28.387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_ziqL2vvQSYke" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="ixv-22688"
      unitRef="Shares">266667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="ixv-22689"
      unitRef="USDPShares">37.380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22690"
      unitRef="Shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22691"
      unitRef="USDPShares">13.370</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22692"
      unitRef="Shares">42188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22693"
      unitRef="USDPShares">19.160</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22694"
      unitRef="Shares">389479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22695"
      unitRef="USDPShares">29.183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22696"
      unitRef="Shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22697"
      unitRef="USDPShares">2.492</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22698"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22699"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22700"
      unitRef="Shares">126146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22701"
      unitRef="USDPShares">28.687</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22702"
      unitRef="Shares">552083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22703"
      unitRef="USDPShares">15.330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-12-31" id="ixv-22704">P3Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22705"
      unitRef="Shares">281979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-22706"
      unitRef="USDPShares">32.834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22707"
      unitRef="Shares">252292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22708"
      unitRef="USDPShares">28.387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-12-31" id="ixv-22709">P2Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-22710"
      unitRef="USD">670000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-12-31" id="ixv-22711">P26M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18092">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zaVbuJjQ1Awa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the outstanding common stock options,, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zaTHki3lO4if" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                 Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
&lt;br/&gt;
Outstanding (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable
                                                                                                                                                                                                                                                                          (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zsOVqVl1W8yg" style="width: 30%; text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrTFMhenCA0k" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOFr8bFgKj7j" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;20,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmG74Svv61Zi" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z8eyyW1MGutk" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlW3WgZ1zwx" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zG3Y24X54r92" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zChzWjLkFQfd" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWbt32QTpC" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpAu8ssEk42f" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbTSCiehNDS1" style="text-align: right" title="Options Outstanding (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zqEaJnX2jzck" style="text-align: right" title="Options Exercisable (Shares)"&gt;44,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIxxkRT7nSGf" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zVpaEjQjKLEh" style="text-align: right" title="Options Outstanding (Shares)"&gt;65,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWtnnhg1v1Z6" style="text-align: right" title="Options Exercisable (Shares)"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z3VQUTFWRira" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVuOOT3HEYl" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z10zP4OpP6Rg" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zX5xiBpdvXf1" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zV6r3sazVpt3" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_ziVJDDvxr6q5" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z110Sw13H9ac" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbt91km4mvHh" style="text-align: right" title="Options Outstanding (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0GaP5FPb2t" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlQTaFGFabI6" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zvcpJKZwvx1d" style="text-align: right" title="Options Outstanding (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zpKXtRoGOIeb" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z62SuWmemyr5" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVLH8Zt4qcC8" style="text-align: right" title="Options Outstanding (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zbEDizTmLd12" style="text-align: right" title="Options Exercisable (Shares)"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zyX7mW3f6Bcj" style="text-align: right" title="Exercise Prices"&gt;66.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0JIKDTbWzr9" style="text-align: right" title="Options Outstanding (Shares)"&gt;3,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxfNEcRsC3Ab" style="text-align: right" title="Options Exercisable (Shares)"&gt;3,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zdPPdgQja3Bi" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zR9IrHmBaSMb" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zDm5x3jpqur6" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zdRaM6sQryx4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zyyKTSlOmXy8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zeXRwZvBnlz5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zdeeRb8UEaa6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_z2qehMfT1TI8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="ixv-22712"
      unitRef="USDPShares">1.950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="ixv-22713"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="ixv-22714"
      unitRef="Shares">20833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="ixv-22715"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="ixv-22716"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="ixv-22717"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="ixv-22718"
      unitRef="USDPShares">5.880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="ixv-22719"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="ixv-22720"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="ixv-22721"
      unitRef="USDPShares">7.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="ixv-22722"
      unitRef="Shares">55000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="ixv-22723"
      unitRef="Shares">44376</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="ixv-22724"
      unitRef="USDPShares">20.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="ixv-22725"
      unitRef="Shares">65000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="ixv-22726"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="ixv-22727"
      unitRef="USDPShares">20.600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="ixv-22728"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="ixv-22729"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="ixv-22730"
      unitRef="USDPShares">28.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="ixv-22731"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="ixv-22732"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="ixv-22733"
      unitRef="USDPShares">30.300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="ixv-22734"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="ixv-22735"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="ixv-22736"
      unitRef="USDPShares">32.100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="ixv-22737"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="ixv-22738"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="ixv-22739"
      unitRef="USDPShares">60.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="ixv-22740"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="ixv-22741"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="ixv-22742"
      unitRef="USDPShares">66.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="ixv-22743"
      unitRef="Shares">3333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="ixv-22744"
      unitRef="Shares">3333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="ixv-22745"
      unitRef="USDPShares">71.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="ixv-22746"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="ixv-22747"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="ixv-22748"
      unitRef="USDPShares">120.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="ixv-22749"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="ixv-22750"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22751"
      unitRef="Shares">552083</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22752"
      unitRef="Shares">252292</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="2"
      id="ixv-22753"
      unitRef="USDPShares">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22754"
      unitRef="USD">8000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-22755"
      unitRef="Shares">299791</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18327">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zMhXDgaRhSo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_821_zAP1WRUS39i3"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets as
of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9mvvZNffDAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zH8ndxbWNeX9" style="display: none"&gt;Schedule of Components of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zDYYnNYHG7bh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zma1HyE6kpJ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_za1o89028jIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;574,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zaMh0fAWNnB5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_zPgW0YCOKjOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zEh9c2FvEaJ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,601,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,135,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_zT7SZsuVpP5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,688,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,846,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_ztB060NVs70g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,688,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,846,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zirtavUmVtIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zduRiwKJXMw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2023 and 2022, management
was unable to determine if it is more likely than not that the Company&#x2019;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwtdaRqYtmib"&gt;&lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z8UkT5IppYZ7"&gt;No&lt;/span&gt;&lt;/span&gt;
federal tax provision has been provided for the years ended December 31, 2023 and 2022 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbGdSjPx7H8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zj9diyxYUj1" style="display: none"&gt;Schedule of Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zwTuNL0UIy8b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zDvQCnh1zpLc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zgBpjzegXLel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.
    S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_ze3hZVnUtkf7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_zNzF3F1CR3I" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expirations
    related to stock-based compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_zxEdgZmUP7U3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment
    to deferred tax asset&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(0.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zUn3s9LEl5f5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_zdA9231C6Fv9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zAKTiw3Imql7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20231231_z7msXVWLyOx9" title="Operating loss carryforwards, federal"&gt;28,111,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231_zvRJKckRK7x" title="Operating loss carryforwards, state"&gt;32,617,000&lt;/span&gt;, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
state net operating loss carryovers include approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zntpcYonTU02" title="Net operating loss carryovers"&gt;19,141,000&lt;/span&gt; that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. &lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zovH0B1EvJKf" title="Prior net operating loss conversion utilization"&gt;The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.&lt;/span&gt; The state net
operating loss carryovers also include approximately $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zR6Xjd05F2Zb" title="Operating loss carryforwards, state"&gt;13,476,000&lt;/span&gt; that was incurred in the State of California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#x201c;ownership change&#x201d;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company&#x2019;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18336">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9mvvZNffDAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zH8ndxbWNeX9" style="display: none"&gt;Schedule of Components of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zDYYnNYHG7bh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zma1HyE6kpJ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_za1o89028jIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;574,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zaMh0fAWNnB5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_zPgW0YCOKjOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zEh9c2FvEaJ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,601,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,135,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_zT7SZsuVpP5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,688,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,846,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_ztB060NVs70g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,688,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,846,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zirtavUmVtIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22756"
      unitRef="USD">612000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22757"
      unitRef="USD">574000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22758"
      unitRef="USD">844000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22759"
      unitRef="USD">1631000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22760"
      unitRef="USD">2137000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22761"
      unitRef="USD">8601000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22762"
      unitRef="USD">8135000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22763"
      unitRef="USD">11688000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22764"
      unitRef="USD">10846000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22765"
      unitRef="USD">11688000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-22766"
      unitRef="USD">10846000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="ixv-22767"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="ixv-22768"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18446">&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbGdSjPx7H8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zj9diyxYUj1" style="display: none"&gt;Schedule of Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zwTuNL0UIy8b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zDvQCnh1zpLc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zgBpjzegXLel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.
    S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(21.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_ze3hZVnUtkf7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_zNzF3F1CR3I" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expirations
    related to stock-based compensation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_zxEdgZmUP7U3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment
    to deferred tax asset&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(0.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zUn3s9LEl5f5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_zdA9231C6Fv9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22769"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22770"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22771"
      unitRef="Pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22772"
      unitRef="Pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22773"
      unitRef="Pure">-0.104</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22774"
      unitRef="Pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22775"
      unitRef="Pure">0.008</LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset>
    <LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22776"
      unitRef="Pure">0.015</LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22777"
      unitRef="Pure">-0.174</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22778"
      unitRef="Pure">-0.268</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-22779"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-22780"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22781"
      unitRef="USD">28111000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22782"
      unitRef="USD">32617000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"
      decimals="0"
      id="ixv-22783"
      unitRef="USD">19141000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="From2023-01-012023-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"
      id="ixv-22784">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      decimals="0"
      id="ixv-22785"
      unitRef="USD">13476000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18660">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcvXxpRiKx1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_829_zjnGezmfzZU6"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2023 and
2022, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company&#x2019;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical
trial monitoring agreements not yet incurred, as described below, aggregated $&lt;span id="xdx_900_eus-gaap--ContractualObligation_iI_c20231231_zSCH6kszsCT" title="Clinical trial contractual commitment"&gt;6,412,000&lt;/span&gt;, including clinical trial agreements of $&lt;span id="xdx_909_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_z6Lnq9l7o5yb" title="Contractual commitment"&gt;6,013,000&lt;/span&gt;
and clinical trial monitoring agreements of $&lt;span id="xdx_901_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zAyeISpIsMg3" title="Contractual commitment"&gt;399,000&lt;/span&gt;, which, based on current estimates, are currently scheduled to be incurred through
approximately December 31, 2027. The Company&#x2019;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#x2019;s current or future clinical trial programs. The Company expects that the full amount of these expenditures will
be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and duration are
not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently
involve a series of changes and modifications over time as clinical data are obtained and analyzed, and are frequently modified, suspended
or terminated before the clinical trial endpoint is reached. Accordingly, such contractual commitments as discussed herein should be
considered as estimates only based on current clinical assumptions and conditions and are typically subject to significant modifications
and revisions over time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zlVIDKd4qdB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z18PItiuPbNj" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 10%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Description
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Type
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Institution&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Start
    Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Estimated
    End Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Number
    of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;in
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Study
                                            Objective&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Update&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;NCT
    No.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Financial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Commitment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zKqLsxKkxJm6" title="Clinical trial, description"&gt;LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;City
    of Hope and Sarah Cannon&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zFj003DVZP38" title="Estimated Start Date"&gt;March
    2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zzC4w2NuVqAe" title="Estimated End Date"&gt;March
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zWpRthhGing2" title="Number of Patients in Trial"&gt;14&lt;/span&gt;
    to &lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zzr4OX51iE1b" title="Number of Patients in Trial"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    RP2D&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Three
    patients entered&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT04560972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;
    &lt;p id="xdx_98B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztAtIZWzhOsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2,433,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zxNJdmnGYtzf" title="Clinical trial, description"&gt;LB-100
    combined with doxorubicin in sarcoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zrF7qrWYgnSg" title="Estimated Start Date"&gt;June
    2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zevffWxihBh" title="Estimated End Date"&gt;June
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zBmFB9LvJPgh" title="Number of Patients in Trial"&gt;9&lt;/span&gt;
    to &lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zKHo6fCyXfc3" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    MTD and RP2D&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;One
    patient entered&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p id="xdx_98E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z0OO1AfG3CK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;3,580,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zw5vzSmBCCfh" title="Clinical trial, description"&gt;LB-100
    in high grade gliomas&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    0 pharmacology study&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;National
    Cancer Institute&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zTiIV1t65IAb" title="Estimated Start Date"&gt;January
    2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zsr0VwnkuAh8" title="Estimated End Date"&gt;August
    2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zj8ceD9m0Vk9" title="Number of Patients in Trial"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    the penetration of LB-100 into high grade gliomas after IV injection&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Closed.
    No or minimal penetration of LB-100 into high grade gliomas after IV injection&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT03027388&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-size: 9pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaWwQbf2nJf5" title="Clinical trial, description"&gt;Doxorubicin
    with or without LB-100 in sarcoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Randomized
    Phase 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zoqYwLNBG0p6" title="Estimated Start Date"&gt;July
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zuZb7uGuUWu" title="Estimated End Date"&gt;June
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaYRwN5QFTV4" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    efficacy: PFS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_905_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zcKzEyBN7Iu6" title="Clinical trial, description"&gt;LB-100
    combined with dostarlimab in ovarian clear cell carcinoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b/2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;MD
    Anderson&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zvabHACetB59" title="Estimated Start Date"&gt;March
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_z5l6cWHN5KYg" title="Estimated End Date"&gt;December
    2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zzgPI8fkWvA6" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    the survival of patients with ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;No
    patients entered at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT06065462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-size: 9pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OtherCommitment_iI_c20231231_zedGZLrQIZ6k" style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;6,013,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-left: 10pt; text-indent: -0.01pt; width: 0.25in"&gt;&lt;span id="xdx_F01_zRzkG6rSBs18" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F14_zaauqrobGOth" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F09_ziSh4RFXLjA1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F1B_zpeuWm5pbeYc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There is no remaining financial contractual commitment associated
with this clinical trial.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AA_zGAIIpKMHZY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#x201c;City of Hope&#x201d;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#x2019;s first-in-class protein phosphatase inhibitor, combined with an
FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#x201c;ED-SCLC&#x201d;). LB-100
will be given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated
ED-SCLC patients. The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase
2 dose (&#x201c;RP2D&#x201d;). Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the
safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration of overall
response, progression-free survival and overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (&#x201c;SCRI&#x201d;), Nashville, Tennessee, joined the City of Hope&#x2019;s
ongoing Phase 1b clinical trial. The Company is continuing its efforts to add additional sites. The addition of SCRI is expected to expedite
and expand the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability,
and efficacy of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company currently expects that
this clinical trial will be completed by March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z8ZCbmkiikU1" title="Research and development expense"&gt;69,001&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zB3P6C7M7bFa" title="Research and development expense"&gt;0&lt;/span&gt;, respectively, pursuant to this agreement, which
are included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of December 31, 2023,
total costs of $&lt;span id="xdx_909_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2JT43J4bAl6" title="Total costs"&gt;447,512&lt;/span&gt; have been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zXq46MUq8lE3" title="Aggregate commitments expected"&gt;2,433,000&lt;/span&gt;
as of December 31, 2023, which is expected to be incurred through March 31, 2026. If a significant number of patients fail during the
dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of approximately
$&lt;span id="xdx_908_ecustom--EstimatedAdditionalCommitment_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zwFE9eDkOOWc" title="Estimated additional commitment amount"&gt;800,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas or &#x201c;GEIS&#x201d;), Madrid, Spain, to carry out a
study entitled &#x201c;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#x201d;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#x201c;ASTS&#x201d;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#x201c;PFS&#x201d;), no evidence of disease progression or death from
any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#x2019;s existing LB-100 inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $&lt;span id="xdx_906_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zzNddjiGs9K5" title="Inventory costs"&gt;1,144,000&lt;/span&gt;. Although the production of new inventory
has been completed, nominal trailing costs subsequent to December 31, 2023 may be incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#xf1;ola de Medicamentos
y Productos Sanitarios or &#x201c;AEMPS&#x201d;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#x2019;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report
prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at
Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial.
The Phase 1b portion of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on
both response and toxicity from this portion of the clinical trial, and subject to clinical results, anticipates that it will be able
to proceed to a related Phase 2 study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zn7ggzuvtuIc" title="Research and development costs"&gt;268,829&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zTtllrZQdws2" title="Research and development costs"&gt;260,770&lt;/span&gt;, respectively, pursuant to this
agreement. Such costs, when incurred, are included in research and development costs in the Company&#x2019;s consolidated statements of
operations. Through December 31, 2023, the Company has paid GEIS an aggregate of $&lt;span id="xdx_903_ecustom--AmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zTRDt66xc1pc" title="Amount related to milestone payment"&gt;684,652&lt;/span&gt; for work done under this agreement through
the fourth milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zWsYmLT6OVDc" title="Aggregate commitments expected"&gt;3,580,000&lt;/span&gt;
as of December 31, 2023, which is expected to be incurred through December 31, 2027. As the work is being conducted in Europe and is
paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations
are recorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Cancer Institute Pharmacologic Clinical Trial. &lt;/b&gt;In May 2019, the National Cancer Institute (&#x201c;NCI&#x201d;) initiated a glioblastoma
(&#x201c;GBM&#x201d;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#x2019;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Clinical Trial&lt;/b&gt;. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#x201c;PD-1&#x201d;) blocking antibody of GSK plc
(&#x201c;GSK&#x201d;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#x201c;OCCC&#x201d;). The clinical trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;)
and is being conducted at The University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly
and financial support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical
trial. The Company currently expects that this clinical trial will be completed by July 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#x201c;Moffitt&#x201d;), effective for a term of five years, unless terminated earlier by the
Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a
Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#x2019;s lead anti-cancer clinical compound
LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (&#x201c;MDS&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#x201c;IND&#x201d;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally
well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilized LB-100 as a single agent
in the treatment of patients with low and intermediate-1 risk MDS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. In this clinical trial, single agent LB-100 was used on a new schedule of
days 1, 3, and 5 every 3 weeks. Although MTD was not achieved, there was no dose-limiting toxicity on this schedule at doses that were
greater than the MTD in the Phase 1 clinical trial of LB-100 on the Monday, Tuesday, Wednesday schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z3qMxlqgaRu7" title="Research and development process costs"&gt;16,165&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zQyu1JmrpCcj" title="Research and development process costs"&gt;26,397&lt;/span&gt;, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of December
31, 2023, total costs of $&lt;span id="xdx_900_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zAv0ZLz4T8y" title="Research and development costs"&gt;147,239&lt;/span&gt; have been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has decided not to pursue further studies in MDS, as other opportunities have become available (see &#x201c;Patent and License
Agreements - Moffitt&#x201d; below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Monitoring Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#x201c;Theradex&#x201d;), an international
contract research organization (&#x201c;CRO&#x201d;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
costs of the Phase 1b/2 clinical trial being paid to or through Theradex have been recorded and charged to operations based on periodic
documentation provided by the CRO. During the years ended December 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_z0StsgANnSu7" title="Research and development costs"&gt;20,884&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zwpKupI9CFQi" title="Research and development costs"&gt;35,403&lt;/span&gt;,
respectively, pursuant to this work order. As of December 31, 2023, total costs of $&lt;span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember_zGLGsIOxn9yk" title="Research and development costs"&gt;148,172&lt;/span&gt; have been incurred pursuant to this work
order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the closure of the Company&#x2019;s Clinical Trial Research Agreement with Moffitt during the year ended December 31, 2023
(see &#x201c;Clinical Trial Agreements &#x2013; Moffitt&#x201d; above), this work order agreement with Theradex to monitor the Clinical
Trial Research Agreement with Moffitt was similarly suspended, although nominal oversight trailing costs subsequent to December 31, 2023
are expected to be incurred relating to the closure of the Moffitt study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zL62WkZJJRSh" title="Research and development costs"&gt;335,000&lt;/span&gt;. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zRvc9O8r5DGc" title="Advance amount related to milestone payment"&gt;20,240&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zgM4wdKq05Sb" title="Advance amount related to milestone payment"&gt;33,815&lt;/span&gt;, respectively, pursuant to this work order. As of December 31, 2023, total costs of $&lt;span id="xdx_908_eus-gaap--DeferredCosts_iI_c20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zGJeMthhviWi" title="Cost incurred total"&gt;78,681&lt;/span&gt; have been incurred
pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zsGZtE0lPTPg" title="Aggregate commitments expected"&gt;258,000&lt;/span&gt; as of December 31, 2023, which is expected to be incurred through March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas. The study
is expected to be completed by June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_90F_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zMlopiGEA6u4" title="Work cost"&gt;153,000&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zoAGXguiJZY6" title="Percentage of payment through services"&gt;72&lt;/span&gt;% to Theradex for services and approximately &lt;span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9j1B0Dd2ZQ9" title="Percentage of payment through software"&gt;28&lt;/span&gt;% for payments for pass-through software costs. During the year ended December 31, 2023,
the Company incurred costs of $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z0f0ehl2MJek" title="Research and development costs"&gt;14,862&lt;/span&gt;, pursuant to this work order. As of December 31, 2023, total costs of $&lt;span id="xdx_907_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_z4ksR7aax2S6" title="Total costs"&gt;14,862&lt;/span&gt; have been incurred
pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zAGJvhyQENVa" title="Aggregate commitments expected"&gt;141,000&lt;/span&gt; as of December 31, 2023, which is expected to be incurred through June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#x201c;Licensed Patents&#x201d;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $&lt;span id="xdx_902_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zJ9tGSljC0o4" title="Non refundable license issue fee"&gt;25,000&lt;/span&gt; after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company was also obligated to pay Moffitt an annual
license maintenance fee of $&lt;span id="xdx_908_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zFLmbiY9Dl5d" title="Maintenance fee"&gt;25,000&lt;/span&gt; commencing on the first anniversary of the Effective Date and every anniversary thereafter until the
Company commences payment of minimum royalty payments. The Company had also agreed to pay non-refundable milestone payments to Moffitt,
which could not be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones
aggregating $&lt;span id="xdx_902_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zVxLqJqnxnq8" title="Payment on non refundable milestone"&gt;1,897,000&lt;/span&gt;, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term
is defined in the License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee shall be due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recorded a credit to operations of $&lt;span id="xdx_904_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z6QMIb0GnsVe" title="Operating costs and expenses"&gt;9,109&lt;/span&gt;, representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement. During the year ended December 31, 2022, the Company recorded charges to operations
of $&lt;span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zfNZKLc4L416" title="Operating costs and expenses"&gt;25,000&lt;/span&gt;, in connection with its obligations under the Exclusive License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual cash compensation
of $&lt;span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zIA4dJmidx6d" title="Salary and compensation"&gt;640,000&lt;/span&gt;, payable monthly (see Note 5). These employment agreements were automatically renewable for additional one-year periods unless
terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination
for cause. These employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2021, the Board of Directors increased the annual cash compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the aggregate annual compensation for all officers increased to $&lt;span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210501__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zNavkSvYyYPl" title="Annual compensation"&gt;775,000&lt;/span&gt;, effective May 1,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $&lt;span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zmRyT0OgmGBk" title="Compensation"&gt;200,000&lt;/span&gt;. In addition,
Mr. Forman is being provided an office allowance of approximately $&lt;span id="xdx_90C_eus-gaap--PaymentsForRent_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zIrrB8gzMuUc" title="Payment of office rent"&gt;1,500&lt;/span&gt; per month through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, the Company entered into an employment agreement with Bastiaan van der Baan to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors with an annual salary of $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BastiaanVanDerBaanMember_ziydiDSQpjg1" title="Compensation"&gt;150,000&lt;/span&gt;. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination as described in the employment agreement. Under the employment agreement, Mr. van der Baan&#x2019;s annual salary
may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan will be eligible to
receive an annual bonus as determined at the sole discretion of the Board of Directors. Mr. van der Baan was appointed as Chairman of
the Board of Directors upon the death of Dr. Kovach, who died on October 5, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate annual cash compensation for all officers was $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember_z1vz99lGrBjb" title="Compensation"&gt;700,000&lt;/span&gt; as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NDA
Consulting Corp.&lt;/b&gt; On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#x2019;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $&lt;span id="xdx_90E_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zkGkC8GEqLfe" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt;. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $&lt;span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zOmZNk05bq1b" title="Consulting and advisory fee"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zwXOHPNYb3Mg" title="Consulting and advisory fee"&gt;16,000&lt;/span&gt; for the years
ended December 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioPharmaWorks&lt;/b&gt;.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#x2019;s
product pipeline; assisting in preparing technical presentations concerning the Company&#x2019;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $&lt;span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zjnvRLQ3UHx8" title="Consulting and advisory fee"&gt;10,000&lt;/span&gt;, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 6). The Company recorded
charges to operations pursuant to this Collaboration Agreement of $&lt;span id="xdx_903_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDXqRHZ6t8ml" title="Reimbursed expense"&gt;120,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ReimbursementExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zn0ukr3Zmww1" title="Reimbursed expense"&gt;120,000&lt;/span&gt; for the years ended December 31, 2023 and 2022,
respectively, which were included in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute&lt;/b&gt;. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#x201c;NKI&#x201d;) (see Note 5), one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto. The Development Collaboration Agreement is intended to identify the most promising drugs to be combined
with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular
mechanisms underlying the identified combinations. The Company agreed to fund the study, at an approximate cost of &lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zBkw1k2RH0G3" title="Aggregate commitments expected"&gt;391,000&lt;/span&gt; Euros and
provide a sufficient supply of LB-100 to conduct the study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and adds
&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQOlTbUv7rP7" title="Aggregate commitments expected"&gt;500,000&lt;/span&gt; Euros (approximately $&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zQIceSAZqBY7" title="Aggregate commitments expected"&gt;526,000&lt;/span&gt; at October 3, 2023) to the operating budget being funded by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, the Company incurred charges in the amount of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zZpc1uW8wiLi" title="Advance amount related to milestone payment"&gt;226,150&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zfnxcAj7qss5" title="Advance amount related to milestone payment"&gt;204,158&lt;/span&gt;, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated statements of operations.
As of December 31, 2023, total costs of $&lt;span id="xdx_901_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zDARE2RFxlKe" title="Research and development costs"&gt;485,556&lt;/span&gt; have been incurred pursuant to this agreement, as amended. The Company&#x2019;s aggregate
commitment pursuant to this agreement, as amended, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zkru21Oz2dy3" title="Aggregate commitments expected"&gt;595,000&lt;/span&gt; as of December
31, 2023, which is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros,
final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MRI
Global. &lt;/b&gt;The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $&lt;span id="xdx_906_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zxcsDkx3E23b" title="Contract price"&gt;273,980&lt;/span&gt; for services to be
rendered through April 30, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of
$&lt;span id="xdx_901_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zyMtECBpFl25" title="Contract price"&gt;326,274&lt;/span&gt; for services to be rendered through April 30, 2024. During the years ended December 31, 2023 and 2022, the Company incurred
costs of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_z18kwnAj6wtf" title="Advance amount related to milestone payment"&gt;32,307&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgJ9YYCrzQ2f" title="Research and developments costs"&gt;27,702&lt;/span&gt;, respectively, pursuant to this work order. As of December 31, 2023, total costs of $&lt;span id="xdx_904_eus-gaap--DeferredCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zqVTNug3zUFi" title="Total costs incurred"&gt;248,298&lt;/span&gt; have been incurred
pursuant to this contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_906_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zNNfDOQkcit8" title="Aggregate commitments expected"&gt;78,000&lt;/span&gt; as
of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;External
Risks Associated with the Company&#x2019;s Business Activities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Covid-19
Virus&lt;/b&gt;. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#x2019;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflation
and Interest Rate Risk. &lt;/b&gt;The Company does not believe that inflation or increasing interest rates has had a material effect on its
operations to date, other than its impact on the general economy. However, there is a risk that the Company&#x2019;s operating costs could
become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#x2019;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#x2019;s working
capital resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supply
Chain Issues. &lt;/b&gt;The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Potential
Recession. &lt;/b&gt;There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Geopolitical
Risk.&lt;/b&gt; The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#x2019;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#x2019;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#x2019;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital may all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#x2019;s business, financial condition and results
of operations may differ from current estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22786"
      unitRef="USD">6412000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2023-12-31_custom_ClinicalTrialAgreementsMember"
      decimals="0"
      id="ixv-22787"
      unitRef="USD">6013000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2023-12-31_custom_ClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="ixv-22788"
      unitRef="USD">399000</us-gaap:ContractualObligation>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-18706">&lt;p id="xdx_899_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zlVIDKd4qdB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the contractual clinical trials discussed below as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z18PItiuPbNj" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 10%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Description
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Type
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Institution&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Start
    Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Estimated
    End Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Number
    of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;in
    Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Study
                                            Objective&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Clinical
    Update&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;NCT
    No.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Financial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;b&gt;Commitment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zKqLsxKkxJm6" title="Clinical trial, description"&gt;LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;City
    of Hope and Sarah Cannon&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zFj003DVZP38" title="Estimated Start Date"&gt;March
    2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zzC4w2NuVqAe" title="Estimated End Date"&gt;March
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MinimumMember_zWpRthhGing2" title="Number of Patients in Trial"&gt;14&lt;/span&gt;
    to &lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember__srt--RangeAxis__srt--MaximumMember_zzr4OX51iE1b" title="Number of Patients in Trial"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    RP2D&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Three
    patients entered&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT04560972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;
    &lt;p id="xdx_98B_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_ztAtIZWzhOsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2,433,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zxNJdmnGYtzf" title="Clinical trial, description"&gt;LB-100
    combined with doxorubicin in sarcoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zrF7qrWYgnSg" title="Estimated Start Date"&gt;June
    2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zevffWxihBh" title="Estimated End Date"&gt;June
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zBmFB9LvJPgh" title="Number of Patients in Trial"&gt;9&lt;/span&gt;
    to &lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zKHo6fCyXfc3" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    MTD and RP2D&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;One
    patient entered&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p id="xdx_98E_eus-gaap--OtherCommitment_iI_c20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z0OO1AfG3CK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;3,580,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zw5vzSmBCCfh" title="Clinical trial, description"&gt;LB-100
    in high grade gliomas&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    0 pharmacology study&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;National
    Cancer Institute&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zTiIV1t65IAb" title="Estimated Start Date"&gt;January
    2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zsr0VwnkuAh8" title="Estimated End Date"&gt;August
    2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseZeroPharmacologyStudyMember_fKDIp_zj8ceD9m0Vk9" title="Number of Patients in Trial"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    the penetration of LB-100 into high grade gliomas after IV injection&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Closed.
    No or minimal penetration of LB-100 into high grade gliomas after IV injection&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT03027388&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-size: 9pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaWwQbf2nJf5" title="Clinical trial, description"&gt;Doxorubicin
    with or without LB-100 in sarcoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Randomized
    Phase 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zoqYwLNBG0p6" title="Estimated Start Date"&gt;July
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zuZb7uGuUWu" title="Estimated End Date"&gt;June
    2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zaYRwN5QFTV4" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    efficacy: PFS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_905_ecustom--ClinicalTrialDescription_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zcKzEyBN7Iu6" title="Clinical trial, description"&gt;LB-100
    combined with dostarlimab in ovarian clear cell carcinoma&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Phase
    1b/2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;MD
    Anderson&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--ContractualClinicalTrialPeriodStartDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zvabHACetB59" title="Estimated Start Date"&gt;March
    2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--ContractualClinicalTrialPeriodEndDate_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_z5l6cWHN5KYg" title="Estimated End Date"&gt;December
    2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--NumberOfPatientInTrial_uInteger_c20230101__20231231__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase2Member_fKDIp_zzgPI8fkWvA6" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Determine
    the survival of patients with ovarian clear cell carcinoma&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;No
    patients entered at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;NCT06065462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;span style="font-size: 9pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OtherCommitment_iI_c20231231_zedGZLrQIZ6k" style="border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;6,013,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-left: 10pt; text-indent: -0.01pt; width: 0.25in"&gt;&lt;span id="xdx_F01_zRzkG6rSBs18" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F14_zaauqrobGOth" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td style="padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F09_ziSh4RFXLjA1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -0.01pt"&gt;&lt;span id="xdx_F1B_zpeuWm5pbeYc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There is no remaining financial contractual commitment associated
with this clinical trial.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <LIXT:ClinicalTrialDescription
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember"
      id="ixv-22789">LB-100
    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember"
      id="ixv-22790">March
    2021</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember"
      id="ixv-22791">March
    2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-22792"
      unitRef="Integer">14</LIXT:NumberOfPatientInTrial>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-22793"
      unitRef="Integer">36</LIXT:NumberOfPatientInTrial>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_ClinicalTrialPhase1bMember"
      decimals="0"
      id="ixv-22794"
      unitRef="USD">2433000</us-gaap:OtherCommitment>
    <LIXT:ClinicalTrialDescription
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember"
      id="ixv-22795">LB-100
    combined with doxorubicin in sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember"
      id="ixv-22796">June
    2023</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember"
      id="ixv-22797">June
    2024</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-22798"
      unitRef="Integer">9</LIXT:NumberOfPatientInTrial>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-22799"
      unitRef="Integer">18</LIXT:NumberOfPatientInTrial>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_ClinicalTrialPhase1bTwoMember"
      decimals="0"
      id="ixv-22800"
      unitRef="USD">3580000</us-gaap:OtherCommitment>
    <LIXT:ClinicalTrialDescription
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember"
      id="Fact001320">LB-100
    in high grade gliomas</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember"
      id="Fact001322">January
    2019</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember"
      id="Fact001324">August
    2022</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhaseZeroPharmacologyStudyMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Integer">7</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember"
      id="Fact001328">Doxorubicin
    with or without LB-100 in sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember"
      id="Fact001330">July
    2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember"
      id="Fact001332">June
    2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialRandomizedPhaseTwoMember"
      decimals="INF"
      id="Fact001334"
      unitRef="Integer">150</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member"
      id="Fact001336">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member"
      id="Fact001338">March
    2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member"
      id="Fact001340">December
    2025</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialPhase2Member"
      decimals="INF"
      id="Fact001342"
      unitRef="Integer">21</LIXT:NumberOfPatientInTrial>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-22813"
      unitRef="USD">6013000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="ixv-22816"
      unitRef="USD">69001</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="ixv-22817"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="ixv-22818"
      unitRef="USD">447512</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="ixv-22819"
      unitRef="USD">2433000</us-gaap:OtherCommitment>
    <LIXT:EstimatedAdditionalCommitment
      contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="ixv-22820"
      unitRef="USD">800000</LIXT:EstimatedAdditionalCommitment>
    <us-gaap:InventoryPartsAndComponentsNetOfReserves
      contextRef="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="ixv-22821"
      unitRef="USD">1144000</us-gaap:InventoryPartsAndComponentsNetOfReserves>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="ixv-22822"
      unitRef="USD">268829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="ixv-22823"
      unitRef="USD">260770</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="ixv-22824"
      unitRef="USD">684652</LIXT:AmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="ixv-22825"
      unitRef="USD">3580000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      id="ixv-22826"
      unitRef="USD">16165</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      id="ixv-22827"
      unitRef="USD">26397</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      id="ixv-22828"
      unitRef="USD">147239</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      id="ixv-22829"
      unitRef="USD">20884</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      id="ixv-22830"
      unitRef="USD">35403</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember"
      decimals="0"
      id="ixv-22831"
      unitRef="USD">148172</us-gaap:DeferredCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22832"
      unitRef="USD">335000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22833"
      unitRef="USD">20240</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22834"
      unitRef="USD">33815</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22835"
      unitRef="USD">78681</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22836"
      unitRef="USD">258000</us-gaap:OtherCommitment>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="ixv-22837"
      unitRef="USD">153000</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="ixv-22838"
      unitRef="Pure">0.72</LIXT:ExpectedPaymentinServices>
    <LIXT:ExpectedPaymentThroughSoftware
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="ixv-22839"
      unitRef="Pure">0.28</LIXT:ExpectedPaymentThroughSoftware>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="ixv-22840"
      unitRef="USD">14862</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22841"
      unitRef="USD">14862</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_WorkOrderAgreementMember"
      decimals="0"
      id="ixv-22842"
      unitRef="USD">141000</us-gaap:OtherCommitment>
    <LIXT:NonRefundableLicenseIssueFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-22843"
      unitRef="USD">25000</LIXT:NonRefundableLicenseIssueFee>
    <LIXT:AnnualLicenseMaintenanceFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-22844"
      unitRef="USD">25000</LIXT:AnnualLicenseMaintenanceFee>
    <LIXT:PaymentsOnNonrefundableMilestone
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-22845"
      unitRef="USD">1897000</LIXT:PaymentsOnNonrefundableMilestone>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-22846"
      unitRef="USD">9109</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-12-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-22847"
      unitRef="USD">25000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember"
      decimals="0"
      id="ixv-22848"
      unitRef="USD">640000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-05-012021-05-01_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember"
      decimals="0"
      id="ixv-22849"
      unitRef="USD">775000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22850"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31_custom_EricJFormanMember"
      decimals="0"
      id="ixv-22851"
      unitRef="USD">1500</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BastiaanVanDerBaanMember"
      decimals="0"
      id="ixv-22852"
      unitRef="USD">150000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_srt_OfficerMember"
      decimals="0"
      id="ixv-22853"
      unitRef="USD">700000</us-gaap:OfficersCompensation>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember"
      decimals="0"
      id="ixv-22854"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2023-01-012023-12-31_custom_NDAConsultingCorpMember"
      decimals="0"
      id="ixv-22855"
      unitRef="USD">16000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2022-01-012022-12-31_custom_NDAConsultingCorpMember"
      decimals="0"
      id="ixv-22856"
      unitRef="USD">16000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="ixv-22857"
      unitRef="USD">10000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ReimbursementExpense
      contextRef="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="ixv-22858"
      unitRef="USD">120000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2022-01-012022-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="ixv-22859"
      unitRef="USD">120000</LIXT:ReimbursementExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22860"
      unitRef="EUR">391000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22861"
      unitRef="EUR">500000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22862"
      unitRef="USD">526000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22863"
      unitRef="USD">226150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22864"
      unitRef="USD">204158</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22865"
      unitRef="USD">485556</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="ixv-22866"
      unitRef="USD">595000</us-gaap:OtherCommitment>
    <LIXT:ContractPrice
      contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22867"
      unitRef="USD">273980</LIXT:ContractPrice>
    <LIXT:ContractPrice
      contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22868"
      unitRef="USD">326274</LIXT:ContractPrice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22869"
      unitRef="USD">32307</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22870"
      unitRef="USD">27702</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22871"
      unitRef="USD">248298</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="ixv-22872"
      unitRef="USD">78000</us-gaap:OtherCommitment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-19760">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zNwA8ZEEixYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_82F_zxvDojBQeNAh"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than those matters described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures
in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Patent
License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
February 23, 2024, the Company entered into a Patent License Agreement (the &#x201c;License Agreement&#x201d;) with the National Institute
of Neurological Disorders and Stroke (&#x201c;NINDS&#x201d;) and the National Cancer Institute (&#x201c;NCI&#x201d;), each an institute or
center of the National Institute of Health (&#x201c;NIH&#x201d;). Pursuant to the License Agreement, the Company has licensed exclusively
NIH&#x2019;s intellectual property rights claimed for a Cooperative Research and Development Agreement (&#x201c;CRADA&#x201d;) subject invention
co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination
with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for
the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis,
until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed
territory, unless sooner terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $&lt;span id="xdx_903_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6N1FIZy3DU8" title="Non refundable license issue royalty"&gt;50,000&lt;/span&gt; and a first minimum annual royalty
of $&lt;span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueWithinSixtyDaysMember_z1uCnYQRHCuf" title="Non refundable license issue royalty"&gt;30,000&lt;/span&gt;, within sixty days from the effective date of the Agreement. The first minimum annual royalty may be prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $&lt;span id="xdx_90B_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zmOGlURMzAKc" title="Minimum annual royalty payable"&gt;30,000&lt;/span&gt; is due each January
1 and may be credited against any earned royalties due for sales made in that year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#x2019;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively,
each with a different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 31, 2024
benchmark is defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The total of all such benchmark payments is $&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzpnbkgb6tm7" title="Payment for royalties"&gt;1,225,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH sublicensing royalties of &lt;span id="xdx_906_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zS8a1cDyQdwl" title="Royalty percentage"&gt;5&lt;/span&gt;% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember"
      decimals="0"
      id="ixv-22873"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueWithinSixtyDaysMember"
      decimals="0"
      id="ixv-22874"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="ixv-22875"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember"
      decimals="0"
      id="ixv-22876"
      unitRef="USD">1225000</us-gaap:PaymentsForRoyalties>
    <LIXT:RoyatiesPercentage
      contextRef="From2024-02-232024-02-23_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="ixv-22877"
      unitRef="Pure">0.05</LIXT:RoyatiesPercentage>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001328"
          xlink:label="Fact001328"
          xlink:type="locator"/>
        <link:footnote id="Footnote001345" xlink:label="Footnote001345" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The financial contractual commitment of the GEIS Randomized
Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001328"
          xlink:to="Footnote001345"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001330"
          xlink:label="Fact001330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001330"
          xlink:to="Footnote001345"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001332"
          xlink:label="Fact001332"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001332"
          xlink:to="Footnote001345"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001334"
          xlink:label="Fact001334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001334"
          xlink:to="Footnote001345"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001320"
          xlink:label="Fact001320"
          xlink:type="locator"/>
        <link:footnote id="Footnote001346" xlink:label="Footnote001346" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">There is no remaining financial contractual commitment associated
with this clinical trial.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001320"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001322"
          xlink:label="Fact001322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001322"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001324"
          xlink:label="Fact001324"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001324"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001326"
          xlink:label="Fact001326"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001326"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001336"
          xlink:label="Fact001336"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001336"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001338"
          xlink:label="Fact001338"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001338"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001340"
          xlink:label="Fact001340"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001340"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001342"
          xlink:label="Fact001342"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001342"
          xlink:to="Footnote001346"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
